<SUBMISSION>
<ACCESSION-NUMBER>0000950123-10-086103
<TYPE>DEFM14A
<PUBLIC-DOCUMENT-COUNT>8
<FILING-DATE>20100914
<DATE-OF-FILING-DATE-CHANGE>20100914
<EFFECTIVENESS-DATE>20100914
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>Abraxis BioScience, Inc.
<CIK>0001409012
<ASSIGNED-SIC>2834
<IRS-NUMBER>300431735
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>DEFM14A
<ACT>34
<FILE-NUMBER>001-33657
<FILM-NUMBER>101072207
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
<PHONE>310-883-1300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Abraxis Biosciences, Inc.
<DATE-CHANGED>20071120
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>New Abraxis, Inc.
<DATE-CHANGED>20070806
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>DEFM14A
<SEQUENCE>1
<FILENAME>y85641dfdefm14a.htm
<DESCRIPTION>DEFM14A
<TEXT>
<HTML>
<HEAD>
<TITLE>defm14a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>UNITED STATES</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Washington,&#160;D.C. 20549</B>
</DIV>

<DIV style="margin-top: 5pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 12pt">SCHEDULE&#160;14A</FONT></B>
</DIV>

<DIV style="margin-top: 5pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Proxy Statement Pursuant to Section&#160;14(a) of</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>the Securities Exchange Act of 1934</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Filed by the Registrant
    <FONT style="font-family: Wingdings; font-variant: normal">&#254;
    </FONT>
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Filed by a Party other than the Registrant
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Check the appropriate box:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;Preliminary
    Proxy Statement
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;<B>Confidential,
    for Use of the Commission Only (as permitted by
    <FONT style="white-space: nowrap">Rule&#160;14a-6(e)(2))</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

    <FONT style="font-family: Wingdings; font-variant: normal">&#254;</FONT>&#160;&#160;Definitive
    Proxy Statement
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;Definitive
    Additional Materials
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;Soliciting
    Material Pursuant to
    <FONT style="white-space: nowrap">&#167;&#160;240.14a-12</FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Abraxis BioScience, Inc.</B>
</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-size: 8pt">(Name of Registrant as Specified In
    Its Charter)
    </FONT>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-size: 8pt">(Name of Person(s) Filing Proxy
    Statement if other than the Registrant)
    </FONT>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Payment of Filing Fee (Check the appropriate box):
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;No
    fee required.
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;</TD>
    <TD align="left">
    Fee computed on table below per Exchange Act
    <FONT style="white-space: nowrap">Rules&#160;14a-6(i)(1)</FONT>
    and 0-11.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (1)&#160;&#160;
</TD>
    <TD align="left">
    Title of each class of securities to which transaction
    applies:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (2)&#160;&#160;
</TD>
    <TD align="left">
    Aggregate number of securities to which transaction applies:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (3)&#160;&#160;
</TD>
    <TD align="left">
    Per unit price or other underlying value of transaction computed
    pursuant to Exchange Act
    <FONT style="white-space: nowrap">Rule&#160;0-11</FONT>
    (set forth the amount on which the filing fee is calculated and
    state how it was determined):<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (4)&#160;&#160;
</TD>
    <TD align="left">
    Proposed maximum aggregate value of transaction:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (5)&#160;&#160;
</TD>
    <TD align="left">
    Total fee paid:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>    <FONT style="font-family: Wingdings; font-variant: normal">&#254;</FONT>&#160;&#160;
</TD>
    <TD align="left">    Fee paid previously with preliminary materials.
</TD>
</TR>


<TR style="line-height: 2pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;
</TD>
    <TD align="left">    Check box if any part of the fee is offset as provided by
    Exchange Act
    <FONT style="white-space: nowrap">Rule&#160;0-11(a)(2)</FONT>
    and identify the filing for which the offsetting fee was paid
    previously. Identify the previous filing by registration
    statement number, or the Form or Schedule and the date of its
    filing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (1)&#160;&#160;
</TD>
    <TD align="left">
    Amount Previously Paid:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (2)&#160;&#160;
</TD>
    <TD align="left">
    Form, Schedule or Registration Statement No.:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (3)&#160;&#160;
</TD>
    <TD align="left">
    Filing Party:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    (4)&#160;&#160;
</TD>
    <TD align="left">
    Date Filed:<BR>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 91%; margin-left: 4%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y85641dfx8564116.gif" alt="(ABRAXIS LOGO)">
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 12pt">NOTICE OF SPECIAL MEETING OF
    STOCKHOLDERS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 12pt">To Be Held October&#160;13,
    2010</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The special meeting of stockholders of Abraxis BioScience, Inc.
    will be held at the Fairmont Miramar, 101&#160;Wilshire
    Boulevard, Santa Monica, California, on October&#160;13, 2010,
    at 10:00&#160;a.m. local time. The purpose of the special
    meeting is to vote on a proposal to adopt the Agreement and Plan
    of Merger, dated as of June&#160;30, 2010, by and among Celgene
    Corporation, Artistry Acquisition Corp., a wholly-owned
    subsidiary of Celgene Corporation, and Abraxis BioScience, Inc.,
    as it may be amended from time to time (the &#147;merger
    agreement&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>The board of directors of Abraxis unanimously recommends a
    vote &#147;FOR&#148; this proposal.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Only holders of record of Abraxis common stock at the close of
    business on September&#160;10, 2010 will be entitled to vote at
    the special meeting or any adjournments or postponements
    thereof. A list of stockholders entitled to vote at the special
    meeting will be available in Abraxis&#146; office located at
    11755 Wilshire Boulevard, Suite&#160;2000, Los Angeles,
    California 90025, during regular business hours for a period not
    less than ten days before the special meeting, as well as at the
    place of the special meeting during the special meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For the security of everyone attending the special meeting, a
    stockholder must present photo identification to be admitted to
    the special meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Whether or not you plan to attend the special meeting, please
    vote in advance by marking, signing, dating and returning the
    proxy card in the enclosed postage-prepaid envelope.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    By Order of the Board of Directors,
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y85641dfx8564117.gif" alt="-s- Patrick Soon Shiong">
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Patrick Soon-Shiong,&#160;M.D.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Executive Chairman
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Los Angeles, California
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
     September&#160;14, 2010
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  <!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">REFERENCES
    TO ADDITIONAL INFORMATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This proxy statement/prospectus incorporates important business
    and financial information about Abraxis and Celgene from other
    documents that Abraxis and Celgene have filed with the
    Securities and Exchange Commission, which we refer to as the
    SEC, and that are included in this proxy statement/prospectus
    and can be found following the annexes. For a listing of
    documents incorporated by reference in this proxy
    statement/prospectus, please see the section entitled
    &#147;Where You Can Find More Information.&#148; This
    information is available for you to review at the SEC&#146;s
    public reference room located at 100&#160;F&#160;Street, N.E.,
    Room&#160;1580, Washington, DC 20549, and through the SEC&#146;s
    website at www.sec.gov. You can also obtain those documents
    incorporated by reference in this proxy statement/prospectus
    free of charge by requesting them in writing or by telephone
    from the appropriate company at the following addresses and
    telephone numbers:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
    Abraxis BioScience, Inc.<BR>
    11755 Wilshire Boulevard, Suite&#160;2000 <BR>
    Los Angeles, California 90025 <BR>
    Attention: Investor Relations <BR>
    Telephone Number:
    <FONT style="white-space: nowrap">(310)&#160;883-1300</FONT>
    <BR>
    www.abraxisbio.com
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene Corporation <BR>
    86 Morris Avenue<BR>
    Summit, New Jersey 07901 <BR>
    Attention: Investor Relations <BR>
    Telephone Number: (908) 673-9000 <BR>
    www.celgene.com
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>QUESTIONS AND ANSWERS ABOUT THE MERGER</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    iii
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>SUMMARY</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>SELECTED HISTORICAL CONSOLIDATED AND COMBINED
    FINANCIAL DATA OF ABRAXIS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA
    OF CELGENE</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>SELECTED UNAUDITED PRO FORMA CONDENSED
    CONSOLIDATED FINANCIAL DATA</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>COMPARATIVE PER SHARE MARKET PRICE AND DIVIDEND
    INFORMATION</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'>COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA
    PER SHARE DATA</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'>RISK FACTORS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
    STATEMENTS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'>INFORMATION ABOUT THE SPECIAL MEETING</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'>THE PARTIES TO THE MERGER</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'>THE MERGER</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#113'>Background of the Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#114'>Reasons for the Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#115'>Opinions of Financial Advisors to Abraxis</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#116'>Certain Illustrative Projections for Abraxis</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#117'>Interests of Directors and Executive Officers of
    Abraxis in the Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#118'>Regulatory Approvals</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#119'>Litigation Related to the Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#120'>Accounting Treatment</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#121'>Delisting and Deregistration of Abraxis Common
    Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#122'>Stock Exchange Listing of Celgene Common Stock
    Issued in the Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#123'>Stock Exchange Listing of CVRs</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#124'>Financing the Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#125'>THE MERGER AGREEMENT</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#126'>The Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#127'>Effective Time</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#128'>Merger Consideration</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#129'>Dissenting Shares</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#130'>Treatment of Abraxis Stock Options and Other
    Equity Awards</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#131'>Payment and Exchange Procedures</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#132'>Representations and Warranties</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#133'>Conduct of Abraxis&#146; Business Pending the
    Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#134'>Obligation to Call Special Meeting and Recommend
    the Merger Agreement</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#135'>Registration Statement and Proxy
    Statement/Prospectus</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#136'>Restrictions on Solicitation of Third Party
    Acquisition Proposals</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    78
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#137'>Termination in Connection with a Superior
    Proposal</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#138'>Agreement to Use Reasonable Best Efforts and Take
    Further Action</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#139'>Employee Benefit Plans</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#140'>Directors and Officers Indemnification and
    Insurance</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#141'>Other Covenants and Agreements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#142'>Conditions to the Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#143'>Termination</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#144'>Termination Fees and Expenses</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#145'>Amendment and Waiver</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#146'>VOTING AGREEMENT</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#147'>Agreement to Vote and Irrevocable Proxy</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#148'>Transfer Restrictions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#149'>&#147;No Shop&#148; Obligations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#150'>Termination</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#151'>DESCRIPTION OF THE CVRS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#153'>Contingent Value Rights Agreement</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#154'>Characteristics of the CVRs</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#155'>Net Sales Payments and Milestone Payments</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#156'>Payment Dates</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#157'>Issuance of CVRs</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#158'>Transferability of CVRs; Listing</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#159'>Selected Definitions Related to the CVR
    Agreement</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#160'>Subordination</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#161'>Reporting Obligations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#162'>Audit</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#163'>Diligent Efforts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#164'>Covenants</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#165'>Events of Default</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#166'>Restrictions on Purchases by Celgene and
    Affiliates</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#167'>Registration and Transfers</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#168'>Amendment of CVR Agreement without Consent of CVR
    Holders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#169'>Amendment of CVR Agreement with Consent of CVR
    Holders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#170'>CVR Redemption&#160;Rights</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#171'>CERTAIN MATERIAL U.S. FEDERAL INCOME TAX
    CONSEQUENCES</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#172'>DESCRIPTION OF THE CAPITAL STOCK OF CELGENE</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#173'>Common Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#174'>Preferred Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <A HREF='#175'>Delaware Law and Bylaw Provisions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#176'>COMPARATIVE RIGHTS OF ABRAXIS STOCKHOLDERS AND
    CELGENE STOCKHOLDERS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#177'>RIGHTS OF STOCKHOLDERS TO SEEK APPRAISAL</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#178'>UNAUDITED PRO FORMA CONDENSED CONSOLIDATED
    FINANCIAL STATEMENTS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#179'>LEGAL MATTERS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#180'>EXPERTS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#181'>STOCKHOLDER PROPOSALS</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#182'>WHERE YOU CAN FIND MORE INFORMATION</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    123
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#183'>Annex&#160;A: Agreement and Plan of Merger</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#184'>Annex&#160;B: Form of Contingent Value Rights
    Agreement</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#185'>Annex&#160;C: Voting Agreement</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    C-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#186'>Annex&#160;D: Non-Competition, Non-Solicitation
    and Confidentiality Agreement</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    D-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#187'>Annex&#160;E: Opinion of Merrill Lynch, Pierce,
    Fenner&#160;&#038; Smith Incorporated</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    E-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#188'>Annex&#160;F: Opinion of Goldman,
    Sachs&#160;&#038; Co.</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#189'>Annex&#160;G: Opinion of Lazard,
    Fr&#232;res&#160;&#038; Co. LLC</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    G-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#190'>Annex&#160;H: Delaware General Corporate
    Law&#160;&#151; Section&#160;262</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    H-1
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    ii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">QUESTIONS
    AND ANSWERS ABOUT THE MERGER</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following questions and answers are intended to address
    briefly some commonly asked questions regarding the merger.
    These questions and answers may not address all questions that
    may be important to you as an Abraxis stockholder. To better
    understand these matters, and for a description of the legal
    terms governing the merger, you should carefully read this
    entire proxy statement/prospectus, including the annexes, as
    well as the documents that we have incorporated by reference
    into this document. See &#147;Where You Can Find More
    Information.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Unless otherwise indicated or required by the context, in this
    proxy statement/prospectus, all references to
    &#147;Celgene&#148; refer to Celgene Corporation and its
    subsidiaries; all references to &#147;merger sub&#148; refer to
    Artistry Acquisition Corp., a direct or indirect wholly-owned
    subsidiary of Celgene; all references to &#147;Abraxis&#148;
    refer to Abraxis BioScience, Inc. and its subsidiaries; all
    references to the &#147;merger agreement&#148; refer to the
    Agreement and Plan of Merger, dated as of June&#160;30, 2010, by
    and among Abraxis, Celgene and merger sub, a copy of which is
    attached as Annex&#160;A to this proxy statement/prospectus, as
    it may be amended from time to time; all references to the
    &#147;merger&#148; refer to the merger contemplated by the
    merger agreement; all references to the &#147;principal
    stockholders&#148; refer to Dr.&#160;Patrick Soon-Shiong and
    certain entities affiliated with him, who together own
    approximately 81.9% of the outstanding shares of Abraxis common
    stock; and all references to the &#147;CVR agreement&#148; refer
    to the Contingent Value Rights Agreement to be entered into by
    Celgene and a mutually acceptable trustee, prior to the
    completion of the merger, a copy of which is attached as
    Annex&#160;B to this proxy statement/prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Why am I receiving this document?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Celgene and Abraxis have agreed to the merger, pursuant to which
    Abraxis will become a direct or indirect wholly-owned subsidiary
    of Celgene and will cease to be a publicly held corporation. In
    order for the companies to complete the merger, the holders of a
    majority of the outstanding shares of Abraxis common stock must
    vote to adopt the merger agreement. Abraxis is holding a special
    meeting of stockholders solely to obtain such stockholder
    approval.</TD>
</TR>
    <FONT style="font-size: 10pt">
    </FONT>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    This document is being delivered to you as both a proxy
    statement of Abraxis and a prospectus of Celgene in connection
    with the merger. It is the proxy statement by which the Abraxis
    board of directors is soliciting proxies from you to vote on the
    adoption of the merger agreement at the special meeting or at
    any adjournment or postponement of the special meeting. It is
    also the prospectus by which Celgene will issue Celgene common
    stock and contingent value rights, which we refer to as CVRs, to
    you in the merger.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>What is the proposed transaction for which I am being asked
    to vote?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    You are being asked to adopt the merger agreement providing for
    the acquisition of Abraxis by Celgene upon the terms and
    conditions of the merger agreement described in this proxy
    statement/prospectus, which is attached as Annex&#160;A to this
    proxy statement/prospectus. This proxy statement/prospectus
    contains important information about the merger, including the
    special meeting of the stockholders of Abraxis. You should read
    it carefully and in its entirety.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>If the merger is completed, what will I receive for my shares
    of Abraxis common stock?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Upon completion of the merger, each share of Abraxis common
    stock that is issued and outstanding (other than those for which
    appraisal rights are validly perfected or owned by Celgene or
    merger sub or any wholly-owned subsidiary of Celgene or Abraxis)
    will be cancelled and converted into the right to receive
    (1)&#160;$58.00 in cash, without interest, (2)&#160;0.2617 of a
    share of Celgene common stock and (3)&#160;one CVR. We refer to
    the consideration payable in the merger described in clauses
    (1), (2)&#160;and (3)&#160;together as the merger consideration.
    See &#147;The Merger Agreement&#160;&#151; Merger
    Consideration&#148; and &#147;The Merger Agreement&#160;&#151;
    Treatment of Abraxis Stock Options and Other Equity Awards.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>How did you determine the merger consideration to be paid to
    holders of Abraxis common stock?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    The merger consideration was determined as a result of
    arm&#146;s length negotiations between the management of Abraxis
    and its board of directors, on the one hand, and the management
    of Celgene and its board of directors, on the other hand.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    iii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>What will happen to Abraxis as a result of the merger?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    The acquisition of Abraxis by Celgene will be accomplished
    through a merger of merger sub, with and into Abraxis, with
    Abraxis surviving the merger as a subsidiary of Celgene. As a
    result of the merger, Abraxis common stock will be cancelled and
    delisted from The NASDAQ Global Select Market and will no longer
    be publicly traded.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Why did the Abraxis board of directors approve the merger
    agreement and the transactions contemplated by the merger
    agreement, including the merger?</B></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    To review the Abraxis board of directors&#146; reasons for
    recommending and approving the merger agreement and the
    transactions contemplated by the merger agreement, including the
    merger, see &#147;The Merger&#160;&#151; Reasons for the
    Merger&#160;&#151; Abraxis&#146; Reasons for the Merger.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>How does the Abraxis board of directors recommend that I
    vote?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    After careful consideration, the Abraxis board of directors
    unanimously recommends that you vote your shares
    <B>&#147;FOR&#148;</B> the adoption of the merger agreement.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Is the approval of stockholders necessary to adopt the merger
    agreement?</B></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Adoption of the merger agreement requires approval of the
    holders of a majority of the outstanding shares of Abraxis
    common stock, voting together as a single class. On
    June&#160;30, 2010, the principal stockholders, who together
    owned at that date approximately 82.1% of the outstanding shares
    of Abraxis common stock and approximately 81.9% of the
    outstanding shares of Abraxis common stock as of September 10,
    2010, the record date established for the special meeting,
    entered into a voting agreement with Celgene and merger sub,
    under which they agreed, subject to the terms thereof, to vote
    all of their shares of Abraxis common stock in favor of the
    approval and adoption of the merger agreement and the
    transactions contemplated by the merger agreement and against,
    among other things, any business combination or extraordinary
    corporate transaction involving Abraxis or any or its
    subsidiaries, other than the merger or any business combination
    or transaction with Celgene or any of its affiliates. Each of
    the principal stockholders also granted an irrevocable proxy to
    Celgene to vote or execute consents with respect to such
    principal stockholder&#146;s shares of Abraxis common stock in
    accordance with the preceding sentence. The voting agreement
    will terminate upon the earliest to occur of: (1)&#160;the
    completion of the merger, (2)&#160;any material amendment to the
    merger agreement that is adverse to the principal stockholders
    that has not been approved by them and (3)&#160;the termination
    of the merger agreement in accordance with its terms. A copy of
    the voting agreement is attached to this proxy
    statement/prospectus as Annex&#160;C. The principal
    stockholders&#146; vote will be sufficient under Delaware law to
    adopt the merger agreement. See &#147;Voting Agreement.&#148;</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>When and where will the special meeting be held?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    The special meeting is scheduled to be held at 10:00&#160;a.m.
    local time, on October&#160;13, 2010, at the Fairmont Miramar,
    101 Wilshire Boulevard, Santa Monica, California.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Who is entitled to vote at the special meeting?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    The Abraxis board of directors has fixed September 10, 2010 as
    the record date for the special meeting. If you were an Abraxis
    stockholder as of the close of business on the record date, you
    are entitled to vote your Abraxis shares at the special meeting.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>How many votes do I have?</B></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    You are entitled to one vote at the special meeting for each
    share of Abraxis common stock that you owned as of the record
    date. As of the close of business on the record date, there were
    40,507,552 outstanding shares of Abraxis common stock. As of
    that date, the principal stockholders owned approximately 81.9%
    of the outstanding shares of Abraxis common stock.</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>What constitutes a quorum?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Stockholders who hold at least a majority of the outstanding
    shares of Abraxis common stock as of the close of business on
    the record date must be present, either in person or represented
    by proxy, in order to constitute a quorum to conduct business at
    the special meeting.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    iv
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>What is the difference between holding shares as a
    stockholder of record or in &#147;street name&#148;?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    If your shares are registered directly in your name with
    Abraxis&#146; transfer agent, American Stock
    Transfer&#160;&#038; Trust&#160;Company, you are considered,
    with respect to those shares, the &#147;stockholder of
    record.&#148; If you are a stockholder of record, this proxy
    statement/prospectus and the enclosed proxy card have been sent
    directly to you by Abraxis.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    If your shares are held in a stock brokerage account or by a
    bank or other nominee, you are considered the beneficial owner
    of shares held in &#147;street name.&#148; This proxy
    statement/prospectus has been forwarded to you by your broker,
    bank or other nominee who is considered, with respect to those
    shares, the stockholder of record. As the beneficial owner of
    shares held in street name, you have the right to direct your
    broker, bank or other nominee how to vote your shares by using
    the voting instruction card provided by your broker, bank or
    other nominee with this proxy statement/prospectus. If you do
    not provide instructions on how to vote your shares to your
    broker, bank or other nominee, your shares will not be voted at
    the special meeting. This will have the same effect as a vote
    &#147;AGAINST&#148; the merger agreement.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>How do I vote my shares at the special meeting?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    If you are entitled to vote at the special meeting and you hold
    your shares in your own name, you can submit a proxy or vote in
    person by completing a ballot at the special meeting. However,
    in order to ensure your vote is counted if you are not able to
    attend the special meeting, Abraxis encourages you to submit a
    proxy before the special meeting, even if you plan to attend the
    special meeting. If you are a stockholder of record, you may
    submit a proxy for your shares by completing, signing and dating
    the enclosed proxy card and mailing it in the pre-paid envelope
    included with these proxy materials. If your shares are held by
    a broker, bank or other nominee, you may direct your broker,
    bank or other nominee to submit a proxy card by following the
    instructions that the broker, bank or other nominee provides to
    you with these materials.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>If my shares are held in &#147;street name&#148; by my
    broker, will my broker automatically vote my shares for me?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    No.&#160;If your shares are held in an account at a broker, bank
    or other nominee, you must instruct the broker, bank or other
    nominee on how to vote your shares by following the instructions
    that the broker, bank or other nominee provides to you with
    these materials.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Brokers do not have discretionary authority to vote on the
    proposal to adopt the merger agreement. The broker may still
    register your shares as being present at the special meeting for
    purposes of determining a quorum but without your specific
    authorization, your shares will not be voted in favor of the
    adoption of the merger agreement or on any other matters over
    which brokers lack discretionary authority. This is called a
    broker non-vote. A broker non-vote will have the same effect as
    a vote &#147;AGAINST&#148; the adoption of the merger agreement.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    If you hold shares through a broker, bank or other nominee and
    wish to vote your shares in person at the special meeting, you
    must obtain a proxy from your broker, bank or other nominee and
    present it to the inspector of elections with your ballot when
    you vote at the special meeting.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>How will my proxy be voted?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    If you vote by completing, signing, dating and mailing your
    proxy card or voting instruction card, your shares will be voted
    in accordance with your instructions. If you are a stockholder
    of record and you sign, date and return your proxy card but do
    not indicate how you want to vote or do not indicate that you
    wish to abstain, your shares will be voted in favor of the
    adoption of the merger agreement.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>As an Abraxis stockholder, what risks should I consider in
    deciding whether to vote in favor of the merger?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    You should carefully review the section of this proxy
    statement/prospectus entitled &#147;Risk Factors,&#148; which
    sets forth and incorporates by reference certain risks and
    uncertainties related to the merger and the CVRs, certain risks
    and uncertainties to which Celgene will be subject following the
    completion of the merger, and certain risks and uncertainties to
    which each of Abraxis and Celgene, as an independent company, is
    subject.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    v
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Can I attend the special meeting?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    All Abraxis stockholders as of the close of business on the
    record date may attend the special meeting by showing photo
    identification and signing in at the special meeting. If you are
    a stockholder of record (i.e., your shares are held in your
    name), you must list your name exactly as it appears on your
    stock ownership records from American Stock Transfer&#160;&#038;
    Trust&#160;Company. If you hold shares through a broker, bank or
    other nominee, you must also provide a copy of your latest bank
    or broker statement showing your ownership as of the close of
    business on the record date.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Can I change my vote after I have submitted a proxy or voting
    instruction card?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Yes. If you are a stockholder of record you can change your vote
    at any time before your proxy is voted at the special meeting.
    You can do this in one of three ways:</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;you can send a signed notice of revocation to the
    Corporate Secretary of Abraxis;</DIV>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;you can submit a revised proxy bearing a later date;
    or</DIV>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;you can attend the special meeting and vote in
    person, which will automatically cancel any proxy previously
    given, or you may revoke your proxy in person, but your
    attendance alone will not revoke any proxy that you have
    previously given.</DIV>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    If you choose either of the first two methods, you must submit
    your notice of revocation or your new proxy no later than the
    beginning of the special meeting. If you are a beneficial owner
    of shares held in street name, you may submit new voting
    instructions by contacting your broker, bank or other nominee.
    You may also vote in person at the special meeting if you obtain
    a proxy from your broker, bank or other nominee and present it
    to the inspectors of election with your ballot when you vote at
    the special meeting.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>What are the CVRs?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    The CVRs are contingent value rights to be issued in the merger
    by Celgene. Each CVR represents the right to receive a pro rata
    portion of certain cash payments required to be paid by Celgene.
    Celgene is obligated to make these cash payments:</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;if certain U.S. regulatory milestones with respect
    to
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    are achieved; and/or</DIV>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;if aggregate annual net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and those pipeline products described in the definition of
    &#147;Products&#148; contained in the CVR agreement, which we
    refer to as the Abraxis pipeline products, exceed
    $1&#160;billion.</DIV>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    See &#147;Description of the CVRs.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Will the merger consideration I receive in the merger
    increase if the results of operations of Abraxis improve or if
    the market price of Abraxis common stock increases?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    No.&#160;The merger consideration payable for each share of
    Abraxis common stock at closing is fixed at (1)&#160;$58.00 in
    cash, without interest, (2)&#160;0.2617 of a share of common
    stock of Celgene and (3)&#160;one CVR, and the payment received
    at closing will not change regardless of the results of
    operations of Abraxis or the price of publicly traded common
    stock of Abraxis.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>What happens if the merger is not completed?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    If the merger agreement is not adopted by Abraxis stockholders
    or if the merger is not completed for any other reason, you will
    not receive any payment for your shares of Abraxis common stock
    in connection with the merger. Instead, Abraxis will remain an
    independent public company and its common stock will continue to
    be listed and traded on The NASDAQ Global Select Market. If the
    merger agreement is terminated under specified circumstances,
    Abraxis may be required to pay Celgene a fee of
    $145&#160;million. See &#147;The Merger Agreement&#160;&#151;
    Termination Fees and Expenses.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>When is the merger expected to be completed?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Abraxis and Celgene are working hard to complete the merger as
    quickly as practicable. A number of conditions must be satisfied
    before we can complete the merger, including the approval of the
    adoption of the merger </TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    vi
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    agreement by Abraxis stockholders. We anticipate that the merger
    will close within two business days following the date of the
    special meeting, if all conditions to the merger (as described
    under &#147;Merger Agreement&#160;&#151; Conditions to the
    Merger&#148;) are fulfilled or waived on or before the closing
    date. However, we cannot guarantee the exact timing of the
    completion of the merger or that the merger will be completed.
    See &#147;Merger Agreement&#160;&#151; Conditions to the
    Merger.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Am I entitled to appraisal rights?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Yes. Stockholders who do not vote &#147;FOR&#148; the adoption
    of the merger agreement and who hold their shares through the
    completion of the merger will be entitled to seek appraisal
    rights under Delaware law in connection with the merger so long
    as they take all the steps required to perfect their rights
    under Delaware law. See &#147;Rights of Stockholders to Seek
    Appraisal.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>What are the material U.S. federal income tax consequences to
    the Abraxis stockholders of the merger?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    The receipt by a U.S. holder of cash, Celgene common stock and
    CVRs in exchange for shares of Abraxis common stock pursuant to
    the merger will be a taxable transaction for U.S. federal income
    tax purposes (and may also be a taxable transaction under
    applicable state, local and foreign income or other tax laws).
    For U.S. federal income tax purposes, a U.S. holder of Abraxis
    common stock generally will recognize capital gain or loss at
    the time of the merger equal to the difference, if any, between</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;the sum of (1)&#160;the amount of cash (including
    any cash received in lieu of fractional shares of Celgene common
    stock), (2)&#160;the fair market value of the Celgene common
    stock and (3)&#160;the fair market value of the CVRs received by
    the U.S. holder in exchange for such Abraxis common stock; and</DIV>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;the U.S. holder&#146;s adjusted tax basis in such
    Abraxis common stock.</DIV>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Pursuant to the merger agreement and the CVR agreement, the
    parties to the merger agreement and the CVR agreement have
    agreed or will agree, as applicable, to treat and report any CVR
    payments (except to the extent of any imputed interest) for all
    tax purposes as additional consideration for the sale of Abraxis
    common stock in the merger, except as required by applicable
    law. Because individual circumstances may differ, we strongly
    recommend that you consult your own tax advisors to determine
    the specific tax consequences to you of the merger. See
    &#147;Certain Material U.S. Federal Income Tax
    Consequences.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Should I send my Abraxis common stock certificates now?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    No.&#160;After the completion of the merger, you will be sent a
    letter of transmittal and detailed instructions for exchanging
    your Abraxis common stock certificates for the merger
    consideration.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Where can I find more information about Abraxis and
    Celgene?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    Abraxis and Celgene file periodic reports and other information
    with the SEC. You may read and copy this information at the
    SEC&#146;s public reference facilities. Please call the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for information about these facilities. This information is also
    available on the website maintained by the SEC, at www.sec.gov,
    and on the appropriate company&#146;s website, at
    www.abraxisbio.com or www.celgene.com. For a more detailed
    description of the information available, please see &#147;Where
    You Can Find More Information.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <B>Q: </B></TD>
    <TD></TD>
    <TD valign="bottom">
    <B>Who can help answer my questions?</B></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    A: </TD>
    <TD></TD>
    <TD valign="bottom">
    If you have additional questions about the merger after reading
    this proxy statement/prospectus, or require assistance or need
    additional copies of this proxy statement/prospectus, please
    contact:</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Abraxis BioScience, Inc.<BR>
    Attention: Investor Relations<BR>
    11755 Wilshire Boulevard, Suite&#160;2000<BR>
    Los Angeles, California 90025</TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Telephone Number:
    <FONT style="white-space: nowrap">(310)&#160;883-1300</FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    vii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>The following summary highlights only selected information,
    and is qualified in its entirety by other information contained
    elsewhere in this proxy statement/prospectus and may not contain
    all the information that may be important to you. Accordingly,
    you are encouraged to read this proxy statement/prospectus
    carefully and in its entirety, including its annexes and the
    documents incorporated by reference in this proxy
    statement/prospectus. See &#147;Where You Can Find More
    Information.&#148;</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Parties
    to the Merger Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Celgene
    Corporation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>86 Morris Avenue<BR>
    Summit, New Jersey 07901<BR>
    Telephone:
    <FONT style="white-space: nowrap">(908)&#160;673-9000</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation, a corporation organized under the laws of
    Delaware, which we refer to as Celgene, is a global integrated
    biopharmaceutical company primarily engaged in the discovery,
    development and commercialization of innovative therapies
    designed to treat cancer and immune-inflammatory related
    diseases. Celgene is dedicated to innovative research and
    development which is designed to bring new therapies to market.
    Celgene is also involved in research in several scientific areas
    that may deliver proprietary next-generation therapies,
    targeting areas such as intracellular signaling pathways in
    cancer and immune cells, immunomodulation in cancer and
    autoimmunity and placental cell, including stem and progenitor
    cell, research. The drug and cell therapies Celgene develops are
    designed to treat life-threatening diseases or chronic
    debilitating conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene common stock is listed on The NASDAQ Global Select
    Market under the symbol &#147;CELG.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Additional information about Celgene is included in the
    documents incorporated by reference into this proxy
    statement/prospectus. See &#147;Where You Can Find More
    Information.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Abraxis
    BioScience, Inc.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>11755 Wilshire Boulevard, Suite&#160;2000<BR>
    Los Angeles, California 90025<BR>
    Telephone:
    <FONT style="white-space: nowrap">(310)&#160;883-1300</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc., a corporation organized under the laws
    of Delaware, which we refer to as Abraxis, is a fully integrated
    global biotechnology company dedicated to the discovery,
    development and delivery of next-generation therapeutics and
    core technologies that offer patients safer and more effective
    treatments for cancer and other critical illnesses.
    Abraxis&#146; product portfolio includes the chemotherapeutic
    compound
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    which is based on Abraxis&#146; proprietary tumor targeting
    technology known as the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    platform. The first product approved by the U.S.&#160;Food and
    Drug Administration, which we refer to as the FDA, to use this
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    platform,
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    was launched in 2005 for the treatment of metastatic breast
    cancer and is now approved in 41&#160;countries. Abraxis
    continues to expand the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    platform through a robust clinical program and deep product
    pipeline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis common stock is listed on The NASDAQ Global Select
    Market under the symbol &#147;ABII.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Additional information about Abraxis is included in the
    documents incorporated by reference into this proxy
    statement/prospectus. See &#147;Where You Can Find More
    Information.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Artistry
    Acquisition Corp.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>86 Morris Avenue<BR>
    Summit, New Jersey 07901<BR>
    Telephone:
    <FONT style="white-space: nowrap">(908)&#160;673-9000</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Artistry Acquisition Corp., a corporation organized under the
    laws of Delaware, which we refer to as merger sub, was formed
    solely for the purpose of facilitating the merger. Merger sub
    has not carried on any activities or operations to date, except
    for those activities incidental to its formation and undertaken
    in connection with the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    transactions contemplated by the merger agreement. By operation
    of the merger, merger sub will be merged with and into Abraxis,
    merger sub&#146;s separate existence will cease and Abraxis will
    become a direct or indirect wholly-owned subsidiary of Celgene.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Merger</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the merger agreement, merger sub will merge with and into
    Abraxis, and Abraxis will be the surviving corporation in the
    merger. As a result of the merger, Abraxis will become a direct
    or indirect wholly-owned subsidiary of Celgene. Common stock of
    Celgene will continue to be listed on the NASDAQ Global Select
    Market under the symbol &#147;CELG.&#148; We anticipate that the
    merger will close within two business days following the date of
    the special meeting, if all conditions to the merger (as
    described under &#147;Merger Agreement&#160;&#151; Conditions to
    the Merger&#148;) are fulfilled or waived on or before the
    closing date. However, we cannot guarantee the exact timing of
    the completion of the merger or that the merger will be
    completed. See &#147;Merger Agreement&#160;&#151; Conditions to
    the Merger.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Merger
    Consideration</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon completion of the merger, each share of Abraxis common
    stock outstanding immediately prior to the completion of the
    merger, other than those held by stockholders who properly
    demand and perfect appraisal rights, shares held in the treasury
    of Abraxis or those owned by Celgene or merger sub or any direct
    or indirect wholly-owned subsidiary of Celgene or Abraxis, will
    be cancelled and converted into the right to receive
    (1)&#160;$58.00 in cash, without interest, (2)&#160;0.2617 of a
    share of common stock of Celgene and (3)&#160;one CVR.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    CVRs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs will be issued under the CVR agreement to be entered
    into by Celgene and a trustee mutually acceptable to Celgene and
    Abraxis prior to the completion of the merger. A copy of the
    form of CVR agreement is attached as Annex&#160;B to this proxy
    statement/prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If required by law, Celgene will use its reasonable best efforts
    to cause the CVR agreement to be qualified under the
    Trust&#160;Indenture Act of 1939, as amended, which we refer to
    as the Trust&#160;Indenture Act. The terms of the CVRs include
    those stated in the CVR agreement and those made part of the CVR
    agreement by reference to the applicable provisions of
    Trust&#160;Indenture Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each holder of a CVR is entitled to receive a pro rata portion,
    based on the number of CVRs then outstanding, of each of the
    following cash payments that Celgene is obligated to pay:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Milestone Payment&#160;#1.</I>&#160;&#160;Celgene agreed to
    pay $250&#160;million upon FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of non-small cell lung cancer, which
    approval permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes a progression free survival claim,
    but only if the foregoing milestone is achieved no later than
    the fifth anniversary of the merger.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Milestone Payment&#160;#2.</I>&#160;&#160;Celgene agreed to
    pay $400&#160;million (if achieved no later than April&#160;1,
    2013)&#160;or $300&#160;million (if achieved after April&#160;1,
    2013 and before the fifth anniversary of the merger) upon FDA
    approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of pancreatic cancer, which approval
    permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes an overall survival claim.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Net Sales Payments.</I>&#160;&#160;For each full one-year
    period ending December&#160;31st&#160;during the term of the CVR
    agreement, which we refer to as a net sales measuring period
    (with the first net sales measuring period beginning
    January&#160;1, 2011 and ending December&#160;31, 2011), Celgene
    agreed to pay:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2.5% of the net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $1&#160;billion
    but are less than or equal to $2&#160;billion for such period,
    plus
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an additional amount equal to 5% of the net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $2&#160;billion
    but are less than or equal to $3&#160;billion for such period,
    plus
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an additional amount equal to 10% of the net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $3&#160;billion
    for such period.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For a description of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products, see &#147;Description of the
    CVRs&#160;&#151; CVR Agreement&#160;&#151; Selected Definitions
    Related to the CVR Agreement.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    No payments will be due under the CVR agreement with respect to
    net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products achieved after
    December&#160;31, 2025, which we refer to as the net sales
    payment termination date, unless net sales for the net sales
    measuring period ending on December&#160;31, 2025 are equal to
    or greater than $1&#160;billion, in which case the net sales
    payment termination date will be extended until the last day of
    the net sales measuring period subsequent to December&#160;31,
    2025 during which net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products are less than $1&#160;billion
    or, if earlier, December&#160;31, 2030.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to use diligent efforts to achieve each of
    the milestones above through the fifth year anniversary of the
    CVR agreement and to obtain regulatory approval for the
    commercial manufacture, marketing and sale of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the treatment of melanoma, ovarian cancer, bladder cancer
    and first-line metastatic breast cancer until the earlier of the
    net sales payment termination date or such time that the data
    generated in an appropriate clinical trial does not support
    further development of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the applicable indication. Celgene has also agreed to use
    diligent efforts, until the net sales payment termination date,
    to sell
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or any of the Abraxis pipeline products for which Celgene has
    obtained regulatory approval for the commercial manufacture,
    marketing and sale thereof. For purposes of the CVR agreement,
    the term &#147;diligent efforts&#148; is defined as, with
    respect to any product, efforts of a person to carry out its
    obligations in a diligent manner using such effort and employing
    such resources normally used by such person in the exercise of
    its reasonable business discretion relating to the research,
    development or commercialization of a product, that is of
    similar market potential at a similar stage in its development
    or product life, taking into account issues of market
    exclusivity (including patent coverage, regulatory and other
    exclusivity), safety and efficacy, product profile, the
    competitiveness of alternate products in the marketplace or
    under development, the launch or sales of a generic or
    biosimilar product, the regulatory structure involved, and the
    profitability of the applicable product (including pricing and
    reimbursement status achieved), and other relevant factors,
    including technical, commercial, legal, scientific,
    <FONT style="white-space: nowrap">and/or</FONT>
    medical factors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene may, at any time on and after the date that 50% of the
    CVRs issued pursuant to the terms of the merger agreement either
    are no longer outstanding,
    <FONT style="white-space: nowrap">and/or</FONT>
    repurchased, acquired, redeemed or retired by Celgene, redeem
    all, but not less than all, of the outstanding CVRs at a cash
    redemption price equal to the average price per CVR paid for all
    CVRs by Celgene in prior transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs are unsecured obligations of Celgene, subordinated to
    an unlimited amount of Celgene&#146;s senior obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There are numerous risks associated with the CVRs, including
    whether Celgene will achieve the milestones and generate
    sufficient net sales to require any payment under the CVR
    agreement, and there is no assurance that the milestones will be
    achieved or the net sales thresholds will be met or exceeded.
    The CVRs are freely transferable (subject to restrictions under
    applicable securities laws) and are being registered with the
    SEC in connection with the merger pursuant to the registration
    statement, of which this proxy statement/prospectus forms a
    part. Celgene has agreed to use its reasonable best efforts to
    cause the CVRs to be approved for listing on The NASDAQ Global
    Select Market and to maintain such listing for as long as CVRs
    remain outstanding. See &#147;Risk Factors&#148; and
    &#147;Description of the CVRs&#148;.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Opinions
    of Financial Advisors to Abraxis</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Merrill
    Lynch, Pierce, Fenner&#160;&#038; Smith
    Incorporated</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;29, 2010, at a meeting of the Abraxis board of
    directors held to evaluate the merger, Merrill Lynch, Pierce,
    Fenner&#160;&#038; Smith Incorporated, which we refer to as BofA
    Merrill Lynch, rendered to the Abraxis board of directors an
    oral opinion, which was confirmed by delivery of a written
    opinion dated June&#160;30, 2010, to the effect
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    that, as of the date of the opinion, and based upon and subject
    to the factors, assumptions and limitations set forth therein,
    the merger consideration to be received in the merger by holders
    of Abraxis common stock (other than Dr.&#160;Soon-Shiong and his
    affiliates) was fair, from a financial point of view, to such
    holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The full text of the written opinion of BofA Merrill Lynch to
    the Abraxis board of directors, dated June&#160;30, 2010, which
    sets forth assumptions made, procedures followed, matters
    considered and limitations on the review undertaken in
    connection with the opinion, is attached as Annex&#160;E to this
    proxy statement/prospectus. BofA Merrill Lynch provided its
    opinion to the Abraxis board of directors for the benefit and
    use of the Abraxis board of directors in connection with and for
    purposes of its evaluation of the merger consideration from a
    financial point of view. BofA Merrill Lynch&#146;s opinion does
    not address any other aspect of the merger and does not
    constitute a recommendation to any stockholder as to how to vote
    or act in connection with the merger or any related matter.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Goldman,
    Sachs&#160;&#038; Co.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;29, 2010, at a meeting of Abraxis board of
    directors held to evaluate the merger, Goldman,
    Sachs&#160;&#038; Co., which we refer to as Goldman Sachs,
    rendered to the board of directors of Abraxis an oral opinion,
    which was confirmed by delivery of a written opinion dated
    June&#160;30, 2010, to the effect that, as of the date of the
    opinion, and based upon and subject to the factors, assumptions
    and limitations set forth therein, the merger consideration to
    be paid to the holders of shares of Abraxis common stock
    pursuant to the merger agreement was fair from a financial point
    of view to such holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The full text of the written opinion of Goldman Sachs, dated
    June&#160;30, 2010, which sets forth assumptions made,
    procedures followed, matters considered and limitations on the
    review undertaken in connection with the opinion, is attached as
    Annex&#160;F to this proxy statement/prospectus. Goldman Sachs
    provided its opinion for the information and assistance of the
    Abraxis board of directors in connection with its consideration
    of the merger. The Goldman Sachs opinion is not a recommendation
    as to how any holder of Abraxis common stock should vote with
    respect to the merger or any other matter.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Lazard
    Fr&#232;res&#160;&#038; Co. LLC</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Lazard Fr&#232;res&#160;&#038; Co. LLC, which we refer to as
    Lazard, rendered its oral opinion to the Abraxis board of
    directors that, as of June&#160;29, 2010, and based upon and
    subject to the factors, assumptions and limitations set forth
    therein, the merger consideration to be paid to holders of
    Abraxis common stock (other than Dr.&#160;Soon-Shiong, any of
    his affiliates, Celgene and merger sub) in the merger was fair
    from a financial point of view to such holders. Lazard
    subsequently confirmed its earlier opinion by delivery of a
    written opinion dated June&#160;30, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The full text of the written opinion of Lazard, dated
    June&#160;30, 2010, which sets forth assumptions made,
    procedures followed, matters considered and limitations on the
    review undertaken in connection with the opinion, is attached as
    Annex&#160;G to this proxy statement/prospectus. Lazard provided
    its opinion for the benefit of the Abraxis board of directors in
    connection with its evaluation of the merger. The Lazard opinion
    is not a recommendation to any stockholder as to how such
    stockholder should vote or act with respect to the merger or any
    matter relating thereto.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Interests
    of Directors and Executive Officers of Abraxis in the
    Merger</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    When reading this proxy statement/prospectus, you should be
    aware that the executive officers and directors of Abraxis may
    have interests in the merger that may be different from, or in
    addition to, the interests of other Abraxis stockholders
    generally. A description of these interests is set forth below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each executive officer and director of Abraxis holds options to
    purchase common stock
    <FONT style="white-space: nowrap">and/or</FONT>
    restricted stock units, which we refer to as RSUs, of Abraxis,
    which, whether or not vested, will immediately vest and be
    cancelled upon the completion of the merger in exchange for a
    cash payment and a CVR as more fully described below. See
    &#147;The Merger Agreement&#160;&#151; Treatment of Abraxis
    Stock Options and Other Equity Awards.&#148; Assuming the merger
    was completed on June&#160;30, 2010, and based upon certain
    assumptions, the total amount that the executive officers and
    directors of Abraxis would have received in respect of their
    vested and unvested equity awards would have been approximately
    $38.5&#160;million and 444,331 CVRs.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under a retention agreement entered into by Abraxis with Bruce
    Wendel, Vice Chairman and Chief Executive Officer, in the event
    of a termination by Abraxis without &#147;cause&#148; or by
    Mr.&#160;Wendel for &#147;good reason&#148; within eighteen
    months after the completion of the merger, Mr.&#160;Wendel will
    be entitled to receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    severance pay equal to two times the sum of his then-current
    base salary plus the amount of his most recently established
    target bonus;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of COBRA premiums for up to eighteen
    months;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    life insurance coverage for two years.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under an offer letter entered into between Abraxis and Mitchell
    Fogelman, Senior Vice President of Finance and Principal
    Financial Officer, Mr.&#160;Fogelman will be entitled to receive
    severance pay equal to six months of his current base salary if
    he is terminated without &#147;cause&#148; prior to
    October&#160;19, 2010, regardless of whether or not the merger
    occurs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Assuming the merger was completed on June&#160;30, 2010 and
    Messrs.&#160;Wendel&#146;s and Fogelman&#146;s employment with
    Abraxis was terminated immediately after completion of the
    merger without &#147;cause&#148; or for &#147;good reason,&#148;
    the total aggregate value of these payments to, and benefits
    for, these two executive officers would have been approximately
    $2.0&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, under agreements with Abraxis, each of
    Dr.&#160;Soon-Shiong and Mr.&#160;Wendel is entitled to a
    <FONT style="white-space: nowrap">gross-up</FONT>
    payment, if necessary, so that the net amount of his total
    payments contingent on the merger received on an after-tax basis
    would equal the amount he would have received in the absence of
    the imposition of golden parachute excise taxes imposed by the
    Internal Revenue Code of 1986, as amended, which we refer to as
    the Code. Based upon the assumptions described herein, the total
    maximum estimated amount that would be due in respect of such a
    <FONT style="white-space: nowrap">gross-up</FONT>
    payment to these executive officers would be approximately
    $17.9&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Abraxis board of directors was aware of these interests and
    considered them, among other factors, in unanimously determining
    that the transactions contemplated by the merger agreement,
    including the merger, are advisable and fair to, and in the best
    interest of, Abraxis and its stockholders, adopting the merger
    agreement and declaring advisable the merger.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Treatment
    of Abraxis Stock Options and Other Equity Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    Options</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At least five business days prior to the completion of the
    merger, each holder of an outstanding option to purchase Abraxis
    common stock that was granted under any stock option or equity
    incentive plan of Abraxis, which we refer to as a stock option,
    and that has an exercise price greater than the &#147;per share
    amount&#148; (which we define below) will, whether such stock
    option is vested or unvested, be provided with written notice
    that such holder has the right, until the business day preceding
    the completion of the merger, which we refer to as the exercise
    period, to exercise such stock option by paying Abraxis a cash
    amount equal to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise price of the stock option, less
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the per share amount.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each such stock option that is exercised during the exercise
    period will be settled in exchange for one CVR. Any such stock
    option that is not exercised during the exercise period will be
    cancelled upon the completion of the merger for no consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each stock option that remains outstanding immediately prior to
    the completion of the merger and that has an exercise price that
    is equal to or less than the per share amount will be cancelled
    in exchange for the right to receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount in cash, without interest, equal to the excess, if
    any, of the per share amount over the exercise price of such
    stock option,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The &#147;per share amount&#148; means the sum of $58.00 and the
    amount obtained by multiplying (1)&#160;the exchange ratio of
    0.2617 by (2)&#160;an amount equal to the average of the closing
    sale prices for Celgene common stock on The NASDAQ Global Select
    Market, as reported in The Wall Street Journal, for each of the
    ten consecutive trading days ending with the seventh complete
    trading day prior to the completion of the merger, with such
    amount rounded up to the nearest cent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    Appreciation Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At least five business days prior to the completion of the
    merger, each holder of an outstanding stock appreciation right
    that was granted under any stock option or equity incentive plan
    of Abraxis, which we refer to as a SAR, and that has a base
    appreciation amount greater than the per share amount will,
    whether such SAR is vested or unvested, be provided with written
    notice that such holder has the right to exercise such SAR
    during the exercise period by paying to Abraxis a cash amount
    equal to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the base appreciation amount of the SAR, less
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the per share amount.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each such SAR that is exercised during the exercise period will
    be settled in exchange for one CVR. Any SAR that is not
    exercised during the exercise period will be cancelled upon the
    completion of the merger for no consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each SAR that remains outstanding immediately prior to the
    completion of the merger and that has a base appreciation amount
    equal to or less than the per share amount will be cancelled
    upon the completion of the merger in exchange for the right to
    receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount in cash, without interest, equal to the excess, if
    any, of the per share amount over the base appreciation amount
    of such SAR,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">RSUs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each RSU granted by Abraxis under any stock option or equity
    incentive plan of Abraxis and which is outstanding immediately
    prior to the completion of the merger will vest upon the
    completion of the merger and will be canceled and converted into
    the right to receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cash, without interest, equal to the per share amount,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Ownership
    of Celgene After the Merger</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based on the number of shares of Abraxis common stock
    outstanding as of September&#160;10, 2010, Celgene expects to
    issue approximately 10.6&#160;million shares of its common stock
    to Abraxis stockholders pursuant to the merger. The actual
    number of shares of Celgene common stock to be issued pursuant
    to the merger will be determined at the completion of the merger
    based on the conversion ratio and the number of shares of
    Abraxis common stock outstanding at such time. Immediately after
    completion of the merger, it is expected that former Abraxis
    stockholders will own approximately 2.1% of the 501,777,751 then
    outstanding shares of Celgene common stock, based on the number
    of shares of Abraxis and Celgene common stock outstanding, on a
    fully diluted basis, as of September&#160;8, 2010.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Key Terms
    of the Merger Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Conditions
    to the Merger</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Before the merger can be completed, a number of conditions must
    be satisfied or waived (to the extent permitted under applicable
    law and the terms of the merger agreement). For a complete
    listing of, and additional information on the conditions to the
    merger, see &#147;The Merger Agreement &#151;&#160;Conditions to
    the Merger.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Restrictions
    on Solicitation of Third Party Acquisition
    Proposals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the merger agreement Abraxis agreed that neither Abraxis nor
    its subsidiaries will, and agreed to use its reasonably best
    efforts to cause its representatives not to: (1)&#160;solicit,
    initiate, or knowingly encourage the making, submission or
    announcement of any third party proposal which would reasonably
    be expected to lead to a transaction involving the acquisition
    of 15% or more of the assets, revenues or voting securities of
    Abraxis, which we refer to as an acquisition proposal,
    (2)&#160;enter into, participate, continue or otherwise engage
    in discussions or negotiations with, or provide any non-public
    information to any third party with respect to any inquiries
    regarding, or the making, submission or announcement of, an
    acquisition proposal, (3)&#160;enter into or approve any letter
    of intent, agreement in principle, option agreement, share
    purchase agreement, acquisition agreement or similar agreement
    for an acquisition proposal, or (4)&#160;subject to certain
    exceptions, terminate, waive, amend or modify any provision of,
    or grant permission under, any standstill, confidentiality
    agreement or similar contract to which Abraxis or any of its
    subsidiaries is a party (we refer to the restrictions described
    in clauses&#160;(1) through (4)&#160;together as the
    &#147;no-shop&#148; restrictions).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    However, before the special meeting, Abraxis may, and may permit
    its representatives to, subject to the terms and conditions set
    forth in the merger agreement, provide information to and engage
    in discussions with a third party that makes an acquisition
    proposal that was not initiated or solicited in violation of the
    &#147;no-shop&#148; restrictions, and that the Abraxis board of
    directors determines constitutes or is reasonably likely to lead
    to a superior proposal (as defined in the merger agreement). The
    merger agreement also permits Abraxis to terminate the merger
    agreement to enter into a definitive agreement for a superior
    proposal with a third party if, among other things, Abraxis has
    complied in all material respects with the &#147;no-shop&#148;
    restrictions, has provided Celgene with five business days to
    modify the merger agreement in a manner that would cause the
    superior proposal to no longer be superior and simultaneously
    with such termination pays to Celgene a termination fee of
    $145&#160;million.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Termination
    of the Merger Agreement</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger agreement specifies limited circumstances under which
    the merger agreement may be terminated by the parties as well as
    termination fees to be paid by Abraxis in such event. Either
    Abraxis or Celgene may terminate the merger agreement if the
    merger has not been completed by the termination date of
    March&#160;31, 2011 (however, the right to terminate the merger
    agreement is not available to any party whose failure to fulfill
    any obligation is the cause of, or results in, the failure of
    the closing to occur on or before the termination date).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis and Celgene may terminate the merger agreement by mutual
    written consent at any time before the completion of the merger
    (whether before or after Abraxis stockholders have adopted the
    merger agreement). In addition, either Abraxis or Celgene may
    terminate the merger agreement if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any permanent injunction or other order issued by any
    governmental entity in the United States, the European Union,
    Canada or Switzerland is in effect preventing or prohibiting the
    completion of the merger has become final and
    non-appealable;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis stockholders do not vote to adopt the merger agreement
    at the special meeting (including any postponement or
    adjournment of the special meeting).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene may terminate the merger agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if Abraxis breaches or fails to perform any of its
    representations, warranties, covenants or obligations contained
    in the merger agreement, which breach or failure to perform
    results in the conditions described under &#147;The Merger
    Agreement&#160;&#151; Conditions to the Merger&#148; relating to
    the accuracy of Abraxis&#146; representations and warranties or
    the performance of Abraxis&#146; obligations and covenants in
    the merger agreement not being able to be satisfied by the
    termination date;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if Abraxis breaches or fails to perform in any material respect
    its obligations with respect to the &#147;no shop&#148;
    restrictions;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the special meeting, if (1)&#160;the Abraxis board of
    directors has publicly withdrawn its approval or recommendation
    of the merger agreement or the merger or has publicly
    recommended to Abraxis stockholders any acquisition proposal or
    (2)&#160;a tender offer or exchange offer has been commenced
    that, if
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    successful, would result in any person or group becoming the
    beneficial owner of 15% or more of Abraxis common stock, and the
    Abraxis board of directors fails to recommend that Abraxis
    stockholders not tender their shares in connection with such
    tender or exchange offer within ten days of the commencement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See &#147;The Merger Agreement&#160;&#151; Termination.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis may terminate the merger agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if Celgene or merger sub breaches or fails to perform any of its
    representations, warranties, covenants or obligations contained
    in the merger agreement, which breach or failure to perform
    results in the conditions described under &#147;The Merger
    Agreement&#160;&#151; Conditions to the Merger&#148; relating to
    the accuracy of Celgene&#146;s or merger sub&#146;s
    representations and warranties or the performance of
    Celgene&#146;s or merger sub&#146;s obligations and covenants in
    the merger agreement not being able to be satisfied by the
    termination date;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the special meeting, in order to concurrently enter
    into a definitive agreement with respect to any superior
    proposal with a third party if, among other things Abraxis has
    complied in all material respects with the &#147;no-shop&#148;
    restrictions of the merger agreement and concurrently pays a
    termination fee of $145&#160;million to Celgene.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See &#147;The Merger Agreement&#160;&#151; Termination in
    Connection with a Superior Proposal.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Termination
    Fee Payable by Abraxis</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis has agreed to pay to Celgene a termination fee of
    $145&#160;million if the merger agreement is terminated under
    any of the following circumstances:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis terminates the merger agreement, prior to the special
    meeting, in order to concurrently with such termination enter
    into a definitive agreement with respect to a superior proposal
    and has complied in all material respects with the &#147;no
    shop&#148; restrictions of the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene terminates the merger agreement if Abraxis breaches or
    fails to perform in any material respect its obligations under
    the &#147;no shop&#148; restrictions of the merger agreement, or
    if prior to the special meeting, (1)&#160;the Abraxis board of
    directors has publicly withdrawn its approval or recommendation
    of the merger agreement or the merger or has publicly
    recommended to the stockholders of Abraxis any acquisition
    proposal, or (2)&#160;a tender offer or exchange offer has been
    commenced that, if successful, would result in any person or
    group becoming the beneficial owner of 15% or more of the
    outstanding stock of Abraxis, and the Abraxis board of directors
    fails to recommend that Abraxis stockholders not tender their
    shares in connection with such tender or exchange offer within
    ten business days of the commencement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;Celgene terminates the merger agreement if Abraxis
    breaches or fails to perform any of its representations,
    warranties, covenants or obligations contained in the merger
    agreement, which breach or failure to perform results in the
    conditions described in &#147;The Merger Agreement&#160;&#151;
    Conditions to the Merger&#148; relating to the accuracy of
    Abraxis&#146; representations and warranties or the performance
    of Abraxis&#146; obligations or covenants not being able to be
    satisfied by the termination date, (2)&#160;prior to the date
    upon which such breach or failure to perform occurs but after
    the date of the merger agreement, a bona fide acquisition
    proposal (for the purposes of this definition of acquisition
    proposal, the references to &#147;15%&#148; will be deemed
    references to &#147;60%&#148;) for Abraxis has been publicly
    announced and (3)&#160;within 12&#160;months after such
    termination either Abraxis has entered into a definitive
    agreement relating to an acquisition proposal or a transaction
    contemplated by an acquisition proposal for Abraxis has been
    completed;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;Celgene or Abraxis terminates the merger agreement if
    the requisite stockholder approval is not obtained at the
    special meeting (including any postponement or adjournment of
    the special meeting), (2)&#160;prior to the date of the special
    meeting but after the date of the merger agreement, a bona fide
    acquisition proposal (for the purposes of this definition of
    acquisition proposal, the references to &#147;15%&#148; will be
    deemed references to &#147;60%&#148;) for Abraxis has been
    publicly announced and (3)&#160;within 12&#160;months after such
    termination either Abraxis has entered into a definitive
    agreement relating to an acquisition proposal or a transaction
    contemplated by an acquisition proposal for Abraxis has been
    completed;&#160;or
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;Celgene or Abraxis terminates the merger agreement if
    the merger has not been completed on or before the termination
    date of March&#160;31, 2011, (2)&#160;prior to such termination,
    the waiting period (and any extension thereof) applicable to the
    merger under the Hart-Scott-Rodino Antitrust Improvements Act of
    1976, which we refer to as the HSR Act, has expired or been
    terminated, (3)&#160;prior to such termination but after the
    date of the merger agreement, a bona fide acquisition proposal
    (for the purposes of this definition of acquisition proposal,
    the references to &#147;15%&#148; will be deemed references to
    &#147;60%&#148;) for Abraxis has been publicly announced and
    (4)&#160;within 12&#160;months after such termination either
    Abraxis has entered into a definitive agreement relating to an
    acquisition proposal or a transaction contemplated by an
    acquisition proposal for Abraxis has been completed.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For additional information on termination fees, see &#147;The
    Merger Agreement&#160;&#151; Termination Fees and Expenses.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Agreement</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010, the principal stockholders, who together
    own approximately 81.9% of the outstanding shares of Abraxis
    common stock as of September&#160;10, 2010, the record date
    established for the special meeting, entered into a voting
    agreement with Celgene and merger sub, under which they agreed
    to vote all of their shares of Abraxis common stock in favor of
    the approval and adoption of the merger agreement and the
    transactions contemplated by the merger agreement and against,
    among other things, any business combination or extraordinary
    corporate transaction involving Abraxis or any or its
    subsidiaries, other than the merger or any business combination
    or transaction with Celgene or any of its affiliates. Each of
    the principal stockholders also granted an irrevocable proxy to
    Celgene to vote or execute consents with respect to such
    principal stockholders&#146; shares of Abraxis common stock in
    accordance with the preceding sentence. Additionally, the
    principal stockholders agreed, among other things, not to
    transfer their shares of Abraxis common stock, subject to
    certain exceptions, or to solicit any acquisition proposal. The
    voting agreement will terminate upon the earliest to occur of:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the completion of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any material amendment to the merger agreement that is adverse
    to the principal stockholders that has not been approved by
    them;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the termination of the merger agreement in accordance with its
    terms.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A copy of the voting agreement is attached to this proxy
    statement/prospectus as Annex&#160;C. See &#147;Voting
    Agreement.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The principal stockholders&#146; vote will be sufficient under
    Delaware law to adopt the merger agreement without the approval
    of any other stockholder of Abraxis.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholders&#146;
    Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010, certain of the principal stockholders,
    including Dr.&#160;Soon-Shiong, entered into a
    stockholders&#146; agreement with Celgene under which they
    agreed, among other things, not to sell, transfer, pledge or
    otherwise dispose of any of the shares of Celgene common stock
    issued to them in the merger, prior to the third anniversary of
    the merger, subject to certain limited exceptions. In addition
    to such limited exceptions, after the second anniversary of the
    merger, these stockholders may, subject to the limitation set
    forth in the following sentence, sell, transfer, pledge or
    otherwise dispose of, in the aggregate, a number of shares of
    Celgene common stock issued to them in the merger equal to 25%
    of the number of shares of Celgene common stock issued to these
    stockholders in the merger. Prior to the fourth anniversary of
    the merger, these stockholders may not, during any calendar
    month, sell, in the aggregate, pursuant to open market
    transactions, shares of Celgene common stock issued to them in
    the merger representing more than 30% of the number of shares of
    Celgene common stock issued to these stockholders in the merger.
    See &#147;The Merger&#160;&#151; Interests of Abraxis Directors
    and Officers in the Merger&#160;&#151; Stockholders&#146;
    Agreement.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Non-Competition,
    Non-Solicitation and Confidentiality Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010, Dr.&#160;Soon-Shiong entered into a
    non-competition, non-solicitation and confidentiality agreement
    with Celgene, which we refer to as the non-competition
    agreement, pursuant to which Dr.&#160;Soon-Shiong will be
    generally prohibited for ten years after completion of the
    merger from, without the prior written consent of Celgene,
    owning, managing, financing, investing in, controlling, engaging
    in, operating or conducting, lending his name to, lending credit
    to, rendering services or advising, devoting material endeavor
    or effort to, or assisting any person or entity to conduct, the
    business of researching, developing, licensing, manufacturing,
    selling, offering for sale, importing, using, marketing,
    distributing, practicing, or otherwise exploiting
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or any other pharmaceutical or diagnostic product developed or
    manufactured using the albumin-bound
    (nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>)

    technology (as defined in the non-competition agreement), which
    we refer to as the business, in the United States and all other
    countries in which Abraxis was engaged in the business at the
    completion of the merger. Additionally, Dr.&#160;Soon-Shiong
    will be generally prohibited for ten years after completion of
    the merger from, without the prior written consent of Celgene:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (i)&#160;soliciting, knowingly encouraging or inducing any
    customer, supplier or licensee with whom Abraxis or its
    subsidiaries were engaged in a contractual relationship, or
    substantive discussions or proposal negotiations, in each case
    as of the completion of the merger, with respect to the business
    to cease doing business with Abraxis, Celgene or any of their
    subsidiaries with respect to the business in the United States
    and all other countries in which Abraxis or its subsidiaries
    were engaged in the business at the completion of the merger; or
    (ii)&#160;otherwise knowingly interfering with Abraxis&#146;,
    Celgene&#146;s or their respective subsidiaries&#146;
    relationship with any customer, supplier or licensee of the
    business,
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    soliciting, encouraging or inducing any employee, consultant or
    independent contractor that was engaged by Abraxis or its
    subsidiaries as of the completion of the merger to terminate or
    breach an employment, contractual or other relationship with
    Abraxis, Celgene or their respective subsidiaries,&#160;and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    making any public statements that directly or indirectly
    disparage Abraxis, Celgene or any of their respective affiliates,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    in each case subject to certain exceptions. Dr.&#160;Soon-Shiong
    has also agreed not to use or disclose, except as required by
    law or as directed by Abraxis or Celgene, confidential
    information that is owned or held by Abraxis as of the
    completion of the merger. The non-competition agreement will
    become effective as of the completion of the merger and will
    have no force or effect if the merger agreement is terminated
    prior to the completion of the merger or if the merger is
    otherwise not completed.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A copy of the non-competition agreement is attached as
    Annex&#160;D to this proxy statement/prospectus. See &#147;The
    Merger&#160;&#151; Interests of Abraxis Directors and Officers
    in the Merger &#151;&#160;Non-Competition, Non-Solicitation and
    Confidentiality Agreement.&#148;
</DIV>

<DIV style="margin-top: 16pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Special Meeting</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The stockholders of Abraxis will hold a special meeting at the
    Fairmont Miramar, 1010&#160;Wilshire Boulevard, Santa Monica,
    California, on October&#160;13, 2010, at 10:00&#160;a.m. local
    time, unless the special meeting is adjourned or postponed. At
    the special meeting, Abraxis stockholders will be asked to
    consider and act on a proposal to adopt the merger agreement.
    Only stockholders listed on Abraxis&#146; records at the close
    of business on September&#160;10, 2010, the record date for the
    special meeting, are entitled to vote at the special meeting or
    any adjournments or postponements of the special meeting. As of
    the close of business on the record date, there were
    40,507,552&#160;shares of Abraxis common stock outstanding and
    entitled to vote at the special meeting. See &#147;Information
    about the Special Meeting&#148; for more information on how to
    cast your vote at the special meeting.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Provided a quorum of stockholders is present in person or by
    proxy at the special meeting, in order to adopt the merger
    agreement, holders of a majority of the outstanding shares of
    Abraxis common stock must cast a vote in favor of the proposal
    to adopt the merger agreement. Abstentions and broker non-votes
    will have the effect of a vote &#147;AGAINST&#148; the proposal
    to adopt the merger agreement.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of the record date, directors and executive officers of
    Abraxis had the right to vote&#160;33,194,952&#160;shares of
    Abraxis common stock, entitling them to collectively cast
    approximately 81.9% of the votes entitled to be cast at the
    special meeting. This includes 33,186,067&#160;shares of Abraxis
    common stock that the principal stockholders had the right to
    vote. As noted above, the principal stockholders have agreed
    collectively to vote their shares of Abraxis common stock in
    favor of the adoption of the merger agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Except as described above as to shares held by the principal
    stockholders, none of Abraxis&#146; directors or officers has
    entered into any agreement requiring them to vote for or against
    the proposal to adopt the merger agreement.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    No vote of the stockholders of Celgene is required to adopt the
    merger agreement or to effect the transactions contemplated by
    the merger agreement.
</DIV>

<DIV style="margin-top: 16pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulatory
    Approvals</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the provisions of the HSR Act, the merger may not be
    completed until notification and report forms have been filed
    with the U.S.&#160;Federal Trade Commission, which we refer to
    as the FTC, and the Antitrust Division of the
    U.S.&#160;Department of Justice, which we refer to as the
    Antitrust Division, and until the expiration of a 30 calendar
    day waiting period, or the early termination of that waiting
    period, following the parties&#146; filing of their respective
    notification and report forms. If the FTC or the Antitrust
    Division issues a Request for Additional Information and
    Documentary Material prior to the expiration of the waiting
    period, the parties must observe a second 30 calendar day
    waiting period, which would begin to run only after both parties
    have substantially complied with the request for information,
    unless the waiting period is terminated earlier or extended with
    the consent of the parties. On July&#160;14, 2010, Abraxis and
    Celgene filed their respective notification and report forms
    under the HSR Act with the FTC and the Antitrust Division.
    Celgene received confirmation of early termination of the
    initial waiting period under the HSR Act effective as of
    August&#160;3, 2010.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Subject to the terms and conditions of the merger agreement,
    Abraxis and Celgene have agreed to use their reasonable best
    efforts to obtain all regulatory clearances necessary to
    complete, in the most expeditious manner practicable, the
    merger; however, Celgene is not required to sell, divest or
    otherwise dispose of, hold separate, enter into any license or
    similar agreement with respect to, restrict the ownership or
    operation of, or agree to sell, divest or otherwise dispose of,
    hold separate, enter into any license or similar agreement with
    respect to, or restrict the ownership or operation of:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (A)&#160;any assets or businesses of Abraxis or any of its
    subsidiaries or (B)&#160;any assets or businesses of Celgene or
    any of its affiliates or subsidiaries, in the case of either
    clause&#160;(A) or (B), to the extent that the sale,
    divestiture, disposition, or agreement would have a material
    adverse effect on the business, operations, financial condition
    or results of operations of the combined business of Abraxis and
    Celgene after giving effect to the completion of merger;&#160;or
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    to the extent such sale, divestiture, disposition, agreement or
    restriction would have a material adverse effect on the ability
    of Abraxis to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in the United States, the European Union, Canada and Switzerland.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, Abraxis is not required to divest, hold separate or
    otherwise take or commit to take any action that limits its
    freedom of action with respect to, or its ability to retain, any
    of the businesses, services, or assets of Abraxis or any of its
    subsidiaries, unless it is conditioned upon the completion of
    the merger.
</DIV>

<DIV style="margin-top: 16pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Rights of
    Stockholders to Seek Appraisal</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under Delaware law, holders of Abraxis common stock other than
    the principal stockholders will have the right to seek appraisal
    of the fair value of their shares of Abraxis common stock as
    determined by the Delaware Court of Chancery if the merger is
    completed, but only if they comply with all applicable
    requirements of Delaware law. This appraisal amount could be
    more than, the same as or less than the merger consideration.
    Among other requirements, any holder of Abraxis common stock
    intending to exercise appraisal rights must not vote in favor of
    the merger and must submit a written demand for an appraisal to
    Abraxis before the vote on the merger at the special
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    meeting. Your failure to strictly follow the procedures
    specified under Delaware law will result in the loss of your
    appraisal rights. For a summary of the requirements for
    asserting and perfecting your appraisal rights, see &#147;Rights
    of Stockholders to Seek Appraisal.&#148; The provisions of
    Delaware law that address appraisal rights and govern the
    required procedures are attached as Annex&#160;H to this proxy
    statement/prospectus.
</DIV>

<DIV style="margin-top: 16pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Certain
    Material U.S. Federal Income Tax Consequences</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The receipt by a U.S.&#160;holder of cash, Celgene common stock
    and CVRs in exchange for shares of Abraxis common stock pursuant
    to the merger will be a taxable transaction for
    U.S.&#160;federal income tax purposes (and may also be a taxable
    transaction under applicable state, local, and foreign income or
    other tax laws). For U.S.&#160;federal income tax purposes, a
    U.S.&#160;holder of Abraxis common stock generally will
    recognize capital gain or loss at the time of the merger equal
    to the difference, if any, between:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sum of (1)&#160;the amount of cash (including any cash
    received in lieu of fractional shares of Celgene common stock),
    (2)&#160;the fair market value of the Celgene common stock and
    (3)&#160;the fair market value of the CVRs received by the
    U.S.&#160;holder in exchange for such Abraxis common
    stock;&#160;and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the U.S.&#160;holder&#146;s adjusted tax basis in such Abraxis
    common stock.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the merger agreement and the CVR agreement, the
    parties to the merger agreement and the CVR agreement have
    agreed or will agree, as applicable, to treat and report any CVR
    payments (except to the extent of any imputed interest) for all
    tax purposes as additional consideration for the sale of Abraxis
    common stock in the merger, except as required by applicable
    law. <B>Tax matters can be complicated. Abraxis stockholders are
    strongly urged to consult their tax advisors as to the specific
    tax consequences to them of the merger. </B>See &#147;Certain
    Material U.S.&#160;Federal Income Tax Consequences&#148; for a
    more detailed discussion.
</DIV>

<DIV style="margin-top: 16pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Accounting
    Treatment</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In accordance with U.S.&#160;generally accepted accounting
    principles, which we refer to as U.S.&#160;GAAP, Celgene will
    account for the merger using the acquisition method of
    accounting for business combinations. Under this method of
    accounting, Celgene will record the acquisition based on the
    fair value of the merger consideration, which includes the cash
    consideration paid, the market value of shares of Celgene common
    stock issued in connection with the merger (based on the closing
    price of Celgene common stock on the date of the completion of
    the merger) and the CVRs issued in connection with the merger.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene will allocate the purchase price to the identifiable
    assets acquired and liabilities assumed based on their
    respective fair values at the date of the completion of the
    merger. Any excess of the value of consideration paid over the
    aggregate fair value of those net assets will be recorded as
    goodwill. Financial statements of Celgene issued after the
    completion of the merger will reflect such fair values and will
    not be restated retroactively to reflect historical financial
    position or results of operations of Celgene. The results of
    operations of Abraxis will be included in the results of
    operations of Celgene beginning on the date of the completion of
    the merger.
</DIV>

<DIV style="margin-top: 16pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Market
    Price of Abraxis Common Stock</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis common stock is listed on The NASDAQ Global Select
    Market under the symbol &#147;ABII.&#148; The closing sale price
    of Abraxis common stock on The NASDAQ Global Select Market on
    June&#160;29, 2010, the last trading day prior to the
    announcement of the merger, was $61.31. The $58.00 cash
    consideration and $13.93, the value of 0.2617 of a share of
    common stock of Celgene on June&#160;29, 2010, represents a
    premium of approximately 17% over the closing sale price of
    Abraxis common stock on June&#160;29, 2010. On
    September&#160;13, 2010, the last trading day before the date of
    this proxy statement/prospectus, the closing sale price of
    Abraxis common stock on The NASDAQ Global Select Market was
    $74.90 per share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Market
    Price of Celgene Common Stock</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene common stock is listed on The NASDAQ Global Select
    Market under the symbol &#147;CELG.&#148; The closing sale price
    of Celgene common stock on The NASDAQ Global Select Market on
    June&#160;29, 2010, the last trading day prior to the
    announcement of the merger, was $53.24. On September&#160;13,
    2010, the last trading day before the date of this proxy
    statement/prospectus, the closing sale price of Celgene common
    stock on The NASDAQ Global Select Market was $54.64 per share.
    It is a condition to the completion of the merger that the
    shares of Celgene common stock issued in the merger will be
    approved for listing on The NASDAQ Global Select Market.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Litigation
    Related to the Merger</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis, the members of the Abraxis board of directors and
    Celgene are named as defendants in putative class action
    lawsuits brought by Abraxis stockholders challenging the merger
    in Los Angeles County Superior Court. The plaintiffs in such
    actions assert claims for breaches of fiduciary duty arising out
    of the merger and allege that Abraxis&#146; directors engaged in
    self-dealing and obtained for themselves personal benefits and
    have failed or are failing to provide stockholders with material
    information relating to the merger. The plaintiffs also allege
    claims for aiding and abetting breaches of fiduciary duty
    against Abraxis and Celgene. These lawsuits generally seek,
    among other things, to enjoin the defendants from consummating
    the merger until such time as Abraxis:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adopts and implements a procedure or process to obtain the
    highest possible price for stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    discloses all material information to stockholders regarding the
    merger;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    institutes a majority of the minority vote provision.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On September&#160;14, 2010, the parties reached an agreement in
    principle to settle the actions pursuant to a memorandum of
    understanding, which we refer to as the MOU. Without admitting
    the validity of any allegations made in the actions, or any
    liability with respect thereto, the defendants elected to settle
    the actions in order to avoid the cost, disruption and
    distraction of further litigation. Under the MOU, the defendants
    agreed, among other things, to make additional disclosures
    relating to the merger as set forth in this proxy
    statement/prospectus, and to provide the plaintiffs&#146;
    counsel with limited discovery to confirm the fairness and
    adequacy of the settlement. Abraxis, on behalf of itself and for
    the benefit of the other defendants in the actions, also agreed
    to pay the plaintiffs&#146; counsel $600,000 for their fees and
    expenses. The parties agreed to use their best efforts to agree
    upon, execute and present to the court within thirty days a
    formal stipulation of settlement and such other documents as may
    be necessary to obtain approval by the court of the settlement
    and the dismissal with prejudice of the actions. Pending
    execution of such stipulation, the parties agreed to stay all
    proceedings in the actions, except those relating to the
    settlement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In evaluating the CVRs and Celgene common stock, you should
    carefully read this proxy statement/prospectus and especially
    consider the factors discussed in the section entitled
    &#147;Risk Factors&#148; beginning on page&#160;22.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    HISTORICAL CONSOLIDATED AND COMBINED FINANCIAL DATA OF
    ABRAXIS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following selected historical consolidated and combined
    financial data of Abraxis for the years ended December&#160;31,
    2009, 2008 and 2007 and as of December&#160;31, 2009 and 2008,
    have been derived from Abraxis&#146; historical audited
    consolidated and combined financial statements contained in
    Abraxis&#146; Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, which is incorporated
    by reference into this proxy statement/prospectus. The following
    selected historical consolidated and combined financial data for
    the years ended December&#160;31, 2006 and 2005 and as of
    December&#160;31, 2007, 2006 and 2005 have been derived from
    Abraxis&#146; historical audited consolidated and combined
    financial statements not required to be incorporated by
    reference into this proxy statement/prospectus. Historical
    results of operations and financial position are not necessarily
    indications of the results that may be expected in the future
    periods. The following selected historical consolidated
    financial data for Abraxis as of and for the six months ended
    June&#160;30, 2010 and 2009 have been derived from Abraxis&#146;
    unaudited interim consolidated financial statements contained in
    Abraxis&#146; Quarterly Report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarter ended June&#160;30, 2010, which is incorporated
    by reference into this proxy statement/prospectus. In the
    opinion of Abraxis management, the unaudited interim
    consolidated financial statements have been prepared on the same
    basis as the audited consolidated and combined financial
    statements and include all adjustments, consisting of normal
    recurring adjustments, necessary for a fair presentation of the
    financial position and results of operations at these dates and
    for these periods. Results of interim periods are not
    necessarily indicative of the results expected for a full year
    or for future periods. This information is only a summary and
    you should read this selected historical consolidated and
    combined financial data together with Abraxis&#146;
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations,&#148; and the unaudited and
    audited consolidated and combined financial statements and notes
    thereto incorporated by reference into this proxy
    statement/prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom">
    <B>(In thousands, except per share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated and Combined Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Abraxane revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    170,008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    145,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    314,545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    335,631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    324,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    174,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    133,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other Products
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,686
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,892
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,819
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    246,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    157,711
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    345,309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    333,686
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    135,675
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cost of sales
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,740
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,665
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,066
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    133,968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    299,236
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,609
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,334
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    154,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,976
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,424
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,073
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110,273
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    233,324
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119,462
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,239
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Reacquisition costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    158,909
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Litigation costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Acquired in-process research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,447
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Impairment charge
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Amortization of intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,429
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Merger related costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,722
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,883
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    409,130
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    599,481
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    357,363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119,360
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom">
    <B>(In thousands, except per share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,498
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,376
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (113,745
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (293,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (58,127
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (148,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,751
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Equity in net (loss) income of unconsolidated entities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,855
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,360
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,090
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,771
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,958
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,887
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,052
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other income (expense)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (503
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,186
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (190
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,741
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,563
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,427
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,632
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107,348
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (278,709
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49,556
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (150,515
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,184
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    (Benefit) provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,959
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (51
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,580
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,938
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,952
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,964
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (19,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (47,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (104,768
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (276,771
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (41,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (124,551
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,662
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net loss attributable to noncontrolling interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (605
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1,227
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1,652
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net loss attributable to common shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (18,863
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (46,354
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (103,116
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (276,771
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (41,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (124,551
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,662
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic and diluted net loss per common share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.47
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.57
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.91
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.04
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3.11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.32
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Weighted-average common shares outstanding(1):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other data:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash flow provided by (used in) operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (315,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2,893
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    170,870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (22,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Purchases of property plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,918
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,382
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (94,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (40,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (64,431
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,212
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash from consolidation of DSC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,099
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash paid for acquisition
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,754
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,998
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Purchases of investments and marketable securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,431
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24,244
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (150
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Purchases of other equity investments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Investment in notes receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from sale of subsidiary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from sale of marketable securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash flow provided by (used in) financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (589
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (561
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,360
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    752,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (94,398
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,728
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B>Consolidated balance sheet data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    175,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    260,578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    192,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    347,321
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    735,181
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,093
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    55,232
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,060,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,086,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,399,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,502,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    764,783
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    179,080
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    851,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    893,465
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    846,265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    929,472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,197,387
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    459,021
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,644
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    As of the completion of Abraxis&#146; separation from APP
    Pharmaceuticals, Inc. on November&#160;13, 2007, Abraxis had
    40.0&#160;million common shares outstanding. The same number of
    shares is being used for both diluted earnings per share and
    basic earnings per share for all periods prior to the separation
    date. All potentially dilutive employee stock awards were
    excluded from the computation of diluted loss per common share
    for all periods as the effect on net loss per share was
    anti-dilutive. The selected historical financial data reflect
    the consolidated operations of Abraxis and its subsidiaries as
    an independent, publicly-traded company as of and subsequent to
    November&#160;13, 2007 and a combined reporting entity
    comprising the assets and liabilities that constituted the
    proprietary business of the predecessor Abraxis Bioscience for
    periods prior to November&#160;13, 2007. The selected historical
    consolidated and combined financial data for periods prior to
    and including November&#160;13, 2007&#160;may not be indicative
    of Abraxis&#146; future performance and do not necessarily
    reflect what the consolidated and combined results of
    operations, financial position and cash flows would have been
    had Abraxis operated as an independent, publicly-traded company
    during the periods presented.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    HISTORICAL CONSOLIDATED FINANCIAL DATA OF CELGENE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following selected historical consolidated financial data of
    Celgene for the years ended December&#160;31, 2009, 2008 and
    2007 and as of December&#160;31, 2009 and 2008 have been derived
    from Celgene&#146;s historical audited financial statements
    contained in Celgene&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009 incorporated by
    reference into this proxy statement/prospectus. The following
    selected historical consolidated financial data for the years
    ended December&#160;31, 2006 and 2005 and as of
    December&#160;31, 2007, 2006 and 2005 have been derived from
    Celgene&#146;s historical audited consolidated financial
    statements not required to be incorporated by reference into
    this proxy statement/prospectus. Historical results of
    operations and financial position are not necessarily
    indications of the results that may be expected in the future
    periods. The following selected historical consolidated
    financial data for Celgene as of and for the six months ended
    June&#160;30, 2010 and 2009 have been derived from
    Celgene&#146;s unaudited consolidated financial statements
    contained in Celgene&#146;s Quarterly Report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarter ended June&#160;30, 2010, which is incorporated
    by reference into this proxy statement/prospectus. In the
    opinion of the management of Celgene, the unaudited consolidated
    financial statements have been prepared on the same basis as the
    audited consolidated financial statements and include all
    adjustments, consisting of normal recurring adjustments,
    necessary for a fair presentation of the financial position and
    results of operations at these dates and for these periods.
    Results of interim periods are not necessarily indicative of the
    results expected for a full year or for future periods. This
    information is only a summary and you should read this selected
    historical consolidated financial data together with
    Celgene&#146;s &#147;Management&#146;s Discussion and Analysis
    of Financial Condition and Results of Operations&#148; and the
    unaudited and audited consolidated financial statements and
    notes thereto incorporated by reference into this proxy
    statement/prospectus.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Years Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom">
    <B>(In thousands, except per share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Statements of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,643,946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,233,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,689,893
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,254,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,405,820
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    898,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    536,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Costs and operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,205,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    910,992
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,848,367
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,718,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    980,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    724,182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    453,357
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    438,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    322,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    841,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,464,218
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    425,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest and investment income, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84,835
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    109,813
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,352
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity in (gains) losses of affiliated companies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,923
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,437
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,417
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,497
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other (expense) income, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,722
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,350
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,502
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,509
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income (loss) before tax
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400,432
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    975,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,368,825
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    516,969
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    202,895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84,212
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,715
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    198,956
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    164,828
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    290,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    133,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,556
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    389,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    305,717
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    776,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1,533,653
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    226,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    68,981
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    63,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Years Ended December&#160;31,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom">
    <B>(In thousands, except per share data)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss) per common share(1):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.67
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.69
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3.46
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.59
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3.46
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average shares(1):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    459,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    459,304
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    442,620
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    383,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    352,217
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    335,512
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467,759
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467,354
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    442,620
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    431,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407,181
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    390,585
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Amounts have been adjusted for the
    <FONT style="white-space: nowrap">two-for-one</FONT>
    stock split effected in February 2006.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="30%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Balance Sheets Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash, cash equivalents and marketable securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,144,617
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,497,968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,996,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,222,091
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,738,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,982,220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    724,260
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,178,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,749,268
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,389,311
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,445,270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,611,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,735,791
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,258,313
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    399,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    399,984
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    (Accumulated deficit) retained earnings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (242,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,103,276
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (632,246
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,408,993
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    124,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (101,773
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170,754
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stockholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,927,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,862,768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,394,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,491,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,843,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,976,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    635,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<A name='105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL
    DATA</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following selected unaudited pro forma condensed
    consolidated financial data gives effect to the proposed merger
    as if it had occurred on January&#160;1, 2009, for statement of
    operations purposes, and on June&#160;30, 2010, for balance
    sheet purposes. The selected unaudited pro forma condensed
    consolidated financial data presented below is based on, and
    should be read together with, the historical financial
    statements of Celgene and Abraxis that are contained in their
    respective filings with the SEC and incorporated by reference
    into this proxy statement/prospectus and the unaudited pro forma
    condensed consolidated financial statements that appear
    elsewhere in this proxy statement/prospectus. See &#147;Where
    You Can Find More Information&#148; and &#147;Unaudited Pro
    Forma Condensed Consolidated Financial Statements.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The unaudited pro forma condensed consolidated financial data is
    presented for illustrative purposes only and is not necessarily
    indicative of the actual or future financial position or results
    of operations that would have been realized if the proposed
    merger had been completed as of the dates indicated or will be
    realized upon the completion of the proposed merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unaudited Pro Forma Consolidated</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2009</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
    <B>(In thousands, except per share data)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Statement of operations data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,890,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,048,943
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,492,513
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,356,086
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Operating income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    397,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    692,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other income and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    69,354
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    409,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    762,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Income tax provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    55,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    153,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    353,939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    608,293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic earnings per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted earnings per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.74
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Balance sheet data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,383,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,874,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Stockholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,499,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<A name='106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPARATIVE
    PER SHARE MARKET PRICE AND DIVIDEND INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene common stock and Abraxis common stock are each listed
    and traded on The NASDAQ Global Select Market under the symbols
    &#147;CELG&#148; and &#147;ABII,&#148; respectively. The
    following table sets forth, for the respective periods of
    Celgene and Abraxis indicated, the high and low sale prices per
    share of Celgene common stock and Abraxis common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Celgene</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Abraxis</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>High</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Low</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Dividend</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>High</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Low</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Dividend</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Year Ended December&#160;31, 2010</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Third Quarter (through September&#160;8, 2010)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    58.01
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    48.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    76.17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    73.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Second Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49.54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    First Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Year Ended December&#160;31, 2009</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fourth Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49.74
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31.20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Third quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45.27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Second quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48.77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    First quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73.98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Year Ended December&#160;31, 2008</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fourth Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46.28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Third Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    78.95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Second Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.88
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    First Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62.20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;29, 2010, the last trading day prior to the date of
    the public announcement of the execution of the merger
    agreement, the closing sale price per share of Abraxis common
    stock was $61.31 and the closing sale price per share of Celgene
    common stock was $53.24. On September&#160;13, 2010, the most
    recent practicable date prior to the date of this proxy
    statement/prospectus, the last reported sale price per share of
    Abraxis common stock was $74.90 and the last reported sale price
    per share of Celgene common stock was $54.64. The market prices
    of shares of Abraxis common stock and Celgene common stock are
    subject to fluctuation. As a result, Abraxis and Celgene
    stockholders are urged to obtain current market quotations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividend
    Policy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has never declared or paid any cash dividends on its
    common stock. Celgene currently intends to retain any future
    earnings for funding growth and, therefore, does not anticipate
    paying any cash dividends on its common stock in the foreseeable
    future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis has never declared or paid any cash dividends on its
    common stock. Any future payment of cash dividends on Abraxis
    common stock will be at the discretion of the Abraxis board of
    directors and will depend upon Abraxis&#146; results of
    operations, earnings, capital requirements, contractual
    restrictions and other factors deemed relevant by the Abraxis
    board of directors. The merger agreement restricts the ability
    of Abraxis to declare or pay dividends.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<A name='107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPARATIVE
    HISTORICAL AND UNAUDITED PRO FORMA PER SHARE DATA</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth for Celgene common stock and
    Abraxis common stock certain historical and unaudited pro forma
    consolidated and pro forma-equivalent per share financial
    information. The unaudited pro forma consolidated and pro
    forma-equivalent per share information gives effect to the
    proposed merger as if it had occurred on January&#160;1, 2009.
    The information in the table is based on, and should be read
    together with, the historical financial information that Celgene
    and Abraxis have presented in their respective filings with the
    SEC and the pro forma financial information that appears
    elsewhere in this proxy statement/prospectus. See &#147;Where
    You Can Find More Information&#148; and &#147;Unaudited Pro
    Forma Consolidated Financial Statements.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The unaudited pro forma consolidated and pro forma-equivalent
    data is presented for illustrative purposes only and is not
    necessarily indicative of actual or future financial position or
    results of operations that would have been realized if the
    proposed merger had been completed as of the dates indicated or
    will be realized upon the completion of the proposed merger.
    Neither Celgene nor Abraxis declared or paid any dividends
    during the periods presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unaudited Pro<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unaudited Pro<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Forma&#160;&#151;<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Consolidated per<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Equivalent per<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Celgene<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Abraxis<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Share of Celgene<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Share of Abraxis<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Historical</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Historical</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net income (loss) per share:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    For the year ended December&#160;31, 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.69
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.57
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.57
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    For the six months ended June&#160;30, 2010:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.47
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.47
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.74
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Book value per share:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    As of December&#160;31, 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.57
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    N/A
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    N/A
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    As of June&#160;30, 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
</DIV><!-- End box 1 -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='108'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Before you vote, you should carefully consider the risks related
    to the merger described below, those described in the section
    entitled &#147;Cautionary Statement Regarding Forward-Looking
    Statements&#148; and the other information contained in this
    proxy statement/prospectus or in Abraxis&#146; and
    Celgene&#146;s documents incorporated by reference herein,
    particularly the risk factors set forth in Abraxis&#146; and
    Celgene&#146;s documents incorporated herein, as set forth under
    &#147;Where You Can Find More Information&#148; (including the
    risk factors contained in Abraxis&#146; Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, as supplemented by
    Abraxis&#146; Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K/A</FONT>
    for the year ended December&#160;31, 2009 and by Abraxis&#146;
    Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarters ended March&#160;31, 2010 and June&#160;30,
    2010, and in Celgene&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, and Celgene&#146;s
    Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarters ended March&#160;31, 2010 and June&#160;30,
    2010). Because the merger consideration is partially comprised
    of Celgene common stock and CVRs, by voting in favor of the
    adoption of the merger agreement, you will be choosing to invest
    in Celgene common stock and the CVRs. The risks and
    uncertainties described below and incorporated by reference are
    not the only risks and uncertainties Celgene may face.
    Additional risks and uncertainties not presently known to
    Celgene, or risks that Celgene currently considers immaterial
    could also negatively affect its business, results and
    operations. If any of the following risks actually occur,
    Celgene&#146;s business, financial condition or results of
    operations could be materially adversely affected, which could
    cause the value of Celgene common stock to decline and adversely
    affect the likelihood of any payments being made under the CVRs
    and the amount of such payments.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to the Merger</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Because the market price of Celgene common stock will
    fluctuate and because of the uncertainty of the ultimate
    realization of the CVRs, Abraxis stockholders cannot be certain
    of the value of the merger consideration that they will be
    entitled to receive in the merger.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At the completion of the merger, each outstanding share of
    Abraxis common stock will be converted into the right to receive
    (1)&#160;$58.00 in cash, without interest,
    (2)&#160;0.2617&#160;shares of Celgene common stock, and
    (3)&#160;one CVR. The 0.2617 exchange ratio is fixed and will
    not be adjusted for changes in the market price of either
    Abraxis common stock or Celgene common stock. The market value
    of the Celgene common stock that Abraxis stockholders will be
    entitled to receive in the merger will depend on the market
    value of Celgene common stock immediately before the merger is
    completed and could vary significantly from the market value on
    the date of the announcement of the merger agreement, the date
    that this proxy statement/prospectus was mailed to stockholders
    of Abraxis or the date of the special meeting of Abraxis
    stockholders. The merger agreement does not provide for any
    price-based termination right. For example, the closing sale
    price of Celgene common stock on June&#160;29, 2010, the last
    trading day prior to the execution of the merger agreement, was
    $53.24 per share and, therefore, if the transaction had closed
    on that date, the value of the merger consideration that Abraxis
    stockholders would have received for each share of common stock,
    including the $58.00 in cash consideration (but excluding any
    value relating to the CVR), would have been $71.93. On
    September&#160;13, 2010, the last trading day before the date of
    this proxy statement/prospectus, the closing sale price of
    Celgene common stock was $54.64 per share, and, therefore, if
    the transactions had closed on that date, the value of the
    merger consideration that Abraxis stockholders would have
    received for each share of common stock, including the $58.00 in
    cash consideration (but excluding any value relating to the
    CVR), would have been $72.30. Moreover, the market value of
    Celgene common stock will likely fluctuate after the completion
    of the merger. See &#147;Comparative Per Share Market Price and
    Dividend Information.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fluctuations in the market price of Celgene common stock could
    result from changes in the business, operations or prospects of
    Abraxis or Celgene prior to the completion of the merger or
    Celgene following the completion of the merger, regulatory
    considerations, general market and economic conditions and other
    factors both within and beyond the control of Abraxis or Celgene.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    issuance of Celgene common stock in connection with the merger
    could decrease the market price of Celgene common
    stock.</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At the completion of the merger, Celgene expects to issue up to
    approximately 10.6&#160;million shares of Celgene common stock,
    or approximately 2.1% of the number of shares of Celgene common
    stock outstanding as of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
     September&#160;8, 2010, to Abraxis stockholders in the merger.
    The issuance of the Celgene common stock may result in
    fluctuations in the market price of Celgene common stock,
    including a stock price decline.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    shares of Celgene common stock to be received by Abraxis
    stockholders as a result of the merger will have different
    rights from the shares of Abraxis common stock.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon completion of the merger, Abraxis stockholders will become
    Celgene stockholders and their rights as stockholders will be
    governed by Celgene&#146;s certificate of incorporation and
    Celgene&#146;s by-laws. Certain of the rights associated with
    Abraxis common stock are different from, and may be viewed as
    less favorable than, the rights associated with Celgene common
    stock. See &#147;Comparative Rights of Abraxis Stockholders and
    Celgene Stockholders&#148; for a discussion of the different
    rights associated with Celgene common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Regulatory
    approvals that are required to complete the merger may not be
    received, may take longer than expected or may impose conditions
    which are not presently anticipated.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the provisions of the
    <FONT style="white-space: nowrap">Hart-Scott-Rodino</FONT>
    Antitrust Improvements Act of 1976, which we refer to as the HSR
    Act, the merger may not be completed until notification and
    report forms have been filed with the FTC and the Antitrust
    Division and the expiration of a 30 calendar day waiting period,
    or the early termination of that waiting period, following the
    parties&#146; filing of their respective notification and report
    forms. If the FTC or the Antitrust Division issues a Request for
    Additional Information and Documentary Material prior to the
    expiration of the waiting period, the parties must observe a
    second 30 calendar day waiting period, which would begin to run
    only after both parties have substantially complied with the
    request for information, unless the waiting period is terminated
    earlier or extended with the consent of the parties. On
    July&#160;14, 2010, Abraxis and Celgene filed their respective
    notification and report forms under the HSR Act with the FTC and
    the Antitrust Division. Celgene received confirmation of early
    termination of the initial waiting period under the HSR Act
    effective as of August&#160;3, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Private parties who may be adversely affected by the merger and
    individual states may bring legal actions under the antitrust
    laws in certain circumstances. Although the parties believe that
    completion of merger would not violate any antitrust law, there
    can be no assurance that a challenge to the merger on antitrust
    grounds will not be made or, if a challenge is made, what the
    result will be. Under the merger agreement, Abraxis and Celgene
    have agreed to use their reasonable best efforts to obtain all
    regulatory clearances necessary to complete, in the most
    expeditious manner practicable, the merger; however, Celgene is
    not required to sell, divest or otherwise dispose of, hold
    separate, enter into any license or similar agreement with
    respect to, restrict the ownership or operation of, or agree to
    sell, divest or otherwise dispose of, hold separate, enter into
    any license or similar agreement with respect to, or restrict
    the ownership or operation of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (A)&#160;any assets or businesses of Abraxis or any of its
    subsidiaries or (B)&#160;any assets or businesses of Celgene or
    any of its affiliates or subsidiaries, in the case of either
    clause&#160;(A) or (B), to the extent that the sale,
    divestiture, disposition, or agreement would have a material
    adverse effect on the business, operations, financial condition
    or results of operations of the combined business of Abraxis and
    Celgene after giving effect to the completion of merger,&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    to the extent such sale, divestiture, disposition, agreement or
    restriction would have a material adverse effect on the ability
    of Abraxis to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in the United States, the European Union, Canada and Switzerland.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If either Celgene or Abraxis becomes subject to any term,
    condition, obligation or restriction (whether because such term,
    condition, obligation or restriction does not rise to the
    specified level of materiality or Celgene otherwise consents to
    its imposition), the imposition of such term, condition,
    obligation or restriction could adversely affect Celgene&#146;s
    ability to integrate Abraxis&#146; operations into
    Celgene&#146;s operations, reduce the anticipated benefits of
    the merger or otherwise adversely affect Celgene&#146;s business
    and results of operations following the completion of the merger.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Legal proceedings in connection with the merger, the
    outcomes of which are uncertain, could delay or prevent the
    completion of the merger.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Since July&#160;1, 2010, several putative class action
    complaints have been filed on behalf of Abraxis stockholders.
    The complaints seek, among other things, (1)&#160;declarations
    that they are maintainable as class actions, (2)&#160;an order
    preliminarily and permanently enjoining the defendants from
    completing the merger until certain conditions are satisfied,
    and (3)&#160;attorneys&#146; fees and costs. On
    September&#160;14, 2010, the parties reached an agreement in
    principle to settle the actions pursuant to the MOU. Such legal
    proceedings could delay or prevent the merger from becoming
    effective. See &#147;The Merger&#160;&#151; Litigation Related
    to the Merger.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>The integration of Abraxis and other acquired businesses
    may present significant challenges to Celgene.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Achieving the anticipated benefits of the merger will depend in
    part upon whether Abraxis and Celgene can integrate their
    businesses in an efficient and effective manner. In addition,
    Celgene has recently acquired and may acquire additional
    businesses from time to time. The integration of Abraxis and any
    future businesses that Celgene may acquire involves a number of
    risks, including, but not limited to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    demands on management related to the increase in the size of
    Celgene after the acquisition;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the diversion of management&#146;s attention from the management
    of daily operations to the integration of operations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    higher integration costs than anticipated;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    failure to achieve synergies and costs savings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties in the assimilation and retention of employees;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties in the assimilation of different cultures and
    practices, as well as in the assimilation of broad and
    geographically dispersed personnel and operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties in the integration of departments, systems,
    including accounting systems, technologies, books and records,
    and procedures, as well as in maintaining uniform standards,
    controls, including internal control over financial reporting
    required by the Sarbanes-Oxley Act of 2002 and related
    procedures and policies.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If Celgene cannot successfully integrate Abraxis or other
    acquired businesses, Celgene may experience material negative
    consequences to its business, financial condition or results of
    operations. Successful integration of Abraxis and other acquired
    businesses will depend on Celgene&#146;s ability to manage these
    operations, to realize opportunities for revenue growth
    presented by offerings and expanded geographic market coverage
    and, to some degree, to eliminate redundant and excess costs.
    Because of difficulties in combining geographically distant
    operations, Celgene may not be able to achieve the benefits that
    it hopes to achieve as a result of the merger.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Failure
    to achieve expected benefits of the merger and integrate
    Abraxis&#146; operations with Celgene&#146;s could adversely
    affect Celgene following the completion of the merger and the
    market price of Celgene common stock.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Although Celgene expects to realize strategic, operational and
    financial benefits as a result of the merger, Celgene cannot be
    certain whether, and to what extent, such benefits will be
    achieved in the future. In particular, the success of the merger
    will depend on achieving efficiencies and cost savings, and no
    assurances can be given that Celgene will be able to do so. In
    addition, in order to obtain the benefits of the merger, Celgene
    must integrate Abraxis&#146; subsidiaries and operations and
    such integration may be complex and the failure to do so quickly
    and effectively may negatively affect earnings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, the market price of Celgene common stock may
    decline as a result of the merger if the integration of Celgene
    and Abraxis is unsuccessful, takes longer than expected or fails
    to achieve financial benefits to the extent anticipated by
    financial analysts or investors, or the effect of the merger on
    Celgene&#146;s financial results is otherwise not consistent
    with the expectations of financial analysts or investors.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Abraxis&#146; and Celgene&#146;s business relationships,
    including customer relationships, may be subject to disruption
    due to uncertainty associated with the merger.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Parties with which Abraxis and Celgene do business, including
    customers and suppliers, may experience uncertainty associated
    with the merger, including with respect to current or future
    business relationships with Abraxis or Celgene. As a result,
    Abraxis&#146; and Celgene&#146;s business relationships may be
    subject to disruptions if customers, suppliers and others
    attempt to negotiate changes in existing business relationships
    or consider entering into business relationships with parties
    other than Abraxis or Celgene. These disruptions could have an
    adverse effect on the businesses, financial condition, results
    of operations or prospects of Celgene following the completion
    of the merger. The adverse effect of such disruptions could be
    exacerbated by a delay in the completion of the merger or
    termination of the merger agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Future results of Celgene following the completion of the
    merger may differ materially from the Unaudited Pro Forma
    Consolidated Financial Statements of Celgene and Abraxis
    presented in this proxy statement/prospectus.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The future results of Celgene following the completion of the
    merger may be materially different from those shown in the
    Unaudited Pro Forma Consolidated Financial Statements presented
    in this proxy statement/prospectus that show only a combination
    of Celgene&#146;s and Abraxis&#146; historical results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Celgene
    will incur significant transaction and merger-related costs in
    connection with the merger.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene expects to incur a number of non-recurring costs
    associated with combining the operations of the two companies.
    Most of these costs will be comprised of transaction costs,
    including fees paid to financial and legal advisors, related to
    the merger, facilities and systems consolidation costs and
    employment-related costs, including
    <FONT style="white-space: nowrap">change-in-control</FONT>
    related payments made to certain Abraxis executives and the cash
    out of unvested stock-based awards. Celgene will also incur
    transaction fees and costs related to formulating integration
    plans. Additional unanticipated costs may be incurred in the
    integration of the two companies&#146; businesses. Although
    Celgene expects that the elimination of duplicative costs, as
    well as the realization of other efficiencies related to the
    integration of the businesses, should allow Celgene to offset
    incremental transaction and merger-related costs over time, this
    net benefit may not be achieved in the near term, or at all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Celgene may be unable to hire and retain sufficient
    qualified personnel; the loss of any of its key executive
    officers could adversely affect Celgene.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene believes that its future success will depend in large
    part on its ability to attract and retain highly skilled,
    knowledgeable, sophisticated and qualified managerial,
    professional and technical personnel. In addition, the success
    of the combined operations after the merger will depend in part
    upon Celgene&#146;s ability to retain key employees of Abraxis.
    Key employees may depart because of issues relating to the
    difficulty of integration or accelerated retirement as a result
    of change in control severance provisions in their agreements
    with Abraxis. Accordingly, no assurance can be given that
    Celgene will be able to retain key employees of Abraxis.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    merger agreement limits Abraxis&#146; ability to pursue
    alternatives to the merger.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger agreement contains &#147;no shop&#148; provisions
    that, subject to limited exceptions, preclude Abraxis from
    (1)&#160;soliciting, initiating, or knowingly encouraging the
    making, submission or announcement of any third party proposal
    which would reasonably be expected to lead to an acquisition
    proposal, (2)&#160;entering into, participating, continuing or
    otherwise engaging in discussions or negotiations with, or
    providing any non-public information to any third party with
    respect to any inquiries regarding, or the making, submission or
    announcement of, an acquisition proposal, (3)&#160;entering into
    or approving any letter of intent, agreement in principle,
    option agreement, share purchase agreement, acquisition
    agreement or similar agreement for an acquisition proposal, or
    (4)&#160;terminating, waiving, amending or modifying any
    provision of, or granting permission under, any standstill,
    confidentiality agreement or similar contract to which Abraxis
    or any of its subsidiaries is a party. The merger agreement also
    provides that Abraxis will be required to pay a termination fee
    of $145&#160;million to Celgene upon termination of the merger
    agreement under certain circumstances. These provisions might
    discourage a potential
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    competing acquiror that might have an interest in acquiring all
    or a significant part of Abraxis from considering or proposing
    an acquisition even if it were prepared to pay consideration
    with a higher per share market price than that proposed in the
    merger, or might result in a potential competing acquiror
    proposing to pay a lower per share price to acquire Abraxis than
    it might otherwise have proposed to pay.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Failure to complete the merger could negatively impact the
    stock price and the future business and financial results of
    Abraxis.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the merger is not completed, the ongoing businesses of
    Abraxis may be adversely affected and, without realizing any of
    the benefits of having completed the merger, Abraxis will be
    subject to a number of risks, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis may be required to pay Celgene a termination fee of
    $145&#160;million if the merger agreement is terminated under
    certain circumstances, as described under &#147;The Merger
    Agreement&#160;&#151; Termination Fees and Expenses;&#148;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis will be required to pay its costs relating to the
    proposed merger if the merger is not completed;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    under the merger agreement, Abraxis is subject to certain
    restrictions on the conduct of its business prior to completing
    the merger which may affect its ability to execute certain of
    its business strategies;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    matters relating to the merger (including integration planning)
    may require substantial commitments of time and resources by
    Abraxis management, which could otherwise have been devoted to
    other opportunities that may have been beneficial to Abraxis as
    an independent company.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, Abraxis could be subject to litigation related to
    any failure to complete the merger or related to any enforcement
    proceeding commenced against Abraxis to perform its respective
    obligations under the merger agreement. If the merger is not
    completed, these risks may materialize and may adversely affect
    Abraxis&#146; business, financial results and market price of
    Abraxis common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    market price of Celgene common stock and Celgene&#146;s results
    of operations may be affected by factors different from those
    affecting the market price of Abraxis common stock and
    Abraxis&#146; results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis stockholders will be entitled to receive merger
    consideration that is partially comprised of Celgene common
    stock and will thus become Celgene stockholders. Celgene&#146;s
    business is different from that of Abraxis, and Celgene&#146;s
    results of operations, as well as the market price of Celgene
    common stock, may be affected by factors different from those
    affecting Abraxis&#146; results of operations and the market
    price of Abraxis common stock. The market price of Celgene
    common stock may fluctuate significantly following the merger,
    including as a result of factors over which Celgene has no
    control.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Abraxis
    executive officers and directors have financial interests in the
    merger that may be different from, or in addition to, the
    interests of Abraxis stockholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Executive officers of Abraxis negotiated the terms of the merger
    agreement with their counterparts at Celgene, and the Abraxis
    board of directors unanimously determined that the transactions
    contemplated by the merger agreement, including the merger, are
    advisable and fair to, and in the best interest of, Abraxis and
    its stockholders, adopted the merger agreement and declared
    advisable the merger and unanimously recommended that Abraxis
    stockholders vote for the adoption of the merger agreement. In
    considering these facts and the other information contained in
    this proxy statement/prospectus, you should be aware that
    Abraxis&#146; executive officers and directors have financial
    interests in the merger that may be different from, or in
    addition to, the interests of Abraxis stockholders. For a
    detailed discussion of the special interests that Abraxis&#146;
    directors and executive officers may have in the merger, please
    see &#147;The Merger&#160;&#151; Interests of Directors and
    Executive Officers of Abraxis in the Merger.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>The market price of Celgene common stock may fluctuate
    significantly, which may make it difficult for you to sell
    Celgene common stock you receive in the merger when you want to
    or at prices you find attractive.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There has been significant volatility in the market prices for
    publicly traded shares of biopharmaceutical companies, including
    shares of Celgene common stock. Celgene expects that the market
    price of its common stock will continue to fluctuate. The price
    of Celgene common stock fluctuated from a high of $58.31 per
    share to a low of $36.90 per share in 2009. The price of Celgene
    common stock may not remain at or exceed current levels. The
    following key factors, among others, may have an adverse impact
    on the market price of Celgene common stock:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adverse results of Celgene&#146;s clinical trials or adverse
    events associated with its marketed products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s products&#146; ability to demonstrate efficacy or
    an acceptable safety profile;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    product introductions and sales by Celgene&#146;s competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    new product discovery and development by Celgene&#146;s
    competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s ability to obtain and maintain regulatory
    approval for its existing products as well as for new products
    in development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements of technical or product developments by
    Celgene&#146;s competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s failure to effectively implement its business
    strategy or Celgene&#146;s adoption and implementation of a
    business strategy that places it at a disadvantage to its
    competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market conditions for pharmaceutical and biotechnology stocks;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market conditions generally;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    governmental regulation;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    new accounting pronouncements, regulatory rulings or actions by
    the FDA;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    health care legislation generally and potential changes in
    insurance or governmental reimbursement policies on
    Celgene&#146;s products and pipeline products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    public announcements by competitors regarding medical advances
    in the treatment of the disease states that Celgene is targeting;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    patent or proprietary rights developments
    <FONT style="white-space: nowrap">and/or</FONT>
    changes in patent laws, including Celgene&#146;s ability to
    successfully protect and enforce its intellectual property
    rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    royalties and contract revenues that Celgene becomes obligated
    to pay;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potential changes in reimbursement policies or rates for
    Celgene&#146;s products
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    product manufacturing, including Celgene&#146;s arrangements
    with third party suppliers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s expenses and net income;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    credit and foreign exchange risk management by Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s liquidity;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    asset and liability risk management by Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the outcome of litigation involving Celgene&#146;s products or
    processes related to production and formulation of those
    products or uses of those products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    competition;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    operational and legal risks.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, the stock market in general and the biotechnology
    sector in particular have experienced extreme volatility that
    has often been unrelated to the operating performance of a
    particular company. These broad market fluctuations may
    adversely affect the market price of Celgene common stock.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Celgene may obtain financing in connection with the
    merger, which may have an adverse effect on the business,
    financial condition and results of operations of Celgene and may
    result in dilution to Celgene stockholders.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene does not require financing for the merger. However,
    Celgene is considering and may pursue financing arrangements on
    terms and conditions favorable to Celgene, including, without
    limitation, an offering of debt securities, to maintain
    financial flexibility. Celgene cannot guarantee that financing,
    in any form, will be available at all, or on the terms
    acceptable to it. In addition, any debt that Celgene incurs in
    connection with the merger may, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    limit Celgene&#146;s ability to borrow additional funds;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    limit Celgene&#146;s flexibility in planning for, or reacting
    to, changes in its operations and the industry in which it
    operates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increase Celgene&#146;s vulnerability to adverse general
    economic and industry conditions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    limit Celgene&#146;s ability to make strategic acquisitions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require Celgene to dedicate a substantial portion of its cash
    flow from operations to principal and interest payments on such
    debt, reducing the availability of cash flow to fund working
    capital, capital expenditures and other general corporate
    activities;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    place Celgene at a competitive disadvantage compared to
    competitors that have less debt.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Additionally, in the event that Celgene pursues an offering of
    debt securities convertible into shares of Celgene common stock,
    the issuance of a substantial number of shares of Celgene common
    stock in connection with the conversion or settlement of such
    securities could depress the market price of Celgene common
    stock and impair its ability to raise capital through the sale
    of additional equity securities. Any transaction involving the
    issuance of shares of Celgene common stock, or securities
    convertible into shares of Celgene common stock, would result in
    dilution, which could be substantial, to Celgene stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to the CVRs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">You
    may not receive any payment on the CVRs.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Your right to receive any future payment on the CVRs will be
    contingent upon the achievement by Abraxis and Celgene of
    certain agreed upon U.S.&#160;regulatory milestones and net
    sales (calculated in accordance with the CVR agreement) in
    excess of the thresholds specified in the CVR agreement within
    the time periods specified in the CVR agreement. If the
    milestones specified in the CVR agreement are not achieved for
    any reason within the time periods specified in the CVR
    agreement, and if net sales do not exceed the thresholds set
    forth in the CVR agreement for any reason within the time
    periods specified in the CVR agreement, no payment will be made
    under the CVRs and the CVRs will expire valueless. Accordingly,
    the value, if any, of the CVRs is speculative, and the CVRs may
    ultimately have no value. See &#147;Description of the
    CVRs.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>You will not be able to determine the amount of cash to be
    received under the CVRs until the achievement of certain agreed
    upon milestones and/or after the conclusion of the first net
    sales measuring period which ends on December&#160;31, 2011,
    which makes it difficult to value the CVRs.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If any payment is made on the CVR, it will not be made until the
    achievement of certain agreed upon milestones and/or, with
    respect to net sales payments, after the conclusion of the first
    net sales measuring period, which ends on December&#160;31, 2011
    (provided that net sales for such net sales measuring period
    exceed the thresholds set forth in the CVR agreement, calculated
    in accordance with the CVR agreement), and the amount of any
    payment will not be paid until after the achievement of such
    milestones and/or, with respect to net sales payments, until
    15&#160;days after the date Celgene is required to provide the
    net sales statement for the net sales measuring period in
    respect of which a net sales payment under the CVR is due. The
    CVR agreement sets forth the time frame in which a CVR payment
    is to be paid if Celgene is no longer required to file with the
    Securities and Exchange Commission,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    which we refer to as the SEC, copies of its annual or quarterly
    reports (provided that net sales for such net sales measuring
    period exceed the thresholds set forth in the CVR agreement,
    calculated in accordance with the CVR agreement). In accordance
    with the CVR agreement, Celgene will provide an annual net sales
    statement. The final calculation of any CVR payment, however,
    will be provided to you no earlier than 15&#160;days after the
    date Celgene is required to provide the net sales statement for
    the net sales measuring period in respect of which a net sales
    payment under the CVR is due. As such, it may be difficult to
    value the CVRs, and accordingly it may be difficult or
    impossible for you to resell your CVRs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    U.S. federal income tax treatment of the CVRs is
    unclear.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the merger agreement and the CVR agreement, the
    parties to the merger agreement and the CVR agreement have
    agreed or will agree, as applicable, to treat and report any CVR
    payments (except to the extent of any imputed interest) for all
    tax purposes as additional consideration for the sale of Abraxis
    common stock in the merger, except as required by applicable
    law. Assuming this treatment is correct, a U.S.&#160;holder
    generally should recognize capital gain as and to the extent
    aggregate CVR payments received (less any imputed interest)
    exceed the U.S.&#160;holder&#146;s adjusted tax basis in the
    CVR. A U.S.&#160;holder&#146;s initial tax basis in CVRs
    received in the merger will equal the fair market value of such
    CVRs as determined for U.S.&#160;federal income tax purposes. A
    U.S.&#160;holder who does not sell, exchange or otherwise
    dispose of a CVR may not be able to recognize a loss with
    respect to the CVR until the U.S.&#160;holder&#146;s right to
    receive CVR payments terminates. In accordance with the CVR
    agreement, Celgene has agreed to report imputed interest on the
    CVRs pursuant to Section&#160;483 of the Code. However, there is
    no legal authority directly addressing the U.S.&#160;federal
    income tax treatment of the CVRs and, therefore, there can be no
    assurance that the Internal Revenue Service would not assert, or
    that a court would not sustain, a position that any CVR payment
    does not attract capital gain treatment, or that a different
    method should be used for purposes of reporting imputed
    interest. If such a position were sustained, all or any part of
    any CVR payment could be treated as ordinary income and could be
    required to be included in income prior to the receipt of the
    CVR payment. See &#147;Certain Material U.S.&#160;Federal Income
    Tax Consequences.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Any payments in respect of the CVRs are subordinated to
    the right of payment of Celgene&#146;s other
    indebtedness.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs are unsecured obligations of Celgene and the CVR
    payments and all other obligations under the CVR agreement,
    together with the CVRs and any rights or claims relating
    thereto, are subordinated in right of payment to the prior
    payment in full of all senior obligations of Celgene. Senior
    obligations of Celgene include any existing or future
    obligations of Celgene, including the principal of, premium (if
    any), interest on, and all other amounts owing thereon:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to borrowed money;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evidenced by notes, debentures, bonds or other similar debt
    instruments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the net obligations owed under interest rate
    swaps or similar agreements or currency exchange transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement obligations in respect of letters of credit and
    similar obligations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in respect of capital leases;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    guarantees in respect of the foregoing obligations, unless the
    instrument creating or evidencing the same provides otherwise.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene&#146;s senior obligations do not include, among other
    things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    trade debt incurred in the ordinary course of business;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any intercompany indebtedness between Celgene and any of its
    subsidiaries or affiliates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness of Celgene that is subordinated in right of payment
    to Celgene&#146;s senior obligations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness or other obligations of Celgene that by its terms
    ranks equal or junior in right of payment to the CVR payments,
    milestone, and net sales payments; and all other obligations
    under the CVR agreement;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness of Celgene that, by operation of applicable law, is
    subordinate to any general unsecured obligations of
    Celgene;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness evidenced by any guarantee of indebtedness ranking
    equal or junior in right of payment to the CVR payments.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, if a default on Celgene&#146;s senior obligations
    would occur as a result of the CVR payment, there is an existing
    payment default on Celgene&#146;s senior obligations, the
    maturity of Celgene&#146;s senior obligations is accelerated, in
    each case in excess of certain agreed upon thresholds as set
    forth in the CVR agreement, or in other circumstances, no CVR
    payment will be payable, if any payment is due, until any such
    default is remedied.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>An active public market for the CVRs may not develop or
    the CVRs may trade at low volumes, both of which could have an
    adverse effect on the resale price, if any, of the CVRs.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs are a new security for which there is currently no
    public trading market. An active public trading market for the
    securities may not develop or be sustained. Celgene has agreed
    to use its reasonable best efforts to cause the CVRs to be
    approved for listing at the completion of the merger on The
    NASDAQ Global Select Market. Notwithstanding its efforts,
    Celgene may be unable to cause the CVRs to be listed for trading.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Even if an active public trading market develops, there may be
    little or no market demand for the CVRs, making it difficult or
    impossible to resell the CVRs, which would have an adverse
    effect on the resale price, if any, of the CVRs. Immediately
    following the completion of the merger, the principal
    stockholders will hold a majority of the CVRs. In addition,
    holders of CVRs may incur brokerage charges in connection with
    the resale of the CVRs, which in some cases could exceed the
    proceeds realized by the holder from the resale of its CVRs.
    Neither Celgene nor Abraxis can predict the price, if any, at
    which the CVRs will trade following the completion of the merger.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Celgene
    may under certain circumstances redeem the CVRs.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVR agreement does not prohibit Celgene or any of its
    subsidiaries or affiliates from acquiring the CVRs, whether in
    open market transactions, private transactions or otherwise.
    Pursuant to the terms of the CVR agreement, subject to certain
    notice requirements, Celgene may, at any time on and after the
    date that 50% of the CVRs either are (1)&#160;no longer
    outstanding
    <FONT style="white-space: nowrap">and/or</FONT>
    (2)&#160;repurchased, acquired, redeemed or retired by Celgene,
    redeem all, but not less than all, of the outstanding CVRs at a
    cash redemption price equal to the average price paid per CVR
    for all CVRs previously purchased by Celgene calculated as of
    the business day immediately prior to the date of the notice of
    redemption. Neither Celgene nor Abraxis can predict the price at
    which the CVRs may be redeemed by Celgene in the future pursuant
    to these rights, if at all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Because there has not been any public market for the CVRs,
    the market price and trading volume of the CVRs may be
    volatile.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Neither Abraxis nor Celgene can predict the extent to which
    investor interest will lead to a liquid trading market in the
    CVRs or whether the market price of the CVRs will be volatile
    following the merger. The market price of the CVRs could
    fluctuate significantly for many reasons, including, without
    limitation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    as a result of the risk factors listed in this proxy
    statement/prospectus;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the ability of Celgene to obtain FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in a manner that will require milestone payments to be made or
    to sell
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or Abraxis pipeline products at a level that will require
    royalties on these products to be paid to the holders of the
    CVRs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    for reasons unrelated to operating performance, such as reports
    by industry analysts, investor perceptions, or negative
    announcements by our customers or competitors regarding their
    own performance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    regulatory changes that could impact Celgene&#146;s
    business;&#160;and
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general economic, securities markets and industry conditions.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Upon expiration of Celgene&#146;s obligations to use
    diligent efforts to achieve each of the CVR milestones and to
    sell
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or any of the other Abraxis pipeline products, Celgene may
    discontinue such efforts, which would have an adverse effect on
    the value, if any, of the CVRs.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to use diligent efforts, until the net sales
    payment termination date, to sell
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or any of the other Abraxis pipeline products for which Celgene
    has obtained regulatory approval for the commercial manufacture,
    marketing and sale thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has also agreed to use diligent efforts to obtain FDA
    approval for the commercial manufacture, marketing and sale of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the treatment of melanoma, ovarian cancer, bladder cancer
    and first-line metastatic breast cancer until the earlier of the
    net sales payment termination date or such time that the data
    generated in an appropriate clinical trial does not support
    further development of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the applicable indication.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    However, under the CVR agreement, the definition of
    &#147;diligent efforts&#148; allows for the consideration of a
    variety of factors in determining the efforts Celgene is
    required to use to sell
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or any of the other Abraxis pipeline products and to obtain
    additional regulatory approvals of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.

    The CVR agreement defines &#147;diligent efforts&#148; as, with
    respect to any product, efforts of a person to carry out its
    obligations in a diligent manner using such effort and employing
    such resources normally used by such person in the exercise of
    its reasonable business discretion relating to the research,
    development or commercialization of a product, that is of
    similar market potential at a similar stage in its development
    or product life, taking into account issues of market
    exclusivity (including patent coverage, regulatory and other
    exclusivity), safety and efficacy, product profile, the
    competitiveness of alternate products in the marketplace or
    under development, the launch or sales of a generic or
    biosimilar product, the regulatory structure involved, and the
    profitability of the applicable product (including pricing and
    reimbursement status achieved), and other relevant factors,
    including technical, commercial, legal, scientific,
    <FONT style="white-space: nowrap">and/or</FONT>
    medical factors.
</DIV>

<A name='109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CAUTIONARY
    STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This proxy statement/prospectus and the documents incorporated
    by reference herein contain forward-looking statements within
    the meaning of Section&#160;27A of the Securities Act and
    Section&#160;21E of the Securities Exchange Act of 1934, as
    amended (the &#147;Exchange Act&#148;) that involve risks and
    uncertainties, as well as assumptions and information that are
    based on the current beliefs and expectations of the respective
    managements of Abraxis and Celgene, as the case may be. All
    statements other than statements of historical fact are
    statements that could be deemed forward-looking statements,
    including any projections of earnings, revenues, synergies,
    margins, royalties, profit split payments, net sales or other
    financial items; any statements of the plans, strategies and
    objectives of management for future operations, including
    integration and any potential restructuring plans and the
    anticipated timing of filings and approvals relating to the
    merger; any statements concerning proposed new products,
    services, developments or industry rankings; any statements
    regarding future economic conditions or performance; any
    statements of belief; and any statements of assumptions
    underlying any of the foregoing. In addition to the foregoing,
    when used in or incorporated by reference into this proxy
    statement/prospectus, the words &#147;anticipate,&#148;
    &#147;believe,&#148; &#147;plan,&#148; &#147;estimate,&#148;
    &#147;expect,&#148; and &#147;intend&#148; and other similar
    expressions, as they relate to Abraxis or Celgene or their
    respective managements or stockholders, are intended to identify
    forward-looking statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Such forward-looking statements, whether expressed or implied,
    reflect the current views of Abraxis and Celgene with respect to
    future events and are subject to a number of known and unknown
    risks, delays, uncertainties and other important factors which
    could cause the actual results of Abraxis or Celgene to differ
    materially from those implied by such forward-looking
    statements, due to a number of factors, many of which are beyond
    either Abraxis&#146; or Celgene&#146;s control, which include,
    but are not limited to, those set forth under the heading
    &#147;Risk Factors&#148;; the risks described in Abraxis&#146;
    filings with the SEC, including Abraxis&#146; Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009 and its Quarterly
    Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarters ended March&#160;31, 2010 and June&#160;30,
    2010; the risks described in Celgene&#146;s filings with the
    SEC, including Celgene&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009 and its Quarterly
    Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarters ended March&#160;31, 2010 and June&#160;30,
    2010; and the following important factors and assumptions that
    could affect the future results of Celgene following the merger,
    or the future results of Abraxis and Celgene if the merger does
    not occur,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and could cause actual results to differ materially from the
    results, performance or other expectations implied or expressed
    in any forward-looking statements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the market adoption of and demand for existing and new
    pharmaceutical products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ability to maintain
    <FONT style="white-space: nowrap">and/or</FONT>
    improve revenues
    <FONT style="white-space: nowrap">and/or</FONT>
    earnings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ability to successfully manufacture products in an
    efficient, timely and cost-effective manner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    anticipated dates on which Abraxis and Celgene will begin
    marketing certain products or therapies or will reach specific
    milestones in the development and implementation of their
    respective business strategies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the impact on products and revenues of patents and other owned
    or licensed proprietary rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compliance with laws, regulations and standards, and the
    application and interpretation of those laws, regulations and
    standards, that govern or affect the pharmaceutical industry,
    the non-compliance with which may delay or prevent the sale of
    products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possibility that the merger may involve unexpected costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the difficulty in predicting the timing or outcome of product
    development efforts and regulatory approvals;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    risks that the merger disrupts Abraxis&#146; current plans and
    operations, and the potential difficulties for Abraxis&#146;
    employee retention as a result of the announcement or completion
    of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the outcome of any pending or future litigation and
    administrative claims;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the impact of recent legislation changes to the governmental
    reimbursement system;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ability of Celgene following the merger to generate net
    sales sufficient to trigger a payment under the CVRs
    <FONT style="white-space: nowrap">and/or</FONT>
    achieve milestones;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    challenges of integration and restructuring associated with the
    merger or other planned acquisitions and the challenges of
    achieving anticipated synergies;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other matters that are not historical facts and other risks that
    are described in the section titled &#147;Risk Factors&#148; and
    in the documents that are incorporated by reference into this
    proxy statement/prospectus.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If any of these risks or uncertainties materialize or any of
    these assumptions prove incorrect, results of Abraxis and
    Celgene could differ materially from the expectations in these
    statements. Abraxis and Celgene do not undertake any obligation
    to update these forward-looking statements, except as required
    by law.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<A name='110'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    ABOUT THE SPECIAL MEETING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This section contains information about the special meeting of
    Abraxis stockholders, which we refer to as the special meeting,
    that has been called to consider and act on the proposal to
    adopt the merger agreement.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Date,
    Time and Place of the Special Meeting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The stockholders of Abraxis will hold a special meeting at the
    Fairmont Miramar, 101&#160;Wilshire Boulevard, Santa Monica,
    California, on October&#160;13, 2010, at 10:00&#160;a.m. local
    time, unless the special meeting is adjourned or postponed.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Purpose
    of the Special Meeting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At the special meeting, Abraxis stockholders will be asked to
    consider and act on a proposal to adopt the merger agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Record
    Date; Shares&#160;Entitled to Vote; Outstanding Shares</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Only stockholders listed on Abraxis&#146; records at the close
    of business on September&#160;10, 2010, the record date for the
    special meeting, are entitled to receive notice of and to vote
    at the special meeting, or any adjournments or postponements of
    the special meeting. As of the close of business on the record
    date, there were 40,507,552 shares
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    of Abraxis common stock outstanding and entitled to vote at the
    special meeting. Each holder of Abraxis common stock is entitled
    to one vote for each share of Abraxis common stock held as of
    the record date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A complete list of Abraxis stockholders entitled to vote at the
    special meeting will be available for inspection at the
    principal place of business of Abraxis during regular business
    hours for a period of no less than ten days before the special
    meeting, as well as the place of the special meeting during the
    meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Ownership
    of Shares</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If your shares are registered directly in your name with
    Abraxis&#146; transfer agent, American Stock
    Transfer&#160;&#038; Trust&#160;Company, you are considered,
    with respect to those shares, the &#147;stockholder of
    record.&#148; If you are a stockholder of record, this proxy
    statement/prospectus and the enclosed proxy card have been sent
    directly to you by Abraxis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If your shares are held in a stock brokerage account or by a
    bank or other nominee, you are considered the beneficial owner
    of shares held in &#147;street name.&#148; This proxy
    statement/prospectus has been forwarded to you by your broker,
    bank or other nominee who is considered, with respect to those
    shares, the stockholder of record. As the beneficial owner of
    shares held in street name, you have the right to direct your
    broker, bank or other nominee how to vote your shares by using
    the voting instruction card included in the mailing.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Quorum</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In order to transact business at the special meeting, a quorum
    of Abraxis stockholders must be present. A quorum will exist if
    holders of a majority of the outstanding shares of Abraxis
    common stock as of the close of business on the record date are
    present in person, or represented by proxy, at the special
    meeting. The presence at the special meeting, either in person
    or by proxy, of the principal stockholders will establish a
    quorum. If a quorum is not present, the special meeting may be
    adjourned to a later date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Holders of shares of Abraxis common stock present in person at
    the special meeting but not voting, and shares of Abraxis common
    stock for which Abraxis has received proxies indicating that
    their holders have abstained, will be counted as present at the
    special meeting for purposes of determining whether a quorum is
    established.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Vote
    Required</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Provided a quorum of stockholders is present in person or by
    proxy at the special meeting, in order to adopt the merger
    agreement, holders of a majority of the outstanding shares of
    Abraxis common stock must cast a vote in favor of the proposal
    to adopt the merger agreement. Because approval is based on the
    affirmative vote of a majority of the outstanding shares of
    Abraxis common stock, an Abraxis stockholder&#146;s failure to
    submit a proxy card or to vote in person at the special meeting
    or an abstention from voting, or the failure of a Abraxis
    stockholder who holds his or her shares in &#147;street
    name&#148; through a broker, bank or other nominee to give
    voting instructions to such broker, bank or other nominee, will
    have the same effect as a vote &#147;AGAINST&#148; the adoption
    of the merger agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If there are not sufficient votes to adopt the merger agreement
    at the time of the special meeting, a majority of the votes
    present in person or by proxy (whether or not a quorum is
    present) may adjourn the meeting to another time and place in
    order to solicit additional proxies. Abstentions and broker
    non-votes will have the same effect as a vote
    &#147;AGAINST&#148; the proposal to adjourn the special meeting.
    Shares not in attendance at the special meeting will have no
    effect on the outcome of any vote to adjourn the special meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Recommendation
    of the Abraxis Board of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Abraxis board of directors unanimously determined that the
    transactions contemplated by the merger agreement, including the
    merger, are advisable and fair to, and in the best interest of,
    Abraxis and its stockholders, adopted the merger agreement and
    declared advisable the merger. The Abraxis board of directors
    unanimously recommends that Abraxis stockholders vote
    <B>&#147;FOR&#148;</B> the proposal to adopt the merger
    agreement. See &#147;The Merger&#160;&#151; Reasons for the
    Merger.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis stockholders should carefully read this proxy
    statement/prospectus in its entirety for more detailed
    information concerning the merger agreement and the transactions
    contemplated by the merger agreement, including the merger. In
    addition, Abraxis stockholders are directed to the merger
    agreement, which is attached as Annex&#160;A to this proxy
    statement/prospectus.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting by
    the Principal Stockholders</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010, the principal stockholders, who together
    own approximately 81.9% of the outstanding shares of Abraxis
    common stock as of the record date, entered into a voting
    agreement with Celgene and merger sub, under which they agreed,
    subject to the terms thereof, to vote all of their shares of
    Abraxis common stock in favor of the approval and adoption of
    the merger agreement and the transactions contemplated by the
    merger agreement and against, among other things, any business
    combination or extraordinary corporate transaction involving
    Abraxis or any or its subsidiaries, other than the merger or any
    business combination or transaction with Celgene or any of its
    affiliates. Each of the principal stockholders also granted an
    irrevocable proxy to Celgene to vote or execute consents with
    respect to such principal stockholder&#146;s shares of Abraxis
    common stock in accordance with the preceding sentence. The
    voting agreement will terminate upon the earliest to occur of:
    (1)&#160;the completion of the merger, (2)&#160;any material
    amendment to the merger agreement that is adverse to the
    principal stockholders that has not been approved by them and
    (3)&#160;the termination of the merger agreement in accordance
    with its terms. The principal stockholders&#146; vote will be
    sufficient under Delaware law to adopt the merger agreement
    without the approval of any other stockholder of Abraxis.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Ownership of, and Voting by, Abraxis&#146; Directors and
    Executive Officers</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of the record date, directors and executive officers of
    Abraxis had the right to vote 33,194,952 shares of Abraxis
    common stock, entitling them to collectively cast approximately
    81.9% of the votes entitled to be cast at the special meeting.
    This includes 33,186,067 shares of Abraxis common stock that the
    principal stockholders had the right to vote. As noted above,
    the principal stockholders have agreed collectively to vote
    their shares of Abraxis common stock in favor of the adoption of
    the merger agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Except as described above as to shares held by the principal
    stockholders, none of Abraxis&#146; directors or officers has
    entered into any agreement requiring them to vote for or against
    the proposal to adopt the merger agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">How to
    Vote</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There are two ways for Abraxis stockholders to vote:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Mail.</I>&#160;&#160;You can vote by mail by completing,
    signing, dating and mailing your proxy card or voting
    instruction card in the postage-paid envelope included with this
    proxy statement/prospectus. Abraxis must receive your proxy card
    no later than the close of business on October&#160;12, 2010.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>In Person.</I>&#160;&#160;In addition, all Abraxis
    stockholders as of the record date may attend the special
    meeting and vote in person. You may also be represented by
    another person at the special meeting by executing a proper
    proxy designating that person. If you are a beneficial owner of
    shares held in street name, you must obtain a proxy from your
    broker, bank or other nominee and present it to the inspectors
    of election with your ballot when you vote at the special
    meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting of
    Shares&#160;Held in Street Name</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If your shares are held in an account at a broker, bank or other
    nominee, you must instruct the broker, bank or other nominee on
    how to vote your shares by following the instructions that the
    broker, bank or other nominee provides you with this proxy
    statement/prospectus. If you do not provide voting instructions
    to your broker, your shares will not be voted on any proposal on
    which your broker does not have discretionary authority to vote.
    This is referred to in this proxy statement/prospectus and in
    general as a broker non-vote. In these cases, the broker, bank
    or other nominee can register your shares as being present at
    the special meeting for purposes of determining a quorum, but
    will not be able to vote your shares on those matters for which
    specific authorization is required. Brokers do not have
    discretionary authority to vote on the proposal to adopt the
    merger agreement. Therefore, a broker non-vote will have the
    same effect as a vote &#147;AGAINST&#148; adoption of the merger
    agreement.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Attending
    the Special Meeting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All Abraxis stockholders as of the close of business on the
    record date may attend the special meeting by showing photo
    identification and signing in at the special meeting. If you are
    a stockholder of record (i.e., your shares are held in your
    name), you must list your name as it appears on your stock
    ownership records from American Stock Transfer&#160;&#038;
    Trust&#160;Company. Your proxy card will admit you and one
    guest. If you hold shares through a broker, bank or other
    nominee, you must also provide a copy of your bank, broker or
    other nominee statement showing your ownership as of the close
    of business on the record date.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting of
    Proxies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you vote by completing, signing, dating and mailing your
    proxy card or voting instruction card, your shares will be voted
    in accordance with your instructions. If you are a stockholder
    of record and you sign, date and return your proxy card but do
    not indicate how you want to vote or do not indicate that you
    wish to abstain, your shares will be voted
    <B>&#147;FOR&#148;</B> the adoption of the merger agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Revoking
    Your Proxy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you are a stockholder of record, you may revoke your proxy at
    any time before it is voted at the special meeting by:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    sending a signed notice of revocation to the Corporate Secretary
    of Abraxis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    submitting a revised proxy bearing a later date;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    attending the special meeting and voting in person, which will
    automatically cancel any proxy previously given, or revoking
    your proxy in person, but your attendance alone will not revoke
    any proxy that you have previously given.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you choose either of the first two methods, you must submit
    your notice of revocation or your new proxy no later than the
    beginning of the special meeting. If you are a beneficial owner
    of shares of Abraxis common stock, you may submit new voting
    instructions by contacting your broker, bank or other nominee.
    You may also vote in person at the special meeting if you obtain
    a proxy from your broker, bank or other nominee and present it
    to the inspectors of election with your ballot when you vote at
    the special meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Solicitation
    of Proxies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This proxy statement/prospectus is furnished in connection with
    the solicitation of proxies by the Abraxis board of directors to
    be voted at the special meeting. Abraxis will bear all costs and
    expenses in connection with the solicitation of proxies,
    including the charges of brokerage houses and other custodians,
    nominees or fiduciaries for forwarding documents to security
    owners. Proxies may also be solicited by certain of
    Abraxis&#146; directors, officers and employees by telephone,
    electronic mail, letter, facsimile or in person, but no
    additional compensation will be paid to them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Stockholders should not send stock certificates with their
    proxies.</I>&#160;&#160;A letter of transmittal and instructions
    for the surrender of Abraxis common stock certificates will be
    mailed to Abraxis stockholders shortly after the completion of
    the merger.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholders
    Sharing an Address</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Consistent with notices sent to record stockholders sharing a
    single address, Abraxis is sending only one copy of this proxy
    statement/prospectus to that address unless Abraxis received
    contrary instructions from any stockholder at that address. This
    &#147;householding&#148; practice reduces Abraxis&#146; printing
    and postage costs. Stockholders may request to discontinue
    householding, or may request a separate copy of this proxy
    statement/prospectus by one of the following methods:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    record stockholders wishing to discontinue or begin
    householding, or any record stockholder residing at a household
    address wanting to request delivery of a copy of this proxy
    statement/prospectus should contact
</TD>
</TR>

</TABLE>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    the Corporate Secretary at Abraxis BioScience, Inc., 11755
    Wilshire Boulevard, Suite&#160;2000, Los Angeles, CA
    90025;&#160;and
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    stockholders owning their shares through a bank, broker or other
    holder of record who wish to either discontinue or begin
    householding should contact their record holder.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Business</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Abraxis board of directors is not aware of any other
    business to be acted upon at the special meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Assistance</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you need assistance in completing your proxy card or have
    questions regarding the special meeting, please contact:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Attention: Investor Relations
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11755 Wilshire Boulevard, Suite&#160;2000
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Los Angeles, California 90025
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Telephone Number:
    <FONT style="white-space: nowrap">(310)&#160;883-1300.</FONT>
</DIV>

<A name='111'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    PARTIES TO THE MERGER</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Celgene
    Corporation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>86 Morris Avenue</I>
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Summit, New Jersey 07901</I>
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Telephone:
    <FONT style="white-space: nowrap">(908)&#160;673-9000</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation, a corporation organized under the laws of
    Delaware, which we refer to as Celgene, is a global integrated
    biopharmaceutical company primarily engaged in the discovery,
    development and commercialization of innovative therapies
    designed to treat cancer and immune-inflammatory related
    diseases. Celgene is dedicated to innovative research and
    development which is designed to bring new therapies to market.
    Celgene is also involved in research in several scientific areas
    that may deliver proprietary next-generation therapies,
    targeting areas such as intracellular signaling pathways in
    cancer and immune cells, immunomodulation in cancer and
    autoimmunity and placental cell, including stem and progenitor
    cell, research. The drug and cell therapies Celgene develops are
    designed to treat life-threatening diseases or chronic
    debilitating conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene common stock is listed on The NASDAQ Global Select
    Market, under the symbol &#147;CELG.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Additional information about Celgene is included in the
    documents incorporated by reference into this proxy
    statement/prospectus. See &#147;Where You Can Find More
    Information.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Abraxis
    BioScience, Inc.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>11755 Wilshire Boulevard, Suite&#160;2000</I>
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Los Angeles, California 90025</I>
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Telephone:
    <FONT style="white-space: nowrap">(310)&#160;883-1300</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc., a corporation organized under the laws
    of Delaware, which we refer to as Abraxis, is a fully integrated
    global biotechnology company dedicated to the discovery,
    development and delivery of next-generation therapeutics and
    core technologies that offer patients safer and more effective
    treatments for cancer and other critical illnesses.
    Abraxis&#146; product portfolio includes the chemotherapeutic
    compound
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    which is based on Abraxis&#146; proprietary tumor targeting
    technology known as the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    platform. The first product approved by the U.S.&#160;Food and
    Drug Administration, which we refer to as FDA, to use this
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    platform,
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    was launched in 2005 for the treatment of metastatic breast
    cancer and is now approved in 41&#160;countries. Abraxis
    continues to expand the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    platform through a robust clinical program and deep product
    pipeline.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis common stock is listed on The NASDAQ Global Select
    Market under the symbol &#147;ABII.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Additional information about Abraxis is included in the
    documents incorporated by reference into this proxy
    statement/prospectus. See &#147;Where You Can Find More
    Information.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Artistry
    Acquisition Corp.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>86 Morris Avenue</I>
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Summit, New Jersey 07901</I>
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Telephone:
    <FONT style="white-space: nowrap">(908)&#160;673-9000</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Artistry Acquisition Corp., a corporation organized under the
    laws of Delaware, which we refer to as merger sub, was formed
    solely for the purpose of facilitating the merger. Merger sub
    has not carried on any activities or operations to date, except
    for those activities incidental to its formation and undertaken
    in connection with the transactions contemplated by the merger
    agreement. By operation of the merger, merger sub will be merged
    into Abraxis, merger sub&#146;s separate existence will cease
    and Abraxis will become a direct or indirect wholly-owned
    subsidiary of Celgene.
</DIV>

<A name='112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    MERGER</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following is a description of the material aspects of the
    merger. While we believe that the following description covers
    the material terms of the merger, the description may not
    contain all of the information that may be important to you. The
    discussion of the merger in this proxy statement/prospectus is
    qualified in its entirety by reference to the merger agreement,
    which is attached to this proxy statement/prospectus as
    Annex&#160;A and incorporated by reference into this proxy
    statement/prospectus. We encourage you to read carefully this
    entire proxy statement/prospectus, including the merger
    agreement, for a more complete understanding of the merger.
</DIV>

<A name='113'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Background
    of the Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On January&#160;20, 2009, Abraxis announced its intention to
    spin-off Abraxis Health, a new company that would hold the
    assets and liabilities constituting the drug discovery,
    manufacturing and development operations then being conducted by
    Abraxis. On January&#160;21, 2009, Abraxis Health filed a
    Registration Statement on Form&#160;10 with respect to the
    spin-off.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On May&#160;15, 2009, Bruce Wendel, Abraxis&#146; current Chief
    Executive Officer and then Executive Vice President of Corporate
    Operations and Development, received a telephone call from a
    senior executive of a company that we refer to as Party A
    inquiring about Abraxis&#146; interest in providing Party A with
    a European license for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.

    Mr.&#160;Wendel indicated that Abraxis was not interested in
    pursuing licensing transactions at that time. Later in May 2009,
    Party A expressed interest in exploring a potential acquisition
    of Abraxis in connection with the then contemplated spin-off of
    Abraxis Health and requested access to non-public information
    regarding Abraxis so that it could formulate a proposal.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Between June 2009 and March 2010, following the execution of a
    confidentiality agreement by Party A, which did not contain a
    standstill provision, Abraxis provided Party A with access to
    certain non-public information requested by Party A. In
    addition, Mr.&#160;Wendel, and other members of Abraxis
    management made presentations to representatives of Party A
    regarding Abraxis and its operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In September 2009, Party A made a preliminary non-binding
    proposal to acquire Abraxis simultaneously with a spin-off of
    Abraxis Health in a transaction in which Abraxis stockholders
    would receive an upfront cash payment and shares of Abraxis
    Health in the spin-off. Abraxis Health would be entitled to
    receive annual royalties based on the net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    through 2020. After reviewing Party A&#146;s proposal with
    representatives of Lazard Fr&#232;res&#160;&#038; Co. LLC, which
    we refer to as Lazard, and Goldman, Sachs&#160;&#038; Co., which
    we refer to as Goldman Sachs, and engaging in further
    discussions with Party A, including a meeting on
    November&#160;19, 2009, Abraxis rejected Party A&#146;s proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In September 2009, after receiving the non-binding proposal from
    Party A, Abraxis directed representatives of Lazard and Goldman
    Sachs to contact potential acquirors to assess their interest in
    a potential acquisition of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis. Representatives of Lazard and Goldman Sachs thereafter
    contacted more than 20 potential acquirors of Abraxis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On September&#160;19, 2009, representatives of Lazard and George
    Golumbeski, Senior Vice President of Business Development for
    Celgene, discussed exploring a possible transaction with
    Abraxis. Celgene and Abraxis executed a mutual non-disclosure
    agreement effective as of October&#160;16, 2009, with only
    limited diligence taking place at this time and no subsequent
    plans for additional meetings.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Between October 2009 and March 2010, of the parties contacted by
    representatives of Lazard and Goldman Sachs, 10 parties executed
    confidentiality agreements and performed due diligence on
    Abraxis. None of the confidentiality agreements contained a
    standstill provision. Following execution of the confidentiality
    agreements, the parties and their legal and financial advisors
    were given access to due diligence materials and several
    attended management presentations given by members of management
    of Abraxis. From October 2009 through March 2010,
    representatives of Abraxis engaged in periodic discussions and
    meetings with parties that had executed confidentiality
    agreements with Abraxis, including Party A. At such meetings,
    the parties discussed general industry trends and the potential
    strategic fit of Abraxis with their companies and various due
    diligence matters.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On January&#160;28, 2010, Abraxis publicly reiterated its
    intention to complete the spin-off of Abraxis Health in 2010.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On March&#160;12, 2010, a potential acquiror, who we refer to as
    Party B, executed a confidentiality agreement, which did not
    contain a standstill provision. Following the execution of the
    confidentiality agreement, Party B and its legal and financial
    advisors were provided access to due diligence information
    regarding Abraxis.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On March&#160;17, 2010, Mr.&#160;Wendel and other members of
    Abraxis management made a presentation to representatives of
    Party B regarding Abraxis and its operations. After this
    meeting, Party B indicated that it was interested in concluding
    a transaction to acquire Abraxis simultaneously with the
    spin-off of Abraxis Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Also on March&#160;17, 2010, Abraxis announced that it had
    achieved the primary endpoint of overall response rate in its
    Phase 3 trial comparing
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    with
    Taxol<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    both in combination with carboplatin, in the first-line
    treatment of patients with advanced non-small cell lung cancer.
    As a result of this announcement, representatives of Lazard and
    Goldman Sachs received several phone calls from parties
    expressing an interest in a possible strategic transaction with
    Abraxis. In addition, discussions with Party A, Party B and four
    other potential acquirors continued.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In light of the March&#160;17th&#160;data announcement, on
    March&#160;18, 2010, Celgene contacted representatives of Lazard
    to schedule a meeting in April with representatives of Abraxis.
    The meeting was scheduled for April&#160;20, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On March 30 and 31, 2010, Party B performed due diligence on
    Abraxis&#146; manufacturing facility in Phoenix, Arizona.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On April&#160;5, 2010, at a meeting of the Abraxis board of
    directors, management delivered an update regarding discussions
    with potential acquirors. After discussion, the Abraxis board of
    directors unanimously authorized management to continue
    discussions with interested parties and invite them to submit a
    preliminary proposal for an acquisition of Abraxis
    simultaneously with the spin-off of Abraxis Health. The Abraxis
    board of directors also unanimously authorized management to
    formally engage investment bankers to assist in this process,
    and Lazard and Goldman Sachs were formally engaged by Abraxis.
    The Abraxis board of directors did not set up a special
    committee in connection with the sale process because a majority
    of the directors of Abraxis are independent.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Following this discussion, during the week of April&#160;5,
    2010, at the direction of Abraxis, representatives of Lazard and
    Goldman Sachs distributed a letter to Party B, Celgene and four
    other potential acquirors inviting them to deliver a non-binding
    proposal for an acquisition of Abraxis simultaneously with a
    spin-off of Abraxis Health. During this time, Party&#160;A and
    representatives of Abraxis continued to have discussions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On April&#160;6, 2010, representatives of Abraxis, Lazard and
    Celgene held a call to discuss the new
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    data from the Phase 3 non-small cell lung cancer trial in
    preparation for the April&#160;20, 2010 meeting. During the
    discussion, Celgene indicated a desire to perform a
    comprehensive due diligence review of Abraxis and its operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On April&#160;20, 2010, Mr.&#160;Wendel and other
    representatives of Abraxis met with representatives of
    Celgene&#146;s Business Development, Clinical Development,
    Marketing and Regulatory departments at Celgene&#146;s
    headquarters in New Jersey. At the meeting, the parties
    discussed due diligence topics, general industry trends and the
    potential strategic opportunity for Celgene to acquire Abraxis.
    Celgene and representatives from its legal counsel, Jones Day,
    subsequently performed
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    due diligence on Abraxis&#146; manufacturing facility in Phoenix
    Arizona on April 29 and 30, 2010 and on the manufacturing
    facilities in Grand Island, New York and Melrose Park, Illinios
    on June 2 and 3, 2010, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At a meeting of the Abraxis board of directors held on
    May&#160;5, 2010, members of management updated the board of
    directors on the on-going discussions with the potential
    acquirors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As a result of the April&#160;20th&#160;meeting and subsequent
    diligence conducted by Celgene representatives on
    April&#160;29th&#160;and 30th, Celgene&#146;s Business
    Development executives recommended to Celgene senior management
    that the company submit a non-binding, preliminary acquisition
    proposal. On May&#160;12, 2010, Celgene submitted a non-binding,
    preliminary proposal, subject to further due diligence, to
    acquire the outstanding shares of Abraxis common stock. This
    initial proposal contemplated the acquisition by Celgene of all
    of the outstanding shares of Abraxis common stock at a price per
    share of $62.00 in cash plus the following post-closing payments
    to the stockholders of Abraxis:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $250&#160;million upon the achievement of FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of non-small cell lung cancer, which
    approval permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes a progression free survival claim;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $300&#160;million upon the achievement of FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of pancreatic cancer, which approval
    permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes an overall survival claim;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Cash payments equal to 5% of annual net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in excess of $2.5&#160;billion in any year.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The proposal indicated that Celgene was open to discussing the
    most efficient manner to deliver the post-closing payments.
    Celgene indicated that the proposal assumed the full acquisition
    of Abraxis&#146;
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    technology platform, all of Abraxis&#146; manufacturing
    operations and all compounds in development by Abraxis but
    indicated that Celgene would consider a simultaneous spin-off of
    Abraxis Health with certain assets, including potential access
    by Abraxis Health to the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    technology, to be determined.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On May&#160;20, 2010, Party B submitted a non-binding,
    preliminary proposal, subject to further due diligence, to
    acquire 100% of the outstanding shares of Abraxis common stock.
    The proposal contemplated the spin-off of Abraxis Health
    simultaneous with the acquisition of Abraxis and included
    up-front cash consideration and post-closing cash payments based
    on the achievement of certain milestones and royalty payments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On May&#160;24, 2010, Sol Barer, the current Executive Chairman
    of Celgene and then Chairman and Chief Executive Officer, and
    Robert Hugin, the current Chief Executive Officer of Celgene and
    then President and Chief Operating Officer, met with
    Dr.&#160;Patrick Soon-Shiong, Executive Chairman of Abraxis in
    Los Angeles. Mr.&#160;Wendel was also present. At this time,
    Dr.&#160;Soon-Shiong discussed
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products and the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    technology, as well as other technologies and assets being
    pursued by Abraxis, including those technologies and assets that
    were previously identified for a potential spin off of Abraxis
    Health. The participants also discussed Celgene&#146;s
    non-binding proposal and Celgene&#146;s principal interest in
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products and the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    technology being the primary strategic fit with Celgene&#146;s
    businesses. Following the meeting, representatives of Abraxis
    and Celgene, together with representatives of the legal and
    financial advisors to Celgene, and representatives of
    Morrison&#160;&#038; Foerster LLP, Abraxis&#146; intellectual
    property counsel, held due diligence meetings in Los Angeles on
    May 25 and 26.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In late May 2010, Abraxis learned from the United States Patent
    and Trademark Office that a pending patent application covering
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    with composition of matter and method of use claims would be
    receiving a notice of allowance that could extend patent
    coverage for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    through the end of 2023. At the direction of Abraxis,
    representatives of Lazard, Goldman Sachs and an additional
    financial advisor retained by Abraxis, Merrill Lynch, Pierce,
    Fenner &#038; Smith Incorporated, which we refer to as BofA
    Merrill Lynch, shared this information with interested parties,
    including Celgene, Parties A and B and several other global
    pharmaceutical companies that had performed due diligence on
    Abraxis. At this time, Abraxis retained BofA Merrill Lynch on
    the basis of its experience and reputation in the investment
    community, its familiarity with Abraxis and its business and its
    familiarity with other global pharmaceutical companies,
    including Celgene.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;1, 2010, at the instruction of Abraxis,
    representatives of Lazard, Goldman Sachs and BofA Merrill Lynch,
    distributed a letter to Celgene and Party B inviting them to
    submit their final proposals for an acquisition of Abraxis.
    Later that week, Dr.&#160;Soon-Shiong and Party B&#146;s Chief
    Executive Officer held a telephone conference to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    discuss Party B&#146;s non-binding proposal in more detail and
    the potential strategic fit of their companies as well as the
    process and timing for a potential transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At a meeting of the Abraxis board of directors held on
    June&#160;3, 2010, management updated the board of directors on
    the transaction process and discussed the non-binding,
    preliminary proposals received from Celgene and Party B.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    From June&#160;2, 2010 to June&#160;4, 2010, representatives of
    Celgene and Jones Day conducted diligence at Abraxis&#146; Grand
    Island, New York and Melrose Park, Illinois manufacturing
    facilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;4, 2010, at the instruction of Abraxis,
    representatives of Lazard distributed to Celgene and Party B
    drafts of a merger agreement, a CVR agreement and a voting
    agreement to be entered into by certain principal stockholders
    of Abraxis. On June&#160;9, 2010, at the instruction of Abraxis,
    representatives of Lazard distributed to Celgene and Party B a
    draft of a term sheet outlining the principal terms and
    agreements of the spin-off of Abraxis Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Subsequent to the draft definitive agreements and term sheet
    being provided to Celgene and Party B and at the direction of
    Abraxis, representatives of Lazard, Goldman Sachs and BofA
    Merrill Lynch requested that Celgene and Party B deliver marked
    copies of the transaction documents by Friday, June&#160;18,
    2010, and deliver a final acquisition proposal on Monday,
    June&#160;21, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    During the week of June&#160;14, representatives of Jones Day
    and Fried Frank Harris Shriver&#160;&#038; Jacobson LLP, counsel
    to Abraxis which we refer to as Fried Frank, engaged in
    telephone conferences to discuss various terms of the draft
    transaction documents circulated to Celgene.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;17, 2010, Dr.&#160;Soon-Shiong and Mr.&#160;Hugin
    met again in Los Angeles to discuss the proposed next steps in
    the transaction and various other matters. At this meeting,
    Mr.&#160;Hugin indicated that, because of the complexity and
    potential delay involved in a simultaneous spin-off and in the
    interest of consummating an acquisition expeditiously, Celgene
    was prepared to acquire all of Abraxis without a simultaneous
    spin-off of Abraxis Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;18, 2010, Celgene delivered to representatives of
    Lazard a markup of the draft merger agreement, voting agreement
    and CVR agreement as well as a markup of the term sheet for the
    Abraxis Health spin-off. The accompanying cover letter and
    subsequent communications re-iterated that, for the sake of
    simplicity and timing, Celgene was interested in acquiring
    Abraxis without the spin-off of Abraxis Health and strongly
    believed proceeding with a full acquisition of Abraxis would
    benefit timing of the completion of the transaction and simplify
    the necessary agreements. The draft agreements provided for
    execution by the principal stockholders of an action by written
    consent approving and adopting the merger agreement immediately
    after the SEC&#146;s declaration that the registration statement
    required for the issuance of the CVRs was effective, providing
    that until such time the Abraxis board of directors could
    terminate the agreement to accept a superior acquisition
    proposal, and prohibited the principal stockholders from
    engaging in discussions with a third party that made an
    unsolicited proposal even in circumstances where Abraxis would
    be permitted under the merger agreement to engage in those
    discussions. The markup also contemplated that
    Dr.&#160;Soon-Shiong and potentially other employees of Abraxis
    would execute noncompetition agreements in favor of Celgene.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;21, 2010, Celgene submitted a revised proposal,
    subject to certain limited confirmatory due diligence items, to
    acquire all of the outstanding shares of Abraxis common stock.
    This proposal contemplated the acquisition by Celgene of all of
    the outstanding shares of Abraxis common stock at a price per
    share of $70.00 in cash plus the following post-closing payments
    through the CVRs:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $250&#160;million upon the achievement of FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of non-small cell lung cancer, which
    approval permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes a progression free survival claim;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $100&#160;million upon the achievement of accelerated FDA
    approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of pancreatic cancer based on phase
    I/II data;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $300&#160;million upon the achievement of FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of pancreatic cancer, which approval
    permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes an overall survival claim;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Cash payments equal to 2.5% of annual net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    between $1.5&#160;billion and $2.5&#160;billion and 5% of annual
    net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in excess of $2.5&#160;billion.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The proposal indicated that the payment of the milestone
    payments in the first three bullets above was contingent on
    achievement of the milestone within 5&#160;years after the
    completion of the merger. The proposal also contemplated a
    potential spin-off of Abraxis Health immediately prior to the
    completion of the merger but did not identify what assets or
    business would be transferred to Abraxis Health or constitute
    the Abraxis Health business. In subsequent conversations,
    Celgene again confirmed its interest in an acquisition of all of
    Abraxis without a spin-off of Abraxis Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;22, 2010, representatives of Celgene and Jones Day
    met with representatives of Abraxis, Goldman Sachs and
    Abraxis&#146; regulatory counsel to discuss the current and
    future potential regulatory approvals of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and Abraxis&#146;
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;22, 2010, Party B submitted a proposal to acquire
    100% of Abraxis that provided for different payments to be made
    to each of Dr.&#160;Soon-Shiong and his affiliated entities and
    to other stockholders of Abraxis. Under the proposal,
    Dr.&#160;Soon-Shiong and his affiliated entities would have
    received only the shares of Abraxis Health at closing plus all
    future milestone and royalty payments based on
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    approvals and revenues. Abraxis stockholders other than
    Dr.&#160;Soon-Shiong and his affiliated entities would receive
    only an up front cash payment for their shares. The up front
    cash payment payable to Abraxis stockholders other than
    Dr.&#160;Soon-Shiong and his affiliated entities would depend on
    a number of variables, including Abraxis&#146; available cash at
    the completion of any such transaction. Abraxis management made
    various assumptions regarding the proposed variables and the
    potential performance of Abraxis pending the completion of such
    a transaction and based on this analysis concluded that the up
    front cash payment that would be received by Abraxis
    stockholders other than Dr.&#160;Soon-Shiong and his affiliated
    entities would be approximately $72 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Also on June&#160;22, 2010, a special meeting of the Abraxis
    board of directors was held to discuss the proposals submitted
    by Celgene and Party B at which members of senior management of
    Abraxis and representatives of Lazard, Goldman Sachs, BofA
    Merrill Lynch, Fried Frank and Morrison&#160;&#038; Foerster,
    counsel to the Abraxis board of directors, were present. At the
    meeting, members of senior management and representatives of
    Lazard, Goldman Sachs, BofA Merrill Lynch and Fried Frank
    discussed with the board the terms of the proposals submitted by
    Celgene and Party B. Also at this meeting, representatives of
    Lazard, Goldman Sachs and BofA Merrill Lynch noted that they
    believed they had contacted or been contacted by the most likely
    potential acquirors for Abraxis. Morrison&#160;&#038; Foerster
    discussed the board&#146;s fiduciary duties in connection with a
    potential acquisition transaction. The Abraxis board of
    directors then authorized its financial and legal advisors to
    continue discussions with Celgene pending a scheduled meeting
    between Dr.&#160;Soon-Shiong and Mr.&#160;Wendel from Abraxis
    and Dr.&#160;Barer and Mr.&#160;Hugin of Celgene on Friday,
    June&#160;25, 2010 and to continue discussions with Party B.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;23, 2010, Fried Frank delivered to Jones Day
    revised copies of the transaction agreements and on
    June&#160;24, 2010 representatives of Fried Frank and Jones Day
    participated in a conference call to discuss the comments to the
    transaction documents. Among other items, the revised
    transaction agreements contemplated that the Abraxis board of
    directors would be permitted to terminate the merger agreement
    to accept a superior proposal until Abraxis stockholders
    approved the merger at a special meeting rather than approving
    the merger by written consent as proposed by Celgene.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;24, 2010, Dr.&#160;Soon-Shiong and Party B&#146;s
    Chief Executive Officer held a telephone conference to discuss
    Party B&#146;s non-binding proposal in more detail as well as
    the process and timing for a potential transaction. Later that
    day, the Abraxis board of directors met and were given an update
    on the discussions with Celgene and Party B.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;25, 2010, Dr.&#160;Soon-Shiong and Mr.&#160;Wendel
    met Dr.&#160;Barer and Mr.&#160;Hugin at the offices of BofA
    Merrill Lynch in New York. At the meeting, Dr.&#160;Soon-Shiong
    indicated that Abraxis would be prepared to consider
    Celgene&#146;s proposal to acquire all of Abraxis if Celgene
    would increase the consideration payable to Abraxis&#146;
    stockholders. During the meeting, Celgene revised its proposal
    offering to pay at closing $72.00 per share of Abraxis common
    stock. The parties discussed that approximately 20% of the total
    merger consideration would be paid in the form of Celgene common
    stock. The revised proposal provided for cash payments through
    the CVRs equal to 2.5% of annual net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and Abraxis&#146; current
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products between $1.0&#160;billion and
    $2.0&#160;billion, 5% of annual net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and Abraxis&#146; current
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products between $2.0 and $3.0&#160;billion and 10% of
    annual net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and Abraxis&#146; current
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products in excess of $3.0&#160;billion. Finally, the
    revised proposal from Celgene provided that the proposed
    additional $100&#160;million
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    milestone for accelerated approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the treatment of pancreatic cancer could be achieved by any
    means (and not only by use of Phase I/II data), as long as such
    approval was achieved by December&#160;31, 2012. At this
    meeting, Dr.&#160;Soon-Shiong indicated that he would review
    with the Abraxis board of directors, and the board of directors
    would consider, Celgene&#146;s revised proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Early in the morning of June&#160;26, 2010, Celgene delivered
    revised drafts of the transaction agreements, including an
    initial draft of a noncompetition agreement proposed to be
    executed by Dr.&#160;Soon-Shiong and potentially other Abraxis
    employees in connection with a transaction and a proposed
    stockholders&#146; agreement to be executed by
    Dr.&#160;Soon-Shiong and his affiliated entities with respect to
    the shares of Celgene common stock they would receive in the
    transaction under Celgene&#146;s revised proposal. The
    stockholders&#146; agreement provided that Dr.&#160;Soon-Shiong
    and his affiliated entities (but not other stockholders of
    Abraxis) would be required to retain the shares of Celgene
    common stock owned by such stockholder for three years following
    the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Around June 26 to 27, 2010, Dr.&#160;Soon-Shiong and Party
    B&#146;s Chief Executive Officer exchanged further telephone
    calls regarding the non-binding proposal and the process and
    timing for a potential transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    From June 26 through June&#160;29, 2010, representatives of
    Fried Frank and Jones Day met in person and exchanged drafts of
    the transaction documents, and made substantial progress toward
    finalizing the definitive documentation for the transaction. In
    addition, Celgene finalized its due diligence review of Abraxis,
    including conducting confirmatory
    <FONT style="white-space: nowrap">on-site</FONT> due
    diligence at Abraxis&#146; Melrose Park manufacturing facilities
    on June&#160;28, 2010. Among the key issues subject to
    negotiation were the period after signing of the merger
    agreement during which the Abraxis board of directors would be
    permitted to terminate the merger agreement to accept a superior
    proposal (with the parties agreeing that the board of directors
    could terminate the merger agreement to accept a superior
    proposal until Abraxis stockholders approved the merger at the
    special meeting) and the size of termination fee payable by
    Abraxis in the event of such a termination (with the parties
    ultimately agreeing to a $145&#160;million termination fee). In
    addition, Abraxis negotiated that the $100&#160;million
    milestone payment for accelerated approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    to treat pancreatic cancer, with a label that includes an
    overall survival claim, would be payable if
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    received such approval prior to April&#160;1, 2013 (rather than
    December&#160;31, 2012)&#160;and the parties determined the
    exchange ratio for the Celgene common stock to be received in
    the merger using the weighted average sales price of Celgene
    common stock in the 30&#160;days prior to the announcement of
    the merger.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;28, 2010, a special meeting of the Abraxis board of
    directors was held to discuss the status of discussions with
    Celgene and Party B. At the meeting, members of management of
    Abraxis and representatives of Lazard, Goldman Sachs, BofA
    Merrill Lynch and Fried Frank discussed with the Abraxis board
    of directors the status of negotiations of the transaction
    documentation and the transaction timeline. At the meeting,
    representatives of Lazard, Goldman Sachs and BofA Merrill Lynch
    also reviewed with the Abraxis board of directors their
    financial analyses of the proposed merger consideration in the
    proposed transaction with Celgene. At this time, the Abraxis
    board of directors determined not to proceed with negotiations
    with Party B because, based on prior discussions with Party B,
    the board believed Party B would be unwilling to materially
    improve its proposal.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;29, 2010, the Abraxis board of directors held a
    special meeting to discuss and consider the negotiated terms of
    the transaction documents with Celgene and to seek to reach a
    final determination of the board of directors&#146; views on the
    merger agreement and the proposed merger. Representatives of
    Lazard, Goldman Sachs and BofA Merrill Lynch discussed and
    responded to additional questions from the Abraxis board of
    directors regarding the financial analyses of the merger
    consideration previously reviewed with the board of directors.
    Following further discussion, Lazard, Goldman Sachs and BofA
    Merrill Lynch orally rendered their respective opinions, each of
    which was subsequently confirmed by delivery of a written
    opinion dated June&#160;30, 2010 to the effect that, as of that
    date and, subject to the qualifications, limitations and
    assumptions reflected in their respective written opinions, the
    merger consideration proposed to be received by the holders
    (other than Dr.&#160;Soon-Shiong and his affiliates to the
    extent excluded from such opinion) of shares of Abraxis common
    stock pursuant to the merger agreement was fair, from a
    financial point of view, to such stockholders as more fully
    described below in &#147;The Merger&#160;&#151; Opinions of
    Financial Advisors to Abraxis&#148;. Representatives of Fried
    Frank then reviewed the terms of the merger agreement and
    related documents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Following additional discussion, after considering, among other
    things, the factors described below under &#147;The
    Merger&#160;&#151; Reasons for the Merger&#160;&#151; the
    Abraxis Board of Directors,&#148; the Abraxis board of directors
    unanimously adopted resolutions reflecting that the proposed
    terms of the merger agreement and other transaction
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    documents, and the merger and other transactions contemplated by
    the merger agreement, are advisable, fair to and in the best
    interests of Abraxis and its stockholders, adopting the merger
    agreement and other transaction documents, approving the merger
    and the other transactions contemplated by the merger agreement,
    and unanimously recommending that Abraxis stockholders adopt the
    merger agreement and approve the merger and the other
    transactions contemplated by the merger agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After the Abraxis board of directors meeting adjourned, Fried
    Frank and Jones Day finalized the definitive documentation for
    the transaction, and the merger agreement and related agreements
    were executed later the following morning. The transaction was
    publicly announced in a press release issued before the opening
    of the market on June&#160;30, 2010.
</DIV>

<A name='114'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Reasons
    for the Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Abraxis&#146;
    Reasons for the Merger</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In evaluating the merger agreement and the merger, the Abraxis
    board of directors consulted with Abraxis management and legal
    and financial advisors and, in reaching its decision to approve
    the merger agreement and to recommend that Abraxis stockholders
    vote for the adoption of the merger agreement, the Abraxis board
    of directors considered a variety of factors, including the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that the upfront consideration payable in a combination
    of cash and shares of Celgene common stock represents a premium
    of (1)&#160;14.3% over the closing price per share of the
    Abraxis common stock on June&#160;28, 2010 and the high per
    share price of the Abraxis common stock over the 52&#160;week
    period ended June&#160;28, 2010; (2)&#160;27.2% over the volume
    weighted average price per share, or VWAP, over the 30 calendar
    days ended June&#160;28, 2010; and (3)&#160;41.7% over the
    closing price per share of the Abraxis common stock on
    June&#160;1, 2010, the first trading day within the 30 calendar
    days prior to June&#160;28, 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that approximately 80% of the upfront merger
    consideration is in the form of cash, which provides immediate
    liquidity and a high degree of certainty of value to Abraxis
    stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that approximately 20% of the upfront merger
    consideration is in the form of SEC-registered and transferable
    and tradable Celgene common stock, which allows Abraxis
    stockholders to participate in the benefits of a more
    diversified company with greater resources and to benefit from
    any future growth of the combined company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that, in addition to cash, each Abraxis stockholder
    will receive SEC-registered and transferable and tradable CVRs
    with a potential duration of 20&#160;years, which may provide
    Abraxis stockholders an opportunity to realize additional value
    by trading those CVRs in the public markets or, to the extent
    Abraxis as the surviving corporation generates net sales
    sufficient to meet certain thresholds
    <FONT style="white-space: nowrap">and/or</FONT>
    achieves certain milestones, through additional cash payments
    under the terms of the CVRs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the board of directors&#146; view that the stand-alone prospects
    of Abraxis may be adversely impacted by Abraxis&#146; limited
    financial resources;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the board of directors&#146; view that Abraxis stockholders will
    receive value in the merger that is materially greater than the
    value realizable by Abraxis stockholders on a stand-alone basis
    and under any reasonably available transaction alternatives;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the board of directors&#146; view that the sales process
    undertaken with assistance of Lazard, Goldman Sachs and BofA
    Merrill Lynch, in which multiple potential acquirors of Abraxis
    were contacted and ten parties executed confidentiality
    agreements and performed due diligence on Abraxis, was an
    effective process;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the board of directors&#146; view that the sale and negotiation
    process yielded a full and fair price for Abraxis;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that none of the executive officers of Abraxis were
    expected to enter into employment agreements with Celgene;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the belief that the business of Abraxis could potentially
    benefit from being part of the larger Celgene corporate group
    and having access to its international distribution network and
    customers, and that by virtue
</TD>
</TR>

</TABLE>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    of the shares of Celgene common stock and CVRs, Abraxis
    stockholders would have an ongoing opportunity to participate in
    those potential benefits;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    management&#146;s assessment, after consultation with Morgan
    Stanley&#160;&#038; Co. Incorporated, Celgene&#146;s financial
    advisor, that Celgene will have adequate capital resources to
    pay the cash portion of the merger consideration;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that Abraxis stockholders who do not vote to adopt the
    merger agreement and who follow certain prescribed procedures
    are entitled to appraisal rights under Delaware law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that Dr.&#160;Soon-Shiong and his related entities,
    which together hold approximately 82% of Abraxis&#146;
    outstanding common stock, indicated their support for the merger
    and their intention to enter into the voting agreement in
    support of the merger;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the respective opinions of Goldman Sachs, Lazard and BofA
    Merrill Lynch to the Abraxis board of directors that, as of the
    date of their opinions, and based upon and subject to the
    qualifications, limitations and assumptions set forth in their
    respective written opinions, the merger consideration to be
    received by the holders (other than Dr.&#160;Soon-Shiong and his
    affiliates to the extent excluded from such opinion) of shares
    of Abraxis common stock pursuant to the merger agreement was
    fair, from a financial point of view, to such holders, and the
    financial analyses related thereto prepared by Goldman Sachs,
    Lazard and BofA Merrill Lynch and described below under
    &#147;The Merger&#160;&#151; Opinions of Financial Advisors to
    Abraxis&#148;.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Abraxis board of directors also specifically considered the
    following terms of the merger agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the merger agreement permits Abraxis to respond to, and engage
    in discussions with, third parties who make unsolicited
    acquisition proposals, and permits the board of directors to
    terminate the merger agreement to accept a superior proposal
    prior to the stockholder vote at the special meeting;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the voting agreement entered into by Dr.&#160;Soon-Shiong and
    his related entities terminates if the merger agreement is
    terminated by Abraxis to accept a superior proposal, allowing
    the principal stockholders to support such superior proposal;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the limited and customary conditions to the parties&#146;
    obligations to complete the merger and the fact that there is no
    financing condition to Celgene&#146;s obligations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the customary nature of the representations, warranties and
    covenants of Abraxis in the merger agreement;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a covenant requiring that Celgene use its reasonable best
    efforts to register the CVRs under the Securities Act and cause
    those securities to be listed on The NASDAQ Global Select Market
    or another exchange, electronic trading network or trading
    platform as agreed by Abraxis and Celgene and a condition that
    the shares of Celgene common stock to be issued in the merger be
    listed on The NASDAQ Global Select Market.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to the merger agreement, the Abraxis board of
    directors also reviewed, considered and discussed the terms and
    potential ramifications of the other transaction documents
    proposed to be executed in connection with the merger agreement,
    including the voting agreement, the form of CVR agreement
    (including the potential 20&#160;year duration, the fact that it
    covers all current
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products and the fact that it contains certain
    diligence requirements with respect to development and
    commercialization), the non-competition agreement pursuant to
    which the principal stockholders will be generally prohibited
    for ten years after completion of the merger, subject to certain
    exceptions, from competing with the Abraxis business in the
    United States and all other countries in which Abraxis was
    engaged in the business at the time of the merger and the
    stockholders&#146; agreement pursuant to which certain of the
    principal stockholders have agreed not to dispose of any of the
    shares of Celgene common stock that they acquired in the merger
    for two years and not to transfer more than 25% of the shares of
    Celgene common stock held by them immediately after the merger
    prior to the third anniversary of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the course of its deliberations, the Abraxis board of
    directors also considered a variety of risks and other
    potentially negative factors, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the price of Celgene common stock at the closing of the merger
    may vary significantly from the price of Celgene common stock at
    the date of the announcement of the merger agreement and the
    date of this proxy
</TD>
</TR>

</TABLE>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    statement/prospectus and the merger agreement does not provide
    for any mechanism to increase the exchange ratio in such
    circumstances;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the milestones and net sales goals necessary to trigger payments
    under the CVRs may not be achieved by Abraxis and Celgene,
    potentially impacting the value and marketability of the CVRs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis has incurred and will continue to incur significant
    transaction costs and expenses in connection with the proposed
    transaction, regardless of whether or not the merger is
    consummated;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    since the merger consideration includes CVRs (which are
    unsecured obligations and are expressly subordinated to all
    senior obligations of the issuer), Abraxis stockholders are
    subject, with respect to the portion of the merger consideration
    represented by the CVRs, to the risk that there may be
    limitations on paying amounts as and when they become payable to
    the holders of the CVRs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the merger agreement precludes Abraxis from actively soliciting
    alternative acquisition proposals from third parties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the deal protection measures in the merger agreement, including
    the fact that the merger agreement included a $145&#160;million
    termination fee and matching rights, may inhibit other potential
    acquirors from submitting potentially superior proposals to
    acquire Abraxis and, if Abraxis terminates the merger agreement
    to accept a superior proposal, would result in an immediate
    $145&#160;million payment obligation to Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if the merger is not consummated for certain reasons, Abraxis
    may be required to pay a termination fee to Celgene equal to
    $145&#160;million (for a full descriptions of the reasons
    Abraxis would be required to pay a termination fee to Celgene,
    see &#147;The Merger Agreement&#160;&#151; Termination Fees and
    Expenses&#148;);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the operations of Abraxis will be restricted by interim
    operating covenants under the merger agreement during the period
    between signing the merger agreement and the closing of the
    merger, which could effectively prohibit Abraxis from
    undertaking any strategic initiatives or other material
    transactions to the detriment of Abraxis and its stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the receipt by a U.S.&#160;holder of the merger consideration in
    exchange for Abraxis common stock pursuant to the merger will be
    a taxable transaction for U.S.&#160;federal income tax
    purposes;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain of Abraxis&#146; directors and executive officers may
    receive certain benefits that are different from, and in
    addition to, those of Abraxis&#146; other stockholders (See
    &#147;The Merger&#160;&#151; Interests of Directors and
    Executive Officers of Abraxis in the Merger&#148;).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The foregoing discussion of the information and factors
    considered by the Abraxis board of directors is not exhaustive
    but is intended to reflect the material factors considered by
    the Abraxis board of directors. The Abraxis board of directors
    did not quantify or assign any relative or specific weight to
    the various factors that it considered. Rather, the Abraxis
    board of directors based its recommendation on the totality of
    the information presented to and considered by it. In addition,
    individual members of the Abraxis board of directors may have
    given different weights to different factors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After careful consideration, the Abraxis board of directors
    unanimously determined that the merger and the other
    transactions contemplated by the merger agreement are advisable,
    fair to and in the best interests of Abraxis stockholders and
    unanimously approved the merger agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Celgene&#146;s
    Reasons for the Merger</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Celgene board of directors unanimously approved the merger
    agreement and the transactions contemplated by the merger
    agreement, including the merger. In evaluating the merger
    agreement and the transactions contemplated by the merger
    agreement, including the merger, the Celgene board of directors
    consulted with the management of Celgene and outside legal and
    financial advisors for Celgene. In determining to approve the
    merger
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    agreement and the transactions contemplated by the merger
    agreement, including the merger, the Celgene board of directors
    considered numerous factors, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the belief that the acquisition of Abraxis accelerates
    Celgene&#146;s strategy to become a global leader in hematology
    and oncology by adding
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    to Celgene&#146;s existing portfolio of leading cancer therapies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    will provide Celgene with an immediate entry into the solid
    tumor therapeutic area (or market) because
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    is marketed and approved for second-line line use in metastatic
    breast cancer in the United States and certain international
    markets. Additionally, based on encouraging clinical data
    recently announced at major medical meetings,
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    holds the potential to serve patients with a number of other
    serious cancers such as non-small cell lung and pancreatic
    cancers, as well as melanoma, ovarian cancer, bladder cancer and
    first-line metastatic breast cancer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; core technology, which is known as the
    nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    platform, facilitates the targeting of compounds to tumor cells.
    The potential of the nab-technology platform coupled with
    Celgene&#146;s innovative drug discovery and development
    capabilities enhances Celgene&#146;s future product pipeline and
    its potential to deliver multiple novel anti-cancer agents;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The management of Celgene, assisted by advisors for Celgene,
    reviewed Abraxis&#146; financial condition, results of
    operations, business, reputation, risks and prospects, and
    concluded that an acquisition of Abraxis provides Celgene with
    additional current revenue that could significantly increase if
    regulatory approvals for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in non-small cell lung and pancreatic cancers are received;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exchange ratio of 0.2617 of a share of Celgene common stock
    for each share of Abraxis common stock is fixed and will not be
    adjusted for fluctuations in the market price of Celgene common
    stock or Abraxis common stock and the fact that, because the
    exchange ratio under the merger agreement is fixed, the per
    share value of the merger consideration to be paid to Abraxis
    stockholders upon completion of the merger could be
    significantly more or less than its implied value immediately
    prior to the announcement of the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the resulting percentage ownership interests and voting power
    that current Celgene stockholders would have in Celgene
    following the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that the CVRs will require Celgene to pay additional
    consideration only if specified regulatory approval milestones
    are achieved for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products exceed at least
    $1.0&#160;billion in annual net sales;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the terms and conditions of the merger agreement;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    current industry, economic and market conditions and trends,
    including Abraxis&#146; market position.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Celgene board of directors also considered a number of
    potentially negative factors in its deliberations considering
    the merger, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risk that the safety
    <FONT style="white-space: nowrap">and/or</FONT>
    efficacy results of clinical trials of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and other Abraxis pipeline products will not support additional
    FDA or other regulatory agencies approval of those products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    competition and its effect on pricing, spending, third-party
    relationships and revenues;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risk that regulatory authorities will condition their
    approval of the merger on Celgene&#146;s agreement to
    divestitures or other actions that could negatively impact the
    business and prospects of the Celgene following the completion
    of the merger, which Celgene has, subject to limited exceptions,
    agreed under the merger agreement to undertake if necessary to
    complete the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possible disruption to Celgene&#146;s business that may
    result from the merger, including the resulting distraction of
    the attention of the management of Celgene, and the costs and
    expenses associated with completing the merger;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risks that the potential benefits, synergies and cost
    savings sought in the merger may not be realized or may not be
    realized within the expected time period, and that the cost of
    achieving such benefits, synergies and savings may be
    significantly higher than estimated;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that Celgene has historically sold or otherwise
    disposed of non-core assets of companies that it acquires and
    may not be able to sell the non-core assets of Abraxis at fair
    market value, if at all, and prior to any such sale, Celgene
    will be required to expend the resources necessary to maintain
    and operate these assets, which may distract from Celgene&#146;s
    core businesses;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potential changes in reimbursement policies or rates for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or the Abraxis pipeline products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ability of Celgene and Abraxis to successfully protect and
    enforce their respective intellectual property rights;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the other risks described in the section entitled &#147;Risk
    Factors.&#148;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In view of the wide variety of factors considered in connection
    with its evaluation of the merger and the complexity of these
    matters, the Celgene board of directors did not find it useful,
    and did not attempt, to quantify, rank or otherwise assign any
    relative or specific weights to the factors that it considered
    in reaching its determination to approve the merger agreement
    and the transactions contemplated by the merger agreement,
    including the merger. In addition, individual members of the
    Celgene board of directors may have given differing weights to
    differed factors. The Celgene board of directors conducted an
    overall analysis of the factors described above, including
    through discussions with, and inquiry of, the management of
    Celgene and outside legal and financial advisors regarding
    certain of the matters described above.
</DIV>

<A name='115'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Opinions
    of Financial Advisors to Abraxis</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Merrill
    Lynch, Pierce, Fenner&#160;&#038; Smith
    Incorporated</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;29, 2010, at a meeting of the Abraxis board of
    directors held to evaluate the merger, BofA Merrill Lynch
    rendered to the Abraxis board of directors an oral opinion,
    which was confirmed by delivery of a written opinion dated
    June&#160;30, 2010, to the effect that, as of the date of the
    opinion, and based upon and subject to the factors, assumptions
    and limitations set forth therein, the merger consideration to
    be received in the merger by holders of Abraxis common stock
    (other than Dr.&#160;Soon-Shiong and his affiliates) was fair,
    from a financial point of view, to such holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>The full text of the written opinion of BofA Merrill Lynch to
    the Abraxis board of directors, dated June&#160;30, 2010, which
    sets forth assumptions made, procedures followed, matters
    considered and limitations on the review undertaken in
    connection with the opinion, is attached to this proxy
    statement/prospectus as Annex&#160;E. The following summary of
    BofA Merrill Lynch&#146;s opinion is qualified in its entirety
    by reference to the full text of the opinion. BofA Merrill Lynch
    provided its opinion to the Abraxis board of directors for the
    benefit and use of the Abraxis board of directors in connection
    with and for purposes of its evaluation of the merger
    consideration from a financial point of view. BofA Merrill
    Lynch&#146;s opinion does not address any other aspect of the
    merger and does not constitute a recommendation to any
    stockholder as to how to vote or act in connection with the
    merger or any related matter.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with rendering its opinion, BofA Merrill Lynch:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed certain publicly available business and financial
    information relating to Abraxis and Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed certain internal financial and operating information
    with respect to the business, operations and prospects of
    Abraxis furnished by or discussed with the management of
    Abraxis, including certain internal financial analyses and
    forecasts relating to Abraxis prepared by Abraxis management, or
    the Abraxis forecasts;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed a certain research analysts&#146; publicly available
    financial forecasts relating to Celgene, which we refer to as
    the Celgene Analyst Forecasts, as well as publicly available
    consensus financial forecasts relating to Celgene, which we
    refer to as the Celgene Consensus Forecasts, and together with
    the Celgene Analyst Forecasts, the Celgene Public Forecasts;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed estimates as to the amount and timing of certain cost
    savings and operating synergies anticipated by the management of
    Abraxis to result from the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    discussed the past and current business, operations, financial
    condition and prospects of Abraxis with members of senior
    managements of Abraxis and Celgene, and discussed the past and
    current business, operations, financial condition and prospects
    of Celgene with members of senior managements of Abraxis and
    Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed the potential pro forma financial impact of the merger
    on the future financial performance of Celgene, including the
    potential effect on Celgene&#146;s estimated earnings per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed the trading histories for Abraxis common stock and
    Celgene common stock and a comparison of such trading histories
    with the trading histories of other companies BofA Merrill Lynch
    deemed relevant;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compared certain financial and stock market information of
    Abraxis and Celgene with similar information of other companies
    BofA Merrill Lynch deemed relevant;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compared certain financial terms of the merger to financial
    terms, to the extent publicly available, of other transactions
    BofA Merrill Lynch deemed relevant;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    considered the results of its efforts on behalf of Abraxis to
    solicit, at the direction of Abraxis, indications of interest
    and definitive proposals from third parties with respect to a
    possible acquisition of Abraxis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed the merger agreement and certain ancillary agreements
    thereto;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    performed such other analyses and studies and considered such
    other information and factors as BofA Merrill Lynch deemed
    appropriate.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In arriving at its opinion, BofA Merrill Lynch assumed and
    relied upon, without independent verification, the accuracy and
    completeness of the financial and other information and data
    publicly available or provided to or otherwise reviewed by or
    discussed with it and relied upon the assurances of the
    managements of Abraxis and Celgene that they were not aware of
    any facts or circumstances that would make such information or
    data inaccurate or misleading in any material respect. With
    respect to the Abraxis forecasts and the estimates as to the
    amount and timing of certain cost savings and operating
    synergies anticipated by the managements of Abraxis to result
    from the merger, BofA Merrill Lynch was advised by Abraxis, and
    assumed that they were reasonably prepared on bases reflecting
    the best currently available estimates and good faith judgments
    of the management of Abraxis as to the future financial
    performance of Abraxis and the other matters covered thereby.
    The management of Celgene did not provide BofA Merrill Lynch
    with, and BofA Merrill Lynch did not have access to, financial
    forecasts relating to Celgene prepared by the management of
    Celgene, but was directed by management of Celgene to the
    Celgene Consensus Forecasts. At Abraxis&#146; direction, BofA
    Merrill Lynch assumed, that the Celgene Analyst Forecasts and
    the Celgene Consensus Forecasts are a reasonable basis upon
    which to evaluate the future financial performance of Celgene
    and, at Abraxis&#146; direction, BofA Merrill Lynch used the
    Celgene Public Forecasts in performing its analyses. BofA
    Merrill Lynch did not make or was not provided with any
    independent evaluation or appraisal of the assets or liabilities
    (contingent or otherwise) of Abraxis or Celgene, nor did it make
    any physical inspection of the properties or assets of Abraxis
    or Celgene. BofA Merrill Lynch did not evaluate the solvency or
    fair value of Abraxis or Celgene under any state, federal or
    other laws relating to bankruptcy, insolvency or similar
    matters. BofA Merrill Lynch assumed, at the direction of
    Abraxis, that the merger would be consummated in accordance with
    its terms, without waiver, modification or amendment of any
    material term, condition or agreement, that the CVRs will not be
    redeemed and that, in the course of obtaining the necessary
    governmental, regulatory and other approvals, consents, releases
    and waivers for the merger, no delay, limitation, restriction or
    condition, including any divestiture requirements or amendments
    or modifications, would be imposed that would have an adverse
    effect on Abraxis, Celgene or the contemplated benefits of the
    merger in any way meaningful to its analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    BofA Merrill Lynch expressed no view or opinion as to any terms
    or other aspects of the merger (other than the merger
    consideration to the extent expressly specified in its opinion),
    including, without limitation, the form or structure of the
    merger. BofA Merrill Lynch&#146;s opinion was limited to the
    fairness, from a financial point of view, of the merger
    consideration to be received in the merger by holders of Abraxis
    common stock (other than Dr.&#160;Soon-Shiong and his
    affiliates) and no opinion or view was expressed with respect to
    any consideration received in connection with the merger by the
    holders of any other class of securities, creditors or other
    constituencies of any party. In addition, no opinion or view was
    expressed with respect to the fairness (financial or otherwise)
    of the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    amount, nature or any other aspect of any compensation to any of
    the officers, directors or employees of any party to the merger,
    or class of such persons, relative to the merger consideration.
    Furthermore, no opinion or view was expressed as to the relative
    merits of the merger in comparison to other strategies or
    transactions that might be available to Abraxis or in which
    Abraxis might engage or as to the underlying business decision
    of Abraxis to proceed with or effect the merger. BofA Merrill
    Lynch did not express any opinion as to what the value of
    Celgene common stock actually will be when issued or the prices
    at which Abraxis common stock, Celgene common stock or the CVRs
    will trade at any time, including following announcement or
    consummation of the merger. In addition, BofA Merrill Lynch
    expressed no opinion or recommendation as to how any stockholder
    should vote or act in connection with the merger or any related
    matter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    BofA Merrill Lynch&#146;s opinion was necessarily based on
    financial, economic, monetary, market and other conditions and
    circumstances as in effect on, and the information made
    available to BofA Merrill Lynch as of, the date of its opinion.
    It should be understood that subsequent developments may affect
    its opinion, and BofA Merrill Lynch does not have any obligation
    to update, revise or reaffirm its opinion. The issuance of BofA
    Merrill Lynch&#146;s opinion was approved by BofA Merrill
    Lynch&#146;s Americas Fairness Opinion Review Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis agreed to pay BofA Merrill Lynch for its services in
    connection with the merger an aggregate fee of $13&#160;million
    (provided, that Abraxis may in its sole discretion, pay an
    additional advisory fee of up to $2&#160;million), all of which
    is contingent upon the consummation of the merger. Abraxis also
    agreed to reimburse BofA Merrill Lynch for its reasonable
    expenses and to indemnify BofA Merrill Lynch and certain related
    parties against certain liabilities arising out of its
    engagement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    BofA Merrill Lynch and its affiliates comprise a full service
    securities firm and commercial bank engaged in securities,
    commodities and derivatives trading, foreign exchange and other
    brokerage activities, and principal investing as well as
    providing investment, corporate and private banking, asset and
    investment management, financing and financial advisory services
    and other commercial services and products to a wide range of
    companies, governments and individuals. In the ordinary course
    of their businesses, BofA Merrill Lynch and its affiliates
    invest on a principal basis or on behalf of customers or manage
    funds that invest, make or hold long or short positions, finance
    positions or trade or otherwise effect transactions in equity,
    debt or other securities or financial instruments (including
    derivatives, bank loans or other obligations) of Abraxis,
    Celgene and certain of their respective affiliates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    BofA Merrill Lynch and its affiliates in the past have provided,
    currently are providing, and in the future may provide,
    investment banking, commercial banking and other financial
    services to Celgene and have received or in the future may
    receive compensation for the rendering of these services,
    including (1)&#160;having acted as a financial advisor to
    Celgene in connection with an acquisition transaction and
    (2)&#160;having acted or acting as lender under, or otherwise
    having extended credit under, certain letters of credit and
    other arrangements with Celgene.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    BofA Merrill Lynch is an internationally recognized investment
    banking firm that is regularly engaged in the valuation of
    businesses and securities in connection with mergers and
    acquisitions, negotiated underwritings, secondary distributions
    of listed and unlisted securities, private placements and
    valuations for corporate and other purposes. Abraxis selected
    BofA Merrill Lynch as a financial advisor in connection with the
    merger because of its qualifications, expertise and reputation
    in investment banking and mergers and acquisitions as well as
    its familiarity with Abraxis and its business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Goldman,
    Sachs&#160;&#038; Co.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;29, 2010, at a meeting of Abraxis board of
    directors held to evaluate the merger, Goldman Sachs rendered to
    the board of directors of Abraxis an oral opinion, which was
    confirmed by delivery of a written opinion dated June&#160;30,
    2010, to the effect that, as of the date of the opinion, and
    based upon and subject to the factors, assumptions and
    limitations set forth therein, the right to receive 0.2617 of a
    share of Celgene common stock, which we refer to as the stock
    consideration, $58.00 in cash, which we refer to as the cash
    consideration and together with the stock consideration as the
    upfront consideration, and a CVR issued by Celgene under the CVR
    agreement, which we refer to as the CVR consideration, to be
    paid to the holders of shares of Abraxis common stock pursuant
    to the merger agreement was fair from a financial point of view
    to such holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>The full text of the written opinion of Goldman Sachs, dated
    June&#160;30, 2010, which sets forth assumptions made,
    procedures followed, matters considered and limitations on the
    review undertaken in connection with </B>
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>the opinion, is attached to this proxy statement/prospectus
    as Annex&#160;F. The following summary of Goldman Sachs&#146;
    opinion is qualified in its entirety by reference to the full
    text of the opinion. Goldman Sachs provided its opinion for the
    information and assistance of the Abraxis board of directors in
    connection with its consideration of the merger. The Goldman
    Sachs opinion is not a recommendation as to how any holder of
    Abraxis common stock should vote with respect to the merger or
    any other matter.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with rendering the opinion described above and
    performing its related financial analyses, Goldman Sachs
    reviewed, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    annual reports to stockholders and Annual Reports on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    of Abraxis for the 3&#160;years ended December&#160;31, 2009,
    and of Celgene for the 5&#160;years ended December&#160;31, 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; initial registration statement on Form&#160;10;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain interim reports to stockholders and Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    of Abraxis and Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain other communications from Abraxis and Celgene to their
    stockholders, respectively;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain publicly available research analyst reports for Abraxis
    and Celgene;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Abraxis forecasts and certain cost savings and operating
    synergies projected by the management of Abraxis to result from
    the merger, or the synergies, each as approved by Abraxis for
    use by Goldman Sachs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The management of Celgene did not make available its forecasts
    of the future financial performance of Celgene. With
    Abraxis&#146; consent, Goldman Sachs&#146; review of the future
    financial performance of Celgene was limited to the current
    consensus forecasts for Celgene, publicly available estimates of
    a certain research analyst and its discussions with the
    management of Celgene regarding the current consensus forecasts
    for Celgene. Goldman Sachs also held discussions with members of
    the senior managements of Abraxis and Celgene regarding their
    assessment of the strategic rationale for, and the potential
    benefits of, the merger and the past and current business
    operations, financial condition and future prospects of Abraxis
    and Celgene. In addition, Goldman Sachs reviewed the reported
    price and trading activity for shares of Abraxis common stock
    and Celgene common stock, respectively, compared certain
    financial and stock market information for Abraxis and Celgene
    with similar information for certain other companies the
    securities of which are publicly traded, reviewed the financial
    terms of certain recent business combinations in the
    pharmaceutical industry specifically and in other industries
    generally and performed such other studies and analyses, and
    considered such other factors, as it deemed appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Goldman Sachs relied upon and assumed, without assuming any
    responsibility for independent verification, the accuracy and
    completeness of all of the financial, legal, regulatory, tax,
    accounting and other information provided to, discussed with or
    reviewed by it. In that regard, Goldman Sachs assumed, with
    Abraxis&#146; consent, that the Abraxis forecasts and the
    synergies have been reasonably prepared on a basis reflecting
    the best then available estimates and judgments of the
    management of Abraxis. In addition, Goldman Sachs did not make
    any independent evaluation or appraisal of the assets and
    liabilities (including any contingent, derivative or other
    off-balance-sheet assets and liabilities) of Abraxis or Celgene
    or any of their respective subsidiaries and was not furnished
    with any such evaluation or appraisal. Goldman Sachs also
    assumed that all governmental, regulatory or other consents and
    approvals necessary for the consummation of the merger would be
    obtained without any adverse effect on Abraxis or Celgene or on
    the expected benefits of the merger in any way meaningful to its
    analysis. Goldman Sachs also assumed that the merger will be
    consummated on the terms set forth in the merger agreement,
    without the waiver or modification of any term or condition the
    effect of which would be in any way meaningful to its analysis
    and that the CVRs will not be redeemed. Goldman Sachs&#146;
    opinion did not address the underlying business decision of
    Abraxis to engage in the merger, or the relative merits of the
    merger as compared to any strategic alternatives that may be
    available to Abraxis, nor did it address any legal, regulatory,
    tax or accounting matters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Goldman Sachs&#146; opinion addressed only the fairness from a
    financial point of view, as of the date of its opinion, of the
    merger consideration to be paid to the holders of shares of
    Abraxis common stock pursuant to the merger agreement. Goldman
    Sachs did not express any view on, and its opinion did not
    address, any other term or aspect of the merger agreement or the
    merger or any term or aspect of any other agreement or
    instrument contemplated by the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    merger agreement or entered into or amended in connection with
    the merger, including, without limitation, the
    stockholders&#146; agreement and the non-competition agreement,
    the fairness of the merger to, or any consideration received in
    connection therewith by, the holders of any other class of
    securities, creditors or other constituencies of Abraxis; nor as
    to the fairness of the amount or nature of any compensation to
    be paid or payable to any of the officers, directors or
    employees of Abraxis, or class of such persons in connection
    with the merger, whether relative to the merger consideration to
    be paid to the holders pursuant to the merger agreement or
    otherwise. In addition, Goldman Sachs expressed no opinion as to
    the prices at which the Celgene common stock or the CVRs would
    trade at any time or as to the impact of the merger on the
    solvency or viability of Abraxis or Celgene or the ability of
    Abraxis to pay its obligations when they come due. Goldman
    Sachs&#146; opinion was necessarily based on economic, monetary,
    market and other conditions as in effect on, and the information
    made available to Goldman Sachs as of, the date of its opinion
    and Goldman Sachs assumed no responsibility for updating,
    revising or reaffirming its opinion based on circumstances,
    developments or events occurring after the date of its opinion.
    Goldman Sachs&#146; advisory services and the opinion expressed
    in its opinion were provided for the information and assistance
    of the Abraxis board of directors in connection with its
    consideration of the merger and such opinion did not constitute
    a recommendation as to how any holder of shares of Abraxis
    common stock should vote with respect to the merger or any other
    matter. Goldman Sachs&#146; opinion was approved by a fairness
    committee of Goldman Sachs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Goldman, Sachs and its affiliates are engaged in investment
    banking and financial advisory services, commercial banking,
    securities trading, investment management, principal investment,
    financial planning, benefits counseling, risk management,
    hedging, financing, brokerage activities and other financial and
    non-financial activities and services for various persons and
    entities. In the ordinary course of these activities and
    services, Goldman Sachs and its affiliates may at any time make
    or hold long or short positions and investments, as well as
    actively trade or effect transactions, in the equity, debt and
    other securities (or related derivative securities) and
    financial instruments (including bank loans and other
    obligations) of third parties, Abraxis, Celgene and any of their
    respective affiliates and affiliates of Dr.&#160;Soon-Shiong or
    any currency or commodity that may be involved in the merger for
    their own account and for the accounts of their customers.
    Goldman Sachs acted as financial advisor to Abraxis in
    connection with, and participated in certain of the negotiations
    leading to, the merger. Goldman Sachs has provided certain
    investment banking and other financial services to Abraxis and
    its affiliates from time to time, for which the investment
    banking division of Goldman Sachs has received, and may receive,
    compensation, including having acted as financial advisor to APP
    Pharmaceuticals, Inc., a former affiliate of Abraxis and
    <FONT style="white-space: nowrap">Dr.&#160;Soon-Shiong,</FONT>
    in its acquisition by Fresenius Kabi Pharmaceuticals Holding,
    LLC. Goldman Sachs also may provide investment banking and other
    financial services to Abraxis, Celgene, Dr.&#160;Soon-Shiong and
    their respective affiliates in the future, for which the
    investment banking division of Goldman Sachs may receive
    compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis selected Goldman Sachs as a financial advisor because of
    its qualifications, expertise and reputation in investment
    banking and mergers and acquisitions as well as its familiarity
    with Abraxis and its business. Abraxis agreed to pay Goldman
    Sachs for its services in connection with the merger an
    aggregate fee of $13&#160;million (provided, that Abraxis may in
    its sole discretion, pay an additional advisory fee of up to
    $2&#160;million), all of which is contingent upon the
    consummation of the merger. In addition, Abraxis has agreed to
    reimburse Goldman Sachs for its reasonable expenses arising in
    connection with the engagement, including attorneys&#146; fees
    and disbursements, plus any sales, use or similar taxes arising
    in connection with the engagement, and to indemnify Goldman
    Sachs and related persons against various liabilities, including
    certain liabilities under the federal securities laws.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Lazard
    Fr&#232;res&#160;&#038; Co. LLC</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Lazard rendered its oral opinion to the Abraxis board of
    directors that, as of June&#160;29, 2010, and based upon and
    subject to the factors, assumptions and limitations set forth
    therein, the merger consideration to be paid to holders of
    Abraxis common stock (other than Dr.&#160;Soon-Shiong, any of
    his affiliates, Celgene and merger sub) in the merger was fair
    from a financial point of view to such holders. Lazard
    subsequently confirmed its earlier opinion by delivery of a
    written opinion dated June&#160;30, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>The full text of the written opinion of Lazard, dated
    June&#160;30, 2010, which sets forth assumptions made,
    procedures followed, matters considered and limitations on the
    review undertaken in connection with the opinion, is attached to
    this proxy statement/prospectus as Annex&#160;G. The following
    summary of Lazard&#146;s opinion is qualified in its entirety by
    reference to the full text of the opinion. Lazard provided its
    opinion for </B>
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>the benefit of the Abraxis board of directors in connection
    with its evaluation of the merger. The Lazard opinion is not a
    recommendation to any stockholder as to how such stockholder
    should vote or act with respect to the merger or any matter
    relating thereto.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Lazard&#146;s opinion was necessarily based on economic,
    monetary, market and other conditions as in effect on, and the
    information available to Lazard as of, the date of Lazard&#146;s
    opinion. Lazard assumed no responsibility for updating or
    revising its opinion based on circumstances or events occurring
    after the date of Lazard&#146;s opinion. Lazard did not express
    any opinion as to the price at which shares of Abraxis common
    stock, Celgene common stock or CVRs may trade at any time
    subsequent to the announcement of the merger. The following is a
    summary of Lazard&#146;s opinion. You are urged to read
    Lazard&#146;s written opinion carefully in its entirety.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with its opinion, Lazard:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed the financial terms and conditions of the merger
    agreement and the ancillary agreements thereto;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    analyzed certain publicly available historical business and
    financial information relating to Abraxis and Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed various financial forecasts and other data provided by
    the management of Abraxis relating to the business of Abraxis,
    the publicly available estimates of a certain research analyst,
    as well as current consensus forecasts for Celgene with respect
    to the business of Celgene, or the Celgene public forecasts, and
    the synergies, as approved for Lazard&#146;s use by Abraxis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    held discussions with members of the senior managements of
    Abraxis and Celgene with respect to the businesses and prospects
    of Abraxis and Celgene, respectively;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed public information with respect to certain other
    companies in lines of business Lazard believed to be generally
    relevant in evaluating the businesses of Abraxis and Celgene,
    respectively;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed the financial terms of certain business combinations
    involving companies in lines of business Lazard believed to be
    generally relevant in evaluating the businesses of Abraxis and
    Celgene, respectively;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewed the historical stock prices and trading volumes of
    Abraxis common stock and Celgene common stock;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    conducted such other financial studies, analyses and
    investigations as Lazard deemed appropriate.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Lazard assumed and relied upon the accuracy and completeness of
    the foregoing information, without independent verification of
    such information. Lazard did not conduct any independent
    valuation or appraisal of any of the assets or liabilities
    (contingent or otherwise) of Abraxis or Celgene or concerning
    the solvency or fair value of Abraxis or Celgene, and Lazard was
    not furnished with such valuation or appraisal. With respect to
    the financial forecasts related to Abraxis it reviewed, Lazard
    assumed, with the consent of Abraxis, that they have been
    reasonably prepared on bases reflecting the best then currently
    available estimates and judgments of the management of Abraxis
    as to the future financial performance of Abraxis. The
    management of Celgene did not make available its forecasts of
    the future financial performance of Celgene but directed Lazard
    to current consensus forecasts for Celgene.  Lazard assumed,
    with the consent of Abraxis, that the Celgene public forecasts
    are a reasonable basis upon which to evaluate the future
    financial performance of Celgene, and are appropriate for Lazard
    to utilize in its analyses. Lazard assumed, with the consent of
    Abraxis, that the Celgene public forecasts are a reasonable
    basis upon which to evaluate the future financial performance of
    Celgene, and are appropriate for Lazard to utilize in its
    analyses. Lazard assumed no responsibility for and expressed no
    view as to such forecasts or the assumptions on which they were
    based.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In rendering its opinion, Lazard assumed, with Abraxis&#146;
    consent, that the merger would be consummated on the terms
    described in the merger agreement, without any waiver or
    modification of any material terms or conditions and that the
    CVRs will not be redeemed. Lazard further assumed, with
    Abraxis&#146; consent, that obtaining the necessary regulatory
    or third party approvals and consents for the merger will not
    have an adverse effect on Abraxis or Celgene in any way
    meaningful to its analysis. Lazard did not express any opinion
    as to any tax or other consequences that might result from the
    merger, nor did Lazard&#146;s opinion address any legal, tax,
    regulatory or accounting matters, as to which Lazard understood
    that Abraxis obtained such advice as it deemed necessary from
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    qualified professionals. Lazard expressed no view or opinion as
    to any terms or other aspects of the merger (other than the
    merger consideration to the extent expressly specified in
    Lazard&#146;s opinion). In addition, Lazard expressed no view or
    opinion as to the fairness of the amount or nature of, or any
    other aspects relating to, the compensation to any officers,
    directors or employees of any parties to the merger, or class of
    such persons, or the holders of any class of securities other
    than Abraxis common stock, creditors, or other constituencies of
    Abraxis; in each case relative to the merger consideration or
    otherwise. Lazard noted that Celgene, merger sub and certain
    stockholders of Abraxis agreed to enter into the voting
    agreement pursuant to which such stockholders, subject to the
    terms thereof, agreed to vote their shares of Abraxis common
    stock in favor of adoption of the merger agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Lazard&#146;s engagement and the opinion are for the benefit of
    the Abraxis board of directors and Lazard&#146;s opinion was
    rendered to the Abraxis board of directors in connection with
    its evaluation of the merger. Lazard&#146;s opinion was not
    intended to and did not constitute a recommendation to any
    stockholder as to how such stockholder should vote or act with
    respect to the merger or any matter relating thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis agreed to pay Lazard for its services in connection with
    the merger an aggregate fee of $13&#160;million (provided, that
    Abraxis may in its sole discretion, pay an additional advisory
    fee of up to $2&#160;million), all of which is contingent upon
    the consummation of the merger. Abraxis has also agreed to
    reimburse Lazard for its reasonable expenses incurred in
    connection with the engagement and to indemnify Lazard and
    certain related parties against certain liabilities under
    certain circumstances that may arise out of the rendering of its
    advice, including certain liabilities under U.S.&#160;federal
    securities laws. Lazard in the past provided investment banking
    services to Abraxis, including having acted as financial advisor
    to APP Pharmaceuticals, Inc., a former affiliate of Abraxis, in
    its acquisition by Fresenius Kabi Pharmaceuticals Holding, LLC,
    for which Lazard received compensation. In addition, in the
    ordinary course of their respective businesses, Lazard
    Fr&#232;res&#160;&#038; Co. LLC and LFCM Holdings LLC (an entity
    indirectly owned in large part by managing directors of Lazard
    Fr&#232;res&#160;&#038; Co. LLC)&#160;and their respective
    affiliates may actively trade securities of Abraxis
    <FONT style="white-space: nowrap">and/or</FONT> the
    securities of Celgene and certain of their respective affiliates
    for their own accounts and for the accounts of their customers
    and, accordingly, may at any time hold a long or short position
    in such securities. The issuance of Lazard&#146;s opinion was
    approved by the Opinion Committee of Lazard.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Lazard is an internationally recognized investment banking firm
    providing a full range of financial advisory and other services.
    Abraxis selected Lazard as a financial advisor because of its
    qualifications, expertise and reputation in investment banking
    and mergers and acquisitions, as well as its familiarity with
    the business of Abraxis.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Financial
    Analyses by Financial Co-Advisors</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following is a summary of the material financial analyses
    delivered by BofA Merrill Lynch, Goldman Sachs and Lazard, which
    we refer to collectively as the &#147;financial
    co-advisors,&#148; to the Abraxis board of directors in
    connection with rendering their respective opinions described
    above. The following summary, however, does not purport to be a
    complete description of the financial analyses performed by the
    financial co-advisors, nor does the order of analyses described
    represent relative importance or weight given to those analyses
    by the financial
    <FONT style="white-space: nowrap">co-advisors.</FONT>
    Some of the summaries of the financial analyses include
    information presented in tabular format. In order to fully
    understand the financial analyses performed by the financial
    co-advisors, the tables must be read together with the full text
    of each summary and are alone not a complete description of the
    financial co-advisors&#146; financial analyses. Considering the
    data set forth in the tables below without considering the
    narrative description of the financial analyses, including the
    methodologies and assumptions underlying the analyses, could
    create a misleading or incomplete view of the financial
    co-advisors&#146; financial analyses. Except as otherwise noted,
    the following quantitative information, to the extent that it is
    based on market data, is based on market data as it existed on
    or before June&#160;29, 2010, and is not necessarily indicative
    of current market conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The preparation of fairness opinions is a complex process
    involving various determinations as to the most appropriate and
    relevant methods of financial analysis and the application of
    those methods to particular circumstances and, therefore, is not
    necessarily susceptible to partial analysis or summary
    description. Selecting portions of the analyses or of the
    summary set forth above, without considering the analyses as a
    whole, could create an incomplete view of the processes
    underlying each financial co-advisors&#146; opinion. In arriving
    at their respective fairness determination, the financial
    co-advisors considered the results of all of their analyses and
    did not attribute
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    any particular weight to any factor or analysis considered by
    them. Rather, each financial co-advisor made its determination
    as to fairness on the basis of its experience and professional
    judgment after considering the results of all of its analyses.
    No company or transaction used in the analyses below as a
    comparison is directly comparable to Abraxis or the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The financial co-advisors prepared these analyses solely for
    purposes of, and the analyses were delivered to the Abraxis
    board of directors in connection with, their provision of their
    respective opinions to the Abraxis board of directors as to the
    fairness from a financial point of view of the merger
    consideration to be received by the holders of Abraxis common
    stock (except for certain holders identified in their respective
    opinions) pursuant to the merger agreement to such holders.
    These analyses do not purport to be appraisals nor do they
    necessarily reflect or purport to reflect the prices at which
    businesses or securities actually may be sold or the prices at
    which any securities have traded or may trade at anytime in the
    future. Analyses based upon forecasts of future results are not
    necessarily indicative of actual future results, which may be
    significantly more or less favorable than suggested by these
    analyses. Because these analyses are inherently subject to
    uncertainty, being based upon numerous factors or events beyond
    the control of the parties or their respective advisors, none of
    Abraxis, BofA Merrill Lynch, Goldman Sachs, Lazard or any other
    person assumes responsibility if future results are materially
    different from those forecast.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The type and amount of consideration payable in the merger was
    determined through arm&#146;s-length negotiations between
    Abraxis and Celgene, rather than by any financial advisor, and
    was approved by the Abraxis board of directors. The financial
    co-advisors did not recommend any specific merger consideration
    to the Abraxis board of directors or to Abraxis or that any
    given merger consideration constituted the only appropriate
    consideration for the merger. The decision to enter into the
    merger agreement was solely that of the Abraxis board of
    directors. The opinions of financial co-advisors were some of
    many factors taken into consideration by the Abraxis board of
    directors in its evaluation of the proposed merger.
    Consequently, the analyses described below should not be viewed
    as determinative of the opinion of the Abraxis board of
    directors with respect to the merger consideration or of whether
    the Abraxis board of directors would have been willing to
    determine that a different merger consideration was fair.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Historical Stock Trading Analysis.</I>&#160;&#160;The
    financial co-advisors analyzed the implied equity premium per
    share of Abraxis common stock represented by each of
    (1)&#160;the $72.00 per share implied value of the upfront
    consideration, without considering any potential CVR payout,
    (2)&#160;the net present value of the merger consideration
    determined by adding the $72.00 per share implied value of the
    upfront consideration and the present value (discounted at 11%)
    of potential CVR payouts calculated using the
    probability-adjusted forecast prepared by Abraxis management and
    (3)&#160;the nominal value of the merger consideration
    determined by adding the $72.00 per share implied value of the
    upfront consideration and the undiscounted amounts of the
    potential CVR payouts calculated using the unadjusted forecast
    prepared by Abraxis management, in each case as compared to
    (w)&#160;the closing price per share of the Abraxis common stock
    on June&#160;28, 2010, (x)&#160;the high per share price of the
    Abraxis common stock over the 52&#160;week period ended
    June&#160;28, 2010, (y)&#160;the volume weighted average price
    per share, or VWAP, over the 30 calendar days ended
    June&#160;28, 2010, and (z)&#160;the closing price per share of
    the Abraxis common stock on June&#160;1, 2010, the first trading
    day within the 30 calendar days prior to June&#160;28, 2010. The
    probability-adjusted forecast used to calculate the
    probability-adjusted CVR payout for purpose of this analysis
    reflected Abraxis management&#146;s estimates of the probability
    of receiving regulatory approval for use of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for additional indications and Abraxis management&#146;s
    estimates of the probability of Celgene achieving estimated
    sales for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    using Celgene&#146;s commercial capabilities. The potential
    unadjusted CVR payout calculation assumes
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    sales are achieved without any probability adjustment. Fully
    diluted share values used in the analysis were calculated
    assuming exercise of options using the treasury method based on
    a $72.00 implied value of the upfront consideration.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The results of these analyses are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>NPV of Merger<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Nominal Value of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Implied Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Consideration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Merger<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>the Upfront<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(Probability-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Consideration<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Consideration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Adjusted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(Unadjusted CVR<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(w/o CVR)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>CVR Payout)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payout)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Implied Value per Share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    72.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    84.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    106.69
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    % Premium to June&#160;28, 2010 ($63.00)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.3
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.6
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    % Premium to 52&#160;week high ($63.00)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.3
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.6
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    % Premium to
    <FONT style="white-space: nowrap">1-Month</FONT> VWAP
    ($56.62)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27.2
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49.8
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    % Premium to
    <FONT style="white-space: nowrap">1-Month</FONT> Spot
    ($50.81)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66.9
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Implied Multiples Analysis.</I>&#160;&#160;In addition, the
    financial co-advisors calculated implied multiples of
    (1)&#160;the implied enterprise value of Abraxis determined
    based on (x)&#160;the $72.00 per share implied value of the
    upfront consideration, without considering any potential CVR
    payout, (y)&#160;the net present value of the merger
    consideration determined by adding the $72.00 per share implied
    value of the upfront consideration and the present value
    (discounted at 11%) of potential CVR payouts calculated using
    the probability-adjusted forecast prepared by Abraxis management
    and (z)&#160;the nominal value of the merger consideration
    determined by adding the $72.00 per share implied value of the
    upfront consideration and the undiscounted amounts of the
    potential CVR payouts calculated using the unadjusted forecast
    prepared by Abraxis management, to (2) (x)&#160;the actual
    revenues of Abraxis for the twelve months ended March&#160;31,
    2010, and (y)&#160;Abraxis management&#146;s
    probability-adjusted estimate of Abraxis&#146; 2010 stand-alone
    revenues. The probability-adjusted forecast used to calculate
    the probability-adjusted CVR payouts for purpose of this
    analysis reflected Abraxis management&#146;s estimates of the
    probability of receiving regulatory approval for use of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for additional indications and Abraxis management&#146;s
    estimates of the probability of Celgene achieving estimated
    sales for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    using Celgene&#146;s commercial capabilities. The
    probability-adjusted estimates of Abraxis&#146; 2010 stand-alone
    revenues used for purposes of this analysis reflected Abraxis
    management&#146;s probability-adjusted estimates of achieving
    potential 2010&#160;net sales for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    using Abraxis&#146; commercial capabilities. The potential
    unadjusted CVR payout calculation assumes
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    sales are achieved without any probability adjustment. Fully
    diluted share values used in the analysis were calculated
    assuming exercise of options using the treasury method based on
    a $72.00 implied value of the upfront consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The results of these implied multiples analyses are summarized
    as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>NPV of Merger<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Nominal Value of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Implied Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Consideration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Merger<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>the Upfront<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(Probability-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Consideration<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Consideration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Adjusted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(Unadjusted CVR<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(w/o CVR)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>CVR Payout)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payout)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Enterprise Value/Revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    LTM (March&#160;31, 2010)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.6
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.9
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010 Estimate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.1
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.4
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.6
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Selected Companies Analysis.</I>&#160;&#160;The financial
    co-advisors reviewed and compared certain financial information
    for Abraxis to corresponding financial information and multiples
    for the following publicly traded corporations:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Amylin Pharmaceuticals, Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    United Therapeutics Corporation
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    BioMarin Pharmaceutical Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Regeneron Pharmaceuticals, Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Cubist Pharmaceuticals, Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Onyx Pharmaceuticals, Inc.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The companies included were chosen because they are publicly
    traded companies in the pharmaceutical industry with public
    market valuations in excess of $1&#160;billion with operations
    that for purposes of analysis may in certain respects be
    considered similar to those of Abraxis. However, none of the
    selected companies is directly comparable to Abraxis.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The financial co-advisors calculated and compared multiples of
    enterprise value to estimated 2010 revenues for Abraxis and for
    the selected companies. For purposes of this analysis,
    enterprise value was calculated for Abraxis and for the selected
    companies to equal the fully diluted market value of the
    company&#146;s common equity as of the close of trading on
    June&#160;28, 2010 plus the book value of the company&#146;s
    debt, minority interest and preferred shares, less the
    company&#146;s cash and cash equivalents as reflected in the
    company&#146;s most recent SEC filings. For purposes of this
    analysis, the co-financial advisors used Abraxis
    management&#146;s probability-adjusted estimate of Abraxis&#146;
    stand-alone 2010 revenues. Estimated 2010 revenues used for each
    of the selected companies reflected consensus estimates of
    financial analysts as published by Thomson.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The derived multiples are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Selected Companies</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Enterprise Value as a Multiple of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Range</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Median</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Abraxis</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010 Estimated Revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.6x-5.4
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.0
</TD>
<TD nowrap align="left" valign="bottom">
    x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.0x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The financial co-advisors then applied the low to high range of
    the multiples of 1.6x to 5.4x calculated for the selected
    companies and applied them to Abraxis management&#146;s
    probability-adjusted estimate of Abraxis&#146; 2010 stand-alone
    revenue. Adjusting for Abraxis&#146; estimated net debt at
    June&#160;30, 2010, this resulted in illustrative per share
    value indications for the Abraxis common stock, rounded to the
    nearest dollar, ranging from $19.00 to $56.00.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Selected Precedent Transactions Analysis.</I>&#160;&#160;The
    financial co-advisors analyzed, to the extent publicly
    available, certain information relating to the following
    selected transactions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Astellas Pharma Inc.&#146;s acquisition of OSI Pharmaceuticals,
    Inc. announced in May 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Bristol-Myers Squibb Company&#146;s acquisition of Medarex, Inc.
    announced in July 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Johnson&#160;&#038; Johnson&#146;s acquisition of Cougar
    Biotechnology announced in May 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    GlaxoSmithKline plc&#146;s acquisition of Stiefel Laboratories
    Inc. announced in April 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Gilead Sciences, Inc.&#146;s acquisition of CV Therapeutics
    announced in March 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Eli Lilly and Company&#146;s acquisition of ImClone Systems
    announced in September 2008;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shionogi Inc.&#146;s acquisition of Sciele Pharma Inc. announced
    in September 2008;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Eisai Co. Ltd.&#146;s acquisition of MGI Pharma, Inc. announced
    in December 2007;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Reckitt Benckiser Plc&#146;s acquisition of Adams Respiratory
    Therapeutics announced in December 2007;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    TPG Capital&#146;s acquisition of Axcan Pharma announced in
    November 2007;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    GlaxoSmithKline plc&#146;s acquisition of Reliant
    Pharmaceuticals Inc. announced in November 2007;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene Corporation&#146;s acquisition of Pharmion Corporation
    announced in November 2007;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    AstraZeneca PLC&#146;s acquisition of MedImmune Inc. announced
    in April 2007;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Schering-Plough Corporation&#146;s acquisition of Organon
    BioSciences NV announced in March 2007.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    None of the companies, businesses or transactions used in this
    analysis is directly comparable to Abraxis or the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For each of the selected transactions, the financial co-advisors
    calculated and compared the enterprise value of the target
    company calculated based on the purchase price paid in the
    transaction as a multiple of latest revenues of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    the target for the last four quarter period ended prior to the
    announcement of the transaction. The following table presents
    the results of this analysis:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="79%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Selected Transactions</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Enterprise Value as a Multiple of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Range</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Median</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    LTM Revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.9x-11.3x
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.1x
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The financial co-advisors then applied the low to high range of
    latest twelve months revenue multiples of 2.9x to 11.3x to
    Abraxis&#146; revenues for the four quarters ended
    March&#160;31, 2010. Adjusting for Abraxis&#146; estimated net
    debt at June&#160;30, 2010, this resulted in illustrative per
    share values for the Abraxis common stock, rounded to the
    nearest dollar, ranging from $32.00 to $109.00.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Discounted Cash Flow Analysis.</I>&#160;&#160;The financial
    co-advisors performed an illustrative discounted cash flow,
    which we refer to as DCF, analysis on Abraxis using the
    stand-alone, probability-adjusted forecast prepared by Abraxis
    management to determine a range of implied values per share of
    Abraxis common stock. The financial
    <FONT style="white-space: nowrap">co-advisors</FONT>
    discounted back to June&#160;30, 2010 the probability-adjusted
    projected unlevered after-tax free cash flows for Abraxis
    through the end of 2020, using discount rates ranging from 10.0%
    to 12.0%, reflecting estimates of Abraxis&#146; weighted average
    cost of capital and a range of terminal values for Abraxis as of
    the end of 2020 derived by multiplying estimated 2020 earnings
    before income, tax, depreciation and amortization, or EBITDA,
    for Abraxis by multiples ranging between 5x and 9x. The
    financial co-advisors selected the range of EBITDA multiples
    utilizing their experience and professional judgment, taking
    into account several factors, including analysis of the forward
    EBITDA multiples of selected companies which exhibited similar
    business characteristics to Abraxis. This analysis resulted in
    illustrative per share value indications for the Abraxis common
    stock, ranging from $61.53 to $79.24.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Using the stand-alone, probability-adjusted forecast prepared by
    Abraxis and based on assumptions and probabilities provided by
    Abraxis, the financial co-advisors performed sensitivity
    analyses on the DCF analysis. For each sensitivity analysis, the
    financial co-advisors applied a discount rate of 11% to the
    sensitivity-adjusted, projected unlevered after-tax free cash
    flows for Abraxis through the end of 2020 and applied a 7x
    terminal multiple to sensitivity-adjusted, projected 2020 EBITDA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    First, the financial co-advisors calculated the sensitivity of
    the DCF analysis to commercial success of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.

    The sensitivity analysis utilized a range of probabilities of
    achieving estimated peak sales for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in the United States and European Union for various indications.
    This analysis resulted in illustrative per share value
    indications for the Abraxis common stock, rounded to the nearest
    25 cents, ranging from $61.75 to $77.75.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Additionally, the financial co-advisors calculated the
    sensitivity of the DCF analysis to a range of assumptions
    provided by Abraxis related to the cost of goods sold, selling,
    general and administrative expenses (or SG&#038;A), a range of
    probabilities of achieving regulatory approval for the use of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    to treat pancreatic cancer, to treat non-small cell lung cancer
    under a label that includes a progression free survival claim
    and for other new indications. The analysis resulted in
    illustrative per share value indications for the Abraxis common
    stock, rounded to the nearest 25 cents, ranging from $60.50 to
    $83.00.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, the financial co-advisors performed additional
    sensitivity analyses applying various hypothetical dates
    provided by Abraxis upon which
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    could begin to face competition from a substitutable generic
    product in the United States and European Union and a
    hypothetical scenario provided by Abraxis of gradual competition
    from other products. This resulted in illustrative per share
    value indications for the Abraxis common stock, rounded to the
    nearest 25 cents, ranging from $19.00 to $86.25.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Accretion/Dilution Analysis.</I>&#160;&#160;The financial
    co-advisors analyzed the potential pro forma financial effects
    of the merger on Celgene&#146;s estimated earnings per share
    using the stand-alone, probability-adjusted forecast of Abraxis
    net revenues prepared by Abraxis management and publicly
    available estimates for Celgene, and taking into account
    projected synergies. The financial co-advisors compared the
    projected earnings per share of Celgene common stock on a
    standalone basis (assuming there is no merger) for 2010, 2011
    and 2012 to the projected earnings per share of Celgene on a
    pro-forma basis assuming the consummation of the merger. This
    analysis indicated that the merger could be dilutive by 11% to
    the resulting company&#146;s estimated earnings per share for
    2010
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and accretive by 1% and 13%, respectively, to the resulting
    company&#146;s estimated earnings per share for 2011 and 2012.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Selected Companies Analysis for Celgene.</I>&#160;&#160;In
    addition to the various financial analyses regarding Abraxis,
    the financial co-advisors reviewed and compared certain
    financial information for Celgene to corresponding financial
    information, ratios and public market multiples for the
    following publicly traded corporations:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Amgen Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Gilead Sciences, Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Genzyme Corporation
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Biogen Idec Inc.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The companies included were chosen because they are publicly
    traded companies with operations that for purposes of analysis
    may in certain respects be considered similar to those of
    Celgene. However, none of the selected companies is directly
    comparable to Celgene.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The financial co-advisors calculated and compared various
    financial multiples based on financial data as of June&#160;28,
    2010 and information they obtained from FactSet, Celgene filings
    and Wall Street research. The multiples of Celgene and each of
    the selected companies were based on the most recent publicly
    available information. With respect to the selected companies,
    the financial co-advisors calculated the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enterprise value as a multiple of EBITDA for 2009 and estimates
    for 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    price as a multiple of earnings per share for 2009 and estimates
    for 2010;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    price over earnings per share as a multiple of earnings per
    share growth rate, or PEG, for 2009 and estimates for 2010.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The derived multiples are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Selected Companies</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Enterprise Value as a Multiple of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Range</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Median</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Celgene</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009 EBITDA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2x-10.8x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.7x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.9x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010 EBITDA Estimates
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;6.0x-10.0x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16.3x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="69%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="6%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="6%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Selected Companies</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Price as a Multiple of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Range</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Median</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Celgene</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009 Earnings per Share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    12.3x-23.6x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    13.7x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    26.9x
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010 Earnings per Share Estimates
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10.0x-22.4x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10.9x
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    21.0x
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="76%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="6%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Selected Companies</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Price/Earnings per Share as a Multiple of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Range</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Median</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Celgene</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009 Earnings per Share Growth Rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0.9-1.6
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010 Earnings per Share Growth Rate estimates
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0.7-1.3
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<A name='116'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Certain
    Illustrative Projections for Abraxis</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with the transaction process, Abraxis management
    prepared illustrative projections of the future financial
    performance of Abraxis on a stand-alone basis. Abraxis is
    including excerpts of these projections below because these
    projections were presented to the Abraxis board of directors as
    part of its review of the transaction and provided to Goldman
    Sachs, Lazard and BofA Merrill Lynch in connection with the
    preparation of their respective fairness opinions and their
    associated financial analyses described above under &#147;The
    Merger&#160;&#151; Opinions of Financial Advisors to
    Abraxis.&#148;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The projections set forth below reflect the following
    assumptions:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    As clinical trials for use of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for certain treatments are completed successfully, there will be
    revenue generation as a result of the use of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for those treatments prior to the time that Abraxis expects FDA
    approval for those treatments;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis will incur research and development expenses for
    non-Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>-related

    products during the projection period;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    No revenue will be generated from
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    pipeline products or any other potential products during the
    projection period;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    will be subject to gradual competition from other new
    therapeutic products beginning in the U.S.&#160;in 2017 and the
    E.U. in 2018;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Assumes that, upon entry of competition,
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    will lose 15% of its market share per year for five years and be
    stable thereafter, and the price of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    will decrease by 10% per year for three years and be stable
    thereafter;&#160;and
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Assumes that, upon entry of competition, annual sales and
    marketing expense decreases at the same rate as
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    market share and general and administrative expenses decrease by
    5% annually.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The illustrative projections excerpted below reflect adjustments
    to the forecasted financial performance of Abraxis that reflect
    management&#146;s estimates of the probability of
    (1)&#160;Abraxis receiving regulatory approval within various
    timeframes to allow marketing of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for different indications, (2)&#160;Abraxis successfully
    commercializing
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and (3)&#160;Abraxis achieving certain sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    as a treatment for those different indications. The illustrative
    revenue projections excerpted below reflect probability of
    success adjustments of 93% in 2010, 88% in 2011, 85% in 2012,
    72% in 2013 and
    <FONT style="white-space: nowrap">66-68%</FONT>
    thereafter.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=12 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=12 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=12 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=12 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2011E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2012E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2013E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2014E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2015E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2016E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2017E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2018E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2019E</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2020E</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="43" align="center" valign="bottom">
    <B>(In millions)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total Revenue</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,081
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,633
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,672
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B>Total R&#038;D</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    239
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    371
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    508
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    371
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B>Total SG&#038;A</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    419
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    471
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    440
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    412
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total Operating Expenses</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    502
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    927
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,065
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    934
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating Income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (129
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,173
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    855
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    386
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The illustrative financial projections set forth above were not
    prepared in connection with a detailed analysis of the
    fundamentals of Abraxis&#146; business and assets nor were they
    prepared on a basis consistent with the historical accounting
    policies included in the section titled &#147;Management&#146;s
    Discussion and Analysis of Financial Conditions and Results of
    Operations&#148; contained in Abraxis&#146; Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, which is incorporated
    by reference in this proxy statement/prospectus. For more
    information, see &#147;Where you Can Find More Information&#148;
    in this proxy statement/prospectus.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The illustrative financial projections are not being included in
    this proxy statement/prospectus for the purpose of influencing
    your decision whether to vote for the adoption of the merger
    agreement or exercise appraisal rights with respect to your
    shares of Abraxis common stock. Such illustrative financial
    projections were not prepared in compliance with
    U.S.&#160;generally accepted accounting principles, which we
    refer to as U.S.&#160;GAAP, or with published guidelines of the
    SEC or the American Institute of Certified Public Accountants
    regarding financial projections. Abraxis&#146; independent
    public registered accounting firm has not examined or compiled
    any of the illustrative financial projections, expressed any
    conclusion or provided any form of assurance with respect to the
    illustrative financial projections and, accordingly, assumes no
    responsibility for them.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis cautions you that the illustrative financial projections
    are speculative in nature and based upon subjective decisions
    and assumptions. The illustrative financial projections were
    prepared prior to Abraxis&#146; most recent quarter ended
    June&#160;30, 2010 and do not reflect actual results through the
    end of that quarter. The illustrative
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
     financial projections are inherently subject to uncertainty
    because they are based upon numerous factors and events beyond
    the control of the parties and their respective advisors, and
    the inclusion of this information should not be regarded as an
    indication that any of Abraxis, Celgene or any other person
    considered, or now considers, it to be necessarily predictive of
    actual future results. Accordingly, none of Celgene, Abraxis or
    their respective affiliates or representatives assumes any
    responsibility for the accuracy of this information.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    While presented with numerical specificity, the illustrative
    financial projections are necessarily speculative given the time
    periods involved and are based upon various assumptions
    regarding, among other things, the timing and receipt of future
    regulatory approvals of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for various indications, its market share for treatment of those
    indications, the price and market share of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.

    The illustrative assumptions are likely to be different than
    actual results for any number of reasons, including general
    economic conditions, competition and the risks discussed in this
    proxy statement/prospectus under the section titled &#147;Risk
    Factors&#148; and the risk factors found under Part&#160;I,
    Item&#160;IA, &#147;Risk Factors&#148; in Abraxis&#146; Annual
    Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Because the illustrative financial projections cover multiple
    years, such information by its nature becomes less reliable with
    each successive year. The illustrative financial projections
    also do not take into account any circumstances or events
    occurring after the date on which they were prepared and do not
    give effect to the transactions contemplated by the merger
    agreement, including the merger. Accordingly, there can be no
    assurance that the results reflected in the illustrative
    financial projections will be realized, and actual results may
    vary materially from those reflected in such illustrative
    financial projections. You should read the section entitled
    &#147;Cautionary Statement Regarding Forward-Looking
    Statements&#148; for additional information regarding the risks
    inherent in forward-looking information such as the illustrative
    financial projections.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Readers of this proxy statement/prospectus are cautioned not to
    place any reliance on the excerpts of the illustrative financial
    projections set forth above. No representation is made by
    Abraxis, Celgene or any other person to any stockholder of
    Abraxis or any stockholder of Celgene regarding the ultimate
    performance of Abraxis compared to the information included in
    the above summary of the illustrative financial projections nor
    with respect to the value of the CVRs or any payments to be made
    under the CVR agreement. In addition, the illustrative financial
    projections above include forecasts of Abraxis&#146; net revenue
    in addition to the net revenue forecasted from sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products. Any such additional net
    revenue is not covered by the CVR agreement and therefore will
    not be taken into consideration in determining the amounts
    payable to the holders of the CVRs. The inclusion of the
    excerpts of the illustrative financial projections in this proxy
    statement/prospectus should not be regarded as an indication
    that such illustrative financial projections will be an accurate
    prediction of future events nor construed as financial guidance,
    and they should not be relied on as such. Abraxis has made no
    representation to Celgene or any other person concerning the
    projected financial data.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Abraxis will not update or otherwise revise the illustrative
    financial projections to reflect circumstances existing after
    the date when made or to reflect the occurrence of future
    events, even in the event that any or all of the assumptions
    underlying such illustrative financial projections are no longer
    appropriate.</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<A name='117'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Interests
    of Directors and Executive Officers of Abraxis in the
    Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    When reading this proxy statement/prospectus, you should be
    aware that the executive officers and directors of Abraxis may
    have interests in the merger that may be different from, or in
    addition to, the interests of other Abraxis stockholders
    generally. The Abraxis board of directors was aware of these
    interests and considered them, among other factors, in
    unanimously determining that the transactions contemplated by
    the merger agreement, including the merger, are advisable and
    fair to, and in the best interest of, Abraxis and its
    stockholders, adopting the merger agreement and declaring
    advisable the merger. A description of these interests is set
    forth below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Value
    of Equity Awards</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each executive officer and director of Abraxis holds options to
    purchase Abraxis common stock, which we refer to as options,
    <FONT style="white-space: nowrap">and/or</FONT>
    restricted stock units, which we refer to as RSUs, of Abraxis
    which, whether or not vested, pursuant to the merger agreement,
    will immediately vest and be cancelled in exchange for a cash
    payment, if any, and a CVR, as more fully described below in the
    sections entitled &#147;&#151;&#160;Stock Options and Stock
    Appreciation Rights&#148; and &#147;&#151;&#160;Restricted Stock
    Units.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth the total amount of cash and
    number of CVRs that executive officers and directors of Abraxis
    would have received in respect of their vested and unvested
    equity awards assuming the merger was completed on June&#160;30,
    2010 and no vested equity awards were disposed of prior to that
    time. For purposes of this table: (1)&#160;the &#147;per share
    amount&#148; described under &#147;The Merger
    Agreement&#160;&#151; Treatment of Abraxis Stock Options and
    Other Equity Awards&#148; has an assumed value of $71.93 per
    share based upon the closing price of Celgene common stock on
    June&#160;29, 2010;
    <FONT style="white-space: nowrap">(2)&#160;out-of-the-money</FONT>
    stock options (<I>i.e.</I>, those with an exercise price greater
    than $71.93 per share) are not included; and (3)&#160;no value
    has been attributed to the CVRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Vested and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unvested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unvested Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Restricted Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Exercise Price)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Units(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total(2)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total CVRs</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Employee Directors</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kirk K. Calhoun
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,773 ($29.44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    N/A
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    881,877
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,925
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,909 ($34.65
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($38.08
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,243 ($47.30
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($55.44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David S. Chen,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,909 ($29.44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    N/A
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    760,186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,909 ($34.65
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($38.08
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,243 ($47.30
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($55.44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen D. Nimer,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,773&#160;&#160;&#160;($6.29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    N/A
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,296,767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,773 ($25.15
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,909 ($29.44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,909 ($34.65
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($38.08
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,243 ($47.30
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($55.44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leonard Shapiro
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,773 ($14.12
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    N/A
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    955,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,925
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,909 ($34.65
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($38.08
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,243 ($47.30
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($55.44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael S. Sitrick
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000 ($38.08
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    N/A
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    338,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Executive Officers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Patrick Soon-Shiong,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150,000 ($39.93
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,684,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    367,164
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Executive Chairman
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,640 ($64.99
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,781 ($70.12
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,539 ($71.49
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce Wendel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138,125 ($39.93
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,756
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,631,605
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    281,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Vice Chairman and Chief
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,678 ($64.99
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,607 ($65.73
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,121&#160;&#160;&#160;(70.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mitchell Fogelman
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,000 ($39.93
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    919,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Principal Financial and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounting Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Upon vesting, each RSU entitles its holder to one share of
    Abraxis common stock.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents (a)&#160;the difference between $71.93 (<I>i.e.</I>,
    the assumed per share amount) and the exercise price, multiplied
    by the number of underlying vested and unvested options, plus
    (b)&#160;the value of the RSUs based on the assumed $71.93 per
    share amount. Under the merger agreement, the value of the stock
    portion of the merger consideration will be calculated by
    multiplying (a)&#160;the exchange ratio of 0.2617 and
    (b)&#160;the average of the </TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    closing sale prices for Celgene common stock on The NASDAQ
    Global Select Market, as reported in The Wall Street Journal,
    for each of the ten consecutive trading days ending with the
    seventh complete trading day prior to the closing of the merger,
    with such amount rounded up to the nearest cent.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Retention
    and Employment Agreements with Executive Officers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Bruce Wendel, the Vice Chairman and Chief Executive Officer of
    Abraxis, is party to a retention agreement with Abraxis under
    which Abraxis is obligated to pay to Mr.&#160;Wendel certain
    benefits if both (1)&#160;a change of control, including the
    pending merger, occurs on or before December&#160;31, 2011 and
    (2)&#160;Mr.&#160;Wendel&#146;s employment is terminated by
    Abraxis without &#147;cause&#148; or by Mr.&#160;Wendel for
    &#147;good reason&#148; at any time during the
    <FONT style="white-space: nowrap">18-month</FONT>
    period following such change of control. Upon such a termination
    and provided he executes and delivers to Abraxis a general
    release, he would receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a lump sum payment equal to two times his annual base salary
    ($500,000) and two times his most recently-established target
    bonus ($325,000) for a total payment of $1.65&#160;million;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of COBRA premiums until he obtains new employment,
    up to a maximum of 18&#160;months;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    life insurance coverage at present levels for a period of
    24&#160;months.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mitchell Fogelman, the Principal Financial and Accounting
    Officer of Abraxis, is party to an offer letter with Abraxis
    under which Abraxis is obligated to make a lump sum severance
    payment to Mr.&#160;Fogelman equal to $162,500, which is six
    months of his annual base salary if Mr.&#160;Fogelman&#146;s
    employment is terminated by Abraxis without &#147;cause&#148; on
    or prior to October&#160;19, 2010. The severance payment is
    conditioned upon Mr.&#160;Fogelman signing a general release.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth for each executive officer of
    Abraxis (other than Dr.&#160;Soon-Shiong, the Executive Chairman
    of Abraxis, who is not entitled under any Abraxis program,
    policy or practice to any severance or other benefits upon
    termination of employment) the estimated amount of cash
    severance pay, the value of health and dental benefits and the
    value of life insurance premiums to which the executive officer
    would have been entitled assuming that the merger was completed
    on June&#160;30, 2010 and all such executive officers were
    terminated immediately after closing without &#147;cause&#148;
    or for &#147;good reason&#148;, as applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Life<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>COBRA<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Insurance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Title</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payments</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payments</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Premiums</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce Wendel<BR>
    Vice Chairman and Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1,650,000
</TD>
<TD nowrap align="left" valign="top">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    25,022
</TD>
<TD nowrap align="left" valign="top">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    133,562
</TD>
<TD nowrap align="left" valign="top">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1,808,584
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mitchell Fogelman<BR>
    Principal Financial and Accounting Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    162,500
</TD>
<TD nowrap align="left" valign="top">
    (4)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    N/A
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    N/A
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    162,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents two times Mr.&#160;Wendel&#146;s current annual base
    salary plus two times his current annual target bonus of 65%.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents 18&#160;months of COBRA premiums.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents life insurance premiums for two years at current
    coverage level.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents six months of Mr.&#160;Fogelman&#146;s current annual
    base salary. If Mr.&#160;Fogelman&#146;s employment is
    terminated, with or without cause, after October&#160;19, 2010,
    then he would not be entitled to any severance.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">280G
    <FONT style="white-space: nowrap">Gross-Up</FONT>
    Agreements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each of Dr.&#160;Soon-Shiong and Mr.&#160;Wendel is party to an
    agreement with Abraxis that requires Abraxis to pay an amount to
    each of these executive officers to compensate for any
    additional taxes that may be payable as a result of the
    application of the excise tax associated with Section&#160;280G
    of the Code on the benefits received in a
    <FONT style="white-space: nowrap">change-in-control</FONT>
    transaction, including the merger, and any other benefits
    contingent on a
    <FONT style="white-space: nowrap">change-in-control</FONT>
    transaction, including the merger. Based upon the assumptions
    described above, the maximum estimated
    <FONT style="white-space: nowrap">gross-up</FONT>
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    payment that Dr.&#160;Soon-Shiong and Mr.&#160;Wendel would be
    entitled to receive is approximately $9.6&#160;million and
    $8.2&#160;million, respectively (Mr.&#160;Wendel&#146;s total
    assumes that he receives benefits under his retention agreement).
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Directors
    and Officers Indemnification and Continuation of
    Insurance</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to cause Abraxis, as the surviving
    corporation in the merger, and its subsidiaries to establish and
    maintain, for a period of not less than six years following the
    completion of the merger, provisions in their certificates of
    incorporation, bylaws and other organizational documents
    concerning the indemnification and exoneration (including
    provisions relating to expense advancement) of Abraxis&#146; and
    its subsidiaries&#146; former and current officers, directors
    and employees that are no less favorable to those persons than
    the provisions of the certificate of incorporation, bylaws and
    other organizational documents of Abraxis and its subsidiaries
    as in effect on the date of the merger agreement. In addition,
    each of Celgene and Abraxis (as the surviving corporation) have
    agreed that during the period ending on the sixth anniversary of
    the merger, they will indemnify and hold harmless, and provide
    advancement of expenses to, to the fullest extent permitted by
    applicable law, each present and former director, officer and
    employee of Abraxis and its subsidiaries against any costs or
    expenses paid in settlement in connection with any actual or
    threatened claim, action, suit, proceeding or investigation in
    connection with (1)&#160;any acts or omissions occurring or
    alleged to occur prior to, or as of, the completion of the
    merger in their capacities as officers, directors, employees or
    controlling stockholders of Abraxis or any of its subsidiaries
    or taken by them at the request of Abraxis or (2)&#160;the
    negotiation, execution, adoption and approval of the merger
    agreement or the transactions contemplated by the merger
    agreement. We refer to each of the persons entitled to
    indemnification as an &#147;indemnified party.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to cause to be maintained, for a period of
    six years after the completion of the merger, without any lapse
    in coverage, the current policies of directors&#146; and
    officers&#146; liability insurance and fiduciary liability
    insurance maintained by Abraxis and its subsidiaries (Celgene
    may, however, substitute policies of at least the same coverage
    and amounts containing terms and conditions that are no less
    advantageous to the directors and officers than the current
    policies) for a claims-reporting or discovery period of at least
    such six-year period with respect to matters arising on or
    before the completion of the merger. In lieu of the purchase of
    such insurance by Celgene, Abraxis may purchase a six-year
    extended reporting period endorsement under its existing
    directors&#146; and officers&#146; liability insurance coverage
    effective for claims asserted for the full six-year period
    referred to above. During this six-year period, Celgene is not
    required to procure any coverage in excess of the amount that
    can be obtained for the remainder of the period for an annual
    premium of 250% of the current annual premium paid by Abraxis
    for existing coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The rights of each indemnified party under the merger agreement
    are in addition to any rights such indemnified party may have
    under the certificate of incorporation, bylaws or any other
    organizational documents of Abraxis or any of its subsidiaries,
    any other indemnification arrangement in existence as of the
    date of the merger agreement, under Delaware law or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed that, if Celgene, Abraxis (as the surviving
    corporation) or any of their successors or assigns consolidates
    with or merges into any other corporation or entity and is not
    the continuing or surviving corporation or entity of the
    consolidation or merger, or transfers all or substantially all
    of its properties and assets to any individual, corporation or
    other entity, then, and in each case, proper provisions will be
    made so that the successors and assigns of Celgene or Abraxis
    (as the surviving corporation), as applicable, will assume the
    indemnification obligations of Celgene, Abraxis or any of their
    respective successors or assigns, as applicable, as set forth in
    the merger agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Continuation
    of Benefit Plans</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    During the period beginning on the completion of the merger and
    ending no earlier than December&#160;31, 2011, Celgene has
    agreed to provide, or cause Abraxis (as the surviving
    corporation) to provide, each active employee of Abraxis or its
    subsidiaries as of the completion of the merger with salary,
    cash bonus opportunities and employee benefits (including
    equity-based benefits) that are not materially less favorable in
    the aggregate than those provided to such employee at the time
    of the merger, those generally provided by Celgene and its
    subsidiaries to similarly situated employees in the country of
    the employee&#146;s principal place of employment or any
    combination of the foregoing.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To the extent that employees of Abraxis and its subsidiaries
    become eligible to participate in any employee benefit plan,
    program or arrangement maintained by Celgene or any of its
    subsidiaries (including any severance plan), then for purposes
    of determining eligibility to participate and vesting and with
    respect to severance, vacation or paid-time off benefits, for
    purposes of benefits accrual, service with Abraxis or any of its
    subsidiaries prior to the completion of the merger will be
    treated as service with Celgene or any of its subsidiaries,
    subject to applicable law and so long as such treatment does not
    result in a duplication of benefits. Celgene has also agreed to
    use reasonable best efforts to (1)&#160;waive all limitations as
    to preexisting conditions, exclusions and waiting periods with
    respect to participation and coverage requirements applicable to
    employees under any such plan, program or arrangement that is a
    welfare benefit plan in which such employees may be eligible to
    participate after the completion of the merger and
    (2)&#160;provide each employee with credit for any co-payments
    and deductibles paid prior to the completion of the merger in
    satisfying any applicable deductible or
    <FONT style="white-space: nowrap">out-of-pocket</FONT>
    requirements under any such plans, programs or arrangement that
    are welfare plans in which such employees are eligible to
    participate after the completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, Celgene has agreed to pay, within thirty days
    following the completion of the merger, to all employees of
    Abraxis and its subsidiaries cash bonuses for the calendar year
    in which the completion of the merger occurs. Such bonuses will
    be paid out based on target bonus levels and prorated for the
    number of days elapsed in the year in which the completion of
    the merger occurs. If the merger were completed on June&#160;30,
    2010, Abraxis&#146; executive officers would have received the
    following bonuses: (1)&#160;Dr.&#160;Soon-Shiong, $518,837;
    (2)&#160;Bruce Wendel, $163,403; and (3)&#160;Mitchell Fogelman,
    $73,531.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Options and Stock Appreciation Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    Options</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At least five business days prior to the completion of the
    merger, each holder of an outstanding option to purchase Abraxis
    common stock that was granted under any stock option or equity
    incentive plan of Abraxis, which we refer to as a stock option,
    and that has an exercise price greater than the &#147;per share
    amount&#148; (which we define below) will, whether such stock
    option is vested or unvested, be provided with written notice
    that such holder has the right until the business day preceding
    the completion of the merger, which we refer to as the exercise
    period, to exercise such stock option by paying Abraxis a cash
    amount equal to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise price of the stock option, less
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the per share amount.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each such stock option that is exercised during the exercise
    period will be settled in exchange for one CVR. Any such stock
    option that is not exercised during the exercise period will be
    cancelled upon the completion of the merger for no consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each stock option that remains outstanding immediately prior to
    the completion of the merger and that has an exercise price that
    is equal to or less than the per share amount will be cancelled
    in exchange for the right to receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount in cash, without interest, equal to the excess, if
    any, of the per share amount over the exercise price of such
    stock option,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The &#147;per share amount&#148; means the sum of $58.00 and the
    amount obtained by multiplying (1)&#160;the exchange ratio of
    0.2617 by (2)&#160;an amount equal to the average of the closing
    sale prices for Celgene common stock on The NASDAQ Global Select
    Market, as reported in The Wall Street Journal, for each of the
    ten consecutive trading days ending with the seventh complete
    trading day prior to the completion of the merger, with such
    amount rounded up to the nearest cent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    Appreciation Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At least five business days prior to the completion of the
    merger, each holder of an outstanding stock appreciation right
    that was granted under any stock option or equity incentive plan
    of Abraxis, which we refer to as a
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    SAR, and that has a base appreciation amount greater than the
    per share amount will, whether such SAR is vested or unvested,
    be provided with written notice that such holder has the right
    to exercise such SAR during the exercise period by paying to
    Abraxis a cash amount equal to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the base appreciation amount of the SAR, less
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the per share amount.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each such SAR that is exercised during the exercise period will
    be settled in exchange for one CVR. Any SAR that is not
    exercised during the exercise period will be cancelled upon the
    completion of the merger for no consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each SAR that remains outstanding immediately prior to the
    completion of the merger and that has a base appreciation amount
    equal to or less than the per share amount will be cancelled
    upon the completion of the merger in exchange for the right to
    receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount in cash, without interest, equal to the excess, if
    any, of the per share amount over the base appreciation amount
    of such SAR,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Restricted
    Stock Units</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each RSU granted by Abraxis under any stock option or equity
    incentive plan of Abraxis and which is outstanding immediately
    prior to the completion of the merger will vest upon the
    completion of the merger and will be canceled and converted into
    the right to receive:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cash, without interest, equal to the per share amount,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Non-Competition,
    Non-Solicitation and Confidentiality Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010, Dr.&#160;Soon-Shiong entered into a
    non-competition, non-solicitation and confidentiality agreement
    with Celgene, which we refer to as the non-competition
    agreement, pursuant to which Dr.&#160;Soon-Shiong will be
    generally prohibited for ten years after completion of the
    merger from, without the prior written consent of Celgene,
    owning, managing, financing, investing in, controlling, engaging
    in, operating or conducting, lending his name to, lending credit
    to, rendering services or advising, devoting material endeavor
    or effort to, or assisting any person or entity to conduct, the
    business of researching, developing, licensing, manufacturing,
    selling, offering for sale, importing, using, marketing,
    distributing, practicing, or otherwise exploiting
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or any other pharmaceutical or diagnostic product developed or
    manufactured using the albumin-bound
    (nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>)

    technology (as defined in the non-competition agreement), which
    we refer to as the business, in the United States and all other
    countries in which Abraxis was engaged in the business at the
    completion of the merger. Additionally,
    <FONT style="white-space: nowrap">Dr.&#160;Soon-Shiong</FONT>
    will be generally prohibited for ten years after completion of
    the merger from, without the prior written consent of Celgene:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (i)&#160;soliciting, knowingly encouraging or inducing any
    customer, supplier or licensee with whom Abraxis or its
    subsidiaries were engaged in a contractual relationship, or
    substantive discussions or proposal negotiations, in each case
    as of the completion of the merger, with respect to the business
    to cease doing business with Abraxis, Celgene or any of their
    subsidiaries with respect to the business in the United States
    and all other countries in which Abraxis or its subsidiaries
    were engaged in the business at the completion of the merger; or
    (ii)&#160;otherwise knowingly interfering with Abraxis&#146;,
    Celgene&#146;s or their respective subsidiaries&#146;
    relationship with any customer, supplier or licensee of the
    business,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    soliciting, encouraging or inducing any employee, consultant or
    independent contractor that was engaged by Abraxis or its
    subsidiaries as of the completion of the merger to terminate or
    breach an employment, contractual or other relationship with
    Abraxis, Celgene or their respective subsidiaries,&#160;and
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    making any public statements that directly or indirectly
    disparage Abraxis, Celgene or any of their respective affiliates,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    in each case subject to certain exceptions. Dr.&#160;Soon-Shiong
    has also agreed not to use or disclose, except as required by
    law or as directed by Abraxis or Celgene, confidential
    information that is owned or held by Abraxis as of the
    completion of the merger. Dr.&#160;Soon-Shiong&#146;s
    confidentiality obligations will survive the expiration of the
    term and any termination of the non-competition agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The non-competition agreement will become effective as of the
    completion of the merger and will have no force or effect if the
    merger agreement is terminated prior to the completion of the
    merger or if the merger is otherwise not completed.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholders&#146;
    Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010, certain of the principal stockholders,
    including Dr.&#160;Soon-Shiong, entered into a
    stockholders&#146; agreement with Celgene, which we refer to as
    the stockholders&#146; agreement, under which they agreed, among
    other things, not to sell, transfer, pledge or otherwise dispose
    of any of the shares of Celgene common stock issued to them in
    the merger prior to the third anniversary of the merger, other
    than sales, transfers, pledges or other dispositions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to any trusts for the benefit of Dr.&#160;Soon-Shiong or any
    member of his immediate family, any other entity in which
    Dr.&#160;Soon-Shiong or any members of his immediate family
    separately or collectively hold, directly or indirectly, a
    majority of the outstanding equity interests, or any charitable
    foundation or organization, in each case only if such persons
    agree to be bound by the terms of the stockholders&#146;
    agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pursuant to a third party tender offer or exchange offer
    (1)&#160;which is approved by the Celgene board of directors or
    (2)&#160;in circumstances in which it is reasonably likely that
    these stockholders would be, as a result of not tendering or
    exchanging, relegated to different consideration than would be
    available to those stockholders who did tender or exchange,
    taking into account any provisions thereof;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to the estate of a deceased holder upon a deceased holder&#146;s
    death;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    from the estate of a deceased holder to the beneficiaries
    thereof;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pursuant to a merger or similar transaction involving Celgene.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to the exceptions set forth in the preceding
    sentence, after the second anniversary of the merger, the
    stockholders that are party to the stockholders&#146; agreement
    may, subject to the limitation set forth in the following
    sentence, sell, transfer, pledge or otherwise dispose of, in the
    aggregate, a number of shares of Celgene common stock issued to
    them in the merger equal to 25% of the number of shares of
    Celgene common stock issued to these stockholders in the merger.
    Prior to the fourth anniversary of the merger, these
    stockholders may not, during any calendar month, sell, in the
    aggregate, pursuant to open market transactions, shares of
    Celgene common stock issued to them in the merger representing
    more than 30% of the number of shares of Celgene common stock
    issued to these stockholders in the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The stockholders&#146; agreement will terminate, as to each
    stockholder party thereto, on the first date on which such
    stockholder does not own any shares of Celgene common stock
    issued to such stockholder in the merger. The stockholders&#146;
    agreement will also terminate in the event of the termination of
    the merger agreement prior to the completion of the merger
</DIV>

<A name='118'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulatory
    Approvals</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the provisions of the
    <FONT style="white-space: nowrap">Hart-Scott-Rodino</FONT>
    Antitrust Improvements Act of 1976, which we refer to as the HSR
    Act, the merger may not be completed until notification and
    report forms have been filed with the U.S.&#160;Federal Trade
    Commission, which we refer to as the FTC, and the Antitrust
    Division of the U.S.&#160;Department of Justice, which we refer
    to as the Antitrust Division, and until the expiration of a 30
    calendar day waiting period, or the early termination of that
    waiting period, following the parties&#146; filing of their
    respective notification and report forms. If the FTC or the
    Antitrust Division issues a Request for Additional Information
    and Documentary Material prior to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    the expiration of the waiting period, the parties must observe a
    second 30 calendar day waiting period, which would begin to run
    only after both parties have substantially complied with the
    request for information, unless the waiting period is terminated
    earlier or extended with the consent of the parties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;14, 2010, Abraxis and Celgene filed their
    respective notification and report forms under the HSR Act with
    the FTC and the Antitrust Division. Celgene received
    confirmation of early termination of the initial waiting period
    under the HSR Act effective as of August&#160;3, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Subject to the terms and conditions of the merger agreement,
    Abraxis and Celgene have agreed to use their reasonable best
    efforts to obtain all regulatory clearances necessary to
    complete in the most expeditious manner practicable, the merger;
    however, Celgene is not required to sell, divest or otherwise
    dispose of, hold separate, enter into any license or similar
    agreement with respect to, restrict the ownership or operation
    of, or agree to sell, divest or otherwise dispose of, hold
    separate, enter into any license or similar agreement with
    respect to, or restrict the ownership or operation of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (A)&#160;any assets or businesses of Abraxis or any of its
    subsidiaries or (B)&#160;any assets or businesses of Celgene or
    any of its affiliates or subsidiaries, in the case of either
    clause&#160;(A) or (B), to the extent that such sale,
    divestiture, disposition, or agreement would have a material
    adverse effect on the business, operations, financial condition
    or results of operations of the combined business of Abraxis and
    Celgene after giving effect to the completion of the
    merger;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    to the extent such sale, divestiture, disposition, agreement or
    restriction would have a material adverse effect on the ability
    of Abraxis to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in the United States, the European Union, Canada and Switzerland.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, Abraxis is not required to divest, hold separate or
    otherwise take or commit to take any action that limits its
    freedom of action with respect to, or its ability to retain, any
    of the businesses, services, or assets of Abraxis or any of its
    subsidiaries, unless it is conditioned upon the completion of
    the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='119'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Litigation
    Related to the Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis, the members of the Abraxis board of directors and
    Celgene are named as defendants in putative class action
    lawsuits brought by Abraxis stockholders challenging the merger
    in Los Angeles County Superior Court. The plaintiffs in such
    actions assert claims for breaches of fiduciary duty arising out
    of the merger and allege that Abraxis&#146; directors engaged in
    self-dealing and obtained for themselves personal benefits and
    have failed or are failing to provide stockholders with material
    information relating to the merger. The plaintiffs also allege
    claims for aiding and abetting breaches of fiduciary duty
    against Abraxis and Celgene. These lawsuits generally seek,
    among other things, to enjoin the defendants from consummating
    the merger until such time as Abraxis:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adopts and implements a procedure or process to obtain the
    highest possible price for stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    discloses all material information to stockholders regarding the
    merger;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    institutes a majority of the minority vote provision.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On September&#160;14, 2010, the parties reached an agreement in
    principle to settle the actions pursuant to the MOU. Without
    admitting the validity of any allegations made in the actions,
    or any liability with respect thereto, the defendants elected to
    settle the actions in order to avoid the cost, disruption and
    distraction of further litigation. Under the MOU, the defendants
    agreed, among other things, to make additional disclosures
    relating to the merger as set forth in this proxy
    statement/prospectus, and to provide the plaintiffs&#146;
    counsel with limited discovery to confirm the fairness and
    adequacy of the settlement. Abraxis, on behalf of itself and for
    the benefit of the other defendants in the actions, also agreed
    to pay the plaintiffs&#146; counsel $600,000 for their fees and
    expenses. The parties agreed to use their best efforts to agree
    upon, execute and present to the court within thirty days a
    formal stipulation of settlement and such other documents as may
    be necessary to obtain approval by the court of the settlement
    and the dismissal with prejudice of the actions. Pending
    execution of such stipulation, the parties agreed to stay all
    proceedings in the actions, except those relating to the
    settlement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='120'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Accounting
    Treatment</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In accordance with U.S.&#160;GAAP, Celgene will account for the
    merger using the acquisition method of accounting for business
    combinations. Under this method of accounting, Celgene will
    record the acquisition based on the fair value of the merger
    consideration, which includes the cash consideration paid, the
    market value of shares of Celgene common stock issued in
    connection with the merger (based on the closing price of
    Celgene common stock on the date of the completion of the
    merger) and the CVRs issued in connection with the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene will allocate the purchase price to the identifiable
    assets acquired and liabilities assumed based on their
    respective fair values at the date of the completion of the
    merger. Any excess of the value of consideration paid over the
    aggregate fair value of those net assets will be recorded as
    goodwill. Financial statements of Celgene issued after the
    completion of the merger will reflect such fair values and will
    not be restated retroactively to reflect historical financial
    position or results of operations of Celgene. The results of
    operations of Abraxis will be included in the results of
    operations of Celgene beginning on the date of the completion of
    the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='121'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Delisting
    and Deregistration of Abraxis Common Stock</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the merger is completed, Abraxis&#146; common stock will be
    delisted from The NASDAQ Global Select Market and deregistered
    under the Exchange Act, and Abraxis will no longer file periodic
    reports with the SEC related to Abraxis common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='122'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Exchange Listing of Celgene Common Stock Issued in the
    Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    It is a condition to the completion of the merger that the
    shares of Celgene common stock issued in the merger will be
    approved for listing on The NASDAQ Global Select Market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='123'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Exchange Listing of CVRs</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    An application will be made to The NASDAQ Global Select Market
    to list and trade the CVRs on The NASDAQ Global Select Market.
    If the CVRs are not accepted for listing on The NASDAQ Global
    Select Market, application will be made to list the CVRs on such
    other exchange(s), electronic trading networks or other suitable
    trading platforms as mutually agreed by Abraxis and Celgene at
    or prior to the completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='124'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Financing
    the Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene does not require financing for the merger. However,
    Celgene is considering and may pursue financing arrangements on
    terms and conditions favorable to Celgene, including, without
    limitation, an offering of debt securities, to maintain
    financial flexibility. The Unaudited Pro Forma Condensed
    Consolidated Financial Statements contemplate the use of
    Celgene&#146;s cash on hand and the sale of Celgene investments
    in marketable securities to finance the merger.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<A name='125'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    MERGER AGREEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following summary describes certain material provisions of
    the merger agreement and is qualified in its entirety by
    reference to the merger agreement, a copy of which is attached
    to this proxy statement/prospectus as Annex&#160;A and which is
    incorporated by reference into this proxy statement/prospectus.
    This summary does not purport to be complete and may not contain
    all of the information about the merger agreement that may be
    important to you. We encourage you to read the merger agreement
    carefully and in its entirety, as it is the legal document
    governing the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='126'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger agreement provides for the merger of merger sub with
    and into Abraxis upon the terms and subject to the conditions of
    the merger agreement, and in accordance with the General
    Corporation Law of the State of Delaware, which we refer to as
    the DGCL, with Abraxis being the surviving corporation. As a
    result of the merger, Abraxis will become a direct or indirect
    wholly-owned subsidiary of Celgene, and will continue its
    corporate existence under the laws of the State of Delaware.
    Upon completion of the merger, the directors of merger sub and
    the officers of Abraxis immediately prior to the completion of
    the merger will be the initial directors and officers of Abraxis
    as the surviving corporation.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='127'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Effective
    Time</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The effective time, or completion, of the merger will occur at
    the time that a certificate of merger is duly executed and filed
    with the Secretary of State of the State of Delaware in
    accordance with the DGCL on the closing date of the merger. The
    closing date will occur on the day that is no later than two
    business days following the satisfaction or waiver (to the
    extent permitted under applicable law and the terms of the
    merger agreement) of the conditions to the completion of the
    merger (other than those that can only be fulfilled at the
    closing, but subject to the satisfaction or waiver of such
    conditions) described under &#147;&#151;&#160;Conditions to the
    Merger,&#148; or another date as Abraxis and Celgene may agree
    in writing. We anticipate that the merger will close within two
    business days following the date of the special meeting, if all
    conditions to the merger (as described under
    &#147;&#151;&#160;Conditions to the Merger&#148;) are fulfilled
    or waived on or before the closing date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='128'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Merger
    Consideration</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each share of Abraxis common stock issued and outstanding
    immediately prior to the completion of the merger, other than
    shares held by stockholders who have properly exercised
    appraisal rights with respect to such shares in accordance with
    Section&#160;262 of the DGCL, which we refer to as dissenting
    shares, and shares held in the treasury of Abraxis or owned by
    Celgene, merger sub or any wholly-owned subsidiary of Celgene or
    Abraxis, which we refer to as excluded shares, will be converted
    in the merger into the right to receive (1)&#160;$58.00 in cash,
    without interest, (2)&#160;0.2617 of a share of common stock of
    Celgene, and (3)&#160;one CVR, issued by Celgene subject to and
    in accordance with the CVR agreement. We refer to the
    consideration for the merger described in clauses (1),
    (2)&#160;and (3)&#160;as the merger consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='129'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Dissenting
    Shares</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Shares of Abraxis common stock held by any stockholder who
    properly demands appraisal with respect to such shares in
    compliance with Section&#160;262 of the DGCL will not be
    converted into the right to receive the merger consideration,
    and holders of such shares will be entitled to receive payment
    of the value of such shares determined in accordance with the
    applicable provisions of the DGCL and as further described in
    the section entitled &#147;Rights of Stockholders to Seek
    Appraisal.&#148; However, if, after the completion of the
    merger, any holder of dissenting shares fails to perfect or
    effectively withdraws or loses its right to appraisal and
    payment under the DGCL, the shares of Abraxis common stock held
    by that stockholder that were dissenting shares will be treated
    as if they had been converted into the right to receive the
    merger consideration, any cash in lieu of fractional shares and
    any dividends or other distributions to which such stockholder
    is entitled to receive, without any interest thereon.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<A name='130'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Treatment
    of Abraxis Stock Options and Other Equity Awards</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    Options</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At least five business days prior to the completion of the
    merger, each holder of an outstanding option to purchase Abraxis
    common stock that was granted under any stock option or equity
    incentive plan of Abraxis, which we refer to as a stock option,
    and that has an exercise price greater than the &#147;per share
    amount&#148; (which we define below) will, whether such stock
    option is vested or unvested, be provided with written notice
    that such holder has the right until the business day preceding
    the completion of the merger, which we refer to as the exercise
    period, to exercise such stock option by paying Abraxis a cash
    amount equal to:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise price of the stock option, less
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the per share amount.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each such stock option that is exercised during the exercise
    period will be settled in exchange for one CVR. Any such stock
    option that is not exercised during the exercise period will be
    cancelled upon the completion of the merger for no consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each stock option that remains outstanding immediately prior to
    the completion of the merger and that has an exercise price that
    is equal to or less than the per share amount will be cancelled
    upon the completion of the merger in exchange for the right to
    receive:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount in cash, without interest, equal to the excess, if
    any, of the per share amount over the exercise price of such
    stock option,&#160;and
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The &#147;per share amount&#148; means the sum of $58.00 and the
    amount obtained by multiplying (1)&#160;the exchange ratio of
    0.2617 by (2)&#160;an amount equal to the average of the closing
    sale prices for Celgene common stock on The NASDAQ Global Select
    Market, as reported in The Wall Street Journal, for each of the
    ten consecutive trading days ending with the seventh complete
    trading day prior to the completion of the merger, with such
    amount rounded up to the nearest cent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    Appreciation Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At least five business days prior to the completion of the
    merger, each holder of an outstanding stock appreciation right
    that was granted under any stock option or equity incentive plan
    of Abraxis, which we refer to as a SAR, and that has a base
    appreciation amount greater than the per share amount will,
    whether such SAR is vested or unvested, be provided with written
    notice that such holder has the right to exercise such SAR
    during the exercise period by paying to Abraxis a cash amount
    equal to:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the base appreciation amount of the SAR, less
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the per share amount.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each such SAR that is exercised during the exercise period will
    be settled in exchange for one CVR. Any SAR that is not
    exercised during the exercise period will be cancelled upon
    completion of the merger for no consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each SAR that remains outstanding immediately prior to the
    completion of the merger and that has a base appreciation amount
    equal to or less than the per share amount will be cancelled
    upon completion of the merger in exchange for the right to
    receive:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount in cash, without interest, equal to the excess, if
    any, of the per share amount over the base appreciation amount
    of such SAR,&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Restricted
    Stock Units</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each restricted stock unit, which we refer to as a RSU, granted
    by Abraxis under any stock option or equity incentive plan of
    Abraxis which is outstanding immediately prior to the completion
    of the merger will vest upon completion of the merger and will
    be canceled and converted into the right to receive:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cash, without interest, equal to the per share amount&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<A name='131'>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Payment
    and Exchange Procedures</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon the completion of the merger, Celgene agreed to deposit, or
    cause to be deposited, with American Stock Transfer&#160;&#038;
    Trust&#160;Company, the paying agent appointed by Celgene, which
    we refer to as the paying agent, (1)&#160;cash in an amount
    sufficient to pay the aggregate cash consideration to be paid to
    stockholders in connection with the merger,
    (2)&#160;certificates representing number of shares of Celgene
    common stock equal to 0.2617 multiplied by the number of
    outstanding shares of Abraxis common stock (other than
    dissenting shares and excluded shares), and (3)&#160;CVR
    certificates representing the aggregate number of CVRs issuable
    pursuant to the CVR agreement in accordance with the merger
    agreement. Celgene also agreed to deposit, or cause to be
    deposited, with the paying agent, immediately available funds
    sufficient to pay cash in lieu of fractional shares and any
    dividends and other distributions payable pursuant to the merger
    agreement. We refer to the aggregate amount described in clauses
    (1), (2)&#160;and (3)&#160;as the exchange fund.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As soon as practicable, and in any event within two business
    days after the completion of the merger, the paying agent will
    mail to each holder of record of Abraxis common stock, other
    than holders of dissenting shares and excluded shares, a letter
    of transmittal (which will specify that the delivery will be
    effected, and risk of loss and title will pass, only upon actual
    delivery of the certificates of Abraxis common stock or transfer
    of the book-entry shares of Abraxis common stock to the paying
    agent) and instructions for use in surrendering the certificates
    or transferring the book-entry shares in exchange for the merger
    consideration.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon surrender of a certificate of Abraxis common stock (or
    delivery of such customary affidavits and indemnities with
    respect to a lost certificate which the paying agent
    <FONT style="white-space: nowrap">and/or</FONT>
    Abraxis&#146; transfer agent may reasonably require) or transfer
    of book-entry shares of Abraxis common stock for cancellation to
    the paying agent, together with a letter of transmittal duly
    executed and in proper form, the holder of such certificate or
    book-entry shares will be entitled to receive the merger
    consideration pursuant to the merger agreement, any cash in lieu
    of fractional shares and any dividends or other distributions
    payable pursuant to the merger agreement. The surrendered
    certificates of Abraxis common stock and the transferred
    book-entry shares will then be canceled. No interest will be
    paid or will accrue on the merger consideration, cash in lieu of
    fractional shares or dividends or other distributions payable to
    such holders upon the surrender of any certificate of Abraxis
    common stock or transfer of book-entry shares of Abraxis common
    stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If a transfer of ownership of Abraxis common stock is not
    registered in the transfer records of Abraxis, payment may be
    made to a person other than the person in whose name the
    surrendered certificate of Abraxis common stock is registered,
    if such certificate is properly endorsed or otherwise in proper
    form for transfer and the person requesting payment pays any
    transfer or other taxes and establishes to Celgene&#146;s
    satisfaction that such tax has been paid or is not applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Until surrendered or transferred as contemplated by the merger
    agreement, each certificate of Abraxis common stock or
    book-entry share of Abraxis common stock (other than those
    representing any dissenting shares or excluded shares) will be
    deemed after the completion of the merger to represent only the
    right to receive the merger consideration pursuant to the merger
    agreement, without interest. No dividends or other distributions
    declared or made after the completion of the merger with respect
    to Celgene common stock, with a record date after the completion
    of the merger, will be paid to the holder of any unsurrendered
    certificate of Abraxis common stock. No cash payment in lieu of
    fractional shares will be paid to any such holder, unless and
    until such holder surrenders such certificate of Abraxis common
    stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Following the surrender of any certificate of Abraxis common
    stock, the holder of the certificates representing whole shares
    of Celgene common stock issued in exchange therefor will be
    paid, without interest, (1)&#160;any cash payable with respect
    to a fractional share of Celgene common stock to which such
    holder is entitled and the dividends or other distributions with
    a record date after the completion of the merger paid with
    respect to such whole shares of Celgene common stock and
    (2)&#160;at the appropriate payment date, the dividends or other
    distributions, with a record date after the completion of the
    merger but prior to surrender and a payment date occurring after
    surrender, payable with respect to such whole shares of Celgene
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    No certificates or scrip representing fractional shares of
    Celgene common stock, or book-entry credit of the same, will be
    issued upon the surrender of certificates of Abraxis common
    stock, and no dividend or distribution with respect to Celgene
    common stock will be payable on or with respect to any
    fractional share. All fractional shares to which a holder of
    Abraxis common stock would be entitled will be aggregated and
    rounded to the fourth decimal point. In lieu of any such
    fractional share of Celgene common stock, each holder of Abraxis
    common stock will be entitled to receive from the paying agent a
    cash payment, rounded up to the nearest cent, equal to the
    product of (1)&#160;the fractional part of a share of Celgene
    common stock multiplied by (2)&#160;the average of the closing
    sale prices for Celgene common stock on The NASDAQ Global Select
    Market, as reported in The Wall Street Journal, for each of the
    ten consecutive trading days ending with the seventh complete
    trading day prior to the completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any portion of the exchange fund that remains undistributed to
    the former holders of Abraxis common stock one year after the
    completion of the merger will be delivered to Celgene at such
    time. Thereafter, former holders of Abraxis common stock will
    only look only to Celgene as a general creditor for payment of
    the merger consideration payable to them pursuant to the merger
    agreement, without interest, upon the surrender of any
    certificates of Abraxis common stock held by them.
</DIV>

<A name='132'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Representations
    and Warranties</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger agreement contains representations and warranties
    which the parties made to each other. The statements embodied in
    those representations and warranties were made for purposes of
    the contract between the parties and are subject to
    qualifications and limitations agreed to by the parties in
    connection with negotiating the terms of that contract. Certain
    representations and warranties were made as of the date of the
    merger agreement (or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    other date specified in the merger agreement), may be subject to
    contractual standards of materiality different from those
    generally applicable to stockholders or may have been used for
    the purpose of allocating risk between the parties rather than
    establishing matters of fact. In addition, the representations
    and warranties are qualified by information in a confidential
    disclosure letter that Abraxis provided to Celgene in connection
    with signing the merger agreement. Accordingly, you should not
    rely on the representations and warranties as characterizations
    of the actual state of facts, since they are qualified as
    described above. Moreover, information concerning the subject
    matter of the representations and warranties may have changed
    since the date of the merger agreement, and these changes may or
    may not be fully reflected in our public disclosures. The merger
    agreement should not be read alone, but should instead be read
    in conjunction with the other information regarding Abraxis,
    Celgene and the merger that is contained in this proxy
    statement/prospectus as well as in the filings that Abraxis and
    Celgene make and have made with the SEC. The representations and
    warranties contained in the merger agreement may or may not have
    been accurate as of the date they were made and we make no
    assertion herein that they are accurate as of the date of this
    proxy statement/prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the merger agreement, Abraxis made various representations
    and warranties that are subject, in some cases, to specified
    exceptions and qualifications. Abraxis&#146; representations and
    warranties relate to, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; and its subsidiaries&#146; organization, good
    standing, and qualification to do business;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; capitalization, including the particular number of
    outstanding shares of Abraxis common stock, stock options, SARs
    and RSUs, and Abraxis&#146; equity interest in its subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; corporate power and authority to enter into the
    merger agreement and to complete the merger and the transactions
    contemplated by the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the execution and delivery of the merger agreement by Abraxis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the approval and authorization by the Abraxis board of directors
    of the merger agreement, the merger and the other transactions
    contemplated by the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the enforceability of the merger agreement against Abraxis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of any violation or conflict with Abraxis&#146; or
    its subsidiaries&#146; governing documents, applicable law or
    certain agreements as a result of the execution and delivery of
    the merger agreement and completion of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the required registrations and consents of governmental entities
    in connection with the merger agreement, the merger and the
    other transactions contemplated by the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; filings with the SEC since January&#160;1, 2008,
    including financial statements, Sarbanes-Oxley certifications,
    absence of complaints regarding accounting practices, controls
    over financial reporting, and the absence of certain undisclosed
    liabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    information supplied by Abraxis for inclusion or incorporation
    by reference in this document;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the conduct of Abraxis and its subsidiaries of their operations
    and the absence of certain events, including an &#147;Abraxis
    material adverse effect&#148; (which we define below), since
    March&#160;31, 2010 until June&#160;30, 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of legal proceedings and orders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; and its subsidiaries&#146; permits and compliance
    with applicable law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    taxes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    employee benefit plans and ERISA matters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    employee matters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    environmental matters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of related-party transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    intellectual property matters;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    inapplicability of takeover statutes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    owned and leased real property;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    material contracts and performance of obligations thereunder;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    receipt by the Abraxis board of directors of a fairness opinion
    from each of Goldman Sachs, Lazard and BofA Merrill Lynch;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    regulatory issues related to pharmaceutical matters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of undisclosed broker&#146;s fees;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    insurance coverage;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    anti-corruption and anti-bribery laws.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The representations and warranties of Abraxis will not survive
    the completion of the merger or the termination of the merger
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Many of Abraxis&#146; representations and warranties are
    qualified by reference to an &#147;Abraxis material adverse
    effect&#148; standard; that is, they will not be deemed to be
    untrue or incorrect unless their failure to be true and correct,
    individually or in the aggregate, would reasonably be expected
    to have an &#147;Abraxis material adverse effect.&#148; For
    purposes of the merger agreement, an &#147;Abraxis material
    adverse effect&#148; means any effect, that, in the aggregate
    with all other effects, is, or would reasonably be expected to
    be, materially adverse to the business, assets, financial
    condition or results of operations of Abraxis and its
    subsidiaries taken as a whole or which would prevent the
    completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In no event will any of the following, alone or in combination,
    be deemed to constitute, nor will any of the following be taken
    into account in determining whether there has been, or there
    would reasonably be expected to be, an Abraxis material adverse
    effect:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect relating to, or resulting from, any change or
    development in or to local, regional, national or foreign
    political, economic or financial conditions or in or to local,
    regional, national or foreign credit, financial, banking or
    securities markets (including any disruption thereof), including
    any effect caused by acts of terrorism or war or armed
    hostilities (whether or not declared);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect affecting generally any of the industries, geographic
    areas or business segments in which Abraxis or any of its
    subsidiaries operate;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect relating to, or resulting from, hurricanes,
    earthquakes or other natural disasters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any change in the share price or trading volume (as opposed to
    the facts underlying such change) of Abraxis&#146; common stock
    on The NASDAQ Global Select Market;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect relating to, or resulting from, the adoption,
    implementation, promulgation, repeal, modification or proposal
    of any applicable law or U.S.&#160;GAAP after June&#160;30, 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any failure, in and of itself (as opposed to the facts
    underlying such failure) by Abraxis to meet any budgets, plans,
    projections or forecasts of Abraxis&#146; or its
    subsidiaries&#146; revenue, earnings or other financial
    performance or results of operations, or any published financial
    forecasts or analyst estimates with respect to the revenue,
    earnings or other financial performance or results of operations
    of Abraxis or its subsidiaries or any change in analyst
    recommendations, for any period;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect directly relating to, or resulting from, the
    execution, performance or announcement of the merger agreement
    or the related agreements (we refer to the non-competition
    agreement with Dr.&#160;Soon-Shiong, the CVR agreement and the
    voting agreement collectively as the related agreements),
    including the impact thereof on relationships with customers,
    suppliers, licensors, licensees, distributors, partners or
    employees, the loss or departure of officers or other employees
    of Abraxis or its subsidiaries and any pending or threatened
    legal proceeding challenging the merger agreement, any of the
    related agreements or the transactions contemplated by the
    merger agreement or the related agreements, or otherwise
    resulting from
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    the pursuit of the completion of the transactions contemplated
    by the merger agreement or the related agreements;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    except that the first, second, third and fifth bullets above
    will not be applicable with respect to effects to the extent
    that any such effects have had, or would reasonable be expected
    to have, a disproportionate impact on Abraxis and its
    subsidiaries, taken as a whole, relative to other participants
    in the industry in which Abraxis and its subsidiaries operate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the merger agreement, Celgene and merger sub also made
    various representations and warranties that are subject, in some
    cases, to specified exceptions and qualifications.
    Celgene&#146;s and merger sub&#146;s representations and
    warranties relate to, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s and merger sub&#146;s organization, good
    standing, and qualification to do business;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s capitalization, including the particular number
    of outstanding shares of Celgene common stock, stock options and
    warrants;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s equity interest in merger sub and the operations
    of merger sub;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s and merger sub&#146;s corporate power and
    authority to enter into the merger agreement and to complete the
    merger and the transactions contemplated by the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the execution and delivery of the merger agreement by each of
    Celgene and merger sub;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the enforceability of the merger agreement against Celgene and
    merger sub;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of any violation or conflict with Celgene&#146;s and
    its subsidiaries&#146; governing documents, applicable law or
    certain agreements as a result of the execution and delivery of
    the merger agreement and the completion of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the required registrations and consents of governmental entities
    in connection with the merger agreement, the merger and the
    other transactions contemplated by the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s filings with the SEC since January&#160;1, 2008,
    including financial statements, Sarbanes-Oxley certifications,
    absence of complaints regarding accounting practices, controls
    over financial reporting and the absence of certain undisclosed
    liabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of a &#147;Celgene material adverse effect&#148;
    (which we define below) since March&#160;31, 2010 until
    June&#160;30, 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    information supplied by Celgene for inclusion or incorporation
    by reference in this document;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s ability to pay the merger consideration at the
    completion of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of legal proceedings and orders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s and its subsidiaries&#146; permits and compliance
    with applicable law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of undisclosed broker&#146;s fees;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    non-ownership by Celgene or merger sub of any shares of Abraxis
    common stock as of June&#160;30, 2010;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    solvency of Celgene and Abraxis as the surviving corporation
    following completion of the merger.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The representations and warranties of Celgene and merger sub do
    not survive the completion of the merger or the termination of
    the merger agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Some of Celgene&#146;s representations and warranties are
    qualified by reference to a &#147;Celgene material adverse
    effect&#148; standard; that is, they will not be deemed to be
    untrue or incorrect unless their failure to be true and correct,
    individually or in the aggregate, would reasonably be expected
    to have a &#147;Celgene material adverse effect.&#148; For
    purposes of the merger agreement, a &#147;Celgene material
    adverse effect&#148; means any effect, that, in the aggregate
    with all other effects, is, or would reasonably be expected to
    be, materially adverse to the business, assets, financial
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    condition or results of operations of Celgene and its
    subsidiaries taken as a whole or which would prevent the
    completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In no event will any of the following, alone or in combination,
    be deemed to constitute, nor will any of the following be taken
    into account in determining whether there has been, or there
    would reasonably expected to be, a Celgene material adverse
    effect:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect relating to, or resulting from, any change or
    developments in or to local, regional, national or foreign
    political, economic or financial conditions or in or to local,
    regional, national or foreign credit, financial, banking or
    securities markets (including any disruption thereof), including
    any effect caused by acts of terrorism or war or armed
    hostilities (whether or not declared);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect affecting generally any of the industries, geographic
    areas or business segments in which Celgene or any of its
    subsidiaries operate;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect relating to, or resulting from, hurricanes,
    earthquakes or other natural disasters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any change in the share price or trading volume (as opposed to
    the facts underlying such change) of Celgene common stock on The
    NASDAQ Global Select Market;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect relating to, or resulting from, the adoption,
    implementation, promulgation, repeal, modification or proposal
    of any applicable law or U.S.&#160;GAAP after June&#160;30, 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any failure, in and of itself (as opposed to the facts
    underlying such failure), to meet any budgets, plans,
    projections or forecasts of Celgene&#146;s or its
    subsidiaries&#146; revenue, earnings or other financial
    performance or results of operations, or any published financial
    forecasts or analyst estimates with respect to the revenue,
    earnings or other financial performance or results of operations
    of Celgene or its subsidiaries or any change in analyst
    recommendations, for any period;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any effect directly relating to, or resulting from, the
    execution, performance or announcement of the merger agreement
    or the related agreements, including the impact thereof on
    relationships with customers, suppliers, licensors, licensees,
    distributors, partners or employees, the loss or departure of
    officers or other employees of Celgene or its subsidiaries and
    any pending or threatened legal proceeding challenging the
    merger agreement, any of the related agreements or the
    transactions contemplated by the merger agreement or the related
    agreements, or otherwise resulting from the pursuit of the
    completion of the transactions contemplated by the merger
    agreement or the related agreements;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    except that the first, second, third and fifth bullets above
    will not be applicable with respect to effects to the extent
    that any such effects have had, or would reasonably be expected
    to have, a disproportionate impact on Celgene and its
    subsidiaries, taken as a whole, relative to other participants
    in the industry in which Celgene and its subsidiaries operate.
</DIV>

<A name='133'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Conduct
    of Abraxis&#146; Business Pending the Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the merger agreement, Abraxis has agreed that, subject to
    specified exceptions or unless consented to in writing by
    Celgene or required by applicable law, between the date of the
    merger agreement and the earlier of the completion of the merger
    and the date on which the merger agreement is terminated,
    Abraxis will, and will cause each of its subsidiaries to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    carry on their respective businesses in the ordinary course in
    all material respects;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    use reasonable best efforts to preserve intact its respective
    current business organization;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    use reasonable best efforts to keep available the services of
    its current officers and employees;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    use reasonable best efforts to preserve its relationships with
    customers, suppliers and others having significant business
    dealings with&#160;it.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis has also agreed that, between the date of the merger
    agreement and the earlier of the completion of the merger and
    the date on which the merger agreement is terminated, subject to
    specified exceptions, it will not, and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    will cause each of its subsidiaries not to, without the prior
    written consent of Celgene (which consent will not be
    unreasonably withheld or delayed):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    split, combine, reclassify, subdivide or amend the terms of any
    of its capital stock; declare, set aside or pay any dividends;
    or acquire any shares of Abraxis&#146; capital stock or any
    securities convertible into shares of Abraxis&#146; capital
    stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    issue, deliver, sell, pledge, transfer, convey, dispose of or
    encumber any shares of its capital stock, other equity
    securities or any securities convertible into any such shares of
    its capital stock (other than the issuance of shares of Abraxis
    common stock upon the exercise of the stock options
    <FONT style="white-space: nowrap">and/or</FONT>
    vesting of the RSUs);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    amend Abraxis&#146; certificate of incorporation, by-laws or
    other organizational documents of Abraxis or its subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    merge or consolidate with any other person, except for any such
    transactions between wholly-owned subsidiaries of Abraxis or
    between Abraxis and any of its wholly-owned subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    make any acquisition or agree to make any acquisition of any
    business, by merger or otherwise;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    dispose of or encumber, or agree to dispose of or encumber, any
    of the assets of Abraxis that have a value in excess of
    $1&#160;million individually and $5&#160;million in the
    aggregate, except sales of inventory or obsolete assets in the
    ordinary course of business;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    except for trade payables of Abraxis or any of its subsidiaries
    incurred in the ordinary course of business, incur any
    additional indebtedness, issue any debt securities or assume,
    guarantee or endorse or otherwise becomes responsible for the
    obligations of any person for borrowed money or make any loans,
    advance or capital contributions to, or investments in, any
    other person (other than a wholly-owned subsidiary of Abraxis);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    except as may be required by changes in regulatory accounting
    standards and practices or in U.S.&#160;GAAP, change any of the
    accounting principles or practices used by it materially
    affecting the reported consolidated assets, liabilities or
    results of operations of Abraxis and its subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    waive, settle or compromise any legal proceeding involving the
    payment of monetary damages of more than $2&#160;million
    individually or $6&#160;million in the aggregate or involving
    the imposition of equitable relief on, or the admission of
    wrongdoing by, Abraxis or any of its subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;terminate, establish, adopt, enter into, make any new
    grants or awards of stock based compensation or other benefits
    under, amend or otherwise modify, any stock option or equity
    incentive plans, employee benefit plans or employment agreements
    or increase the salary, wage, bonus or other compensation of any
    directors or employee of Abraxis or its subsidiaries at or above
    the level of &#147;Vice President&#148; or its equivalent,
    (2)&#160;enter into any severance, change of control,
    termination or retention arrangements with, or accelerate the
    compensation or benefits of, any employee or director;
    (3)&#160;subject to certain specified exceptions, hire any
    person or promote any person at the level of &#147;Vice
    President&#148; or above, or with an annual base salary in
    excess of $200,000; or (4)&#160;make or forgive any loan to
    employees or directors (other than reasonable travel and other
    business expenses in the ordinary course of business);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    make or change any material tax election, change any tax
    accounting period, adopt or change any tax accounting method,
    amend any material tax return, enter into any material closing
    agreement, settle any material tax claim or assessment,
    surrender any right to claim a refund of material taxes, or
    consent to any extension or waiver of the limitation period
    applicable to any material tax claim or assessment, except as
    required by applicable law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize, recommend, adopt, propose or announce an intention of
    adopt a plan of complete or partial liquidation or other
    reorganization of Abraxis or any of its subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    incur or commit to any capital expenditures in excess of the
    capital expenditure budget provided to Celgene, except to the
    extent that such excess is not greater than $10&#160;million in
    the aggregate;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;except for certain material contracts specified in the
    merger agreement, enter into, terminate or modify in any
    material respect any material contract or waive, release or
    assign any material rights or claims thereunder; (2)&#160;grant
    or acquire, agree to grant or to acquire from any third party,
    or dispose of or permit to lapse any rights, title or interest
    to, any intellectual property or, subject to certain specified
    exceptions, encumber, impair, abandon, fail to diligently
    maintain, transfer or otherwise dispose of any right, title or
    interest of Abraxis or any of its subsidiaries in any
    intellectual property of Abraxis, or (3)&#160;divulge, furnish
    or make accessible any trade secret to any person not subject to
    an enforceable written confidentiality agreement with respect to
    such trade secret;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announce, implement or effect any reduction in force, lay-off,
    early retirement program, severance program or other program or
    effort concerning the termination of employment of employees of
    Abraxis or any of its subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into, amend or cancel any insurance policies other than in
    the ordinary course of business;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adopt or enter into stockholder rights agreement or &#147;poison
    pill&#148;;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    acquire or dispose of any manufacturing facilities;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    agree in writing or otherwise to take any of the foregoing
    actions.
</TD>
</TR>

</TABLE>

<A name='134'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Obligation
    to Call Special Meeting and Recommend the Merger
    Agreement</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis has agreed to take all lawful action reasonably
    necessary in accordance with the DGCL and its certificate of
    incorporation and by-laws to call a special meeting of its
    stockholders for the purpose of voting upon the adoption of the
    merger agreement and the approval of the merger, as soon as
    reasonably practicable after the registration statement of which
    this proxy statement/prospectus forms a part is declared
    effective by the SEC, this proxy statement/prospectus is cleared
    by the SEC and, if required by law, the CVR Agreement has been
    qualified under the Trust&#160;Indenture Act. Abraxis has
    agreed, in consultation with Celgene, to establish a record date
    for, call, give notice of, convene and use its reasonable best
    efforts to hold the special meeting within the shortest time
    period allowed under applicable law and the rules and
    regulations of The NASDAQ Global Select Market after the date
    that the registration statement has been declared effective by
    the SEC. The special meeting of Abraxis stockholders is
    scheduled to be held on October&#160;13, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Abraxis board of directors will, subject to the provisions
    of the merger agreement and their fiduciary duties under
    applicable law as determined by the Abraxis board of directors
    in good faith after consultation with Abraxis&#146; outside
    counsel, recommend to Abraxis stockholders the adoption of the
    merger agreement and approval of the merger.
</DIV>

<A name='135'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Statement and Proxy Statement/Prospectus</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the merger agreement, each of Celgene, Abraxis and
    merger sub agreed to use its reasonable best efforts to respond
    to any comments of the SEC or its staff and to cause the
    registration statement of which this proxy statement/prospectus
    forms a part to be declared effective by the SEC, to have this
    proxy statement/prospectus cleared by the SEC and, if required
    by applicable law, to have the CVR Agreement become qualified
    under the Trust&#160;Indenture Act, in each case as soon as
    reasonably practicable after the date of the merger agreement.
    The parties agreed to use their respective reasonable best
    efforts to keep the registration statement effective as long as
    is necessary to complete the merger and the transactions
    contemplated by merger agreement. Each of Abraxis, merger sub
    and Celgene agreed to use its reasonable best efforts, after
    consultation with the other parties, to respond promptly to all
    comments of and requests by the SEC. Each of the Abraxis, merger
    sub and Celgene agreed to notify the other parties promptly of
    the receipt of any written or oral comments from the SEC or its
    staff and of any request by the SEC or its staff for amendments
    or supplements to the registration statement or this proxy
    statement/prospectus or for additional information. Each of the
    Abraxis, merger sub and Celgene agreed to supply the other
    parties with copies of all correspondence between such party or
    any of its representatives, on the one hand, and the SEC or its
    staff, on the other hand, with respect to the registration
    statement or this proxy statement/prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the merger agreement, as soon as practicable and in
    any event within ten business days after the date that the
    registration statement has been declared effective by the SEC,
    Abraxis agreed to mail this proxy
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    statement/prospectus to the holders of shares of Abraxis common
    stock, soliciting each Abraxis stockholder to vote in favor of
    adopting the merger agreement and approving the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the merger agreement, after the time that the
    registration statement becomes effective, each of Celgene,
    Abraxis and merger sub will promptly advise the other parties of
    the issuance of any stop order or the suspension of the
    qualification of the CVRs issuable in connection with the
    merger. If, prior to the completion of the merger, any
    information relating to merger sub or Abraxis or any of their
    respective affiliates is discovered by Celgene, Abraxis or
    merger sub that should be set forth in an amendment or
    supplement to any of the registration statement or this proxy
    statement/prospectus so that they would not include any
    misstatement of a material fact or omit to state any material
    fact necessary to make the statements therein, in light of the
    circumstances under which they were made, not misleading, the
    party discovering this information will promptly notify the
    other parties and, to the extent required by applicable law, the
    parties will cause an appropriate amendment or supplement
    describing this information to be promptly filed with the SEC
    and, to the extent required by applicable law, disseminated to
    the stockholders of Abraxis.
</DIV>

<A name='136'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Restrictions
    on Solicitation of Third Party Acquisition Proposals</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After the date of the merger agreement until the completion of
    the merger, Abraxis has agreed that it and its subsidiaries will
    not, and has agreed to use its reasonably best efforts to cause
    its representatives and the representatives of its subsidiaries
    not to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    solicit, initiate or knowingly encourage the making, submission
    or announcement of any inquiry regarding, or any proposal or
    offer which would reasonably be expected to lead to a merger,
    acquisition, consolidation, tender offer, exchange offer or
    other transaction involving, or any proposal or offer to
    purchase or acquire in any manner, directly or indirectly
    (1)&#160;assets representing 15% or more of the assets or
    revenues of Abraxis and its subsidiaries, taken as a whole, or
    (2)&#160;15% or more of the voting securities of Abraxis, other
    than, in each case, transactions with Celgene (we refer to each
    proposal or offer described in clauses&#160;(1) and (2)&#160;as
    an acquisition proposal);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into, participate, continue or otherwise engage in
    discussions or negotiations with, or provide any non-public
    information to any third party with respect to any inquiries
    regarding, or the making, submission or announcement of, an
    acquisition proposal;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into or approve any letter of intent, agreement in
    principle, option agreement, share purchase agreement,
    acquisition agreement or similar agreement for an acquisition
    proposal;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    subject to certain exceptions, terminate, waive, amend or modify
    any provision of, or grant permission under, any standstill,
    confidentiality agreement or similar contract to which Abraxis
    or any of its subsidiaries is a party;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    except that the above &#147;no shop&#148; restrictions will not
    prohibit the Abraxis board of directors from terminating,
    waiving, amending or modifying any provision of, or granting
    permission under, any standstill, confidentiality agreement or
    similar contract if the Abraxis board of directors determines in
    good faith that the failure to take such action would be
    reasonably likely to constitute a breach of its fiduciary duties
    to Abraxis stockholders under applicable law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis is obligated to immediately cease any existing
    solicitation, discussion or negotiation with any third party
    conducted prior to the date of the merger agreement with respect
    to any actual or potential acquisition proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notwithstanding the &#147;no shop&#148; restrictions described
    above, prior to the date on which stockholder approval for the
    merger is obtained, Abraxis has the right to, and may authorize
    its representatives to, (1)&#160;provide information in response
    to a request by a person who has made a bona fide written
    acquisition proposal that was not initiated or solicited in
    violation of the &#147;no shop&#148; restrictions if Abraxis
    receives from that person an executed confidentiality agreement
    no more favorable in any material respect to such person than
    the confidentiality agreement, dated October&#160;16, 2009,
    between Abraxis and Celgene, is to Celgene,
    <FONT style="white-space: nowrap">and/or</FONT>
    (2)&#160;engage in discussions or negotiations with any person
    who had made a bona fide written acquisition proposal that was
    not initiated or solicited in violation
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    of the &#147;no shop&#148; restrictions, if, in each case, the
    Abraxis board of directors determines in good faith after
    consultation with Abraxis&#146; financial advisor and outside
    legal counsel that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    failure to take such action would be reasonably likely to
    constitute a breach of its fiduciary duties to Abraxis
    stockholders under applicable law;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the acquisition proposal either constitutes a superior proposal
    (which we define below) or is reasonably likely to lead to a
    superior proposal.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis has agreed to notify Celgene orally and in writing
    promptly (and in any event within 24&#160;hours) after receipt
    of any acquisition proposal or any request for information or
    inquiry which could reasonably be expected to lead to an
    acquisition proposal. The notice from Abraxis to Celgene must
    include the identity of the person making such acquisition
    proposal, request or inquiry and the material terms of the
    acquisition proposal, request or inquiry (including any material
    written amendments or modifications thereto). Abraxis has agreed
    to keep Celgene reasonably informed on a current basis of any
    material changes with respect to such acquisition proposal,
    request or inquiry. In addition, Abraxis has agreed to provide
    Celgene with at least 36&#160;hours prior notice of any meeting
    of the Abraxis board of directors at which the Abraxis board of
    directors is reasonably expected to determine that an
    acquisition proposal is a superior proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of the merger agreement, a &#147;superior
    proposal&#148; means an unsolicited bona fide acquisition
    proposal made after the date of the merger agreement that the
    Abraxis board of directors determines in good faith (after
    consultation with Abraxis&#146; financial advisor and outside
    legal counsel) is reasonably expected to be completed on the
    terms proposed, taking into account all legal, financial and
    regulatory aspects of the proposal, including the financing
    terms thereof and the person making the proposal, and if
    completed, would result in a transaction that is more favorable
    to Abraxis stockholders from a financial point of view than the
    transactions contemplated by the merger agreement (after taking
    into account any revisions to the terms of the transactions
    contemplated by the merger agreement agreed to by Celgene
    pursuant to the merger agreement). For the purposes of the
    definition of &#147;superior proposal,&#148; the references to
    &#147;15% or more&#148; in the definition of &#147;acquisition
    proposal&#148; are deemed to be references to &#147;60% or
    more.&#148;
</DIV>

<A name='137'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Termination
    in Connection with a Superior Proposal</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger agreement permits Abraxis to terminate the merger
    agreement prior to the special meeting in order to concurrently
    enter into a definitive agreement with respect to a superior
    proposal if Abraxis complies with certain notice and other
    requirements set forth in the merger agreement and pays Celgene
    a termination fee of $145&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis can terminate the merger agreement to enter into a
    definitive agreement with respect to a superior proposal. Before
    effecting such a termination, however, Abraxis must give Celgene
    written notice, advising Celgene that the Abraxis board of
    directors has received a superior proposal, specifying the
    material terms and conditions of the superior proposal (and
    attaching a copy of the definitive agreement related thereto, if
    available) and stating that the Abraxis board of directors
    intends to exercise its right to terminate the merger agreement.
    Abraxis cannot exercise its right to terminate the merger
    agreement until after the fifth business day following
    Celgene&#146; receipt of such notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After notifying Celgene that an acquisition proposal is a
    superior proposal, including during this five business day
    period, Celgene is permitted to propose to Abraxis revisions to
    the terms of the transactions contemplated by the merger
    agreement, and Abraxis and its representatives will, if
    requested by Celgene, consider in good faith any revisions to
    the terms of the transactions contemplated by the merger
    agreement proposed by Celgene. Abraxis cannot terminate the
    merger agreement if during the five business day review period
    Celgene makes a binding offer that, after consideration of such
    offer by the Abraxis board of directors in good faith and after
    consultation with Abraxis&#146; financial advisor and outside
    legal counsel, results in the Abraxis board of directors
    concluding that such superior proposal no longer constitutes a
    superior proposal. In the event of any amendment to the
    consideration or any other material revisions to the superior
    proposal, Abraxis is required to deliver a new written notice to
    Celgene and permit Celgene an additional three business day
    review period. Upon termination of the merger agreement by
    Abraxis to accept a superior proposal, Abraxis is required to
    pay to Celgene a termination fee of $145&#160;million, described
    below under &#147;&#151;&#160;Termination Fees and
    Expenses.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='138'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Agreement
    to Use Reasonable Best Efforts and Take Further Action</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the merger agreement, Celgene, merger sub, and
    Abraxis agreed to use their reasonable best efforts to complete,
    in the most expeditious manner practicable, the merger including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtaining the consents and making the registrations required
    under the merger agreement and taking all reasonable steps as
    may be necessary to obtain such consents and to make such
    registrations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtaining all necessary approvals, consents or waivers from
    third parties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    defending any lawsuits or other legal proceedings challenging
    the merger agreement or the completion of the merger;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    executing and delivering any additional instruments necessary to
    complete the merger and to fully carry out the purposes of the
    merger agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene, merger sub and Abraxis will not take or agree to take
    any action that could reasonably be expected to result in any of
    the conditions to the completion of the merger described under
    &#147;&#151;&#160;Conditions to the Merger&#148; not being
    satisfied or to prevent or materially delay the completion of
    the merger or the transactions contemplated by the merger
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;14, 2010, Abraxis and Celgene filed the appropriate
    pre-merger notification forms under the HSR Act with the United
    States Federal Trade Commission, which we refer to as the FTC,
    and the Antitrust Division of the United States Department of
    Justice, which we refer to as the Antitrust Division. Celgene
    received confirmation of early termination of the initial
    waiting period under the HSR ACT effective as of August&#160;3,
    2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis and Celgene have agreed to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    respond as promptly as practicable to any inquiries received
    from the FTC or the Antitrust Division for additional
    information or documentation and to all inquiries and requests
    received from any state attorney general or other governmental
    entity in connection with antitrust matters,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    not extend any waiting period under the HSR Act or enter into
    any agreement with the FTC or the Antitrust Division not to
    complete the transactions contemplated by the merger agreement,
    except with the prior written consent of the other parties to
    the merger agreement (which consent will not be unreasonably
    withheld or delayed).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, Celgene has agreed to use its reasonable best
    efforts to avoid or eliminate impediments under any antitrust,
    competition, or trade regulation law that may be asserted by the
    FTC, the Antitrust Division, any state attorney general or any
    other governmental entity with respect to the merger so as to
    enable the completion of the merger as promptly as reasonably
    practicable. Celgene has also agreed to defend through
    litigation on the merits any claim asserted in any court by any
    party, including appeals. Celgene has agreed to divest or
    dispose of such assets or businesses of Celgene or, after the
    completion of the merger, Abraxis as the surviving corporation,
    or their respective subsidiaries, to take such action that
    limits its freedom of action with respect to, or its ability to
    retain, any of the businesses, services or assets of Celgene,
    Abraxis as the surviving corporation or their respective
    subsidiaries, in order to avoid the entry of, or to effect the
    dissolution of, any order or any impediment under any antitrust
    law, competition, or trade regulation law, which would otherwise
    have the effect of preventing the completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene is not required to sell, divest or otherwise dispose of,
    hold separate, enter into any license or similar agreement with
    respect to, restrict the ownership or operation of, or agree to
    any of the foregoing with respect to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;any assets or businesses of Abraxis or any of its
    subsidiaries, (2)&#160;any assets or businesses of Celgene, any
    of its subsidiaries or affiliates, in either case, to the extent
    that such sale, divestiture, disposition, or agreement would
    have a material adverse effect on the business, operations,
    financial condition or results of operations of the combined
    business of Abraxis and Celgene after giving effect to the
    completion of the transactions contemplated by the merger
    agreement;&#160;or
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    to the extent such sale, divestiture, disposition, agreement or
    restriction would have a material adverse effect on the ability
    of Abraxis to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    in the United States, the European Union, Canada and Switzerland.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If requested by Celgene, Abraxis will agree to divest, hold
    separate or otherwise take any action that limits its freedom of
    action with respect to, or its ability to retain, any of the
    businesses, services, or assets of Abraxis or any of its
    subsidiaries, provided that any such action is conditioned upon
    the completion of the merger and the transactions contemplated
    by the merger agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis and Celgene have agreed to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    promptly notify the other party of any material communication to
    that party from the FTC, the Antitrust Division, any state
    attorney general or any other governmental entity and permit the
    other party to review in advance any proposed written
    communication to any of the foregoing;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to the extent practicable not agree to participate in any
    substantive meeting or discussion with any governmental entity
    in respect of any filings, investigation or inquiry concerning
    the merger agreement or the merger unless it consults with the
    other party in advance and, to the extent permitted by such
    governmental entity, gives the other party the opportunity to
    attend and participate thereat;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    furnish the other party with copies of all correspondence,
    filings, and communications (and memoranda setting forth the
    substance thereof) between them on the one hand, and any
    governmental entity or members of their respective staffs on the
    other hand, with respect to the merger agreement and the merger.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene will have the right to determine and direct the strategy
    and process by which the parties will seek required approvals
    under antitrust, competition or trade regulation laws; provided
    that Celgene will consult with and consider in good faith the
    views of Abraxis in connection with proceedings under or
    relating to any such laws.
</DIV>

<A name='139'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    During the period beginning on the completion of the merger and
    ending no earlier than December&#160;31, 2011, Celgene has
    agreed to provide, or cause Abraxis as the surviving corporation
    to provide, each active employee of Abraxis or its subsidiaries
    as of the completion of the merger with salary, cash bonus
    opportunities and employee benefits (including equity-based
    benefits) that are not materially less favorable in the
    aggregate than those provided to such employee currently, those
    generally provided by Celgene and its subsidiaries to similarly
    situated employees in the country of the employee&#146;s
    principal place of employment, or any combination of the
    foregoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To the extent that employees of Abraxis and its subsidiaries
    become eligible to participate in any employee benefit plan,
    program or arrangement maintained by Celgene or any of its
    subsidiaries (including any severance plan), then for purposes
    of determining eligibility to participate and vesting and with
    respect to any such plan that provides severance, vacation or
    paid-time off benefits, for purposes of benefits accrual,
    service with Abraxis or any of its subsidiaries prior to the
    completion of the merger will be treated as service with Celgene
    or any of its subsidiaries subject to applicable law and so long
    as such treatment does not result in a duplication of benefits.
    Celgene has also agreed to use reasonable best efforts to
    (1)&#160;waive all limitations as to preexisting conditions,
    exclusions and waiting periods with respect to participation and
    coverage requirements applicable to employees under any such
    plan, program or arrangement that is a welfare benefit plan in
    which such employees may be eligible to participate after the
    merger, and (2)&#160;provide each employee with credit for any
    co-payments and deductibles paid prior to the merger in
    satisfying any applicable deductible or
    <FONT style="white-space: nowrap">out-of-pocket</FONT>
    requirements under any such plans, programs or arrangement that
    are welfare plans in which such employees are eligible to
    participate after the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, Celgene has agreed to pay, within thirty days
    following the completion of the merger, to all employees of
    Abraxis and its subsidiaries cash bonuses for the calendar year
    in which the completion of the merger occurs. Such bonuses will
    be paid out based on target bonus levels and prorated for the
    number of days elapsed in the year in which the completion of
    the merger occurs.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='140'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Directors
    and Officers Indemnification and Insurance</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to cause Abraxis, as the surviving
    corporation, and its subsidiaries to establish and maintain, for
    a period of not less than six years following the completion of
    the merger, provisions in their certificates of incorporation,
    by-laws and other organizational documents concerning the
    indemnification and exoneration (including provisions relating
    to expense advancement) of Abraxis&#146; and its
    subsidiaries&#146; former and current officers, directors and
    employees that are no less favorable to those persons than the
    provisions of the certificate of incorporation, by-laws and
    other organizational documents of Abraxis and its subsidiaries
    as in effect on the date of the merger agreement, and such
    provisions will not be amended, repealed or otherwise modified
    in any manner adverse to such officer, director or employee,
    except as required by applicable law. In addition, each of
    Celgene and Abraxis (as the surviving corporation) have agreed
    that during the period ending on the sixth anniversary of the
    merger, they will indemnify and hold harmless, and provide
    advancement of expenses to, to the fullest extent permitted
    under applicable law, each present and former director, officer
    and employee of Abraxis and its subsidiaries against any costs
    or expenses paid in settlement in connection with any actual or
    threatened claim, action, suit, proceeding or investigation in
    connection with (1)&#160;any acts or omissions occurring or
    alleged to occur prior to, or as of, the completion of the
    merger in their capacities as officers, directors, employees or
    controlling stockholders of Abraxis or any of its subsidiaries
    or taken by them at the request of Abraxis or (2)&#160;the
    negotiation, execution, adoption and approval of the merger
    agreement, the merger or the transactions contemplated by the
    merger agreement. We refer to each of the persons entitled to
    indemnification as an &#147;indemnified party.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to cause to be maintained, for a period of
    six years after the completion of the merger, without any lapse
    in coverage, the current policies of directors&#146; and
    officers&#146; liability insurance and fiduciary liability
    insurance maintained by Abraxis and its subsidiaries (Celgene
    may, however, substitute policies of at least the same coverage
    and amounts containing terms and conditions that are no less
    advantageous to the directors and officers than the current
    policies) for a claims-reporting or discovery period of at least
    such six-year period with respect to matters arising on or
    before the completion of the merger. In lieu of the purchase of
    such insurance by Celgene, Abraxis may purchase a six-year
    extended reporting period endorsement under Abraxis&#146;
    existing directors&#146; and officers&#146; liability insurance
    coverage effective for claims asserted for the full six-year
    period referred to above. During this six-year period, Celgene
    is not required to procure any coverage in excess of the amount
    that can be obtained for the remainder of the period for an
    annual premium of 250% of the current annual premium paid by
    Abraxis for existing coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The rights of each indemnified party under the merger agreement
    are in addition to any rights such indemnified party may have
    under the certificate of incorporation, by-laws or any other
    organizational documents of Abraxis or any of its subsidiaries,
    any other indemnification arrangement in existence as of the
    date of the merger agreement, the DGCL or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the merger agreement, if Celgene, Abraxis as the
    surviving corporation or any of their respective successors or
    assigns consolidates with or merges into any other corporation
    or entity and is not the continuing or surviving corporation or
    entity of the consolidation or merger, or transfers all or
    substantially all of its properties and assets to any
    individual, corporation or other entity, then, and in each case,
    proper provisions will be made so that the successors and
    assigns of Celgene or Abraxis, as applicable, will assume the
    indemnification obligations of Celgene, Abraxis or any of their
    respective successors or assigns, as applicable, as set forth in
    the merger agreement.
</DIV>

<A name='141'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Covenants and Agreements</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger agreement contains additional agreements among
    Abraxis, Celgene and merger sub relating to, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis providing Celgene and its representatives reasonable
    access to Abraxis&#146; and its subsidiaries&#146; employees,
    agents, properties, books, contracts, commitments and records;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    coordination of press releases and other public statements with
    respect to the merger agreement, the merger and the other
    transactions contemplated by the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    actions by Celgene to cause merger sub to fulfill its
    obligations under the merger agreement to complete the merger in
    accordance with the terms and subject to the conditions set
    forth in the merger agreement and
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    ensure that, prior to the completion of the merger, merger sub
    does not conduct any business or make any investment other than
    as specifically contemplated by the merger agreement;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene adopting, executing and delivering, and ensuring that a
    duly qualified trustee executes and delivers, the CVR agreement,
    subject to any reasonable revisions to the CVR agreement
    requested by such trustee;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s assumption of liability for all transfer taxes
    resulting from the transactions effected pursuant to the merger
    agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene, as promptly as practicable after the date of the merger
    agreement, preparing and submitting to The NASDAQ Global Select
    Market (or such other exchange(s), electronic trading networks
    or other suitable trading platforms as agreed by Abraxis and
    Celgene) an application to list the CVRs and the shares of
    Celgene common stock being issued as part of the merger
    consideration and Celgene using its reasonable best efforts to
    cause such CVRs and shares of Celgene common stock to be
    approved for listing for trading on The NASDAQ Global Select
    Market (or such other exchange(s), electronic trading networks
    or other suitable trading platforms as agreed by Abraxis and
    Celgene) at or prior to the completion of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Abraxis board of directors adopting a resolution consistent
    with SEC guidance so that the disposition by any officer or
    director of Abraxis who is a covered person for purposes of
    Section&#160;16 of the Exchange Act of Abraxis common stock,
    stock options, RSUs and SARs will be an exempt transaction for
    purposes of Section&#160;16 of the Exchange Act;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis using reasonable best efforts to deliver to Celgene a
    FIRPTA statement on or prior to the completion of the merger.
</TD>
</TR>

</TABLE>

<A name='142'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Conditions
    to the Merger</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The respective obligation of each party to effect the merger is
    subject to the satisfaction or waiver (to the extent permitted
    under applicable law and the terms of the merger agreement) on
    or prior to the completion of the merger, of the following
    conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Stockholder Approval.</I>&#160;&#160;The merger agreement and
    the merger must have been adopted by the holders of a majority
    of the outstanding shares of Abraxis common stock in accordance
    with the DGCL.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>No Injunctions or Restraints.</I>&#160;&#160;No temporary
    restraining order, preliminary or permanent injunction or other
    order will have been issued or entered by any governmental
    entity in the United States, the European Union, Canada or
    Switzerland, that is in effect and that prohibits the completion
    of the merger.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>HSR Act.</I>&#160;&#160;The waiting period (and any extension
    thereof) applicable to the merger under the HSR Act must have
    expired or been terminated.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Registration Statement.</I>&#160;&#160;The registration
    statement of which this proxy statement/prospectus forms a part,
    must have been declared effective and no stop order suspending
    the effectiveness of the registration statement may be in effect.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene&#146;s and merger sub&#146;s obligation to effect the
    merger is subject to the satisfaction or waiver (to the extent
    permitted under applicable law and the terms of the merger
    agreement) by Celgene on or prior to the completion of the
    merger, of the following additional conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Representations and Warranties.</I>&#160;&#160;The
    representations and warranties relating to the capitalization of
    Abraxis must be true and correct in all but de minimis respects
    (which means 2% or less of the aggregate outstanding shares of
    Abraxis common stock on a fully diluted basis) on the date of
    the merger agreement and at the closing as though made on and as
    of the closing date (except to the extent any representation and
    warranty speaks as of a particular date, in which case the
    representation and warranty need only be true and correct as of
    that date), and the other representations and warranties of
    Abraxis set forth in the merger agreement must be true and
    correct (without giving effect to any limitation as to
    &#147;materiality&#148; or Abraxis material adverse effect set
    forth therein) on the date of the merger agreement and at the
    closing as though made on and as of the closing date (except to
    the extent any representation and warranty speaks as of a
    particular date, in which case the representation and warranty
    need only be true and correct as of that date),
</TD>
</TR>

</TABLE>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    except where the failure of the representations and warranties
    to so be true and correct has not had and would not reasonably
    be expected to have, individually or in the aggregate, an
    Abraxis material adverse effect.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Performance of Obligations.</I>&#160;&#160;Abraxis must have
    performed or complied with, in all material respects, its
    obligations and covenants required to be performed or complied
    with by it under the merger agreement at or prior to the closing.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Absence of Material Adverse Effect.</I>&#160;&#160;Since the
    date of the merger agreement, there must not have occurred any
    Abraxis material adverse effect.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Related Agreements.</I>&#160;&#160;The related agreements
    (the non-competition agreement with Dr.&#160;Soon-Shiong, the
    CVR agreement and the voting agreement) must be in full force
    and effect in accordance with their terms.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis&#146; obligation to effect the merger is subject to the
    satisfaction or waiver (to the extent permitted under applicable
    law and the terms of the merger agreement) on or prior to the
    completion of the merger, of the following additional conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Representations and Warranties.</I>&#160;&#160;The
    representations and warranties of Celgene set forth in the
    merger agreement must be true and correct in all material
    respects (without giving effect to any limitation as to
    &#147;materiality&#148; or Celgene material adverse effect set
    forth therein) on the date of the merger agreement and at the
    closing as though made on and as of the closing date (except to
    the extent any representation and warranty speaks as of a
    particular date, in which case the representation and warranty
    need only be true and correct as of that date), except where the
    failure of the representations and warranties to so be true and
    correct has not had and would not reasonably be expected to
    have, individually or in the aggregate, a Celgene material
    adverse effect.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Performance of Obligations.</I>&#160;&#160;Celgene and merger
    sub must have performed or complied with, in all material
    respects, their respective obligations and covenants required to
    be performed or complied with by them under the merger agreement
    at or prior to the closing.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Absence of Material Adverse Effect.</I>&#160;&#160;Since the
    date of the merger agreement, there must not have occurred any
    Celgene material adverse effect.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>CVR Agreement.</I>&#160;&#160;The CVR agreement must have
    been duly executed and delivered by Celgene and the trustee and
    be in full force and effect.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Listing.</I>&#160;&#160;The shares of Celgene common stock
    being issued in the merger must have been approved for listing
    (subject to notice of issuance) for trading on The NASDAQ Global
    Select Market.
</TD>
</TR>

</TABLE>

<A name='143'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Termination</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis and Celgene may terminate the merger agreement by mutual
    written consent at any time before the completion of the merger
    (whether before or after the special meeting). In addition,
    either Abraxis or Celgene may terminate the merger agreement if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the completion of the merger has not occurred on or before
    March&#160;31, 2011, the termination date specified in the
    merger agreement. However, the right to terminate the merger
    agreement on these grounds is not available to any party whose
    failure to fulfill any obligation under the merger agreement is
    the cause of, or resulted in, the failure of the completion of
    the merger to occur on or before the termination date;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any permanent injunction or other order issued by any
    governmental entity in the United States, the European Union,
    Canada or Switzerland is in effect preventing or prohibiting the
    completion of the merger has become final and non-appealable.
    However, the right to terminate the merger agreement on these
    grounds is not available to any party whose failure to fulfill
    any obligation under the merger agreement has been the cause of,
    or resulted in, the imposition of the permanent injunction or
    other order;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis stockholders do not vote to adopt the merger agreement
    at the special meeting (including any postponement or
    adjournment of the special meeting).
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene may terminate the merger agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if Abraxis breaches or fails to perform any of its
    representations, warranties, covenants or obligations contained
    in the merger agreement, which breach or failure to perform
    results in the conditions described in
    &#147;&#151;&#160;Conditions to the Merger&#148; relating to the
    accuracy of Abraxis&#146; representations and warranties or the
    performance of Abraxis&#146; obligations and covenants to the
    merger agreement not being able to be satisfied by the
    termination date;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if Abraxis breaches or fails to perform in any material respect
    its obligations under the &#147;no shop&#148; restrictions of
    the merger agreement;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the special meeting, if (1)&#160;the Abraxis board of
    directors has publicly withdrawn its approval or recommendation
    of the merger agreement or the merger or has publicly
    recommended to the stockholders of Abraxis any acquisition
    proposal, or (2)&#160;a tender offer or exchange offer has been
    commenced that, if successful, would result in any person or
    group becoming the beneficial owner of 15% or more of Abraxis
    common stock, and the Abraxis board of directors fails to
    recommend that Abraxis stockholders not tender their shares in
    connection with such tender or exchange offer within ten
    business days of the commencement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis may terminate the merger agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if Celgene or merger sub breaches or fails to perform any of its
    representations, warranties, covenants or obligations contained
    in the merger agreement, which breach or failure to perform
    results in the conditions described in
    &#147;&#151;&#160;Conditions to the Merger&#148; relating to the
    accuracy of Celgene&#146;s or merger sub&#146;s representations
    and warranties or the performance of Celgene&#146;s or
    merger&#146;s sub&#146;s obligations and covenants to the merger
    agreement not being able to be satisfied by the termination
    date;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the special meeting, in order to concurrently enter
    into a definitive agreement with respect to any superior
    proposal, provided that Abraxis has complied in all material
    respects with the &#147;no shop&#148; restrictions of the merger
    agreement and concurrently pays a termination fee of
    $145&#160;million to Celgene.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See &#147;&#151;&#160;Termination in Connection with a Superior
    Proposal.&#148;
</DIV>

<A name='144'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Termination
    Fees and Expenses</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All fees and expenses incurred by the parties to the merger
    agreement in connection with the merger and the other
    transactions contemplated by the merger agreement will be paid
    by the party incurring such fees or expenses, whether or not the
    merger is completed. Abraxis is obligated to pay a
    $145&#160;million
    <FONT style="white-space: nowrap">break-up</FONT> fee
    to Celgene if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis terminates the merger agreement, prior to the special
    meeting, in order to concurrently enter into a definitive
    agreement with respect to a superior proposal and has complied
    in all material respects with the &#147;no shop&#148;
    restrictions of the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene terminates the merger agreement if Abraxis breaches or
    fails to perform in any material respect its obligations under
    the &#147;no shop&#148; restrictions of the merger agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the special meeting, (1)&#160;the Abraxis board of
    directors has publicly withdrawn its approval or recommendation
    of the merger agreement or the merger or has publicly
    recommended to Abraxis stockholders any acquisition proposal, or
    (2)&#160;a tender offer or exchange offer has been commenced
    that, if successful, would result in any person or group
    becoming the beneficial owner of 15% or more of the outstanding
    stock of Abraxis, and the Abraxis board of directors fails to
    recommend that Abraxis stockholders not tender their shares in
    connection with such tender or exchange offer within ten
    business days of the commencement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;Celgene terminates the merger agreement if Abraxis
    breaches or fails to perform any of its representations,
    warranties, covenants or obligations contained in the merger
    agreement, which breach or failure to perform results in the
    conditions described in &#147;&#151;&#160;Conditions to the
    Merger&#148; relating to the accuracy of Abraxis&#146;
    representations and warranties or the performance of
    Abraxis&#146; obligations or covenants not being able to be
    satisfied by the termination date, (2)&#160;prior to the date
    upon which such breach or failure to perform
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    occurs but after the date of the merger agreement, a bona fide
    acquisition proposal (for the purposes of this definition of
    acquisition proposal, the references to &#147;15%&#148; will be
    deemed references to &#147;60%&#148;) for Abraxis has been
    publicly announced and (3)&#160;within 12&#160;months after such
    termination either Abraxis has entered into a definitive
    agreement relating to an acquisition proposal or a transaction
    contemplated by an acquisition proposal for Abraxis has been
    consummated;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;Celgene or Abraxis terminates the merger agreement if
    Abraxis stockholders do not vote to adopt the merger agreement
    at the special meeting (including any postponement or
    adjournment thereof), (2)&#160;prior to the date of the special
    meeting but after the date of the merger agreement, a bona fide
    acquisition proposal (for the purposes of this definition of
    acquisition proposal, the references to &#147;15%&#148; will be
    deemed references to &#147;60%&#148;) for Abraxis has been
    publicly announced and (3)&#160;within 12&#160;months after such
    termination either Abraxis has entered into a definitive
    agreement relating to an acquisition proposal or a transaction
    contemplated by an acquisition proposal for Abraxis has been
    consummated;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    (1)&#160;Celgene or Abraxis terminates the merger agreement if
    the merger has not been completed on or before the termination
    date of March&#160;31, 2011, (2)&#160;prior to such termination,
    the waiting period (and any extension thereof) applicable to the
    merger under the HSR Act has expired or been terminated,
    (3)&#160;prior to such termination but after the date of the
    merger agreement, a bona fide acquisition proposal (for the
    purposes of this definition of acquisition proposal, the
    references to &#147;15%&#148; will be deemed references to
    &#147;60%&#148;) for Abraxis has been publicly announced and
    (4)&#160;within 12&#160;months after such termination either
    Abraxis has entered into a definitive agreement relating to an
    acquisition proposal or a transaction contemplated by an
    acquisition proposal for Abraxis has been consummated.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See &#147;&#151;&#160;Termination in Connection with a Superior
    Proposal.&#148;
</DIV>

<A name='145'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Amendment
    and Waiver</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger agreement may be amended, modified or supplemented by
    a written instrument signed by Abraxis, Celgene and merger sub
    at any time before or after Abraxis stockholders have approved
    the merger agreement.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<A name='146'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">VOTING
    AGREEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010, the principal stockholders entered into a
    voting agreement with Celgene and merger sub. The following
    summary describes certain material provisions of the voting
    agreement and is qualified in its entirety by reference to the
    voting agreement, a copy of which is attached to this proxy
    statement/prospectus as Annex&#160;C and which is incorporated
    by reference into this proxy statement/prospectus. This summary
    does not purport to be complete and may not contain all of the
    information about the voting agreement that may be important to
    you. We encourage you to read the voting agreement carefully and
    in its entirety.
</DIV>

<A name='147'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Agreement
    to Vote and Irrevocable Proxy</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the voting agreement, the principal stockholders agreed to
    vote all of their shares of Abraxis common stock (representing
    approximately 81.9% of the outstanding shares of Abraxis common
    stock as of September&#160;10, 2010, the record date established
    for the special meeting, in favor of the approval and adoption
    of the merger agreement and the transactions contemplated by the
    merger agreement at any meeting of, or in connection with any
    proposed action by written consent of, Abraxis stockholders at
    or in connection with which any of Abraxis stockholders vote or
    execute consent with respect to the approval and adoption of the
    merger agreement or the transactions contemplated by the merger
    agreement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each of the principal stockholders also agreed, while the voting
    agreement remains in effect and subject to certain exceptions,
    to vote or execute consents, as applicable, with respect to
    their shares of Abraxis common stock, against:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any merger agreement or merger (other than the merger agreement,
    the merger, or any business combination or transaction with
    Celgene or any of its affiliates), consolidation, combination,
    reorganization, recapitalization, dissolution, liquidation or
    winding up of or by Abraxis or any other business combination or
</TD>
</TR>

</TABLE>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    extraordinary corporate transaction involving Abraxis or any of
    its subsidiaries, or any sale, lease or transfer of a material
    amount of assets of Abraxis or any of its subsidiaries;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any amendment of Abraxis&#146; certificate of incorporation,
    unless such amendment is consented to by Celgene;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any action, proposal, transaction or agreement that would
    reasonably be expected to result in a breach in any respect of
    any covenant, representation or warranty or any other obligation
    or agreement of Abraxis contained in the merger agreement or of
    such principal stockholder contained in the voting
    agreement;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any action, proposal, transaction or agreement involving Abraxis
    or any of its subsidiaries that would reasonably be expected to
    prevent, impede, frustrate, interfere with, delay, postpone or
    adversely affect the merger and the other transactions
    contemplated by the merger agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with the foregoing voting covenants and to secure
    their duties under the voting agreement, each of the principal
    stockholders irrevocably appointed Celgene and any designee of
    Celgene, and each of them individually, as such principal
    stockholder&#146;s proxy and attorney-in-fact, with full power
    of substitution and re-substitution, to vote or execute
    consents, with respect to the shares of Abraxis common stock
    owned by such principal stockholder. The proxy and power of
    attorney granted is irrevocable during the period beginning on
    June&#160;30, 2010 and ending on the earliest to occur of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the completion of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any material amendment to merger agreement that is adverse to
    the principal stockholders that has not been approved by the
    principal stockholders;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the termination of the merger agreement in accordance with its
    terms.
</TD>
</TR>

</TABLE>

<A name='148'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Transfer
    Restrictions</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    While the voting agreement remains in effect, each of the
    principal stockholders agreed not to (1)&#160;transfer any
    shares of Abraxis common stock that are subject to the voting
    agreement or (2)&#160;grant any proxies or powers of attorney,
    deposit any shares of Abraxis common stock that are subject to
    the voting agreement into a voting trust or enter into a voting
    agreement with respect to such shares of Abraxis common stock.
    The foregoing does not prevent:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers upon the death of a principal stockholder pursuant to
    the terms of any trust or will of such principal stockholder or
    by the laws of intestate succession, but only if the transferee
    executes and delivers to Celgene an agreement to be bound by the
    terms of the voting agreement to the same extent as such
    principal stockholder;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers to Dr.&#160;Soon-Shiong, the trusts established for
    the benefit of Dr.&#160;Soon-Shiong or any members of his
    immediate family, any other entity in which Dr.&#160;Soon-Shiong
    or any members of his immediate family hold a majority of the
    outstanding equity interests, or any charitable foundation or
    organization, in each case only if such persons agree to be
    bound by the terms of the voting agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers solely in connection with the payment of the exercise
    price <FONT style="white-space: nowrap">and/or</FONT>
    the satisfaction of any tax withholding obligation arising from
    the exercise of any option or the vesting of any RSU;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the conversion of any shares of Abraxis common stock that are
    subject to the voting agreement into the right to receive the
    merger consideration pursuant to the merger in accordance with
    the merger agreement;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the granting of proxies to vote shares of Abraxis common stock
    that are subject to the voting agreement with respect to the
    election of directors and ratification of the appointment of
    Abraxis&#146; auditors at Abraxis&#146; annual meeting of
    stockholders, in accordance with the recommendation of the
    Abraxis board of directors.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='149'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">&#147;No
    Shop&#148; Obligations</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each of the principal stockholders agreed, subject to certain
    exceptions, that it will not, and will use reasonable best
    efforts to cause its respective representatives not to, directly
    or indirectly:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    solicit, initiate or knowingly encourage the making, submission
    or announcement of any inquiry regarding, or any proposal or
    offer which would reasonably be expected to lead to, an
    acquisition proposal;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into, participate, continue or otherwise engage in
    discussions or negotiations with, or provide any non-public
    information to any person (other than Celgene, merger sub and
    their representatives) with respect to any inquiries regarding,
    or the making, submission or announcement of, an acquisition
    proposal;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into or approve any letter of intent, agreement in
    principle, option agreement, share purchase agreement,
    acquisition agreement or similar agreement relating to an
    acquisition proposal.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The foregoing restrictions do not prohibit the principal
    stockholders, or their respective representatives, from
    providing non-public information to, and participating in
    discussions or negotiations with, any person if the principal
    stockholders have been notified by Abraxis that its board of
    directors is permitted to provide non-public information to, or
    engage in discussions or negotiations with, such person in
    accordance with the merger agreement. The principal stockholders
    are required to notify Celgene within 24&#160;hours after the
    receipt of any acquisition proposal or any request for
    information or inquiry which could reasonably be expected to
    lead to an acquisition proposal, detailing the identity of the
    person making the acquisition proposal, request or inquiry and
    the terms thereof. The principal stockholders must keep Celgene
    reasonably informed of any material changes with respect to such
    acquisition proposal, request or inquiry.
</DIV>

<A name='150'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Termination</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The voting agreement will terminate upon the earliest to occur
    of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the completion of the merger;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any material amendment to the merger agreement that is adverse
    to the principal stockholders that has not been approved by the
    principal stockholders, including any amendment which decreases
    or changes the form of the merger consideration, unless
    consented to in writing by each of the principal
    stockholders;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the termination of the merger agreement in accordance with its
    terms.
</TD>
</TR>

</TABLE>

<A name='151'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF THE CVRS</FONT></B>
</DIV>

</A>
<A name='153'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Contingent
    Value Rights Agreement</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The rights of holders of the CVRs will be governed by and
    subject to the terms and conditions of a CVR agreement to be
    entered into between Celgene and a trustee mutually acceptable
    to Celgene and Abraxis prior to the completion of the merger.
    The following summary describes the material provisions of the
    CVR agreement. This summary may not contain all of the
    information about the CVRs that is important to you. The form of
    CVR agreement is attached as Annex&#160;B to this proxy
    statement/prospectus and is incorporated by reference into this
    proxy statement/prospectus, and we encourage you to read it
    carefully for a more complete understanding of the CVRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If required by applicable law, Celgene will use its reasonable
    best efforts to cause the CVR agreement to be qualified under
    the Trust&#160;Indenture Act. The terms of the CVRs include
    those that will be stated in the CVR agreement and those that
    will be made part of the CVR agreement by reference to the
    applicable provisions of the Trust&#160;Indenture Act.
</DIV>

<A name='154'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Characteristics
    of the CVRs</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs are not equity or voting securities of Celgene, do not
    represent ownership interests in Celgene and holders of the CVRs
    are not entitled to any rights of a stockholder or other equity
    or voting security of Celgene,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    either at law or in equity. The rights of the CVR holders will
    be limited to those expressly provided for in the CVR agreement.
</DIV>

<A name='155'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Net Sales
    Payments and Milestone Payments</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each holder of a CVR is entitled to receive a pro rata portion,
    based on the number of the CVRs then outstanding, of each of the
    following cash payments that Celgene is obligated to pay:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Milestone Payment&#160;#1.</I>&#160;&#160;Celgene agreed to
    pay $250&#160;million upon FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of non-small cell lung cancer, which
    approval permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes a progression free survival claim,
    but only if the foregoing milestone is achieved no later than
    the fifth anniversary of the merger.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Milestone Payment&#160;#2.</I>&#160;&#160;Celgene agreed to
    pay $400&#160;million (if achieved no later than April&#160;1,
    2013)&#160;or $300&#160;million (if achieved after April&#160;1,
    2013 and before the fifth anniversary of the merger) upon FDA
    approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of pancreatic cancer, which approval
    permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes an overall survival claim.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Net Sales Payments.</I>&#160;&#160;For each full one-year
    period ending December&#160;31st&#160;during the term of the CVR
    agreement, which we refer to as a net sales measuring period
    (with the first net sales measuring period beginning
    January&#160;1, 2011 and ending December&#160;31, 2011), Celgene
    agreed to pay:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2.5% of the net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products, that exceeds $1&#160;billion
    but are less than or equal to $2&#160;billion for such period,
    plus
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an additional amount equal to 5% of the net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $2&#160;billion
    but are less than or equal to $3&#160;billion for such period,
    plus
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an additional amount equal to 10% of the net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $3&#160;billion
    for such period.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    No payments will be due under the CVR agreement with respect to
    net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products achieved after
    December&#160;31, 2025, which we refer to as the &#147;net sales
    payment termination date,&#148; unless net sales for the net
    sales measuring period ending on December&#160;31, 2025 are
    equal to or greater than $1&#160;billion, in which case the net
    sales payment termination date will be extended until the last
    day of the net sales measuring period subsequent to
    December&#160;31, 2025 during which net sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products are less than $1&#160;billion
    or, if earlier, December&#160;31, 2030.
</DIV>

<A name='156'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Payment
    Dates</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Within ten days after Celgene files its annual report with the
    SEC (or within 90&#160;days after each calendar year if Celgene
    is not required to file periodic reports under Section&#160;13
    or 15(d) of the Exchange Act), Celgene is required to provide a
    net sales statement to the trustee that includes a calculation
    of net sales for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products with respect to the last
    completed calendar year. The net sales payments on the CVRs, if
    any, will be paid 15&#160;days after delivery of such net sales
    statement. The milestone payments, if any, will be paid 20
    business days after the achievement of the relevant milestone.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Amounts payable by Celgene in respect of the CVRs will be
    considered paid on the date due if on such date the trustee or
    the paying agent holds money sufficient to pay all such amounts
    then due in accordance with the CVR agreement. The trustee and
    the paying agent will comply with all U.S.&#160;federal
    withholding requirements with respect to payments to holders of
    CVRs that Celgene, the trustee or the paying agent reasonably
    believes are applicable under the Code and the treasury
    regulations thereunder. The consent of the CVR holder is not
    required for any such withholding.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='157'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Issuance
    of CVRs</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs will be issued following the completion of the merger.
    The number of CVRs to be issued will be equal to the sum of
    (1)&#160;the number of shares of Abraxis common stock and RSUs
    outstanding immediately prior to the completion of the merger
    and (2)&#160;any CVRs issued to holders of options and SARs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVR agreement provides for authentication of the CVRs by the
    trustee upon execution and delivery of such CVRs pursuant to the
    CVR agreement.
</DIV>

<A name='158'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Transferability
    of CVRs; Listing</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs are freely transferable and any interest therein may be
    sold, assigned, pledged, encumbered or in any manner transferred
    or disposed of, in whole or in part, as long as the transfer or
    other disposition is made in accordance with the applicable
    provisions of the CVR agreement and in compliance with
    applicable United States federal and state securities laws and
    any other applicable securities laws. A sale or exchange of a
    CVR would be a taxable transaction. See &#147;Certain Material
    U.S.&#160;Federal Income Tax Consequences&#148; for a more
    detailed explanation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to use its reasonable best efforts to cause
    the CVRs to be approved for listing on The NASDAQ Global Select
    Market and maintain such listing for as long as the CVRs remain
    outstanding. If the CVRs are not accepted for listing on The
    NASDAQ Global Select Market, application will be made to list
    the CVRs on such other exchange(s), electronic trading networks
    or other suitable trading platforms as mutually agreed by
    Abraxis and Celgene at or prior to the completion of the merger.
    Notwithstanding its efforts, Celgene may be unable to cause the
    CVRs to be listed for trading.
</DIV>

<A name='159'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Selected
    Definitions Related to the CVR Agreement</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following terms are defined in the CVR agreement attached as
    Annex&#160;B to this proxy statement/prospectus. For the
    purposes of the CVRs and CVR agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;Diligent Efforts&#148;</I> means, with respect to any
    Product, efforts of a person to carry out its obligations in a
    diligent manner using such effort and employing such resources
    normally used by such person in the exercise of its reasonable
    business discretion relating to the research, development or
    commercialization of a product, that is of similar market
    potential at a similar stage in its development or product life,
    taking into account issues of market exclusivity (including
    patent coverage, regulatory and other exclusivity), safety and
    efficacy, product profile, the competitiveness of alternate
    products in the marketplace or under development, the launch or
    sales of a generic or biosimilar product, the regulatory
    structure involved, and the profitability of the applicable
    product (including pricing and reimbursement status achieved),
    and other relevant factors, including technical, commercial,
    legal, scientific,
    <FONT style="white-space: nowrap">and/or</FONT>
    medical factors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;Existing Licenses&#148;</I> means licenses and related
    agreements (for so long as they are in effect) with respect to
    the Products granted by Celgene or its affiliates to third
    parties (other than Celgene or its affiliates) as in effect
    immediately prior to the completion of the merger (with such
    modifications thereto after the completion of the merger that do
    not reduce the amounts of royalties, milestone payments or
    profit split payments thereunder).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;Net Sales&#148;</I> means, for each net sales measuring
    period, the sum of, without any duplication: (1)&#160;the gross
    amounts invoiced for the Products sold by Celgene, its
    affiliates or its licensees (other than licensees under Existing
    Licenses) to third parties (other than Celgene, its affiliates
    or its licensees) during such net sales measuring period,
    including wholesale distributors, less deductions from such
    amounts calculated in accordance with accounting standards so as
    to arrive at &#147;net sales&#148; under applicable accounting
    standards as reported by Celgene, its affiliate or its licensee,
    as applicable, in such person&#146;s financial statements, and
    further reduced by write-offs of accounts receivables or
    increased for collection of accounts that were previously
    written off; plus (2) (A)&#160;the amount of royalties and
    profit split payments received by Celgene or its affiliates from
    their respective licensees under Existing Licenses for sales
    (but not the supply) of Products sold by such licensees to third
    parties (other than Celgene or its affiliates) during such net
    sales measuring period, and (B)&#160;the amount of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    any milestone payments received during such net sales measuring
    period by Celgene or its affiliates from their licensees under
    Existing Licenses with respect to the Products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any and all set-offs against gross invoice prices shall be
    calculated in accordance with applicable accounting standards.
    Sales or other commercial dispositions of a Product between
    Celgene and its affiliates and its licensees shall be excluded
    from the computation of Net Sales; Product provided to third
    parties without charge, in connection with research and
    development, clinical trials, compassionate use, humanitarian
    and charitable donations, or indigent programs or for use as
    samples shall be excluded from the computation of Net Sales; and
    no payments will be payable on such sales or such other
    commercial dispositions, except where such an affiliate or
    licensee is an end user of the Product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notwithstanding the foregoing, if a Product is sold or otherwise
    commercially disposed of for consideration other than cash or in
    a transaction that is not at arm&#146;s length between the buyer
    and the seller, then the gross amount to be included in the
    calculation of Net Sales shall be the amount that would have
    been invoiced had the transaction been conducted at arm&#146;s
    length and for cash. Such amount that would have been invoiced
    shall be determined, wherever possible, by reference to the
    average selling price of such Product in arm&#146;s length
    transactions in the relevant country.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notwithstanding the foregoing, in the event a Product is sold in
    conjunction with another active component, which we refer to as
    a combination product, in a particular country, Net Sales shall
    be calculated by multiplying the Net Sales of the combination
    product by the fraction A/(A+B), where A is the gross invoice
    price of the Product if sold separately in a country and B is
    the gross invoice price of the other product(s) included in the
    combination product if sold separately in such country. If no
    such separate sales are made by Celgene, its affiliates or
    licensees in a country, Net Sales of the combination product
    shall be calculated in a manner determined by Celgene in good
    faith based upon the relative value of the active components of
    such combination product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;Products&#148;</I> means each of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the pharmaceutical product comprising the chemical compound
    having the chemical name of 5&#946;,20-Epoxy-1,
    <FONT style="white-space: nowrap">2a,4,7&#946;,10&#946;,13a-hexahydroxytax-11-en-9-one</FONT>
    4,10-diacetate 2-benzoate 13-ester with
    (2R,3S)-N-benzoyl-3-phenylisoserine, known by the generic name
    &#147;paclitaxel&#148; and bound to albumin that is the subject
    of the New Drug Application
    <FONT style="white-space: nowrap">No.&#160;21-660</FONT>
    filed with the FDA and subject of the European Medicines Agency
    Marketing Authorization granted on January&#160;11, 2008,
    together with all amendments and supplements to such FDA and
    European Medicines Agency approvals (identified by Abraxis as
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>);

    provided that in all cases such Product is an injectable
    formulation.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the pharmaceutical product comprising the chemical compound
    having the chemical name of (2R,3S)-
    N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with
    5&#946;-20-epoxy-1,2 ,4,7&#946;,10&#946;,13
    -hexahydroxytax-11-en-9-one
    <FONT style="white-space: nowrap">4-acetate</FONT>
    2-benzoate, anhydrous bound to albumin that is the subject of
    the Investigational New Drug Application No.&#160;73,527 filed
    with the FDA together with all amendments (identified by Abraxis
    as &#147;nab-docetaxel (ABI-008)&#148;); provided that in all
    cases such Product is an injectable formulation.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the pharmaceutical product comprising the chemical compound
    having the chemical name of (3S, 6R, 7E, 9R, 10R, 12R, 14S, 15E,
    17E, 19E, 21S, 23S, 26R, 27R, 34aS)-9, 10, 12, 13, 14, 21, 22,
    23, 24, 25, 26, 27, 32, 33, 34,
    <FONT style="white-space: nowrap">34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,</FONT>
    3R,
    4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,
    8, 12, 14, 20, 26-hexamethyl-23, 27-epoxy-3H-pyrido[2, 1-c][1,4]
    oxaazacyclohentriacontine -1, 5, 11, 28, 29 (4H,6H,31H)-pentone
    bound to albumin that is the subject of the Investigational New
    Drug Application No.&#160;74.610 filed with the FDA together
    with all amendments (identified by Abraxis as
    &#147;nab-rapamycin (ABI-009)&#148;); provided that in all cases
    such Product is an injectable formulation.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the pharmaceutical product comprising the chemical compound
    having the chemical name of
    <FONT style="white-space: nowrap">17-allylamino-17-demethoxygeldanamycin,</FONT>
    <FONT style="white-space: nowrap">17-allylamino</FONT>
    geldanamycin bound to albumin that is the subject of the
    Investigational New Drug Application No.&#160;78,298 filed with
    the FDA together with all amendments (identified by Abraxis as
    &#147;nab-17AAG (ABI-010)&#148;); provided that in all cases
    such Product is an injectable formulation.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the pharmaceutical product comprising the chemical compound
    having the chemical name of
    N-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-3-[3-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-ureido]-propionamide
    bound to albumin that is the subject of the Investigational New
    Drug Application No.&#160;103,698 filed with the FDA together
    with all amendments (identified by Abraxis as
    &#147;nab-thiocolchicine dimer (ABI-011)&#148;); provided that
    in all cases the Product is an injectable formulation.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the pharmaceutical product comprising the chemical compound
    having the chemical name of (<I>&#945;R,
    &#946;S</I>)-<I>&#946;</I>-[[(1,
    1-Dimethylethoxy)carbonyl]amino]-<I>&#945;</I>-(hexanoyloxy)benzenepropanoic
    acid
    (2aR,&#160;4S,&#160;4aS,&#160;6R,&#160;9S,&#160;11S,&#160;12S,&#160;12aR,&#160;12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,&#160;3,&#160;4,&#160;4a,&#160;5,&#160;6,&#160;9,&#160;10,&#160;11,&#160;12,&#160;12a,&#160;12b-dodecahydro-4,&#160;6,&#160;11-trihydroxy-4a,&#160;8,&#160;13,&#160;13-tetramethyl-5-oxo-7,&#160;11-methano-1H-cyclodecal[3,&#160;4]benz[1,&#160;2-b]oxet-9-yl
    ester bound to albumin (identified by Abraxis as &#147;nab-novel
    taxane (ABI-013)&#148;) provided that in all cases the Product
    is an injectable formulation.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the pharmaceutical product comprising the chemical compound
    having the chemical name of Benzenepropanoic
    acid,&#160;&#946;-(benzoylamino)-&#945;-hydroxy-,&#160;6,&#160;12bbis(acetyloxy)-12-(benzoyloxy)-2a,&#160;3,&#160;4,&#160;4a,&#160;5,&#160;6,&#160;9,&#160;10,&#160;11,&#160;12,&#160;12a,&#160;12bdodecahydro-4,&#160;11-dihydroxy-4a,&#160;8,&#160;13,&#160;13-tetramethyl-5-oxo-7,&#160;11-methano-1H-cyclodeca[3,&#160;4]benz[1,&#160;2-b]-oxet-9-yl
    ester,&#160;[2aR-[2a&#945;,&#160;4&#946;,&#160;4a&#946;,&#160;6&#946;,&#160;9&#945;(&#945;R*,&#160;&#946;S*),&#160;11&#945;,&#160;12&#945;,&#160;12a&#945;,&#160;12b&#945;]]
    bound to albumin that is the subject of the Investigational New
    Drug Application No.&#160;63,&#160;082 filed with the FDA
    together with all amendments (identified by Abraxis as
    &#147;Coroxane&#148;); provided that in all cases the Product is
    an injectable formulation.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;Regulatory Approval&#148;</I> means all approvals from
    the FDA or other
    <FONT style="white-space: nowrap">non-U.S.&#160;regulatory</FONT>
    authority necessary for the commercial manufacture, marketing
    and sale of a product in the United States or other jurisdiction
    in accordance with applicable law.
</DIV>

<A name='160'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Subordination</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVRs are unsecured obligations of Celgene and all payments
    on the CVRs, all other obligations under the CVR agreement and
    any rights or claims relating to the CVRs and the CVR Agreement
    will be subordinated in right of payment to the prior payment in
    full of senior obligations of Celgene, including the principal
    of, premium (if any) and interest on, and all other amounts
    owing thereon:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to borrowed money;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evidenced by notes, debentures, bonds or other similar debt
    instruments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the net obligations owed under interest rate
    swaps or similar agreements or currency exchange transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    as a result of reimbursement obligations in respect of letters
    of credit and similar obligations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in respect of capital leases;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    as a result of guarantees in respect of obligations referred to
    in the first five bullets above; unless, in any case, the
    instrument creating or evidencing the foregoing or pursuant to
    which the foregoing is outstanding provides that such
    obligations are pari passu to or subordinate in right of payment
    to the CVRs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene&#146;s senior obligations do not include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    trade debt incurred in the ordinary course of business;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any intercompany indebtedness between Celgene and any of its
    subsidiaries or affiliates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness of Celgene that is subordinated in right of payment
    to Celgene&#146;s senior obligations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness or other obligations of Celgene that by its terms
    ranks equal or junior in right of payment to the CVR payments,
    milestone, and net sales payments, and all other obligations
    under the CVR agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness of Celgene that, by operation of applicable law, is
    subordinate to any general unsecured obligations of
    Celgene;&#160;and
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    indebtedness evidenced by any guarantee of indebtedness ranking
    equal or junior in right of payment to the CVR payments.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon any distribution to creditors of Celgene in liquidation,
    dissolution, bankruptcy, reorganization, insolvency,
    receivership or similar proceedings of Celgene, holders of
    senior obligations of Celgene (as described above) will be
    entitled to payment in full in cash of all such obligations
    prior to any payment being made on the CVRs. In addition,
    Celgene may not make any payment or distribution to any CVR
    holder of the CVR payments or other obligation under the CVR
    agreement or acquire from any CVR holder for cash any CVR, or
    propose the foregoing:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if any default on any senior obligations exceeding
    $25&#160;million in aggregate principal amount would occur as a
    result of such payment, distribution or acquisition;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    during the continuance of any payment default in respect of any
    senior obligations (after expiration of any applicable grace
    period) exceeding $25&#160;million in aggregate principal amount;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if the maturity of any senior obligations representing more than
    $25&#160;million in aggregate principal amount is accelerated in
    accordance with its terms and such acceleration has not been
    rescinded;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    following the occurrence of any default (other than a payment
    default, and after the expiration of any applicable grace
    period) with respect to any senior obligations with an aggregate
    principal amount of more than $25&#160;million, the effect of
    which is to permit the holders of such senior obligations (or a
    trustee or agent acting on their behalf) to cause, with the
    giving of notice if required, the maturity of such senior
    obligations to be accelerated, for a period commencing upon the
    receipt by the trustee (with a copy to Abraxis) of a written
    notice of such default from the representative of the holders of
    such senior obligations and ending when such senior obligations
    are paid in full in cash or cash equivalents or, if earlier,
    when such default is cured or waived.
</TD>
</TR>

</TABLE>

<A name='161'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Reporting
    Obligations</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVR agreement provides that Celgene will file with the
    trustee:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    within 15&#160;days after Celgene is required to file the same
    with the SEC, copies of the annual reports and of the
    information, documents and other reports (or copies of such
    portions of the foregoing as the SEC may from time to time by
    rules and regulations prescribe) which Celgene is required to
    file with the SEC pursuant to Section&#160;13 or Section 15(d)
    of the Exchange Act;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if Celgene is not required to file periodic reports under
    Section&#160;13 or 15(d) the Exchange Act, within 45&#160;days
    after each calendar quarter (other than the last quarter of each
    calendar year), quarterly financial information and, within
    90&#160;days after each calendar year, annual financial
    information that would be required pursuant to Section&#160;13
    of the Exchange Act in respect of a security listed and
    registered on a national securities exchange (provided that
    Celgene also delivers with, or includes within, the annual
    reports referred to in this bullet point and the preceding
    bullet point a calculation of net sales for
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products for the annual period to date);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    within ten days after Celgene files its annual report with the
    SEC for any year if Celgene is required to file periodic reports
    under Section&#160;13 or 15(d) of the Exchange Act, or if
    Celgene is not required to file periodic reports under
    Section&#160;13 or 15(d) of the Exchange Act within ninety
    (90)&#160;days after each calendar year, a net sales statement
    with respect to the last completed calendar year;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    within four business days after the occurrence of any milestone,
    a notice stating that the milestone has occurred, the amount of
    the corresponding milestone payment and the applicable milestone
    payment date.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, Celgene is required to file with the trustee such
    additional information, documents and reports with respect to
    compliance by Celgene with the conditions and covenants of the
    CVR agreement, and make available to the CVR holders on
    Celgene&#146;s website as of the date of the filing of the
    foregoing materials with the trustee, the information, documents
    and reports required to be filed by Celgene as described above.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='162'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Audit</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon the written request of holders representing at least a
    majority of the outstanding CVRs and no more than once during
    any calendar year, and upon reasonable notice, Celgene is
    required to permit an independent certified public accounting
    firm of nationally recognized standing (jointly agreed by such
    holders and Celgene) to have access to such records of Celgene
    as may be reasonably necessary to verify the accuracy of the net
    sales statements and the figures underlying the calculations set
    forth in such net sales statement for any period within the
    preceding three years that has not previously been audited.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the independent certified public accountant concludes that
    any net sales payment should have been greater than the net
    sales payment as set forth in the net sales statement, Celgene
    is required to pay such shortfall with respect to each CVR
    within six months of the date that the holders representing at
    least a majority of the outstanding CVRs deliver the written
    report of the independent certified public accountants to
    Celgene. The decision of the independent certified public
    accountant shall be final, conclusive and binding on Celgene and
    the CVR holders. The fees charged by the independent certified
    public accounting firm will be paid by Celgene if the amount
    originally paid is more than 10% below the amount due pursuant
    to the independent written report. The CVR holders shall pay the
    fees charged by the independent certified public accounting firm
    if the amount originally paid by Celgene is equal to or less
    than 10% below the amount due pursuant to the independent
    written report, which amount Celgene may deduct from any future
    CVR payments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If no review of the net sales statement is requested by holders
    of a majority of the CVRs within three years following the end
    of any net sales measuring period, the calculation of the net
    sales payment set forth in the net sales statement shall be
    binding on all CVR holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed not to, and to cause its affiliates not to,
    enter into any license or distribution agreement with any third
    party (other than Celgene or its affiliates) with respect to any
    Product unless such agreement contains provisions that would
    allow an independent certified public accountant appointed
    pursuant to the CVR agreement such access to the records of the
    other party to such license or distribution agreement as may be
    reasonably necessary to perform such independent certified
    public accountant&#146;s duties under the CVR agreement;
    provided that Celgene and its affiliates will not be required to
    amend any Existing Licenses.
</DIV>

<A name='163'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Diligent
    Efforts</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to use Diligent Efforts to achieve each of
    the milestones through the fifth anniversary of the CVR
    agreement. Celgene has agreed to use Diligent Efforts to obtain
    Regulatory Approvals for the commercial manufacture, marketing
    and sale of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the treatment of melanoma, ovarian cancer, bladder cancer
    and first-line metastatic breast cancer until the earlier of the
    net sales payment termination date or such time that the data
    generated in an appropriate clinical trial does not support
    further development of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the applicable indication. Celgene has also agreed to use
    Diligent Efforts, until the net sales payment termination date,
    to sell
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    or any of the Abraxis pipeline products for which Celgene has
    obtained Regulatory Approval for the commercial manufacture,
    marketing and sale thereof.
</DIV>

<A name='164'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Covenants</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVR agreement provides that while any CVRs remain
    outstanding, Celgene will not merge or consolidate with or into
    any other person or sell or convey all or substantially all of
    its assets to any person, unless (1)&#160;Celgene shall be the
    continuing person, or the successor person which acquires by
    sale or conveyance substantially all the assets of Celgene
    (including the shares of Abraxis) shall be a person organized
    under the laws of the United States of America or any State
    thereof and shall expressly assume by an instrument, executed
    and delivered to the trustee, in form satisfactory to the
    trustee, the due and punctual payment of the CVRs, and the due
    and punctual performance and observance of all of the covenants
    and conditions of the CVR agreement to be performed or observed
    by the Celgene and (2)&#160;Celgene or its successor would not
    be in default of the covenants and conditions of the CVR
    agreement immediately following the merger, consolidation or
    sale.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene agreed not to enter into any binding agreement,
    arrangement or understanding or take or permit to be taken any
    action that would, or would reasonably be expected to, delay or
    prevent Celgene&#146;s ability to timely make payment of the net
    sales payments or milestone payments, if any, when due.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVR agreement provides that while any CVRs remain
    outstanding, Celgene and its affiliates will not, directly or
    indirectly, sell, transfer, convey or otherwise dispose of their
    respective rights in any Product to a third party (other than
    Celgene or its affiliates), unless at all times after any such
    sale, transfer, conveyance or other disposition, the gross
    amounts invoiced for the Products by the applicable transferee
    (or the amounts of royalties, profit split payments and
    milestone payments, as described in clause&#160;(2) of the
    definition of Net Sales, with respect to Existing Licenses, as
    applicable) will be reflected in Net Sales in accordance with
    the terms of the CVR agreement (with the transferee substituted
    for Celgene for purposes of the definition of Net Sales) as if
    such transferee was Celgene, and the contract for such sale,
    transfer, conveyance or other disposition (which Celgene will
    take all reasonable actions necessary to enforce in all material
    respects) will provide for such treatment and will require the
    transferee to comply with certain covenants in the CVR agreement
    to the same extent as Celgene.
</DIV>

<A name='165'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Events of
    Default</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each one of the following events is an event of default under
    the CVR agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    default in the payment of all or any part of the net sales
    payments or milestone payments after a period of ten business
    days when they become due and payable;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    material default in the performance, or breach in any material
    respect, of any other covenant or warranty of Celgene in respect
    of the CVRs, and continuance of such default or breach for a
    period of ninety days after written notice has been given to
    Celgene by the trustee or to Celgene and the trustee by the
    holders of a majority of the outstanding CVRs specifying such
    default or breach and requiring it to be remedied;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a court having jurisdiction in the premises entering a decree or
    order for relief in respect of Celgene in an involuntary case
    under any applicable bankruptcy, insolvency or other similar law
    now or hereafter in effect, or appointing a receiver,
    liquidator, assignee, custodian, trustee or sequestrator (or
    similar official) of Celgene or for any substantial part of its
    property or ordering the winding up or liquidation of its
    affairs, and such decree or order remaining unstayed and in
    effect for a period of 90 consecutive days;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene commencing a voluntary case under any applicable
    bankruptcy, insolvency or other similar law now or hereafter in
    effect, or consenting to the entry of an order for relief in an
    involuntary case under any such law, or consent to the
    appointment of or taking possession by a receiver, liquidator,
    assignee, custodian, trustee or sequestrator (or similar
    official) of Celgene or for any substantial part of its
    property, or making any general assignment for the benefit of
    creditors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If an event of default described above occurs and is continuing,
    then, and in each and every such case, either the trustee or the
    trustee upon the written request of holders of a majority of the
    outstanding CVRs, shall bring suit to protect the rights of the
    holders, including to obtain payment for any amounts then due
    and payable, which amounts shall bear interest at the default
    interest rate (as set forth in the CVR agreement) until payment
    is made to the trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The foregoing provisions, however, are subject to the condition
    that if, at any time after the trustee shall have begun such
    suit, and before any judgment or decree for the payment of the
    moneys due shall have been obtained or entered, Celgene shall
    pay or shall deposit with the trustee a sum sufficient to pay
    all amounts which shall have become due (with interest upon such
    overdue amount at the default interest rate specified in the CVR
    agreement to the date of such payment or deposit) and such
    amount as shall be sufficient to cover reasonable compensation
    to the trustee, its agents, attorneys and counsel, and all other
    expenses and liabilities incurred and all advances made, by the
    trustee, and if any and all events of default under the CVR
    agreement shall have been cured, waived or otherwise remedied as
    provided herein, then and in every such case the holders of a
    majority of all the CVRs then outstanding, by written notice to
    Celgene and to the trustee, may waive all defaults with respect
    to the CVRs, but no such waiver or rescission and annulment will
    extend to or will affect any subsequent default or shall impair
    any right consequent thereof.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene has agreed to file with the trustee written notice of
    the occurrence of any event of default or other default under
    the CVR agreement within five business days of its becoming
    aware of any such default or event of default. Celgene has also
    agreed to deliver to the trustee within 90&#160;days after the
    end of each fiscal year (beginning with the fiscal year ending
    December&#160;31, 2010)&#160;an officer&#146;s certificate
    stating whether Celgene is in default in the performance and
    observance of any of the conditions or covenants under the CVR
    agreement and if Celgene is in default, specifying all such
    defaults and their nature and status.
</DIV>

<A name='166'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Restrictions
    on Purchases by Celgene and Affiliates</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVR agreement does not prohibit Celgene or any of its
    subsidiaries or affiliates from acquiring the CVRs, whether in
    open market transactions, private transactions or otherwise.
</DIV>

<A name='167'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    and Transfers</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene will cause to be kept at the office of the trustee a
    register in which, subject to such reasonable regulations as it
    may prescribe, Celgene shall provide for the registration and
    transfer of the CVRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon surrender for registration of transfer of any CVR at the
    office or agency of Celgene, Celgene shall execute, and the
    trustee shall authenticate and deliver, in the name of the
    designated transferee or transferees, one or more new CVR
    certificates representing the same aggregate number of CVRs
    represented by the CVR certificate so surrendered that are to be
    transferred and Celgene shall execute and the trustee shall
    authenticate and deliver, in the name of the transferor, one or
    more new CVR certificates representing the aggregate number of
    CVRs represented by such CVR certificate that are not to be
    transferred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    No service charge shall be made for any registration of transfer
    or exchange of CVRs, but Celgene may require payment of a sum
    sufficient to cover any tax or other governmental charge that
    may be imposed in connection with any registration of transfer
    or exchange of CVRs.
</DIV>

<A name='168'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Amendment
    of CVR Agreement without Consent of CVR Holders</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Without the consent of any CVR holders, Celgene and the trustee
    may amend the CVR agreement for any of the following purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to convey, transfer, assign, mortgage or pledge to the trustee
    as security for the CVRs any property or assets;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to evidence the succession of another person to Celgene, and the
    assumption by any such successor of the covenants of Celgene in
    the CVR agreement and in the CVRs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to add to Celgene&#146;s covenants such further covenants,
    restrictions, conditions or provisions as its board of directors
    and the trustee shall consider to be for the protection of CVR
    holders, and to make the occurrence, or the occurrence and
    continuance, of a default in any such additional covenants,
    restrictions, conditions or provisions an event of default
    permitting the enforcement of all or any of the several remedies
    provided in the CVR agreement, provided that in respect of any
    such additional covenant, restriction, condition or provision,
    such amendment may (1)&#160;provide for a particular grace
    period after default, (2)&#160;provide for an immediate
    enforcement upon such event of default, (3)&#160;limit the
    remedies available to the trustee upon such event of default, or
    (4)&#160;limit the right of the holders of a majority of the
    outstanding CVRs to waive an event of default;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to cure any ambiguity, to correct or supplement any provision in
    the CVR agreement or in the CVRs which may be defective or
    inconsistent with any other provision in the CVR agreement,
    provided that these provisions shall not materially reduce the
    benefits of the CVR agreement or the CVRs to the CVR holders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to make any other provisions with respect to matters or
    questions arising under the CVR agreement, provided that such
    provisions shall not adversely affect the interests of the CVR
    holders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to make any amendments or changes necessary to comply or
    maintain compliance with the Trust&#160;Indenture Act, if
    applicable;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to make any change that does not adversely affect the interests
    of the CVR holders.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='169'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Amendment
    of CVR Agreement with Consent of CVR Holders</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    With the consent of the holders of at least a majority of the
    outstanding CVRs, Celgene and the trustee may make other
    amendments to the CVR agreement, provided that no such amendment
    shall, without the consent of each holder of a CVR affected
    thereby:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    modify in a manner adverse to the CVR holders (1)&#160;any
    provision contained in the CVR agreement with respect to the
    termination of the CVR agreement or the CVRs, (2)&#160;the time
    for payment and amount of the net sales payment or milestone
    payment or otherwise extend the maturity of the CVRs or reduce
    the amounts payable in respect of the CVRs or modify any other
    payment term or payment date (except that this provision does
    not impair the right of Celgene to redeem the CVRs as described
    under &#147;&#151;&#160;CVR Redemption&#160;Rights&#148; below;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reduce the number of CVRs, the consent of whose holders is
    required for any such amendment;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    modify any of the provisions of the CVR agreement regarding
    amendments to the CVR agreement, except to increase the
    percentage of outstanding CVRs required for an amendment or to
    provide that certain other provisions of the CVR agreement
    cannot be modified or waived without the consent of each CVR
    holder affected by such modification or waiver.
</TD>
</TR>

</TABLE>

<A name='170'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CVR
    Redemption&#160;Rights</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Subject to certain notice requirements described below, Celgene
    may, at any time on and after the date that 50% of the CVRs
    either are no longer outstanding
    <FONT style="white-space: nowrap">and/or</FONT>
    repurchased, acquired, redeemed or retired by Celgene,
    optionally redeem all (but not less than all) of the outstanding
    CVRs at a cash redemption price equal to the average price paid
    per CVR for all CVRs previously purchased by Celgene calculated
    as of the business day immediately prior to the date of the
    notice of redemption.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In order to optionally redeem the CVRs, Celgene must give a
    notice to the trustee at least 45&#160;days but not more than
    60&#160;days prior to the redemption date and a notice to each
    CVR holder whose CVRs are to be redeemed at least 30&#160;days
    but not more than 60&#160;days prior to the redemption date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The notice to the trustee must include (1)&#160;the clause of
    the CVR agreement pursuant to which the redemption shall occur,
    (2)&#160;the redemption date, (3)&#160;the amount of CVRs to be
    redeemed and (4)&#160;the redemption price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The notice to the CVR holders must include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the redemption date;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the redemption price;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the name and address of the paying agent;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a statement that CVRs called for redemption must be surrendered
    to the paying agent to collect the redemption price;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a statement that unless Celgene defaults in making such
    redemption payment, all right, title and interest in and to the
    CVRs and any CVR payments will cease to accrue on and after the
    redemption date;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the clause of the CVR agreement pursuant to which the CVRs
    called for redemption are being redeemed;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a statement that no representation is made as to the correctness
    or accuracy of the CUSIP and ISIN number, if any, listed in such
    notice or printed on the CVRs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If less than all of the CVRs are to be redeemed or purchased at
    any time, the trustee will select the CVRs to be redeemed or
    purchased among the CVR holders in compliance with the
    requirements of the principal national securities exchange, if
    any, on which the CVRs are listed or, if the CVRs are not so
    listed, on a pro rata basis, by lot or in any other method the
    trustee considers fair and appropriate.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='171'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following is a general discussion of certain material
    U.S.&#160;federal income tax consequences of the merger to
    U.S.&#160;holders (as defined below) of Abraxis common stock
    whose shares are exchanged for the merger consideration in the
    merger. This discussion is for general information only and is
    not tax advice. This discussion does not purport to consider all
    aspects of U.S.&#160;federal income taxation that might be
    relevant to Abraxis stockholders. This discussion is based on
    the provisions of the Code, applicable current and proposed
    U.S.&#160;Treasury Regulations, judicial authority, and
    administrative rulings and practice, all of which are subject to
    change, possibly on a retroactive basis. Any such change could
    alter the tax consequences described herein.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of this discussion, the term
    &#147;U.S.&#160;holder&#148; means a beneficial owner of shares
    of Abraxis common stock that is, for U.S.&#160;federal income
    tax purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual citizen or resident of the United States;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (or other entity taxable as a corporation) created
    or organized under the laws of the United&#160;States or any
    state thereof (or the District of Columbia);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust if it (1)&#160;is subject to the primary supervision of
    a court within the United States and one or more
    U.S.&#160;persons have the authority to control all substantial
    decisions of the trust or (2)&#160;has a valid election in
    effect under applicable U.S.&#160;Treasury Regulations to be
    treated as a U.S.&#160;person;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate the income of which is subject to U.S.&#160;federal
    income tax regardless of its source.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This discussion assumes that a U.S.&#160;holder holds its shares
    of Abraxis common stock as a capital asset, and will hold its
    CVRs as a capital asset, in each case within the meaning of
    Section&#160;1221 of the Code (generally, property held for
    investment). This discussion does not address all aspects of
    U.S.&#160;federal income tax that may be relevant to an Abraxis
    stockholder in light of its particular circumstances, or that
    may apply to Abraxis stockholders that are subject to special
    treatment under the U.S.&#160;federal income tax laws
    (including, for example, insurance companies, dealers in
    securities or foreign currencies, traders in securities who
    elect the
    <FONT style="white-space: nowrap">mark-to-market</FONT>
    method of accounting for their securities, persons subject to
    the alternative minimum tax, persons that have a functional
    currency other than the U.S.&#160;dollar, tax-exempt
    organizations (including private foundations), financial
    institutions, mutual funds, subchapter S&#160;corporations,
    partnerships or other pass-through entities for
    U.S.&#160;federal income tax purposes, holders that are not
    U.S.&#160;holders, controlled foreign corporations, passive
    foreign investment companies, certain expatriates, corporations
    that accumulate earnings to avoid U.S.&#160;federal income tax,
    persons who hold shares of Abraxis common stock as part of a
    hedge, straddle, constructive sale, conversion or other
    integrated transaction, persons who acquired their shares of
    Abraxis common stock through the exercise of options or other
    compensation arrangements, persons who exercise statutory
    appraisal rights or persons whose ability to sell their Abraxis
    common stock is limited by SEC Rule&#160;144). In addition, this
    discussion does not address any aspect of state, local, foreign,
    estate, gift or other tax law that may apply to Abraxis
    stockholders. <B>The U.S.&#160;federal income tax consequences
    described below are not intended to constitute a complete
    description of all tax consequences relating to the merger.
    Abraxis stockholders are urged to consult their own tax advisors
    to determine the tax consequences to them of, including the
    application and effect of any U.S.&#160;federal, state, local
    and foreign income, estate, gift and other tax laws to, the
    receipt of cash, Celgene common stock and CVRs in exchange for
    Abraxis common stock pursuant to the merger, and receipt of any
    CVR payments.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If any entity that is treated as a partnership for
    U.S.&#160;federal tax purposes holds Abraxis common stock, the
    tax treatment of its partners or members generally will depend
    upon the status of the partner or member and the activities of
    the entity. If you are a partner of a partnership or a member of
    a limited liability company or other entity classified as a
    partnership for U.S.&#160;federal tax purposes and that entity
    holds shares of Abraxis common stock, you should consult your
    tax advisor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The receipt by a U.S.&#160;holder of cash, Celgene common stock
    and CVRs in exchange for shares of Abraxis common stock pursuant
    to the merger will be a taxable transaction for
    U.S.&#160;federal income tax purposes (and may also be a taxable
    transaction under applicable state, local, and foreign income or
    other tax laws). For U.S.&#160;federal
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    income tax purposes, a U.S.&#160;holder of Abraxis common stock
    generally will recognize capital gain or loss at the time of the
    merger equal to the difference, if any, between:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sum of (1)&#160;the amount of cash (including any cash
    received in lieu of fractional shares of Celgene common stock),
    (2)&#160;the fair market value of the Celgene common stock and
    (3)&#160;the fair market value of the CVRs received by the
    U.S.&#160;holder in exchange for such Abraxis common
    stock;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the U.S.&#160;holder&#146;s adjusted tax basis in such Abraxis
    common stock.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Such gain or loss generally will be long-term capital gain or
    loss provided the U.S.&#160;holder&#146;s holding period for the
    Abraxis common stock surrendered in the merger exceeds one year
    as of the date of the merger. In general, long-term capital gain
    of individuals currently is subject to U.S.&#160;federal income
    tax at a maximum rate of 15%. The legislation providing for this
    15% rate is scheduled to expire at the end of 2010, at which
    time the rate may increase. The deductibility of capital losses
    is subject to limitations under the Code. The amount and
    character of gain or loss must be determined separately for each
    block of Abraxis common stock (i.e., shares acquired at the same
    cost in a single transaction) exchanged for the merger
    consideration in the merger. The installment method of reporting
    any gain attributable to receipt of a CVR will not be available
    because Abraxis common stock is traded on an established
    securities market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A U.S.&#160;holder&#146;s initial tax basis in Celgene common
    stock received in the merger will equal the fair market value of
    such stock upon receipt, and the holding period for such stock
    will begin on the day following the date of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A U.S.&#160;holder&#146;s initial tax basis in CVRs received in
    the merger will equal the fair market value of such CVRs as
    determined for U.S.&#160;federal income tax purposes, and the
    holding period for such CVRs will begin on the day following the
    date of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There is no legal authority directly addressing the
    U.S.&#160;federal income tax treatment of the CVRs. Pursuant to
    the merger agreement and the CVR agreement, the parties to the
    merger agreement and the CVR agreement have agreed or will
    agree, as applicable, to treat and report any CVR payments
    (except to the extent of any imputed interest, as described
    below) for all tax purposes as additional consideration for the
    sale of Abraxis common stock in the merger, except as required
    by applicable law. Assuming this treatment is correct, a
    U.S.&#160;holder should recognize gain as and to the extent
    aggregate CVR payments received (less imputed interest, as
    described below) exceed the U.S.&#160;holder&#146;s adjusted tax
    basis in the CVR, and such gain should be long-term capital gain
    if the U.S.&#160;holder has held the CVR for more than one year.
    A U.S.&#160;holder who does not sell, exchange or otherwise
    dispose of a CVR may not be able to recognize a loss with
    respect to the CVR until the U.S.&#160;holder&#146;s right to
    receive CVR payments terminates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In accordance with the CVR agreement, Celgene has agreed to
    report imputed interest on the CVRs pursuant to Section&#160;483
    of the Code. Under Section&#160;483 of the Code, a portion of
    any CVR payment due more than six months after the date of the
    merger should be treated as interest income that is ordinary
    income to a U.S.&#160;holder, and the amount of such a CVR
    payment treated as imputed interest generally should be equal to
    the excess of (1)&#160;the amount of the CVR payment over
    (2)&#160;the present value of such amount as of the completion
    of the merger, discounted at the relevant applicable federal
    rate. The relevant applicable federal rate will be the lower of
    (a)&#160;the lowest applicable federal rate in effect during the
    three-month period ending with the month that includes the date
    on which the merger agreement was signed, and (b)&#160;the
    lowest applicable federal rate in effect during the three-month
    period ending with the month that includes the completion of the
    merger. Under Section&#160;483, the imputed interest is
    accounted for in accordance with the holder&#146;s regular
    method of accounting. Upon the making of any CVR payment,
    Celgene will report to the holder of the CVR and to the Internal
    Revenue Service, which we refer to as the IRS, the amount of
    such interest income, if any, as calculated above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Upon a sale or exchange of a CVR, a U.S.&#160;holder should
    recognize capital gain or loss equal to the difference between
    (1)&#160;the sum of the amount of any cash received upon such
    sale or exchange and the fair market value of any property
    received upon such sale or exchange (less any imputed interest,
    as described below) and (2)&#160;the U.S.&#160;holder&#146;s
    adjusted tax basis in the CVR. Such gain or loss generally will
    be long-term capital gain or loss if the U.S.&#160;holder has
    held the CVR for more than one year. A portion of the amount
    received by a U.S.&#160;holder upon the sale or exchange of a
    CVR may be treated as imputed interest income, determined under
    the method described above.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    99
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As discussed above, the U.S.&#160;federal income tax treatment
    of the CVRs is unclear. Thus, there can be no assurance that the
    IRS would not assert, or that a court would not sustain, a
    position that any CVR payment or a sale or exchange of a CVR
    does not attract capital gain treatment, or that a different
    method should be used for purposes of reporting imputed
    interest. If such a position were sustained, all or any part of
    any CVR payment (or a payment in exchange for a CVR) could be
    treated as ordinary income and could be required to be included
    in income prior to receipt.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the Code, consideration received in the merger and any CVR
    payment received by a U.S.&#160;holder may be subject to
    U.S.&#160;information reporting and backup withholding. Backup
    withholding (currently at a rate of 28%) will apply with respect
    to the amount of cash received by a non-corporate
    U.S.&#160;holder, unless the U.S.&#160;holder provides proof of
    an applicable exemption or a correct taxpayer identification
    number, and otherwise complies with the applicable requirements
    of the backup withholding rules. Backup withholding is not an
    additional tax and any amounts withheld under the backup
    withholding rules may be refunded or credited against a
    U.S.&#160;holder&#146;s U.S.&#160;federal income tax liability,
    if any, provided that such U.S.&#160;holder furnishes the
    required information to the IRS in a timely manner.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>TAX MATTERS CAN BE COMPLICATED.&#160;&#160;THE FOREGOING
    DISCUSSION DOES NOT PURPORT TO BE A COMPLETE DISCUSSION OF THE
    POTENTIAL TAX CONSEQUENCES OF THE MERGER. ABRAXIS STOCKHOLDERS
    ARE STRONGLY URGED TO CONSULT THEIR TAX ADVISORS AS TO THE
    SPECIFIC TAX CONSEQUENCES TO THEM OF THE MERGER, INCLUDING THE
    APPLICABILITY AND EFFECT OF U.S.&#160;FEDERAL, STATE, LOCAL AND
    FOREIGN INCOME, ESTATE, GIFT AND OTHER TAX LAWS IN THEIR
    PARTICULAR CIRCUMSTANCES. NOTHING IN THIS DISCUSSION IS INTENDED
    TO BE, OR SHOULD BE CONSTRUED AS, TAX ADVICE.</B>
</DIV>

<A name='172'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF THE CAPITAL STOCK OF CELGENE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following discussion is a summary of the terms of the
    capital stock of Celgene and should be read in conjunction with
    the section entitled &#147;Comparative Rights of Abraxis
    Stockholders and Celgene Stockholders.&#148; This summary is not
    meant to be complete and is qualified by reference to the
    relevant provisions of the DGCL and Celgene&#146;s certificate
    of incorporation, as amended, which we refer to as
    Celgene&#146;s certificate of incorporation, and Celgene&#146;s
    by-laws, as amended, which we refer to as Celgene&#146;s bylaws.
    You are urged to read those documents carefully. Copies of
    Celgene&#146;s certificate of incorporation and bylaws are
    incorporated by reference as exhibits to the reports Celgene
    files with the SEC, which are incorporated by reference in this
    proxy statement/prospectus. See &#147;Where You Can Find More
    Information&#148; for the location of information incorporated
    by reference into this proxy statement/prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene&#146;s authorized capital stock consists of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    575,000,000&#160;shares of common stock, par value $.01 per
    share;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    5,000,000&#160;shares of preferred stock, par value $.01 per
    share, of which 520&#160;shares have been designated
    Series&#160;A convertible preferred stock and 20,000&#160;shares
    have been designated as Series&#160;B convertible preferred
    stock.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of September&#160;8, 2010, there were 459,766,127&#160;shares
    of Celgene common stock outstanding and no shares of Celgene
    preferred stock outstanding.
</DIV>

<A name='173'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Common
    Stock</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Holders of Celgene common stock are entitled to one vote for
    each share held on all matters submitted to a vote of
    stockholders and do not have cumulative voting rights. Holders
    of Celgene common stock are entitled to receive ratably such
    dividends, if any, as may be declared by the Celgene board of
    directors out of funds legally available therefor, and subject
    to any preferential dividend rights of any then-outstanding
    preferred stock. Upon Celgene&#146;s liquidation, dissolution or
    winding up, the holders of Celgene common stock are entitled to
    receive ratably Celgene&#146;s net assets available after the
    payment of all debts and other liabilities and subject to any
    liquidation preference of any then outstanding preferred stock.
    Holders of Celgene common stock have no preemptive,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    100
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    subscription or conversion rights. There are no redemption or
    sinking fund provisions applicable to the Celgene common stock.
    The outstanding shares of Celgene common stock are, and the
    shares to be issued in connection with the merger will be, fully
    paid and non-assessable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    American Stock Transfer&#160;&#038; Trust&#160;Company is the
    transfer agent and registrar for Celgene common stock. Shares of
    Celgene common stock are listed on The NASDAQ Global Select
    Market under the symbol &#147;CELG.&#148;
</DIV>

<A name='174'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Preferred
    Stock</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Celgene board of directors has the authority, subject to
    certain restrictions, without further stockholder approval, to
    issue, at any time and from time to time, shares of preferred
    stock in one or more series. Each such series shall have such
    number of shares, designations, preferences, voting powers,
    qualifications and special or relative rights or privileges as
    shall be determined by the Celgene board of directors, which may
    include, among others, dividend rights, voting rights,
    redemption and sinking fund provisions, liquidation preferences,
    conversion rights and preemptive rights, to the full extent now
    or hereafter permitted by the DGCL.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The rights of the holders of Celgene common stock will be
    subject to, and may be adversely affected by, the rights of
    holders of any Celgene preferred stock that may be issued in the
    future. Such rights may include voting and conversion rights
    which could adversely affect the holders of Celgene common
    stock. Satisfaction of any dividend or liquidation preferences
    of outstanding Celgene preferred stock would reduce the amount
    of funds available, if any, for the payment of dividends or
    liquidation amounts on Celgene common stock. Holders of Celgene
    preferred stock would typically be entitled to receive a
    preference payment.
</DIV>

<A name='175'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Delaware
    Law and Bylaw Provisions</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Celgene board of directors has adopted certain provisions
    in, and amendments to, Celgene&#146;s bylaws intended to
    strengthen the Celgene board of directors&#146; position in the
    event of a hostile takeover attempt. These bylaw provisions
    provide:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    that only persons who are nominated in accordance with the
    procedures set forth in the bylaws shall be eligible for
    election as directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    for the election of directors by majority voting in uncontested
    elections and by plurality voting in contested elections;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    that only business brought before the annual meeting by the
    Celgene board of directors or by a stockholder who complies with
    the procedures set forth in the bylaws may be transacted at an
    annual meeting of stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    that only the chairman of the board, if any, the chief executive
    officer, the president, the secretary or a majority of the
    Celgene board of directors may call special meetings of Celgene
    stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a procedure for the Celgene board of directors to fix the record
    date whenever stockholder action by written consent is
    undertaken;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    that a vote of holders of not less than a majority of the
    outstanding shares of Celgene common stock may amend bylaw
    provisions, and the Celgene board of directors, except as
    otherwise provided by law, shall have power equal to that of the
    stockholders to amend the bylaws by vote of not less than a
    majority of the entire board of directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Furthermore, Celgene is subject to the provisions of
    Section&#160;203 of the DGCL. In general, the statute prohibits
    a publicly held Delaware corporation from engaging in a
    &#147;business combination&#148; with an &#147;interested
    stockholder&#148; for a period of three years after the time of
    the transaction in which the person became an interested
    stockholder, subject to certain exceptions. For purposes of
    Section&#160;203, a &#147;business combination&#148; includes a
    merger, asset sale or other transaction resulting in a financial
    benefit to the interested stockholder, and an &#147;interested
    stockholder&#148; is a person who, together with affiliates and
    associates, owns, or is an affiliate or associate of the
    corporation and within the prior three years, did own, 15% or
    more of the corporation&#146;s voting stock.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    101
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='176'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPARATIVE
    RIGHTS OF ABRAXIS STOCKHOLDERS AND CELGENE
    STOCKHOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Both Abraxis and Celgene are incorporated under the laws of the
    State of Delaware and, accordingly, the rights of the
    stockholders of each are currently, and will continue to be,
    governed by the DGCL. Before the completion of the merger, the
    rights of holders of Abraxis common stock are also governed by
    the certificate of incorporation and the bylaws of Abraxis, as
    amended, which we refer to as Abraxis&#146; bylaws. After the
    completion of the merger, Abraxis stockholders will become
    stockholders of Celgene, and their rights will be governed by
    the DGCL, the certificate of incorporation of Celgene and
    Celgene&#146;s bylaws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following is a summary of the material differences between
    the rights of Abraxis stockholders and the rights of Celgene
    stockholders. While we believe that this summary covers the
    material differences between the two, this summary may not
    contain all of the information that is important to you. This
    summary is not intended to be a complete discussion of the
    respective rights of Abraxis and Celgene stockholders and is
    qualified in its entirety by reference to the DGCL and the
    various documents of Abraxis and Celgene that we refer to in
    this summary. You should carefully read this proxy
    statement/prospectus in its entirety and the other documents we
    refer to in this proxy statement/prospectus for a more complete
    understanding of the differences between being a stockholder of
    Abraxis and being a stockholder of Celgene. Abraxis and Celgene
    have filed their respective documents referred to herein with
    the SEC
    <FONT style="white-space: nowrap">and/or</FONT> have
    attached them as exhibits to this proxy statement/prospectus,
    and will send copies of these documents to you upon your
    request. Please see the section entitled &#147;Where You Can
    Find More Information.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Abraxis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Celgene&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Authorized Capital Stock:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    The authorized capital stock of Abraxis currently consists of
    106,000,000&#160;shares, consisting of 100,000,000&#160;shares
    of common stock, $.001&#160;par value per share, and
    6,000,000&#160;shares of preferred stock, $.001&#160;par value
    per share.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    The authorized capital stock of Celgene currently consists of
    580,000,000&#160;shares, consisting of 575,000,000&#160;shares
    of common stock, $.01&#160;par value per share, and
    5,000,000&#160;shares of preferred stock, $.01&#160;par value
    per share.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Rights of Preferred Stock:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    The Abraxis board of directors has the authority, without
    stockholder approval, to create or provide for any series of
    preferred stock, and to fix the designations, preferences and
    rights, and qualifications, limitations or restrictions thereof,
    which designations, preferences or rights may be superior to
    those of Abraxis common stock. Abraxis currently has no shares
    of preferred stock outstanding.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -0pt; margin-left: 0pt;">
The Celgene board of directors has the authority, without stockholder approval, to issue shares of authorized preferred stock from time to time in one or more series and to fix the designations, powers, preferences and rights and the qualifications, limitations and restrictions of each series of preferred stock, which rights and preferences may be superior to those of Celgene common stock. <BR><BR>Celgene currently has no shares of preferred stock outstanding.</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Number of Directors:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws currently provide that a majority of the
    members of the Abraxis board of directors can determine the
    number of directors on its board, provided that the board
    consists of at least one member. There currently are seven
    directors serving on the Abraxis board of directors.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws currently provide that the number of
    members of the Celgene board of directors shall consist of no
    less than three and no more than 15&#160;directors; provided,
    however, that a majority of the then authorized number of
    directors may increase or decrease the number of directors.
    There are currently nine directors serving on the Celgene board
    of directors.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Election of Directors:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provide that, directors shall be elected by
    a plurality vote of the shares present in person, by remote
    communication, if applicable, or represented by proxy at the
    stockholders&#146; annual meeting in each year and entitled to
    vote on the election of directors.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that, at any meeting duly called
    and held for the election of directors at which a quorum is
    present, each nominee for director shall be elected to the board
    of directors if the votes cast for such nominee&#146;s election
    exceed the votes cast against such nominee&#146;s election;
    provided, however, that directors shall be elected by a
    plurality of the votes cast by the holders (acting as such) of
    shares of stock of Celgene entitled to elect such directors at
    any meeting of stockholders for which (1) the secretary of
    Celgene receives a notice that a stockholder has nominated a
    person for election to the board of directors in compliance with
    the advance notice requirements for stockholder nominees for
    director set forth in Celgene&#146;s bylaws and (2) such
    nomination has not been withdrawn by such stockholder on or
    prior to the day next preceding the date Celgene first mails its
    notice of meeting for such meeting to the stockholders.  If
    directors are to be elected by a plurality of the votes cast,
    stockholders shall not be permitted to vote against a nominee.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <B>Cumulative Voting:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; certificate of incorporation and bylaws do not
    provide for cumulative voting, and as a result, holders of
    Abraxis&#146; capital stock have no cumulative voting rights in
    connection with the election of directors.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s certificate of incorporation and bylaws do not
    provide for cumulative voting, and as a result, holders of
    Celgene&#146;s capital stock have no cumulative voting rights in
    connection with the election of directors.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    102
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Abraxis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Celgene&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Classification of Board of Directors:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis does not have a classified board of directors.
    Abraxis&#146; bylaws provide that the directors shall be elected
    at each annual meeting of Abraxis stockholders and shall hold
    office until the next annual meeting and until their successors
    shall be duly elected and qualified, or until such
    director&#146;s earlier death, resignation or removal.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene does not have a classified board of directors.
    Celgene&#146;s bylaws provide that the directors shall be
    elected at each annual meeting of Celgene stockholders and shall
    serve until the next succeeding annual meeting of stockholders
    and until their respective successors have been elected and
    qualified.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Removal of Directors:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provide that any director or the entire
    board of directors may be removed from office, with or without
    cause, by the affirmative vote of the holders of a majority of
    the outstanding shares entitled to vote at an election of
    directors.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that any director or the entire
    board of directors may be removed, with or without cause, by the
    holders of a majority of the shares at the time entitled to vote
    at an election of directors.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <B>Board Vacancies:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provide that vacancies on the board of
    directors or newly created directorships resulting from an
    increase in the authorized number of directors may, unless
    otherwise provided in the certificate of incorporation, be
    filled by the affirmative vote of a majority of directors then
    in office, even though less than a quorum, or by a sole
    remaining director. Any director so elected shall hold office
    for the unexpired portion of the term of the director whose
    place shall be vacant, and until his successor shall have been
    duly elected and qualified.  A board vacancy shall be deemed to
    exist in the case of the death, removal or resignation of any
    director, or if the stockholders fail at any meeting of
    stockholders at which directors are to be elected to elect the
    number of directors then constituting the whole board of
    directors.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that vacancies on the board of
    directors caused by death, resignation, removal,
    disqualification, or other cause, or additional directorships
    resulting from an increase in the number of directors may be
    filled at any time by a majority of directors then in office,
    even though less than a quorum, or in the case of any vacancy in
    the office of any director, by the stockholders. Any director so
    chosen shall hold office until his successor shall have been
    elected and qualified; or, if the person so chosen is a director
    elected to fill a vacancy, he shall hold office for the
    unexpired term of his predecessor.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    103
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Abraxis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Celgene&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Director Nominations  by Stockholders:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provide that nominations of persons for
    election to the Abraxis board of directors may be made at a
    meeting of stockholders by or at the direction of the board of
    directors, by any nominating committee or person appointed by
    the board of directors or by any stockholder entitled to vote
    for the election of directors at the meeting who complies with
    the applicable notice procedures set forth in Abraxis&#146;
    bylaws.  Such nominations, other than those made by or at the
    direction of the board of directors, shall be made pursuant to
    timely notice in writing to the secretary of Abraxis. To be
    timely, a stockholder&#146;s notice must be delivered to or
    mailed and received not less than 120 calendar days prior to the
    date on which Abraxis first mailed its proxy materials for the
    previous year&#146;s annual meeting of stockholders.  If during
    the prior year Abraxis did not hold an annual meeting, or if the
    date of the annual meeting was changed more than 30&#160;days
    from the previous year&#146;s meeting, then the deadline is a
    reasonable time before Abraxis begins to print and mail its
    proxy materials. Such stockholder&#146;s notice shall set forth
    (a) as to each person whom the stockholder proposes to nominate
    for election or re-election as a director, (1) the name, age,
    business address and residence address of the person, (2) the
    principal occupation or employment of the person, (3) the class
    and number of shares of Abraxis which are beneficially owned by
    the person and (4) any other information relating to the person
    that is required to be disclosed in solicitations for proxies
    for election of directors pursuant to Rule 14a under the
    Exchange Act; and (b) as to the stockholder giving the notice,
    (1) the name and record address of the stockholder, and (2) the
    class and number of shares of Abraxis which are beneficially
    owned by the stockholder. These provisions do not apply to
    nomination of any persons entitled to be separately elected by
    holders of Abraxis preferred stock.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that nominations of persons for
    election to the Celgene board of directors may be made at any
    annual meeting of stockholders, (a) by or at the direction of
    the board of directors (or any duly authorized committee
    thereof) or (b) by any Celgene stockholder (1) who is a
    stockholder of record on the date of the giving of the required
    notice and on the record date for the determination of
    stockholders entitled to vote at such annual meeting and (2) who
    complies with the notice procedures set forth in the bylaws. For
    a nomination to be made by a stockholder, such stockholder must
    have given timely notice thereof in proper written form to the
    secretary of Celgene.  To be timely, a stockholder&#146;s notice
    to the secretary must be delivered to or mailed and received at
    the principal executive offices of Celgene not less than
    60&#160;days nor more than 90&#160;days prior to the date of the
    annual meeting; provided, however, that in the event that less
    than 70&#160;days&#146; notice or prior public disclosure of the
    date of the annual meeting is given or made to stockholders,
    notice by the stockholder (in order to be timely) must be so
    received not later than the close of business on the
    10th&#160;day following the day on which such notice of the date
    of the annual meeting was mailed or such public disclosure of
    the date of the annual meeting was made, whichever first
    occurs.  To be in proper written form, a stockholder&#146;s
    notice to the secretary must set forth (a) as to each person
    whom the stockholder proposes to nominate for election as a
    director (1) the name, age, business address and residence
    address of the person, (2) the principal occupation or
    employment of the person, (3) the class or series and number of
    shares of capital stock of Celgene which are owned beneficially
    or of record by the person and (4) any other information
    relating to the person that would be required to be disclosed in
    a proxy statement or other filing required to be made in
    connection with solicitations of proxies for election of
    directors pursuant to Section 14 of the Exchange Act, and the
    rules and regulations promulgated thereunder; and (b) as to the
    stockholder giving the notice (1) the name and record address of
    such stockholder, (2) the class or series and number of shares
    of capital stock of Celgene which are owned beneficially or of
    record by such stockholder, (3) a description of all
    arrangements or understandings between such stockholder and each
    proposed nominee and any other person or persons (including
    their names) pursuant to which the nomination(s) are to be made
    by such stockholder, (4) a representation that such stockholder
    intends to appear in person or by proxy at the annual meeting to
    nominate the persons named in his notice and (5) any other
    information relating to such stockholder that would be required
    to be disclosed in a proxy statement or other filing required to
    be made in connection with solicitations of proxies for election
    of directors pursuant to Section 14 of the Exchange Act and the
    rules and regulations promulgated thereunder.  Such notice must
    be accompanied by a written consent of each proposed nominee to
    being named as a nominee and to serve as a director if elected.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Stockholder Action by Written Consent:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provide that, unless otherwise provided in
    the certificate of incorporation, any action required by statute
    to be taken at any annual or special meeting of the
    stockholders, or any action which may be taken at any annual or
    special meeting of the stockholders, may be taken by written
    consent if the written consent is signed by the holders of
    outstanding stock having not less than the minimum number of
    votes that would be necessary to authorize or take such action
    at a meeting at which all shares entitled to vote thereon were
    present and voted. No written consent shall be effective to take
    the corporate action referred to therein unless, within
    60&#160;days of the earliest dated consent duly delivered to
    Abraxis, written consents signed by a sufficient number of
    stockholders to take such action are duly delivered to Abraxis.
    Abraxis&#146; certificate of incorporation does not prohibit
    stockholders from taking action by written consent as provided
    in Abraxis&#146; bylaws.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s certificate of incorporation does not provide for
    action to be taken by the stockholders of Celgene by written
    consent. Accordingly, the default DGCL Section 228 applies,
    providing that any action required by statute to be taken at any
    annual or special meeting of the stockholders, or any action
    which may be taken at any annual or special meeting of the
    stockholders, may be taken by written consent if the written
    consent is signed by the holders of outstanding stock having not
    less than the minimum number of votes that would be necessary to
    authorize or take such action at a meeting at which all shares
    entitled to vote thereon were present and voted.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    104
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Abraxis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Celgene&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Certificate of Incorporation Amendments:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis reserves the right to amend, alter, change or repeal any
    provision contained in its certificate of incorporation, in the
    manner now or hereafter prescribed by statute, and all rights
    conferred upon Abraxis stockholders therein are granted subject
    to this reservation. The DGCL requires that any amendment to
    Abraxis&#146; certificate of incorporation must be approved by
    the board of directors and that a resolution be adopted
    recommending that the amendment be approved by a majority of the
    outstanding stock entitled to vote on the amendment, plus the
    amendment must be approved by a majority of the outstanding
    stock of any class entitled under the DGCL to vote separately as
    a class on the amendment.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    The DGCL requires that any amendment to Celgene&#146;s
    certificate of incorporation must be approved by the board of
    directors and that a resolution be adopted recommending that the
    amendment be approved by a majority of the outstanding stock
    entitled to vote on the amendment, plus the amendment must be
    approved by a majority of the outstanding stock of any class
    entitled under the DGCL to vote separately as a class on the
    amendment.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <B>Bylaw Amendments:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws may be repealed, altered or amended or new
    bylaws adopted at any meeting of the stockholders, either annual
    or special, by the affirmative vote of at least 80% of the stock
    entitled to vote at such meeting, unless a larger vote is
    required by Abraxis&#146; bylaws or certificate of
    incorporation.  The Abraxis board of directors also has the
    authority to repeal, alter or amend Abraxis&#146; bylaws or
    adopt new bylaws (including, without limitation, the amendment
    of any bylaws setting forth the number of directors who
    constitute the whole board of directors) by unanimous written
    consent or at any annual, regular or special meeting by the
    affirmative vote of a majority of the whole number of directors,
    subject to the power of Abraxis stockholders to change or repeal
    such bylaws and provided that the Abraxis board of directors
    will not make or alter any bylaws fixing the qualifications,
    classifications or term of office of directors.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that the holders of shares
    entitled at the time to vote for the election of directors have
    power to adopt, amend, or repeal the bylaws by vote of not less
    than a majority of such shares, and except as otherwise provided
    by law, the board of directors has power equal in all respects
    to that of the stockholders to adopt, amend, or repeal the
    bylaws by vote of not less than a majority of the entire board.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Special Meetings of Stockholders:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provide that special meetings of the
    stockholders may be called, for any purpose or purposes, by the
    chairman of the board of directors, the president, the secretary
    or the board of directors at any time.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that special meetings of the
    stockholders may be called, for any purpose or purposes, by the
    chairman of the board of directors, if any, the chief executive
    officer, the president, the secretary, or a majority of the
    board of directors at any time.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Notice of Special Meetings of Stockholders:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws require that written notice of a special
    meeting be given to stockholders not less than ten days or more
    than 60&#160;days before the date of the meeting, except that
    where the matter to be acted on is a merger or consolidation of
    Abraxis or a sale, lease or exchange of all or substantially all
    of its assets, such notice must be given not less than 20 nor
    more than 60&#160;days prior to such meeting.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws require that notice of a special meeting
    must be given by the chairman of the board of directors, if any,
    the chief executive officer, the president, any vice-president,
    the secretary, or an assistant secretary, to stockholders not
    less than ten days or more than 60&#160;days before the date of
    the meeting, unless a different period is prescribed by law.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Stockholder Nominations and Proposals (Requirements for
    Delivery and Notice):</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -0pt; margin-left: 0pt;">
Abraxis&#146; bylaws provide that in order for a stockholder to make a nomination or propose business at an annual meeting of the stockholders, the stockholder must give timely written notice to Abraxis&#146; secretary not less than 120 calendar days prior to the date on which Abraxis first mailed its proxy materials for the prior year&#146;s annual meeting. If during the prior year Abraxis did not hold an annual meeting, or if the date of the annual meeting was changed more than 30&#160;days from the prior year&#146;s meeting, then the deadline is a reasonable time before Abraxis begins to print and mail its proxy materials. <BR><BR>A stockholder&#146;s notice to the secretary must set forth as to each matter the stockholder proposes to bring before the annual meeting (1) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (2) the name and record address of the stockholder proposing such business, (3) the class and number of shares of Abraxis which are beneficially owned by the stockholder and (4) any material interest of the stockholder in such business.</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that in order for a stockholder to
    make a nomination or propose business at an annual meeting of
    the stockholders, the stockholder must give timely written
    notice to Celgene&#146;s secretary not less than 60&#160;days
    nor more than 90&#160;days prior to the date of the annual
    meeting; provided, however, that in the event that less than
    70&#160;days&#146; notice or prior public disclosure of the date
    of the annual meeting is given or made to stockholders, notice
    by the stockholder (in order to be timely) must be so received
    not later than the close of business on the tenth (10th) day
    following the day on which such notice of the date of the annual
    meeting was mailed or such public disclosure of the date of the
    annual meeting was made, whichever first occurs. A
    stockholder&#146;s notice to the secretary must set forth as to
    each matter such stockholder proposes to bring before the annual
    meeting (1) a brief description of the business desired to be
    brought before the annual meeting and the reasons for conducting
    such business at the annual meeting, (2) the name and record
    address of such stockholder, (3) the class or series and number
    of shares of capital stock of Celgene which are owned
    beneficially or of record by such stockholder, (4) a description
    of all arrangements or understandings between such stockholder
    and any other person or persons (including their names) in
    connection with the proposal of such business by such
    stockholder and any material interest of such stockholder in
    such business, and (v) a representation that such stockholder
    intends to appear in person or by proxy at the annual meeting to
    bring such business before the meeting.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    105
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="39%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Abraxis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Celgene&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <B>Proxy:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provide that every person entitled to vote
    or execute consents has the right to do so either in person, by
    remote communication, if applicable, or by an agent or agents
    authorized by a written proxy executed by such person or his
    duly authorized agent, which proxy must be filed with the
    secretary of Abraxis at or before the meeting at which it is to
    be used.  The proxy so appointed need not be a stockholder.  No
    proxy may be voted on after three years from its date of
    creation unless the proxy provides for a longer period. Unless
    and until voted, every proxy will be revocable at the pleasure
    of the person who executed it or of his legal representatives or
    assigns, except in those cases where an irrevocable proxy
    permitted by statute has been given.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s bylaws provide that at any meeting duly called
    and held at which a quorum is present, every person entitled to
    vote or execute consents has the right to do so either in person
    or by proxy to decide such matters.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Limitation of Personal Liability of Directors:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; certificate of incorporation provides that to the
    fullest extent permitted by Delaware statutory or decisional
    law, as amended or interpreted, no Abraxis director will be
    personally liable to Abraxis or its stockholders for monetary
    damages for breach of fiduciary duty as a director.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s certificate of incorporation provides that no
    director of Celgene will be liable to Celgene or any of its
    stockholders for monetary damages for breach of fiduciary duty
    as a director, except for liability (1) for any breach of the
    director&#146;s duty of loyalty to Celgene or its stockholders,
    (2) for acts or omissions not in good faith or which involve
    intentional misconduct or a knowing violation of law, (3) under
    Section 174 of the DGCL, or (4) for any transaction from which
    the director derived an improper personal benefit.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Indemnification of Directors and Officers:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Abraxis&#146; bylaws provides that Abraxis will indemnify and
    hold harmless, to the fullest extent permitted by the DGCL (as
    the same exists or may be subsequently amended or interpreted),
    any person made or threatened to be made a party to an action or
    proceeding, whether criminal, civil, administrative or
    investigative, by reason of the fact that such person, or a
    person of whom he is the legal representative, is or was a
    director, officer, employee or agent of Abraxis, or is or was
    serving as a director, officer, employee or agent of another
    entity at the request of Abraxis. Abraxis will indemnify such
    person with respect to legal proceedings initiated by such
    person only if such legal proceedings were approved by the
    Abraxis board of directors.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Celgene&#146;s certificate of incorporation provides that
    Celgene will indemnify, to the fullest extent permitted by law,
    any person made or threatened to be made a party to an action or
    proceeding, whether criminal, civil, administrative or
    investigative, by reason of the fact that such person is or was
    a director, officer, incorporator, employee or agent of Celgene,
    or is or was serving as a director, officer, incorporator,
    employee or agent of another entity at the request of Celgene.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>DGCL Section&#160;203 Election:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -0pt; margin-left: 0pt;">
Under Delaware law a corporation can elect not to be governed by Section 203 of the DGCL, which generally protects publicly traded Delaware corporations from hostile takeovers and from certain actions following such takeovers. <BR><BR>Abraxis has expressly opted not to be governed by Section 203 of the DGCL.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -0pt; margin-left: 0pt;">
Under Delaware law a corporation can elect not to be governed by Section 203 of the DGCL, which generally protects publicly traded Delaware corporations from hostile takeovers and from certain actions following such takeovers. <BR><BR>Celgene has not made this election and is therefore governed by Section 203 of the DGCL.
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
    <B>Vote on Business Combinations:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Neither Abraxis&#146; certificate of incorporation nor its
    bylaws contain any provisions relating to business combinations.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Neither Celgene&#146;s certificate of incorporation nor its
    bylaws contain any provisions relating to business combinations.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<A name='177'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">RIGHTS OF
    STOCKHOLDERS TO SEEK APPRAISAL</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under Delaware law, holders of Abraxis common stock who do not
    wish to accept the merger consideration have the right to
    dissent from the merger and to receive payment in cash for the
    fair value of their shares of Abraxis common stock together with
    a fair rate of interest, if any, as determined by the Delaware
    Court of Chancery. These rights are known as appraisal rights.
    Stockholders may only exercise these appraisal rights by
    strictly complying with the provisions of Section&#160;262 of
    the DGCL, which is referred to in this proxy
    statement/prospectus as Section&#160;262.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following is intended as a brief summary of the material
    provisions of the Delaware statutory procedures required to be
    followed by a stockholder in order to dissent from the merger
    and perfect its appraisal rights. This summary, however, is not
    a complete statement of all applicable requirements and is
    qualified in its entirety by reference to Section&#160;262, the
    full text of which appears in Annex&#160;H to this proxy
    statement/prospectus. Failure to precisely follow any of the
    statutory procedures set forth in Section&#160;262 may result in
    a termination or waiver of your appraisal rights. This summary
    does not constitute legal or other advice, nor does it
    constitute a recommendation that holders of Abraxis common stock
    exercise their appraisal rights.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    106
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis is required to send a notice of appraisal rights to each
    of its stockholders not less than 20&#160;days prior to the
    special meeting. This proxy statement/prospectus constitutes the
    notice to Abraxis stockholders of the availability of appraisal
    rights in connection with the merger in compliance with the
    requirements of Section&#160;262. If you wish to consider
    exercising your appraisal rights, you should carefully review
    the text of Section&#160;262 contained in Annex&#160;H to this
    proxy statement/prospectus because failure to timely and
    properly comply with the requirements of Section&#160;262 will
    result in the loss of your appraisal rights under Delaware law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Holders of shares of Abraxis common stock who desire to exercise
    their appraisal rights must (1)&#160;not vote in favor of the
    merger and (2)&#160;deliver a written demand for appraisal of
    his or her shares to the Corporate Secretary of Abraxis before
    the vote on the merger at the special meeting. A demand for
    appraisal must reasonably inform Abraxis of the identity of the
    stockholder and that such stockholder intends thereby to demand
    appraisal of the shares of Abraxis common stock held by such
    stockholder. All demands for appraisal should be addressed to
    Abraxis BioScience, Inc., 11755 Wilshire Boulevard,
    Suite&#160;2000, Los Angeles, CA 90025, Attention: Corporate
    Secretary, and should be executed by, or on behalf of, the
    record holder of shares of Abraxis common stock. ALL DEMANDS
    MUST BE RECEIVED BY ABRAXIS BEFORE THE VOTE ON THE MERGER AT THE
    SPECIAL MEETING AT 10:00&#160;A.M. LOCAL TIME ON
    OCTOBER&#160;13, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you fail to deliver a written demand for appraisal within the
    time period specified above and the merger is completed, you
    will be entitled to receive the merger consideration for your
    shares of Abraxis common stock as provided for in the merger
    agreement, but you will have no appraisal rights with respect to
    your shares of Abraxis common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To be effective, a demand for appraisal by a holder of shares of
    Abraxis common stock must be made by, or in the name of, the
    registered stockholder, fully and correctly, as the
    stockholder&#146;s name appears on the stockholder&#146;s stock
    certificate(s). Beneficial owners who do not also hold the
    shares of record may not directly make appraisal demands to
    Abraxis. The beneficial owner must, in these cases, have the
    registered owner, such as a broker, bank or other custodian,
    submit the required demand in respect of those shares. If shares
    are owned of record in a fiduciary capacity, such as by a
    trustee, guardian or custodian, execution of a demand for
    appraisal should be made by or for the fiduciary; and if the
    shares are owned of record by more than one person, as in a
    joint tenancy or tenancy in common, the demand should be
    executed by or for all joint owners. An authorized agent,
    including an authorized agent for two or more joint owners, may
    execute the demand for appraisal for a stockholder of record;
    however, the agent must identify the record owner or owners and
    expressly disclose the fact that, in executing the demand, he or
    she is acting as agent for the record owner. A record owner,
    such as a broker, who holds shares as a custodian for others,
    may exercise the record owner&#146;s right of appraisal with
    respect to the shares held for one or more beneficial owners,
    while not exercising this right for other beneficial owners. In
    that case, the written demand should state the number of shares
    as to which appraisal is sought. Where no number of shares is
    expressly mentioned, the demand will be presumed to cover all
    shares held in the name of the record owner. In addition, the
    stockholder must continuously hold the shares of record from the
    date of making the demand through the completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you hold your shares of Abraxis common stock in a brokerage
    account or in other custodian form and you wish to exercise
    appraisal rights, you should consult with your bank, broker or
    other custodian to determine the appropriate procedures for the
    making of a demand for appraisal by the custodian.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Within ten days after the completion of the merger, the
    surviving corporation must give written notice that the merger
    has become effective to each stockholder who is entitled to
    appraisal rights and has properly filed a written demand for
    appraisal in accordance with Section&#160;262. At any time
    within 60&#160;days after the completion of the merger, any
    stockholder who has demanded an appraisal has the right to
    withdraw the demand and accept the terms of the merger by
    delivering a written withdrawal of the stockholder&#146;s
    demands for appraisal. If, following a demand for appraisal, you
    have withdrawn your demand for appraisal in accordance with
    Section&#160;262, you will have the right to receive the merger
    consideration for your shares of Abraxis common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Within one hundred and twenty days after the effective date of
    the merger, any stockholder who has delivered a demand for
    appraisal in accordance with Section&#160;262 will, upon written
    request to the surviving corporation, be entitled to receive a
    written statement setting forth the aggregate number of shares
    not voted in favor of the merger agreement and with respect to
    which demands for appraisal rights have been received and the
    aggregate number of holders of these shares. This written
    statement will be mailed to the requesting stockholder within
    ten days after the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    107
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    stockholder&#146;s written request is received by the surviving
    corporation or within ten days after expiration of the period
    for delivery of demands for appraisal, whichever is later.
    Within 120&#160;days after the effective date of the merger,
    either the surviving corporation or any stockholder who has
    delivered a demand for appraisal in accordance with
    Section&#160;262 may file a petition in the Delaware Court of
    Chancery demanding a determination of the fair value of the
    shares held by all such stockholders. Upon the filing of the
    petition by a stockholder, service of a copy of the petition
    must be made upon the surviving corporation. The surviving
    corporation has no obligation to file a petition in the Delaware
    Court of Chancery in the event there are dissenting
    stockholders, and the surviving corporation has no present
    intent to file a petition in the Delaware Court of Chancery.
    Accordingly, the failure of a stockholder to file a petition
    within the period specified could nullify the stockholder&#146;s
    previously written demand for appraisal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If a petition for appraisal is duly filed by a stockholder and a
    copy of the petition is delivered to the surviving corporation,
    the surviving corporation will then be obligated, within twenty
    days after receiving service of a copy of the petition, to
    provide the Delaware Court of Chancery with a duly verified list
    containing the names and addresses of all stockholders who have
    demanded an appraisal of their shares and with whom agreements
    as to the value of their shares have not been reached by the
    surviving corporation. After notice to dissenting stockholders
    who demanded appraisal of their shares, the Delaware Court of
    Chancery is empowered to conduct a hearing upon the petition,
    and to determine those stockholders who have complied with
    Section&#160;262 and who have become entitled to the appraisal
    rights provided thereby. The Delaware Court of Chancery may
    require the stockholders who have demanded appraisal for their
    shares and who hold stock represented by certificates to submit
    their stock certificates to the Register in Chancery for
    notation thereon of the pendency of the appraisal proceedings;
    and if any stockholder fails to comply with that direction, the
    Delaware Court of Chancery may dismiss the proceedings as to
    that stockholder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After determination of the stockholders entitled to appraisal of
    their shares, the Delaware Court of Chancery will appraise the
    &#147;fair value&#148; of the shares owned by those
    stockholders. This value will be exclusive of any element of
    value arising from the accomplishment or expectation of the
    merger, but will include a fair rate of interest, if any, upon
    the amount determined to be the fair value. When the value is
    determined, the Delaware Court of Chancery will direct the
    payment of the value, with interest thereon accrued during the
    pendency of the proceeding, if the Delaware Court of Chancery so
    determines, to the stockholders entitled to receive the same,
    upon surrender by the holders of the certificates representing
    those shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In determining fair value, and, if applicable, a fair rate of
    interest, the Delaware Court of Chancery is required to take
    into account all relevant factors. In <I>Weinberger&#160;v. UOP,
    Inc.</I>, the Delaware Supreme Court discussed the factors that
    could be considered in determining fair value in an appraisal
    proceeding, stating that &#147;proof of value by any techniques
    or methods which are generally considered acceptable in the
    financial community and otherwise admissible in court&#148;
    should be considered, and that &#147;fair price obviously
    requires consideration of all relevant factors involving the
    value of a company.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Section&#160;262 provides that fair value is to be
    &#147;exclusive of any element of value arising from the
    accomplishment or expectation of the merger.&#148; In
    <I>Cede&#160;&#038; Co.&#160;v. Technicolor, Inc.</I>, the
    Delaware Supreme Court stated that this exclusion is a
    &#147;narrow exclusion [that] does not encompass known elements
    of value,&#148; but which rather applies only to the speculative
    elements of value arising from such accomplishment or
    expectation. In <I>Weinberger</I>, the Delaware Supreme Court
    construed Section&#160;262 to mean that &#147;elements of future
    value, including the nature of the enterprise, which are known
    or susceptible of proof as of the date of the merger and not the
    product of speculation, may be considered.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You should be aware that the fair value of your shares as
    determined under Section&#160;262 could be more than, the same
    as, or less than the value that you are entitled to receive
    under the terms of the merger agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Costs of the appraisal proceeding may be imposed upon the
    surviving corporation and the stockholders participating in the
    appraisal proceeding by the Delaware Court of Chancery as the
    Court deems equitable in the circumstances. Upon the application
    of a stockholder, the Delaware Court of Chancery may order all
    or a portion of the expenses incurred by any stockholder in
    connection with the appraisal proceeding, including, without
    limitation, reasonable attorneys&#146; fees and the fees and
    expenses of experts, to be charged pro rata against the value of
    all shares entitled to appraisal. In the absence of such a
    determination of assessment, each party bears its own expenses.
    Any stockholder who had demanded appraisal rights will not,
    after the completion of the merger, be
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    108
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    entitled to vote shares subject to that demand for any purpose
    or to receive payments of dividends or any other distribution
    with respect to those shares, other than with respect to payment
    as of a record date prior to the completion; however, if no
    petition for appraisal is filed within one hundred and twenty
    days after the completion of the merger, or if the stockholder
    delivers a written withdrawal of his or her demand for appraisal
    and an acceptance of the terms of the merger within sixty days
    after the completion of the merger, then the right of that
    stockholder to appraisal will cease and that stockholder will be
    entitled to receive the merger consideration for his or her
    shares of Abraxis common stock pursuant to the merger agreement.
    Any withdrawal of a demand for appraisal made more than sixty
    days after the completion of the merger may only be made with
    the written approval of the surviving corporation. No appraisal
    proceeding in the Delaware Court of Chancery will be dismissed
    as to any stockholder without the approval of the court.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Failure to follow the steps required by Section&#160;262 for
    perfecting appraisal rights may result in the loss of appraisal
    rights. In view of the complexity of Section&#160;262,
    stockholders who may wish to dissent from the merger and pursue
    appraisal rights should consult their legal advisors.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    109
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='178'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The unaudited pro forma condensed consolidated financial
    statements presented below are based on, and should be read
    together with, the historical financial statements of Celgene
    and Abraxis that are contained in their respective filings with
    the SEC and incorporated by reference into this proxy
    statement/prospectus. See &#147;Where You Can Find More
    Information.&#148; The unaudited pro forma condensed
    consolidated balance sheet gives effect to the proposed merger
    as if it had occurred on June&#160;30, 2010, and combines the
    historical balance sheets of Celgene and Abraxis as of
    June&#160;30, 2010. The unaudited pro forma condensed
    consolidated statements of operations are presented as if the
    proposed merger had occurred on January&#160;1, 2009, and
    combines the historical results of operations of Celgene and
    Abraxis for the year ended December&#160;31, 2009 and for the
    six months ended June&#160;30, 2010. The historical financial
    information is adjusted to give effect to pro forma events that
    are (1)&#160;directly attributable to the merger,
    (2)&#160;factually supportable and (3)&#160;with respect to the
    statement of operations, expected to have a continuing impact on
    the combined results of Celgene and Abraxis. The unaudited pro
    forma condensed consolidated financial statements should be read
    in conjunction with the accompanying notes to the unaudited pro
    forma condensed financial statements presented below and with
    the separate historical financial statements of Celgene and
    Abraxis incorporated by reference into this proxy
    statement/prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The pro forma adjustments related to the merger have been
    prepared using the acquisition method of accounting and are
    based on a preliminary purchase price allocation whereby the
    cost to acquire Abraxis was allocated to the assets acquired and
    the liabilities assumed, based upon their estimated fair values.
    Actual adjustments will be based on analyses of fair values of
    identifiable tangible and intangible assets, in-process research
    and development, deferred tax assets and liabilities and
    estimates of the useful lives of tangible and amortizable
    intangible assets, which will be completed following the
    completion of the merger and after Celgene obtains a final
    third-party valuation, performs its own assessments and reviews
    all available data. The final purchase price allocation will be
    performed using estimated fair values as of the date of the
    completion of the merger. Differences between the preliminary
    and final purchase price allocations could have a material
    impact on the unaudited pro forma condensed consolidated
    financial statements and Celgene&#146;s future results of
    operations and financial position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The unaudited pro forma condensed consolidated financial
    statements do not reflect the realization of potential cost
    savings, or any related restructuring or integration costs that
    may result from the integration of Abraxis. Although Celgene
    believes that certain cost savings may result from the merger,
    there can be no assurance that these cost savings will be
    achieved.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The unaudited pro forma condensed consolidated financial
    statements are based on estimates and assumptions, are presented
    for illustrative purposes only and are not necessarily
    indicative of the consolidated financial position or results of
    operations in future periods or the results that actually would
    have been realized if the proposed merger had been completed as
    of the dates indicated.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    110
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CELGENE
    CORPORATION AND SUBSIDIARIES<BR>
    <BR>
    <!-- XBRL,bs -->UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    BALANCE SHEET<BR>
    As of June&#160;30, 2010<BR>
    (In thousands)</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL,body -->
<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Celgene<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Abraxis<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>See<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Historical)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Historical)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Adjustments</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Note 4</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Consolidated</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="21" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Assets</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    855,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    171,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1,000,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (a
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Marketable securities available for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,289,009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,478,056
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (a
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    810,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    477,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    533,527
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Inventory
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,797
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,834
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (b
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    273,185
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    107,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (e
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    201,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,368
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,202
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,554
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (b
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    326,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total current assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,094,894
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    338,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,260,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,172,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    309,401
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    262,160
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    571,561
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Investment in affiliated companies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,412
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,992
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    806,313
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131,807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,538,193
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (c
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,476,313
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    764,612
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    892,432
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (d
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,910,865
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    179,438
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,484
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24,658
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (e
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    212,264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,178,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,060,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,145,129
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,383,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="21">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="21" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Liabilities and Stockholders&#146; Equity</B>
</DIV>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    66,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    48,831
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (f
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    134,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    307,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84,563
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,208
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (g
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    495,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued litigation costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Related party payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Income taxes payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Current portion of deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,886
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total current liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    473,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152,039
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    788,783
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Contingent value rights
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (h
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,891
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Non-current income taxes payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    458,694
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    458,694
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred income taxes, non-current
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,686
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    963,549
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (e
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    995,235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other non-current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    309,064
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,862
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    319,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,250,428
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    208,513
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,415,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,874,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stockholders&#146; equity:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (i
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,803
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common stock in treasury, at cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (458,417
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (458,417
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,565,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,236,298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (646,404
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (j
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,154,950
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (242,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (394,668
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    376,612
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (k
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (260,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    733
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (733
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (l
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,927,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    842,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,459
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,499,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Noncontrolling interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,927,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    851,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,459
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,508,958
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total liabilities and equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,178,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,060,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,145,129
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,383,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- /XBRL,bs -->
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See Notes to Unaudited Pro Forma Condensed Consolidated
    Financial Statements
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    111
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CELGENE
    CORPORATION AND SUBSIDIARIES<BR>
    <BR>
    <!-- XBRL,op -->UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    STATEMENT OF OPERATIONS<BR>
    For the Six Months Ended June&#160;30, 2010<BR>
    (In thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL,body -->
<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Celgene<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Abraxis<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>See<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Historical)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Historical)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Adjustments</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Note 4</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Consolidated</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net product sales
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,582,508
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    239,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.i
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,821,741
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaborative agreements and other revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,924
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,892
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (80
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.i
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Royalty revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.i
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,643,946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    246,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,890,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cost of goods sold (excluding amortization of acquired
    intangible assets)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,740
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    202,648
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    547,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,334
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    616,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    427,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110,273
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,169
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.iii
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    536,345
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.ii
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Acquisition related charges
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,698
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,944
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.iii
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,205,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,492,513
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    438,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,498
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,964
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    397,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other income and expense:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest and investment income, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,958
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,348
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.iv
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,819
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Equity in (gains) losses of affiliated companies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,855
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,217
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other (loss) income, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,427
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27,312
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    409,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax provision (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,959
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,925
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.v
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    389,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,387
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to noncontrolling interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (605
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (605
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss) attributable to common shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    389,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (18,863
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,387
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    354,544
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income per common share:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.74
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average shares:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,574
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (n
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    470,686
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,574
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (n
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    478,131
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- /XBRL,op -->
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See Notes to Unaudited Pro Forma Condensed Consolidated
    Financial Statements
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    112
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CELGENE
    CORPORATION AND SUBSIDIARIES<BR>
    <BR>
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED <BR>
    <!-- XBRL,op -->STATEMENT OF OPERATIONS<BR>
    For the Year Ended December&#160;31, 2009<BR>
    (In thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL,body -->
<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Celgene<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Abraxis<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>See<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Historical)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Historical)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Adjustments</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Note 4</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Consolidated</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net product sales
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,567,354
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    314,545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (749
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.i
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,881,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaborative agreements and other revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,248
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Royalty revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108,796
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.i
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    109,545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,689,893
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,048,943
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cost of goods sold (excluding amortization of acquired
    intangible assets)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,665
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    279,954
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    794,848
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    154,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    949,463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    753,827
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    954,561
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,924
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.ii
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    158,109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Impairment charge
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,848,367
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    472,795
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,924
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,356,086
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    841,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (113,745
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,924
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    692,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other income and expense:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest and investment income, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,052
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (71,220
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.iv
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,617
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Equity in losses (gains) of affiliated companies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,090
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other income, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    975,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107,348
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    762,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax provision (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    198,956
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,580
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,458
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (m.v
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    776,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (104,768
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (63,686
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    608,293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to noncontrolling interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,652
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,652
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss) attributable to common shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    776,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (103,116
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (63,686
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    609,945
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income per common share:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.69
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average shares:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    459,304
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,574
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (n
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    469,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467,354
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,574
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (n
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    477,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- /XBRL,op -->
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See Notes to Unaudited Pro Forma Condensed Consolidated
    Financial Statements
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    113
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL,ns -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS</FONT></B>
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">(1)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Description
    of Transaction</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On June&#160;30, 2010 Celgene, Abraxis and merger sub entered
    into a merger agreement pursuant to which merger sub will merge
    with and into Abraxis, and Abraxis will become a wholly-owned
    subsidiary of Celgene. This transaction will be accounted for by
    Celgene under the acquisition method of accounting, with Celgene
    as the acquirer. Under the acquisition method of accounting, the
    assets and liabilities of Abraxis will be recorded as of the
    acquisition date, at their respective fair values, and
    consolidated with those of Celgene. The reported consolidated
    financial condition and results of operations of Celgene after
    completion of the merger will reflect these fair values.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the terms and subject to the conditions of the merger
    agreement, each share of Abraxis common stock will be converted
    into the right to receive (1)&#160;$58.00 in cash, without
    interest, (2)&#160;0.2617 of a share of Celgene common stock and
    (3)&#160;one CVR issued by Celgene. Holders of stock options and
    stock appreciation rights, whether vested or unvested, with an
    exercise price or base appreciation amount below the per share
    amount (as defined below) will receive, for each share of
    Abraxis common stock subject to such stock option or stock
    appreciation right, (1)&#160;a cash payment equal to the
    difference between the per share amount and the exercise price
    or base appreciation amount of the stock option or stock
    appreciation right, as applicable, and (2)&#160;one CVR. Holders
    of stock options and stock appreciation rights with an exercise
    price or base appreciation amount above the per share amount
    will be given the right to elect to pay to Abraxis a cash
    payment equal to the difference between the exercise price or
    base appreciation amount of the stock option or stock
    appreciation right, as applicable, and the per share amount, and
    in exchange receive one CVR. Holders of restricted stock units
    will receive (1)&#160;a cash payment equal to the per share
    amount and (2)&#160;one CVR.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The &#147;per share amount&#148; means the sum of $58.00, plus
    the amount obtained by multiplying (1)&#160;the exchange ratio
    of 0.2617 and (2)&#160;an amount equal to the average of the
    closing sale prices for Celgene common stock on The NASDAQ
    Global Select Market, as reported in The Wall Street Journal,
    for each of the ten consecutive trading days ending with the
    seventh complete trading day prior to the completion of the
    merger, with such amount rounded up to the nearest cent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene estimates that the aggregate value of the consideration
    to be paid in the merger will be approximately
    $3.35&#160;billion. The value of the shares of Celgene common
    stock and CVRs to be issued pursuant to the merger will not be
    determined until the completion of the merger and therefore, the
    final aggregate value of the consideration paid in the merger
    may be more or less than $3.35&#160;billion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The merger is subject to customary closing conditions, including
    the adoption of the merger agreement by Abraxis stockholders. We
    anticipate that the merger will close within two business days
    following the date of the special meeting, if all conditions to
    the merger (as described under &#147;Merger
    Agreement&#160;&#151; Conditions to the Merger&#148;) are
    fulfilled or waived on or before the closing date. However, we
    cannot guarantee the exact timing of the completion of the
    merger or that the merger will be completed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Prior to June&#160;30, 2010, there were no material transactions
    between Celgene or its subsidiaries, on the one hand, and
    Abraxis and its subsidiaries, on the other hand.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">(2)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Contingent
    Value Rights</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The unaudited pro forma balance sheet as of June&#160;30, 2010
    includes Celgene&#146;s estimate of the fair value of the total
    potential payments under the CVRs. Subsequent to the completion
    of the merger, the liability relating to the CVRs will be
    re-measured to fair value at each reporting date, with changes
    reflected in earnings. Each CVR will entitle its holder to
    receive a pro rata portion of the following payments:
    (1)&#160;$250&#160;million upon FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of non-small cell lung cancer, which
    approval permits Celgene to market
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes a progression free survival claim,
    but only if the foregoing milestone is achieved no later than
    the fifth anniversary of the merger, (2)&#160;$400&#160;million
    (if achieved no later than April&#160;1, 2013)&#160;or
    $300&#160;million (if achieved after April&#160;1, 2013 and
    before the fifth anniversary of the merger) upon FDA approval of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for use in the treatment of pancreatic cancer, which approval
    permits Celgene to market
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    114
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    under a label that includes an overall survival claim, and
    (3)&#160;for each full one-year period ending
    December&#160;31st&#160;during the term of the CVR agreement,
    which we refer to as a net sales measuring period (with the
    first net sales measuring period beginning January&#160;1, 2011
    and ending December&#160;31, 2011) (a)&#160;2.5% of the net
    sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $1&#160;billion
    but are less than or equal to $2&#160;billion for such period,
    plus (b)&#160;an additional amount equal to 5% of the net sales
    of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $2&#160;billion
    but are less than or equal to $3&#160;billion for such period,
    plus (c)&#160;an additional amount equal to 10% of the net sales
    of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products that exceed $3&#160;billion
    for such period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The unaudited pro forma condensed consolidated balance sheet as
    of June&#160;30, 2010 reflects an estimated value of
    $300&#160;million in the aggregate attributable to the CVRs to
    be issued in the merger, based on Celgene&#146;s internal
    valuation considering the probability of approval and the
    expected timing of such approvals and future sales of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and the Abraxis pipeline products. The value placed on the CVRs
    by Celgene for purposes of these unaudited pro forma condensed
    consolidated financial statements may not be indicative of the
    actual fair value of the CVRs or of the payment to be made or
    the value at which the CVRs will trade following the completion
    of the merger. In addition, no accretion expense has been
    included in the unaudited pro forma condensed consolidated
    statement of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The CVR payments, all other obligations under the CVR agreement
    and the CVRs and any rights or claims relating thereto, are
    subordinated in right of payment to the prior payment in full in
    cash or cash equivalents of all senior obligations of Celgene.
    For a description of the senior obligations of Celgene, see
    &#147;Description of the CVRs&#160;&#151; Subordination.&#148;
    If any default on any senior obligations of Celgene exceeding
    $25&#160;million in aggregate principal amount would occur as a
    result of CVR payment, there is an existing payment default on
    senior obligations of Celgene exceeding $25&#160;million in
    aggregate principal amount, the maturity of any senior
    obligations of Celgene representing more than $25&#160;million
    in aggregate principal amount is accelerated or in other
    circumstances, no CVR payment will be made, so long as such
    circumstance remains in effect.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">(3)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Estimated
    Purchase Price</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The accompanying unaudited pro forma condensed consolidated
    financial statements reflect an estimated purchase price of
    approximately $3.35&#160;billion. This amount is comprised of
    the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To holders of Abraxis common stock, for each share of Abraxis
    common stock: (1)&#160;$58.00 in cash, without interest,
    (2)&#160;0.2617 of a share of Celgene common stock and
    (3)&#160;one CVR, and reflect approximately 40.4&#160;million
    shares of Abraxis common stock to be exchanged in the merger,
    based on the number of Abraxis common stock outstanding at
    June&#160;30, 2010.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To holders of Abraxis stock options and stock appreciation
    rights with an exercise price or base appreciation amount below
    the per share amount (as defined above), for each stock option
    or stock appreciation right, as applicable: (1)&#160;a cash
    payment equal to the difference between the per share amount and
    the exercise price or base appreciation amount of the stock
    option or stock appreciation right, as applicable, and
    (2)&#160;one CVR.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To holders of Abraxis restricted stock units, for each
    restricted stock unit: (1)&#160;a cash payment equal to the per
    share amount and (2)&#160;one CVR.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The actual number of shares of Celgene common stock and CVRs
    that are to be exchanged in the merger will not be determined
    until the completion of the merger.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    115
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The total estimated purchase price is summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Estimated amount of cash to be received by Abraxis stockholders,
    stock option holders, stock appreciation right holders and
    restricted stock unit holders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,460,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Estimated fair value of shares of Celgene common stock to be
    issued
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    590,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Estimated fair value of contingent value rights
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total preliminary estimated purchase price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,350,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of this pro forma analysis, the above estimated
    purchase price has been allocated based on a preliminary
    estimate of the fair value of assets and liabilities to be
    acquired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net book value of assets acquired as of June&#160;30, 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    842,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Write-off of existing goodwill, other intangible assets
    and certain deferred taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (242,617
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Adjusted net book value of assets acquired
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    599,786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Remaining allocation:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase inventory to fair value(i)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Acquired identifiable intangible assets at fair value:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Developed products(ii)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    In-process research and development (iii)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Licensing agreement and other(ii)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Abraxis transaction costs(iv)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fair value adjustment of contingent liability
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (103,208
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,024,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Goodwill(v)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,146,253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total preliminary estimated purchase price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,350,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (i) </TD>
    <TD></TD>
    <TD valign="bottom">
    The estimated fair value of inventory is based on estimated fair
    value of finished goods on hand and estimated completion of work
    in progress.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (ii) </TD>
    <TD></TD>
    <TD valign="bottom">
    Developed products relate to
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for the treatment of breast cancer, which has a finite life
    estimated at 17&#160;years. The licensing agreement and other
    also have finite lives primarily estimated at 17&#160;years.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (iii) </TD>
    <TD></TD>
    <TD valign="bottom">
    In-process research and development, which we refer to as
    IPR&#038;D, represents the research and development projects of
    Abraxis which were in-process, but not yet completed, and which
    Celgene plans to complete. They include the development of
    Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    for treatment of pancreatic cancer and non-small cell lung
    cancer. Current accounting standards require that the fair value
    of IPR&#038;D projects acquired in a business combination be
    capitalized at the acquisition date and subsequently accounted
    as an indefinite-lived intangible asset until completion or
    abandonment of the associated research and development efforts.
    Accordingly, during the development period after the completion
    of the merger, these assets will not be amortized into earnings;
    instead these assets will be subject to periodic impairment
    testing. Upon successful completion of the development process
    for an acquired in-process research and development project,
    determination as to the useful life of the asset will be made.
    The asset would then be considered a finite-lived intangible
    asset and amortization of the asset into earnings would begin
    over the estimated useful life of the asset.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    116
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    As part of the final purchase price allocation, the fair value
    estimates will be finalized and adjusted, if necessary, using
    estimated fair values as of the date of completion of the merger.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (iv) </TD>
    <TD></TD>
    <TD valign="bottom">
    Adjustment relates to the transaction costs to be incurred by
    Abraxis in connection with the merger, which will reduce
    Abraxis&#146; net working capital to be acquired by Celgene at
    the completion of the merger.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (v) </TD>
    <TD></TD>
    <TD valign="bottom">
    The amount allocated to goodwill is preliminary and subject to
    change, depending on the results of the final purchase price
    allocation. In accordance with current accounting standards,
    goodwill associated with the transaction will not be amortized
    and will be subject to review for impairment.</TD>
</TR>

</TABLE>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">(4)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Pro Forma
    Adjustments</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Adjustments included in the column under the heading &#147;Pro
    Forma Adjustments&#148; are primarily based on the preliminary
    purchase price valuation and certain adjustments to conform
    Abraxis&#146; historical amounts to Celgene&#146;s financial
    statements presentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of these unaudited pro forma condensed consolidated
    financial statements, the fixed asset book value approximates
    fair value. There are no fair value adjustments to leases, other
    contracts or the non-controlling financial interests included
    herein. Further analysis will be performed after the completion
    of the merger to confirm these estimates or make adjustments in
    the final purchase price allocation, as necessary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene does not require financing for the merger. However,
    Celgene is considering and may pursue financing arrangements on
    terms and conditions favorable to Celgene, including, without
    limitation, an offering of debt securities, to maintain
    financial flexibility. These unaudited pro forma condensed
    consolidated financial statements contemplate the use of
    Celgene&#146;s cash on hand and the sale of Celgene investments
    in marketable securities to finance the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The cash consideration estimated in these unaudited pro forma
    condensed consolidated financial statements assumes that Abraxis
    stock options currently outstanding will not be exercised prior
    to the completion of the merger and that option holders will
    receive a cash payment equal to the difference between the per
    share amount and the exercise price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The adjustments relate to the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Cash and cash equivalents and marketable securities
    available for sale adjustments consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Estimated amount of cash to be received by Abraxis stockholders,
    stock option holders, and restricted stock unit holders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,460,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Celgene&#146;s estimated transaction fees (to accumulated
    deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,478,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    To be funded by:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Marketable securities available for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,478,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,478,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    117
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Inventory and other current assets adjustments consist
    of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Inventory
    <FONT style="white-space: nowrap">step-up</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    110,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reclassification from other current assets to inventory
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    111,554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;To adjust intangible assets for the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elimination of Abraxis intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (131,807
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquired identifiable amortizable intangible assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Developed products
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    In-process research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Licensing agreements and other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,538,193
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;To record the following goodwill adjustments:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elimination of pre-existing Abraxis goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (253,821
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquired goodwill(i)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,146,253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    892,432
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    (i) </TD>
    <TD></TD>
    <TD valign="bottom">
    Goodwill is the excess of the purchase price over the interest
    in the fair value of the acquired assets and liabilities. The
    purchase price, summarized in Note&#160;3 above, includes equity
    consideration, and therefore, is dependent upon the value of
    Celgene common stock. Thus, changes in the market value of
    Celgene common stock will result in changes in the purchase
    price and consequently in goodwill. Based on the price of
    Celgene common stock at June&#160;30, 2010, a 10% increase or
    decrease in market value of the common stock will result in an
    increase or decrease in goodwill of approximately
    $54&#160;million.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    118
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Adjustments to income taxes in the pro forma balance
    sheet presentation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred income taxes (current):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    To release the valuation allowance against the current deferred
    income tax assets of Abraxis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    60,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    To record deferred taxes on a fair value adjustment to the
    contingent liability in purchase accounting (see(g)&#160;below
    for additional information)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    107,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred income taxes (non-current):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    To release the valuation allowance against the non-current
    deferred income tax assets of Abraxis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (71,325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    To record non-current deferred tax liabilities net of
    non-current tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (24,658
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    To record deferred taxes on a fair value adjustment to the
    assets and liabilities of Abraxis in purchase accounting
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,059,532
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    963,549
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Adjustments to reverse deferred taxes related to Abraxis&#146;
    historical intangible assets and the contingent liability were
    based on the actual historical amounts recorded for these items.
    Deferred taxes recorded by Celgene for those intangible assets
    and the contingent liability were based on Celgene&#146;s
    U.S.&#160;statutory tax rate estimated at 40%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Adjustments to income taxes in pro forma statements of
    operations reflect changes to income taxes from pro forma
    adjustments, as presented in (m.iv).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;To record transaction costs to be incurred by Abraxis
    in connection with the merger, which will reduce Abraxis&#146;
    net working capital to be acquired by Celgene upon the
    completion of the merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;To record a fair value adjustment to the contingent
    liability related to a lawsuit Abraxis is currently defending,
    which is anticipated to be a continuing liability of Celgene.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;To record the liability for the CVRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;To record the following common stock adjustments:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elimination of Abraxis common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (40
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Celgene common stock(i)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    (i) </TD>
    <TD></TD>
    <TD valign="bottom">
    Based on the exchange of 40.4&#160;million shares of Abraxis
    common stock (obtained from the number of shares of Abraxis
    common stock outstanding at June&#160;30, 2010), the 0.2617
    exchange ratio and the $0.01&#160;par value of Celgene common
    stock.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    119
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (j)&#160;To record the following adjustments to additional
    paid-in capital:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elimination of Abraxis additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1,236,298
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Celgene common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    589,894
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (646,404
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (k)&#160;To record the following accumulated deficit adjustments:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="87%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elimination of Abraxis accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    394,668
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transaction fees (see(a)&#160;above)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,056
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    376,612
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (l)&#160;To record the elimination of Abraxis&#146; accumulated
    other comprehensive income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (m)&#160;To record the following adjustments to revenues and
    expenses for the year ended December&#160;31, 2009 and the six
    months ended June&#160;30, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Increase (Decrease)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Revenues and Expenses</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(In thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net product sales(i)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (749
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaborative agreements and other revenue(i)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (80
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Royalty revenue(i)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amortization of acquired intangible assets(ii)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,924
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Acquisition and general administrative charges(iii)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,113
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,924
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other income and expense:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest and investment income, net(iv)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (71,220
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (13,348
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (71,220
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (13,348
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax provision (benefit)(v)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (42,458
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (10,925
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (42,458
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (10,925
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (i) </TD>
    <TD></TD>
    <TD valign="bottom">
    To conform Abraxis&#146; royalty revenues to Celgene&#146;s
    presentation.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (ii) </TD>
    <TD></TD>
    <TD valign="bottom">
    Adjustment reflects amortization expenses for finite-lived
    intangible assets acquired by Celgene upon the completion of the
    merger less the historical amortization of intangible assets
    from Abraxis.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (iii) </TD>
    <TD></TD>
    <TD valign="bottom">
    To adjust for $1,944 and $1,169 of acquisition charges paid by
    Celgene and Abraxis, respectively, during the six-month period
    ended June&#160;30, 2010.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    120
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    UNAUDITED PRO FORMA CONDENSED CONSOLIDATED<BR>
    FINANCIAL STATEMENTS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (iv) </TD>
    <TD></TD>
    <TD valign="bottom">
    To record interest income forgone on net cash and cash
    equivalents and marketable securities available for sale
    anticipated to be used in the merger.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (v) </TD>
    <TD></TD>
    <TD valign="bottom">
    To record the income tax benefit, calculated using
    Celgene&#146;s U.S. statutory tax rate estimated at 40%, as a
    result of pro forma adjustments (ii)&#160;and (iii).</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (n)&#160;To adjust basic and diluted shares of Celgene common
    stock issued to Abraxis stockholders as contemplated in the
    merger. Based on the exchange of 40.4&#160;million shares of
    Abraxis common stock (obtained from the number of shares of
    Abraxis common stock outstanding at June&#160;30, 2010), the
    0.2617 exchange ratio and the $0.01&#160;par value of Celgene
    common stock. The common stock was assumed to have been issued
    as of January&#160;1, 2009.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">(5)&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Subsequent
    integration costs</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After the completion of the merger, Celgene may incur additional
    integration costs. These costs have not been reflected in the
    pro forma condensed consolidated financial statements and may be
    material.
</DIV>
<!-- /XBRL,ns -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    121
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='179'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The legality of the CVRs and the shares of Celgene common stock
    to be issued pursuant to the merger will be passed upon for
    Celgene by Jones Day.
</DIV>

<A name='180'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The consolidated financial statements and schedule of Celgene
    and its subsidiaries as of December&#160;31, 2009 and 2008 and
    for each of the years in the three-year period ended
    December&#160;31, 2009, and the effectiveness of Celgene&#146;s
    internal control over financial reporting as of
    December&#160;31, 2009, have been incorporated by reference
    herein and in the registration statement in reliance upon the
    reports of KPMG LLP, independent registered public accounting
    firm, incorporated by reference herein, and upon the authority
    of said firm as experts in accounting and auditing. The audit
    report covering the December&#160;31, 2009 consolidated
    financial statements refers to a change in its method of
    accounting for business combinations as of January&#160;1, 2008,
    change in its method of accounting for the measurement of the
    fair value of financial assets and liabilities as of
    January&#160;1, 2008 and a change in its method of recognizing
    and measuring the tax effects related to uncertain tax positions
    as of January&#160;1, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The consolidated financial statements of Abraxis BioScience,
    Inc. appearing in Abraxis BioScience, Inc.&#146;s Annual Report
    <FONT style="white-space: nowrap">(Form&#160;10-K)</FONT>
    for the year ended December&#160;31, 2009, and the effectiveness
    of Abraxis BioScience, Inc.&#146;s internal control over
    financial reporting as of December&#160;31, 2009, have been
    audited by Ernst&#160;&#038; Young LLP, independent registered
    public accounting firm, as set forth in their reports thereon
    (which contains an explanatory paragraph describing a change in
    its method of accounting for noncontrolling interests in
    consolidated financial statements as of January&#160;1, 2009 as
    described in Note&#160;2 to the consolidated financial
    statements), included therein, and incorporated by reference
    herein. Such consolidated financial statements and Abraxis
    BioScience, Inc.&#146;s management&#146;s assessment of the
    effectiveness of internal control over financial reporting as of
    December&#160;31, 2009 are incorporated by reference herein in
    reliance upon such reports given on the authority of such firm
    as experts in accounting and auditing.
</DIV>

<A name='181'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">STOCKHOLDER
    PROPOSALS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the merger is completed, Abraxis will have no public
    stockholders and no public participation in any of its future
    stockholder meetings. If the merger is not completed, Abraxis
    stockholders will continue to be entitled to attend and
    participate in Abraxis stockholders meetings and Abraxis will
    hold an annual meeting of stockholders in 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As set forth in Abraxis&#146; definitive proxy statement filed
    with the SEC on October&#160;30, 2009, which is referred to as
    Abraxis&#146; last proxy statement, notice of any proposal of a
    stockholder of Abraxis intended to be included in Abraxis&#146;
    proxy statement and form of proxy relating to its 2010 annual
    meeting of stockholders (i.e., Abraxis&#146; next annual
    meeting) must have been received in writing by Abraxis&#146;
    Corporate Secretary at 11755 Wilshire Boulevard,
    Suite&#160;2000, Los Angeles, CA 90025 not less than
    120&#160;days prior to the one year anniversary from the first
    date of mailing of the proxy materials for the 2009 annual
    meeting, or by July&#160;2, 2010. However, if the 2010 annual
    meeting is held earlier than November&#160;5, 2010, then the
    deadline will be a reasonable time before Abraxis begins to
    print and mail its proxy materials for the 2010 annual meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Also as set forth in Abraxis&#146; last proxy statement, for any
    other proposal that a stockholder wishes to have considered at
    the 2010 annual meeting of Abraxis stockholders, and for any
    nomination of a person for election to the Abraxis board of
    directors at the 2010 annual meeting of Abraxis stockholders,
    Abraxis must have received written notice of such proposal or
    nomination not less than 120&#160;days prior to the one year
    anniversary from the first date of mailing of proxy materials
    for the 2009 annual meeting, or July&#160;2, 2010, or if the
    date of the 2010 annual meeting has been changed by more than
    30&#160;days from the date of the 2009 annual meeting, then the
    deadline for submitting proposals will be a reasonable time
    before Abraxis begins to print and mail its proxy materials for
    the 2010 annual meeting.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    122
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposals and nominations that are not received by the dates
    specified above will be considered untimely. In addition,
    proposals and nominations must comply with Delaware law,
    Abraxis&#146; bylaws and the rules and regulations of the SEC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You may contact the Corporate Secretary, at Abraxis BioScience,
    Inc., 11755 Wilshire Boulevard, Suite&#160;2000, Los Angeles, CA
    90025, for a copy of the relevant bylaw provisions regarding the
    requirements for making stockholder proposals and nominating
    director candidates.
</DIV>

<A name='182'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND MORE INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis and Celgene file annual, quarterly and current reports,
    proxy statements and other information with the SEC. You may
    read and copy any reports, statements or other information filed
    by Abraxis or Celgene at the SEC&#146;s Public Reference Room at
    100&#160;F&#160;Street, N.E., Washington,&#160;D.C. 20549.
    Please call the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for further information on the operation of the Public Reference
    Room.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You may also obtain copies of this information by mail from the
    Public Reference Section of the SEC, 100&#160;F&#160;Street,
    N.E., Room&#160;1024, Washington,&#160;D.C. 20549, at prescribed
    rates, or from commercial document retrieval services.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The SEC maintains a website that contains reports, proxy
    statements and other information, including those filed by
    Abraxis and Celgene, at
    <FONT style="white-space: nowrap">http://www.sec.gov.</FONT>
    You may also access the SEC filings and obtain other information
    about Abraxis and Celgene through the websites maintained by
    Abraxis and Celgene, which are
    <FONT style="white-space: nowrap">http://www.abraxisbio.com</FONT>
    and
    <FONT style="white-space: nowrap">http://www.celgene.com,</FONT>
    respectively. The information contained in those websites is not
    incorporated by reference into this proxy statement/prospectus
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Statements contained in this proxy statement/prospectus, or in
    any document incorporated by reference in this proxy
    statement/prospectus regarding the content of any contract or
    other document, are not necessarily complete, and each of these
    statements is qualified in its entirety by reference to that
    contract or other document filed as an exhibit with the SEC. As
    allowed by SEC rules, this proxy statement/prospectus
    &#147;incorporates by reference&#148; into this proxy
    statement/prospectus certain information required to be included
    in the registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-4</FONT>
    filed by Celgene to register the CVRs and the shares of Celgene
    common stock to be issued pursuant to the merger and the
    exhibits to the registration statement, which means that
    important information can be disclosed to you by referring you
    to other documents filed separately with the SEC. The
    information incorporated by reference is deemed to be part of
    this proxy statement/prospectus, except for any information
    superseded by information in this proxy statement/prospectus.
    This proxy statement/prospectus incorporates by reference the
    documents set forth below that Abraxis and Celgene have
    previously filed with the SEC as well as all documents filed by
    Abraxis and Celgene pursuant to Section&#160;13(a), 13(c), 14 or
    15(d) of the Exchange Act from the date of this proxy
    statement/prospectus to the date of the special meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Abraxis</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K/A</FONT>
    for the year ended December&#160;31, 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarters ended March&#160;31, 2010 and June&#160;30,
    2010;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Abraxis&#146; Current Reports on
    <FONT style="white-space: nowrap">Form&#160;8-K</FONT>
    filed with the SEC on January&#160;28, 2010, February&#160;5,
    2010, June&#160;30, 2010 and July&#160;1, 2010.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You may request a copy of these filings free of charge by
    writing or telephoning Abraxis at:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11755 Wilshire Boulevard, Suite&#160;2000
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Los Angeles, California 90025
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Attention: Investor Relations
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Telephone Number:
    <FONT style="white-space: nowrap">(310)&#160;883-1300</FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    123
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Celgene</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarters ended March&#160;31, 2010 and June&#160;30,
    2010;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Celgene&#146;s Current Reports on
    <FONT style="white-space: nowrap">Form&#160;8-K</FONT>
    filed with the SEC on January&#160;6, 2010, January&#160;15,
    2010, February&#160;12, 2010, April&#160;15, 2010, June&#160;18,
    2010, June&#160;30, 2010, July&#160;1, 2010, August&#160;4, 2010
    and August&#160;27, 2010.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You may request a copy of these filings free of charge by
    writing or telephoning Celgene at:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    86 Morris Avenue
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Summit, New Jersey 07901
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Attention: Investor Relations
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Telephone Number:
    <FONT style="white-space: nowrap">(908)&#160;673-9000</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any statements made in a document incorporated by reference in
    this proxy statement/prospectus is deemed to be modified or
    superseded for purposes of this proxy statement/prospectus to
    the extent that a statement in this proxy statement/prospectus
    or in any other subsequently filed document, which is also
    incorporated by reference, modifies or supersedes the statement.
    Any statement made in this proxy statement/prospectus is deemed
    to be modified or superseded to the extent a statement in any
    subsequently filed document, which is incorporated by reference
    in this proxy statement/prospectus, modifies or supersedes such
    statement. Any statement so modified or superseded will not be
    deemed, except as so modified or superseded, to constitute a
    part of this proxy statement/prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Neither Celgene nor Abraxis has authorized anyone to give any
    information or make any representation about the merger or our
    companies that is different from, or in addition to, that
    contained in this proxy statement/prospectus or in any of the
    materials that are incorporated into this proxy
    statement/prospectus. Therefore, if anyone does give you
    information of this sort, you should not rely on it. If you are
    in a jurisdiction where offers to exchange or sell, or
    solicitations of offers to exchange or purchase, the securities
    offered by this proxy statement/prospectus is unlawful, or if
    you are a person to whom it is unlawful to direct these types of
    activities, then the offer presented in this proxy
    statement/prospectus does not extend to you. The information
    contained in this proxy statement/prospectus is accurate only as
    of the date of this document unless the information specifically
    indicates that another date applies.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    124
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='183'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;A</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">AGREEMENT
    AND PLAN<BR>
    OF MERGER<BR>
    DATED AS OF<BR>
    JUNE 30, 2010<BR>
    AMONG<BR>
    CELGENE CORPORATION,<BR>
    ARTISTRY ACQUISITION CORP.<BR>
    AND<BR>
    ABRAXIS BIOSCIENCE, INC.</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="15%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="76%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE I&#160;&#160;THE
    MERGER
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    The Merger
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Effective Time of the Merger
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    By-laws
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Board of Directors and Officers
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Effects of Merger
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    II&#160;&#160;CONVERSION OF SHARES
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Conversion of Shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Payment and Exchange of Certificates
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Dissenting Company Shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    No Further Ownership Rights in the Shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Closing of Company Transfer Books
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Adjustments
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Options, RSUs, SARs
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Withholding of Tax
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Closing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    III&#160;&#160;REPRESENTATIONS AND WARRANTIES OF THE COMPANY
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Organization, Standing and Power
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Capital Structure
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Authority; Non-Contravention
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    SEC Documents
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Proxy Statement/Prospectus and Registration Statement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Absence of Certain Events
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Litigation
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    No Violation of Law
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Taxes
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Benefit Plans; ERISA
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Employment Matters
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Environmental Matters
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Affiliate Transactions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.14
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Intellectual Property
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.15
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Takeover Statutes
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.16
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Title to Properties; Assets/Services
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.17
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Material Contracts
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.18
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Financial Advisors
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.19
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Pharmaceutical Matters
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.20
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Brokers and Finders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.21
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Insurance
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.22
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Anti-Corruption and Anti-Bribery
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.23
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    No Other Representations or Warranties
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="15%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="76%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    IV&#160;&#160;REPRESENTATIONS AND WARRANTIES OF PARENT AND SUB
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Organization, Standing and Power
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Capital Structure
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Operations of Sub
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Authority; Non-Contravention
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    SEC Documents
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Absence of Certain Events
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Proxy Statement/Prospectus and Registration Statement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Availability of Funds; Parent Common Stock
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Litigation
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    No Violation of Law
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Brokers and Finders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Ownership of Shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Solvency
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.14
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    No Other Representations or Warranties
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    V&#160;&#160;COVENANTS RELATING TO CONDUCT OF BUSINESS
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 5.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Conduct of Business by the Company Pending the Merger
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 5.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Control of the Company&#146;s Operations
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    VI&#160;&#160;ADDITIONAL AGREEMENTS
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Company Stockholder Approval; Proxy Statement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Directors&#146; and Officers&#146; Indemnification
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    No Solicitation
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Access to Information; Confidentiality
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Reasonable Best Efforts; Notification
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Benefit Plans
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Fees and Expenses
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Public Announcements
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Sub
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    CVR Agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Transfer Taxes
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Listing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Certain Notices
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.14
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Section&#160;16 Matters
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.15
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    State Takeover Laws
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.16
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    FIRPTA Statement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.17
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Further Actions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    VII&#160;&#160;CONDITIONS PRECEDENT
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Conditions to Each Party&#146;s Obligation to Effect the Merger
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Additional Conditions to Obligations of Parent and Sub
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Additional Conditions to Obligations of the Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Frustration of Closing Conditions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Invoking Certain Provisions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-ii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="15%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="76%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    VIII&#160;&#160;TERMINATION, AMENDMENT AND WAIVER
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Termination
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Effect of Termination
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Amendment
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Extension; Waiver
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Procedure for Termination, Amendment, Extension or Waiver
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">ARTICLE
    IX&#160;&#160;MISCELLANEOUS
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Non-Survival of Representations, Warranties and Agreements
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Notices
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Specific Performance
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Assignment; Binding Effect
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Entire Agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Governing Law
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Counterparts
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Headings and Table of Contents; Interpretation
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    No Third Party Beneficiaries
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Incorporation of Exhibits
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Severability
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Subsidiaries
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Person
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.14
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Applicable Jurisdictions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.15
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Knowledge of the Company; Knowledge of Parent
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.16
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Mutual Drafting
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.17
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Tax Reporting
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-iii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    DEFINED TERMS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="15%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2007 Separation and Distribution Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.9(f)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2007 Spin-Off
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.9(f)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2007 Tax Allocation Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.9(f)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition Proposal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.3(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Affiliate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.13
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Preamble
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Anti-Corruption and Anti-Bribery Laws
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.22(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Antitrust Approval
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 7.1(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Antitrust Division
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.5(b)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Applicable Exercise Price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Applicable Jurisdiction
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 9.14
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Applicable SAR Base Amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(b)(i)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Board of Directors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(e)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Book Entry Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Business Day
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.2(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash Consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Certificate of Incorporation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 1.3
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Certificate of Merger
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 1.2
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Certificates
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Closing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.9
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Closing Date
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.9
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Code
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.8
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Preamble
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.3(b)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Financial Advisors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.18
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Financial Statements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.4(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Intellectual Property
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14(b)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Material Adverse Effect
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.1
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Patents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14(e)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Permits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.8
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company SEC Documents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.4(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Stock Plan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Company Stockholder Meeting
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.1(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Confidentiality Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.4
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Consent
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.3(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.3(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.13
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Copyrights
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CVR
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CVR Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CVR Certificate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    DGCL
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 1.1
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Disclosure Schedule
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Article&#160;III
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dissenting Company Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.3
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effective Time
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 1.2
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effects
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.1
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Employee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.6(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Employee Benefit Plans
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.10(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Employment Practices
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Section 3.11(b)
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-iv
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="15%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Environmental Laws
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.12(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Environmental Liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.12(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ERISA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.10(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ERISA Affiliate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.10(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange Act
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Article&#160;III
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange Fund
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.2(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange Ratio
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Excluded Company Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exercise Period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    FDA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.19(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    FDCA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.19(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign Plan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.10(h)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    FTC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.5(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Governmental Entity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.3(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hazardous Materials
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.12(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HSR Act
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.3(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Indemnified Parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.2(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Indemnified Party
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.2(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Insurance Policies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.21
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Intellectual Property
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    IRS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.10(b)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Knowledge of Parent
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 9.15
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Knowledge of the Company
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 9.15
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Law
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.3(b)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leased Real Property
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.16(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liens
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.2(d)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Material Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.17(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Material Employment Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.10(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merger
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merger Consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>Technology

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASDAQ
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.1
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-Competition and Confidentiality Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Option
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Preamble
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent Financial Statements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 4.5(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent Material Adverse Effect
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 4.6
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent Permits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 4.10
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent Plans
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.6(b)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent Review Period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.3(c)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent SEC Documents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 4.5(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Parent Share Cash Value
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.2(e)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Patents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Paying Agent
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.2(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per Share Amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(a)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Person
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 9.13
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pharmaceutical Products
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pipeline Products
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeding
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Section 3.7
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A-v
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="15%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Product
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Programs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.19(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proxy Statement/Prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.2(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Real Property
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.16(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Registration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.3(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Registration Statement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.2(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Regulatory Authorities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.19(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Regulatory Registrations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.19(f)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Related Agreements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Representatives
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.3(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    RSU
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(c))
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    RSUs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SAR
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(b)(i)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sarbanes Oxley Act
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.4(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SARs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.7(b)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Screening Test
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.19(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.4(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Section&#160;16
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Securityholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.2(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Solvent
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 4.13
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stock Consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 2.1(a)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stockholder Approval
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 7.1(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sub
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Preamble
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Subsidiary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 9.12
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Superior Proposal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.3(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Surviving Corporation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 1.1
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.9(f)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax Return
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.9(f)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Termination Date
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 8.1(b)(i)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Trade Secrets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Trademarks
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.14
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transfer Taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.11
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transition Period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 6.6(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Trust&#160;Indenture Act
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 4.4(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Trustee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    U.S. GAAP
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.1
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Voting Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WARN Act
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.11(e)(i)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    willful and material breach
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 8.2
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Worker
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Section 3.11(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Workers
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Section 3.11(c)
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A-vi
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    THIS AGREEMENT AND PLAN OF MERGER (this
    &#147;<U>Agreement</U>&#148;), dated as of June&#160;30, 2010,
    is entered into by and among Celgene Corporation, a Delaware
    corporation (&#147;<U>Parent</U>&#148;); Artistry Acquisition
    Corp., a Delaware corporation and a wholly owned subsidiary of
    Parent (&#147;<U>Sub</U>&#148;); and Abraxis BioScience Inc., a
    Delaware corporation (the &#147;<U>Company</U>&#148;).
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><U><FONT style="font-family: 'Times New Roman', Times">W I T
    N E S S E T
    H</FONT></U><FONT style="font-family: 'Times New Roman', Times">:</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, the respective Boards of Directors of Parent, Sub and
    the Company have approved the acquisition of the Company by
    Parent on the terms and subject to the conditions set forth in
    this Agreement;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, the respective Boards of Directors of Parent, Sub and
    the Company have approved a merger of Sub with and into the
    Company (the &#147;<U>Merger</U>&#148;), upon the terms and
    subject to the conditions set forth in this Agreement, and have
    declared the Merger advisable;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, the Company, Parent and Sub desire to make certain
    representations, warranties, covenants and agreements in
    connection with this Agreement;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, concurrently with the execution of this Agreement,
    Parent, Sub and certain stockholders of the Company are entering
    into a voting agreement of even date herewith (the
    &#145;&#145;<U>Voting Agreement</U>&#148;) pursuant to which
    such stockholders have agreed, subject to the terms thereof, to
    vote their shares of Company Common Stock (as defined below) in
    favor of adoption of this Agreement;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, (i)&#160;concurrently with the execution of this
    Agreement, Parent, Dr.&#160;Patrick Soon-Shiong will execute and
    deliver a Noncompetition and Confidentiality Agreement in
    substantially the form attached hereto as <U>Exhibit&#160;A</U>
    (the &#147;<U>Noncompetition and Confidentiality
    Agreement</U>&#148;), which will become effective at the
    Effective Time (as hereinafter defined), and (ii)&#160;as of or
    prior to the Closing, Parent and a trustee mutually agreeable to
    Parent and the Company (the &#147;<U>Trustee</U>&#148;) will
    enter into a Contingent Value Rights Agreement in substantially
    the form attached hereto as <U>Exhibit&#160;B</U> (the
    &#147;<U>CVR Agreement</U>&#148; and, together with the
    Noncompetition and Confidentiality Agreement and the Voting
    Agreement, the &#145;&#145;<U>Related
    Agreements</U>&#148;);&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    NOW, THEREFORE, in consideration of the foregoing premises and
    the representations, warranties and agreements contained herein,
    the parties hereto agree as follows:
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;I<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">THE MERGER
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.1&#160;&#160;<I><U>The
    Merger</U>.</I>&#160;&#160;Upon the terms and subject to the
    conditions hereof, and in accordance with the General
    Corporation Law of the State of Delaware (the
    &#147;<U>DGCL</U>&#148;), at the Effective Time, Sub shall be
    merged with and into the Company and the separate existence of
    Sub shall thereupon cease, and the Company, as the corporation
    surviving the Merger (the &#147;<U>Surviving
    Corporation</U>&#148;), shall by virtue of the Merger continue
    its corporate existence under the laws of the State of Delaware.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.2&#160;&#160;<I><U>Effective
    Time of the Merger</U>.</I>&#160;&#160;The Merger shall become
    effective at the date and time (the &#147;<U>Effective
    Time</U>&#148;) when the certificate of merger (the
    &#147;<U>Certificate of Merger</U>&#148;) shall have been duly
    executed and filed with the Secretary of State of the State of
    Delaware in accordance with the DGCL, or at such other time as
    is specified in the Certificate of Merger in accordance with the
    DGCL, which Certificate of Merger shall be filed on the Closing
    Date as soon as practicable following the Closing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.3&#160;&#160;<I><U>Certificate
    of Incorporation</U>.</I>&#160;&#160;Subject to
    <U>Section&#160;6.2(a)</U>, at the Effective Time, the amended
    and restated certificate of incorporation of the Company (the
    &#145;&#145;<U>Certificate of Incorporation</U>&#148;) shall, by
    virtue of the Merger, be amended and restated in a form mutually
    agreed and, as so amended, shall be the certificate of
    incorporation of the Surviving Corporation, until thereafter
    changed or amended in accordance with its terms and as provided
    by Law and this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.4&#160;&#160;<I><U>By-laws</U>.</I>&#160;&#160;Subject
    to <U>Section&#160;6.2(a)</U>, at the Effective Time, the
    by-laws of Sub in effect immediately prior to the Effective Time
    shall be the by-laws of the Surviving Corporation, except that
    all references
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    to Sub therein shall be automatically amended and replaced with
    references to the Surviving Corporation, until thereafter
    changed or amended in accordance with their terms and as
    provided by Law and this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.5&#160;&#160;<I><U>Board
    of Directors and Officers</U>.</I>&#160;&#160;The directors of
    Sub and the officers of the Company in office immediately prior
    to the Effective Time shall, from and after the Effective Time,
    be the directors and officers, respectively, of the Surviving
    Corporation, in each case until their respective successors have
    been duly elected or appointed and qualified or until their
    earlier death, resignation or removal, in accordance with the
    Surviving Corporation&#146;s Certificate of Incorporation and
    by-laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.6&#160;&#160;<I><U>Effects
    of Merger</U>.</I>&#160;&#160;The Merger shall have the effects
    set forth in the DGCL.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;II<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">CONVERSION
    OF SHARES
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.1&#160;&#160;<I><U>Conversion
    of Shares</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<U>Conversion of Shares</U>.&#160;&#160;As of the
    Effective Time, by virtue of the Merger and without any action
    on the part of Parent, Sub, the Company or any holders of shares
    of capital stock of the Company:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;Each outstanding share of common stock, par value
    $0.001 per share, of the Company (the &#145;&#145;<U>Company
    Common Stock</U>&#148;) that is held in the treasury of the
    Company and any shares of Company Common Stock owned by Parent,
    Sub or any wholly owned subsidiary of Parent or the Company
    shall be canceled and no consideration shall be delivered in
    exchange therefor (such shares, the &#145;&#145;<U>Excluded
    Company Shares</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;Subject to <U>Section&#160;2.3</U>, each share of
    Company Common Stock issued and outstanding immediately prior to
    the Effective Time (other than Excluded Company Shares) shall be
    converted into the right to receive from Parent (1)&#160;an
    amount in cash, without interest, equal to $58.00 (the
    &#145;&#145;<U>Cash Consideration</U>&#148;), (2)&#160;0. 2617
    (the &#147;<U>Exchange Ratio</U>&#148;) of a share of common
    stock, par value $.01 per share (the &#147;<U>Parent Common
    Stock</U>&#148;), of Parent (the &#147;<U>Stock
    Consideration</U>&#148;), and (3)&#160;one contingent value
    right (a &#147;<U>CVR</U>&#148;) issued by Parent subject to and
    in accordance with the CVR Agreement (the consideration
    contemplated by subclauses (1), (2)&#160;and (3)&#160;together,
    the &#147;<U>Merger Consideration</U>&#148;). Each CVR issued as
    Merger Consideration hereunder will be substantially in the form
    attached as Annex&#160;A to the CVR Agreement (the &#147;<U>CVR
    Certificate</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All such shares of Company Common Stock, when so converted,
    shall no longer be outstanding and shall automatically be
    canceled and retired, and each holder of a certificate or
    certificates (the &#145;&#145;<U>Certificates</U>&#148;)
    representing any such shares of Company Common Stock, and each
    holder of non-certificated shares of Company Common Stock
    represented by book-entry on the records of the Company or the
    Company&#146;s transfer agent (&#147;<U>Book-Entry
    Shares</U>&#148;), shall cease to have any rights with respect
    thereto, except the right to receive the Merger Consideration,
    any cash in lieu of fractional shares payable pursuant to
    <U>Section&#160;2.2(e)</U> and any dividends or other
    distributions to which such holder is entitled pursuant to
    <U>Section&#160;2.2(d)</U>, without interest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Each share of common stock of Sub issued and
    outstanding immediately prior to the Effective Time shall, by
    virtue of the Merger and without any action on the part of the
    holder thereof, be converted into and become at the Effective
    Time one validly issued, fully paid and nonassessable share of
    common stock, par value $0.001 per share, of the Surviving
    Corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.2&#160;&#160;<I><U>Payment
    and Exchange of Certificates</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Prior to the mailing of the proxy statement/prospectus
    to be included in the registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-4</FONT>
    to be filed by Parent with the SEC (as defined in
    <U>Section&#160;3.4(a)</U>) to register the shares of Parent
    Common Stock and CVRs to be issued in connection with the Merger
    (such proxy statement/prospectus, together with any amendments
    or supplements thereto, the &#145;&#145;<U>Proxy
    Statement/Prospectus</U>&#148;, and such registration statement,
    together with any amendments, supplements and exhibits thereto,
    the &#147;<U>Registration Statement</U>&#148;), Parent shall
    appoint a commercial bank or trust company reasonably acceptable
    to the Company to act as paying agent hereunder (the
    &#147;<U>Paying Agent</U>&#148;) for the purpose of payment of
    the aggregate Merger Consideration to be paid and delivered to
    Securityholders (as defined in <U>Section&#160;2.2(b)</U>) under
    this <U>ARTICLE&#160;II</U>.&#160;&#160;Parent will enter into a
    paying agent agreement in form and substance reasonably
    acceptable to the Company at least two Business Days prior to
    the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    mailing of the Proxy Statement/Prospectus to the stockholders of
    the Company. As used herein, &#147;<U>Business Day</U>&#148;
    means any day of the year on which national banking institutions
    in New York are open to the public for conducting business and
    are not required or authorized to close.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;At the Closing, Parent shall deposit, or cause to be
    deposited, with the Paying Agent (i)&#160;cash in an amount
    sufficient to pay the aggregate Cash Consideration
    (ii)&#160;certificates representing a number of shares of Parent
    Common Stock equal to the Exchange Ratio multiplied by the
    number of outstanding shares of Company Common Stock held by
    holders (collectively, the
    &#145;&#145;<U>Securityholders</U>&#148;) of all shares of
    Company Common Stock (other than Excluded Company Shares and
    Dissenting Company Shares), and (iii)&#160;CVR Certificates
    representing the aggregate number of CVRs issuable pursuant to
    the CVR Agreement in accordance with
    <U>Section&#160;2.1(a)(ii)</U> to which the Securityholders will
    become entitled under this ARTICLE&#160;II at the Effective
    Time. Parent further agrees to deposit, or cause to be
    deposited, with the Paying Agent, from time to time as needed,
    immediately available funds sufficient to pay cash in lieu of
    fractional shares pursuant to <U>Section&#160;2.2(e)</U> and any
    dividends and other distributions pursuant to
    <U>Section&#160;2.2(d)</U>. The aggregate amount of such Cash
    Consideration and other cash amounts, certificates representing
    shares of Parent Common Stock and CVRs deposited with the Paying
    Agent is referred to herein as the &#147;<U>Exchange
    Fund</U>.&#148; The Paying Agent shall cause the Exchange Fund
    to be (1)&#160;held for the benefit of the Securityholders and
    (2)&#160;promptly applied to making the payments and deliveries
    provided for in this <U>ARTICLE&#160;II</U>.&#160;&#160;The
    Exchange Fund shall not be used for any purpose that is not
    provided for herein. The Paying Agent shall invest any cash
    included in the Exchange Fund as directed by Parent, in direct
    obligations of the United States of America or obligations for
    which the full faith and credit of the United States of America
    is pledged to provide for the payment of all principal and
    interest, or a combination thereof. Any interest and other
    income resulting from such investments shall be kept in the
    Exchange Fund. To the extent that there are losses with respect
    to such investments, or the Exchange Fund diminishes for other
    reasons below the level required to make prompt payments of the
    aggregate cash consideration to be paid to Securityholders as
    contemplated hereby, Parent shall promptly replace or restore
    the portion of the Exchange Fund lost through investments or
    other events so as to ensure that the Exchange Fund is, at all
    times, maintained at a level sufficient to make such payments.
    Any portion of the Exchange Fund (including the proceeds of any
    interest and other income received by the Paying Agent in
    respect of such funds) that remains undistributed to the
    Securityholders one year after the Effective Time of the Merger
    shall be delivered to Parent at such time. Thereafter,
    Securityholders shall look only to Parent (subject to the terms
    of this Agreement and to abandoned property, escheat or other
    similar Laws) as a general creditor for payment of the
    consideration payable to them under this <U>ARTICLE&#160;II</U>,
    without interest, upon the surrender of any Certificates held by
    them. Notwithstanding any provision of this Agreement to the
    contrary, none of the Paying Agent, Parent, the Surviving
    Corporation or any other party hereto shall be liable to any
    Person for any amount properly paid to a public official
    pursuant to any applicable abandoned property, escheat or other
    similar Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;As soon as practicable (but in any event within two
    Business Days) after the Effective Time, Parent shall cause the
    Paying Agent to mail to each holder of record of shares of
    Company Common Stock represented by Certificates and to each
    holder of Book-Entry Shares, other than Excluded Company Shares
    and Dissenting Company Shares: (i)&#160;a letter of transmittal
    (which shall specify that delivery shall be effected, and risk
    of loss and title to the Certificates or Book-Entry Shares shall
    pass, only upon actual delivery of the Certificates or transfer
    of Book-Entry Shares, as the case may be, to the Paying Agent
    and shall be in a form reasonably agreed upon by Parent and the
    Company prior to the Closing); and (ii)&#160;instructions for
    use in effecting the surrender of the Certificates or transfer
    of Book-Entry Shares, as the case may be, in exchange for the
    Merger Consideration. Upon surrender of a Certificate (or
    delivery of such customary affidavits and indemnities with
    respect to a lost Certificate which the Paying Agent
    <FONT style="white-space: nowrap">and/or</FONT> the
    Company&#146;s transfer agent may reasonably require) or
    transfer of Book-Entry Shares for cancellation to the Paying
    Agent, together with such letter of transmittal duly executed
    and in proper form, and such other documents as may reasonably
    be required by the Paying Agent, the holder of such Certificate
    or Book-Entry Shares shall be entitled to receive in exchange
    therefor the Merger Consideration into which the shares of
    Company Common Stock theretofore represented by such Certificate
    or Book-Entry Shares shall have been converted pursuant to
    <U>Section&#160;2.1</U>, any cash in lieu of fractional shares
    payable pursuant to <U>Section&#160;2.2(e)</U> and any dividends
    or other distributions to which such holder is entitled pursuant
    to <U>Section&#160;2.2(d)</U>, and the Certificates so
    surrendered or Book-Entry Shares so transferred shall forthwith
    be canceled. No interest will be paid or will accrue on the
    Merger Consideration, cash in lieu of fractional shares payable
    pursuant to <U>Section&#160;2.2(e)</U> or dividends or other
    distributions to which such holder is entitled pursuant to
    <U>Section&#160;2.2(d)</U>, payable upon the surrender of any
    Certificate or transfer
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    of Book-Entry Shares. In the event of a transfer of ownership of
    Company Common Stock that is not registered in the transfer
    records of the Company, payment may be made to a Person other
    than the Person in whose name the Certificate so surrendered is
    registered, if such Certificate shall be properly endorsed or
    otherwise be in proper form for transfer and the Person
    requesting such payment shall pay any transfer or other Taxes
    required by reason of such Certificate and establish to the
    satisfaction of Parent that such Tax has been paid or is not
    applicable. Until surrendered or transferred as contemplated by
    this <U>Section&#160;2.2</U>, each Certificate or Book-Entry
    Share (other than Certificates or Book-Entry Shares representing
    any Dissenting Company Shares or Excluded Company Shares) shall
    be deemed at any time after the Effective Time to represent only
    the right to receive upon such surrender or transfer the amount
    of Merger Consideration, without interest, into which the shares
    of Company Common Stock theretofore represented by such
    Certificate or Book-Entry Shares shall have been converted
    pursuant to <U>Section&#160;2.1</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;No dividends or other distributions declared or made
    after the Effective Time with respect to Parent Common Stock,
    with a record date after the Effective Time, shall be paid to
    the holder of any unsurrendered Certificate, and no cash payment
    in lieu of fractional shares shall be paid to any such holder
    pursuant to <U>Section&#160;2.2(e)</U>, unless and until the
    holder of such Certificate shall surrender such Certificate in
    accordance with <U>Section&#160;2.2(c)</U>. Subject to the
    effect of escheat, Tax or other applicable Laws, following
    surrender of any such Certificate, there shall be paid to the
    holder of the certificates representing whole shares of Parent
    Common Stock issued in exchange therefor, without interest,
    (i)&#160;the amount of any cash payable with respect to a
    fractional share of Parent Common Stock to which such holder is
    entitled pursuant to <U>Section&#160;2.2(e)</U> and the amount
    of dividends or other distributions with a record date after the
    Effective Time theretofore paid with respect to such whole
    shares of Parent Common Stock and (ii)&#160;at the appropriate
    payment date, the amount of dividends or other distributions,
    with a record date after the Effective Time but prior to
    surrender and a payment date occurring after surrender, payable
    with respect to such whole shares of Parent Common Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;No certificates or scrip representing fractional shares
    of Parent Common Stock, or book-entry credit of the same, shall
    be issued upon the surrender for exchange of Certificates, no
    dividend or distribution with respect to Parent Common Stock
    shall be payable on or with respect to any fractional share and
    such fractional share interests shall not entitle the owner
    thereof to any rights of a stockholder of Parent. For purposes
    of this <U>Section&#160;2.2(e)</U>, all fractional shares to
    which a single holder of shares of Company Common Stock would be
    entitled shall be aggregated and calculations shall be rounded
    to the fourth decimal point. In lieu of any such fractional
    share of Parent Common Stock, each holder of Company Common
    Stock otherwise entitled to a fraction of a share of Parent
    Common Stock will be entitled to receive from the Paying Agent a
    cash payment in an amount, rounded up to the nearest cent, equal
    to the product of (i)&#160;such fractional part of a share of
    Parent Common Stock multiplied by (ii)&#160;an amount equal to
    the average of the closing sale prices for Parent Common Stock
    on NASDAQ, as reported in The Wall Street Journal, for each of
    the ten consecutive trading days ending with the seventh
    complete trading day prior to the Effective Time (the
    &#147;<U>Parent Share Cash Value</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.3&#160;&#160;<I><U>Dissenting
    Company Shares</U>.</I>&#160;&#160;Notwithstanding any provision
    of this Agreement to the contrary, shares of Company Common
    Stock which are issued and outstanding immediately prior to the
    Effective Time and which are held by holders who have properly
    exercised appraisal rights with respect thereto in accordance
    with Section&#160;262 of the DGCL (the &#147;<U>Dissenting
    Company Shares</U>&#148;) will not be converted as described in
    <U>Section&#160;2.1(a)(ii)</U>, and holders of such shares will
    be entitled to receive payment of the value of such shares
    determined in accordance with the applicable provisions of the
    DGCL. Notwithstanding the foregoing, if, after the Effective
    Time, any such holder fails to perfect or effectively withdraws
    or loses its right to appraisal and payment under the DGCL, the
    shares of Company Common Stock held by such holder that were
    Dissenting Company Shares will thereupon be treated as if they
    had been converted into, at the Effective Time, the right to
    receive the Merger Consideration, any cash in lieu of fractional
    shares payable pursuant to <U>Section&#160;2.2(e)</U> and any
    dividends or other distributions to which such holder is
    entitled pursuant to <U>Section&#160;2.2(d)</U>, without any
    interest thereon. Upon the Company&#146;s receipt of any notice
    of intent to demand payment in accordance with the provisions of
    the DGCL, or any withdrawal of such notice, and any other
    instruments served pursuant to Section&#160;262 of the DGCL and
    received by the Company, the Company shall as promptly as
    reasonably practicable provide Parent with a copy of such notice
    or instrument. The Company shall give Parent the opportunity to
    participate in and control all negotiations and proceedings with
    respect to the exercise of dissenters&#146; rights under
    Section&#160;262 of the DGCL. The Company, on the one hand, and
    Parent, prior to the Closing, on the other hand, shall not,
    except with the prior written consent of the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    other party hereto or pursuant to a court order, make any
    payment with respect to any such election to dissent or offer to
    settle or settle any such election to dissent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.4&#160;&#160;<I><U>No
    Further Ownership Rights in the Shares</U>.</I>&#160;&#160;From
    and after the Effective Time, the holders of shares of Company
    Common Stock which were outstanding immediately prior to the
    Effective Time shall cease to have any rights with respect to
    such shares except as otherwise provided in this Agreement or by
    applicable Law. All cash paid (including pursuant to
    <U>Section&#160;2.2(d)</U> or <U>Section 2.2(e)</U>) and all
    shares of Parent Common Stock and CVR Certificates issued upon
    the surrender of Certificates and Book-Entry Shares, in each
    case in accordance with the terms hereof, shall be deemed to
    have been paid and issued in full satisfaction of all rights
    pertaining to the shares of Company Common Stock represented by
    such Certificates
    <FONT style="white-space: nowrap">and/or</FONT> such
    Book-Entry Shares, as applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.5&#160;&#160;<I><U>Closing
    of Company Transfer Books</U>.</I>&#160;&#160;At the Effective
    Time, the stock transfer books of the Company shall be closed
    and no transfer of shares of Company Common Stock outstanding
    immediately prior to the Effective Time shall thereafter be
    made. If, after the Effective Time, Certificates representing
    shares of Company Common Stock outstanding immediately prior to
    the Effective Time are presented to the Surviving Corporation or
    the Paying Agent for any reason, they shall be canceled and
    exchanged as provided in this <U>ARTICLE&#160;II</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.6&#160;&#160;<I><U>Adjustments</U>.</I>&#160;&#160;If
    prior to the Effective Time there is an increase in the number
    of shares of outstanding Company Common Stock or Company Common
    Stock subject to outstanding Options or SARs (as each such term
    is defined in <U>Section&#160;2.7</U>) as a result of a
    distribution, reclassification, stock split (including a reverse
    split), stock dividend or distribution, recapitalization,
    reorganization, merger, subdivision, spin-off, issuer tender or
    exchange offer, or other similar transaction, the Cash Merger
    Consideration, the Exchange Ratio, and any other payments to
    Securityholders based upon the Merger Consideration will be
    equitably adjusted to eliminate the effects of such event on the
    Merger Consideration and such other payments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.7&#160;&#160;<I><U>Stock
    Options, RSUs, SARs</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<I><U>Options</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;At least five Business Days prior to the Closing Date,
    each holder of an outstanding option, whether vested or unvested
    (individually, an &#147;<U>Option</U>&#148; and collectively,
    the &#145;&#145;<U>Options</U>&#148;), that was granted under
    any Company stock option or equity incentive plan
    (&#147;<U>Company Stock Plan</U>&#148;) and that has an exercise
    price per share of Company Common Stock underlying such Option
    (the &#147;<U>Applicable Exercise Price</U>&#148;) that is
    greater than the Per Share Amount shall be provided with written
    notice that such holder shall, during the period beginning on
    the date of such notice and ending on the Business Day preceding
    the Closing Date (the &#145;&#145;<U>Exercise Period</U>&#148;),
    have the right to exercise such Option by providing the Company
    with a notice of exercise and a cash amount equal to
    (A)&#160;the Applicable Exercise Price, less (B)&#160;the Per
    Share Amount, with such exercise conditioned on the occurrence
    of the Effective Time. Each Option that is exercised pursuant to
    this <U>Section&#160;2.7(a)(i)</U> shall be settled at the
    Effective Time in exchange for, in respect of each share of
    Company Common Stock subject to such Option, one CVR. Any Option
    described in this <U>Section&#160;2.7(a)(i)</U> that is not
    exercised during the Exercise Period shall be cancelled at the
    Effective Time for no consideration therefor. For purposes of
    this Agreement, &#147;<U>Per Share Amount</U>&#148; means the
    sum of (x)&#160;the amount obtained by multiplying (1)&#160;the
    Exchange Ratio and (2)&#160;the Parent Share Cash Value, with
    such amount rounded up to the nearest cent, and (y)&#160;the
    Cash Consideration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;Each Option that remains outstanding immediately prior
    to the Effective Time and that has an Applicable Exercise Price
    that is equal to or less than the Per Share Amount shall be
    cancelled at the Effective Time in exchange for the right of the
    holder of such Option to receive, for each share of Company
    Common Stock subject to such Option, (A)&#160;an amount in cash,
    without interest, equal to the excess, if any, of the Per Share
    Amount over the Applicable Exercise Price, with the aggregate
    amount of such payment rounded down to the nearest cent, and
    (B)&#160;one CVR.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<I><U>SARs</U></I>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;At least five Business Days prior to the Closing Date,
    each holder of an outstanding stock appreciation right, whether
    vested or unvested (individually, a &#147;<U>SAR</U>&#148; and
    collectively, the &#145;&#145;<U>SARs</U>&#148;), that was
    granted under any Company Stock Plan and that has a base
    appreciation amount (the &#147;<U>Applicable SAR Base
    Amount</U>&#148;) that is greater than the Per Share Amount
    shall be provided with written notice that such holder shall
    have the right to exercise
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    such SAR during the Exercise Period by providing the Company
    with a notice of exercise and a cash amount equal to
    (A)&#160;the Applicable SAR Base Amount, less (B)&#160;the Per
    Share Amount, with such exercise conditioned on the occurrence
    of the Effective Time. Each SAR that is exercised pursuant to
    this <U>Section&#160;2.7(b)(i)</U> shall be settled at the
    Effective Time in exchange for one CVR. Any SAR described in
    this <U>Section&#160;2.7(b)(i)</U> that is not exercised during
    the Exercise Period shall be cancelled at the Effective Time for
    no consideration therefor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;Each SAR that remains outstanding immediately prior to
    the Effective Time and that has an Applicable SAR Base Amount
    that is equal to or less than the Per Share Amount shall be
    cancelled at the Effective Time in exchange for the right of the
    holder of such SAR to receive (A)&#160;an amount in cash,
    without interest, equal to the excess, if any, of the Per Share
    Amount over the Applicable SAR Base Amount, with the aggregate
    amount of such payment rounded up to the nearest cent, and
    (B)&#160;one CVR.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I><U>RSUs</U></I>.&#160;&#160;Each restricted stock
    unit (individually, an &#147;<U>RSU</U>&#148; and collectively,
    the &#147;<U>RSUs</U>&#148;) granted by the Company under any
    Company Stock Plan which is outstanding immediately prior to the
    Effective Time shall vest as of the Effective Time and shall be
    cancelled and converted at the Effective Time into the right to
    receive, and the holder thereof shall be entitled to receive,
    (i)&#160;cash, without interest, equal to the Per Share Amount,
    with the aggregate amount of such payment rounded up to the
    nearest cent, and (ii)&#160;one CVR.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;<I><U>Payment for Awards</U>.</I>&#160;&#160;Parent
    shall pay, or cause the Surviving Corporation to pay through its
    payroll system, to each holder of Options, SARs and RSUs the
    cash payments and CVRs subject to and in accordance with this
    <U>Section&#160;2.7</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;<I><U>Termination of Plans; Determinations by the
    Board</U></I>.&#160;&#160;Each Company Stock Plan shall
    terminate as of the Effective Time, and any other plan, program
    or arrangement providing for the issuance or grant of any
    interest in respect of the capital stock (or any interest
    convertible into or exchangeable for such capital stock) of the
    Company or any Subsidiary thereof shall be canceled as of the
    Effective Time. At or prior to the Effective Time, the
    Company&#146;s board of directors (the &#145;&#145;<U>Board of
    Directors</U>&#148;) (or a committee thereof) will
    (i)&#160;adopt amendments to, or make determinations with
    respect to, the Employee Benefit Plans (as defined in
    <U>Section&#160;3.10(a)</U>), the Company Stock Plans, and the
    individual agreements evidencing the grant of Options, SARs and
    RSUs, as necessary, to implement the provisions of this
    <U>Section&#160;2.7</U> and (ii)&#160;take such other actions as
    may be reasonably requested by Parent to implement the
    provisions of this <U>Section&#160;2.7</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.8&#160;&#160;<I><U>Withholding
    of Tax</U>.</I>&#160;&#160;Notwithstanding anything to the
    contrary in this Agreement, Parent, the Company, any Affiliate
    thereof (including the Surviving Corporation, as applicable),
    Trustee or the Paying Agent shall be entitled to deduct and
    withhold, or cause to be deducted and withheld, from amounts
    (including shares of Parent Common Stock and CVRs) otherwise
    payable pursuant to this Agreement or the Related Agreements to
    any holder of shares of Company Common Stock, Options, SARs or
    RSUs, such amounts as Parent, the Company, any Affiliate
    thereof, Trustee or the Paying Agent is required to deduct and
    withhold with respect to the making of such payment under the
    Internal Revenue Code of 1986, as amended (the
    &#147;<U>Code</U>&#148;), or any provision of state, local or
    foreign Tax Law. To the extent that amounts are so withheld by
    Parent, the Company, any Affiliate thereof, Trustee or the
    Paying Agent, such withheld amounts shall be (a)&#160;paid over
    to the applicable Governmental Entity (as defined in
    <U>Section&#160;3.3(c)</U>) in accordance with applicable Law
    and (b)&#160;treated for all purposes of this Agreement as
    having been paid to such holder in respect of which such
    deduction and withholding was made by Parent, the Company, any
    Affiliate thereof, Trustee or the Paying Agent, as the case may
    be.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;2.9&#160;&#160;</FONT><I><U>Closing</U>.</I>&#160;&#160;The
    closing of the transactions contemplated by this Agreement (the
    &#147;<U>Closing</U>&#148;) shall take place at the offices of
    Fried, Frank, Harris, Shriver&#160;&#038; Jacobson LLP, One New
    York Plaza, New York, New York 10004, at 9:00&#160;A.M. local
    time on the day which is no later than two Business Days after
    the day on which the last of the conditions set forth in
    <U>ARTICLE&#160;VII</U> (other than those that can only be
    fulfilled at the Closing, but subject to the fulfillment or
    waiver of such conditions) is fulfilled or waived, or at such
    other time and place as Parent and the Company shall agree in
    writing. The date on which the Closing is required to occur
    pursuant to the foregoing is referred to herein as the
    &#147;<U>Closing Date</U>.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;III<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">REPRESENTATIONS
    AND WARRANTIES OF THE COMPANY
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Except (i)&#160;as disclosed in the Company&#146;s Annual Report
    on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, as amended, the
    Company&#146;s Quarterly Report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarter ended March&#160;31, 2010 or any of the
    Company&#146;s Current Reports on Form&#160;8&#160;&#151; K
    dated after December&#160;31, 2009 filed by the Company with the
    SEC pursuant to the Securities Exchange Act of 1934, as amended
    (the &#147;<U>Exchange Act</U>&#148;) prior to the date of this
    Agreement but excluding any disclosures contained or referenced
    therein under the captions &#147;Risk Factors,&#148;
    &#147;Forward-Looking Statements,&#148; and &#147;Quantitative
    and Qualitative Disclosures About Market Risk&#148; and any
    other disclosures contained or referenced therein of
    information, factors or risks that are predictive, cautionary or
    forward-looking in nature, and provided that any matters
    required to be disclosed for purposes of
    <U>Section&#160;3.2(a)</U> (Capital Structure),
    <U>Section&#160;3.14</U> (Intellectual Property) and
    <U>Section&#160;3.17</U> (Material Contracts) of this Agreement
    shall be specifically disclosed in sections of the Disclosure
    Schedule pertaining thereto, or (ii)&#160;as set forth in the
    Disclosure Schedule of the Company delivered concurrent with the
    execution of this Agreement (the &#147;<U>Disclosure
    Schedule</U>&#148;) (it being understood that any information
    set forth in one section or subsection of the Disclosure
    Schedule shall be deemed to apply to and qualify the Section or
    subsection of this Agreement to which it corresponds in number
    and each other Section or subsection of this Agreement to the
    extent that it is reasonably apparent that such information is
    relevant to such other Section or subsection), the Company
    represents and warrants to Parent and Sub as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.1&#160;&#160;<I><U>Organization,
    Standing and Power</U>.</I>&#160;&#160;Each of the Company and
    its Subsidiaries (as defined in <U>Section&#160;9.12</U>) is a
    legal entity duly organized, validly existing and in good
    standing under the laws of its jurisdiction of organization and
    has all requisite corporate or similar power and authority to
    own, lease and operate its properties and assets and to carry on
    its business as presently conducted and is qualified to do
    business and is in good standing as a foreign legal entity in
    each jurisdiction where the ownership, leasing or operation of
    its assets or properties or conduct of its business requires
    this qualification, except where the failure to be so organized,
    qualified or in good standing, or to have such power or
    authority, would not reasonably be expected to have a Company
    Material Adverse Effect. For purposes of this Agreement,
    &#145;&#145;<U>Company Material Adverse Effect</U>&#148; means
    any change, effect, event, development, occurrence, condition or
    state of facts (collectively, &#147;<U>Effects</U>&#148;), that,
    in the aggregate with all other Effects, is, or would reasonably
    be expected to be, (1)&#160;materially adverse to the business,
    assets, financial condition or results of operations of the
    Company and its Subsidiaries taken as a whole, or
    (2)&#160;prevent the consummation of the Merger; provided that
    in no event shall any of the following, alone or in combination,
    be deemed to constitute, nor shall any of the following be taken
    into account in determining whether there has been, or there
    would reasonably be expected to be, a Company Material Adverse
    Effect: (a)&#160;any Effect relating to, or resulting from, any
    change or developments in or to local, regional, national or
    foreign political, economic or financial conditions or in or to
    local, regional, national or foreign credit, financial, banking
    or securities markets (including any disruption thereof),
    including any Effect caused by acts of terrorism or war or armed
    hostilities (whether or not declared), (b)&#160;any Effect
    affecting generally any of the industries, geographic areas or
    business segments in which the Company or any of its
    Subsidiaries operates, (c)&#160;any Effect relating to, or
    resulting from, any hurricane, earthquake or other natural
    disasters, (d)&#160;any change in the share price or trading
    volume (as opposed to the facts underlying such change) of the
    Company Common Stock on the Nasdaq Global Select Market of The
    NASDAQ Stock Market LLC (&#147;<U>NASDAQ</U>&#148;) (provided,
    however, that the facts and circumstances giving rise to such
    Effect that are not otherwise excluded from the definition of
    Company Material Adverse Effect may be considered for purposes
    of determining whether there has been, or would reasonably be
    expected to be, a Company Material Adverse Effect), (e)&#160;any
    Effect relating to, or resulting from, the adoption,
    implementation, promulgation, repeal, modification or proposal
    of any Law (as defined in <U>Section&#160;3.3(b)</U>) or
    U.S.&#160;generally accepted accounting principles
    (&#147;<U>U.S.&#160;GAAP</U>&#148;), after the date of this
    Agreement, (f)&#160;any failure, in and of itself (as opposed to
    the facts underlying such failure), to meet any budgets, plans,
    projections or forecasts of the Company&#146;s or its
    Subsidiaries&#146; revenue, earnings or other financial
    performance or results of operations, or any published financial
    forecasts or analyst estimates with respect to the revenue,
    earnings or other financial performance or results of operations
    of the Company or its Subsidiaries or any change in analyst
    recommendations, for any period (provided, however, that the
    facts and circumstances giving rise to such failures that are
    not otherwise excluded from the definition of Company Material
    Adverse Effect may be considered for purposes of determining
    whether there has been, or there would
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    reasonably be expected to be, a Company Material Adverse Effect
    may be considered for purposes of determining whether there has
    been, or would reasonably be expected to be, a Company Material
    Adverse Effect) or (g)&#160;any Effect directly relating to, or
    resulting from, the execution, performance or announcement of
    this Agreement or the Related Agreements (including the impact
    thereof on relationships, contractual or otherwise, with
    customers, suppliers, licensors, licensees, distributors,
    partners or employees, the loss or departure of officers or
    other employees of the Company or its Subsidiaries and any
    pending or threatened Proceeding (as defined in
    <U>Section&#160;3.7</U>) challenging this Agreement, any of the
    Related Agreements or the transactions contemplated hereby or
    thereby, or otherwise resulting from the pursuit of the
    consummation of the transactions contemplated hereby or thereby;
    except that clauses (a), (b), (c)&#160;and (e), shall not be
    applicable with respect to Effects to the extent, but only to
    the extent, that any such Effects have had, or would reasonably
    be expected to have, a disproportionate impact on the Company
    and its Subsidiaries, taken as a whole, relative to other
    participants in the industry in which the Company and its
    Subsidiaries operate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.2&#160;&#160;<I><U>Capital
    Structure</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The authorized capital stock of the Company consists of
    100,000,000&#160;shares of Company Common Stock and
    6,000,000&#160;shares of preferred stock, par value $0.001 per
    share. As of the close of business on June&#160;25, 2010,
    (i)&#160;40,403,163&#160;shares of Company Common Stock were
    issued and outstanding, (ii)&#160;no shares of preferred stock
    were outstanding, (iii)&#160;an aggregate of
    1,810,167&#160;shares of Company Common Stock were issuable upon
    exercise of then outstanding Options and SARs (whether or not
    exercisable as of such date), and (iv)&#160;939,570 RSUs were
    outstanding. In addition to the shares of Company Common Stock
    referred to in clauses (i), (iii)&#160;and (iv), as of the close
    of business on June&#160;25, 2010, 3,472,973&#160;shares of
    Company Common Stock were available for additional grants under
    the Company Stock Plans. All of the outstanding shares of
    Company Common Stock are validly issued and outstanding, fully
    paid and non assessable and free of preemptive rights. All
    shares of Company Common Stock subject to issuance under the
    Company Stock Plans, including outstanding Options, SARs and
    RSUs, will upon issuance be validly issued and outstanding,
    fully paid and non-assessable and free of preemptive rights.
    <U>Section&#160;3.2(a)</U> of the Disclosure Schedule sets forth
    an accurate and complete list of the Options and SARs
    outstanding as of June&#160;25, 2010 and the exercise or base
    prices thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Each Option and SAR was validly and properly approved
    by the Board of Directors (or a duly authorized committee or
    subcommittee thereof), was granted in compliance in all material
    respects with all applicable legal requirements and was recorded
    on the Company&#146;s financial statements in accordance with
    GAAP consistently applied, and no such grants involved any
    &#147;back dating,&#148; &#147;forward dating&#148; or similar
    practices with respect to the effective date of grant. All
    Options, SARs and RSUs are in compliance in all material
    respects with the terms of the applicable Company Stock Plan
    under which such Options, SARs and RSUs were granted. The
    Company has not granted any Options or SARs at an exercise or
    base price that represents a discount from the fair market value
    of the Company Common Stock underlying such Option or SAR on the
    date of grant and the Company has disclosed any re-pricing of
    Options or SARs in the Company Financial Statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Except as otherwise set forth in this
    <U>Section&#160;3.2</U>, as of the date of this Agreement, the
    Company has no (i)&#160;outstanding stock or securities
    convertible into or exchangeable for any shares of its equity
    securities, or any outstanding rights to subscribe for or to
    purchase any shares of its equity securities, or any outstanding
    options for the purchase thereof, (ii)&#160;any agreements
    providing for the issuance of any equity securities or any stock
    or securities convertible into or exchangeable for any equity
    securities of the Company or (iii)&#160;outstanding bonds,
    debentures, notes or other indebtedness having the right to vote
    (or convertible into or exchangeable for securities having the
    right to vote) on any matters on which stockholders of the
    Company may vote. The Company is not subject to any obligation
    to repurchase or otherwise acquire any shares of its equity
    securities or any convertible securities, rights or options of
    the type described in the preceding sentence (other than the
    acquisition of Company Common Stock, Options, SARs or RSUs upon
    the exercise, settlement or forfeiture thereof). From
    June&#160;25, 2010 to the date of this Agreement, the Company
    has not (i)&#160;issued any shares of Company Common Stock
    except in connection with the conversion, exercise or settlement
    of any Options or RSUs or (ii)&#160;issued or granted any
    options, warrants or securities convertible into or exercisable
    for shares of its Company Common Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;All of the outstanding shares of capital stock or other
    equity securities of each Subsidiary of the Company are validly
    issued, fully paid, nonassessable and free of preemptive rights
    and are owned directly or indirectly by the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Company free and clear of any pledges, liens, charges,
    mortgages, encumbrances and securities interests
    (&#147;<U>Liens</U>&#148;) (other than Liens arising by
    operation of Law, under securities Laws or under the
    organizational documents applicable to such Subsidiary of the
    Company). There are no subscriptions, options, warrants, rights,
    calls, contracts, voting trusts, proxies or other arrangements
    to which the Company or any of its Subsidiaries is a party
    (other than with the Company or any of its Subsidiaries)
    relating to the issuance, sale, voting, transfer, ownership or
    other rights with respect to any shares of capital stock or
    other equity securities of any Subsidiary of the Company,
    including any right of conversion or exchange under any
    outstanding securities, instrument or agreement.
    <U>Section&#160;3.2(d)</U> of the Disclosure Schedule sets
    forth, as of the date of this Agreement, (i)&#160;for each
    Subsidiary of the Company, the name of such Subsidiary, together
    with the jurisdiction of organization or incorporation, as the
    case may be, of such Subsidiary and (ii)&#160;for each
    Subsidiary of the Company that is not wholly-owned by the
    Company, the percentage of equity of such Subsidiary owned by
    the Company or any of its Subsidiaries. No Subsidiary of the
    Company owns any share of capital stock or other equity security
    of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.3&#160;&#160;<I><U>Authority;
    Non-Contravention</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Company has the requisite corporate power and
    authority to enter into this Agreement and, subject to approval
    of this Agreement by the stockholders of the Company, to
    consummate the Merger and the transactions contemplated by this
    Agreement. The execution and delivery of this Agreement by the
    Company and the consummation by the Company of the Merger and
    the transactions contemplated by this Agreement have been duly
    authorized by all necessary corporate action on the part of the
    Company, subject only to the receipt of the Stockholder
    Approval. The only vote of the stockholders of the Company
    necessary to approve this Agreement, the Related Agreements, and
    the transactions contemplated by this Agreement and the Related
    Agreements is the Stockholder Approval. The Company has duly
    executed and delivered this Agreement and (assuming the valid
    authorization, execution and delivery of this Agreement by
    Parent and Sub, as applicable) this Agreement constitutes a
    valid and binding obligation of the Company, enforceable against
    the Company in accordance with its terms, subject to bankruptcy,
    insolvency, fraudulent transfer, reorganization, moratorium and
    similar Laws of general applicability relating to or affecting
    creditors&#146; rights and general equity principles. The Board
    of Directors has unanimously determined that the transactions
    contemplated by this Agreement, including the Merger, and the
    Related Agreements, are advisable and fair to, and in the best
    interest of, the Company and its stockholders, adopted this
    Agreement, approved the execution of this Agreement, approved
    and declared advisable the Merger, and resolved to recommend
    adoption of this Agreement by the holders of shares of Company
    Common Stock (subject to its right to change its recommendation
    in accordance with this Agreement).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The execution and delivery of this Agreement
    <FONT style="white-space: nowrap">and/or</FONT> any
    of the Related Agreements does not, and the consummation of the
    Merger and compliance with the provisions hereof and thereof
    will not, (i)&#160;conflict with, or result in any violation of,
    the certificate of incorporation or by-laws of the Company,
    (ii)&#160;conflict with, or result in any violation of
    organizational documents of any of the Subsidiaries of the
    Company, (iii)&#160;result in any violation or breach of, or
    default (with or without notice or lapse of time, or both)
    under, or give rise to a right of termination, cancellation or
    acceleration of any obligation, or result in the creation of any
    Lien upon any of the properties or assets of the Company or any
    of its Subsidiaries under, or impair the Company&#146;s or any
    of its Subsidiaries&#146; rights under, or alter the rights of a
    third party under, any provision of any agreement, note, bond,
    mortgage, indenture, lease or other contractual obligation
    (each, a &#145;&#145;<U>Contract</U>&#148;) binding on the
    Company or any of its Subsidiaries or any of their properties or
    assets (each, a &#147;<U>Company Contract</U>&#148;), except for
    any such violation, breach, default or right of termination,
    cancellation or acceleration or Lien as to which requisite
    waivers or consents have been obtained or (iv)&#160;assuming
    that the Registrations and Consents set forth in
    <U>Section&#160;3.3(c)</U> are duly and timely made or obtained
    and that Stockholder Approval (as defined in
    <U>Section&#160;7.1(a)</U>) has been duly obtained, violate any
    foreign, federal, state, local or municipal laws, rules,
    judgments orders, regulations, statutes, ordinances, codes,
    decisions, injunctions, orders, decrees or requirements of any
    Governmental Entity (each a &#145;&#145;<U>Law</U>&#148;)
    applicable to the Company or any of its Subsidiaries or their
    properties or assets, other than, in the case of
    clauses&#160;(iii) or (iv), any such conflict, violation,
    default, termination, cancellation, acceleration or Lien that
    would not reasonably be expected to have, individually or in the
    aggregate, a Company Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;No registration or filing with (each, a
    &#147;<U>Registration</U>&#148;) or clearance, authorization,
    consent or approval (each, a &#147;<U>Consent</U>&#148;) of any
    domestic (federal or state), or foreign court, commission,
    governmental body, regulatory or administrative agency or other
    political subdivision thereof (each, a &#147;<U>Governmental
    Entity</U>&#148;) is required on the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    part of the Company or any of its Subsidiaries in connection
    with the execution and delivery of this Agreement, the Related
    Agreements by the Company or the consummation by the Company of
    the Merger or by the Company of the other transactions
    contemplated hereby or thereby, except for (i)&#160;compliance
    with and filings under the
    <FONT style="white-space: nowrap">Hart-Scott-Rodino</FONT>
    Antitrust Improvements Act of 1976, as amended (the &#147;<U>HSR
    Act</U>&#148;), (ii)&#160;compliance with the provisions of the
    Exchange Act and the rules of any national securities exchange,
    (iii)&#160;the filing of the Certificate of Merger with the
    Secretary of State of the State of Delaware and appropriate
    documents with the relevant authorities of other states in which
    the Company or any of its Subsidiaries is qualified to do
    business, (iv)&#160;such as may be required in connection with
    the Taxes described in <U>Section&#160;6.11</U>&#160;and
    (v)&#160;such other Consents or Registrations the failure of
    which to be obtained or made would not reasonably be expected to
    have, individually or in the aggregate, a Company Material
    Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.4&#160;&#160;<I><U>SEC
    Documents</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Since January&#160;1, 2008, the Company has filed with,
    or furnished to, the Securities and Exchange Commission (the
    &#147;<U>SEC</U>&#148;) all documents required to be filed or
    furnished by the Company under the Securities Act or the
    Exchange Act (collectively, the &#147;<U>Company SEC
    Documents</U>&#148;). None of the Subsidiaries of the Company
    is, or has at any time been, subject to the reporting
    requirements of Sections&#160;13(a) and 15(d) of the Exchange
    Act. As of their respective dates, the Company SEC Documents
    complied in all material respects with the requirements of the
    Securities Act or the Exchange Act, as the case may be, and as
    of their respective dates and except as amended or supplemented
    prior to the date hereof (or with respect to Company SEC
    Documents filed or furnished after the date hereof, except as
    amended or supplemented prior to the Closing Date), none of the
    Company SEC Documents contained any untrue statement of a
    material fact or omitted to state a material fact required to be
    stated therein or necessary in order to make the statements
    therein, in light of the circumstances under which they were
    made, not misleading, except that no representation is made by
    the Company with respect to information supplied by Parent, Sub
    or their respective Subsidiaries in writing for inclusion in the
    Proxy Statement/Prospectus. Each of the consolidated financial
    statements of the Company (including, in each case, any notes
    thereto) included in the Company SEC Documents (collectively,
    the &#147;<U>Company Financial Statements</U>&#148;) have been
    prepared in accordance with U.S.&#160;GAAP applied on a
    consistent basis during the periods involved (except as may be
    indicated therein or in the notes thereto) and fairly present in
    all material respects the financial position of the Company and
    its consolidated Subsidiaries as at the dates thereof and the
    results of their operations and cash flows for the periods then
    ended (subject, in the case of unaudited statements, to normal
    year-end audit adjustments and to any other adjustments set
    forth therein). As of the date of this Agreement, neither the
    Company nor any of its Subsidiaries has any pending or
    unresolved comments from the SEC or any other Governmental
    Entity with respect to any of the Company SEC Documents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;To the Knowledge of the Company, neither the Company
    nor any of its Subsidiaries has any liability or obligation of
    any nature (whether accrued, absolute, contingent or otherwise),
    except for liabilities, obligations or contingencies which
    (i)&#160;are reflected, or for which reserves are established,
    on the consolidated balance sheet of the Company as of
    March&#160;31, 2010, (ii)&#160;were incurred in the ordinary
    course of business since March&#160;31, 2010, (iii)&#160;would
    not reasonably be expected to have, individually or in the
    aggregate, a Company Material Adverse Effect or (iv)&#160;have
    been incurred in connection with the performance by the Company
    of its obligations under this Agreement or the transactions
    contemplated hereby. As of the date of this Agreement, neither
    the Company nor any of its Subsidiaries has any indebtedness for
    borrowed money or has guaranteed indebtedness for borrowed money
    of another Person (other than the Company or a wholly owned
    Subsidiary of the Company).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Each of the principal executive officer and the
    principal financial officer of the Company (or each former
    principal executive officer and each former principal financial
    officer of the Company, as applicable) has made the
    certifications required by
    <FONT style="white-space: nowrap">Rules&#160;13a-14</FONT>
    and <FONT style="white-space: nowrap">15d-14</FONT>
    promulgated under the Exchange Act or Sections&#160;302 and 906
    of the Sarbanes-Oxley Act of 2002 and the related rules and
    regulations promulgated thereunder (the &#147;<U>Sarbanes-Oxley
    Act</U>&#148;) with respect to the Company SEC Documents. For
    purposes of the preceding sentence, &#147;principal executive
    officer&#148; and &#147;principal financial officer&#148; have
    the meanings ascribed to those terms under the Sarbanes-Oxley
    Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;To the Knowledge of the Company, since January&#160;1,
    2008 and prior to the date of this Agreement, none of the
    Company, any of its Subsidiaries or any director, officer,
    auditor, accountant or representative of the Company or any of
    its Subsidiaries has received any substantive complaint,
    allegation, assertion or claim, whether written or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    oral, that the Company or any of its Subsidiaries has engaged in
    questionable accounting or auditing practices. No current or
    former attorney representing the Company or any of its
    Subsidiaries has reported evidence of a material violation of
    securities Laws, breach of fiduciary duty or similar violation
    by the Company or any of its Subsidiaries, or any of their
    respective officers, directors, employees or agents, to the
    current Board of Directors or any committee thereof or to any
    current director or executive officer of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;The Company and its Subsidiaries have designed and
    maintain internal controls over financial reporting (as defined
    in
    <FONT style="white-space: nowrap">Rules&#160;13a-15(f)</FONT>
    and
    <FONT style="white-space: nowrap">15d-15(f)</FONT>
    promulgated under the Exchange Act) to provide reasonable
    assurances (i)&#160;regarding the reliability of the
    Company&#146;s financial reporting and the preparation of
    financial statements for external purposes in accordance with
    U.S.&#160;GAAP (ii)&#160;that receipts and expenditures of the
    Company and its Subsidiaries are being made only in accordance
    with the authorization of management and directors of the
    Company and such Subsidiaries and (iii)&#160;regarding
    prevention or timely detection of the unauthorized acquisition,
    use or disposition of the Company&#146;s or its
    Subsidiaries&#146; assets that could have a material effect on
    the Company&#146;s financial statements. The Company has
    designed and maintains disclosure controls and procedures (as
    defined in
    <FONT style="white-space: nowrap">Rules&#160;13a-15(e)</FONT>
    and
    <FONT style="white-space: nowrap">15d-15(e)</FONT>
    promulgated under the Exchange Act) to ensure that material
    information required to be disclosed by the Company in the
    reports that the Company files or submits under the Exchange Act
    is recorded, processed, summarized and reported within the time
    periods specified in the SEC&#146;s rules and forms and is
    accumulated and communicated to the Company&#146;s management as
    appropriate to allow timely decisions regarding required
    disclosure and to make the certifications of the principal
    executive officer and principal financial officer of the Company
    required under the Exchange Act with respect to such reports.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;Neither the Company nor any of its Subsidiaries is a
    party to, or has any commitment to become a party to, any joint
    venture, off balance sheet partnership or any similar Company
    Contract (including any Company Contract or arrangement relating
    to any transaction or relationship between or among the Company
    and any of its Subsidiaries, on the one hand, and any
    unconsolidated affiliate, including any structured finance,
    special purpose or limited purpose entity or person, on the
    other hand, or any &#147;off balance sheet arrangements&#148;
    (as defined in Item&#160;303(a) of
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    under the Exchange Act)), where the result, purpose or intended
    effect of such Company Contract is to avoid disclosure of any
    material transaction involving, or material liabilities of, the
    Company or any of its Subsidiaries in the Company&#146;s or such
    Subsidiary&#146;s published financial statements or other
    Company SEC Documents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;Since January&#160;1, 2009, the Company has not
    received any oral or written notification of any &#147;material
    weakness&#148; in the Company&#146;s internal control over
    financial reporting. There is no outstanding &#147;significant
    deficiency&#148; or &#147;material weakness&#148; that the
    Company&#146;s independent accountants certify has not been
    appropriately and adequately remedied by the Company. For
    purposes of this Agreement, the terms &#147;significant
    deficiency&#148; and &#147;material weakness&#148; shall have
    the meanings assigned to them in Release
    <FONT style="white-space: nowrap">No.&#160;2007-005</FONT>
    of the Public Company Accounting Oversight Board, as in effect
    on the date hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.5&#160;&#160;<I><U>Proxy
    Statement/Prospectus and Registration
    Statement</U>.</I>&#160;&#160;None of the information supplied
    or to be supplied by the Company for inclusion or incorporation
    by reference in the Registration Statement or the Proxy
    Statement/Prospectus, at the time the Registration Statement
    becomes effective under the Securities Act, at the time the
    Proxy Statement/Prospectus is mailed to stockholders of the
    Company and at the time of the Company Stockholders Meeting,
    will contain any untrue statement of a material fact or omit to
    state any material fact required to be stated therein or
    necessary in order to make the statements therein, in light of
    the circumstances under which they are made, not misleading,
    except that no representation is made by the Company with
    respect to information supplied by Parent or Sub in writing
    expressly for inclusion in any of such documents. The Proxy
    Statement/Prospectus and the Registration Statement shall each
    comply in all material respects with the requirements of the
    Securities Act and the Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.6&#160;&#160;<I><U>Absence
    of Certain Events</U>.</I>&#160;&#160;From March&#160;31, 2010
    to the date of this Agreement, (i)&#160;the Company and its
    Subsidiaries have conducted their operations in all material
    respects in the ordinary course of business, (ii)&#160;there has
    not occurred any Effect that, individually or in the aggregate
    with all other Effects, has had, or would reasonably be expected
    to have, a Company Material Adverse Effect, and (iii)&#160;there
    has not been any action taken by the Company or any of its
    Subsidiaries that, if taken after the date of this Agreement,
    would constitute a breach of <U>Section&#160;5.1(a)</U>,
    <U>(c</U>), <U>(d</U>), <U>(e</U>), <U>(f</U>), <U>(g</U>),
    <U>(h</U>), <U>(k</U>), <U>(l</U>), <U>(o</U>), <U>(p</U>),
    <U>(q)</U> or <U>(r</U>).
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.7&#160;&#160;<I><U>Litigation</U>.</I>&#160;&#160;There
    is no material suit, action, arbitration, proceeding, claim,
    charge, regulatory or accrediting agency investigation or other
    proceeding (each, a &#145;&#145;<U>Proceeding</U>&#148;) pending
    or, to the Knowledge of the Company (as defined in
    <U>Section&#160;9.14</U>), threatened against the Company or any
    of its Subsidiaries or any property or asset of the Company or
    any of its Subsidiaries. None of the Company or any of its
    Subsidiaries is subject to any writ, judgment, settlement
    agreement, injunction or decree that would reasonably be
    expected to have, individually or in the aggregate, a Company
    Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.8&#160;&#160;<I><U>No
    Violation of Law</U>.</I>&#160;&#160;Neither the Company nor any
    of its Subsidiaries is or since January&#160;1, 2008 has been in
    material violation of any Law. To the Knowledge of the Company,
    no material investigation or review by any Governmental Entity
    is pending or threatened against the Company or any of its
    Subsidiaries. The Company and its Subsidiaries have all material
    permits, licenses, franchises, variances, exemptions, orders and
    other governmental authorizations, consents and approvals
    necessary to conduct its businesses in all material respects as
    presently conducted (collectively, the &#147;<U>Company
    Permits</U>&#148;). None of the Company or any of its
    Subsidiaries is in violation of the terms of any Company Permit,
    except for delays in filing reports or violations which would
    not reasonably be expected to have, individually or in the
    aggregate, a Company Material Adverse Effect. This
    <U>Section&#160;3.8</U> does not relate to matters which are the
    subject of <U>Section&#160;3.10</U> or <U>Section&#160;3.12</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.9&#160;&#160;<I><U>Taxes</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Except as would not be material to the Company,
    (i)&#160;the Company and its Subsidiaries have timely filed or
    have had timely filed on their behalf (taking into account
    extensions of time to file) all Tax Returns required to be filed
    by them, and such Tax Returns are correct and complete in all
    respects, (ii)&#160;the Company and its Subsidiaries have paid
    (or have had paid on their behalf) all Taxes due and payable
    with respect to such Tax Returns, except with respect to Taxes
    for which adequate reserves have been established in accordance
    with U.S.&#160;GAAP on the most recent financial statements of
    the Company or its Subsidiaries, (iii)&#160;the Company and its
    Subsidiaries have withheld or collected, and have paid over to
    the appropriate Governmental Entities (or are properly holding
    for such payment), all Taxes required to be withheld or
    collected, (iv)&#160;neither the Company nor any of its
    Subsidiaries has received any written notice of any pending or
    ongoing audit, investigation, assessment, deficiency, or claim
    with respect to Taxes (including any Taxes described in clause
    (viii)(B) of this <U>Section&#160;3.9(a)</U>) which remains
    unresolved, (v)&#160;there are no Liens on any of the assets of
    the Company or any of its Subsidiaries that arose in connection
    with any failure or alleged failure to pay Taxes (other than
    Taxes not yet due and payable, or Taxes for which adequate
    reserves have been established in accordance with U.S.&#160;GAAP
    on the most recent financial statements of the Company or its
    Subsidiaries), (vi)&#160;neither the Company nor any of its
    Subsidiaries has incurred any liability for Taxes subsequent to
    the date of its most recent respective financial statements
    other than in the ordinary course of business, (vii)&#160;no
    written claim has been received by the Company or its
    Subsidiaries from any Governmental Entity in a jurisdiction
    where the Company or any of its Subsidiaries does not file Tax
    Returns that the Company or any of its Subsidiaries is or may be
    subject to taxation in that jurisdiction, (viii)&#160;with the
    exception of the affiliated group of which the Company is the
    parent within the meaning of Section&#160;1504 of the Code,
    neither the Company nor any of its Subsidiaries (A)&#160;is or
    has ever been a member of an affiliated group filing a
    consolidated federal income Tax Return or (B)&#160;has any
    liability for the Taxes of any Person (other than the Company
    and its Subsidiaries) under
    <FONT style="white-space: nowrap">Section&#160;1.1502-6</FONT>
    of the Treasury Regulations (or any similar provision of Law),
    as a transferee or successor, by contract, or otherwise,
    (ix)&#160;neither the Company nor any of its Subsidiaries is a
    party to, has participated in, or is currently participating in,
    a &#147;tax shelter&#148; or &#147;listed transaction&#148; as
    defined in Section&#160;6111 of the Code or a &#147;reportable
    transaction&#148; within the meaning of
    <FONT style="white-space: nowrap">Section&#160;1.6011-4(b)</FONT>
    of the Treasury Regulations or any transaction requiring
    disclosure under a corresponding or similar provision of state,
    local or foreign Law, (x)&#160;neither the Company nor any of
    its Subsidiaries will be required to include any item of income
    in, or exclude any item of deduction from, taxable income for
    any taxable period (or portion thereof) ending after the
    Effective Time as a result of any (A)&#160;change in the method
    of accounting for a taxable period ending on or prior to the
    Effective Time, (B)&#160;&#147;closing agreement&#148; as
    described in Section&#160;7121 of the Code (or any corresponding
    or similar provision of state, local or foreign Tax Law)
    executed prior to the Effective Time, (C)&#160;installment sale
    or open transaction disposition made prior to the Effective
    Time, or (D)&#160;prepaid amount received prior to the Effective
    Time, and (xi)&#160;the Company is not now, nor has it ever
    been, a &#147;United States real property holding
    corporation&#148; within the meaning of Section&#160;897(c)(2)
    of the Code during the applicable period specified in
    Section&#160;897(c)(1)(A)(ii) of the Code.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Neither the Company nor any of its Subsidiaries is a
    party to any agreement providing for the allocation or sharing
    of Taxes with any entity (other than the Company or any of its
    Subsidiaries).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Without regard to the execution of this Agreement and
    the consummation of the transactions contemplated by this
    Agreement and the Related Agreements, the 2007 Spin-Off
    qualified for nonrecognition treatment under
    Sections&#160;355(a) and 361(c) of the Code. The Company has not
    constituted either a &#147;distributing corporation&#148; or a
    &#147;controlled corporation&#148; (within the meaning of
    Section&#160;355 or Section&#160;361 of the Code) in a
    distribution of stock purported to or intended to be governed by
    Section&#160;355 or Section&#160;361 of the Code in any
    transaction other than the 2007 Spin-Off. Neither the Company or
    its Subsidiaries, nor any of their respective stockholders, has
    received, as a result of its rights under Section&#160;3.01 of
    the 2007 Tax Allocation Agreement or otherwise, any notice of,
    or is otherwise aware of, any pending or ongoing audit,
    investigation, review, assessment, deficiency, or claim with
    respect to Taxes related to the qualification of the 2007
    Spin-Off for nonrecognition treatment under Sections&#160;355(a)
    and 361(c) of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Neither the Company nor any of its Subsidiaries has any
    deferred intercompany gain, excess loss account or gain
    recognition agreement in effect under any applicable U.S.,
    state, local or foreign Tax Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;None of the Tax Returns of the Company or any of its
    Subsidiaries contains any position that is, or would be, subject
    to material penalties under Section&#160;6662 of the Code (or
    any corresponding provisions of state, local, or foreign Tax
    Law).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;For purposes of this Agreement: &#147;<U>Tax</U>&#148;
    means any federal, state, local or foreign income, profits,
    gross receipts, license, payroll, employment, severance, stamp,
    occupation, premium, windfall profits, environmental, customs
    duty, capital stock, franchise, sales, social security,
    unemployment, disability, use, property, withholding, excise,
    transfer, registration, production, value added, alternative
    minimum, occupancy, estimated or any other tax of any kind
    whatsoever, together with any interest, penalty or addition
    thereto, imposed by any Governmental Entity responsible for the
    imposition of any such tax, whether disputed or not;
    &#147;<U>Tax Return</U>&#148; means any return, report,
    declaration, claim or other statement (including attached
    schedules) relating to Taxes; &#147;<U>2007 Tax Allocation
    Agreement</U>&#148; means that certain Tax Allocation Agreement
    entered into by the Company, APP Pharmaceuticals, Inc., APP
    Pharmaceuticals, LLC and Abraxis BioScience, LLC and dated
    November&#160;13, 2007; &#147;<U>2007 Separation and
    Distribution Agreement</U>&#148; means that certain Separation
    and Distribution Agreement entered into by the Company, APP
    Pharmaceuticals, Inc., APP Pharmaceuticals, LLC and Abraxis
    BioScience, LLC and dated November&#160;13, 2007; and
    &#147;<U>2007 Spin-Off</U>&#148; means the distribution by APP
    Pharmaceuticals, Inc. to its stockholders, on November&#160;13,
    2007, of all of the then-issued and outstanding shares of common
    stock of the Company pursuant to the 2007 Separation and
    Distribution Agreement, and the transactions entered into
    therewith.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.10&#160;&#160;<I><U>Employee
    Benefit Plans; ERISA</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<U>Section&#160;3.10(a)</U> of the Disclosure Schedule
    includes a complete list as of the date of this Agreement of
    (i)&#160;each material employee benefit plan, program or policy
    providing benefits to any current or former employee, officer,
    director, independent contractor or consultant of the Company or
    its Subsidiaries, or any beneficiary or dependent thereof, that
    is sponsored or maintained by the Company or any of its
    Subsidiaries or any trade or business (whether or not
    incorporated) under common control with the Company or any of
    its Subsidiaries and which, together with the Company or any of
    its Subsidiaries, is treated as a single employer within the
    meaning of Section&#160;414(b), (c), (m)&#160;or (o)&#160;of the
    Code (an &#147;<U>ERISA Affiliate</U>&#148;) or with respect to
    which the Company or any of its Subsidiaries or ERISA Affiliates
    has any current or potential material liability, including any
    employee welfare benefit plan within the meaning of
    Section&#160;3(1) of the Employee Retirement Income Security Act
    of 1974, as amended (&#147;<U>ERISA</U>&#148;), any employee
    pension benefit plan within the meaning of Section&#160;3(2) of
    ERISA (whether or not such plan is subject to ERISA) and any
    material bonus, incentive, deferred compensation, vacation,
    stock purchase, stock option, severance, employment, change of
    control or fringe benefit plan, program or policy (collectively,
    the &#147;<U>Employee Benefit Plans</U>&#148;) (but excluding,
    for all purposes of this Agreement other than
    <U>Section&#160;6.6</U> and <U>Section&#160;3.10(h)</U> hereof,
    any Employee Benefit Plan that is primarily subject to the Laws
    of any jurisdiction outside of the United States),
    (ii)&#160;each employment and severance agreement pursuant to
    which the Company or any of its Subsidiaries has or would have
    any obligation to provide compensation
    <FONT style="white-space: nowrap">and/or</FONT>
    benefits in an amount or having a value reasonably likely to be
    in excess of $200,000 per year or $500,000 in the aggregate; and
    (iii)&#160;any agreement which prohibits the Company or any of
    its Subsidiaries from terminating the employment of any
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    employee on an at-will basis (which means that their employment
    cannot be terminated at any time, with or without notice, for
    any reason or no reason at all
    <FONT style="white-space: nowrap">and/or</FONT> they
    have been granted the right to continued employment by the
    Company, its Subsidiaries, or any successor) (each agreement
    referenced in (ii)&#160;and (iii), a &#147;<U>Material
    Employment Agreement</U>&#148;). As of the date of this
    Agreement, neither the Company nor any of its Subsidiaries has
    agreed or committed to institute any material plan, program,
    arrangement or agreement for the benefit of employees or former
    employees of the Company or its Subsidiaries other than the
    Employee Benefit Plans or Material Employment Agreements or to
    make any amendments to any of the Employee Benefit Plans or
    Material Employment Agreements, and the Company
    <FONT style="white-space: nowrap">and/or</FONT> its
    Subsidiaries, as applicable, have reserved all rights necessary
    to amend or terminate each Employee Benefit Plan with regard to
    their respective service providers without the consent of any
    other person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;With respect to each Employee Benefit Plan, the Company
    has delivered or made available to Parent a true, correct and
    complete copy of: (i)&#160;all plan documents and trust
    agreements; (ii)&#160;the most recent Annual Report
    (Form&#160;5500 Series) and accompanying schedule, if any;
    (iii)&#160;the current summary plan description, if any;
    (iv)&#160;the most recent annual financial report, if any;
    (v)&#160;the most recent actuarial report, if any; and
    (vi)&#160;the most recent determination letter from the Internal
    Revenue Service (&#147;<U>IRS</U>&#148;), if any. The Company
    has delivered or made available to Parent a true, correct and
    complete copy of each Material Employment Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;The Company has an IRS determination letter or opinion
    letter with respect to each Employee Benefit Plan that is
    intended to be a &#147;qualified plan&#148; within the meaning
    of Section&#160;401(a) of the Code, and the trust maintained
    pursuant thereto has been determined to be so qualified and
    exempt from federal income taxation under Section&#160;501 of
    the Code by the IRS, and to the Knowledge of the Company,
    nothing has occurred with respect to the operation of any such
    Employee Benefit Plan that would reasonably be expected to cause
    the loss of such qualification or exemption from Tax that cannot
    be corrected without material liability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Except as would not, individually or in the aggregate,
    reasonably be expected to have a Company Material Adverse Effect
    (i)&#160;each Employee Benefit Plan and each Material Employment
    Agreement has been administered in accordance with its terms and
    the applicable provisions of ERISA, the Code and other
    applicable Laws and (ii)&#160;neither the Company nor any of its
    Subsidiaries has engaged in any &#147;prohibited
    transaction&#148; (as defined in Section&#160;4975 of the Code
    or Section&#160;406 of ERISA) with respect to any Employee
    Benefit Plan which could subject the Company or any of its
    Subsidiaries to any tax or penalty imposed under
    Section&#160;4975 of the Code or Section&#160;502 of ERISA, and
    no Proceeding has been brought, or to the Knowledge of the
    Company is threatened, against or with respect to any such
    Employee Benefit Plan, including any audit or inquiry by the IRS
    or United States Department of Labor (other than routine
    benefits claims).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Except as set forth in <U>Section&#160;3.10(e)</U> of
    the Disclosure Schedule, neither the execution and delivery of
    this Agreement nor the consummation of the transactions
    contemplated hereby will (either alone or in conjunction with
    any other event) (i)&#160;constitute an event under an Employee
    Benefit Plan or a Material Employment Agreement that will result
    in, cause the accelerated vesting, funding or delivery of, or
    increase the amount or value of, any material payment or benefit
    to any employee, officer or director of the Company or any of
    its Subsidiaries or (ii)&#160;could reasonably be expected to
    cause any material amount to fail to be deductible under
    Section&#160;280G of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;Neither the Company nor any Subsidiary or ERISA
    Affiliate has ever (i)&#160;maintained an Employee Benefit Plan
    or any other plan, program or arrangement that (A)&#160;was
    subject to Section&#160;412 of the Code or Title&#160;IV of
    ERISA, (B)&#160;is a &#147;multiple employer plan&#148; (as
    defined in Section&#160;210(a) of ERISA), or had any liability
    with respect to such a plan, program or arrangement or
    (C)&#160;is funded through or maintained by a &#147;voluntary
    employees&#146; beneficiary association&#148; within the meaning
    of Section&#160;501(c)(9) of the Code, or a &#147;welfare
    benefit fund&#148; as defined in Section&#160;419(e) of the Code
    or a supplemental unemployment benefit plan within the meaning
    of Section&#160;501(c)(17) of the Code or (ii)&#160;been
    obligated to contribute to a &#147;multiemployer plan&#148; (as
    defined in Section&#160;4001(a)(3) of ERISA).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;Except as required by Law or as provided in a Material
    Employment Agreement, upon a severance event, no Employee
    Benefit Plan provides any retiree or post-employment health,
    disability, life insurance or other welfare benefits (whether or
    not insured) to any Person.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;The term &#147;<U>Foreign Plan</U>&#148; shall mean any
    Employee Benefit Plan or Material Employment Contract that is
    maintained pursuant to the laws of any country other than the
    United States. Each Foreign Plan complies with all applicable
    Law (including applicable Law regarding the form, funding and
    operation of the Foreign Plan) in all material respects. The
    Company Financial Statements accurately reflect the material
    Foreign Plan liabilities and accruals for contributions required
    to be paid to the Foreign Plans, in accordance with applicable
    generally accepted accounting principles consistently applied.
    All material contributions required to have been made to all
    Foreign Plans as of the Closing will have been made as of the
    Closing. There are no material actions, suits or claims pending
    or, to the Knowledge of the Company, threatened with respect to
    the Foreign Plans (other than routine claims for benefits).
    There have not occurred, nor are there continuing any
    transactions or breaches of fiduciary duty under applicable Law
    with respect to any Foreign Plan which would reasonably be
    expected to have, individually or in the aggregate, a Company
    Material Adverse Effect. With respect to each Foreign Plan,
    there are (A)&#160;no pending material investigations by any
    Governmental Entity, (B)&#160;no material claims pending or, to
    the Knowledge of the Company, threatened in writing (except for
    claims for benefits payable in the normal operation of such
    plan) and (C)&#160;no material suits or proceedings against such
    plan or asserting any rights or claims to benefits under such
    plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.11&#160;&#160;<I><U>Employment
    Matters</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Neither the Company nor any of its Subsidiaries is a
    party to any collective bargaining agreement or any other
    labor-related agreement with any labor union, labor organization
    or works council. As of the date of this Agreement, (i)&#160;no
    such agreement is presently being negotiated by the Company or
    any of its Subsidiaries, (ii)&#160;no labor union, labor
    organization or works council has made a pending demand of the
    Company or any of its Subsidiaries for recognition or
    certification, (iii)&#160;there are no representation or
    certification proceedings or petitions seeking a representation
    proceeding with respect to the Company or any of its
    Subsidiaries presently pending or, to the Knowledge of the
    Company, threatened in writing to be brought or filed with the
    National Labor Relations Board or any other labor relations
    tribunal or authority, (iv)&#160;to the Knowledge of Company,
    there are no labor union organizing activities with respect to
    any employees of the Company or its Subsidiaries and
    (v)&#160;there are no threatened, labor strikes, slowdowns, work
    stoppages, lockouts, or any similar activity, by employees of
    the Company or its Subsidiaries. None of the Company or any of
    its Subsidiaries has experienced any strike, lockout or work
    stoppage or other material labor difficulty involving its
    employees since January&#160;1, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Company and its Subsidiaries are in compliance in
    all material respects with all Laws respecting employment and
    employment practices, harassment, discrimination, retaliation,
    terms and conditions of employment, immigration, workers&#146;
    compensation, long term disability, occupational safety, plant
    closings, compensation and benefits, wages and hours, proper
    classification of employees and independent contractors, and the
    payment of social security and other Taxes (&#147;<U>Employment
    Practices</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Except as indicated in <U>Section&#160;3.11(c)</U> of
    the Disclosure Schedule, (i)&#160;there are no material
    Proceedings pending or, to the Knowledge of the Company,
    threatened involving any individuals providing services as an
    employee or independent contractor to the Company
    <FONT style="white-space: nowrap">and/or</FONT> any
    of its Subsidiaries (collectively &#147;<U>Worker</U>&#148; or
    &#147;<U>Workers</U>&#148;), group of Workers, or individual and
    (ii)&#160;there are no material Proceedings relating to any
    Employment Practices pending, or to the Knowledge of the
    Company, threatened, before the Equal Employment Opportunity
    Commission, the National Labor Relations Board, the
    U.S.&#160;Department of Labor, the U.S.&#160;Occupational Health
    and Safety Administration, the Workers Compensation Appeals
    Board, or any other Governmental Authority against the Company
    or any of its Subsidiaries pertaining to any Worker, nor, to the
    Knowledge of the Company, are there any facts or circumstances
    which would reasonably be expected to give rise to such a claim
    being made.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;To the Knowledge of the Company, neither the Company
    nor any of its Subsidiaries are delinquent in any material
    payments to any current or former Worker for any wages,
    salaries, commissions, bonuses, or other compensation for any
    services performed by any current or former Worker or for any
    other amounts required to be reimbursed by the Company or any of
    its Subsidiaries to any current or former Worker (including
    vacation, sick leave, other paid time off or severance pay).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;(i)&#160;The Company and its Subsidiaries are in
    compliance in all material respects with the Worker Readjustment
    and Notification Act (the &#147;<U>WARN Act</U>&#148;)
    (29&#160;USC &#167;2101) and any applicable state laws or other
    Laws regarding redundancies, reductions in force, mass layoffs,
    and plant closings, including all obligations to promptly and
    correctly furnish all notices required to be given thereunder in
    connection with any redundancy,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    reduction in force, mass layoff, or plant closing to affected
    employees, representatives, any state dislocated worker unit and
    local government officials, or any other governmental authority,
    (ii)&#160;neither the Company nor any of its Subsidiaries have
    taken any action that would constitute a &#147;mass layoff&#148;
    or &#147;plant closing&#148; within the meaning of the WARN Act
    or would otherwise trigger notice requirements or liability
    under any other comparable state or local law in the United
    States and (iii)&#160;neither the Company nor any of its
    Subsidiaries have taken any action that resulted in the
    termination of employment of 50 or more employees or more than
    10% of the employees in any country outside of the United States
    during any 90&#160;day period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;As of the date of this Agreement, to the Knowledge of
    the Company, no employee of the Company or any of its
    Subsidiaries is in violation in any material respect of any term
    of any employment agreement, non-disclosure or confidentiality
    agreement with the Company or any of its Subsidiaries or
    non-competition agreement, non-solicitation agreement or any
    restrictive covenant with a former employer relating to the
    right of any such employee to be employed by or provide services
    to the Company or any of its Subsidiaries because of the nature
    of the business conducted or presently proposed to be conducted
    by it or to the use of trade secrets or proprietary information
    of others.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.12&#160;&#160;<I><U>Environmental
    Matters</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Except as otherwise set forth in
    <U>Section&#160;3.12</U> of the Disclosure Schedule, (i)&#160;to
    the Knowledge of the Company, the Company and its Subsidiaries
    are and have been since January&#160;1, 2008 in material
    compliance with all applicable Environmental Laws (as defined in
    <U>Section&#160;3.12(c)</U>), (ii)&#160;there are no pending or,
    to the Knowledge of the Company, threatened, material
    Proceedings under or pursuant to Environmental Laws against the
    Company or any of its Subsidiaries or, to the Knowledge of the
    Company, any other Person whose Environmental Liabilities the
    Company or any of its Subsidiaries has or may have retained or
    assumed by contract or operation of Law, or involving any real
    property currently or, to the Knowledge of the Company, formerly
    owned, operated or leased by the Company or its Subsidiaries;
    (iii)&#160;the Company and its Subsidiaries and, to the
    Knowledge of the Company, Persons whose Environmental
    Liabilities the Company or its Subsidiaries has or may have
    retained or assumed by contract or operation of Law are not
    subject to any material Environmental Liabilities; and
    (iv)&#160;to the Knowledge of the Company, there are no actions,
    activities, circumstances, conditions, events or incidents,
    including the release, threatened release or presence of any
    Hazardous Material (as defined in <U>Section&#160;3.12(c)</U>),
    which could reasonably be expected to form the basis of any such
    material Environmental Liability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Company has delivered to or otherwise made
    available for inspection by Parent true, correct and complete
    copies and results of any reports, studies, analyses, tests or
    monitoring initiated by the Company or its Subsidiaries since
    January&#160;1, 2008 pertaining to Hazardous Materials in, on,
    beneath or adjacent to any property currently or formerly owned,
    operated or leased by the Company or any of its Subsidiaries, or
    regarding the Company&#146;s or its Subsidiaries&#146;
    compliance with applicable Environmental Laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;As used herein, &#147;<U>Environmental Laws</U>&#148;
    means any and all Laws concerning pollution, Hazardous Materials
    (as defined below) or the protection of human health or safety,
    or the environment, and includes the Comprehensive Environmental
    Response, Compensation and Liability Act, 42&#160;U.S.C.
    Section&#160;9601 <I>et seq</I>., the Hazardous Materials
    Transportation Act, 49&#160;U.S.C. Section&#160;1801 <I>et
    seq</I>., the Resource Conservation and Recovery Act,
    42&#160;U.S.C. Section&#160;6901 <I>et seq</I>., the Clean Water
    Act, 33&#160;U.S.C. Section&#160;1251 <I>et seq</I>., the Clean
    Air Act, 33&#160;U.S.C. Section&#160;2601 <I>et seq</I>., the
    Toxic Substances Control Act, 15&#160;U.S.C. Section&#160;2601
    <I>et seq</I>., the Occupational Safety and Health Act,
    29&#160;U.S.C. Section&#160;651 <I>et seq</I>. (but solely as it
    relates to the exposure of Hazardous Materials) and the Oil
    Pollution Act of 1990, 33&#160;U.S.C. Section&#160;2701 <I>et
    seq</I>., as such laws have been amended or supplemented, and
    the regulations promulgated pursuant thereto, and all analogous
    state or local statutes. As used in this Agreement,
    &#147;<U>Environmental Liabilities</U>&#148; with respect to any
    Person means any and all liabilities of or relating to such
    Person (including any entity which is, in whole or in part, a
    predecessor of such Person), whether vested or unvested,
    contingent or fixed, actual or potential, known or unknown,
    which arise under or relate to the presence, release or
    threatened release of any Hazardous Materials at any location or
    which otherwise arise under or relate to matters covered or
    regulated by, or for which liability is imposed under,
    Environmental Laws, including the alleged violation of any
    Environmental Law. As used in this Agreement, &#147;<U>Hazardous
    Materials</U>&#148; means all substances defined in, regulated
    under or for which liability is imposed by Environmental Laws,
    including hazardous substances, oils, pollutants or
    contaminants, asbestos, mold, polychlorinated biphenyls and
    radioactive materials.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;The representations and warranties in this
    <U>Section&#160;3.12</U> constitute the sole representations and
    warranties of the Company in this Agreement concerning
    Environmental Laws and Hazardous Materials.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.13&#160;&#160;<I><U>Affiliate
    Transactions</U>.</I>&#160;&#160;As of the date of this
    Agreement, there are no transactions, agreements, arrangements
    or understandings between the Company or its Subsidiaries, on
    the one hand, and the Company&#146;s Affiliates (other than
    wholly-owned Subsidiaries of the Company) or other Persons on
    the other hand, that would be required to be disclosed under
    Item&#160;404 of
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    under the Securities Act. For purposes of this Agreement, the
    term &#145;&#145;<U>Affiliate</U>&#148; when used with respect
    to any Person, means any other Person directly or indirectly
    controlling, controlled by, or under common control with such
    Person. As used in the definition of Affiliate the term
    &#147;<U>control</U>&#148; means possession, directly or
    indirectly, of the power to direct or cause the direction of the
    management or policies of a Person, whether through the
    ownership of voting securities, by contract or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.14&#160;&#160;<I><U>Intellectual
    Property</U>.</I>&#160;&#160;For purposes of this Agreement,
    &#147;<U>Intellectual Property</U>&#148; means any or all of the
    following in any jurisdiction throughout the world:
    (i)&#160;patents, patent applications, provisional patent
    applications and similar instruments (including any and all
    substitutions, divisions, continuations,
    <FONT style="white-space: nowrap">continuations-in-part,</FONT>
    reissues, renewals, extensions, reexaminations, patents of
    addition, supplementary protection certificates, inventors&#146;
    certificates, pediatric data package exclusivity extensions, or
    the like) (collectively, &#145;&#145;<U>Patents</U>&#148;);
    (ii)&#160;trademarks, service marks, trade dress, trade names
    and Internet domain names (including all registrations or
    applications for any of the foregoing), together with all
    goodwill associated with each of the foregoing (collectively,
    &#147;<U>Trademarks</U>&#148;); (iii)&#160;copyrights, copyright
    registrations, and copyright applications (collectively,
    &#145;&#145;<U>Copyrights</U>&#148;); (iv)&#160;trade secrets,
    know-how and other confidential and proprietary information,
    including product specifications, manufacturing processes, batch
    records and other documentation outlining manufacturing
    processes, design of and modifications to machinery necessary
    for use in the manufacturing process, compounds, formulae, and
    inventions (&#147;<U>Trade Secrets</U>&#148;); and (v)&#160;all
    other intellectual property or proprietary rights (in each case
    whether or not subject to statutory registration or protection).
    For purposes of this Agreement,
    &#145;&#145;<U>Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Technology</U>&#148; means (A)&#160;any and all methods,
    techniques, know-how, trade secrets, and other technologies
    (including manufacturing methods, techniques, know-how, trade
    secrets, and other technologies) for the noncovalent association
    of, or related to the association of, any agent (such as a
    therapeutic or diagnostic agent) with one or more polymers such
    as carbohydrates or polypeptides (including albumin),
    (B)&#160;any product resulting therefrom, including any
    intermediate or the Product (as defined in the CVR Agreement),
    and (C)&#160;any methods of using such product;
    &#147;<U>Product</U>&#148; means the Pharmaceutical Product
    comprising the chemical compound having a chemical name of
    <FONT style="white-space: nowrap">5&#223;,20-Epoxy-1,2a,4,7&#223;,10&#223;,13a-hexahydroxytax-11-en-9-one</FONT>
    4,10-diacetate 2-benzoate 13-ester with
    (2R,3S)-N-benzoyl-3-phenylisoserine known by the generic name
    &#147;paclitaxel&#148; and bound to albumin that is in the
    subject of the New Drug Application
    <FONT style="white-space: nowrap">No.&#160;21-660</FONT>
    filed with the FDA and subject of the European Medicines Agency
    Marketing Authorization granted on January&#160;11, 2008,
    together with all amendments and supplements to such FDA and
    European Medicines Agency approvals (identified by the Company
    as ABRAXANE); &#147;<U>Pharmaceutical Products</U>&#148; means
    all biological and drug candidates, compounds or products being
    researched, developed, labeled, manufactured, tested, stored,
    used, sold, offered for sale, imported, and otherwise
    distributed or commercially exploited by the Company or any of
    its Subsidiaries; and &#145;&#145;<U>Pipeline Products</U>&#148;
    means COROXANE, nab-docetaxel (ABI-008), nab-rapamycin
    (ABI-009), nab-17AAG (ABI-010), nab-thiocolchicine dimer
    (ABI-011), and nab-novel taxane (ABI 013).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<U>Section&#160;3.14(a)</U> of the Disclosure Schedule
    sets forth a true, correct, and complete list (with owner(s),
    country(ies) or region, registration and application numbers and
    dates indicated, as applicable) of all U.S.&#160;and foreign
    (i)&#160;Patents, (ii)&#160;Trademarks that are registered or
    for which an application for registration is pending, and
    (iii)&#160;Copyrights that are registered or for which an
    application for registration is pending, in each case that is
    owned (in whole or in part) by, or licensed to, the Company or
    its Subsidiaries, in each case as directed to the Product, the
    Pipeline Products or the
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Company or its Subsidiaries owns or has a valid and
    enforceable right to use or practice the Intellectual Property
    required to be listed on <U>Section&#160;3.14(a)</U> of the
    Disclosure Schedule and the Trade Secrets used in connection
    with the
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Technology or necessary for the manufacturing of the Product and
    the Pipeline Products (collectively, the &#147;<U>Company
    Intellectual Property</U>&#148;) in all material respects. As of
    the date hereof, and to the Knowledge of the Company, no
    Proceedings are pending or threatened against the Company or its
    Subsidiaries
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    challenging in any material respect the validity,
    enforceability, use, inventorship, or ownership, or seeking to
    deny or restrict the use by the Company or its Subsidiaries of,
    the Company Intellectual Property.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;As of the date hereof, and to the Knowledge of the
    Company, (i)&#160;neither the Company nor any Subsidiary nor the
    operation of their respective businesses (including the use and
    practice of the Company Intellectual Property, the products and
    services of the Company and its Subsidiaries, and the research,
    development, labeling, manufacture, use, sale, offer for sale,
    importation, and other distribution or commercial exploitation
    of the Product, the Pipeline Products or the
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>Technology)

    infringes, dilutes, misappropriates or otherwise violates in any
    material respect the Intellectual Property of any other Person;
    and (ii)&#160;no Proceeding is pending or threatened, and no
    third party is asserting or threatening to assert, a claim of
    such infringement, dilution, misappropriation or violation
    against the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;To the Knowledge of the Company, no third party is
    infringing, diluting, misappropriating, or otherwise violating
    in any material respect any Company Intellectual Property, and
    the Company has not asserted or threatened to assert a claim of
    such infringement, dilution, misappropriation or violation
    against any third party.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;To the Knowledge of the Company, as of the date hereof,
    (i)&#160;none of the Company Intellectual Property that consists
    of Patents (the &#147;<U>Company Patents</U>&#148;) is the
    subject of any litigation, reissue, interference, reexamination,
    or opposition, (ii)&#160;the Company and its Subsidiaries have
    not received any written notice that any such proceeding will
    hereafter be commenced, (iii)&#160;the issued Company Patents
    are subsisting and have not been declared invalid
    <FONT style="white-space: nowrap">and/or</FONT>
    unenforceable, and (iv)&#160;the Company Patents have been
    prosecuted in compliance in all material respects with all
    applicable Laws. The Company Patents listed in the FDA&#146;s
    Orange Book with respect to New Drug Application
    <FONT style="white-space: nowrap">No.&#160;21-660</FONT>
    for the Product cover the Product; and U.S.&#160;Patent
    Application No.&#160;11/553,339, when issued, will be listed and
    is properly listable in the FDA&#146;s Orange Book with respect
    to such New Drug Application.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;All current and former employees of, and all
    consultants and independent contractors to, the Company and its
    Subsidiaries who have contributed in any material respect to the
    creation or development of any Company Intellectual Property
    owned by the Company or any of its Subsidiaries have executed
    and delivered to the Company or its Subsidiaries an agreement
    regarding the assignment to the Company or its Subsidiaries of
    any Intellectual Property rights arising from services performed
    for the Company or its Subsidiaries by such Persons, the current
    forms of which agreements have been made available to Parent.
    All current and former employees of, and all consultants and
    independent contractors to, the Company and its Subsidiaries,
    and all other Persons, with access to the Company&#146;s and its
    Subsidiaries&#146; Trade Secrets included in the Company
    Intellectual Property owned by the Company or any of its
    Subsidiaries are parties to written agreements under which each
    is obligated to maintain the confidentiality of such Trade
    Secrets of the Company and its Subsidiaries and not to use such
    Trade Secrets except as authorized by the Company or its
    Subsidiaries. To the Knowledge of the Company, none of such
    employees, consultants, contractors or other Persons is in
    violation in any material respect of such inventions or
    confidentiality agreements. To the Knowledge of the Company, no
    current or former employee, stockholder, consultant, contractor,
    or independent contractor of the Company or its Subsidiaries
    owns or claims any rights in (nor has any of them made
    application for) any Company Intellectual Property.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;The Company and its Subsidiaries have taken
    commercially reasonable actions to maintain and preserve the
    Company Intellectual Property, including such measures to
    protect the secrecy and confidentiality of the Company&#146;s
    and its Subsidiaries&#146; Trade Secrets included in the Company
    Intellectual Property.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;All manufacturing operations conducted by, or, to the
    Knowledge of the Company, for the benefit of, the Company and
    its Subsidiaries with respect to any Product or Pipeline Product
    and all manufacturing facilities of the Company or its
    Subsidiaries have since January&#160;1, 2008 been and are being
    conducted in all material respects in accordance with the
    FDA&#146;s current Good Manufacturing Practice Regulations at
    21&#160;C.F.R. Parts 210 and 211 for products sold in the United
    States and the respective counterparts thereof promulgated by
    Governmental Entities in countries outside the United States.
    The Company has sufficient capacity and capability and all
    Regulatory Registrations and Company Permits necessary as of the
    date of this Agreement to manufacture the Product in sufficient
    quantities, taking into account safety stock, to meet the
    current and the Company&#146;s expected demand for the Product
    for the next 12&#160;months in all countries where it is sold.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.15&#160;&#160;<I><U>Takeover
    Statutes</U>.</I>&#160;&#160;No &#147;fair price,&#148;
    &#147;moratorium,&#148; &#147;control share acquisition,&#148;
    &#147;business combination&#148; or other similar antitakeover
    statute or regulation enacted under state or federal laws in the
    United States (with the exception of Section&#160;203 of the
    DGCL) is applicable to the transactions contemplated by this
    Agreement. The Company has taken all action necessary such that
    the restrictions contained in Section&#160;203 of the DGCL do
    not apply to the Merger, this Agreement and the transactions
    contemplated hereby; provided, however, that, for purposes
    hereof, Parent and Sub hereby specifically represent and warrant
    to the Company that neither of them is an &#147;interested
    stockholder&#148; in the Company, as such term is defined in
    Section&#160;203 of the DGCL.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.16&#160;&#160;<I><U>Title
    to Properties; Assets/Services</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Company and its Subsidiaries have valid and legal
    title to, a leasehold interest in, license or easement in the
    real and personal properties as reflected in the Company&#146;s
    consolidated balance sheet as of March&#160;31, 2010, except for
    properties and assets that have been disposed of in the ordinary
    course of business since March&#160;31, 2010, free and clear of
    all Liens of any nature whatsoever, except (i)&#160;Liens for
    current Taxes, payments of which are not yet delinquent and for
    which adequate reserves have been established in accordance with
    GAAP on the books and records of the Company;
    (ii)&#160;mechanics, carriers&#146;, workmen&#146;s,
    warehouseman&#146;s, repairmen&#146;s, materialmen&#146;s or
    other Liens or security interests arising in the ordinary course
    of business securing obligations that are not yet due and
    payable or are being contested in good faith; (iii)&#160;Liens
    imposed by applicable Law (other than Tax Law) arising in the
    ordinary course of business securing obligations for sums that
    are not yet due and payable or are being contested in good
    faith; (iv)&#160;pledges or deposits to secure obligations under
    workers&#146; compensation Laws or similar legislation or to
    secure public or statutory obligations; (v)&#160;pledges and
    deposits to secure the performance of bids, trade contracts,
    leases, surety and appeal bonds, performance bonds and other
    obligations of a similar nature; or (vi)&#160;such imperfections
    in title and easements and encumbrances as are not substantial
    in character, amount or extent and do not materially detract
    from the business subject thereto or affected thereby, or
    materially interfere with or materially adversely affect or
    impair the present and continued use of the property subject
    thereto or affected thereby, or otherwise materially impair the
    operations of the Company or any of its Subsidiaries (in the
    manner presently carried on by the Company and its
    Subsidiaries). <U>Section&#160;3.16(a)</U> of the Disclosure
    Schedule sets forth a true, complete and correct list of all
    real property owned, leased, subleased or licensed by the
    Company and each of its Subsidiaries and the location of such
    properties (collectively, the &#147;<U>Real Property</U>&#148;).
    All Real Property leased or subleased by the Company or its
    Subsidiaries is referred to herein as the &#147;<U>Leased Real
    Property</U>.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;As of the date of this Agreement, there are no material
    leases, subleases, licenses, concessions or other agreements,
    written or oral, granting to any party or parties the right of
    use or occupancy of any portion of any Real Property and Leased
    Real Property. Except as would not reasonably be expected to
    have, individually or in the aggregate, a Company Material
    Adverse Effect, the Company or its Subsidiaries have a valid and
    subsisting leasehold estate in and the right to quiet enjoyment
    of each Leased Real Property for the full term of the lease or
    sublease creating such interest. As of the date of this
    Agreement, to the Knowledge of the Company there are no eminent
    domain, condemnation or other similar actions or proceedings
    pending or threatened with respect to any of the Real Property
    by any Governmental Entity having jurisdiction over any such
    Real Property. As currently operated and maintained, each of the
    Real Properties is in compliance in all material respects with
    all federal, state and local Law applicable to each such Real
    Property.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.17&#160;&#160;<I><U>Material
    Contracts</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<U>Section&#160;3.17(a)</U> of the Disclosure Schedule
    sets forth a true and complete list as of the date of this
    Agreement of each of the following Company Contracts, together
    with all amendments thereto: (i)&#160;each Company Contract that
    restricts in any material respect the ability of the Company or
    any of its Subsidiaries or any of the Company&#146;s current or
    future Affiliates to sell products in or otherwise compete in
    any geographic area or line of business; (ii)&#160;any Company
    Contract pursuant to which any Person provides manufacturing
    services involving the Product, any Pipeline Product or any
    product using
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Technology for the Company or any of its Subsidiaries,
    (iii)&#160;each Company Contract pursuant to which the Company
    or any of its Subsidiaries grants or is granted any license to
    use or exploit, covenant not to sue, immunity from suit or
    similar rights under any Intellectual Property of a third party
    that, in each case, is related to the Product, any Pipeline
    Product, or the
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Technology; (iv)&#160;each Company Contract pursuant to which
    raw materials are supplied, or equipment is supplied or leased,
    to the Company or any of its Subsidiaries (excluding purchase
    orders given or received in the ordinary course of business),
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    in each case relating to any key component or manufacturing
    involved in the compounding or formulation of the Product or any
    products using
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Technology; (v)&#160;each Company Contract that grants any right
    of first refusal or right of first offer or similar right or
    that limits or purports to limit the ability of the Company or
    any of its Subsidiaries to own, operate, sell, transfer, pledge
    or otherwise dispose of any material amount of assets or
    businesses relating to the Product, any Pipeline Product, or the
    Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Technology; (vi)&#160;each Company Contract providing for future
    performance by the Company or any of its Subsidiaries in
    consideration of amounts previously paid, the balance of which
    exceeds $5,000,000 as of the date of this Agreement; and
    (vii)&#160;any other &#147;material contract&#148; (as such term
    is defined in Item&#160;601(b)(10) of
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    of the Securities Act) that were required to be filed with or
    furnished to the SEC prior to the date of this Agreement. Each
    Company Contract (A)&#160;of the type described in
    <U>Section&#160;3.17(a)</U> of the Disclosure Schedule, whether
    or not disclosed in response to this
    <U>Section&#160;3.17(a)</U>, or referred to in
    <U>Section&#160;3.17(b)</U>, whether or not provided or publicly
    filed, and (B)&#160;entered into after the date of this
    Agreement and of the type required to be described in
    <U>Section&#160;3.17(a)</U> or referred to in
    <U>Section&#160;3.17(b)</U>, whether or not provided or publicly
    filed of the Disclosure Schedule if such Company Contract were
    in effect as of the date of this Agreement, is referred to
    herein as a &#147;<U>Material Contract</U>.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Company has provided to Parent or publicly filed
    with the SEC true and complete copies of each Company Contact
    referred to in <U>Section&#160;3.17(a)</U> and each of the
    following Company Contacts, in each case that are in effect as
    of the date of this Agreement: (i)&#160;each Company Contract
    with customers (excluding purchase orders given or received in
    the ordinary course of business) under which the Company or any
    of its Subsidiaries received in excess of $10,000,000 in 2009 or
    is expected to receive in excess of $10,000,000 in 2010 or any
    year thereafter; (ii)&#160;each Company Contract pursuant to
    which the Company or any of its Subsidiaries occupies Leased
    Real Property and under which the Company or any of its
    Subsidiaries is required to pay an annual rental in excess of
    $5,000,000 in 2010 or any year thereafter; and (iii)&#160;each
    Company Contract for any joint venture (whether in partnership,
    limited liability company or other organizational form),
    co-promote agreements or co-branding agreements (other than
    distribution agreements) or agreements pursuant to which the
    Company or any of its Subsidiaries permitted distribution of the
    Product or the Pipeline Products under another party&#146;s name
    or trademarks.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;All Material Contracts are valid and in full force and
    effect and enforceable in accordance with their respective
    terms, subject to bankruptcy, insolvency, fraudulent transfer,
    reorganization, moratorium and similar Laws of general
    applicability relating to or affecting creditors&#146; rights
    and general equity principles, except to the extent that
    (i)&#160;such Material Contracts have previously expired or
    otherwise terminated in accordance with their terms or
    (ii)&#160;the failure to be in full force and effect would not
    reasonably be expected to have a Company Material Adverse
    Effect. Neither the Company nor any of its Subsidiaries, nor, to
    the Knowledge of the Company, any counterparty to any such
    Material Contract, has violated any provision of, or committed
    or failed to perform any act which, with or without notice,
    lapse of time or both, would constitute a default under, or give
    rise to a right of termination, modification, cancellation,
    foreclosure, imposition of a Lien, prepayment or acceleration
    under the provisions of any Material Contract, except in each
    case for those violations or defaults which would not reasonably
    be expected to have a Company Material Adverse Effect. Neither
    the Company nor any of its Subsidiaries has received written
    notice that it has breached, violated or defaulted under any
    Material Contract. Prior to the date of this Agreement, the
    Company and its Subsidiaries have not received any written
    claims for indemnification pursuant to the 2007 Separation and
    Distribution Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.18&#160;&#160;<I><U>Opinion
    of Financial Advisors</U>.</I>&#160;&#160;The Company&#146;s
    financial advisors, Goldman, Sachs&#160;&#038; Co., Lazard,
    Freres&#160;&#038; Co. LLC and Merrill Lynch, Pierce,
    Fenner&#160;&#038; Smith Incorporated (the
    &#145;&#145;<U>Company Financial Advisors</U>&#148;), have each
    delivered to the Board of Directors an opinion, to the effect
    that, as of the date of this Agreement and subject to the
    matters and assumptions set forth in their respective opinions,
    the Merger Consideration to be paid to the holders (other than
    Parent, Patrick Soon-Shiong,&#160;M.D. and any of their
    respective Affiliates) of shares of Company Common Stock
    pursuant to the Merger Agreement is fair to such holders from a
    financial point of view. The Company will provide, solely for
    informational purposes, a true, complete and correct copy of
    such opinions to Parent after receipt thereof in writing by the
    Company.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="13%"></TD>
    <TD width="83%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    <FONT style="font-variant: SMALL-CAPS">Section&#160;3.19</FONT>&#160;&#160;
</TD>
    <TD align="left">
    <I><U>Pharmaceutical Matters</U>.</I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Company and its Subsidiaries and to the Knowledge
    of the Company its respective directors, officers, employees,
    and agents (while acting in such capacity) are, and at all times
    have been, in compliance, and the Company&#146;s business
    (including the research, development, labeling, manufacture,
    testing, storage, use, sale, offer for sale, importation, and
    other distribution or commercial exploitation of the Product,
    the Pipeline Products, and the cervical cancer screening test
    marketed by the Company&#146;s Subsidiary Neodiagnostix, Inc.
    (the &#147;<U>Screening Test</U>&#148;) and all preclinical
    studies, clinical trials, and other studies and tests conducted
    thereon) has been operated in accordance, in all material
    respects with (i)&#160;all applicable Laws of the United States
    Drug Enforcement Administration, the United States Department of
    Health and Human Services and its constituent agencies, the
    Centers for Medicare&#160;&#038; Medicaid Services, the Office
    of Inspector General and the United States Food and Drug
    Administration (the &#147;<U>FDA</U>&#148; and, collectively
    with other applicable U.S.&#160;or foreign drug regulatory
    authorities, &#147;<U>Regulatory Authorities</U>&#148;),
    (including the federal Food, Drug, and Cosmetic Act
    (21&#160;U.S.C. &#167;&#160;321 et seq.) (the
    &#147;<U>FDCA</U>&#148;), the Controlled Substances Act (21
    U.S.C. &#167;&#160;801 et seq.), the federal Anti-kickback
    Statute (42&#160;U.S.C.
    <FONT style="white-space: nowrap">&#167;&#160;1320a-7b(b)),</FONT>
    the Anti-Inducement Law (42&#160;U.S.C.
    <FONT style="white-space: nowrap">&#167;&#160;1320a-7a(a)(5)),</FONT>
    the Stark Law (42&#160;U.S.C. &#167;&#160;1395nn), the Health
    Insurance Portability and Accountability Act of 1996
    (42&#160;U.S.C. &#167;&#160;1320d et seq.), the exclusion laws
    (42&#160;U.S.C.
    <FONT style="white-space: nowrap">&#167;&#160;1320a-7),</FONT>
    the regulations promulgated pursuant to the foregoing laws, and
    the Federal Acquisition Regulations (48&#160;C.F.R. Parts
    1-53)), (ii)&#160;the drug price reporting requirements of
    titles XVIII and XIX of the Social Security Act, (iii)&#160;the
    applicable laws precluding off-label marketing of drugs,
    (iv)&#160;all other United States laws and regulations with
    respect to the marketing, sale, pricing, price reporting, and
    reimbursement of prescription drug products, including the
    provisions of the Federal False Claims Act, 31&#160;U.S.C.
    &#167;&#160;3729 et seq., the Medicare Program (Title&#160;XVIII
    of the Social Security Act), the Medicaid Program
    (Title&#160;XIX of the Social Security Act), the regulations
    promulgated pursuant to such Laws, requirements of the Medicaid
    Drug Rebate Program (42&#160;U.S.C.
    <FONT style="white-space: nowrap">&#167;&#160;1396r-8)</FONT>
    and any state supplemental rebate program, requirements of
    Medicare average sales price reporting (42&#160;U.S.C.
    <FONT style="white-space: nowrap">&#167;&#160;1395w-3a),</FONT>
    the Public Health Service Act (42&#160;U.S.C. &#167;&#160;256b),
    the VA Federal Supply Schedule (38&#160;U.S.C.
    &#167;&#160;8126)&#160;state pharmaceutical assistance programs
    and regulations under such Laws, and (v)&#160;comparable state
    and foreign laws. The Company and its Subsidiaries have complied
    with any and all obligations pertaining to listing any relevant
    Patents included in the Company Intellectual Property in the FDA
    Orange Book and have also complied with any and all obligations
    under the Bayh-Dole Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Neither the Company nor any of its Subsidiaries is
    excluded or debarred under the Generic Drug Enforcement Act of
    1992 or any government health care program, including Medicare
    and Medicaid; and no employee of the Company or any of its
    Subsidiaries or to the Knowledge of the Company no consultants
    or subcontractors of the Company or any of its Subsidiaries is
    excluded or debarred. No claims, actions, proceedings or
    investigations that would reasonably be expected to result in
    such a material debarment are pending, and the Company has not
    received written notice that any such claims, actions,
    proceedings or investigations are threatened against the
    Company, the Company&#146;s Subsidiaries, or any of their
    respective officers or key employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;(i)&#160;Except as would not reasonably be expected to
    have, individually or in the aggregate, a Company Material
    Adverse Effect, the Company and its Subsidiaries meet all of the
    requirements of participation and payment of Medicare, Medicaid,
    any other state or federal government health care programs, and
    any other public or private third party payor programs
    (collectively, &#145;&#145;<U>Programs</U>&#148;) that the
    Company or any of its Subsidiaries participates in or receives
    payment from, and (ii)&#160;there is no investigation, audit,
    claim review, or other action pending, or, to the Knowledge of
    the Company, threatened, against the Company or any of its
    Subsidiaries which could reasonably be expected to result in the
    exclusion of the Company&#146;s business from any Program.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Except as set forth on <U>Section&#160;3.19(d)</U> of
    the Disclosure Schedule, (i)&#160;to the Knowledge of the
    Company, there is no pending action, investigation or inquiry of
    any type by any Regulatory Authority (other than non-material
    routine or periodic inspections or reviews) against the Company
    or its Subsidiaries relating to the Product, the Pipeline
    Products, or the Screening Test; (ii)&#160;since January&#160;1,
    2008, no Product, Pipeline Product, or Screening Test has been
    recalled, suspended or discontinued; and (iii)&#160;since
    January&#160;1, 2008, none of the Company or any of its
    Subsidiaries has received any written notification,
    correspondence or any other written communication from any
    Governmental Entity, including the FDA, the Centers for Medicare
    and Medicaid Services, and the Department of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Health and Human Services Office of Inspector General, of
    potential or actual material non-compliance by, or liability of,
    the Company or any of its Subsidiaries, under any of the Laws
    referenced in <U>Section&#160;3.19(a)</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;To the Knowledge of the Company, there are no facts or
    circumstances that could reasonably be construed as indicating
    that marketing approval for the Product will be withdrawn.
    Neither the Company nor its Subsidiaries has received any
    written notification, correspondence or any other written
    communication from the FDA or the European Medicines Agency
    requesting that the Company or its Subsidiaries make any
    material change in the labeling of the Product or any Pipeline
    Product, or indicating that such a request may be made.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;Neither the Company nor its Subsidiaries have marketed,
    sold, offered for sale, or distributed any Pharmaceutical
    Products other than the Product and the Screening Test. For
    purposes of this Agreement, &#147;<U>Regulatory
    Registrations</U>&#148; means all investigational new drug
    applications, new drug applications, product license
    application, or biologics license application or similar
    regulatory applications of the Company and its Subsidiaries that
    have been submitted to or approved by the FDA or any applicable
    Governmental Entity. All applications, notifications,
    submissions, information, claims, reports and statistics and
    other data, utilized as the basis for or submitted in connection
    with any and all Regulatory Registrations from the FDA or other
    Regulatory Authority relating to the Company and its
    Subsidiaries or their respective business operations and
    Pharmaceutical Products, when submitted to the FDA or other
    Regulatory Authority were true, complete and correct in all
    material respects as of the date of submission and any necessary
    or required updates, changes, corrections or modification to
    such applications, submissions, information and data have been
    submitted to the FDA or such other Regulatory Authority.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;None of the Company or any of its Subsidiaries is a
    party to any corporate integrity agreements, monitoring
    agreements, consent decrees, settlement orders, or other similar
    written agreements, in each case, entered into with or imposed
    by any Regulatory Authority.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.20&#160;&#160;<I><U>Brokers
    and Finders</U>.</I>&#160;&#160;The Company has not entered into
    any Contract, arrangement or understanding with any Person which
    may result in the obligation of the Company to pay any
    investment banking fees, finder&#146;s fees, brokerage or agent
    commissions or other like payments in connection with the
    Merger, other than fees payable to the Company Financial
    Advisors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.21&#160;&#160;<I><U>Insurance</U>.</I>&#160;&#160;Each
    of the material insurance policies and material self insurance
    programs and arrangements relating to the business, assets and
    operations of the Company and its Subsidiaries (the
    &#147;<U>Insurance Policies</U>&#148;) is in full force and
    effect, all premiums due thereon have been paid in full and the
    Company and its Subsidiaries are in compliance in all material
    respects with the terms and conditions of such Insurance
    Policies. Since January&#160;1, 2009, and prior to the date of
    this Agreement, none of the Company or any of its Subsidiaries
    has received any written notice regarding any actual or possible
    (a)&#160;cancellation of any Insurance Policy that has not been
    renewed in the ordinary course without any lapse in coverage,
    (b)&#160;invalidation of any Insurance Policy, (c)&#160;refusal
    of any coverage, limitation in coverage or rejection of any
    material claim under any Insurance Policy, or (d)&#160;material
    adjustment in the amount of the premiums payable with respect to
    any Insurance Policy. As of the date of this Agreement, there is
    no material claim by the Company or any of its Subsidiaries
    pending under any of the Insurance Policies and no material
    claim made since January&#160;1, 2009 that is still pending has
    been questioned or disputed by the underwriters of such
    Insurance Policies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.22&#160;&#160;<I><U>Anti-Corruption
    and Anti-Bribery</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;For the purposes of this Agreement, the term
    &#147;<U>Anti-Corruption and Anti-Bribery Laws</U>&#148; shall
    mean all applicable Laws governing corrupt or illicit business
    practices, including laws dealing with improper or illegal
    payments, gifts or gratuities
    <FONT style="white-space: nowrap">and/or</FONT> the
    payment or receipt of money or anything of value directly or
    indirectly to or from any Person (whether a government official
    or private individual) for the purpose of illegally inducing any
    Person or government official, or political party or official
    thereof, or any candidate for any such position, in making any
    decision or illegally assisting any Person in obtaining or
    retaining business or taking any other action favorable to such
    Person,
    <FONT style="white-space: nowrap">and/or</FONT>
    dealing with business practices in relation to investments
    outside of the United States (including, by way of example, if
    applicable, the United States Foreign Corrupt Practices Act of
    1977, as amended, any rules or regulations thereunder).
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Neither the Company nor its directors, officers,
    agents, employees, Subsidiaries or Affiliates has, directly or
    indirectly, (i)&#160;used any corporate funds in a manner which
    would cause it to be in violation of any Anti-Corruption or
    Anti-Bribery Laws, (ii)&#160;established or maintained any
    unrecorded fund or asset for any purpose or made any false
    entries on the books and records of the Company or any of its
    Subsidiaries for any reason, (iii)&#160;paid, delivered or
    received any fee, commission or any other sum or money or item
    of property, however characterized, to or from any finder,
    principal, agent, governmental official or other party in the
    United States or any other country, which in any manner relates
    to the assets, business or operations of the Company or any of
    its Subsidiaries in violation of any Laws or (iv)&#160;made or
    received any other unlawful payment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;There are no pending or, to the Knowledge of the
    Company, threatened claims against the Company with respect to
    such Anti-Corruption or Anti-Bribery laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;The Company has established and maintains a compliance
    program and internal controls and procedures appropriate to the
    requirements of the Anti-Corruption and Anti-Bribery Laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.23&#160;&#160;<I><U>No
    Other Representations or Warranties</U>.</I>&#160;&#160;Except
    for the representations and warranties expressly contained in
    this Agreement, each of Parent and Sub acknowledges that neither
    the Company nor any other Person on behalf of the Company makes
    any other express or implied representation or warranty with
    respect to the Company, any of its Subsidiaries or their
    respective businesses or any other matter or with respect to any
    other information provided or made available to Parent or Sub,
    and that all such representations and warranties, other than the
    representations and warranties of the Company expressly
    contained in this Agreement, are expressly disclaimed. Neither
    the Company nor any other Person makes any representation or
    warranty with respect to any such information, including any
    information, projections, forecasts or other material made
    available to Parent and Sub in a &#147;data room&#148; or
    &#147;virtual data room,&#148; confidential information
    memoranda or management presentations in expectation of the
    transactions contemplated by this Agreement, except that the
    foregoing limitations shall not (i)&#160;apply to the Company to
    the extent the Company makes the specific representations and
    warranties set forth in this Agreement, but always subject to
    the limitations and restrictions contained herein, or
    (ii)&#160;preclude Parent or Sub from seeking any remedy for
    fraud.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;IV<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">REPRESENTATIONS
    AND WARRANTIES OF PARENT AND SUB
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Except as disclosed in Parent&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, Parent&#146;s
    Quarterly Report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarter ended March&#160;31, 2010 or any of
    Parent&#146;s Current Reports on Form&#160;8&#160;&#151; K dated
    after December&#160;31, 2009 filed by Parent with the SEC
    pursuant to the Exchange Act prior to the date of this Agreement
    but excluding (i)&#160;any disclosures contained or referenced
    therein under the captions &#147;Risk Factors,&#148;
    &#147;Forward-Looking Statements,&#148; and &#147;Quantitative
    and Qualitative Disclosures About Market Risk&#148; and any
    other disclosures contained or referenced therein of
    information, factors or risks that are predictive, cautionary or
    forward-looking in nature, and (ii)&#160;with respect to
    <U>Section&#160;4.2(a)</U>, any disclosures contained or
    referenced therein, Parent and Sub, jointly and severally,
    represent and warrant to the Company as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.1&#160;&#160;<I><U>Organization,
    Standing and Power</U>.</I>&#160;&#160;Each of Parent and Sub is
    a legal entity duly organized, validly existing and in good
    standing under the Laws of its jurisdiction of organization and
    has all requisite corporate or similar power and authority to
    own, lease and operate its properties and assets and to carry on
    its business as presently conducted and is qualified to do
    business and is in good standing as a foreign legal entity in
    each jurisdiction where the ownership, leasing or operation of
    its assets or properties or conduct of its business requires
    such qualification, except where the failure to be so organized,
    qualified or in good standing, or to have such power or
    authority, would not reasonably be expected to have a Parent
    Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.2&#160;&#160;<I><U>Capital
    Structure</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The authorized capital stock of Parent consists of
    575,000,000&#160;shares of Parent Common Stock and
    5,000,000&#160;shares of preferred stock, par value $0.01 per
    share. As of the close of business on May&#160;31, 2010,
    (i)&#160;459,949,694&#160;shares of Parent Common Stock were
    issued and outstanding, (ii)&#160;no shares of preferred stock
    were outstanding, (iii)&#160;an aggregate of
    40,736,541&#160;shares of Parent Common Stock were issuable upon
    exercise of then
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    outstanding stock options (whether or not exercisable as of such
    date) and the vesting of restricted stock units, and
    (iv)&#160;35,000&#160;shares of Parent Common Stock were
    issuable upon the exercise of then outstanding warrants. In
    addition to the shares of Parent Common Stock referred to in
    clauses&#160;(i) and (iii), as of the close of business on
    May&#160;31, 2010, 20,935,840&#160;shares of Parent Common Stock
    were available for additional grants under Parent&#146;s stock
    option or equity incentive plans. All of the outstanding shares
    of Parent Common Stock are validly issued and outstanding, fully
    paid and non assessable and free of preemptive rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Except as otherwise set forth in this
    <U>Section&#160;4.2</U>, as of the date of this Agreement,
    Parent has no (i)&#160;outstanding stock or securities
    convertible into or exchangeable for any shares of its equity
    securities, or any outstanding rights to subscribe for or to
    purchase any shares of its equity securities, or any outstanding
    options for the purchase thereof, (ii)&#160;any agreements
    providing for the issuance of any equity securities or any stock
    or securities convertible into or exchangeable for any equity
    securities of Parent or (iii)&#160;outstanding bonds,
    debentures, notes or other indebtedness having the right to vote
    (or convertible into or exchangeable for securities having the
    right to vote) on any matters on which stockholders of Parent
    may vote. From June&#160;25, 2010 to the date of this Agreement,
    Parent has not (i)&#160;issued any shares of Parent Common Stock
    except in connection with the conversion, exercise or settlement
    of any stock options or (ii)&#160;issued or granted any options,
    warrants or securities convertible into or exercisable for
    shares of its Parent Common Stock other than in the ordinary
    course of business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;The shares of Parent Common Stock to be issued in the
    Merger have been duly authorized and, when issued and delivered
    in accordance with the terms of this Agreement, will have been
    validly issued and will be fully paid and nonassessable and the
    issuance thereof is not subject to any preemptive or other
    similar right.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.3&#160;&#160;<I><U>Operations
    of Sub</U>.</I>&#160;&#160;All of the issued and outstanding
    capital stock of Sub is, and at the Effective Time will be,
    owned by Parent or a direct or indirect wholly-owned Subsidiary
    of Parent. Sub was formed solely for the purpose of effecting
    the Merger. Sub has not conducted any business prior to the date
    hereof and has no, and prior to the Effective Time will have no,
    assets, liabilities or obligations of any nature other than
    those incident to its formation and pursuant to this Agreement
    and the Merger and the other transactions contemplated by this
    Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.4&#160;&#160;<I><U>Authority;
    Non-Contravention</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Each of Parent and Sub has the requisite power and
    authority to enter into this Agreement and to consummate the
    Merger and the transactions contemplated by this Agreement. The
    execution and delivery of this Agreement by each of Parent and
    Sub and the consummation by Parent and Sub of the Merger and the
    transactions contemplated by this Agreement have been duly
    authorized by all necessary action on the part of each of Parent
    and Sub. This Agreement has been duly executed and delivered by
    each of Parent and Sub and (assuming the valid authorization,
    execution and delivery of this Agreement by the Company)
    constitutes a valid and binding obligation of Parent and Sub,
    enforceable against Parent and Sub in accordance with its terms,
    subject to bankruptcy, insolvency, fraudulent transfer,
    reorganization, moratorium and similar Laws of general
    applicability relating to or affecting creditors&#146; rights
    and general equity principles. No vote or approval of the
    stockholders of Parent is required in connection with the
    execution, delivery or performance by Parent and Sub of their
    obligations hereunder or for the consummation of the Merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The execution and delivery of this Agreement does not,
    and the consummation of the Merger and compliance with the
    provisions hereof will not, (i)&#160;conflict with, or result in
    any violation of, the organizational documents of Parent,
    (ii)&#160;conflict with, or result in any violation of the
    organizational documents of any of Parent&#146;s Subsidiaries,
    (iii)&#160;result in any violation or breach of, or default
    (with or without notice or lapse of time, or both) under, or
    give rise to a right of termination, cancellation or
    acceleration of any obligation, or result in the creation of any
    Lien upon any of the properties or assets of Parent or any of
    its Subsidiaries under, any provision of any Contract to which
    Parent or any of its Subsidiaries is a party or by which their
    respective properties and assets are bound, except for any such
    violation, breach, default or right of termination, cancellation
    or acceleration or Lien as to which requisite waivers or
    consents have been obtained or (iv)&#160;assuming that the
    Registrations and Consents set forth in this
    <U>Section&#160;4.3(b)</U> are duly and timely made or obtained,
    violate any Law applicable to Parent or any of its Subsidiaries
    or any of their respective properties or assets, other than, in
    the case of clauses&#160;(iii) or (iv), any such conflict,
    violation, default, termination, cancellation, acceleration or
    Lien that would not, individually or in the aggregate,
    reasonably be expected to materially impair the ability of
    Parent
    <FONT style="white-space: nowrap">and/or</FONT> Sub
    to perform their obligations
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    hereunder or prevent or materially delay the consummation of the
    Merger or any of the other transactions contemplated hereby.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;No Consents of, or Registrations with, any Governmental
    Entity is required on the part of Parent or any of its
    Subsidiaries in connection with the execution and delivery of
    this Agreement by Parent or Sub or is necessary for the
    consummation by Parent and Sub of the Merger and the other
    transactions contemplated hereby, except for (i)&#160;compliance
    with and filings under the HSR Act, (ii)&#160;compliance with
    the provisions of Exchange Act and the Securities Act or the
    rules of any national securities exchange, (iii)&#160;the
    qualification of the CVR Agreement under the
    Trust&#160;Indenture Act of 1939, as amended (the
    &#147;<U>Trust&#160;Indenture Act</U>&#148;), if required by
    Law, (iv)&#160;the filing of the Certificate of Merger with the
    Secretary of State of Delaware and appropriate documents with
    the relevant authorities of other states in which the Company is
    qualified to do business, (v)&#160;such as may be required in
    connection with the Taxes described in <U>Section&#160;6.11</U>,
    and (vi)&#160;such other Consents or Registrations the failure
    of which to be obtained or made would not, individually or in
    the aggregate, materially impair the ability of Parent and Sub
    to perform their obligations hereunder or prevent or materially
    delay the consummation of the Merger or any of the transactions
    contemplated hereby.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.5&#160;&#160;<I><U>SEC
    Documents</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Since January&#160;1, 2008, Parent has filed with, or
    furnished to, the SEC all documents required to be filed or
    furnished by Parent under the Securities Act or the Exchange Act
    (collectively, the &#147;<U>Parent SEC Documents</U>&#148;). As
    of their respective dates, Parent SEC Documents complied in all
    material respects with the requirements of the Securities Act or
    the Exchange Act, as the case may be, and as of their respective
    dates and except as amended or supplemented prior to the date
    hereof (or with respect to Parent SEC Documents filed or
    furnished after the date hereof, except as amended or
    supplemented prior to the Closing Date), none of Parent SEC
    Documents contained any untrue statement of a material fact or
    omitted to state a material fact required to be stated therein
    or necessary in order to make the statements therein, in light
    of the circumstances under which they were made, not misleading,
    except that no representation is made by Parent with respect to
    information supplied by the Company or its Subsidiaries in
    writing for inclusion in the Registration Statement. Each of the
    consolidated financial statements of Parent (including, in each
    case, any notes thereto) included in Parent SEC Documents
    (collectively, the &#145;&#145;<U>Parent Financial
    Statements</U>&#148;) have been prepared in accordance with
    U.S.&#160;GAAP applied on a consistent basis during the periods
    involved (except as may be indicated therein or in the notes
    thereto) and fairly present in all material respects the
    financial position of Parent and its consolidated Subsidiaries
    as at the dates thereof and the results of their operations and
    cash flows for the periods then ended (subject, in the case of
    unaudited statements, to normal year-end audit adjustments and
    to any other adjustments set forth therein). As of the date of
    this Agreement, neither Parent nor any of its Subsidiaries has
    any pending or unresolved comments from the SEC or any other
    Governmental Entity with respect to any of Parent SEC Documents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;To the Knowledge of Parent, neither Parent nor any of
    its Subsidiaries has any liability or obligation of any nature
    (whether accrued, absolute, contingent or otherwise), except for
    liabilities, obligations or contingencies which (i)&#160;are
    reflected, or for which reserves are established, on the
    consolidated balance sheet of Parent as of March&#160;31, 2010,
    (ii)&#160;were incurred in the ordinary course of business since
    March&#160;31, 2010, (iii)&#160;would not reasonably be expected
    to have, individually or in the aggregate, a Parent Material
    Adverse Effect or (iv)&#160;have been incurred in connection
    with the performance by Parent of its obligations under this
    Agreement or the transactions contemplated hereby.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Each of the principal executive officer and the
    principal financial officer of Parent (or each former principal
    executive officer and each former principal financial officer of
    Parent, as applicable) has made the certifications required by
    <FONT style="white-space: nowrap">Rules&#160;13a-14</FONT>
    and <FONT style="white-space: nowrap">15d-14</FONT>
    promulgated under the Exchange Act or Sections&#160;302 and 906
    of the Sarbanes-Oxley Act with respect to Parent SEC Documents.
    For purposes of the preceding sentence, &#147;principal
    executive officer&#148; and &#147;principal financial
    officer&#148; have the meanings ascribed to those terms under
    the Sarbanes-Oxley Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;To the Knowledge of Parent, since January&#160;1, 2008
    and prior to the date of this Agreement, none of Parent, any of
    its Subsidiaries or any director, officer, auditor, accountant
    or representative of Parent or any of its Subsidiaries has
    received any substantive complaint, allegation, assertion or
    claim, whether written or oral, that Parent or any of its
    Subsidiaries has engaged in questionable accounting or auditing
    practices. No current or former attorney representing Parent or
    any of its Subsidiaries has reported evidence of a material
    violation of securities
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Laws, breach of fiduciary duty or similar violation by Parent or
    any of its Subsidiaries, or any of their respective officers,
    directors, employees or agents, to Parent&#146;s current board
    of directors or any committee thereof or to any current director
    or executive officer of Parent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Parent and its Subsidiaries have designed and maintain
    internal controls over financial reporting (as defined in
    <FONT style="white-space: nowrap">Rules&#160;13a-15(f)</FONT>
    and
    <FONT style="white-space: nowrap">15d-15(f)</FONT>
    promulgated under the Exchange Act) to provide reasonable
    assurances (i)&#160;regarding the reliability of Parent&#146;s
    financial reporting and the preparation of financial statements
    for external purposes in accordance with U.S.&#160;GAAP
    (ii)&#160;that receipts and expenditures of Parent and its
    Subsidiaries are being made only in accordance with the
    authorization of management and directors of Parent and such
    Subsidiaries and (iii)&#160;regarding prevention or timely
    detection of the unauthorized acquisition, use or disposition of
    Parent&#146;s or its Subsidiaries&#146; assets that could have a
    material effect on Parent&#146;s financial statements. Parent
    has designed and maintains disclosure controls and procedures
    (as defined in
    <FONT style="white-space: nowrap">Rules&#160;13a-15(e)</FONT>
    and <FONT style="white-space: nowrap">15d-</FONT>
    15(e) promulgated under the Exchange Act) to ensure that
    material information required to be disclosed by Parent in the
    reports that Parent files or submits under the Exchange Act is
    recorded, processed, summarized and reported within the time
    periods specified in the SEC&#146;s rules and forms and is
    accumulated and communicated to Parent&#146;s management as
    appropriate to allow timely decisions regarding required
    disclosure and to make the certifications of the principal
    executive officer and principal financial officer of Parent
    required under the Exchange Act with respect to such reports.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;Neither Parent nor any of its Subsidiaries is a party
    to, or has any commitment to become a party to, any joint
    venture, off balance sheet partnership or any similar Contract
    binding on Parent or any of its Subsidiaries or any of their
    properties or assets (including any Contract binding on Parent
    or any of its Subsidiaries or any of their properties or assets
    or arrangement relating to any transaction or relationship
    between or among Parent and any of its Subsidiaries, on the one
    hand, and any unconsolidated affiliate, including any structured
    finance, special purpose or limited purpose entity or person, on
    the other hand, or any &#147;off balance sheet
    arrangements&#148; (as defined in Item&#160;303(a) of
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    under the Exchange Act)), where the result, purpose or intended
    effect of such Contract is to avoid disclosure of any material
    transaction involving, or material liabilities of, Parent or any
    of its Subsidiaries in Parent&#146;s or such Subsidiary&#146;s
    published financial statements or other documents required to be
    filed or furnished by Parent under the Securities Act or the
    Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;Since January&#160;1, 2009, Parent has not received any
    oral or written notification of any &#147;material
    weakness&#148; in Parent&#146;s internal control over financial
    reporting. There is no outstanding &#147;significant
    deficiency&#148; or &#147;material weakness&#148; that
    Parent&#146;s independent accountants certify has not been
    appropriately and adequately remedied by Parent. For purposes of
    this Agreement, the terms &#147;significant deficiency&#148; and
    &#147;material weakness&#148; shall have the meanings assigned
    to them in Release
    <FONT style="white-space: nowrap">No.&#160;2007-005</FONT>
    of the Public Company Accounting Oversight Board, as in effect
    on the date hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.6&#160;&#160;<I><U>Absence
    of Certain Events</U>.</I>&#160;&#160;From March&#160;31, 2010
    to the date of this Agreement, there has not occurred any Effect
    that, individually or in the aggregate with all other Effects,
    has had, or would reasonably be expected to have, a Parent
    Material Adverse Effect. For purposes of this Agreement,
    &#147;<U>Parent Material Adverse Effect</U>&#148; means any
    Effects, that, in the aggregate with all other Effects, is, or
    would reasonably be expected to be, (1)&#160;materially adverse
    to the business, assets, financial condition or results of
    operations of Parent and its Subsidiaries taken as a whole, or
    (2)&#160;prevent the consummation of the Merger; provided that
    in no event shall any of the following, alone or in combination,
    be deemed to constitute, nor shall any of the following be taken
    into account in determining whether there has been, or there
    would reasonably be expected to be, a Parent Material Adverse
    Effect: (a)&#160;any Effect relating to, or resulting from, any
    change or developments in or to local, regional, national or
    foreign political, economic or financial conditions or in or to
    local, regional, national or foreign credit, financial, banking
    or securities markets (including any disruption thereof),
    including any Effect caused by acts of terrorism or war or armed
    hostilities (whether or not declared), (b)&#160;any Effect
    affecting generally any of the industries, geographic areas or
    business segments in which Parent or any of its Subsidiaries
    operates, (c)&#160;any Effect relating to, or resulting from,
    any hurricane, earthquake or other natural disasters,
    (d)&#160;any change in the share price or trading volume (as
    opposed to the facts underlying such change) of Parent Common
    Stock on NASDAQ (provided, however, that the facts and
    circumstances giving rise to such Effect that are not otherwise
    excluded from the definition of Parent Material Adverse Effect
    may be considered for purposes of determining whether there has
    been, or would reasonably be expected to be, a Parent Material
    Adverse Effect), (e)&#160;any Effect relating to, or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    resulting from, the adoption, implementation, promulgation,
    repeal, modification or proposal of any Law or U.S.&#160;GAAP,
    after the date of this Agreement, (f)&#160;any failure, in and
    of itself (as opposed to the facts underlying such failure), to
    meet any budgets, plans, projections or forecasts of
    Parent&#146;s or its Subsidiaries&#146; revenue, earnings or
    other financial performance or results of operations, or any
    published financial forecasts or analyst estimates with respect
    to the revenue, earnings or other financial performance or
    results of operations of Parent or its Subsidiaries or any
    change in analyst recommendations, for any period (provided,
    however, that the facts and circumstances giving rise to such
    failures that are not otherwise excluded from the definition of
    Parent Material Adverse Effect may be considered for purposes of
    determining whether there has been, or there would reasonably be
    expected to be, a Parent Material Adverse Effect may be
    considered for purposes of determining whether there has been,
    or would reasonably be expected to be, a Parent Material Adverse
    Effect), or (g)&#160;any Effect directly relating to, or
    resulting from, the execution, performance or announcement of
    this Agreement or the Related Agreements (including the impact
    thereof on relationships, contractual or otherwise, with
    customers, suppliers, licensors, licensees, distributors,
    partners or employees, the loss or departure of officers or
    other employees of Parent or its Subsidiaries and any pending or
    threatened Proceeding challenging this Agreement, any of the
    Related Agreements or the transactions contemplated hereby or
    thereby, or otherwise resulting from the pursuit of the
    consummation of the transactions contemplated hereby or thereby;
    except that clauses (a), (b), (c)&#160;and (e), shall not be
    applicable with respect to Effects to the extent, but only to
    the extent, that any such Effects have had, or would reasonably
    be expected to have, a disproportionate impact on Parent and its
    Subsidiaries, taken as a whole, relative to other participants
    in the industry in which Parent and its Subsidiaries operate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.7&#160;&#160;<I><U>Proxy
    Statement/Prospectus and Registration
    Statement</U>.</I>&#160;&#160;None of the information supplied
    or to be supplied by Parent or any of its Subsidiaries for
    inclusion or incorporation by reference in the Registration
    Statement or the Proxy Statement/Prospectus at the time the
    Registration Statement becomes effective under the Securities
    Act or at the time the Proxy Statement/Prospectus is mailed to
    stockholders of the Company and at the time of the Company
    Stockholders Meeting will contain any untrue statement of a
    material fact or omit to state any material fact required to be
    stated therein or necessary in order to make the statements
    therein, in light of the circumstances under which they are
    made, not misleading, except that no representation is made by
    Parent or Sub with respect to information supplied by the
    Company for inclusion or incorporation by reference in any of
    such documents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.8&#160;&#160;<I><U>Availability
    of Funds; Parent Common Stock</U>.</I>&#160;&#160;Parent shall
    have available at the Closing (i)&#160;sufficient funds to pay
    the Cash Consideration and all amounts payable in lieu of
    fractional shares pursuant to Section&#160;2.2(e) in respect of
    all of the then outstanding shares of Company Common Stock, pay
    all cash amounts payable in respect of then outstanding Options,
    SARs and RSUs, and pay all fees, expenses and other amounts
    payable by the Company and its Subsidiaries in connection with
    the Merger, and (ii)&#160;sufficient authorized but unissued
    shares of Parent Common Stock to issue the shares of Parent
    Common Stock to be issued pursuant to
    <U>Section&#160;2.1(a)(ii)</U>. Parent and Sub expressly
    acknowledge and agree that their obligations hereunder,
    including their obligations to consummate the Merger, are not
    subject to, or conditioned on, receipt of financing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.9&#160;&#160;<I><U>Litigation</U>.</I>&#160;&#160;There
    is no Proceeding pending or, to the Knowledge of Parent (as
    defined in <U>Section&#160;9.15</U>), threatened against Parent
    or Sub or any of their Subsidiaries or any property or asset of
    the Parent or Sub or any of their respective Subsidiaries which,
    if adversely determined, would reasonably be expected to have,
    individually or in the aggregate, a Parent Material Adverse
    Effect. As of the date of this Agreement, neither Parent nor Sub
    is subject to any writ, judgment, injunction or decree that
    would reasonably be expected to have, individually or in the
    aggregate, a Parent Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.10&#160;&#160;<I><U>No
    Violation of Law</U>.</I>&#160;&#160;Except for which would not
    reasonably be expected to have, individually or in the
    aggregate, a Parent Material Adverse Effect: (i)&#160;neither
    Parent nor any of its Subsidiaries is or since January&#160;1,
    2008, has been in violation of any Law; (ii)&#160;to the
    Knowledge of Parent, no investigation or review by any
    Governmental Entity is pending or threatened against Parent or
    any of its Subsidiaries; (iii)&#160;Parent and its Subsidiaries
    have all permits, licenses, franchises, variances, exemptions,
    orders and other governmental authorizations, consents and
    approvals necessary to conduct its businesses in all material
    respects as presently conducted (collectively, the
    &#147;<U>Parent Permits</U>&#148;); and (iv)&#160;none of Parent
    or any of its Subsidiaries is in violation of the terms of any
    Parent Permit.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.11&#160;&#160;<I><U>Brokers
    and Finders</U>.</I>&#160;&#160;No broker, investment banker or
    other Person, other than Morgan&#160;Stanley&#160;&#038; Co.
    Incorporated, the fees and expenses of which will be paid by
    Parent, is entitled to any broker&#146;s, finder&#146;s or other
    similar fee or commission in connection with the Merger and the
    transactions contemplated by this Agreement based upon
    arrangements made by or on behalf of the Parent or Sub.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.12&#160;&#160;<I><U>Ownership
    of Shares</U>.</I>&#160;&#160;As of the date of this Agreement,
    none of Parent, Sub or their respective Affiliates owns
    (beneficially or of record) any shares of Company Common Stock,
    and none of Parent, Sub or their respective Affiliates is a
    party to any agreement, arrangement or understanding for the
    purpose of acquiring, holding, voting or disposing of any shares
    of Company Common Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.13&#160;&#160;<I><U>Solvency</U>.</I>&#160;&#160;Assuming
    satisfaction of the conditions to Parent&#146;s obligation to
    consummate the Merger, and after giving effect to the
    transactions contemplated by this Agreement, and the payment of
    the aggregate cash consideration payable to the Securityholders
    pursuant to <U>ARTICLE&#160;II</U>, payment of all amounts
    required to be paid in connection with the consummation of the
    Merger and the other transactions contemplated hereby, and
    payment of all related fees and expenses, each of Parent and the
    Surviving Corporation will be Solvent as of the Effective Time
    and immediately after the consummation of the transactions
    contemplated hereby. For the purposes of this Agreement, the
    term &#147;<U>Solvent</U>&#148; when used with respect to any
    Person, means that, as of any date of determination (a)&#160;the
    amount of the &#147;fair saleable value&#148; of the assets of
    such Person will, as of such date, exceed (i)&#160;the value of
    all &#147;liabilities of such Person, including contingent and
    other liabilities,&#148; as of such date, as such quoted terms
    are generally determined in accordance with applicable Laws
    governing determinations of the insolvency of debtors, and
    (ii)&#160;the amount that will be required to pay the probable
    liabilities of such Person on its existing debts (including
    contingent and other liabilities) as such debts become absolute
    and mature, and (b)&#160;such Person will be able to pay its
    liabilities, including contingent and other liabilities, as they
    mature. For purposes of this definition, &#147;able to pay its
    liabilities, including contingent and other liabilities, as they
    mature&#148; means that such Person will be able to generate
    enough cash from operations, asset dispositions or refinancing,
    or a combination thereof, to meet its obligations as they become
    due.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.14&#160;&#160;<I><U>No
    Other Representations or Warranties</U>.</I>&#160;&#160;Except
    for the representations and warranties expressly contained in
    this Agreement, the Company acknowledges that neither Parent,
    Sub or any other Person on behalf of Parent or Sub makes any
    other express or implied representation or warranty with respect
    to Parent, any of its Subsidiaries or their respective
    businesses or any other matter or with respect to any other
    information provided or made available to the Company, and that
    all such representations and warranties, other than the
    representations and warranties of Parent and Sub expressly
    contained in this Agreement, are expressly disclaimed. Neither
    Parent, Sub nor any other Person makes any representation or
    warranty with respect to any such information, including any
    information, projections, forecasts, confidential information
    memoranda or management presentations in expectation of the
    transactions contemplated by this Agreement, except that the
    foregoing limitations shall not (i)&#160;apply to Parent or Sub
    to the extent Parent or Sub makes the specific representations
    and warranties set forth in this Agreement, but always subject
    to the limitations and restrictions contained herein, or
    (ii)&#160;preclude the Company from seeking any remedy for fraud.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;V<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">COVENANTS
    RELATING TO CONDUCT OF BUSINESS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.1&#160;&#160;<I><U>Conduct
    of Business by the Company Pending the
    Merger</U>.</I>&#160;&#160;Except as otherwise expressly
    contemplated by this Agreement, as consented in writing by
    Parent, as set forth in the Disclosure Schedule or as required
    by applicable Law, during the period from the date of this
    Agreement to the earlier to occur of (x)&#160;the date of the
    termination of this Agreement or (y)&#160;the Effective Time,
    the Company shall, and shall cause each of its Subsidiaries to,
    in all material respects carry on their respective businesses in
    the ordinary course and, to the extent consistent therewith, use
    its reasonable best efforts to preserve intact its current
    business organizations, keep available the services of its
    current officers and employees and preserve its relationships
    with customers, suppliers and others having significant business
    dealings with the Company or any of its Subsidiaries. Without
    limiting the generality of the foregoing, and except as
    otherwise expressly contemplated by this Agreement or as set
    forth in <U>Section&#160;5.1</U> of the Disclosure Schedule or
    as required by applicable Law, and subject to the provisions of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <U>ARTICLE&#160;VIII</U>, the Company shall not, and shall cause
    each of its Subsidiaries not to, without the prior written
    consent of Parent (which consent shall not be unreasonably
    withheld or delayed):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;(i)&#160;split, combine, reclassify, subdivide or amend
    the terms of any of its capital stock, (ii)&#160;declare, set
    aside or pay any dividends on, or make any other distributions
    (whether in cash, stock or property) in respect of, any shares
    of its capital stock or enter into any agreement with respect to
    the voting or registration of any shares of its capital stock,
    or (iii)&#160;repurchase, redeem or otherwise acquire any shares
    of its capital stock or any securities convertible into or
    exchangeable or exercisable for shares of its capital stock;
    provided that (A)&#160;the Company may acquire Options, RSUs and
    SARs upon their exercise, settlement or forfeiture and
    (B)&#160;each wholly-owned Subsidiary of the Company may
    repurchase, redeem or otherwise acquire shares of its capital
    stock or other equity interests or securities convertible into
    or exchangeable or exercisable for any shares of its capital
    stock or other equity interests;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;issue, deliver, sell, pledge, transfer, convey, dispose
    of or encumber any shares of its capital stock, other equity
    securities or any securities convertible into, or any rights,
    warrants or options to acquire, any such shares of its capital
    stock, such other equity securities or such convertible
    securities (provided that the Company may issue shares of
    Company Common Stock upon exercise of Options
    <FONT style="white-space: nowrap">and/or</FONT>
    vesting of RSUs);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;amend the Company&#146;s certificate of incorporation
    or by-laws or other organizational documents of the Company or
    its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;merge or consolidate with any other Person, except for
    any such transactions between wholly-owned Subsidiaries of the
    Company or between the Company and any of its wholly-owned
    Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;make any acquisition or agree to make any acquisition
    of any business, by merger or otherwise;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;transfer, sell, lease, license, dispose of or encumber,
    or agree to transfer, sell, lease, license, dispose of or
    encumber, any of assets of the Company or any of its
    Subsidiaries that have a value in excess of $1,000,000
    individually and $5,000,000 in the aggregate, except sales of
    inventory or obsolete assets in the ordinary course of business;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;except for trade payables of the Company or any of its
    Subsidiaries incurred in the ordinary course of business,
    (i)&#160;incur any additional indebtedness; (ii)&#160;issue any
    debt securities or assume, guarantee or endorse, or otherwise
    become responsible for (whether directly, contingently or
    otherwise), the obligations of any Person for borrowed money; or
    (iii)&#160;make any loans, advances or capital contributions to,
    or investments in, any other Person (other than any wholly-owned
    Subsidiary of the Company);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;except as may be required as a result of a change in
    regulatory accounting standards and practice or in
    U.S.&#160;GAAP (or any interpretation), change any of the
    accounting principles or practices used by it materially
    affecting the reported consolidated assets, liabilities or
    results of operations of the Company and its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;waive, settle or compromise any Proceeding, other than
    waivers, settlements or compromises that involve only the
    payment of monetary damages by the Company or any of its
    Subsidiaries of no more than $2,000,000 individually and
    $6,000,000 in the aggregate, in any case without the imposition
    of equitable relief on, or the admission of wrongdoing by, the
    Company or any of its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (j)&#160;(i)&#160;terminate, establish, adopt, enter into, make
    any new grants or awards of stock based compensation or other
    benefits under, amend or otherwise modify, any Company Stock
    Plans, Employee Benefit Plans or employment agreements (or any
    plan or arrangement that would be a Company Stock Plan, Employee
    Benefit Plan or employment agreement if in existence on the date
    hereof) or increase the salary, wage, bonus or other
    compensation of any directors or employee of the Company or any
    of its Subsidiaries except (A)&#160;with respect to employees
    with a designation or title that is below the level of
    &#147;Vice President,&#148; or the equivalent, increases in
    compensation in connection with annual performance and salary
    reviews or upon promotion, payment of annual bonuses or
    non-material increases in benefits, in each case, in the
    ordinary course of business, (B)&#160;for grants of RSUs as
    permitted under <U>Section&#160;5.1(b)</U> or (C)&#160;to the
    extent required by any of the Employee Benefit Plans, Company
    Stock Plans or employment agreements existing as of the date of
    this Agreement; (ii)&#160;enter into any severance, change of
    control, termination or retention arrangements with, or
    accelerate the compensation or benefits of, any employee or
    director; (iii)&#160;hire any Person or promote any Person
    (A)&#160;to be an officer or an employee
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with a designation of &#147;Vice President&#148; or above,
    except to fill a vacancy in the ordinary course of business or
    (B)&#160;with an annual base salary in excess of $200,000, other
    than Persons hired (x)&#160;to replace employees who are no
    longer with the Company or its Subsidiaries, or (y)&#160;to fill
    vacancies created by employee promotions; or (iv)&#160;make or
    forgive any loan to employees or directors (other than making
    advances of reasonable travel and other business expenses in the
    ordinary course of business);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (k)&#160;except as required by applicable Law, make or change
    any material Tax election, change any Tax accounting period,
    adopt or change any Tax accounting method, amend any material
    Tax Return, enter into any material closing agreement, settle
    any material Tax claim or assessment relating to the Company or
    any of its Subsidiaries, surrender any right to claim a refund
    of material Taxes, or consent to any extension or waiver of the
    limitation period applicable to any material Tax claim or
    assessment relating to the Company or any of its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (l)&#160;authorize, recommend, adopt, propose or announce an
    intention to adopt a plan of complete or partial liquidation,
    dissolution, restructuring, recapitalization or other
    reorganization of the Company or any of its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (m)&#160;make or commit to any capital expenditures in excess of
    the capital expenditures budget set forth in
    <U>Section&#160;5.1(m)</U> of the Disclosure Schedule, except to
    the extent that such excess is not greater than $10,000,000 in
    the aggregate;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (n)&#160;(i)&#160;except for Material Contracts of the type
    described in <U>Section&#160;3.17(b)(i)</U> and entered into in
    the ordinary course of business with respect to customers and
    suppliers, enter into, terminate (except at the end of its term)
    or modify in any material respect any Material Contract (or any
    contract or agreement that if in existence on the date hereof
    would be a Material Contract) or waive, release or assign any
    material rights or claims thereunder, (ii)&#160;grant or
    acquire, agree to grant or to acquire from any third party, or
    dispose of or permit to lapse any right, title or interest to,
    any Intellectual Property, or encumber, impair, abandon, fail to
    diligently maintain, transfer or otherwise dispose of any right,
    title or interest of the Company or any of its Subsidiaries in
    any Company Intellectual Property (other than, in each case,
    pursuant to any Company Contract that is (A)&#160;a material
    transfer or sponsored research agreement, (B)&#160;a clinical
    trial agreement, or (C)&#160;a clinical research agreement
    entered into with a clinical research organization, in each
    case, that solely grants non-exclusive rights in the ordinary
    course of business consistent with past practices), or
    (iii)&#160;divulge, furnish to or make accessible any trade
    secrets within the Company Intellectual Property to any Person
    who is not subject to an enforceable written agreement to
    maintain the confidentiality of such trade secrets;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (o)&#160;announce, implement or effect any reduction in force,
    lay-off, early retirement program, severance program or other
    program or effort concerning the termination of employment of
    employees of the Company or any of its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (p)&#160;enter into, amend or cancel any insurance policies
    other than in ordinary course of business;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (q)&#160;adopt or enter into stockholder rights agreement or
    &#147;poison pill&#148;;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (r)&#160;acquire or dispose of any manufacturing
    facilities;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (s)&#160;agree in writing or otherwise to take any of the
    foregoing actions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.2&#160;&#160;<I><U>Control
    of the Company&#146;s Operations</U>.</I>&#160;&#160;Nothing
    contained in this Agreement shall give to Parent, directly or
    indirectly, rights to control or direct the Company&#146;s or
    its Subsidiaries&#146; operations prior to the Effective Time.
    Prior to the Effective Time, the Company and its Subsidiaries
    shall exercise, consistent with the terms of this Agreement,
    complete control of its business and operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VI<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ADDITIONAL
    AGREEMENTS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.1&#160;&#160;<I><U>Company
    Stockholder Approval; Proxy Statement</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Company shall take all lawful action reasonably
    necessary in accordance with the DGCL and its certificate of
    incorporation and by-laws to call a meeting of its stockholders
    (the &#145;&#145;<U>Company Stockholder Meeting</U>&#148;) for
    the purpose of voting upon the adoption of this Agreement and
    the approval of the Merger, as soon as reasonably practicable
    after the Registration Statement is declared effective by the
    SEC, the Proxy Statement/Prospectus is cleared by the SEC and,
    if required by Law, the CVR Agreement has been qualified under
    the Trust&#160;Indenture Act. Without limiting the generality of
    the foregoing, the Company, in consultation with Parent, shall
    establish a record date for, call, give notice of, convene and
    shall use its reasonable best efforts to hold the Company
    Stockholder Meeting within the shortest time period allowed
    under Law and the rules and regulations of the NASDAQ after the
    date that the Registration Statement has been declared effective
    by the SEC. The Board of Directors shall, subject to the
    provisions of <U>Section&#160;6.3</U> and their fiduciary duties
    under applicable Law as determined by the Board of Directors in
    good faith after consultation with the Company&#146;s outside
    counsel, recommend to the Company&#146;s stockholders the
    adoption of this Agreement and approval of the Merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;As soon as is reasonably practicable (A)&#160;Parent,
    the Company and Sub shall prepare the Registration Statement,
    which shall include the Proxy Statement/Prospectus,
    (B)&#160;Parent shall file the Registration Statement, and the
    Company shall file the Proxy Statement/Prospectus, in each case
    with the SEC, and (C)&#160;each party shall cooperate with the
    other party in the preparation of, and will provide the other
    party with all information within such party&#146;s control that
    is required to be included in, the foregoing documents. Each of
    the parties shall use its reasonable best efforts to respond to
    any comments of the SEC or its staff and to cause the
    Registration Statement to be declared effective by the SEC, to
    have the Proxy Statement/Prospectus cleared by the SEC and, if
    required by Law, to have the CVR Agreement become qualified
    under the Trust&#160;Indenture Act, in each case as soon as
    reasonably practicable after the date of this Agreement. The
    parties shall use their respective reasonable best efforts to
    keep the Registration Statement effective as long as is
    necessary to consummate the Merger and the transactions
    contemplated by this Agreement. Each of the Company, Sub and
    Parent agrees to use its reasonable best efforts, after
    consultation with the other parties hereto, to respond promptly
    to all such comments of and requests by the SEC. Each of the
    Company, Sub and Parent agrees to notify the other parties
    promptly of the receipt of any written or oral comments from the
    SEC or its staff and of any request by the SEC or its staff for
    amendments or supplements to the Registration Statement or the
    Proxy Statement/Prospectus or for additional information and
    shall supply the other parties with copies of all correspondence
    between such party or any of its representatives, on the one
    hand, and the SEC or its staff, on the other hand, with respect
    to the Registration Statement or the Proxy Statement/Prospectus.
    Notwithstanding the foregoing, prior to filing the Registration
    Statement or Proxy Statement/Prospectus (or any respective
    amendment or supplement thereto) or responding to any comments
    of the SEC with respect thereto, each party (i)&#160;shall
    provide the other parties with a reasonable opportunity to
    review and comment on such document or response and
    (ii)&#160;shall reasonably consider all comments reasonably
    proposed by the other party. As soon as practicable and in any
    event within 10 Business Days after the date that the
    Registration Statement has been declared effective by the SEC,
    the Company shall mail the Proxy Statement/Prospectus
    (including, with the cooperation of Parent, all Company SEC
    Documents and Company SEC Documents incorporated therein by
    reference) to the holders of shares of Company Common Stock,
    soliciting each of the Company&#146;s stockholders to vote in
    favor of adopting this Agreement and approving the Merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Each of the Company, Sub, and Parent shall advise the
    other party, promptly after it receives notice, after the time
    when the Registration Statement has become effective, of the
    issuance of any stop order or the suspension of the
    qualification of the CVRs issuable in connection with the
    Merger. If, at any time prior to the Effective Time, any
    information relating to Sub or the Company or any of their
    respective Affiliates is discovered by the Company, Sub or
    Parent that should be set forth in an amendment or supplement to
    any of the Registration Statement or the Proxy
    Statement/Prospectus so that any of such documents would not
    include any misstatement of a material fact or omit to state any
    material fact necessary to make the statements therein, in light
    of the circumstances under which they were made, not misleading,
    the party discovering this information shall promptly notify the
    other parties and, to the extent
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    required by Law, the parties shall cause an appropriate
    amendment or supplement describing this information to be
    promptly filed with the SEC and, to the extent required by Law,
    disseminated to the stockholders of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.2&#160;&#160;<I><U>Directors&#146;
    and Officers&#146; Indemnification</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Parent shall cause the Surviving Corporation and its
    Subsidiaries (and their successors) to establish and maintain
    for a period of not less than six years from and after the
    Effective Time provisions in their certificates of
    incorporation, by-laws and other organizational documents
    concerning the indemnification and exoneration (including
    provisions relating to expense advancement) of the
    Company&#146;s and its Subsidiaries&#146; former and current
    officers, directors and employees that are no less favorable to
    those persons than the provisions of the certificate of
    incorporation, by-laws and other organizational documents of the
    Company and its Subsidiaries as in effect as of the date hereof,
    and such provisions shall not be amended, repealed or otherwise
    modified in any manner adverse to such officer, director or
    employee, except as required by applicable Law. Parent shall
    assume, be jointly and severally liable for, and honor, guaranty
    and stand surety for, and shall cause the Surviving Corporation
    to honor, in accordance with their respective terms each of the
    covenants contained in this <U>Section&#160;6.2</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;In addition to and not in limitation of the terms of
    <U>Section&#160;6.2(a)</U>, during the period ending on the
    sixth anniversary of the Effective Time, each of Parent and the
    Surviving Corporation shall indemnify and hold harmless, and
    provide advancement of expenses to, to the fullest extent
    permitted under applicable Law, each present and former
    director, officer and employee of the Company or any of its
    Subsidiaries (each such director, officer or employee, together
    with such person&#146;s heirs, executors or administrators, an
    &#147;<U>Indemnified Party</U>&#148; and collectively, the
    &#147;<U>Indemnified Parties</U>&#148;) against any costs or
    expenses (including attorneys&#146; fees), judgments, fines,
    losses, claims, damages, liabilities and amounts paid in
    settlement in connection with any actual or threatened claim,
    action, suit, Proceeding or investigation, whether civil,
    criminal, administrative or investigative, arising out of,
    relating to or in connection with (i)&#160;any acts or omissions
    occurring or alleged to occur prior to, or as of, the Effective
    Time in their capacities as officers, directors, employees or
    controlling stockholders of the Company or any of its
    Subsidiaries or taken by them at the request of the Company or
    any of its Subsidiaries (including acts or omissions in
    connection with such persons serving as an officer or director
    or in their capacity as a controlling stockholder in any entity
    if such service was at the request or for the benefit of the
    Company) or (ii)&#160;the negotiation, execution, adoption and
    approval of this Agreement, the Merger or the other transactions
    contemplated by this Agreement or arising out of or pertaining
    to the transactions contemplated by this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;For a period of six years after the Effective Time,
    Parent shall cause to be maintained in effect, without any lapse
    in coverage, the current policies of directors&#146; and
    officers&#146; liability insurance and fiduciary liability
    insurance maintained by the Company and its Subsidiaries
    (provided that Parent may substitute therefor policies of at
    least the same coverage and amounts containing terms and
    conditions that are no less advantageous to the directors and
    officers than the current policies) for a claims-reporting or
    discovery period of at least such six year period with respect
    to matters arising on or before the Effective Time; provided,
    however, that (i)&#160;in lieu of the purchase of such insurance
    by Parent, the Company or the Surviving Corporation may purchase
    a six-year extended reporting period endorsement under the
    Company&#146;s existing directors&#146; and officers&#146;
    liability insurance coverage effective for claims asserted for
    the full six year period referred to above, and (ii)&#160;during
    this period, Parent shall not be required to procure any
    coverage in excess of the amount that can be obtained for the
    remainder of the period for an annual premium of 250% of the
    current annual premium paid by the Company for its existing
    coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;The Surviving Corporation and Parent shall pay all
    reasonable expenses, including reasonable attorneys&#146; fees,
    that may be incurred by any Indemnified Party in enforcing the
    indemnity and other obligations provided in this
    <U>Section&#160;6.2</U> as such fees are incurred upon the
    written request of any Indemnified Party.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Each Indemnified Party shall, at the cost and expense
    of Parent, reasonably cooperate with Parent and the Surviving
    Corporation in the defense of any Proceeding for which
    indemnification may be sought pursuant to this
    <U>Section&#160;6.2</U> and shall furnish, at the cost and
    expense of Parent, or cause to be furnished records, documents,
    information and testimony, as may be reasonably requested by
    Parent in connection therewith.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;In the event of any Proceeding for which
    indemnification may be sought pursuant to this
    <U>Section&#160;6.2</U>, at the Effective Time, Parent will have
    the right to control the defense thereof; provided, that any
    Indemnified Party may participate in such defense with counsel
    retained by such Indemnified Party reasonably satisfactory to
    Parent.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;The rights of each Indemnified Party hereunder shall be
    in addition to, and not in limitation of, any other rights such
    Indemnified Party may have under the certificate of
    incorporation or by-laws or any other organizational documents
    of the Company or any of its Subsidiaries, any other
    indemnification arrangement in existence as of the date of this
    Agreement, the DGCL or otherwise. The provisions of this
    <U>Section&#160;6.2</U> shall survive the consummation of the
    Merger and are expressly intended to be for the benefit of, and
    shall be enforceable by, each of the Indemnified Parties and
    shall be binding on the Parent, the Surviving Corporation and
    their respective successors and assigns.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;If Parent or the Surviving Corporation or any of their
    respective successors or assigns (i)&#160;consolidates with or
    merges into any other corporation or entity and is not the
    continuing or surviving corporation or entity of the
    consolidation or merger or (ii)&#160;transfers all or
    substantially all of its properties and assets to any
    individual, corporation or other entity, then and in each case,
    proper provisions will be made so that the successors and
    assigns of Parent or the Surviving Corporation, as applicable,
    assume all of the obligations set forth in this
    <U>Section&#160;6.2</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.3&#160;&#160;<I><U>No
    Solicitation</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Subject to the provisions of this
    <U>Section&#160;6.3</U>, after the date hereof and prior to the
    Effective Time, the Company agrees that the Company and its
    Subsidiaries shall not, and that it shall use its reasonably
    best efforts to cause the officers, directors, employees,
    investment bankers, attorneys and other advisors or
    representatives (collectively,
    &#147;<U>Representatives</U>&#148;) of the Company or its
    Subsidiaries to not, (i)&#160;solicit, initiate, or knowingly
    encourage the making, submission or announcement of any inquiry
    regarding, or any proposal or offer which would reasonably be
    expected to lead to, a merger, acquisition, consolidation,
    tender offer, exchange offer or other transaction involving, or
    any proposal or offer to purchase or acquire in any manner,
    directly or indirectly, (A)&#160;assets (including equity
    interests of a Company Subsidiary) representing 15% or more of
    the assets or revenues of the Company and its Subsidiaries taken
    as a whole, or (B)&#160;15% or more of the voting securities of
    the Company, other than, in each case, transactions with Parent
    (any such proposal or offer being hereinafter referred to as an
    &#145;&#145;<U>Acquisition Proposal</U>&#148;), (ii)&#160;enter
    into, participate, continue or otherwise engage in discussions
    or negotiations with, or provide any non-public information to
    any Person (other than Parent, Sub and their Representatives)
    with respect to any inquiries regarding, or the making,
    submission or announcement of, an Acquisition Proposal,
    (iii)&#160;enter into or approve any letter of intent, agreement
    in principle, option agreement, share purchase agreement,
    acquisition agreement or similar agreement for an Acquisition
    Proposal, or (iv)&#160;terminate, waive, amend or modify any
    provision of, or grant permission under, any standstill,
    confidentiality agreement or similar contract to which the
    Company or any Company Subsidiary is a party; provided, that the
    foregoing shall not prohibit the Board of Directors from
    terminating, waiving, amending or modifying any provision of, or
    granting permission under, any standstill, confidentiality
    agreement or similar contract if the Board of Directors
    determines in good faith that the failure to take such action,
    would be reasonably likely to constitute a breach of the Board
    of Directors&#146; fiduciary duties to the Company&#146;s
    stockholders under applicable Law. The Company shall
    (i)&#160;immediately cease and cause to be terminated any
    existing solicitation, discussion or negotiation with any Person
    (other than Parent, Sub or their Representatives) conducted
    prior to the date of this Agreement by the Company, its
    Subsidiaries or any of their respective Representatives with
    respect to any actual or potential Acquisition Proposal and
    (ii)&#160;as promptly as reasonably practicable request that all
    confidential information provided by or on behalf of the Company
    or any of its Subsidiaries to such third party be returned or
    destroyed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Subject to the provisions of this
    <U>Section&#160;6.3</U>, the Company may, and may authorize any
    of its Representatives to, prior to the date on which the
    Stockholder Approval is obtained, (A)&#160;in response to a
    request by a Person who has made a bona fide written Acquisition
    Proposal that was not initiated or solicited in violation of
    <U>Section&#160;6.3(a)</U>, provide information to such Person
    (including to potential financing sources of such Person), if
    the Company receives from such Person so requesting the
    information an executed confidentiality agreement no more
    favorable in any material respect to such Person than the
    Confidentiality Agreement (as defined in
    <U>Section&#160;6.4</U>) is to Parent (it being agreed that the
    Company shall promptly provide to Parent, in accordance with the
    terms of the Confidentiality Agreement, any information
    concerning the Company or its Subsidiaries provided to such
    other Person which was not previously provided to Parent);
    <FONT style="white-space: nowrap">and/or</FONT>
    (B)&#160;engage in discussions or negotiations with any Person
    (and such Person&#146;s potential financing sources) who has
    made a bona fide written Acquisition Proposal that was not
    initiated or solicited in violation of
    <U>Section&#160;6.3(a)</U>, if, in each case, the Board of
    Directors determines in good faith after consultation with the
    Company&#146;s financial advisor and outside legal counsel that
    (1)&#160;failure to take
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    this action would be reasonably likely to constitute a breach of
    its fiduciary duties to the Company&#146;s stockholders under
    applicable Law and (2)&#160;the Acquisition Proposal either
    constitutes a Superior Proposal or is reasonably likely to lead
    to a Superior Proposal. As used in this Agreement,
    &#147;<U>Superior Proposal</U>&#148; means an unsolicited, bona
    fide written Acquisition Proposal made after the date hereof
    (for this purpose substituting &#147;60%&#148; for each
    reference to 15% in the definition of &#147;Acquisition
    Proposal&#148;) and that the Board of Directors determines in
    good faith (after consultation with the Company&#146;s financial
    advisor and outside legal counsel) is reasonably expected to be
    consummated on the terms proposed, taking into account all
    legal, financial and regulatory aspects of the proposal,
    including the financing terms thereof and the Person making such
    proposal, and if consummated would result in a transaction that
    is more favorable to the stockholders of the Company from a
    financial point of view than the transactions contemplated by
    this Agreement (after taking into account any revisions to the
    terms of the transactions contemplated by this Agreement agreed
    to by Parent pursuant to <U>Section&#160;6.3(c)</U>).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;The Company shall notify Parent orally and in writing
    promptly (and in any event within 24&#160;hours) after receipt
    of any Acquisition Proposal or any request for information or
    inquiry which could reasonably be expected to lead to an
    Acquisition Proposal. The written notice shall include the
    identity of the Person making such Acquisition Proposal, request
    or inquiry, the material terms of the Acquisition Proposal,
    request or inquiry (including any material written amendments or
    modifications, or any proposed material written amendments or
    modifications, thereto), and the Company shall keep Parent
    reasonably informed on a current basis of any material changes
    with respect to such Acquisition Proposal, request or inquiry.
    The Company shall provide Parent with at least 36&#160;hours
    prior notice (or such shorter notice as may be provided to the
    Board of Directors) of any meeting of the Board of Directors at
    which the Board of Directors is reasonably expected to determine
    that an Acquisition Proposal is a Superior Proposal. The Company
    shall not exercise its right to terminate this Agreement
    pursuant to <U>Section&#160;8.1(e)</U> hereof, and any purported
    termination pursuant thereto shall be void of no force or
    effect, until after the fifth Business Day following
    Parent&#146;s receipt from the Company of written notice
    (i)&#160;advising Parent that the Board of Directors has
    received a Superior Proposal, specifying the material terms and
    conditions of the Superior Proposal (and attaching a copy of the
    definitive agreement related thereto, if available) and stating
    that the Board of Directors intends to exercise its right to
    terminate this Agreement pursuant to <U>Section&#160;8.1(e)</U>.
    The Company agrees that after notifying Parent that an
    Acquisition Proposal is a Superior Proposal, including during
    the five-Business Day period specified in the preceding sentence
    (such period, the &#147;<U>Parent Review Period</U>&#148;),
    Parent will be permitted to propose to the Company revisions to
    the terms of the transactions contemplated by this Agreement,
    and the Company and its Representatives will, if requested by
    Parent, consider in good faith any revisions to the terms of the
    transactions contemplated by this Agreement proposed by Parent.
    The Company shall not be entitled to terminate this Agreement
    pursuant to <U>Section&#160;8.1(e)</U> if Parent has, during the
    Parent Review Period, made a binding offer that, after
    consideration of such offer by the Board of Directors in good
    faith and after consultation with the Company&#146;s financial
    advisor and outside legal counsel, results in the Board of
    Directors concluding that such Superior Proposal no longer
    constitutes a Superior Proposal. In the event of any amendment
    to the consideration or any other material revisions to the
    Superior Proposal, the Company shall be required to deliver a
    new written notice to Parent and to comply with the requirements
    of this <U>Section&#160;6.3(c)</U> with respect to such new
    written notice (including a new Parent Review Period except that
    the new Parent Review Period shall be three Business Days).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;The Company agrees that any action taken by any of its
    Subsidiaries or a Representative of the Company or any of its
    Subsidiaries that, if taken by the Company, would constitute a
    breach of the restrictions set forth in this
    <U>Section&#160;6.3</U>, shall be deemed to be a breach of this
    Agreement (including this <U>Section&#160;6.3</U>) by the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Nothing contained in this <U>Section&#160;6.3</U> shall
    prohibit the Company or its Board of Directors from taking and
    disclosing to the Company&#146;s stockholders a position with
    respect to a tender offer by a third party pursuant to
    <FONT style="white-space: nowrap">Rules&#160;14d-9</FONT>
    and <FONT style="white-space: nowrap">14e-2(a)</FONT>
    promulgated under the Exchange Act or from making such
    disclosure to the Company&#146;s stockholders which, in the
    judgment of the Board of Directors after receiving advice of
    outside legal counsel, is reasonably likely to be required under
    applicable Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.4&#160;&#160;<I><U>Access
    to Information; Confidentiality</U>.</I>&#160;&#160;The Company
    shall, and shall cause each of its Subsidiaries to,
    (i)&#160;afford to Parent and its Representatives, upon
    reasonable notice, reasonable access during normal business
    hours during the period prior to the Effective Time to all their
    respective employees, agents, properties, books, Contracts,
    commitments and records; provided, however<I>, </I>that such
    access shall not unreasonably disrupt the Company&#146;s
    operations, and (ii)&#160;furnish promptly such information
    concerning the business, properties,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Contracts, assets, liabilities, personnel and other aspects of
    the Company and its Subsidiaries as Parent or its
    Representatives may reasonably request. Notwithstanding anything
    to the contrary in this <U>Section&#160;6.4</U>, (x)&#160;the
    Company shall not be required to provide any information which
    it reasonably believes it may not provide Parent or Sub by
    reason of applicable Law (including antitrust Laws), which
    constitutes information protected by attorney/client privilege,
    or which the Company or any Subsidiary is required to keep
    confidential by reason of Contracts with third parties and
    (y)&#160;with respect to the Trade Secrets included in the
    Company Intellectual Property, prior to the Effective Time the
    Company will provide during normal business hours, to not more
    than three Representatives of Parent selected by Parent,
    reasonable access to documentation related to Trade Secrets,
    provided that such individuals execute a separate
    confidentiality agreement with the Company covering chemistry,
    manufacturing and controls and related matters in a form
    substantially identical to the form previously executed by
    Parent&#146;s employees. The parties will use reasonable best
    efforts to make appropriate substitute disclosure arrangements
    under circumstances in which the restrictions of the preceding
    sentence apply. All information exchanged pursuant to this
    <U>Section&#160;6.4</U> shall be subject to the confidentiality
    agreement, dated October&#160;16, 2009 (the
    &#145;&#145;<U>Confidentiality Agreement</U>&#148;), between the
    Company and Parent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.5&#160;&#160;<I><U>Reasonable
    Best Efforts; Notification</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Upon the terms and subject to the conditions set forth
    in this Agreement, each of the parties shall use its reasonable
    best efforts to take, or cause to be taken, all reasonable
    actions, and to do, or cause to be done, and to assist and
    cooperate with the other parties in doing, all things reasonably
    necessary, proper or advisable to consummate and make effective,
    in the most expeditious manner practicable, the Merger,
    including (i)&#160;the obtaining of all Consents and the making
    of all Registrations specified in <U>Section&#160;3.3(c)</U> and
    <U>Section&#160;4.4</U> and the taking of all reasonable steps
    as may be necessary to obtain such Consents and to make such
    Registrations, (ii)&#160;the obtaining of all necessary
    consents, approvals or waivers from third parties,
    (iii)&#160;the defending of any lawsuits or other Proceedings,
    whether judicial or administrative, challenging this Agreement
    or the consummation of the Merger, including, seeking to have
    any stay or temporary restraining order entered by any court or
    other Governmental Entity vacated or reversed, and (iv)&#160;the
    execution and delivery of any additional instruments necessary
    to consummate the Merger and to fully carry out the purposes of
    this Agreement; <I>provided, however</I>, that the obligations
    set forth in this sentence shall not be deemed to have been
    breached as a result of actions taken by the Company that are
    permitted under <U>Section&#160;6.3</U>. Notwithstanding the
    foregoing, neither Parent or Sub, on the one hand, and the
    Company, on the other hand, shall be obligated to amend or waive
    the provisions of any Contract, or obligated to pay any consent
    or similar fees or payments, unless such action is conditioned
    upon the consummation of the Merger. Without limiting the
    foregoing, none of the parties shall take or agree to take any
    action that could reasonably be expected to result in any of the
    conditions set forth in <U>Article&#160;VII</U> not being
    satisfied or to prevent or materially delay the consummation of
    the Merger or the transactions contemplated by this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Without limiting the foregoing, each of Parent and the
    Company undertakes and agrees to file as soon as practicable,
    and in any event prior to 10 Business Days after the date
    hereof, a Notification and Report Form under the HSR Act with
    the United States Federal Trade Commission (the
    &#145;&#145;<U>FTC</U>&#148;) and the Antitrust Division of the
    United States Department of Justice (the
    &#145;&#145;<U>Antitrust Division</U>&#148;). Each of Parent and
    the Company shall (i)&#160;respond as promptly as practicable to
    any inquiries received from the FTC or the Antitrust Division
    for additional information or documentation and to all inquiries
    and requests received from any state attorney general or other
    Governmental Entity in connection with antitrust matters, and
    (ii)&#160;not extend any waiting period under the HSR Act or
    enter into any agreement with the FTC or the Antitrust Division
    not to consummate the transactions contemplated by this
    Agreement, except with the prior written consent of the other
    parties hereto (which consent shall not be unreasonably withheld
    or delayed). Parent shall use its reasonable best efforts to
    avoid or eliminate impediments under any antitrust, competition,
    or trade regulation law that may be asserted by the FTC, the
    Antitrust Division, any state attorney general or any other
    Governmental Entity with respect to the Merger so as to enable
    the consummation thereof as promptly as reasonably practicable
    and shall defend through litigation on the merits any claim
    asserted in any court by any party, including appeals. Without
    limiting the foregoing and subject to this
    <U>Section&#160;6.5(b)</U>, Parent shall propose, negotiate,
    commit to and effect, by consent decree, hold separate order, or
    otherwise, the sale, divestiture or disposition of such assets
    or businesses of Parent or, effective as of the Effective Time,
    the Surviving Corporation, or their respective Subsidiaries or
    otherwise commit to take any action which it is capable of
    taking, take or commit to take such action that limits its
    freedom of action with respect to, or its ability to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    retain, any of the businesses, services or assets of Parent, the
    Surviving Corporation or their respective Subsidiaries, in order
    to avoid the entry of, or to effect the dissolution of, any
    injunction, temporary restraining order or other order in any
    suit or Proceeding, or any impediment under any antitrust Law,
    competition, or trade regulation&#160;Law, which would otherwise
    have the effect of preventing the consummation of the Merger.
    Notwithstanding any of the foregoing, nor anything else
    contained in this Agreement, Parent shall not be required to
    sell, divest or otherwise dispose of, hold separate, enter into
    any license or similar agreement with respect to, restrict the
    ownership or operation of, or agree to sell, divest or otherwise
    dispose of, hold separate, enter into any license or similar
    agreement with respect to, or restrict the ownership or
    operation of (i)(A) any assets or businesses of the Company or
    any of its Subsidiaries or (B)&#160;any assets or businesses of
    Parent or any of its Affiliates or Subsidiaries, in the case of
    either clause&#160;(A) or (B), to the extent that such sale,
    divestiture, disposition, or agreement would have a material
    adverse effect on the business, operations, financial condition
    or results of operations of the combined business of Parent and
    the Company after giving effect to the consummation of the
    transactions contemplated by this Agreement, or (ii)&#160;the
    Product to the extent such sale, divestiture, disposition,
    agreement or restriction would have a material adverse effect on
    the ability of the Company to exploit the Product in the
    Applicable Jurisdictions. The Company shall agree if, and solely
    if, requested by Parent, to divest, hold separate or otherwise
    take or commit to take any action that limits its freedom of
    action with respect to, or its ability to retain, any of the
    businesses, services, or assets of the Company or any of its
    Subsidiaries, provided that any such action shall be conditioned
    upon the consummation of the Merger and the transactions
    contemplated hereby. Each party shall (i)&#160;promptly notify
    the other party of any material communication to that party from
    the FTC, the Antitrust Division, any state attorney general or
    any other Governmental Entity and, subject to applicable Law,
    permit the other party to review in advance any proposed written
    communication to any of the foregoing; (ii)&#160;to the extent
    practicable not agree to participate in any substantive meeting
    or discussion with any Governmental Entity in respect of any
    filings, investigation or inquiry concerning this Agreement or
    the Merger unless it consults with the other party in advance
    and, to the extent permitted by such Governmental Entity, gives
    the other party the opportunity to attend and participate
    thereat; and (iii)&#160;furnish the other party with copies of
    all correspondence, filings, and communications (and memoranda
    setting forth the substance thereof) between them and their
    Affiliates and their respective Representatives on the one hand,
    and any Governmental Entity or members of their respective
    staffs on the other hand, with respect to this Agreement and the
    Merger. Subject to its obligations in
    <U>Section&#160;6.5(a)</U>, Parent shall have the right to
    determine and direct the strategy and process by which the
    parties will seek required approvals under antitrust,
    competition or trade regulation&#160;Laws; provided that Parent
    will consult with and consider in good faith the views of the
    Company in connection with proceedings under or relating to any
    such Laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.6&#160;&#160;<I><U>Benefit
    Plans</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;During the period beginning on the Effective Time and
    ending no earlier than December&#160;31, 2011 (the
    &#147;<U>Transition Period</U>&#148;), Parent shall provide, or
    shall cause the Surviving Corporation to provide, each active
    employee of the Company or its Subsidiaries as of the Effective
    Time (each, an &#147;<U>Employee</U>&#148;) with salary, cash
    bonus opportunities and employee benefits (including
    equity-based benefits) that are not materially less favorable in
    the aggregate than (i)&#160;the salary, cash bonus opportunities
    and employee benefits in effect with respect to such Employee on
    the date of this Agreement or as increased after the date of
    this Agreement consistent with the provisions of
    <U>Section&#160;5.1(j)</U>; (ii)&#160;the salary, cash bonus
    opportunities and employee benefits generally provided by Parent
    and its Subsidiaries (other than the Surviving Corporation and
    its Subsidiaries) from time to time to employees of Parent and
    its Subsidiaries (other than the Surviving Corporation and its
    Subsidiaries) in the country that is such Employee&#146;s
    principal place of employment who are similarly situated to such
    Employee in title, rank, tenure (counting tenure with the
    Company and its Subsidiaries prior to the Effective Time to the
    extent recognized by the Company or its Subsidiaries prior to
    the Effective Time and reflected on the books and records of the
    Company) and job duties; or (iii)&#160;any combination of the
    foregoing (e.g., during the Transition Period, Parent may
    transition an Employee into one or more of its employee benefit
    programs while maintaining the Employee&#146;s salary and cash
    bonus opportunities as in effect immediately prior to the
    Effective Time); provided, that, (x)&#160;for purposes of and
    subject to this <U>Section&#160;6.6(a)</U>, Parent shall
    determine in its sole discretion the combination of compensation
    and benefits described in clauses&#160;(i) through (iii)&#160;to
    be provided to any Employee during the Transition Period and
    (y)&#160;nothing in this <U>Section&#160;6.6(a)</U> shall be
    deemed to prohibit Parent from changing the title, rank or job
    duties of any Employee at any time after the Effective Time.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;To the extent that Employees become eligible to
    participate in any &#147;employee benefit plan,&#148; as defined
    in Section&#160;3(3) of ERISA, maintained by Parent or any of
    its Subsidiaries (collectively, the &#147;<U>Parent
    Plans</U>&#148;), then for purposes of determining eligibility
    to participate and vesting and, with respect to any Parent Plan
    that provides severance, vacation or paid-time off benefits, for
    purposes of benefit accrual, service with the Company or any of
    its Subsidiaries prior to the Effective Time shall be treated as
    service with Parent or any of its Subsidiaries, in each case
    except as prohibited by an insurer or service provider under a
    Parent Plan or by applicable Law; <I>provided, however, </I>that
    such service shall not be recognized to the extent that such
    recognition would result in any duplication of benefits. In
    addition, subject to the terms of the applicable Parent Plan and
    applicable Law, Parent shall use reasonable best efforts to
    (i)&#160;waive all limitations as to preexisting conditions,
    exclusions and waiting periods with respect to participation and
    coverage requirements applicable to the Employees under any
    Parent Plan that is a welfare benefit plan in which such
    Employees may be eligible to participate after the Effective
    Time and (ii)&#160;provide each Employee with credit for any
    co-payments and deductibles paid prior to the Effective Time in
    satisfying any applicable deductible or
    <FONT style="white-space: nowrap">out-of-pocket</FONT>
    requirements under any Parent Plans that are welfare plans in
    which such Employees are eligible to participate after the
    Effective Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Unless Parent directs the Company otherwise in writing
    no later than five Business Days prior to the Effective Time,
    the Board of Directors shall adopt resolutions terminating,
    effective at least one day prior to the Effective Time, the
    Company&#146;s 401(k) Retirement Plan. Prior to the Effective
    Time, the Company shall provide Parent with executed resolutions
    of the Board of Directors authorizing such termination in a form
    reasonably acceptable to Parent. The Company shall also take
    such other actions in furtherance of the termination of the
    Company&#146;s 401(k) Retirement Plan as Parent may reasonably
    require.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Nothing contained in this <U>Section&#160;6.6</U> shall
    (i)&#160;be treated as an amendment of any particular Parent
    Plan, (ii)&#160;give any third party any right to enforce or
    confer upon the applicability of the provisions of this
    <U>Section&#160;6.6</U> or (iii)&#160;obligate Parent or any of
    its Subsidiaries to (A)&#160;maintain any particular Employee
    Benefit Plan or Parent Plan or (B)&#160;retain the employment of
    any particular Employee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Parent shall, or shall cause the Surviving Corporation
    to, comply with the provisions set forth on
    <U>Section&#160;6.6(e)</U> of the Disclosure Schedule.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.7&#160;&#160;<I><U>Fees
    and Expenses</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Except as otherwise provided by this Agreement, all
    fees and expenses incurred in connection with the Merger and the
    other transactions contemplated by this Agreement shall be paid
    by the party incurring such fees or expenses, whether or not the
    Merger is consummated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Subject to <U>Section&#160;6.7(d)</U>, the Company
    agrees to pay Parent a fee equal to $145,000,000 if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;this Agreement is terminated by (A)&#160;the Company
    pursuant to <U>Section&#160;8.1(e)</U> (in which case, the fee
    shall be payable at the time of termination) or (B)&#160;Parent
    pursuant to <U>Section&#160;8.1(c)(ii)</U> or
    <U>Section&#160;8.1(d)</U> (in which case, the fee shall be
    payable within two Business Days after such termination);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;(x)&#160;this Agreement is terminated by Parent
    pursuant to <U>Section&#160;8.1(c)(i)</U>, (y)&#160;prior to the
    date upon which the breach giving rise to Parent&#146;s right to
    terminate this Agreement pursuant to
    <U>Section&#160;8.1(c)(i)</U> occurs but after the date hereof,
    a bona fide Acquisition Proposal (which, for purposes of this
    <U>Section&#160;6.7(b)</U>, shall have the meaning set forth in
    the definition of Acquisition Proposal contained in
    <U>Section&#160;6.3(a)</U>, except that all references to 15%
    shall be deemed references to &#147;60%&#148;) for the Company
    shall have been publicly announced (other than by Parent or its
    Affiliates) and (z)&#160;within 12&#160;months after such
    termination either the Company shall have entered into a
    definitive agreement relating to an Acquisition Proposal or a
    transaction contemplated by an Acquisition Proposal for the
    Company shall have been consummated (in which case, the fee
    shall be payable within two Business Days thereafter);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;(x)&#160;this Agreement is terminated by Parent or
    the Company pursuant to <U>Section&#160;8.1(b)(iii),</U>
    (y)&#160;prior to the date of the Company Stockholder Meeting
    but after the date hereof, a bona fide Acquisition Proposal for
    the Company shall have been publicly announced (other than by
    Parent or its Affiliates) and (z)&#160;within 12&#160;months
    after such termination either the Company shall have entered
    into a definitive agreement relating to an Acquisition
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposal or a transaction contemplated by an Acquisition
    Proposal for the Company shall have been consummated (in which
    case, the fee shall be payable within two Business Days
    thereafter);&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iv)&#160;(w)&#160;this Agreement is terminated by Parent or the
    Company pursuant to <U>Section&#160;8.1(b)(i)</U>,
    (x)&#160;prior to such termination, the Antitrust Approval shall
    have been obtained, (y)&#160;prior to such termination but after
    the date hereof, a bona fide Acquisition Proposal for the
    Company shall have been publicly announced (other than by Parent
    or its Affiliates) and (z)&#160;within 12&#160;months after such
    termination either the Company shall have entered into a
    definitive agreement relating to an Acquisition Proposal or a
    transaction contemplated by an Acquisition Proposal for the
    Company shall have been consummated (in which case, the fee
    shall be payable within two Business Days thereafter).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;The fee payable pursuant to <U>Section&#160;6.7(b)</U>
    shall be made by wire transfer of same day funds to an account
    designated in writing by Parent. The Company acknowledges that
    the agreements contained in <U>Section&#160;6.7(b)</U> are an
    integral part of the transactions contemplated by this
    Agreement, and that, without these agreements, Parent and Sub
    would not enter into this Agreement; accordingly, if the Company
    fails to promptly pay the amount due pursuant to
    <U>Section&#160;6.7(b)</U>, and, in order to obtain such
    payment, Parent or Sub commences a suit which results in a
    binding nonappealable judgment rendered by a court of competent
    jurisdiction against the Company for the fee set forth in
    <U>Section&#160;6.7(b)</U>, the Company shall pay to Parent or
    Sub its reasonable documented costs and expenses (including
    reasonable attorneys&#146; fees) in connection with such suit
    together with interest on the amount due at the prime rate of
    Bank of America N.A. in effect on the date such payment was
    required to be made hereunder plus 2% per annum.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Parent agrees that, except in the case of fraud or a
    willful and material breach hereof (as defined in
    <U>Section&#160;8.2</U>), the payment provided for in
    <U>Section&#160;6.7(b)</U> shall be the sole and exclusive
    remedy of Parent upon termination of this Agreement under
    circumstances giving rise to an obligation (or potential
    obligation) of the Company to pay the amounts set forth in
    <U>Section&#160;6.7(b)</U> and such remedy shall be limited to
    the aggregate of the sums stipulated in such
    <U>Section&#160;6.7(b)</U>.&#160;&#160;In no event shall the
    Company be required to pay to Parent more than one termination
    fee pursuant to <U>Section&#160;6.7(b)</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.8&#160;&#160;<I><U>Public
    Announcements</U>.</I>&#160;&#160;The initial press release with
    respect to this Agreement, the Merger and the other transactions
    contemplated hereby shall be a joint release mutually agreed
    upon by the Company and Parent. Thereafter, Parent and Sub, on
    the one hand, and the Company, on the other hand, shall use
    reasonable efforts to consult with each other before issuing,
    and provide each other the opportunity to review and comment
    upon, any press release or other public statements with respect
    to the Merger and the other transactions contemplated by this
    Agreement and, unless it has made reasonable efforts to do the
    foregoing, shall not issue any such press release or make any
    such public statement prior to such consultation, except as may
    be required by applicable Law, court process or by obligations
    pursuant to any listing agreement with any national securities
    exchange. Notwithstanding the foregoing provisions of this
    <U>Section&#160;6.8</U>, Parent and the Company and their
    respective Representatives may make public releases or
    announcements concerning the transactions contemplated hereby
    that are not inconsistent with previous press releases or other
    public statements made by Parent
    <FONT style="white-space: nowrap">and/or</FONT> the
    Company in compliance with this <U>Section&#160;6.8</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.9&#160;&#160;<I><U>Sub</U>.</I>&#160;&#160;Parent
    will take all action necessary (a)&#160;to cause Sub to perform
    its obligations under this Agreement to consummate the Merger in
    accordance with the terms and subject to the conditions set
    forth in this Agreement and (b)&#160;to ensure that, prior to
    the Effective Time, Sub shall not conduct any business or make
    any investments other than as specifically contemplated by this
    Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.10&#160;&#160;<I><U>CVR
    Agreement</U>.</I>&#160;&#160;At or prior to the Closing, Parent
    will duly adopt, execute and deliver, and shall ensure that a
    duly qualified Trustee executes and delivers, the CVR Agreement,
    subject to any reasonable revisions to the CVR Agreement that
    are requested by such Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.11&#160;&#160;<I><U>Transfer
    Taxes</U>.</I>&#160;&#160;Parent shall assume liability for and
    pay all sales, use, transfer, real property transfer,
    documentary, recording, gains, stock transfer and similar Taxes
    and fees, and any deficiency, interest or penalty asserted with
    respect thereof (collectively, &#145;&#145;<U>Transfer
    Taxes</U>&#148;) resulting from the transactions effected
    pursuant to this Agreement. The Company shall cooperate with
    Parent as to the filing of all necessary documentation and Tax
    Returns with respect to such Transfer Taxes.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.12&#160;&#160;<I><U>Listing</U>.</I>&#160;&#160;As
    promptly as practicable after the date hereof, Parent shall
    prepare and submit to the NASDAQ (or such other exchange(s),
    electronic trading networks or other suitable trading platforms
    as are mutually agreed by Parent and the Company) an application
    covering the CVRs and the shares of Parent Common Stock being
    issued in the Merger and shall use its reasonable best efforts
    to cause the CVRs and the shares of Parent Common Stock being
    issued in the Merger (including any CVRs which may be issued
    pursuant to <U>Section&#160;2.7(a)(i)</U> and
    <U>Section&#160;2.7(b)(i)</U>) to be approved for listing
    (subject to notice of issuance) for trading on the NASDAQ (or
    such other exchange(s), electronic trading networks or other
    suitable trading platforms as are mutually agreed by Parent and
    the Company) at or prior to the Effective Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.13&#160;&#160;<I><U>Certain
    Notices</U>.</I>&#160;&#160;Subject to compliance with all
    applicable Laws, the Company and Parent, as the case may be,
    shall confer on a regular basis with each other, report on
    operational matters and shall promptly advise each other orally
    and in writing upon becoming aware of any Event having, or which
    would be reasonably likely to have, individually or in the
    aggregate, a Company Material Adverse Effect. Parent and the
    Company shall give prompt notice to the other of any Event of
    which it obtains Knowledge that would be reasonably expected to
    materially delay or prevent the consummation of the Merger.
    Furthermore, the Company shall give prompt notice to Parent, and
    Parent or Sub shall give prompt notice to the Company, upon, to
    the Knowledge of the Company or the Knowledge of Parent, as
    applicable (i)&#160;any representation or warranty made by it in
    this Agreement becoming untrue or inaccurate in any material
    respect, (ii)&#160;the occurrence of any condition, event or
    circumstance that would be reasonably expected to result in any
    of the conditions in <U>Section&#160;7.2(a)</U> or
    <U>Section&#160;7.3(a)</U> not being met, or (iii)&#160;the
    failure by it to comply with or satisfy in any material respect
    any covenant or agreement to be complied with or satisfied by it
    under this Agreement; provided, however, that no such
    notification shall affect the representations, warranties,
    covenants or agreements of, or the conditions to the obligations
    of, the parties hereto under this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.14&#160;&#160;<I><U>Section&#160;16
    Matters</U>.</I>&#160;&#160;Prior to the Effective Time, the
    Board of Directors, or an appropriate committee of non-employee
    directors thereof, shall adopt a resolution consistent with the
    interpretive guidance of the SEC so that the disposition by any
    officer or director of the Company who is a covered Person of
    the Company for purposes of Section&#160;16 of the Exchange Act
    and the rules and regulations thereunder
    (&#147;<U>Section&#160;16</U>&#148;) of Company Common Stock,
    Options, RSUs and SARs pursuant to this Agreement and the Merger
    shall be an exempt transaction for purposes of Section&#160;16.
    Prior to the Effective Time, Parent&#146;s board of directors,
    or an appropriate committee of non-employee directors thereof,
    shall adopt a resolution consistent with the interpretive
    guidance of the SEC so that the acquisition by any officer or
    director of the Company who is a covered Person of the Company
    for purposes of Section&#160;16 of Parent Common Stock pursuant
    to this Agreement and the Merger shall be an exempt transaction
    for purposes of Section&#160;16.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.15&#160;&#160;<I><U>State
    Takeover Laws</U>.</I>&#160;&#160;If any &#147;fair price,&#148;
    &#147;moratorium,&#148; &#147;control share acquisition,&#148;
    &#147;business combination&#148; or other similar anti-takeover
    statute or regulation enacted under state or federal laws in the
    United&#160;States becomes or is deemed to be applicable to the
    Company, Parent, Sub, the Merger or the Voting Agreement or any
    other transaction contemplated by this Agreement, the Board of
    Directors shall take all action necessary to render such Law
    inapplicable to the foregoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.16&#160;&#160;<I><U>FIRPTA
    Statement</U>.</I>&#160;&#160;The Company shall use reasonable
    best efforts to deliver to Parent on or prior to the Closing
    Date a statement conforming to the requirements of
    <FONT style="white-space: nowrap">Section&#160;1.1445-2(c)(3)</FONT>
    of the Treasury Regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.17&#160;&#160;<I><U>Further
    Actions</U>.</I>&#160;&#160;The Company shall use reasonable
    best efforts to take the actions listed on
    <U>Section&#160;6.17</U> of the Disclosure Schedule prior to the
    Effective Time.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VII<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">CONDITIONS
    PRECEDENT
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.1&#160;&#160;<I><U>Conditions
    to Each Party&#146;s Obligation to Effect the
    Merger</U>.</I>&#160;&#160;The respective obligation of each
    party to effect the Merger is subject to the satisfaction or
    waiver on or prior to the Closing Date of the following
    conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<I><U>Stockholder Approval</U>.</I>&#160;&#160;This
    Agreement and the Merger shall have been duly adopted by the
    holders of a majority of the outstanding shares of Company
    Common Stock in accordance with the DGCL (the
    &#147;<U>Stockholder Approval</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<I><U>No Injunctions or
    Restraints</U>.</I>&#160;&#160;No Governmental Entity in an
    Applicable Jurisdiction shall have issued or entered a temporary
    restraining order, preliminary or permanent injunction or other
    order that is in effect and that prohibits the consummation of
    the Merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I><U>HSR Act</U>.</I>&#160;&#160;The waiting period
    (and any extension thereof) under the HSR Act applicable to the
    Merger shall have expired or been terminated (the
    &#147;<U>Antitrust Approval</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;<I><U>Registration Statement</U>.</I>&#160;&#160;The
    Registration Statement shall have been declared effective and no
    stop order suspending the effectiveness of the Registration
    Statement shall be in effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.2&#160;&#160;<I><U>Additional
    Conditions to Obligations of Parent and
    Sub</U>.</I>&#160;&#160;The obligation of Parent and Sub to
    effect the Merger is subject to the satisfaction or waiver by
    Parent on or prior to the Closing Date of the following
    additional conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)<I>&#160;<U>Representations and
    Warranties</U>.</I>&#160;&#160;(i)&#160;The representations and
    warranties of the Company set forth in
    <U>Section&#160;3.2(a)</U> shall be true and correct in all but
    de minimis respects (which for purposes of this
    <U>Section&#160;7.2</U> shall mean 2% or less of the aggregate
    outstanding shares of Company Common Stock on a fully diluted
    basis) on the date of this Agreement and at the Closing as
    though made on and as of the Closing Date (except to the extent
    that such representation and warranty speaks as of a particular
    date, in which case such representation and warranty shall be
    true and correct as of that date), and (ii)&#160;the other
    representations and warranties of the Company set forth in this
    Agreement shall be true and correct (without giving effect to
    any limitation as to &#147;materiality&#148; or &#147;Company
    Material Adverse Effect&#148; set forth therein) on the date of
    this Agreement and at the Closing as though made on and as of
    the Closing Date (except to the extent that such representation
    and warranty speaks as of a particular date, in which case such
    representation and warranty shall be true and correct as of that
    date), except where the failure of the representations and
    warranties to so be true and correct has not had and would not
    reasonably be expected to have, individually or in the
    aggregate, a Company Material Adverse Effect. Parent shall have
    received a certificate to such effect signed on behalf of the
    Company by an executive officer of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<I><U>Performance of
    Obligations</U>.</I>&#160;&#160;The Company shall have performed
    or complied with, in all material respects, its obligations and
    covenants required to be performed or complied with by it under
    this Agreement at or prior to the Closing, and Parent shall have
    received a certificate signed on behalf of the Company by an
    executive officer of the Company to such effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I><U>Absence of Material Adverse
    Effect</U>.</I>&#160;&#160;Since the date of this Agreement,
    there shall not have occurred any Company Material Adverse
    Effect, and Parent shall have received a certificate signed on
    behalf of the Company by an executive officer of the Company to
    such effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;<I><U>Related Agreements</U>.</I>&#160;&#160;The
    Related Agreements shall be in full force and effect in
    accordance with their terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.3&#160;&#160;<I><U>Additional
    Conditions to Obligations of the Company</U>.</I>&#160;&#160;The
    obligation of the Company to effect the Merger is subject to the
    satisfaction or waiver by the Company on or prior to the Closing
    Date of the following additional conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<I><U>Representations and
    Warranties</U>.</I>&#160;&#160;The representations and
    warranties of Parent set forth in this Agreement shall be true
    and correct (without giving effect to any limitation as to
    &#147;materiality&#148; or &#147;Parent Material Adverse
    Effect&#148; set forth therein) on the date of this Agreement
    and at the Closing as though made on and as of the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Closing Date (except to the extent that such representation and
    warranty speaks as of a particular date, in which case such
    representation and warranty shall be true and correct as of that
    date), except where the failure of the representations and
    warranties to so be true and correct has not had and would not
    reasonably be expected to have, individually or in the
    aggregate, a Parent Material Adverse Effect. The Company shall
    have received a certificate to such effect signed on behalf of
    Parent by an executive officer of Parent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<I><U>Performance of
    Obligations</U>.</I>&#160;&#160;Parent and Sub shall have
    performed or complied with, in all material respects, its
    obligations and covenants required to be performed or complied
    with by them under this Agreement at or prior to Closing, and
    the Company shall have received a certificate signed on behalf
    of Parent and Sub by an executive officer of each of Parent and
    Sub to such effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I><U>Absence of Material Adverse
    Effect</U>.</I>&#160;&#160;Since the date of this Agreement,
    there shall not have occurred any Parent Material Adverse
    Effect, and the Company shall have received a certificate signed
    on behalf of Parent by an executive officer of Parent to such
    effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;<I><U>CVR Agreement</U>.</I>&#160;&#160;The CVR
    Agreement shall have been duly executed and delivered by Parent
    and the Trustee and be in full force and effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;<I><U>Listing</U>.</I>&#160;&#160;The shares of Parent
    Common Stock being issued in the Merger shall have been approved
    for listing (subject to notice of issuance) for trading on
    NASDAQ.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.4&#160;&#160;<I><U>Frustration
    of Closing Conditions</U>.</I>&#160;&#160;None of the Company,
    Parent or Sub may rely on the failure of any condition precedent
    set forth in this <U>ARTICLE&#160;VII</U> to be satisfied if
    such failure was caused by such party&#146;s failure to comply
    with its obligations set forth in this Agreement to consummate
    and make effective the transactions provided for herein, as
    required by and subject to <U>Section&#160;6.5</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.5&#160;&#160;<I><U>Invoking
    Certain Provisions</U>.</I>&#160;&#160;If Parent and Sub wish to
    invoke any of the conditions set forth in
    <U>Section&#160;7.2</U> as a basis not to consummate the Merger,
    Parent or Sub, as applicable, will have the burden of proof to
    establish that such condition has not been satisfied; provided,
    that if Parent and Sub satisfy the burden of proof that a
    Company Material Adverse Effect has occurred (without regard to
    the exclusions applicable thereto), the Company will have the
    burden of proof to establish that any exclusion in the
    definition of Company Material Adverse Effect is applicable. If
    the Company wishes to invoke any of the conditions set forth in
    <U>Section&#160;7.3</U> as a basis not to consummate the Merger,
    the Company will have the burden of proof to establish that such
    condition has not been satisfied; provided, that if the Company
    satisfies the burden of proof that a Parent Material Adverse
    Effect has occurred (without regard to the exclusions applicable
    thereto), Parent will have the burden of proof to establish that
    any exclusion in the definition of Parent Material Adverse
    Effect is applicable.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VIII<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">TERMINATION,
    AMENDMENT AND WAIVER
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.1&#160;&#160;<I><U>Termination</U>.</I>&#160;&#160;This
    Agreement may be terminated at any time prior to the Effective
    Time, whether before or after receipt of the Stockholder
    Approval:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;by mutual written consent of Parent and the Company;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;by either Parent or the Company:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;if the Closing shall not have occurred on or before
    March&#160;31, 2011 (the &#147;<U>Termination Date</U>&#148;);
    provided, however<I>, </I>that the right to terminate this
    Agreement under this <U>Section&#160;8.1(b)(i)</U> shall not be
    available to any party whose failure to fulfill any obligation
    under this Agreement has been the cause of, or resulted in, the
    failure of the Closing to occur on or before the Termination
    Date;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;if any Governmental Entity in an Applicable
    Jurisdiction shall have issued or entered a permanent injunction
    or other order that is in effect preventing or prohibiting the
    consummation of the Merger and such injunction or order shall
    have become final and nonappealable; provided that the right to
    terminate this Agreement pursuant to this
    <U>Section&#160;8.1(b)(ii)</U> shall not be available to any
    party whose failure to fulfill any obligation under this
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Agreement (including such party&#146;s obligations set forth in
    <U>Section&#160;6.5</U>) has been the cause of, or resulted in,
    such action;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;if, upon a vote at a duly held Company Stockholder
    Meeting (including any postponement or adjournment thereof) to
    obtain the Stockholder Approval in accordance with this
    Agreement, the Stockholder Approval is not obtained;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;by Parent, if (i)&#160;the Company breaches or fails to
    perform any of its representations, warranties, covenants or
    obligations contained in this Agreement, in any case, as a
    result of which a condition set forth in
    <U>Section&#160;7.2(a)</U> or <U>Section&#160;7.2(b)</U> will
    not be able to be satisfied prior to or as of the Termination
    Date (provided that Parent or Sub is not then in breach of any
    representation, warranty or covenant contained in this Agreement
    such that the conditions set forth in <U>Section&#160;7.3(a)</U>
    or <U>Section&#160;7.3(b)</U> would not then be satisfied), or
    (ii)&#160;the Company breaches or fails to perform in any
    material respect its obligations under <U>Section&#160;6.3</U>;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;by Parent, prior to the Company Stockholder Meeting, if
    (i)&#160;the Board of Directors shall have publicly withdrawn
    its approval or recommendation of this Agreement or the Merger
    or shall have publicly recommended to the stockholders of the
    Company any Acquisition Proposal, or (ii)&#160;a tender or
    exchange offer, that if successful, would result in any Person
    or group becoming the beneficial owner of 15% or more of the
    outstanding Company Stock, has been commenced (other than by
    Parent or any Affiliate of Parent) and the Board of Directors
    fails to recommend that the stockholders of the Company not
    tender their shares in such tender or exchange offer within 10
    Business Days of such commencement;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;by the Company, prior to the date on which the
    Stockholder Approval is obtained, in order to concurrently enter
    into a definitive agreement with respect to a Superior Proposal,
    provided that the Company shall have complied in all material
    respects with the terms of <U>Section&#160;6.3</U> and
    concurrently pays to Parent all amounts payable pursuant to
    <U>Section&#160;6.7(b)</U>;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;by the Company, if Parent or Sub breaches or fails to
    perform any of its representations, warranties, covenants or
    obligations contained in this Agreement, in any case, as a
    result of which a condition set forth in
    <U>Section&#160;7.3(a)</U> or <U>Section&#160;7.3(b)</U> will
    not be able to be satisfied prior to or as of the Termination
    Date (provided that the Company is not then in material breach
    of any representation, warranty or covenant contained in this
    Agreement).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.2&#160;&#160;<I><U>Effect
    of Termination</U>.</I>&#160;&#160;In the event of termination
    of this Agreement by either the Company or Parent as provided in
    <U>Section&#160;8.1</U>, this Agreement shall forthwith become
    void and have no effect, without any liability or obligation on
    the part of Parent, Sub or the Company, other than the last
    sentence of <U>Section&#160;6.4</U>, <U>Section&#160;6.7</U>,
    this <U>Section&#160;8.2</U> and <U>Article&#160;IX</U>, which
    provisions shall survive such termination, and provided that
    nothing herein shall relieve any party from liability for any
    fraud or willful and material breach hereof. For purposes
    hereof, a &#147;<U>willful and material breach</U>&#148; shall
    mean a material breach that is a consequence of an act
    undertaken by a breaching party with the knowledge (actual or
    constructive) that the taking of such action would, or would
    reasonably be expected to, give rise to a breach hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.3&#160;&#160;<I><U>Amendment</U>.</I>&#160;&#160;Subject
    to applicable Law, this Agreement may be amended, modified or
    supplemented by the parties at any time before or after receipt
    of the Stockholder Approval. This Agreement may not be amended,
    modified or supplemented except by an instrument in writing
    signed on behalf of each of the parties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.4&#160;&#160;<I><U>Extension;
    Waiver</U>.</I>&#160;&#160;At any time prior to the Effective
    Time, the parties may (a)&#160;extend the time for the
    performance of any of the obligations or other acts of the other
    parties, (b)&#160;waive any inaccuracies in the representations
    and warranties of the other parties contained in this Agreement
    or in any document delivered pursuant to this Agreement or
    (c)&#160;subject to the proviso of <U>Section&#160;8.3</U>,
    waive compliance with any of the agreements of the other parties
    or conditions in favor of such party contained in this Agreement
    (provided, that a waiver must be in writing and signed by the
    party against whom the waiver is to be effective). Any agreement
    on the part of a party to any such extension or waiver shall be
    valid only if set forth in an instrument in writing signed on
    behalf of such party. The failure of any party to this Agreement
    to assert any of its rights under this Agreement or otherwise
    shall not constitute a waiver of such rights.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.5&#160;&#160;<I><U>Procedure
    for Termination, Amendment, Extension or
    Waiver</U>.</I>&#160;&#160;A termination of this Agreement
    pursuant to <U>Section&#160;8.1</U>, an amendment of this
    Agreement pursuant to <U>Section&#160;8.3</U> or an extension or
    waiver pursuant to <U>Section&#160;8.4</U> shall, in order to be
    effective, require in the case of Parent, Sub or the Company,
    action by its board of directors or the duly authorized designee
    of its board of directors.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;IX<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">MISCELLANEOUS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.1&#160;&#160;<I><U>Non-Survival
    of Representations, Warranties and
    Agreements</U>.</I>&#160;&#160;All representations and
    warranties set forth in this Agreement or in any instrument
    delivered pursuant to this Agreement shall terminate at the
    Effective Time. None of the covenants or agreements of the
    parties in this Agreement shall survive the Effective Time,
    other than (a)&#160;the covenants and agreements of the parties
    contained in this <U>ARTICLE&#160;IX</U>, in
    <U>ARTICLE&#160;II</U> and in <U>Section&#160;6.2</U> and
    <U>Section&#160;6.6</U>, and (b)&#160;those other covenants and
    agreements contained herein that by their terms apply, or that
    are to be performed in whole or in part, after the Effective
    Time, which shall survive the consummation of the Merger until
    fully performed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.2&#160;&#160;<I><U>Notices</U>.</I>&#160;&#160;Except
    for notices that are specifically required to be delivered
    orally, all notices, requests, claims, demands and other
    communications hereunder shall be in writing and shall be deemed
    given (a)&#160;on the date of delivery, if delivered in person
    or by facsimile or
    <FONT style="white-space: nowrap">e-mail</FONT> (upon
    confirmation of receipt) prior to 5:00&#160;p.m. in the time
    zone of the receiving party or on the next Business Day, if
    delivered after 5:00&#160;p.m. in the time zone of the receiving
    party, (b)&#160;on the first Business Day following the date of
    dispatch, if delivered by a recognized overnight courier service
    (upon proof of delivery) or (c)&#160;on the fifth Business Day
    following the date of mailing, if delivered by registered or
    certified mail, postage prepaid, return receipt requested,
    addressed as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If to the Company:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience Inc.<BR>
    11755 Wilshire Blvd., 20th Floor<BR>
    Los Angeles, CA 90025<BR>
    Tel: 310.883.1300<BR>
    Fax: 310.998.8553
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Dr.&#160;Patrick Soon-Shiong, Executive Chairman<BR>
    <U>pss@abraxisbio.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with copies to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience Inc.<BR>
    11755 Wilshire Blvd., 20th Floor<BR>
    Los Angeles, CA 90025<BR>
    Tel: 310.883.1300<BR>
    Fax: 310.998.8553
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Charles Kim, General Counsel<BR>
    <U>CKim@abraxisbio.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fried, Frank, Harris, Shriver&#160;&#038; Jacobson LLP<BR>
    One New York Plaza<BR>
    New York, New York 10004<BR>
    Tel: 212.859.8000<BR>
    Fax: 212.859.4000
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Philip Richter,&#160;Esq.<BR>
    <U>philip.richter@friedfrank.com<BR>
    </U>Brian Mangino,&#160;Esq.<BR>
    <U>brian.mangino@friedfrank.com</U>
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If to Parent or Sub:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation<BR>
    86 Morris Avenue<BR>
    Summit, New Jersey 07901<BR>
    Tel: 908.673.9000<BR>
    Fax: 908.673.2769
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    George Golumbeski, Senior Vice President Business Development<BR>
    <U>ggolumbeski@celgene.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with copies to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation<BR>
    86 Morris Avenue<BR>
    Summit, New Jersey 07901<BR>
    Tel: 908.673.9000<BR>
    Fax: 908.673.2771
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Thomas Perone, Corporate Counsel<BR>
    <U>tperone@celgene.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Jones Day<BR>
    3161 Michelson Drive<BR>
    Suite&#160;800<BR>
    Irvine, CA 92612<BR>
    Tel: 949.851.3939<BR>
    Fax: 949.553.7539
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Jonn R. Beeson,&#160;Esq.<BR>
    <U>jbeeson@jonesday.com<BR>
    </U>Kevin Espinola,&#160;Esq.<BR>
    <U>kbespinola@jonesday.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    or to such other address as any party may have furnished to the
    other parties in writing in accordance with this
    <U>Section&#160;9.2</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.3&#160;&#160;<I><U>Specific
    Performance</U>.</I>&#160;&#160;The parties hereby acknowledge
    and agree that the failure of any party to perform its
    agreements and covenants hereunder in accordance with their
    specific terms, including its failure to take all actions as are
    necessary on its part to consummate the transactions
    contemplated hereby, will cause irreparable injury to the other
    party, for which damages, even if available, will not be an
    adequate remedy. Accordingly, each party hereby consents to the
    issuance of temporary, preliminary and permanent injunctive
    relief in any court of the United States or any state having
    jurisdiction to compel performance of such party&#146;s
    obligations, or to prevent breaches or threatened breaches of
    this Agreement, and to the granting by any such court of the
    remedy of specific performance of its obligations hereunder,
    without, in any such case, the requirement to post any bond or
    other undertaking, in addition to any other rights or remedies
    available hereunder or at law or in equity. Each of the parties
    further agrees that it will not oppose, and hereby waives any
    defense to, the granting of an injunction, specific performance
    and other equitable relief on the basis that the other parties
    have an adequate remedy at law or an award of specific
    performance is not an appropriate remedy for any reason at law
    or equity. Each of the parties further waives any requirement
    under any Law to post security as a prerequisite to obtaining
    equitable relief.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.4&#160;&#160;<I><U>Assignment;
    Binding Effect</U>.</I>&#160;&#160;Neither this Agreement nor
    any of the rights, interests or obligations hereunder shall be
    assigned by any of the parties hereto (whether by operation of
    Law or otherwise) without the prior written consent of the other
    parties. Subject to the preceding sentence, this Agreement shall
    be binding upon and shall inure to the benefit of the parties
    hereto and their respective successors and permitted assigns.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.5&#160;&#160;<I><U>Entire
    Agreement</U>.</I>&#160;&#160;This Agreement, the Disclosure
    Schedule, the Confidentiality Agreement, the Related Agreements
    constitute the entire agreement among the parties with respect
    to the subject matter hereof and supersede all prior agreements
    and understandings among the parties with respect thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;9.6</FONT>&#160;&#160;<I><U>Governing
    Law</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
    ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT
    REGARD TO ITS RULES&#160;OF CONFLICT OF LAWS. Each of the
    parties hereto (i)&#160;consents to submit itself to the
    personal jurisdiction of any court of the United States located
    in the State of Delaware or of the Court of Chancery in the
    State of Delaware in the event any dispute arises out of this
    Agreement or the transactions contemplated by this Agreement,
    (ii)&#160;agrees that it will not attempt to deny or defeat such
    personal jurisdiction by motion or other request for leave from
    any such court and (iii)&#160;agrees that, except as permitted
    by <U>Section&#160;9.3</U>, it will not bring any action
    relating to this Agreement or the transactions contemplated by
    this Agreement in any court other than a court of the United
    States located in the State of Delaware or the Court of Chancery
    in the State of Delaware.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY
    WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
    COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY
    HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH
    PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
    DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
    AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.
    EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i)&#160;NO
    REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS
    REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD
    NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
    WAIVER, (ii)&#160;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED
    THE IMPLICATIONS OF THIS WAIVER, (iii)&#160;EACH SUCH PARTY
    MAKES THIS WAIVER VOLUNTARILY, AND (iv)&#160;EACH SUCH PARTY HAS
    BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
    THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.7&#160;&#160;<I><U>Counterparts</U>.</I>&#160;&#160;This
    Agreement may be executed by the parties hereto in separate
    counterparts, each of which when so executed and delivered shall
    be an original, but all such counterparts shall together
    constitute one and the same instrument. Each counterpart may
    consist of a number of copies hereof each signed by less than
    all, but together signed by all of the parties hereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.8&#160;&#160;<I><U>Headings
    and Table of Contents;
    Interpretation</U>.</I>&#160;&#160;Headings of the Articles and
    Sections of this Agreement, the Table of Contents, and the Index
    of Defined Terms are for the convenience of the parties only,
    and shall be given no substantive or interpretive effect
    whatsoever. If a term is defined as one part of speech (such as
    a noun), it shall have a corresponding meaning when used as
    another part of speech (such as a verb). Whenever the context so
    requires, the singular shall include the plural, the plural
    shall include the singular, and the use of a gender shall
    include all genders. The terms &#147;hereof,&#148;
    &#147;herein&#148; and &#147;hereunder&#148; and terms of like
    import used in this Agreement shall refer to this Agreement as a
    whole and not to any particular provision of this Agreement.
    Whenever the terms &#147;include,&#148; &#147;includes&#148; or
    &#147;including&#148; are used in this Agreement, they shall be
    deemed to be followed by the words &#147;without
    limitation,&#148; whether or not they are in fact followed by
    those words or words of like import. The terms
    &#147;writing&#148; and &#147;written&#148; and terms of like
    import used in this Agreement shall refer to printing, typing
    and other means of reproducing words (including electronic
    media) in a visible form.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.9&#160;&#160;<I><U>No
    Third Party Beneficiaries</U>.</I>&#160;&#160;Except as provided
    in <U>Section&#160;2.2(c)</U> (Exchange of Certificates) and
    <U>Section&#160;6.2</U> (Directors&#146; and Officers&#146;
    Indemnification) and except for the right of the Company, on
    behalf of its stockholders, to pursue damages in the event of
    Parent&#146;s or Sub&#146;s breach of this Agreement, this
    Agreement is not intended to, and does not, confer upon any
    Person other than the parties hereto any rights or remedies
    hereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.10&#160;&#160;<I><U>Incorporation
    of Exhibits</U>.</I>&#160;&#160;The Disclosure Schedule and the
    Exhibits attached hereto and referred to herein are hereby
    incorporated herein and made a part hereof for all purposes as
    if fully set forth herein.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.11&#160;&#160;<I><U>Severability</U>.</I>&#160;&#160;Any
    term or provision of this Agreement which is invalid or
    unenforceable in any jurisdiction shall, as to that
    jurisdiction, be ineffective to the extent of such invalidity or
    unenforceability
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    without rendering invalid or unenforceable the remaining terms
    and provisions of this Agreement or affecting the validity or
    enforceability of any of the terms or provisions of this
    Agreement in any other jurisdiction. If any provision of this
    Agreement is so broad as to be unenforceable, the provision
    shall be interpreted to be only so broad as is enforceable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.12&#160;&#160;<I><U>Subsidiaries</U>.</I>&#160;&#160;As
    used in this Agreement, &#147;<U>Subsidiary</U>&#148; of any
    Person means another Person, an amount of the voting securities,
    other voting ownership or voting partnership interests of which
    is sufficient to elect at least a majority of its board of
    directors or other governing body (or, if there are no such
    voting interests, 50% or more of the equity interests of which)
    is owned directly or indirectly by such Person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.13&#160;&#160;<I><U>Person</U>.</I>&#160;&#160;As
    used in this Agreement, &#147;<U>Person</U>&#148; means an
    individual, corporation, partnership, joint venture, limited
    liability company, association, trust, unincorporated
    organization, entity (including Governmental Entity) or group
    (as defined in the Exchange Act).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.14&#160;&#160;<I><U>Applicable
    Jurisdictions</U>.</I>&#160;&#160;As used in this Agreement,
    &#147;<U>Applicable Jurisdiction</U>&#148; means any of the
    United States, the European Union, Canada or Switzerland.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.15&#160;&#160;<I><U>Knowledge
    of the Company; Knowledge of Parent</U>.</I>&#160;&#160;As used
    in this Agreement, &#145;&#145;<U>Knowledge of the
    Company</U>&#148; means the actual knowledge of the individuals
    listed in <U>Section&#160;9.14</U> of the Disclosure Schedule.
    As used in this Agreement, &#147;<U>Knowledge of
    Parent</U>&#148; means the actual knowledge of Parent&#146;s
    Chief Executive Officer, Chief Financial Officer, Chief
    Operating Officer and General Counsel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.16&#160;&#160;<I><U>Mutual
    Drafting</U>.</I>&#160;&#160;This Agreement shall be deemed to
    be the joint work product of Parent, Sub, and Company, and any
    rule of construction that a document shall be interpreted or
    construed against a drafter of such document shall not be
    applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.17&#160;&#160;<I><U>Tax
    Reporting</U>.</I>&#160;&#160;Except to the extent any portion
    of any CVR Payment (as that term is defined in the CVR
    Agreement) is required to be treated as imputed interest
    pursuant to applicable Law, the parties hereto agree to treat
    the Cash Consideration, the Stock Consideration, the CVRs and
    all CVR Payments for all Tax purposes as consideration for the
    shares of Common Stock, the Options, the SARs and the RSUs, and
    none of the parties hereto shall take any position to the
    contrary on any Tax Return or for other Tax purposes except as
    required by applicable Law.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    IN WITNESS WHEREOF, Parent, Sub and the Company have caused this
    Agreement to be signed by their respective officers thereunder
    duly authorized all as of the date first written above.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>CELGENE CORPORATION</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Robert
    J. Hugin</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Robert J. Hugin
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Chief Executive Officer
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>ARTISTRY ACQUISITION CORP.</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Sandesh
    Mahatme</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Sandesh Mahatme
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Secretary and Treasurer
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>ABRAXIS BIOSCIENCE, INC.</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Dr.&#160;Patrick
    Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Dr.&#160;Patrick Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Executive Chairman
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    A-47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='184'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;B</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">FORM&#160;OF<BR>
    CONTINGENT VALUE RIGHTS AGREEMENT<BR>
    by and between<BR>
    CELGENE CORPORATION<BR>
    and<BR>
    AMERICAN STOCK TRANSFER AND TRUST&#160;COMPANY<BR>
    Dated as of [&#160;&#149;&#160;], 2010</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="16%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="75%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 1&#160;&#160;DEFINITIONS AND OTHER PROVISIONS OF GENERAL
    APPLICATION
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Definitions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Compliance and Opinions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Documents Delivered to Trustee
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Acts of Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Notices, etc., to Trustee and Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Notice to Holders; Waiver
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Conflict with Trust&#160;Indenture Act
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Effect of Headings and Table of Contents
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Benefits of Agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Governing Law
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Legal Holidays
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Separability Clause
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    No Recourse Against Others
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.14
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Counterparts
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 1.15
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Acceptance of Trust
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 2&#160;&#160;SECURITY FORMS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 2.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Forms&#160;Generally
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 3&#160;&#160;THE SECURITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Title and Terms
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Registrable Form
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Execution, Authentication, Delivery and Dating
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Temporary Securities
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Registration, Registration of Transfer and Exchange
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Mutilated, Destroyed, Lost and Stolen Securities
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Payments with respect to CVR Certificates
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Persons Deemed Owners
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 3.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Cancellation
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 4&#160;&#160;THE TRUSTEE
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certain Duties and Responsibilities
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certain Rights of Trustee
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Notice of Default
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Not Responsible for Recitals or Issuance of Securities
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    May Hold Securities
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Money Held in Trust
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Compensation and Reimbursement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Disqualification; Conflicting Interests
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Corporate Trustee Required; Eligibility
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Resignation and Removal; Appointment of Successor
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Acceptance of Appointment of Successor
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Merger, Conversion, Consolidation or Succession to Business
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 4.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferential Collection of Claims Against Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="16%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="75%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 5&#160;&#160;HOLDERS&#146; LISTS AND REPORTS BY THE
    TRUSTEE AND COMPANY
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 5.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Company to Furnish Trustee Names and Addresses of Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 5.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preservation of Information; Communications to Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 5.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Reports by Trustee
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 5.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Reports by Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 6&#160;&#160;AMENDMENTS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendments Without Consent of Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendments with Consent of Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Execution of Amendments
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Effect of Amendments; Notice to Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Conformity with Trust&#160;Indenture Act
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 6.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Reference in Securities to Amendments
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 7&#160;&#160;COVENANTS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Payment of Amounts, if any, to Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Maintenance of Office or Agency
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Money for Security Payments to Be Held in Trust
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certain Purchases and Sales
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Books and Records
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Audits
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Listing of CVRs
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Conflicting Arrangements
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Product Transfer
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Milestones
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Product Sale and Development
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Notice of Default
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Confidentiality
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 7.14
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Non-Use of Name
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 8&#160;&#160;REMEDIES OF THE TRUSTEE AND HOLDERS ON
    EVENT OF DEFAULT
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Event of Default Defined; Waiver of Default
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Collection by the Trustee; the Trustee May Prove Payment
    Obligations
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Application of Proceeds
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Suits for Enforcement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Restoration of Rights on Abandonment of Proceedings
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Limitations on Suits by Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Unconditional Right of Holders to Institute Certain Suits
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Powers and Remedies Cumulative; Delay or Omission Not Waiver of
    Default
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Control by Holders
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Waiver of Past Defaults
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    The Trustee to Give Notice of Default, But May Withhold in
    Certain Circumstances
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 8.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Right of Court to Require Filing of Undertaking to Pay Costs
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 9&#160;&#160;CONSOLIDATION, MERGER, SALE OR CONVEYANCE
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Company May Consolidate, etc., on Certain Terms
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Successor Person Substituted
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    B-ii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="16%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="75%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Counsel to the Trustee
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 9.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Successors
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 10&#160;&#160;SUBORDINATION
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Agreement to Subordinate
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Liquidation; Dissolution; Bankruptcy
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Default on Senior Obligations
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    When Distribution Must Be Paid Over
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Notice by Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.6
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Subordination Effective Notwithstanding Deficiencies with
    Respect to Senior Obligations; Waiver of Right to Contest Senior
    Obligation; Reinstatement of Subordination Provisions
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.7
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Subrogation
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.8
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Relative Rights
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.9
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Subordination May Not Be Impaired by Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution or Notice to Representative
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Rights of the Trustee
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Authorization to Effect Subordination
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 10.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Amendments
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ARTICLE 11&#160;&#160;REDEMPTION&#160;OF SECURITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 11.1
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Notice to Trustee
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 11.2
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Notice of Redemption
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 11.3
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Effect of Notice of Redemption
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 11.4
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Deposit of Redemption&#160;Price
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section 11.5
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Optional Redemption by the Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    B-37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Annex A&#160;&#151;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of CVR Certificate.&#160;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Note: This table of contents shall not, for any purpose, be
    deemed to be a part of this CVR Agreement.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    B-iii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Reconciliation and tie between Trust&#160;Indenture Act of 1939
    and Contingent Value Rights Agreement, dated as of
    [&#160;&#149;&#160;], 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="12%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="69%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Trust Indenture Act Section</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Agreement Section</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 310
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.9
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.9
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(4)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(5)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.9
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.8, 4.10
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 311
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.13
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.13
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 312
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.1, 5.2(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.2(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.2(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 313
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.3(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.3(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.3(a), 8.11
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (d)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.3(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 314
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.4, 7.12
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)(1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1.2(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)(2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1.2(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)(3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (d)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (e)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1.2(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (f)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 315
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.1(a), 4.1(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8.11
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.1(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (d)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.1(c)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (d)(1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.1(a), 4.1(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (d)(2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.1(c)(ii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (d)(3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4.1(c)(iii)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (e)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8.12
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 316
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(last sentence)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(1)(A)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8.9
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(1)(B)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8.10
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8.7
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (c)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Not Applicable
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 317
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8.2
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)(2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8.2
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    7.3
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-variant: SMALL-CAPS">Section 318
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    (a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1.7
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Note: This reconciliation and tie shall not, for any purpose, be
    deemed to be a part of this CVR Agreement.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-iv
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of
    [&#160;&#149;&#160;], 2010 (this &#147;<U>CVR
    Agreement</U>&#148;), by and between Celgene Corporation, a
    Delaware corporation (the &#147;<U>Company</U>&#148;), and
    American Stock Transfer&#160;&#038; Trust Company, a New York
    limited liability trust company, as trustee (the
    &#147;<U>Trustee</U>&#148;), in favor of each person who from
    time to time holds one or more Contingent Value Rights (the
    &#147;<U>Securities</U>&#148; or &#147;<U>CVRs</U>&#148;) to
    receive cash payments in the amounts and subject to the terms
    and conditions set forth herein.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><U><FONT style="font-family: 'Times New Roman', Times">W I T
    N E S S E T
    H</FONT></U><FONT style="font-family: 'Times New Roman', Times">:</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, this CVR Agreement is entered into pursuant to the
    Agreement and Plan of Merger, dated as of June&#160;30, 2010 (as
    amended prior to the effective time thereof, the &#147;<U>Merger
    Agreement</U>&#148;), by and among the Company, Artistry
    Acquisition Corp., a Delaware corporation and wholly owned
    Subsidiary of the Company (&#147;<U>Sub</U>&#148;), and Abraxis
    BioScience, Inc., a Delaware corporation
    (&#147;<U>Abraxis</U>&#148;);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, pursuant to the Merger Agreement, Sub will merge with
    and into Abraxis (the &#147;<U>Merger</U>&#148;), with Abraxis
    being the surviving corporation in the Merger and becoming a
    wholly-owned Subsidiary of the Company;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, in the Merger, one (1)&#160;CVR will be issued in
    respect of (a)&#160;each share of common stock, par value
    $0.001&#160;per share, of Abraxis (&#147;<U>Common
    Stock</U>&#148;) (other than shares of Common Stock that are
    Excluded Company Shares or Dissenting Company Shares) (all as
    defined in the Merger Agreement), (b)&#160;each share of Common
    Stock underlying each Option (as defined in the Merger
    Agreement) having an exercise price that is less than or equal
    to the Per Share Amount (as defined in the Merger Agreement),
    (c)&#160;each share of Common Stock underlying each Option
    having an exercise price that is greater than the Per Share
    Amount, if such Option is exercised and settled in accordance
    with the Merger Agreement, (d)&#160;each SAR (as defined in the
    Merger Agreement) having a base appreciation amount that is less
    than or equal to the Per Share Amount, (e)&#160;each SAR having
    a base appreciation amount that is greater than the Per Share
    Amount, if such SAR is exercised and settled in accordance with
    the Merger Agreement, and (f)&#160;each RSU (as defined in the
    Merger Agreement), in each case, outstanding immediately prior
    to the Effective Time (as defined in the Merger
    Agreement);&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-4</FONT>
    <FONT style="white-space: nowrap">(No.&#160;333-168369)</FONT>
    (the &#147;<U>Registration Statement</U>&#148;) with respect to
    the CVRs has been prepared and filed by the Company with the
    Commission (as defined below) and has become effective in
    accordance with the Securities Act of 1933, as amended (the
    &#147;<U>Securities Act</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    NOW, THEREFORE, in consideration of the foregoing premises and
    the consummation of the transactions contemplated by the Merger
    Agreement, it is covenanted and agreed, for the equal and
    proportionate benefit of all Holders of the Securities, as
    follows:
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;1<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">DEFINITIONS
    AND OTHER PROVISIONS OF GENERAL APPLICATION
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section</FONT>&#160;1.1&#160;&#160;<I>Definitions.</I>&#160;&#160;For
    all purposes of this CVR Agreement, except as otherwise
    expressly provided or unless the context otherwise requires:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;the terms defined in this Article have the meanings
    assigned to them in this Article, and include the plural as well
    as the singular;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;all accounting terms used herein and not expressly
    defined herein shall, except as otherwise noted, have the
    meanings assigned to such terms in accordance with applicable
    Accounting Standards, where &#147;<U>Accounting
    Standards</U>&#148; means (A)&#160;GAAP (United States Generally
    Accepted Accounting Principles); or (B)&#160;to the extent that
    the Company adopts International Financial Reporting Standards
    (IFRS), then &#147;<U>Accounting Standards</U>&#148; means
    International Financial Reporting Standards (IFRS), in either
    case consistently applied;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;all capitalized terms used in this CVR Agreement
    without definition shall have the respective meanings ascribed
    to them in the Merger Agreement;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;all other terms used herein which are defined in the
    Trust Indenture Act (as defined herein), either directly or by
    reference therein, have the respective meanings assigned to them
    therein;&#160;and
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;the words &#147;<U>herein</U>,&#148;
    &#147;<U>hereof</U>&#148; and &#147;<U>hereunder</U>&#148; and
    other words of similar import refer to this CVR Agreement as a
    whole and not to any particular Article, Section or other
    subdivision.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Affiliate</U>&#148;</I> of any specified Person
    means any other Person directly or indirectly controlling or
    controlled by or under direct or indirect common control with
    such specified Person. For the purposes of this definition,
    &#147;control&#148; when used with respect to any specified
    Person means the power to direct the management and policies of
    such Person, directly or indirectly, whether through the
    ownership of voting securities, by contract or otherwise; and
    the terms &#147;controlling&#148; and &#147;controlled&#148;
    have meanings correlative to the foregoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Board of Directors</U>&#148;</I> means the board of
    directors of the Company or any other body performing similar
    functions, or any duly authorized committee of that board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Board Resolution</U>&#148;</I> means a copy of a
    resolution certified by the Secretary or an Assistant Secretary
    of the Company, to have been duly adopted by the Board of
    Directors and to be in full force and effect on the date of such
    certification, and delivered to the Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Business Day</U>&#148;</I> means any day (other than
    a Saturday or a Sunday) on which banking institutions in The
    City of New York, New York are not authorized or obligated by
    Law or executive order to close and, if the CVRs are listed on a
    national securities exchange, electronic trading network or
    other suitable trading platform, such exchange, electronic
    network or other trading platform is open for trading.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Call Notice</U>&#148;</I> shall have the meaning set
    forth in Section&#160;11.2 of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Combination Product</U>&#148;</I> means any product
    that comprises a Product sold in conjunction with another active
    component (whether packaged together or in the same therapeutic
    formulation or otherwise) or service.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Commission</U>&#148;</I> means the Securities and
    Exchange Commission, as from time to time constituted, created
    under the Exchange Act (as defined herein), or if at any time
    after the execution of this instrument such Commission is not
    existing and performing the duties now assigned to it under the
    Trust Indenture Act, then the body performing such duties at
    such time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Common Stock</U>&#148;</I> shall have the meaning
    set forth in the Recitals of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Company</U>&#148;</I> means the Person (as defined
    herein) named as the &#147;Company&#148; in the first paragraph
    of this CVR Agreement, until a successor Person shall have
    become such pursuant to the applicable provisions of this CVR
    Agreement, and thereafter &#147;Company&#148; shall mean such
    successor Person. To the extent necessary to comply with the
    requirements of the provisions of Trust&#160;Indenture Act
    Sections&#160;310 through 317, inclusive, to the extent that
    they are applicable to the Company, the term &#147;Company&#148;
    shall include any other obligor with respect to the Securities
    for the purposes of complying with such provisions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Company Request</U>&#148;</I> or <I>&#147;<U>Company
    Order</U>&#148;</I> means a written request or order signed in
    the name of the Company by the chairman of the Board of
    Directors or the president or any vice president, the controller
    or assistant controller and the treasurer or assistant treasurer
    or the secretary or any assistant secretary, and delivered to
    the Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Confidential Information</U>&#148;</I> shall have
    the meaning set forth in Section&#160;7.13 of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Consent and Purchase Offer</U>&#148;</I> shall have
    the meaning set forth in Section&#160;11.1 of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Corporate Trust&#160;Office</U>&#148;</I> means the
    office of the Trustee at which at any particular time its
    corporate trust business shall be principally administered,
    which office at the date of execution of this CVR Agreement is
    located at 59 Maiden Lane&#160;&#151; Plaza Level, New York, New
    York 10038.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>CVRs</U>&#148;</I> shall have the meaning set forth
    in the Preamble of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>CVR Agreement</U>&#148;</I> means this instrument as
    originally executed and as it may from time to time be
    supplemented or amended pursuant to the applicable provisions
    hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>CVR Certificate</U>&#148;</I> means a certificate
    representing any of the CVRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>CVR Payment</U>&#148;</I> means any Net Sales
    Payment and any Milestone Payment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>CVR Shortfall</U>&#148;</I> shall have the meaning
    set forth in Section&#160;7.6(b) of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Default Interest Rate</U>&#148;</I> means a rate
    equal to the sum of three percent (3%) plus the prime rate of
    interest quoted in the Money Rates section of <I>The Wall Street
    Journal </I>(New York Edition), or similar reputable data
    source, calculated daily on the basis of a three hundred
    sixty-five (365)&#160;day year or, if lower, the highest rate
    permitted under applicable Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Diligent Efforts</U>&#148;</I> means, with respect
    to any Product, efforts of a Person to carry out its obligations
    in a diligent manner using such effort and employing such
    resources normally used by such Person in the exercise of its
    reasonable business discretion relating to the research,
    development or commercialization of a product, that is of
    similar market potential at a similar stage in its development
    or product life, taking into account issues of market
    exclusivity (including patent coverage, regulatory and other
    exclusivity), safety and efficacy, product profile, the
    competitiveness of alternate products in the marketplace or
    under development, the launch or sales of a generic or
    biosimilar product, the regulatory structure involved, and the
    profitability of the applicable product (including pricing and
    reimbursement status achieved), and other relevant factors,
    including technical, commercial, legal, scientific,
    <FONT style="white-space: nowrap">and/or</FONT>
    medical factors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Existing Licenses</U>&#148;</I> means those licenses
    and related agreements (for so long as they are in effect) with
    respect to the Products granted by the Company or its Affiliates
    to third parties (other than the Company or its Affiliates) as
    in effect immediately prior to the consummation of the Merger
    (with such modifications thereto after the consummation of the
    Merger that do not reduce the amounts of royalties, milestone
    payments or profit split payments thereunder).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Event of Default</U>&#148;</I> shall have the
    meaning set forth in Section&#160;8.1 of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Exchange Act</U>&#148;</I> means the Securities
    Exchange Act of 1934, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Exchange Act Documents</U>&#148;</I> shall have the
    meaning set forth in Section&#160;5.4 of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>FDA</U>&#148;</I> means the United States Food and
    Drug Administration or any successor agency.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Governmental Entity</U>&#148;</I> means any domestic
    (federal or state), or foreign court, commission, governmental
    body, regulatory or administrative agency or other political
    subdivision thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Holder</U>&#148;</I> means a Person in whose name a
    Security is registered in the Security Register.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Independent Accountant</U>&#148;</I> shall have the
    meaning set forth in Section&#160;7.6(a) of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Indications</U>&#148;</I> means U.S.&#160;Regulatory
    Approval of the Product described in clause&#160;(a) of the
    definition of &#147;Product&#148; for use in the treatment of:
    (i)&#160;melanoma; (ii)&#160;ovarian cancer; (iii)&#160;bladder
    cancer; and (iv)&#160;first-line metastatic breast cancer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Junior Obligations</U>&#148;</I> has the meaning set
    forth in Section&#160;10.1.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Law</U>&#148;</I> means any foreign, federal, state,
    local or municipal laws, rules, judgments orders, regulations,
    statutes, ordinances, codes, decisions, injunctions, orders,
    decrees or requirements of any Governmental Entity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Majority Holders</U>&#148;</I> means, at the time of
    determination, Holders of at least a majority of the Outstanding
    CVRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Merger</U>&#148;</I> shall have the meaning set
    forth in the Recitals of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Merger Agreement</U>&#148;</I> shall have the
    meaning set forth in the Recitals of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Milestone</U>&#148;</I> means each of
    (i)&#160;Milestone&#160;#1, and (ii)&#160;Milestone&#160;#2.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Milestone&#160;#1</U>&#148;</I> means
    U.S.&#160;Regulatory Approval of the Product described in
    clause&#160;(a) of the definition of &#147;Product&#148; for use
    in the treatment of non-small cell lung cancer (NSCLC), which
    U.S.&#160;Regulatory Approval permits the Company to market such
    Product under a label that includes a progression free survival
    claim, but only if the foregoing milestone is achieved no later
    than the Milestone Target Date. For the avoidance of doubt, an
    &#147;approvable letter&#148; or similar communication published
    by the FDA shall not constitute approval for purposes of the
    foregoing.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Milestone&#160;#2</U>&#148;</I> means
    U.S.&#160;Regulatory Approval of the Product described in
    clause&#160;(a) of the definition of &#147;Product&#148; for use
    in the treatment of pancreatic cancer, which
    U.S.&#160;Regulatory Approval permits the Company to market such
    Product under a label that includes an overall survival claim,
    but only if the foregoing milestone is achieved no later than
    the Milestone Target Date. For the avoidance of doubt, an
    &#147;approvable letter&#148; or similar communication published
    by the FDA shall not constitute approval for purposes of the
    foregoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Milestone Payment</U>&#148;</I> means, as
    applicable, (i)&#160;two hundred fifty million dollars
    ($250,000,000), with respect to the achievement of
    Milestone&#160;#1; and (ii)&#160;(a)&#160;four hundred million
    dollars ($400,000,000), with respect to the achievement of
    Milestone&#160;#2 if Milestone&#160;#2 is achieved no later than
    April&#160;1, 2013, and (b)&#160;three hundred million dollars
    ($300,000,000), with respect to the achievement of
    Milestone&#160;#2 if Milestone&#160;#2 is achieved after
    April&#160;1, 2013 but no later than the Milestone Target Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Milestone Payment Date</U>&#148;</I> means, with
    respect to each Milestone, the date that is twenty
    (20)&#160;Business Days following the date of the achievement of
    such Milestone.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Milestone Target Date</U>&#148;</I> means the fifth
    anniversary of the date of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Net Sales</U>&#148;</I> means, for each Net Sales
    Measuring Period, the sum of, without any duplication:
    (i)&#160;the gross amounts invoiced for the Products sold by the
    Company, its Affiliates or its licensees (other than licensees
    under Existing Licenses) to third parties (other than the
    Company, its Affiliates or its licensees) during such Net Sales
    Measuring Period, including wholesale distributors, less
    deductions from such amounts calculated in accordance with
    Accounting Standards so as to arrive at &#147;net sales&#148;
    under Accounting Standards as reported by the Company, its
    Affiliate or its licensee, as applicable, in such Person&#146;s
    financial statements, and further reduced by write-offs of
    accounts receivables or increased for collection of accounts
    that were previously written off; plus (ii)&#160;(A)&#160;the
    amount of royalties and profit split payments received by the
    Company or its Affiliates from their respective licensees under
    Existing Licenses for sales (but not the supply) of Products
    sold by such licensees to third parties (other than the Company
    or its Affiliates) during such Net Sales Measuring Period, and
    (B)&#160;the amount of any milestone payments received during
    such Net Sales Measuring Period by the Company or its Affiliates
    from their licensees under Existing Licenses with respect to the
    Products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any and all set-offs against gross invoice prices shall be
    calculated in accordance with Accounting Standards. Sales or
    other commercial dispositions of a Product between the Company
    and its Affiliates and its licensees shall be excluded from the
    computation of Net Sales; Product provided to third parties
    without charge, in connection with research and development,
    clinical trials, compassionate use, humanitarian and charitable
    donations, or indigent programs or for use as samples shall be
    excluded from the computation of Net Sales; and no payments will
    be payable on such sales or such other commercial dispositions,
    except where such an Affiliate or licensee is an end user of the
    Product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notwithstanding the foregoing, if a Product is sold or otherwise
    commercially disposed of for consideration other than cash or in
    a transaction that is not at arm&#146;s length between the buyer
    and the seller, then the gross amount to be included in the
    calculation of Net Sales shall be the amount that would have
    been invoiced had the transaction been conducted at arm&#146;s
    length and for cash. Such amount that would have been invoiced
    shall be determined, wherever possible, by reference to the
    average selling price of such Product in arm&#146;s length
    transactions in the relevant country.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notwithstanding the foregoing, in the event a Product is sold as
    a Combination Product in a particular country, Net Sales shall
    be calculated by multiplying the Net Sales of the Combination
    Product by the fraction A/(A+B), where A is the gross invoice
    price of the Product if sold separately in a country and B is
    the gross invoice price of the other product(s) included in the
    Combination Product if sold separately in such country. If no
    such separate sales are made by the Company, its Affiliates or
    licensees in a country, Net Sales of the Combination Product
    shall be calculated in a manner determined by the Company in
    good faith based upon the relative value of the active
    components of such Combination Product.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Net Sales Measuring Period</U>&#148;</I> means the
    one-year period beginning January&#160;1st&#160;of each year
    during the term of this CVR Agreement and ending
    December&#160;31st&#160;of each year during the term of this CVR
    Agreement; provided that the first Net Sales Measuring Period
    will begin on January&#160;1, 2011 and end on December&#160;31,
    2011.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Net Sales Payment</U>&#148;</I> means, with respect
    to any Net Sales Measuring Period, an amount equal to
    (i)&#160;two and one-half percent (2.5%) of that portion of Net
    Sales of the Products that exceeds one billion dollars
    ($1,000,000,000) but is less than or equal to two billion
    dollars ($2,000,000,000) for such period, plus (ii)&#160;an
    additional amount equal to five percent (5.0%) of that portion
    of Net Sales of the Products that exceeds two billion dollars
    ($2,000,000,000) but is less than or equal to three billion
    dollars ($3,000,000,000) for such period, plus (iii)&#160;an
    additional amount equal to ten percent (10.0%) of that portion
    of Net Sales of the Products that exceeds three billion dollars
    ($3,000,000,000) for such period; provided that no Net Sales
    Payments will be due following a Net Sales Payment Termination
    Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Net Sales Payment Dates</U>&#148;</I> means the
    fifteenth (15th) day after the date the Company is required to
    provide the Net Sales Statement pursuant to Section&#160;5.4 for
    the Net Sales Measuring Period in respect of which a Net Sales
    Payment is due.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Net Sales Payment Termination Date</U>&#148;</I>
    means the last day of the Net Sales Measuring Period ending on
    December&#160;31, 2025; provided that, if Net Sales of the
    Products for the Net Sales Measuring Period ending on
    December&#160;31, 2025 are equal to or greater than one billion
    dollars ($1,000,000,000), then the Net Sales Payment Termination
    Date shall be extended until the earlier of (a)&#160;the last
    day of the first Net Sales Measuring Period subsequent to
    December&#160;31, 2025 during which Net Sales of the Products
    are less than one billion dollars ($1,000,000,000) and
    (b)&#160;December&#160;31, 2030.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Net Sales Statement</U>&#148;</I> means, with
    respect to each Net Sales Measuring Period, the written
    statement of the Company, certified by the Chief Financial
    Officer of the Company and setting forth with reasonable detail
    (i)(a), for the Products for all countries in the aggregate,
    (X)&#160;the total of the gross invoice price charged by the
    Company, its Affiliates and its licensees (other than licensees
    under Existing Licenses) for sales of the Products by the
    Company, its Affiliates and their respective licensees (other
    than licensees under Existing Licenses) to third parties (other
    than the Company or its Affiliates) during the applicable
    period, (Y)&#160;an itemized calculation of Net Sales for the
    Products showing deductions for such Net Sales Measuring Period
    provided for in accordance with the definition of Net Sales, and
    (Z)(1) the total of all royalties and profit split payments
    received by the Company and its Affiliates from their respective
    licensees under Existing Licenses for sales of the Products by
    their respective licensees during the applicable period, and
    (2)&#160;the amount of any milestone payments received during
    such Net Sales Measuring Period by the Company or its Affiliates
    from their licensees under Existing Licenses with respect to the
    Products, (b)&#160;to the extent that Net Sales for the Products
    for an applicable period is determined based on Net Sales of a
    Combination Product for such period, the method of determining
    the Net Sales of the Combination Product attributable to the
    Products in accordance with the definition of Net Sales, and
    (c)&#160;to the extent that sales for the Products for an
    applicable period is recorded in currencies other than United
    States dollars, the exchange rates used for conversion of such
    foreign currency into United States dollars and (ii)&#160;the
    calculation of the Net Sales Payment due, if any, in respect of
    the applicable Net Sales Measuring Period in accordance with
    this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Officer&#146;s Certificate</U>&#148;</I> when used
    with respect to the Company means a certificate signed by the
    chairman of the Board of Directors or the president or any vice
    president, the controller or assistant controller and the
    treasurer or assistant treasurer or the secretary or any
    assistant secretary of the Company delivered to the Trustee or
    any other person authorized to act on behalf of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Opinion of Counsel</U>&#148;</I> means a written
    opinion of counsel, who may be counsel for the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Outstanding</U>&#148;</I> when used with respect to
    Securities means, as of the date of determination, all
    Securities theretofore authenticated and delivered under this
    CVR Agreement, except: (i)&#160;Securities theretofore cancelled
    by the Trustee or delivered to the Trustee for cancellation and
    (ii)&#160;Securities in exchange for or in lieu of which other
    Securities have been authenticated and delivered pursuant to
    this CVR Agreement, other than any such Securities in respect of
    which there shall have been presented to the Trustee proof
    satisfactory to it that such Securities are held by a bona fide
    purchaser in whose hands the Securities are valid obligations of
    the Company; provided, however, that in determining whether the
    Holders of the requisite Outstanding Securities have given any
    request, demand, direction, consent or waiver hereunder,
    Securities owned by the Company or any Affiliate of the Company,
    whether held as treasury securities or otherwise, shall be
    disregarded and deemed not to be Outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Party</U>&#148;</I> shall mean the Trustee, the
    Company
    <FONT style="white-space: nowrap">and/or</FONT>
    Holder(s), as applicable.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Paying Agent</U>&#148;</I> means any Person
    authorized by the Company to pay the amount determined pursuant
    to Section&#160;3.1, if any, on any Securities on behalf of the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Payment Date</U>&#148;</I> means any Net Sales
    Payment Date, any Milestone Payment Date, and any such date as
    shall be required for any CVR Shortfall payment pursuant to the
    review procedure set forth in Section&#160;7.6.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Person</U>&#148;</I> means any individual,
    corporation, partnership, joint venture, association,
    joint-stock company, trust, limited liability company,
    unincorporated organization or government or any agency or
    political subdivision thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Products</U>&#148;</I> means each of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;the pharmaceutical product comprising the chemical
    compound having the chemical name of
    <FONT style="white-space: nowrap">5&#223;,20-Epoxy-1,2a,4,7&#223;,10&#223;,13a-hexahydroxytax-11-en-9-one</FONT>
    4,10-diacetate 2-benzoate 13-ester with
    (2R,3S)-N-benzoyl-3-phenylisoserine (with the structure below),
    known by the generic name &#147;paclitaxel&#148; and bound to
    albumin that is the subject of the New Drug Application
    <FONT style="white-space: nowrap">No.&#160;21-660</FONT>
    filed with the FDA and subject of the European Medicines Agency
    Marketing Authorization granted on January&#160;11, 2008,
    together with all amendments and supplements to such FDA and
    European Medicines Agency approvals (identified by the Company
    as ABRAXANE); provided that in all cases such Product is an
    injectable formulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y85641dfx8564120.gif" alt="(CHART)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;the pharmaceutical product comprising the chemical
    compound having the chemical name of
    (2R,3S)-N-carboxy-3-phenylisoserine,N-<I>tert</I>-butyl ester,
    13-ester with 5&#223;-20-epoxy-1,2 ,4,7&#223;,10&#223;,13
    <FONT style="white-space: nowrap">-hexahydroxytax-11-en-9-one</FONT>
    <FONT style="white-space: nowrap">4-acetate</FONT>
    2-benzoate, anhydrous(with the structure below) bound to albumin
    that is the subject of the Investigational New Drug Application
    No.&#160;73,527 filed with the FDA together with all amendments
    (identified by the Company as &#147;nab-docetaxel
    (ABI-008)&#148;); provided that in all cases such Product is an
    injectable formulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;the pharmaceutical product comprising the chemical
    compound having the chemical name of (3<I>S</I>, 6<I>R</I>,
    7<I>E</I>, 9<I>R</I>, 10<I>R</I>, 12<I>R</I>, 14<I>S</I>,
    15<I>E</I>, 17<I>E</I>, 19<I>E</I>, 21<I>S</I>, 23<I>S</I>,
    26<I>R</I>, 27<I>R</I>, 34a<I>S</I>)-9,&#160;10, 12,&#160;13,
    14,&#160;21, 22,&#160;23, 24,&#160;25, 26,&#160;27, 32, 33, 34,
    <FONT style="white-space: nowrap">34a-hexadecahydro-9,27-dihydroxy-3-[(1</FONT><I>R</I>)-2-[(1<I>S</I>,
    3<I>R</I>,
    4<I>R</I>)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,&#160;8,
    12,&#160;14,&#160;20, 26-hexamethyl-23,
    27-epoxy-3<I>H</I>-pyrido[2, 1-c][1,4] oxaazacyclohentriacontine
    -1,&#160;5, 11,&#160;28, 29 (4H,6H,31H)-pentone (with the
    structure below) bound to albumin that is the subject of the
    Investigational New Drug Application No.&#160;74.610 filed with
    the FDA together with all amendments (identified
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    by the Company as &#147;nab-rapamycin (ABI-009)&#148;); provided
    that in all cases such Product is an injectable formulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y85641dfx8564121.gif" alt="(CHART)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;the pharmaceutical product comprising the chemical
    compound having the chemical name of
    <FONT style="white-space: nowrap">17-allylamino-17-demethoxygeldanamycin,</FONT>
    <FONT style="white-space: nowrap">17-allylamino</FONT>
    geldanamycin (with the structure below) bound to albumin that is
    the subject of the Investigational New Drug Application
    No.&#160;78,298 filed with the FDA together with all amendments
    (identified by the Company as &#147;nab-17AAG (ABI-010)&#148;);
    provided that in all cases such Product is an injectable
    formulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y85641dfx8564122.gif" alt="(CHART)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;the pharmaceutical product comprising the chemical
    compound having the chemical name of
    <FONT style="white-space: nowrap">N-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-</FONT>
    tetrahydro-benzo[a]heptalen-7-yl)-3-[3-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-
    benzo[a]heptalen-7-yl)-ureido]-propionamide(with the structure
    below) bound to albumin that is the subject of the
    Investigational New Drug Application No.&#160;103,698 filed with
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    the FDA together with all amendments (identified by the Company
    as &#147;nab-thiocolchicine dimer (ABI-011)&#148;); provided
    that in all cases the Product is an injectable formulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y85641dfx8564123.gif" alt="(CHART)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;the pharmaceutical product comprising the chemical
    compound having the chemical name of (<I>&#945;R,
    &#223;S</I>)-<I>&#223;</I>-[[(1,1-Dimethylethoxy)carbonyl]amino]-<I>&#945;</I>-(hexanoyloxy)benzenepropanoic
    acid
    (2a<I>R</I>,4<I>S</I>,4a<I>S</I>,6<I>R</I>,9<I>S</I>,11<I>S</I>,<BR>
    12<I>S</I>,12a<I>R</I>,12b<I>S</I><FONT style="white-space: nowrap">)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1</FONT><I>H</I>-cyclodecal[3,4]benz[1,2
    -b]oxet-9-yl ester (with the structure below) bound to albumin
    (identified by the Company as &#147;nab-novel taxane
    (ABI-013)&#148;) provided that in all cases the Product is an
    injectable formulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y85641dfx8564124.gif" alt="(CHART)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;the pharmaceutical product comprising the chemical
    compound having the chemical name of Benzenepropanoic acid,
    <FONT style="white-space: nowrap">&#223;-(benzoylamino)-&#945;-hydroxy-,6,12bbis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,</FONT><BR>
    11,12,12a,12bdodecahydro-
    4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1<I>H</I>-cyclodeca[3,4]<BR>
    benz[1,2-b]-oxet-9-yl
    ester,[2a<I>R</I>-[2a&#945;,4&#223;,4a&#223;,6&#223;,<BR>
    9&#945;(&#945;R*,&#223;S*),11&#945;,12&#945;,12a&#945;,
    12b&#945;]] bound to albumin that is the subject of the
    Investigational New Drug Application No.&#160;63,082 filed with
    the FDA together with all amendments (identified by the Company
    as &#147;COROXANE&#148;); provided that in all cases the Product
    is an injectable formulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Redemption&#160;Eligibility Date</U>&#148;</I> means
    the date that fifty percent (50%) of the Securities issued
    pursuant to the terms of the Merger Agreement either are
    (i)&#160;no longer Outstanding,
    <FONT style="white-space: nowrap">and/or</FONT>
    (ii)&#160;repurchased, acquired, redeemed or retired by the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Registration Statement</U>&#148;</I> shall have the
    meaning set forth in the Recitals of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Regulatory Approval</U>&#148;</I> means all
    approvals from the FDA or other
    <FONT style="white-space: nowrap">non-U.S.&#160;regulatory</FONT>
    authority necessary for the commercial manufacture, marketing
    and sale of a product in the United States or other jurisdiction
    in accordance with applicable Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Representatives</U>&#148;</I> shall have the meaning
    set forth in Section&#160;7.13 of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Responsible Officer</U>&#148;</I> when used with
    respect to the Trustee means any officer assigned to the
    Corporate Trust&#160;Office and also means, with respect to any
    particular corporate trust matter, any other officer of the
    Trustee to whom such matter is referred because of his knowledge
    of and familiarity with the particular subject.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Securities</U>&#148;</I> shall have the meaning set
    forth in the Preamble of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Securities Act</U>&#148;</I> shall have the meaning
    set forth in the Recitals of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Security Register</U>&#148;</I> shall have the
    meaning set forth in Section&#160;3.5(a) of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Senior Obligations</U>&#148;</I> means any existing
    or future obligations of the Company, including the principal
    of, premium (if any), interest (including, without limitation,
    any interest accruing subsequent to the filing of a petition of
    bankruptcy at the rate provided for in the documentation with
    respect thereto, whether or not such interest is an allowed
    claim under applicable Law) on, and all other amounts owing
    thereon, (i)&#160;with respect to borrowed money,
    (ii)&#160;evidenced by notes, debentures, bonds or other similar
    debt instruments, (iii)&#160;with respect to the net obligations
    owed under interest rate swaps or similar agreements or currency
    exchange transactions, (iv)&#160;reimbursement obligations in
    respect of letters of credit and similar obligations,
    (v)&#160;in respect of capital leases, or (vi)&#160;guarantees
    in respect of obligations referred to in clauses&#160;(i)
    through (v)&#160;above; unless, in any case, the instrument
    creating or evidencing the same or pursuant to which the same is
    outstanding provides that such obligations are pari passu to or
    subordinate in right of payment to the Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notwithstanding the foregoing, &#147;Senior Obligations&#148;
    shall not include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Junior Obligations;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;trade debt incurred in the ordinary course of business;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;any intercompany indebtedness between the Company and
    any of its Subsidiaries or Affiliates;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;indebtedness of the Company that is subordinated in
    right of payment to Senior Obligations;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;indebtedness or other obligations of the Company that
    by its terms ranks equal or junior in right of payment to the
    Junior Obligations;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;indebtedness of the Company that, by operation of Law,
    is subordinate to any general unsecured obligations of the
    Company;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;indebtedness evidenced by any guarantee of indebtedness
    ranking equal or junior in right of payment to the Junior
    Obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Shortfall Interest Rate</U>&#148;</I> means a rate
    equal to the sum of two percent (2%) plus the prime rate of
    interest quoted in the Money Rates section of <I>The Wall Street
    Journal </I>(New York Edition), or similar reputable data
    source, calculated daily on the basis of a three hundred
    sixty-five (365)&#160;day year or, if lower, the highest rate
    permitted under applicable Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Shortfall Report</U>&#148;</I> shall have the
    meaning set forth in Section&#160;7.6(b) of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Sub</U>&#148;</I> shall have the meaning set forth
    in the Recitals of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;Subsidiary&#148;</I> means, with respect to any Person,
    any corporation, limited liability company, association,
    partnership or other business entity of which more than fifty
    percent (50%) of the total voting power of shares of Voting
    Securities is at the time owned or controlled, directly or
    indirectly, by: (i)&#160;such Person; (ii)&#160;such Person and
    one or more Subsidiaries of such Person; or (iii)&#160;one or
    more Subsidiaries of such Person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Tax</U>&#148;</I> means any federal, state, local or
    foreign income, profits, gross receipts, license, payroll,
    employment, severance, stamp, occupation, premium, windfall
    profits, environmental, customs duty, capital stock, franchise,
    sales, social security, unemployment, disability, use, property,
    withholding, excise, transfer, registration, production, value
    added, alternative minimum, occupancy, estimated or any other
    tax of any kind whatsoever, together with any interest, penalty
    or addition thereto, imposed by any Governmental Entity
    responsible for the imposition of any such tax, whether disputed
    or not.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Tax Return</U>&#148;</I> means any return, report,
    declaration, claim or other statement (including attached
    schedules) relating to Taxes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Trust Indenture Act</U>&#148;</I> means the Trust
    Indenture Act of 1939, as amended from time to time.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Trustee</U>&#148;</I> means the Person named as the
    &#147;Trustee&#148; in the first paragraph of this CVR
    Agreement, until a successor Trustee shall have become such
    pursuant to the applicable provisions of this CVR Agreement, and
    thereafter &#147;Trustee&#148; shall mean such successor Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Vice President</U>&#148;</I> when used with respect
    to the Company or the Trustee, means any vice president, whether
    or not designated by a number or a word or words added before or
    after the title of &#147;vice president.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>&#147;<U>Voting Securities</U>&#148;</I> means securities or
    other interests having voting power, or the right, to elect or
    appoint a majority of the directors, or any Persons performing
    similar functions, irrespective of whether or not stock or other
    interests of any other class or classes shall have or might have
    voting power or any right by reason of the happening of any
    contingency.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.2&#160;&#160;<I><U>Compliance
    and Opinions</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Upon any application or request by the Company to the
    Trustee to take any action under any provision of this CVR
    Agreement, the Company shall furnish to the Trustee an
    Officers&#146; Certificate stating that, in the opinion of the
    signor, all conditions precedent, if any, provided for in this
    CVR Agreement relating to the proposed action have been complied
    with and an Opinion of Counsel stating, subject to customary
    exceptions, that in the opinion of such counsel all such
    conditions precedent, if any, have been complied with, except
    that, in the case of any such application or request as to which
    the furnishing of such documents is specifically required by any
    provision of this CVR Agreement relating to such particular
    application or request, no additional certificate or opinion
    need be furnished.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Every certificate or opinion with respect to compliance
    with a condition or covenant provided for in this CVR Agreement
    shall include: (i)&#160;a statement that each individual signing
    such certificate or opinion has read such covenant or condition
    and the definitions herein relating thereto; (ii)&#160;a brief
    statement as to the nature and scope of the examination or
    investigation upon which the statements or opinions contained in
    such certificate or opinion are based; (iii)&#160;a statement
    that, in the opinion of each such individual, he or she has made
    such examination or investigation as is necessary to enable him
    to express an informed opinion as to whether or not such
    covenant or condition has been complied with; and (iv)&#160;a
    statement as to whether, in the opinion of each such individual,
    such condition or covenant has been complied with.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.3&#160;&#160;<I><U>Form
    of Documents Delivered to Trustee</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;In any case where several matters are required to be
    certified by, or covered by an opinion of, any specified Person,
    it is not necessary that all such matters be certified by, or
    covered by the opinion of, only one such Person, or that they be
    so certified or covered by only one document, but one such
    Person may certify or give an opinion with respect to some
    matters and one or more other such Persons as to other matters,
    and any such Person may certify or give an opinion as to such
    matters in one or several documents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Any certificate or opinion of an officer of the Company
    may be based, insofar as it relates to legal matters, upon a
    certificate or opinion of, or representations by, counsel. Any
    such certificate or Opinion of Counsel may be based, insofar as
    it relates to factual matters, upon a certificate or opinion of,
    or representations by, an officer or officers of the Company
    stating that the information with respect to such factual
    matters is in the possession of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Any certificate, statement or opinion of an officer of
    the Company or of counsel may be based, insofar as it relates to
    accounting matters, upon a certificate or opinion of or
    representations by an accountant or firm of accountants in the
    employ of the Company. Any certificate or opinion of any
    independent firm of public accountants filed with the Trustee
    shall contain a statement that such firm is independent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Where any Person is required to make, give or execute
    two or more applications, requests, consents, certificates,
    statements, opinions or other instruments under this CVR
    Agreement, they may, but need not, be consolidated and form one
    instrument.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.4&#160;&#160;<I><U>Acts
    of Holders</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Any request, demand, authorization, direction, notice,
    consent, waiver or other action provided by this CVR Agreement
    to be given or taken by Holders may be embodied in and evidenced
    by one or more instruments of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    substantially similar tenor signed by such Holders in person or
    by an agent duly appointed in writing; and, except as herein
    otherwise expressly provided, such action shall become effective
    when such instrument or instruments are delivered to the Trustee
    and, where it is hereby expressly required, to the Company. Such
    instrument or instruments (and the action embodied therein and
    evidenced thereby) are herein sometimes referred to as the
    &#147;Act&#148; of the Holders signing such instrument or
    instruments. Proof of execution of any such instrument or of a
    writing appointing any such agent shall be sufficient for any
    purpose of this CVR Agreement and (subject to Section&#160;4.1)
    conclusive in favor of the Trustee and the Company, if made in
    the manner provided in this Section. The Company may set a
    record date for purposes of determining the identity of Holders
    entitled to vote or consent to any action by vote or consent
    authorized or permitted under this CVR Agreement. If not
    previously set by the Company, (i)&#160;the record date for
    determining the Holders entitled to vote at a meeting of the
    Holders shall be the date preceding the date notice of such
    meeting is mailed to the Holders, or if notice is not given, on
    the day next preceding the day such meeting is held, and
    (ii)&#160;the record date for determining the Holders entitled
    to consent to any action in writing without a meeting shall be
    the first date on which a signed written consent setting forth
    the action taken or proposed to be taken is delivered to the
    Company. If a record date is fixed, those Persons who were
    Holders of Securities at such record date (or their duly
    designated proxies), and only those Persons, shall be entitled
    to take such action by vote or consent or, except with respect
    to clause&#160;(d) below, to revoke any vote or consent
    previously given, whether or not such Persons continue to be
    Holders after such record date. No such vote or consent shall be
    valid or effective for more than one hundred twenty
    (120)&#160;days after such record date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The fact and date of the execution by any Person of any
    such instrument or writing may be proved in any reasonable
    manner which the Trustee deems sufficient.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;The ownership of Securities shall be proved by the
    Security Register. Neither the Company nor the Trustee nor any
    Agent of the Company or the Trustee shall be affected by any
    notice to the contrary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;At any time prior to (but not after) the evidencing to
    the Trustee, as provided in this Section&#160;1.4, of the taking
    of any action by the Holders of the Securities specified in this
    CVR Agreement in connection with such action, any Holder of a
    Security the serial number of which is shown by the evidence to
    be included among the serial numbers of the Securities the
    Holders of which have consented to such action may, by filing
    written notice at the Corporate Trust&#160;Office and upon proof
    of holding as provided in this Section&#160;1.4, revoke such
    action so far as concerns such Security. Any request, demand,
    authorization, direction, notice, consent, waiver or other
    action by the Holder of any Security shall bind every future
    Holder of the same Security or the Holder of every Security
    issued upon the registration of transfer thereof or in exchange
    therefor or in lieu thereof, in respect of anything done,
    suffered or omitted to be done by the Trustee, any Paying Agent
    or the Company in reliance thereon, whether or not notation of
    such action is made upon such Security.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.5&#160;&#160;<I><U>Notices,
    etc., to Trustee and Company</U>.</I>&#160;&#160;Any request,
    demand, authorization, direction, notice, consent, waiver or Act
    of Holders or other document provided or permitted by this CVR
    Agreement to be made upon, given or furnished to, or filed with:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;the Trustee by any Holder or by the Company shall be
    sufficient for every purpose hereunder if made, given, furnished
    or filed, in writing, to or with the Trustee at its Corporate
    Trust&#160;Office;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;the Company by the Trustee or by any Holder shall be
    sufficient for every purpose hereunder if in writing and mailed,
    first-class postage prepaid, to the Company addressed to it at
    Celgene Corporation, 86&#160;Morris Avenue, Summit, New Jersey
    07901, Legal Department, Attention: Senior Vice President and
    Chief Counsel, or at any other address previously furnished in
    writing to the Trustee by the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.6&#160;&#160;<I><U>Notice
    to Holders; Waiver</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Where this CVR Agreement provides for notice to Holders
    of any event, such notice shall be sufficiently given (unless
    otherwise herein expressly provided) if in writing and mailed,
    first-class postage prepaid, to each Holder affected by such
    event, at his address as it appears in the Security Register,
    not later than the latest date, and not earlier than the
    earliest date, prescribed for the giving of such notice. In any
    case where notice to Holders is given by mail, neither the
    failure to mail such notice, nor any defect in any notice so
    mailed, to any particular Holder shall affect the sufficiency of
    such notice with respect to other Holders. Where this CVR
    Agreement provides for notice in any manner, such notice may be
    waived in writing by the Person entitled to receive such notice,
    either
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    before or after the event, and such waiver shall be the
    equivalent of such notice. Waivers of notice by Holders shall be
    filed with the Trustee, but such filing shall not be a condition
    precedent to the validity of any action taken in reliance upon
    such waiver.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;In case by reason of the suspension of regular mail
    service or by reason of any other cause, it shall be
    impracticable to mail notice of any event as required by any
    provision of this CVR Agreement, then any method of giving such
    notice as shall be satisfactory to the Trustee shall be deemed
    to be a sufficient giving of such notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.7&#160;&#160;<I><U>Conflict
    with Trust Indenture Act</U>.</I>&#160;&#160;If any provision
    hereof limits, qualifies or conflicts with another provision
    hereof which is required to be included in this CVR Agreement by
    any of the provisions of the Trust Indenture Act, such required
    provision shall control.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.8&#160;&#160;<I><U>Effect
    of Headings and Table of Contents</U>.</I>&#160;&#160;The
    Article and Section headings herein and the Table of Contents
    are for convenience only and shall not affect the construction
    hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.9&#160;&#160;<I><U>Benefits
    of Agreement</U>.</I>&#160;&#160;Nothing in this CVR Agreement
    or in the Securities, express or implied, shall give to any
    Person (other than the Parties hereto and their successors
    hereunder, any Paying Agent and the Holders) any benefit or any
    legal or equitable right, remedy or claim under this CVR
    Agreement or under any covenant or provision herein contained,
    all such covenants and provisions being for sole benefit of the
    Parties hereto and their successors, any Paying Agent and of the
    Holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.10&#160;&#160;<I><U>Governing
    Law</U>.</I>&#160;&#160;THIS CVR AGREEMENT SHALL BE GOVERNED BY
    AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
    YORK INCLUDING, WITHOUT LIMITATION,
    <FONT style="white-space: nowrap">SECTIONS&#160;5-1401</FONT>
    AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW WITHOUT
    REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. EACH OF THE
    COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE
    OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE
    JURISDICTION OF ANY NEW YORK STATE COURT SITTING IN THE BOROUGH
    OF MANHATTAN IN THE CITY OF NEW YORK OR ANY FEDERAL COURT
    SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN
    RESPECT OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR
    RELATING TO THIS CVR AGREEMENT AND THE SECURITIES, AND
    IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY,
    GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID
    COURTS. EACH OF THE COMPANY AND THE TRUSTEE AGREES THAT PROCESS
    MAY BE SERVED UPON THEM IN ANY MANNER AUTHORIZED BY THE LAWS OF
    THE STATE OF NEW YORK FOR SUCH PERSONS AND IRREVOCABLY WAIVES,
    TO THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO UNDER APPLICABLE
    LAW, ANY OBJECTION IT MAY NOW OR HEREAFTER HAVE TO SUCH SERVICE
    OF PROCESS, THE LAYING OF THE VENUE OF ANY SUCH SUIT, ACTION OR
    PROCEEDING BROUGHT IN ANY SUCH COURT AND ANY CLAIM THAT ANY SUCH
    SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN
    BROUGHT IN AN INCONVENIENT FORUM.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.11&#160;&#160;<I><U>Legal
    Holidays</U>.</I>&#160;&#160;In the event that a Payment Date
    shall not be a Business Day, then (notwithstanding any provision
    of this CVR Agreement or the Securities to the contrary) payment
    on the Securities need not be made on such date, but may be
    made, without the accrual of any interest thereon, on the next
    succeeding Business Day with the same force and effect as if
    made on such Payment Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.12&#160;&#160;<I><U>Separability
    Clause</U>.</I>&#160;&#160;In case any provision in this CVR
    Agreement or in the CVRs shall be invalid, illegal or
    unenforceable, the validity, legality and enforceability of the
    remaining provisions shall not in any way be affected or
    impaired thereby.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.13&#160;&#160;<I><U>No
    Recourse Against Others</U>.</I>&#160;&#160;A director, officer
    or employee, as such, of the Company or the Trustee shall not
    have any liability for any obligations of the Company or the
    Trustee under the Securities or this CVR Agreement or for any
    claim based on, in respect of or by reason of such obligations
    or their creation. By accepting a Security each Holder waives
    and releases all such liability. The waiver and release are part
    of the consideration for the issue of the Securities.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.14&#160;&#160;<I><U>Counterparts</U>.</I>&#160;&#160;This
    CVR Agreement shall be signed in any number of counterparts with
    the same effect as if the signatures to each counterpart were
    upon a single instrument, and all such counterparts together
    shall be deemed an original of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.15&#160;&#160;<I><U>Acceptance
    of Trust</U>.</I>&#160;&#160;American Stock Transfer&#160;&#038;
    Trust Company, the Trustee named herein, hereby accepts the
    trusts in this CVR Agreement declared and provided, upon the
    terms and conditions set forth herein.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;2<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">SECURITY
    FORMS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.1&#160;&#160;<I><U>Forms&#160;Generally</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Securities and the Trustee&#146;s certificate of
    authentication shall be in substantially the forms set forth in
    Annex&#160;A, attached hereto and incorporated herein by this
    reference, with such appropriate insertions, omissions,
    substitutions and other variations as are required or permitted
    by this CVR Agreement and may have such letters, numbers or
    other marks of identification and such legends or endorsements
    placed thereon as may be required to comply with the rules of
    any securities exchange or as may be required by Law or any rule
    or regulation pursuant thereto, all as may be determined by the
    officers executing such Securities, as evidenced by their
    execution of the Securities. Any portion of the text of any
    Security may be set forth on the reverse thereof, with an
    appropriate reference thereto on the face of the Security.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The definitive Securities shall be typewritten,
    printed, lithographed or engraved on steel engraved borders or
    produced by any combination of these methods or may be produced
    in any other manner permitted by the rules of any securities
    exchange on which the Securities may be listed, all as
    determined by the officers executing such Securities, as
    evidenced by their execution of such Securities.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;3<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">THE
    SECURITIES
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.1&#160;&#160;<I><U>Title
    and Terms</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The aggregate number of CVRs in respect of which CVR
    Certificates may be authenticated and delivered under this CVR
    Agreement is limited to a number equal to
    [&#160;&#149;&#160;]<SUP style="font-size: 85%; vertical-align: top">1</SUP>,

    except for Securities authenticated and delivered upon
    registration of transfer of, or in exchange for, or in lieu of,
    other Securities pursuant to Section&#160;3.4, 3.5, 3.6 or 6.6.
    From and after the Effective Time, the Company shall not be
    permitted to issue any CVRs that have the right to receive any
    portion of the Milestone Payments or the Net Sales Payments,
    except as provided and in accordance with the terms and
    conditions of the Merger Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Securities shall be known and designated as the
    &#147;Series&#160;A Contingent Value Rights&#148; of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;On each Net Sales Payment Date, the Company shall pay
    to the Trustee, by wire transfer to the account designated by
    the Trustee, the Net Sales Payment due, if any, in respect of
    the Net Sales Measuring Period ended immediately preceding such
    Net Sales Payment Date, and the Trustee shall pay the Holders of
    the Securities as of such Net Sales Payment Date, a pro rata
    portion of such Net Sales Payment based on the number of CVRs
    held by each Holder as of such date. Notwithstanding the
    foregoing, the Company&#146;s obligations to pay any Net Sales
    Payment shall terminate in its entirety on the Net Sales Payment
    Termination Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;On each Milestone Payment Date, the Company shall pay
    to the Trustee, by wire transfer to the account designated by
    the Trustee, the applicable Milestone Payment, and the Trustee
    shall pay to the Holders of the Securities as of such Milestone
    Payment Date, a pro rata portion of such Milestone Payment based
    on the number of CVRs held by each Holder as of such date.
    Notwithstanding the foregoing, the Company&#146;s obligations to
    pay any
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
<!-- XBRL Footnotes Begin -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <SUP style="font-size: 85%; vertical-align: top">1</SUP>&#160;Insert

    total, as of the closing of the Merger, of all CVRs to be issued
    pursuant to the Merger Agreement.
</DIV>
<!-- XBRL Footnotes End -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Milestone Payment shall terminate in its entirety if the
    corresponding Milestone for such Milestone Payment has not been
    achieved by the Milestone Target Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;The Holders of the CVR Certificates, by acceptance
    thereof, agree that no joint venture, partnership or other
    fiduciary relationship is created hereby or by the Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;Other than in the case of interest on amounts due and
    payable after the occurrence of an Event of Default or with
    respect to any CVR Shortfall, no interest or dividends shall
    accrue on any amounts payable in respect of the CVRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;Except to the extent any portion of any CVR Payment is
    required to be treated as imputed interest pursuant to
    applicable Law, the Parties hereto agree to treat the CVRs and
    all CVR Payments for all Tax purposes as additional
    consideration for the shares of Common Stock, the Options, the
    SARs and the RSUs pursuant to the Merger Agreement, and none of
    the Parties hereto will take any position to the contrary on any
    Tax Return or for other Tax purposes except as required by
    applicable Law. The Company shall report imputed interest on the
    CVRs pursuant to Section&#160;483 of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;The CVRs and any interest thereon may be sold,
    assigned, pledged encumbered or in any manner transferred or
    disposed of, in whole or in part, only in compliance with
    applicable United States federal and state securities Laws and,
    to the extent applicable, in accordance with Section&#160;3.5
    hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;The Holder of any CVR or CVR Certificate is not, and
    shall not, by virtue thereof, be entitled to any rights of a
    holder of any Voting Securities or other equity security or
    other ownership interest of the Company or in any constituent
    company to the Merger, either at Law or in equity, and the
    rights of the Holders are limited to those contractual rights
    expressed in this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (j)&#160;Except as provided in this CVR Agreement (including,
    without limitation, Section&#160;7.6), none of the Company or
    any of its Affiliates shall have any right to set-off any
    amounts owed or claimed to be owed by any Holder to any of them
    against such Holder&#146;s Securities or any CVR Payment or
    other amount payable to such Holder in respect of such
    Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (k)&#160;In the event that all of the CVR Certificates not
    previously cancelled shall have become due and payable pursuant
    to the terms hereof, all disputes with respect to amounts
    payable to the Holders brought pursuant to the terms and
    conditions of this CVR Agreement have been resolved, and the
    Company has paid or caused to be paid or deposited with the
    Trustee all amounts payable to the Holders under this CVR
    Agreement (including any amounts determined in accordance with
    Section&#160;7.6 herein), then this CVR Agreement shall cease to
    be of further effect and shall be deemed satisfied and
    discharged. Notwithstanding the satisfaction and discharge of
    this CVR Agreement, the obligations of the Company under
    Section&#160;4.7(c) shall survive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.2&#160;&#160;<I><U>Registrable
    Form</U>.</I>&#160;&#160;The Securities shall be issuable only
    in registered form.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.3&#160;&#160;<I><U>Execution,
    Authentication, Delivery and Dating</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Securities shall be executed on behalf of the
    Company by its chairman of the Board of Directors or its
    president or any vice president or its treasurer, but need not
    be attested. The signature of any of these officers on the
    Securities may be manual or facsimile.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Securities bearing the manual or facsimile signatures
    of individuals who were, at the time of execution, the proper
    officers of the Company shall bind the Company, notwithstanding
    that such individuals or any of them have ceased to hold such
    offices prior to the authentication and delivery of such
    Securities or did not hold such offices at the date of such
    Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;At any time and from time to time after the execution
    and delivery of this CVR Agreement, the Company may deliver
    Securities executed by the Company to the Trustee for
    authentication, together with a Company Order for the
    authentication and delivery of such Securities; and the Trustee,
    in accordance with such Company Order, shall authenticate and
    deliver such Securities as provided in this CVR Agreement and
    not otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Each Security shall be dated the date of its
    authentication.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;No Security shall be entitled to any benefit under this
    CVR Agreement or be valid or obligatory for any purpose unless
    there appears on such Security a certificate of authentication
    substantially in the form provided for herein duly executed by
    the Trustee, by manual or facsimile signature of an authorized
    officer, and such certificate upon any Security shall be
    conclusive evidence, and the only evidence, that such Security
    has been duly authenticated and delivered hereunder and that the
    Holder is entitled to the benefits of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.4&#160;&#160;<I><U>Temporary
    Securities</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Pending the preparation of definitive Securities, the
    Company may execute, and upon Company Order, the Trustee shall
    authenticate and deliver, temporary Securities which are
    printed, lithographed, typewritten, mimeographed or otherwise
    produced, substantially of the tenor of the definitive
    Securities in lieu of which they are issued and with such
    appropriate insertions, omissions, substitutions and other
    variations as the officers executing such Securities may
    determine with the concurrence of the Trustee. Temporary
    Securities may contain such reference to any provisions of this
    CVR Agreement as may be appropriate. Every temporary Security
    shall be executed by the Company and be authenticated by the
    Trustee upon the same conditions and in substantially the same
    manner, and with like effect, as the definitive Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;If temporary Securities are issued, the Company will
    cause definitive Securities to be prepared without unreasonable
    delay. After the preparation of definitive Securities, the
    temporary Securities shall be exchangeable for definitive
    Securities upon surrender of the temporary Securities at the
    office or agency of the Company designated for such purpose
    pursuant to Section&#160;7.2, without charge to the Holder. Upon
    surrender for cancellation of any one or more temporary
    Securities, the Company shall execute and the Trustee shall
    authenticate and deliver in exchange therefor a like amount of
    definitive Securities. Until so exchanged, the Temporary
    Securities shall in all respects be entitled to the same
    benefits under this CVR Agreement as definitive Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.5&#160;&#160;<I><U>Registration,
    Registration of Transfer and Exchange</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Company shall cause to be kept at the office of the
    Trustee a register (the register maintained in such office and
    in any other office or agency designated pursuant to
    Section&#160;7.2 being herein sometimes referred to as the
    &#147;<U>Security Register</U>&#148;) in which, subject to such
    reasonable regulations as it may prescribe, the Company shall
    provide for the registration of Securities and of transfers of
    Securities. The Trustee is hereby initially appointed
    &#147;Security Registrar&#148; for the purpose of registering
    Securities and transfers of Securities as herein provided.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Upon surrender for registration of transfer of any
    Security at the office or agency of the Company designated
    pursuant to Section&#160;7.2, the Company shall execute, and the
    Trustee shall authenticate and deliver, in the name of the
    designated transferee or transferees, one or more new CVR
    Certificates representing the same aggregate number of CVRs
    represented by the CVR Certificate so surrendered that are to be
    transferred and the Company shall execute and the Trustee shall
    authenticate and deliver, in the name of the transferor, one or
    more new CVR Certificates representing the aggregate number of
    CVRs represented by such CVR Certificate that are not to be
    transferred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;At the option of the Holder, CVR Certificates may be
    exchanged for other CVR Certificates that represent in the
    aggregate the same number of CVRs as the CVR Certificates
    surrendered at such office or agency. Whenever any CVR
    Certificates are so surrendered for exchange, the Company shall
    execute, and the Trustee shall authenticate and deliver, the CVR
    Certificates which the Holder making the exchange is entitled to
    receive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;All Securities issued upon any registration of transfer
    or exchange of Securities shall be the valid obligations of the
    Company, evidencing the same rights, and entitled to the same
    benefits under this CVR Agreement, as the Securities surrendered
    upon such registration of transfer or exchange.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Every Security presented or surrendered for
    registration of transfer or for exchange shall (if so required
    by the Company or the Security Registrar) be duly endorsed, or
    be accompanied by a written instrument of transfer in form
    satisfactory to the Company and the Security Registrar, duly
    executed by the Holder thereof or his attorney duly authorized
    in writing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;No service charge shall be made for any registration of
    transfer or exchange of Securities, but the Company may require
    payment of a sum sufficient to cover any tax or other
    governmental charge that may be imposed in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    connection with any registration of transfer or exchange of
    Securities, other than exchanges pursuant to Section&#160;3.4 or
    6.6 not involving any transfer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.6&#160;&#160;<I><U>Mutilated,
    Destroyed, Lost and Stolen Securities</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;If (i)&#160;any mutilated Security is surrendered to
    the Trustee, or (ii)&#160;the Company and the Trustee receive
    evidence to their satisfaction of the destruction, loss or theft
    of any Security, and there is delivered to the Company and the
    Trustee such security or indemnity as may be required by them to
    save each of them harmless, then, in the absence of notice to
    the Company or the Trustee that such Security has been acquired
    by a bona fide purchaser, the Company shall execute and, upon
    delivery of a Company Order, the Trustee shall authenticate and
    deliver, in exchange for any such mutilated Security or in lieu
    of any such destroyed, lost or stolen Security, a new CVR
    Certificate of like tenor and amount of CVRs, bearing a number
    not contemporaneously outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;In case any such mutilated, destroyed, lost or stolen
    Security has become or is to become finally due and payable
    within fifteen (15)&#160;days, the Company in its discretion
    may, instead of issuing a new CVR Certificate, pay to the Holder
    of such Security on the applicable Payment Date, as the case may
    be, all amounts due and payable with respect thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Every new Security issued pursuant to this
    Section&#160;3.6 in lieu of any destroyed, lost or stolen
    Security shall constitute an original additional contractual
    obligation of the Company, whether or not the destroyed, lost or
    stolen Security shall be at any time enforceable by anyone, and
    shall be entitled to all benefits of this CVR Agreement equally
    and proportionately with any and all other Securities duly
    issued hereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;The provisions of this Section are exclusive and shall
    preclude (to the extent lawful) all other rights and remedies
    with respect to the replacement or payment of mutilated,
    destroyed, lost or stolen Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.7&#160;&#160;<I><U>Payments
    with respect to CVR Certificates</U>.</I>&#160;&#160;Payment of
    any amounts pursuant to the CVRs shall be made in such coin or
    currency of the United States of America as at the time is legal
    tender for the payment of public and private debts. The Company
    may, at its option, pay such amounts by wire transfer or check
    payable in such money.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.8&#160;&#160;<I><U>Persons
    Deemed Owners</U>.</I>&#160;&#160;Prior to the time of due
    presentment for registration of transfer, the Company, the
    Trustee and any agent of the Company or the Trustee may treat
    the Person in whose name any Security is registered as the owner
    of such Security for the purpose of receiving payment on such
    Security and for all other purposes whatsoever, whether or not
    such Security be overdue, and neither the Company, the Trustee
    nor any agent of the Company or the Trustee shall be affected by
    notice to the contrary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.9&#160;&#160;<I><U>Cancellation</U>.</I>&#160;&#160;All
    Securities surrendered for payment, registration of transfer or
    exchange shall, if surrendered to any Person other than the
    Trustee, be delivered to the Trustee and shall be promptly
    canceled by it. The Company may at any time deliver to the
    Trustee for cancellation any Securities previously authenticated
    and delivered hereunder which the Company may have acquired in
    any manner whatsoever, and all Securities so delivered shall be
    promptly canceled by the Trustee. No Securities shall be
    authenticated in lieu of or in exchange for any Securities
    canceled as provided in this Section, except as expressly
    permitted by this CVR Agreement. All cancelled Securities held
    by the Trustee shall be destroyed and a certificate of
    destruction shall be issued by the Trustee to the Company,
    unless otherwise directed by a Company Order.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;4<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">THE TRUSTEE
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.1&#160;&#160;<I><U>Certain
    Duties and Responsibilities</U>.</I>&#160;&#160;(a)&#160;With
    respect to the Holders, the Trustee, prior to the occurrence of
    an Event of Default (as defined in Section&#160;8.1) with
    respect to the Securities and after the curing or waiving of all
    Events of Default which may have occurred, undertakes to perform
    such duties and only such duties as are specifically set forth
    in this CVR Agreement and no implied covenants shall be read
    into this CVR Agreement against the Trustee. In case an Event of
    Default with respect to the Securities has occurred (which has
    not been cured or waived), the Trustee shall exercise such of
    the rights and powers vested in it by this CVR Agreement, and
    use the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    same degree of care and skill in their exercise, as a prudent
    person would exercise or use under the circumstances in the
    conduct of his own affairs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;In the absence of bad faith on its part, prior to the
    occurrence of an Event of Default and after the curing or
    waiving of all such Events of Default which may have occurred,
    the Trustee may conclusively rely, as to the truth of the
    statements and the correctness of the opinions expressed
    therein, upon certificates or opinions furnished to the Trustee
    which conform to the requirements of this CVR Agreement; but in
    the case of any such certificates or opinions which by any
    provision hereof are specifically required to be furnished to
    the Trustee, the Trustee shall be under a duty to examine the
    same to determine whether or not they conform to the
    requirements of this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;No provision of this CVR Agreement shall be construed
    to relieve the Trustee from liability for its own negligent
    action, its own negligent failure to act, or its own willful
    misconduct, except that (i)&#160;this Subsection&#160;(c) shall
    not be construed to limit the effect of Subsections&#160;(a) and
    (b)&#160;of this Section; (ii)&#160;the Trustee shall not be
    liable for any error of judgment made in good faith by a
    Responsible Officer, unless it shall be proved that the Trustee
    was negligent in ascertaining the pertinent facts; and
    (iii)&#160;the Trustee shall not be liable with respect to any
    action taken or omitted to be taken by it in good faith in
    accordance with the direction of the Holders pursuant to
    Section&#160;8.9 relating to the time, method and place of
    conducting any proceeding for any remedy available to the
    Trustee, or exercising any trust or power conferred upon the
    Trustee, under this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Whether or not therein expressly so provided, every
    provision of this CVR Agreement relating to the conduct or
    affecting the liability of or affording protection to the
    Trustee shall be subject to the provisions of this Section.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.2&#160;&#160;<I><U>Certain
    Rights of Trustee</U>.</I>&#160;&#160;Subject to the provisions
    of Section&#160;4.1, including without limitation, the duty of
    care that the Trustee is required to exercise upon the
    occurrence of an Event of Default:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;the Trustee may rely and shall be protected in acting
    or refraining from acting upon any resolution, certificate,
    statement, instrument, opinion, report, notice, request,
    direction, consent, order, bond, debenture, note, other evidence
    of indebtedness or other paper or document believed by it to be
    genuine and to have been signed or presented by the proper party
    or parties and the Trustee need not investigate any fact or
    matter stated in the document;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;any request or direction or order of the Company
    mentioned herein shall be sufficiently evidenced by a Company
    Request or Company Order and any resolution of the Board of
    Directors may be sufficiently evidenced by a Board Resolution
    and the Trustee shall not be liable for any action it takes or
    omits to take in good faith reliance thereon;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;whenever in the administration of this CVR Agreement
    the Trustee shall deem it desirable that a matter be proved or
    established prior to taking, suffering or omitting any action
    hereunder, the Trustee (unless other evidence be herein
    specifically prescribed) may, in the absence of bad faith on its
    part, rely upon an Officers&#146; Certificate and the Trustee
    shall not be liable for any action it takes or omits to take in
    good faith reliance thereon or an Opinion of Counsel;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;the Trustee may consult with counsel and the written
    advice of such counsel or any Opinion of Counsel shall be full
    and complete authorization and protection in respect of any
    action taken, suffered or omitted by it hereunder in good faith
    and in accordance with such advice or Opinion of Counsel;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;the Trustee shall be under no obligation to exercise
    any of the rights or powers vested in it by this CVR Agreement
    at the request or direction of any of the Holders pursuant to
    this CVR Agreement, unless such Holders shall have offered to
    the Trustee reasonable security or indemnity against the costs,
    expenses and liabilities which might be incurred by it in
    compliance with such request or direction;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;the Trustee shall not be bound to make any
    investigation into the facts or matters stated in any
    resolution, certificate, statement, instrument, opinion, report,
    notice, request, consent, order, approval, appraisal, bond,
    debenture, note, coupon, security, or other paper or document,
    but the Trustee in its discretion may make such further inquiry
    or investigation into such facts or matters as it may see fit,
    and if the Trustee shall determine to make
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    such further inquiry or investigation, it shall be entitled to
    examine the books, records and premises of the Company,
    personally or by agent or attorney;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;the Trustee may execute any of the trusts or powers
    hereunder or perform any duties hereunder either directly or by
    or through agents or attorneys and the Trustee shall not be
    responsible for any misconduct or negligence on the part of any
    agent or attorney appointed with due care by it
    hereunder;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;the Trustee shall not be liable for any action taken,
    suffered or omitted to be taken by it in good faith and believed
    by it to be authorized or within the discretion or rights or
    powers conferred upon it by this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;The Trustee shall not be deemed to have notice of any
    Default or Event of Default unless a Responsible Officer of the
    Trustee has actual knowledge thereof or unless written notice
    thereof has been received by such Responsible Officer at the
    offices of the Trustee and such notice references the CVRs and
    this Indenture and the fact that such notice constitutes
    notification of Default.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.3&#160;&#160;<I><U>Notice
    of Default</U>.</I>&#160;&#160;If a default occurs hereunder
    with respect to the Securities, the Trustee shall give the
    Holders notice of any such default actually known to it as and
    to the extent applicable and provided by the Trust Indenture
    Act; provided, however, that in the case of any default of the
    character specified in Section&#160;8.1(b) with respect to the
    Securities, no notice to Holders shall be given until at least
    thirty (30)&#160;days after the occurrence thereof. For the
    purpose of this Section&#160;4.3, the term &#147;default&#148;
    means any event that is, or after notice or lapse of time or
    both would become, an Event of Default with respect to the
    Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.4&#160;&#160;<I><U>Not
    Responsible for Recitals or Issuance of
    Securities</U>.</I>&#160;&#160;The Trustee shall not be
    accountable for the Company&#146;s use of the Securities or the
    proceeds from the Securities. The recitals contained herein and
    in the Securities, except the Trustee&#146;s certificates of
    authentication, shall be taken as the statements of the Company,
    and the Trustee assumes no responsibility for their correctness.
    The Trustee makes no representations as to the validity or
    sufficiency of this CVR Agreement or of the Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.5&#160;&#160;<I><U>May
    Hold Securities</U>.</I>&#160;&#160;The Trustee, any Paying
    Agent, Security Registrar or any other agent of the Company, in
    its individual or any other capacity, may become the owner or
    pledgee of Securities, and, subject to Sections&#160;4.8 and
    4.13, may otherwise deal with the Company with the same rights
    it would have if it were not Trustee, Paying Agent, Security
    Registrar or such other agent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.6&#160;&#160;<I><U>Money
    Held in Trust</U>.</I>&#160;&#160;Money held by the Trustee in
    trust hereunder need not be segregated from other funds except
    to the extent required by Law. The Trustee shall be under no
    liability for interest on any money received by it hereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.7&#160;&#160;<I><U>Compensation
    and Reimbursement</U>.</I>&#160;&#160;The Company agrees:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;to pay to the Trustee from time to time reasonable
    compensation for all services rendered by it hereunder in such
    amount as the Company and the Trustee shall agree from time to
    time (which compensation shall not be limited by any provision
    of Law in regard to the compensation of a trustee of an express
    trust);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;except as otherwise expressly provided herein, to
    reimburse the Trustee upon its request for all reasonable
    expenses, disbursements and advances incurred or made by the
    Trustee in accordance with any provision of this CVR Agreement
    (including the reasonable compensation and the reasonable
    expenses and disbursements of its agents and counsel), except
    any such expense, disbursement or advance as may be attributable
    to the Trustee&#146;s negligence or willful misconduct;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;to indemnify the Trustee and each of its agents,
    officers, directors and employees (each an
    &#147;indemnitee&#148;) for, and to hold it harmless against,
    any loss, liability or expense (including attorneys fees and
    expenses) incurred without negligence or bad faith on its part,
    arising out of or in connection with the acceptance or
    administration of this trust and the performance of its duties
    hereunder, including the reasonable costs and expenses of
    defending itself against any claim or liability in connection
    with the exercise or performance of any of its powers or duties
    hereunder. The Company&#146;s payment obligations pursuant to
    this Section shall survive the termination of this CVR
    Agreement. When the Trustee incurs expenses after the occurrence
    of an Event of Default specified in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Section&#160;8.1(c) or 8.1(d) with respect to the Company, the
    expenses are intended to constitute expenses of administration
    under bankruptcy Laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.8&#160;&#160;<I><U>Disqualification;
    Conflicting Interests</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;If applicable, to the extent that the Trustee or the
    Company determines that the Trustee has a conflicting interest
    within the meaning of the Trust Indenture Act, the Trustee
    shall, within ninety (90)&#160;days after ascertaining that it
    has such conflicting interest, either eliminate such conflicting
    interest or resign to the extent and in the manner provided by,
    and subject to the provisions of, the Trust Indenture Act and
    this CVR Agreement. The Company shall take prompt steps to have
    a successor appointed in the manner provided in this CVR
    Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;In the event the Trustee shall fail to comply with the
    foregoing subsection&#160;4.8(a), the Trustee shall, within ten
    (10)&#160;days of the expiration of such ninety (90)&#160;day
    period, transmit a notice of such failure to the Holders in the
    manner and to the extent provided in the Trust&#160;Indenture
    Act and this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;If the Trustee fails to comply with Section&#160;4.8(a)
    after written request therefore by the Company or any Holder,
    any Holder of any Security who has been a bona fide Holder for
    at least six (6)&#160;months may on behalf of himself and all
    others similarly situated, petition any court of competent
    jurisdiction for the removal of such Trustee and the appointment
    of a successor Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.9&#160;&#160;<I><U>Corporate
    Trustee Required; Eligibility</U>.</I>&#160;&#160;There shall at
    all times be a Trustee hereunder which satisfies the applicable
    requirements of Sections&#160;310(a)(1) and (5)&#160;of the
    Trust Indenture Act and has a combined capital and surplus of at
    least one hundred fifty million dollars ($150,000,000). If such
    corporation publishes reports of condition at least annually,
    pursuant to Law or to the requirements of a supervising or
    examining authority, then for the purposes of this
    Section&#160;4.9, the combined capital and surplus of such
    corporation shall be deemed to be its combined capital and
    surplus as set forth in its most recent report of condition so
    published. If at any time the Trustee shall cease to be eligible
    in accordance with the provisions of this Section, it shall
    resign immediately in the manner and with the effect hereinafter
    specified in this Article.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.10&#160;&#160;<I><U>Resignation
    and Removal; Appointment of Successor</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;No resignation or removal of the Trustee and no
    appointment of a successor Trustee pursuant to this Article
    shall become effective until the acceptance of appointment by
    the successor Trustee under Section&#160;4.11.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Trustee, or any trustee or trustees hereafter
    appointed, may resign at any time by giving written notice
    thereof to the Company. If an instrument of acceptance by a
    successor Trustee shall not have been delivered to the Trustee
    within thirty (30)&#160;days after the giving of such notice of
    resignation, the resigning Trustee may petition any court of
    competent jurisdiction for the appointment of a successor
    Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;The Trustee may be removed at any time by an act of the
    Majority Holders, delivered to the Trustee and to the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;If at any time:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (1)&#160;the Trustee shall fail to comply with Section&#160;4.8
    after written request therefor by the Company or by any Holder
    who has been a bona fide Holder of a Security for at least six
    months,&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (2)&#160;the Trustee shall cease to be eligible under
    Section&#160;4.9 and shall fail to resign after written request
    therefor by the Company or by any such Holder,&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (3)&#160;the Trustee shall become incapable of acting or shall
    be adjudged a bankrupt or insolvent, or a receiver of the
    Trustee or of its property shall be appointed, or any public
    officer shall take charge or control of the Trustee or of its
    property or affairs for the purpose of rehabilitation,
    conservation or liquidation, then, in any case, (i)&#160;the
    Company, by a Board Resolution, may remove the Trustee, or
    (ii)&#160;the Holder of any Security who has been a bona fide
    Holder of a Security for at least six months may, on behalf of
    himself and all others similarly situated, petition any court of
    competent jurisdiction for the removal of the Trustee and the
    appointment of a successor Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;If the Trustee shall resign, be removed or become
    incapable of acting, or if a vacancy shall occur in the office
    of Trustee for any cause, the Company, by a Board Resolution,
    shall promptly appoint a successor Trustee. If,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    within one year after any removal by Holders of a majority of
    the Outstanding Securities, a successor Trustee shall be
    appointed by act of the Holders of a majority of the Outstanding
    Securities delivered to the Company and the retiring Trustee the
    successor Trustee so appointed shall, forthwith upon its
    acceptance of such appointment in accordance with
    Section&#160;4.11, become the successor Trustee and supersede
    the successor Trustee appointed by the Company. If no successor
    Trustee shall have been so appointed by the Company or the
    Holders of the Securities and accepted appointment within sixty
    (60)&#160;days after the retiring Trustee tenders its
    resignation or is removed, the retiring Trustee may, or, the
    Holder of any Security who has been a bona fide Holder for at
    least six (6)&#160;months may on behalf of himself and all
    others similarly situated, petition any court of competent
    jurisdiction for the appointment of a successor Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;The Company shall give notice of each resignation and
    each removal of the Trustee and each appointment of a successor
    Trustee by mailing written notice of such event by first-class
    mail, postage prepaid, to the Holders of Securities as their
    names and addresses appear in the Security Register. Each notice
    shall include the name of the successor Trustee and the address
    of its Corporate Trust&#160;Office. If the Company fails to send
    such notice within ten (10)&#160;days after acceptance of
    appointment by a successor Trustee, it shall not be a default
    hereunder but the successor Trustee shall cause the notice to be
    mailed at the expense of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.11&#160;&#160;<I><U>Acceptance
    of Appointment of Successor</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Every successor Trustee appointed hereunder shall
    execute, acknowledge and deliver to the Company and to the
    retiring Trustee an instrument accepting such appointment, and
    thereupon the resignation or removal of the retiring Trustee
    shall become effective and such successor Trustee, without any
    further act, deed or conveyance, shall become vested with all
    the rights, powers, trusts and duties of the retiring Trustee;
    but, upon request of the Company or the successor Trustee, such
    retiring Trustee shall, upon payment of its charges, execute and
    deliver an instrument transferring to such successor Trustee all
    the rights, powers and trusts of the retiring Trustee, and shall
    duly assign, transfer and deliver to such successor Trustee all
    property and money held by such retiring Trustee hereunder. Upon
    request of any such successor Trustee, the Company shall execute
    any and all instruments for more fully and certainly vesting in
    and confirming to such successor Trustee all such rights, powers
    and trusts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;No successor Trustee shall accept its appointment
    unless at the time of such acceptance such successor Trustee
    shall be qualified and eligible under this Article.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.12&#160;&#160;<I><U>Merger,
    Conversion, Consolidation or Succession to
    Business</U>.</I>&#160;&#160;Any corporation into which the
    Trustee may be merged or converted or with which it may be
    consolidated, or any corporation resulting from any merger,
    conversion or consolidation to which the Trustee shall be a
    party, or any corporation succeeding to all or substantially all
    of the corporate trust business of the Trustee, by sale or
    otherwise shall be the successor of the Trustee hereunder,
    provided such corporation shall be otherwise qualified and
    eligible under this Article, without the execution or filing of
    any paper or any further act on the part of any of the Parties
    hereto. In case any Securities shall have been authenticated,
    but not delivered, by the Trustee then in office, any successor
    by merger, conversion, sale or consolidation to such
    authenticating Trustee may adopt such authentication and deliver
    the Securities so authenticated with the same effect as if such
    successor Trustee had itself authenticated such Securities; and
    such certificate shall have the full force which it is anywhere
    in the Securities or in this CVR Agreement provided that the
    certificate of the Trustee shall have; provided that the right
    to adopt the certificate of authentication of any predecessor
    Trustee shall apply only to its successor or successors by
    merger, conversion or consolidation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.13&#160;&#160;<I><U>Preferential
    Collection of Claims Against Company</U>.</I>&#160;&#160;If and
    when the Trustee shall be or shall become a creditor, directly
    or indirectly, secured or unsecured, of the Company (or any
    other obligor upon the Securities), excluding any creditor
    relationship set forth in Section&#160;311(b) of the Trust
    Indenture Act, if applicable, the Trustee shall be subject to
    the applicable provisions of the Trust Indenture Act regarding
    the collection of claims against the Company (or any such other
    obligor).
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;5<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">HOLDERS&#146;
    LISTS AND REPORTS BY THE TRUSTEE AND COMPANY
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.1&#160;&#160;<I><U>Company
    to Furnish Trustee Names and Addresses of
    Holders</U>.</I>&#160;&#160;The Company will furnish or cause to
    be furnished to the Trustee (i)&#160;promptly after the issuance
    of the Securities, and semi-annually thereafter, a list, in such
    form as the Trustee may reasonably require, of the names and
    addresses of the Holders as of a recent date, and (ii)&#160;at
    such times as the Trustee may request in writing, within thirty
    (30)&#160;days after receipt by the Company of any such request,
    a list, in such form as the Trustee may reasonably require, of
    the names and addresses of the Holders as of a date not more
    than fifteen (15)&#160;days prior to the time such list is
    furnished; provided, however, that if and so long as the Trustee
    shall be the Security Registrar, no such list need be furnished.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.2&#160;&#160;<I><U>Preservation
    of Information; Communications to Holders</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Trustee shall preserve, in as current a form as is
    reasonably practicable, the names and addresses of Holders
    contained in the most recent list furnished to the Trustee as
    provided in Section&#160;5.1 and the names and addresses of
    Holders received by the Trustee in its capacity as Security
    Registrar. The Trustee may destroy any list furnished to it as
    provided in Section&#160;5.1 upon receipt of a new list so
    furnished.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The rights of the Holders to communicate with other
    Holders with respect to their rights under this CVR Agreement
    and the corresponding rights and privileges of the Trustee shall
    be as provided by Section&#160;312(b)(2) of the Trust Indenture
    Act, if applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Every Holder of Securities, by receiving and holding
    the same, agrees with the Company and the Trustee that neither
    the Company nor the Trustee shall be deemed to be in violation
    of Law or held accountable by reason of the disclosure of any
    such information as to the names and addresses of the Holders
    made pursuant to the Trust Indenture Act (if applicable)
    regardless of the source from which such information was derived.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.3&#160;&#160;<I><U>Reports
    by Trustee</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Within sixty (60)&#160;days after December&#160;31 of
    each year commencing with the December&#160;31 following the
    date of this CVR Agreement, the Trustee shall transmit to all
    Holders such reports concerning the Trustee and its actions
    under this CVR Agreement as may be required pursuant to the
    Trust Indenture Act to the extent and in the manner provided
    pursuant thereto. The Trustee shall also comply with
    Section&#160;313(b)(2) of the Trust Indenture Act, if
    applicable. The Trustee shall also transmit by mail all reports
    as required by Section&#160;313(c) of the Trust Indenture Act,
    if applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;A copy of each such report shall, at the time of such
    transmission to the Holders, be filed by the Trustee with each
    stock exchange, if any, upon which the Securities are listed,
    with the Commission and also with the Company. The Company will
    promptly notify the Trustee when the Securities are listed on
    any stock exchange.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.4&#160;&#160;<I><U>Reports
    by Company</U>.</I>&#160;&#160;The Company shall:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;file with the Trustee, (i)&#160;within fifteen
    (15)&#160;days after the Company is required to file the same
    with the Commission, copies of the annual and quarterly reports
    and of the information, documents and other reports (or copies
    of such portions of any of the foregoing as the Commission may
    from time to time by rules and regulations prescribe) which the
    Company is required to file with the Commission pursuant to
    Section&#160;13 or Section&#160;15(d) of the Exchange Act (such
    required information, documents and other reports, together the
    &#147;<U>Exchange Act Documents</U>&#148;); and (ii)&#160;if the
    Company is not required to file Exchange Act Documents under
    Section&#160;13 or 15(d) of the Exchange Act, within forty-five
    (45)&#160;days after each calendar quarter of the Company (other
    than the last quarter of each calendar year), quarterly
    financial information and, within ninety (90)&#160;days after
    each calendar year of the Company, annual financial information
    that would be required pursuant to Section&#160;13 of the
    Exchange Act in respect of a security listed and registered on a
    national securities exchange as may be prescribed from time to
    time in such rules and regulations (provided that the Company
    also delivers with, or includes within, the annual reports
    referred to in (i)&#160;and (ii)&#160;a calculation of Net Sales
    for the Products for the annual period to date);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;file with the Trustee, (i)&#160;within ten
    (10)&#160;days after the Company files its annual report with
    the Commission for any year if the Company is required to file
    Exchange Act Documents under Section&#160;13 or 15(d) of the
    Exchange Act, or if the Company is not required to file Exchange
    Act Documents under Section&#160;13 or 15(d) of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    the Exchange Act within ninety (90)&#160;days after each
    calendar year, a Net Sales Statement with respect to the last
    completed calendar year, and (ii)&#160;within four
    (4)&#160;Business Days after the occurrence of any Milestone, a
    notice setting forth the Milestone that occurred, the amount of
    the Milestone Payment payable in connection therewith and the
    applicable Milestone Payment Date;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;file with the Trustee such additional information,
    documents and reports with respect to compliance by the Company
    with the conditions and covenants of this CVR Agreement as may
    be required from time to time by the rules and regulations of
    the Commission;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;make available to the Holders on the Company&#146;s
    website as of an even date with the filing of such materials
    with the Trustee, the information, documents and reports
    required to be filed by the Company pursuant to subsections (a),
    (b)&#160;and (c)&#160;of this Section&#160;5.4.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Delivery of the reports, information and documents described in
    Section&#160;5.4(a) and (c)&#160;shall not constitute
    constructive notice of any information contained therein or
    determinable there from, including the Company&#146;s compliance
    with any of its covenants or other obligations hereunder as to
    which the Trustee is entitled to rely exclusively on
    Officer&#146;s Certificates.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;6<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">AMENDMENTS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.1&#160;&#160;<I><U>Amendments
    Without Consent of Holders</U>.</I>&#160;&#160;Without the
    consent of any Holders, the Company and the Trustee, at any time
    and from time to time, may enter into one or more amendments
    hereto or to the Securities, for any of the following purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;to convey, transfer, assign, mortgage or pledge to the
    Trustee as security for the Securities any property or
    assets;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;to evidence the succession of another Person to the
    Company, and the assumption by any such successor of the
    covenants of the Company herein and in the Securities;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;to add to the covenants of the Company such further
    covenants, restrictions, conditions or provisions as its Board
    of Directors and the Trustee shall consider to be for the
    protection of the Holders of Securities, and to make the
    occurrence, or the occurrence and continuance, of a default in
    any such additional covenants, restrictions, conditions or
    provisions an Event of Default permitting the enforcement of all
    or any of the several remedies provided in this CVR Agreement as
    herein set forth; provided, that in respect of any such
    additional covenant, restriction, condition or provision, such
    amendment may provide for a particular period of grace after
    default (which period may be shorter or longer than that allowed
    in the case of other defaults) or may provide for an immediate
    enforcement upon such an Event of Default or may limit the
    remedies available to the Trustee upon such an Event of Default
    or may limit the right of the Majority Holders to waive such an
    Event of Default;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;to cure any ambiguity, or to correct or supplement any
    provision herein or in the Securities which may be defective or
    inconsistent with any other provision herein; provided, that
    such provisions shall not materially reduce the benefits of this
    CVR Agreement or the Securities to the Holders;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;to make any other provisions with respect to matters or
    questions arising under this CVR Agreement; provided, that such
    provisions shall not adversely affect the interests of the
    Holders;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;to make any amendments or changes necessary to comply
    or maintain compliance with the Trust Indenture Act, if
    applicable;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;make any change that does not adversely affect the
    interests of the Holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;Promptly following any amendment of this CVR Agreement
    or the Securities in accordance with this Section&#160;6.1, the
    Trustee shall notify the Holders of the Securities of such
    amendment; provided that any failure so to notify the Holders
    shall not affect the validity of such amendment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section</FONT>&#160;6.2&#160;&#160;<I><U>Amendments
    with Consent of Holders</U>.</I>&#160;&#160;With the consent of
    the Majority Holders, by Act of said Holders delivered to the
    Company and the Trustee, the Company (when authorized by a Board
    Resolution) and the Trustee may enter into one or more
    amendments hereto or to the Securities for the purpose of adding
    any provisions to or changing in any manner or eliminating any
    of the provisions of this CVR Agreement or to the Securities or
    of modifying in any manner the rights of the Holders under this
    CVR Agreement or to the Securities; provided, however, that no
    such amendment shall, without the consent of the Holder of each
    Outstanding Security affected thereby:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;modify in a manner adverse to the Holders (i)&#160;any
    provision contained herein with respect to the termination of
    this CVR Agreement or the Securities, (ii)&#160;the time for
    payment and amount of any Net Sales Payment or any Milestone
    Payment, or otherwise extend the time for payment of the
    Securities or reduce the amounts payable in respect of the
    Securities or modify any other payment term or payment date.
    Notwithstanding the foregoing, each Holder of a Security, by
    acceptance thereof, consents to the optional redemption
    provisions set forth in Article&#160;11 hereof;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;reduce the number of CVRs, the consent of whose Holders
    is required for any such amendment;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;modify any of the provisions of this Section, except to
    increase any such percentage or to provide that certain other
    provisions of this CVR Agreement cannot be modified or waived
    without the consent of the Holder of each Security affected
    thereby.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    It shall not be necessary for any Act of Holders under this
    Section to approve the particular form of any proposed
    amendment, but it shall be sufficient if such Act shall approve
    the substance thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.3&#160;&#160;<I><U>Execution
    of Amendments</U>.</I>&#160;&#160;In executing any amendment
    permitted by this Article, the Trustee (subject to
    Section&#160;4.1) shall be fully protected in relying upon an
    Opinion of Counsel stating that the execution of such amendment
    is authorized or permitted by this CVR Agreement. The Trustee
    shall execute any amendment authorized pursuant to this Article
    if the amendment does not adversely affect the Trustee&#146;s
    own rights, duties or immunities under this CVR Agreement or
    otherwise. Otherwise, the Trustee may, but need not, execute
    such amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.4&#160;&#160;<I><U>Effect
    of Amendments; Notice to Holders</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Upon the execution of any amendment under this Article,
    this CVR Agreement and the Securities shall be modified in
    accordance therewith, and such amendment shall form a part of
    this CVR Agreement and the Securities for all purposes; and
    every Holder of Securities theretofore or thereafter
    authenticated and delivered hereunder shall be bound thereby.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Promptly after the execution by the Company and the
    Trustee of any amendment pursuant to the provisions of this
    Article, the Company shall mail a notice thereof by first class
    mail to the Holders of Securities at their addresses as they
    shall appear on the Security Register, setting forth in general
    terms the substance of such amendment. Any failure of the
    Company to mail such notice, or any defect therein, shall not,
    however, in any way impair or affect the validity of any such
    amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.5&#160;&#160;<I><U>Conformity
    with Trust Indenture Act</U>.</I>&#160;&#160;Every amendment
    executed pursuant to this Article shall conform to the
    applicable requirements of the Trust Indenture Act, if any.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.6&#160;&#160;<I><U>Reference
    in Securities to Amendments</U>.</I>&#160;&#160;If an amendment
    changes the terms of a Security, the Trustee may require the
    Holder of the Security to deliver it to the Trustee. Securities
    authenticated and delivered after the execution of any amendment
    pursuant to this Article may, and shall if required by the
    Trustee, bear a notation in form approved by the Trustee as to
    any matter provided for in such amendment. If the Company shall
    so determine, new Securities so modified as to conform, in the
    opinion of the Trustee and the Board of Directors, to any such
    amendment may be prepared and executed by the Company and
    authenticated and delivered by the Trustee in exchange for
    Outstanding Securities. Failure to make the appropriate notation
    or to issue a new Security shall not affect the validity of such
    amendment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;7<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">COVENANTS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.1&#160;&#160;<I><U>Payment
    of Amounts, if any, to Holders</U>.</I>&#160;&#160;The Company
    will duly and punctually pay the amounts, if any, on the
    Securities in accordance with the terms of the Securities and
    this CVR Agreement. Such amounts shall be considered paid on the
    applicable Payment Date if on such date the Trustee or the
    Paying Agent holds in accordance with this CVR Agreement money
    sufficient to pay all such amounts then due. Notwithstanding any
    other provision of this CVR Agreement, the Company or any of its
    Affiliates (including the Surviving Corporation, as applicable),
    the Trustee or the Paying Agent, shall be entitled to deduct and
    withhold, or cause to be deducted and withheld, from amounts
    (including CVRs) otherwise payable pursuant to this CVR
    Agreement or the Merger Agreement to any holder of shares of
    Common Stock, Options, SARs, RSUs or CVRs, such amounts as the
    Company or any of its Affiliates, the Trustee or the Paying
    Agent is required to deduct and withhold with respect to the
    making of such payment under the Internal Revenue Code of 1986,
    as amended, or any provision of state, local or foreign Tax Law.
    To the extent that amounts are so withheld by the Company or any
    of its Affiliates, the Trustee or the Paying Agent, such
    withheld amounts shall be (a)&#160;paid over to the applicable
    Governmental Entity in accordance with applicable Law and
    (b)&#160;treated for all purposes of this CVR Agreement as
    having been paid to such Holder in respect of which such
    deduction and withholding was made by the Company or any of its
    Affiliates, the Trustee or the Paying Agent, as the case may be.
    The consent of Holder shall not be required for any such
    withholding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.2&#160;&#160;<I><U>Maintenance
    of Office or Agency</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;As long as any of the Securities remain Outstanding,
    the Company will maintain in the Borough of Manhattan, The City
    of New York, an office or agency (i)&#160;where Securities may
    be presented or surrendered for payment, (ii)&#160;where
    Securities may be surrendered for registration of transfer or
    exchange and (iii)&#160;where notices and demands to or upon the
    Company in respect of the Securities and this CVR Agreement may
    be served. The office or agency of the Trustee at 59 Maiden
    Lane&#160;&#151; Plaza Level, New York, New York 10038 shall be
    such office or agency of the Company, unless the Company shall
    designate and maintain some other office or agency for one or
    more of such purposes. The Company or any of its Subsidiaries
    may act as Paying Agent, registrar or transfer agent; provided
    that such Person shall take appropriate actions to avoid the
    commingling of funds. The Company will give prompt written
    notice to the Trustee of any change in the location of any such
    office or agency. If at any time the Company shall fail to
    furnish the Trustee with the address thereof, such
    presentations, surrenders, notices and demands may be made or
    served at the Corporate Trust&#160;Office of the Trustee, and
    the Company hereby appoints the Trustee as its agent to receive
    all such presentations, surrenders, notices and demands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Company may from time to time designate one or more
    other offices or agencies (in or outside of The City of New
    York) where the Securities may be presented or surrendered for
    any or all such purposes, and may from time to time rescind such
    designation; provided, however, that no such designation or
    rescission shall in any manner relieve the Company of its
    obligation to maintain an office or agency in the Borough of
    Manhattan, The City of New York for such purposes. The Company
    will give prompt written notice to the Trustee of any such
    designation or rescission and any change in the location of any
    such office or agency.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.3&#160;&#160;<I><U>Money
    for Security Payments to Be Held in Trust</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;If the Company or any of its Subsidiaries shall at any
    time act as the Paying Agent, it will, on or before the Payment
    Date, as the case may be, segregate and hold in trust for the
    benefit of the Holders all sums held by such Paying Agent for
    payment on the Securities until such sums shall be paid to the
    Holders as herein provided, and will promptly notify the Trustee
    of any default by the Company in making payment on the
    Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Whenever the Company shall have one or more Paying
    Agents for the Securities, it will, on or before a Payment Date
    deposit with a Paying Agent a sum in same day funds sufficient
    to pay the amount, if any, so becoming due; such sum to be held
    in trust for the benefit of the Persons entitled to such amount,
    and (unless such Paying Agent is the Trustee) the Company will
    promptly notify the Trustee of such action or any failure so to
    act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;The Company will cause each Paying Agent other than the
    Trustee to execute and deliver to the Trustee an instrument in
    which such Paying Agent shall agree with the Trustee, subject to
    the provisions of this Section, that (i)&#160;such Paying Agent
    will hold all sums held by it for the payment of any amount
    payable on Securities in trust for
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    the benefit of the Persons entitled thereto until such sums
    shall be paid to such Persons or otherwise disposed of as herein
    provided and will notify the Trustee of the sums so held and
    (ii)&#160;that it will give the Trustee notice of any failure by
    the Company (or by any other obligor on the Securities) to make
    any payment on the Securities when the same shall be due and
    payable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Any money deposited with the Trustee or any Paying
    Agent, or then held by the Company, in trust for the payment on
    any Security and remaining unclaimed for one year after the
    Payment Date shall be paid to the Company on Company Request, or
    (if then held by the Company) shall be discharged from such
    trust; and the Holder of such Security shall thereafter, as an
    unsecured general creditor, look only to the Company for payment
    thereof, and all liability of the Trustee or such Paying Agent
    with respect to such trust money shall thereupon cease.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.4&#160;&#160;<I><U>Certain
    Purchases and Sales</U>.</I>&#160;&#160;Nothing contained herein
    shall prohibit the Company or any of its Subsidiaries or
    Affiliates from acquiring in open market transactions, private
    transactions or otherwise, the Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.5&#160;&#160;<I><U>Books
    and Records</U>.</I>&#160;&#160;The Company shall keep, and
    shall cause its Subsidiaries to keep, true, complete and
    accurate records in sufficient detail to enable the amounts
    payable under this CVR Agreement to be determined by the Holders
    and their consultants or professional advisors, for a period of
    three (3)&#160;years following the end of any Net Sales
    Measuring Period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.6&#160;&#160;<I><U>Audits</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Upon the written request of the Majority Holders and no
    more than once during any calendar year, and upon reasonable
    notice, the Company shall provide an independent certified
    public accounting firm of nationally recognized standing
    selected by the Majority Holders and the Company (the
    &#147;<U>Independent Accountant</U>&#148;) with access during
    normal business hours to such of the records of the Company as
    may be reasonably necessary to verify the accuracy of the Net
    Sales Statements and the figures underlying the calculations set
    forth therein for any period within the preceding three
    (3)&#160;years that has not previously been audited in
    accordance with this Section&#160;7.6. The Company shall pay for
    the fees charged by the Independent Accountant in the event that
    the Independent Accountant determines that the amount paid by
    the Company is more than ten percent (10%) below the amount due;
    provided, however, that the Majority Holders shall pay for the
    fees charged by such Independent Accountant in the event that
    the Independent Accountant determines that the amount paid by
    the Company is equal to or less than ten percent (10%) below the
    amount due, which amount the Company may deduct from any future
    CVR Payments payable pursuant to this CVR Agreement. The
    Independent Accountant shall disclose to the Majority Holders
    only the amounts that the Independent Accountant believes to be
    due and payable by the Company, details concerning any
    discrepancy from the amount paid and the amount due, and shall
    disclose no other information revealed in such audit. The
    Independent Accountant shall provide the Company with a copy of
    all disclosures made to the Majority Holders. This covenant
    shall survive the termination of this CVR Agreement for a period
    of three (3)&#160;years; provided that the Holders shall only be
    entitled to one audit following termination of this CVR
    Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;If the Independent Accountant concludes that any Net
    Sales Payment amount should have been greater than the Net Sales
    Payment set forth in an applicable Net Sales Statement (the
    difference being the &#147;<U>CVR Shortfall</U>&#148;), the
    Company shall pay the CVR Shortfall, within six (6)&#160;months
    of the date the Majority Holders deliver to the Company the
    Independent Accountant&#146;s written report (the
    &#147;<U>Shortfall Report</U>&#148;); provided that the CVR
    Shortfall amount shall bear interest at the Shortfall Interest
    Rate beginning from thirty (30)&#160;days after the date the
    Majority Holders deliver to the Company the Shortfall Report
    until payment is made to the Trustee. The decision of such
    Independent Accountant shall be final, conclusive and binding on
    the Company and the Holders, shall be non-appealable and shall
    not be subject to further review.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Upon the expiration of three (3)&#160;years following
    the end of any Net Sales Measuring Period, the calculation of
    the Net Sales Payment payable with respect to such Net Sales
    Measuring Period shall be conclusive and binding on each Holder,
    and the Company shall be released from any liability or
    accountability with respect to payments in respect of such Net
    Sales Measuring Period in excess of such Net Sales Payment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Each person seeking to receive information from the
    Company in connection with a review or audit shall enter into,
    and shall cause its accounting firm to enter into, a reasonable
    and mutually satisfactory confidentiality
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    agreement with the Company obligating such party to retain all
    such financial information disclosed to such party in confidence
    pursuant to such confidentiality agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;The Company shall not, and shall cause its Affiliates
    not to, enter into any license or distribution agreement with
    any third party (other than the Company or its Affiliates) with
    respect to any Product unless such agreement contains provisions
    that would allow any Independent Accountant appointed pursuant
    to this Section&#160;7.6 such access to the records of the other
    party to such license or distribution agreement as may be
    reasonably necessary to perform its duties pursuant to this
    Section&#160;7.6; provided that the Company and its Affiliates
    shall not be required to amend any Existing Licenses. The
    Parties agree that, if the Company or its Affiliates have
    exercised audit rights under any license or distribution
    agreement prior to the Majority Holders&#146; request for an
    audit under this Section&#160;7.6 and under such license or
    distribution agreement the Company and its Affiliates cannot
    request another audit, the results of the Company&#146;s prior
    audit of such licensee or distributor will be used for purposes
    of the audit requested by the Majority Holders under this
    Section&#160;7.6 and that the Company shall not have any further
    obligation to provide access to an Independent Accountant with
    respect to such licensee until such time as the Company may
    again exercise its rights of audit under the license agreement
    with such licensee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.7&#160;&#160;<I><U>Listing
    of CVRs</U>.</I>&#160;&#160;The Company hereby covenants and
    agrees to use reasonable best efforts to cause the Securities to
    be approved for listing (subject to notice of issuance) for
    trading on the Nasdaq Capital Market and will use its reasonable
    best efforts to maintain such listing for so long as any CVRs
    remain Outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.8&#160;&#160;<I><U>Conflicting
    Arrangements</U>.</I>&#160;&#160;So long as any of the
    Securities remain Outstanding, the Company shall not enter into
    any binding agreement, arrangement or understanding, or take or
    permit to be taken any action, which would, or would reasonably
    be expected to, delay or prevent the Company&#146;s ability to
    timely make any CVR Payment that becomes due under this CVR
    Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.9&#160;&#160;<I><U>Product
    Transfer</U>.</I>&#160;&#160;Subject to Article&#160;9, so long
    as the Securities remain Outstanding, the Company and its
    Affiliates may not, directly or indirectly, by a sale or swap of
    assets, merger, reorganization, joint venture, lease, license or
    any other transaction or arrangement, sell, transfer, convey or
    otherwise dispose of their respective rights in and to any
    Product to a third party (other than the Company or its
    Affiliates), unless at all times after any such sale, transfer,
    conveyance or other disposition, the gross amounts invoiced for
    the Products by the applicable transferee (or the amounts of
    royalties, profit split payments and milestone payments, as
    described in clause&#160;(ii) of the definition of &#147;Net
    Sales,&#148; with respect to Existing Licenses, as applicable)
    will be reflected in Net Sales in accordance with the terms
    hereunder (with the transferee substituted for the Company for
    purposes of the definition of &#147;Net Sales&#148;) as if such
    transferee was the Company, and the contract for such sale,
    transfer, conveyance or other disposition (which the Company
    shall take all reasonable actions necessary to enforce in all
    material respects) shall provide for such treatment and shall
    require the transferee to comply with the covenants in this
    Section&#160;7.9 and Sections&#160;7.6, 7.10 and 7.11 hereof to
    the same extent as the Company. For purposes of clarification,
    this Section&#160;7.9 shall not apply to sales of Products made
    by the Company or its Affiliates or ordinary course licensing
    arrangements between the Company and its Affiliates, on the one
    hand, and third party licensees, distributors and contract
    manufacturers, on the other hand, entered into in the ordinary
    course of business for purposes of developing, manufacturing,
    distributing and selling Products and for which the gross
    amounts invoiced for sales of Products by the applicable third
    party licensee, distributor or contract manufacturer (or the
    amounts of royalties, profit split payments and milestone
    payments, as described in clause&#160;(ii) of the definition of
    &#147;Net Sales,&#148; with respect to Existing Licenses, as
    applicable) will be reflected in Net Sales of such Products in
    accordance with the terms of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.10&#160;&#160;<I><U>Milestones</U>.</I>&#160;&#160;The
    Company shall use Diligent Efforts to achieve each of the
    Milestones; provided, however, that such obligation to use
    Diligent Efforts to achieve each of the Milestones shall
    terminate upon the Milestone Target Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.11&#160;&#160;<I><U>Product
    Sale and Development</U>.</I>&#160;&#160;The Company shall use
    Diligent Efforts to obtain Regulatory Approval for the
    Indications; provided, however, that such obligation to use
    Diligent Efforts to obtain such Regulatory Approval shall
    terminate upon the earlier of (a)&#160;the Net Sales Payment
    Termination Date and (b)&#160;on an
    <FONT style="white-space: nowrap">Indication-by-Indication</FONT>
    basis, such time as the data generated in an appropriate
    clinical trial does not support further development of the
    Product described in clause&#160;(a) of the definition of
    &#147;Product.&#148; The Company shall use Diligent Efforts to
    sell the Products for which the Company has obtained Regulatory
    Approval; provided, however,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    that such obligation to use Diligent Efforts to sell the
    Products shall terminate upon the Net Sales Payment Termination
    Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.12&#160;&#160;<I><U>Notice
    of Default</U>.</I>&#160;&#160;The Company shall file with the
    Trustee written notice of the occurrence of any Event of Default
    or other default under this CVR Agreement within five
    (5)&#160;business days of its becoming aware of any such Default
    or Event of Default. The Company shall deliver to the Trustee
    within 90&#160;days after the end of each fiscal year (beginning
    with the fiscal year ending December&#160;31, 2010)&#160;an
    Officer&#146;s Certificate stating whether or not to the best
    knowledge of the signer thereof the Company is in default in the
    performance and observance of any of the conditions or covenants
    under this CVR Agreement (without regard to any period of grace
    or requirement of notice provided hereunder) and if the Company
    shall be in default, specifying all such defaults and the nature
    and status thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.13&#160;&#160;<I><U>Confidentiality</U>.</I>&#160;&#160;The
    Trustee and the Holders hereby agree that any confidential or
    non-public information (including Net Sales Statements) they
    receive from or on behalf of the Company or any Affiliate of the
    Company, which receipt arises out of the transactions
    contemplated by this CVR Agreement (the &#147;<U>Confidential
    Information</U>&#148;), shall: (a)&#160;not be used for any
    purpose other than for purposes permitted under this CVR
    Agreement; (b)&#160;not be used directly or indirectly in any
    way that is for competitive purposes; and (c)&#160;not be
    disclosed by, and be kept confidential by, such Trustee and the
    Holders and its directors, officers, members, managers,
    employees, affiliates, and agents (collectively,
    &#147;<U>Representatives</U>&#148;); provided, however, that any
    such Confidential Information may be disclosed only to their
    Representatives (including the Independent Accountant) who
    (i)&#160;need to know such Confidential Information and
    (ii)&#160;are bound in writing to a non-disclosure agreement no
    less restrictive than this Section&#160;7.13. It is understood
    that such Representatives shall be informed by the Trustee or
    the applicable Holder of the confidential nature of such
    Confidential Information, and that the Trustee or such Holder,
    as applicable, shall be responsible for any disclosure or use
    made by its Representatives in breach of obligations under this
    CVR Agreement to the same extent as if such disclosure or use
    had been made directly by the Trustee or such Holder, as
    applicable. Each of the Trustee and the Holders will as soon as
    practicable notify the Company of any breach of this CVR
    Agreement of which they become aware, and will use commercially
    reasonable efforts to assist and cooperate with the Company in
    minimizing the consequences of such breach. &#147;Confidential
    Information&#148; shall not include any information that is
    (i)&#160;publicly available other than because of disclosure by
    the Trustee or the Holders or any of their respective
    Representatives or (ii)&#160;is lawfully disclosed to the
    Trustee or Holders by sources (other than the Company or its
    Affiliates) rightfully in possession of the Confidential
    Information. If the Trustee, Holders or their respective
    Representatives are legally required or requested to disclose
    any Confidential Information, they will in advance of such
    disclosure, unless otherwise prohibited by Law, promptly notify
    the Company of such request or requirement so that the Company
    may seek to avoid or minimize the required disclosure
    <FONT style="white-space: nowrap">and/or</FONT>
    obtain an appropriate protective order or other appropriate
    relief to ensure that any Confidential Information so disclosed
    is maintained in confidence to the maximum extent possible by
    the person receiving the disclosure, or, in the Company&#146;s
    discretion, to waive compliance with the provisions of this CVR
    Agreement. In any such case, the Trustee and the Holders agree
    to cooperate and use reasonable efforts to avoid or minimize the
    required disclosure
    <FONT style="white-space: nowrap">and/or</FONT>
    obtain such protective order or other relief. If, in the absence
    of a protective order or the receipt of a waiver hereunder, the
    Trustee, Holders or their respective Representatives are legally
    obligated to disclose any Confidential Information, they will
    disclose only so much thereof to the party compelling disclosure
    as they believe in good faith, on the basis of advice of
    counsel, is required by Law. The Trustee and Holders shall give
    the Company prior written notice of the specific Confidential
    Information that they believe they are required to disclose
    under such circumstances. All Confidential Information disclosed
    by or on behalf of the Company or any of its Affiliates shall
    be, and shall remain, the property of the Company or such
    Affiliate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.14&#160;&#160;<I><U>Non-Use
    of Name</U>.</I>&#160;&#160;Neither the Trustee nor the Holders
    shall use the name, trademark, trade name, or logo of the
    Company, its Affiliates, or their respective employees in any
    publicity or news release relating to this CVR Agreement or its
    subject matter, without the prior express written permission of
    the Company.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;8<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">REMEDIES OF
    THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.1&#160;&#160;<I><U>Event
    of Default Defined; Waiver of
    Default</U>.</I>&#160;&#160;<I>&#147;<U>Event of
    Default</U>&#148;</I> with respect to the Securities, means each
    one of the following events which shall have occurred and be
    continuing (whatever the reason for such Event of Default and
    whether it shall be voluntary or involuntary or be effected by
    operation of Law or pursuant to any judgment, decree or order of
    any court or any order, rule or regulation of any administrative
    or governmental body):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;default in the payment of all or any part of any CVR
    Payment after a period of ten (10)&#160;Business Days after such
    CVR Payment shall become due and payable on a Payment Date or
    otherwise;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;material default in the performance, or breach in any
    material respect, of any covenant or warranty of the Company in
    respect of the Securities (other than a covenant or warranty in
    respect of the Securities, a default in whose performance or
    whose breach is elsewhere in this Section specifically dealt
    with), and continuance of such default or breach for a period of
    ninety (90)&#160;days after there has been given, by registered
    or certified mail, to the Company by the Trustee or to the
    Company and the Trustee by the Majority Holders, a written
    notice specifying such default or breach and requiring it to be
    remedied and stating that such notice is a &#147;Notice of
    Default&#148; hereunder;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;a court having jurisdiction in the premises shall enter
    a decree or order for relief in respect of the Company in an
    involuntary case under any applicable bankruptcy, insolvency or
    other similar Law now or hereafter in effect, or appointing a
    receiver, liquidator, assignee, custodian, trustee or
    sequestrator (or similar official) of the Company or for any
    substantial part of its property or ordering the winding up or
    liquidation of its affairs, and such decree or order shall
    remain unstayed and in effect for a period of ninety
    (90)&#160;consecutive days;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;the Company shall commence a voluntary case under any
    applicable bankruptcy, insolvency or other similar Law now or
    hereafter in effect, or consent to the entry of an order for
    relief in an involuntary case under any such Law, or consent to
    the appointment of or taking possession by a receiver,
    liquidator, assignee, custodian, trustee or sequestrator (or
    similar official) of the Company or for any substantial part of
    its property, or make any general assignment for the benefit of
    creditors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If an Event of Default described above occurs and is continuing,
    then, and in each and every such case, either the Trustee or the
    Trustee upon the written request of the Majority Holders by
    notice in writing to the Company (and to the Trustee if given by
    the Majority Holders), shall bring suit to protect the rights of
    the Holders, including to obtain payment for any amounts then
    due and payable, which amounts shall bear interest at the
    Default Interest Rate until payment is made to the Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The foregoing provisions, however, are subject to the condition
    that if, at any time after the Trustee shall have begun such
    suit, and before any judgment or decree for the payment of the
    moneys due shall have been obtained or entered as hereinafter
    provided, the Company shall pay or shall deposit with the
    Trustee a sum sufficient to pay all amounts which shall have
    become due (with interest upon such overdue amount at the
    Default Interest Rate to the date of such payment or deposit)
    and such amount as shall be sufficient to cover reasonable
    compensation to the Trustee, its agents, attorneys and counsel,
    and all other expenses and liabilities incurred and all advances
    made, by the Trustee, and if any and all Events of Default under
    this CVR Agreement shall have been cured, waived or otherwise
    remedied as provided herein, then and in every such case the
    Majority Holders, by written notice to the Company and to the
    Trustee, may waive all defaults with respect to the Securities,
    but no such waiver or rescission and annulment shall extend to
    or shall affect any subsequent default or shall impair any right
    consequent thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.2&#160;&#160;<I><U>Collection
    by the Trustee; the Trustee May Prove Payment
    Obligations</U>.</I>&#160;&#160;The Company covenants that in
    case default shall be made in the payment of all or any part of
    the Securities when the same shall have become due and payable,
    whether at a Payment Date or otherwise, then upon demand of the
    Trustee, the Company will pay to the Trustee for the benefit of
    the Holders of the Securities the whole amount that then shall
    have become due and payable on all Securities (with interest
    from the date due and payable to the date of such payment upon
    the overdue amount at the Default Interest Rate); and in
    addition thereto, such further amount as shall be sufficient to
    cover the costs and expenses of collection, including reasonable
    compensation to the Trustee and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    each predecessor Trustee, their respective agents, attorneys and
    counsel, and any expenses and liabilities incurred, and all
    advances made, by the Trustee and each predecessor Trustee,
    except as a result of its negligence or bad faith.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Trustee may in its discretion proceed to protect and enforce
    its rights and the rights of the Holders by such appropriate
    judicial proceedings as the Trustee shall deem most effectual to
    protect and enforce any such rights, whether for the specific
    enforcement of any covenant or agreement in this CVR Agreement
    or in aid of the exercise of any power granted herein, or to
    enforce any other remedy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In case the Company shall fail forthwith to pay such amounts
    upon such demand, the Trustee, in its own name and as trustee of
    an express trust, shall be entitled and empowered to institute
    any action or proceedings at Law or in equity for the collection
    of the sums so due and unpaid, and may prosecute any such action
    or proceedings to judgment or final decree, and may enforce any
    such judgment or final decree against the Company or other
    obligor upon such Securities and collect in the manner provided
    by Law out of the property of the Company or other obligor upon
    such Securities, wherever situated, the moneys adjudged or
    decreed to be payable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In any judicial proceedings relative to the Company or other
    obligor upon the Securities, irrespective of whether any amount
    is then due and payable with respect to the Securities, the
    Trustee is authorized:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;to file and prove a claim or claims for the whole
    amount owing and unpaid in respect of the Securities, and to
    file such other papers or documents as may be necessary or
    advisable in order to have the claims of the Trustee (including
    any claim for reasonable compensation to the Trustee and each
    predecessor Trustee, and their respective agents, attorneys and
    counsel, and for reimbursement of all expenses and liabilities
    incurred, and all advances made, by the Trustee and each
    predecessor Trustee, except as a result of negligence or bad
    faith) and of the Holders allowed in any judicial proceedings
    relative to the Company or other obligor upon the Securities, or
    to their respective property;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;unless prohibited by and only to the extent required by
    applicable Law, to vote on behalf of the Holders in any election
    of a trustee or a standby trustee in arrangement,
    reorganization, liquidation or other bankruptcy or insolvency
    proceedings or person performing similar functions in comparable
    proceedings;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;to collect and receive any moneys or other property
    payable or deliverable on any such claims, and to distribute all
    amounts received with respect to the claims of the Holders and
    of the Trustee on their behalf; and any trustee, receiver, or
    liquidator, custodian or other similar official is hereby
    authorized by each of the Holders to make payments to the
    Trustee, and, in the event that the Trustee shall consent to the
    making of payments directly to the Holders, to pay to the
    Trustee such amounts as shall be sufficient to cover reasonable
    compensation to the Trustee, each predecessor Trustee and their
    respective agents, attorneys and counsel, and all other expenses
    and liabilities incurred, and all advances made, by the Trustee
    and each predecessor Trustee, except as a result of its
    negligence or bad faith, and all other amounts due to the
    Trustee or any predecessor Trustee pursuant to Section&#160;4.6.
    To the extent that such payment of reasonable compensation,
    expenses, disbursements, advances and other amounts out of the
    estate in any such proceedings shall be denied for any reason,
    payment of the same shall be secured by a lien on, and shall be
    paid out of, any and all distributions, dividends, moneys,
    securities and other property which the Holders may be entitled
    to receive in such proceedings, whether in liquidation or under
    any plan of reorganization or arrangement or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Nothing herein contained shall be deemed to authorize the
    Trustee to authorize or consent to or vote for or accept or
    adopt on behalf of any Holder any plan of reorganization,
    arrangement, adjustment or composition affecting the Securities,
    or the rights of any Holder thereof, or to authorize the Trustee
    to vote in respect of the claim of any Holder in any such
    proceeding except, as aforesaid, to vote for the election of a
    trustee in bankruptcy or similar person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All rights of action and of asserting claims under this CVR
    Agreement, or under any of the Securities, may be enforced by
    the Trustee without the possession of any of the Securities or
    the production thereof and any trial or other proceedings
    instituted by the Trustee shall be brought in its own name as
    trustee of an express trust, and any recovery of judgment,
    subject to the payment of the expenses, disbursements and
    compensation of the Trustee, each predecessor Trustee and their
    respective agents and attorneys, shall be for the ratable
    benefit of the Holders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In any proceedings brought by the Trustee (and also any
    proceedings involving the interpretation of any provision of
    this CVR Agreement to which the Trustee shall be a party) the
    Trustee shall be held to represent all the Holders, and it shall
    not be necessary to make any Holders of such Securities parties
    to any such proceedings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.3&#160;&#160;<I><U>Application
    of Proceeds</U>.</I>&#160;&#160;Any monies collected by the
    Trustee pursuant to this Article in respect of any Securities
    shall be applied in the following order at the date or dates
    fixed by the Trustee upon presentation of the several Securities
    in respect of which monies have been collected and stamping (or
    otherwise noting) thereon the payment in exchange for the
    presented Securities if only partially paid or upon surrender
    thereof if fully paid:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>FIRST:</I>&#160;&#160;To the payment of costs and expenses in
    respect of which monies have been collected, including
    reasonable compensation to the Trustee and each predecessor
    Trustee and their respective agents and attorneys and of all
    expenses and liabilities incurred, and all advances made, by the
    Trustee and each predecessor Trustee, except as a result of its
    negligence or willful misconduct, and all other amounts due to
    the Trustee or any predecessor Trustee pursuant to
    Section&#160;4.6;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>SECOND:</I>&#160;&#160;To the payment of the whole amount
    then owing and unpaid upon all the Securities, with interest at
    the Default Interest Rate on all such amounts, and in case such
    monies shall be insufficient to pay in full the whole amount so
    due and unpaid upon the Securities, then to the payment of such
    amounts without preference or priority of any security over any
    other Security, ratably to the aggregate of such amounts due and
    payable;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>THIRD:</I>&#160;&#160;To the payment of the remainder, if
    any, to the Company or any other person lawfully entitled
    thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.4&#160;&#160;<I><U>Suits
    for Enforcement</U>.</I>&#160;&#160;In case an Event of Default
    has occurred, has not been waived and is continuing, the Trustee
    may in its discretion proceed to protect and enforce the rights
    vested in it by this CVR Agreement by such appropriate judicial
    proceedings as the Trustee shall deem most effectual to protect
    and enforce any of such rights, either at Law or in equity or in
    bankruptcy or otherwise, whether for the specific enforcement of
    any covenant or agreement contained in this CVR Agreement or in
    aid of the exercise of any power granted in this CVR Agreement
    or to enforce any other legal or equitable right vested in the
    Trustee by this CVR Agreement or by Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.5&#160;&#160;<I><U>Restoration
    of Rights on Abandonment of Proceedings</U>.</I>&#160;&#160;In
    case the Trustee or any Holder shall have proceeded to enforce
    any right under this CVR Agreement and such proceedings shall
    have been discontinued or abandoned for any reason, or shall
    have been determined adversely to the Trustee or to such Holder,
    then and in every such case the Company and the Trustee and the
    Holders shall be restored respectively to their former positions
    and rights hereunder, and all rights, remedies and powers of the
    Company, the Trustee and the Holders shall continue as though no
    such proceedings had been taken.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.6&#160;&#160;<I><U>Limitations
    on Suits by Holders</U>.</I>&#160;&#160;Subject to the right of
    the Majority Holders under Section&#160;7.6, no Holder of any
    Security shall have any right by virtue or by availing of any
    provision of this CVR Agreement to institute any action or
    proceeding at Law or in equity or in bankruptcy or otherwise
    upon or under or with respect to this CVR Agreement, or for the
    appointment of a trustee, receiver, liquidator, custodian or
    other similar official or for any other remedy hereunder, unless
    such Holder previously shall have given to the Trustee written
    notice of default and of the continuance thereof, as
    hereinbefore provided, and unless also the Majority Holders
    shall have made written request upon the Trustee to institute
    such action or proceedings in its own name as trustee hereunder
    and shall have offered to the Trustee such reasonable indemnity
    as it may require against the costs, expenses and liabilities to
    be incurred therein or thereby and the Trustee for fifteen
    (15)&#160;days after its receipt of such notice, request and
    offer of indemnity shall have failed to institute any such
    action or proceeding and no direction inconsistent with such
    written request shall have been given to the Trustee pursuant to
    Section&#160;8.9. For the protection and enforcement of the
    provisions of this Section, each and every Holder and the
    Trustee shall be entitled to such relief as can be given either
    at Law or in equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.7&#160;&#160;<I><U>Unconditional
    Right of Holders to Institute Certain
    Suits</U>.</I>&#160;&#160;Notwithstanding any other provision in
    this CVR Agreement and any provision of any Security, the right
    of any Holder of any Security to receive payment of the amounts
    payable in respect of such Security on or after the respective
    due dates expressed in such
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Security, or to institute suit for the enforcement of any such
    payment on or after such respective dates, shall not be impaired
    or affected without the consent of such Holder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.8&#160;&#160;<I><U>Powers
    and Remedies Cumulative; Delay or Omission Not Waiver of
    Default</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Except as provided in Section&#160;8.6, no right or
    remedy herein conferred upon or reserved to the Trustee or to
    the Holders is intended to be exclusive of any other right or
    remedy, and every right and remedy shall, to the extent
    permitted by Law, be cumulative and in addition to every other
    right and remedy given hereunder or now or hereafter existing at
    Law or in equity or otherwise. The assertion or employment of
    any right or remedy hereunder, or otherwise, shall not prevent
    the concurrent assertion or employment of any other appropriate
    right or remedy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;No delay or omission of the Trustee or of any Holder to
    exercise any right or power accruing upon any Event of Default
    occurring and continuing as aforesaid shall impair any such
    right or power or shall be construed to be a waiver of any such
    Event of Default or an acquiescence therein; and, subject to
    Section&#160;8.6, every power and remedy given by this CVR
    Agreement or by Law to the Trustee or to the Holders may be
    exercised from time to time, and as often as shall be deemed
    expedient, by the Trustee or by the Holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.9&#160;&#160;<I><U>Control
    by Holders</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Majority Holders shall have the right to direct the
    time, method, and place of conducting any proceeding for any
    remedy available to the Trustee, or exercising any power
    conferred on the Trustee with respect to the Securities by this
    CVR Agreement; provided that such direction shall not be
    otherwise than in accordance with Law and the provisions of this
    CVR Agreement; and provided further that (subject to the
    provisions of Section&#160;4.1) the Trustee shall have the right
    to decline to follow any such direction if the Trustee, being
    advised by counsel, shall determine that the action or
    proceeding so directed may not lawfully be taken or if the
    Trustee in good faith by its board of directors, the executive
    committee, or a committee of directors or responsible officers
    of the Trustee shall determine that the action or proceedings so
    directed would involve the Trustee in personal liability or if
    the Trustee in good faith shall so determine that the actions or
    forbearances specified in or pursuant to such direction would be
    unduly prejudicial to the interests of Holders of the Securities
    not joining in the giving of said direction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Nothing in this CVR Agreement shall impair the right of
    the Trustee in its discretion to take any action deemed proper
    by the Trustee and which is not inconsistent with such direction
    or directions by Holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.10&#160;&#160;<I><U>Waiver
    of Past Defaults</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;In the case of a default or an Event of Default
    specified in clause&#160;(b), (c)&#160;or (d)&#160;of
    Section&#160;8.1, the Majority Holders may waive any such
    default or Event of Default, and its consequences except a
    default in respect of a covenant or provisions hereof which
    cannot be modified or amended without the consent of the Holder
    of each Security affected. In the case of any such waiver, the
    Company, the Trustee and the Holders of the Securities shall be
    restored to their former positions and rights hereunder,
    respectively; but no such waiver shall extend to any subsequent
    or other default or impair any right consequent thereon.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Upon any such waiver, such default shall cease to exist
    and be deemed to have been cured and not to have occurred, and
    any Event of Default arising therefrom shall be deemed to have
    been cured, and not to have occurred for every purpose of this
    CVR Agreement; but no such waiver shall extend to any subsequent
    or other default or Event of Default or impair any right
    consequent thereon.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.11&#160;&#160;<I><U>The
    Trustee to Give Notice of Default, But May Withhold in Certain
    Circumstances</U>.</I>&#160;&#160;The Trustee shall transmit to
    the Holders, as the names and addresses of such Holders appear
    on the Security Register (as provided under Section&#160;313(c)
    of the Trust Indenture Act, if applicable), notice by mail of
    all defaults which have occurred and are known to the Trustee,
    such notice to be transmitted within ninety (90)&#160;days after
    the occurrence thereof, unless such defaults shall have been
    cured before the giving of such notice (the term
    &#147;default&#148; for the purposes of this Section being
    hereby defined to mean any event or condition which is, or with
    notice or lapse of time or both would become, an Event of
    Default); provided that, except in the case of default in the
    payment of the amounts payable in respect of any of the
    Securities, the Trustee shall be protected in withholding such
    notice if and so long as the board of directors, the executive
    committee, or a trust committee of directors or trustees
    <FONT style="white-space: nowrap">and/or</FONT>
    Responsible Officers of the Trustee in good faith determines
    that the withholding of such notice is in the interests of the
    Holders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.12&#160;&#160;<I><U>Right
    of Court to Require Filing of Undertaking to Pay
    Costs</U>.</I>&#160;&#160;All Parties to this CVR Agreement
    agree, and each Holder of any Security by his acceptance thereof
    shall be deemed to have agreed, that any court may in its
    discretion require, in any suit for the enforcement of any right
    or remedy under this CVR Agreement or in any suit against the
    Trustee for any action taken, suffered or omitted by it as the
    Trustee, the filing by any party litigant in such suit of an
    undertaking to pay the costs of such suit, and that such court
    may in its discretion assess reasonable costs, including
    attorneys&#146; fees, against any party litigant in such suit,
    having due regard to the merits and good faith of the claims or
    defenses made by such party litigant; but the provisions of this
    Section&#160;8.12 shall not apply to any suit instituted by the
    Trustee, to any suit instituted by any Holder or group of
    Holders holding in the aggregate more than ten percent (10%) of
    the Securities Outstanding or to any suit instituted by any
    Holder for the enforcement of the payment of any Security on or
    after the due date expressed in such Security.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;9<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">CONSOLIDATION,
    MERGER, SALE OR CONVEYANCE
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.1&#160;&#160;<I><U>Company
    May Consolidate, etc., on Certain Terms</U>.</I>&#160;&#160;The
    Company covenants that it will not merge or consolidate with or
    into any other Person or sell or convey all or substantially all
    of its assets to any Person, unless, (i)&#160;the Company shall
    be the continuing Person, or the successor Person or the Person
    which acquires by sale or conveyance substantially all the
    assets of the Company (including the shares of Abraxis) shall be
    a Person organized under the Laws of the United States of
    America or any State thereof and shall expressly assume by an
    instrument supplemental hereto, executed and delivered to the
    Trustee, in form satisfactory to the Trustee, the due and
    punctual payment of the Securities, according to their tenor,
    and the due and punctual performance and observance of all of
    the covenants and conditions of this CVR Agreement to be
    performed or observed by the Company and (ii)&#160;the Company,
    or such successor Person, as the case may be, shall not,
    immediately after such merger or consolidation, or such sale or
    conveyance, be in default in the performance of any such
    covenant or condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.2&#160;&#160;<I><U>Successor
    Person Substituted</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;In case of any such consolidation, merger, sale or
    conveyance, and following such an assumption by the successor
    Person, such successor Person shall succeed to and be
    substituted for the Company with the same effect as if it had
    been named herein. Such successor Person may cause to be signed,
    and may issue either in its own name or in the name of the
    Company prior to such succession any or all of the Securities
    issuable hereunder which theretofore shall not have been signed
    by the Company and delivered to the Trustee; and, upon the order
    of such successor corporation instead of the Company and subject
    to all the terms, conditions and limitations in this CVR
    Agreement prescribed, the Trustee shall authenticate and shall
    deliver any Securities which previously shall have been signed
    and delivered to the Trustee for authentication, and any
    Securities which such successor corporation thereafter shall
    cause to be signed and delivered to the Trustee for that
    purpose. All of the Securities so issued shall in all respects
    have the same legal rank and benefit under this CVR Agreement as
    the Securities theretofore or thereafter issued in accordance
    with the terms of this CVR Agreement as though all of such
    Securities had been issued at the date of the execution hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;In case of any such consolidation, merger, sale or
    conveyance, such changes in phraseology and form (but not in
    substance) may be made in the Securities thereafter to be issued
    as may be appropriate. The successor entity to such
    consolidation, merger, sale or conveyance may satisfy the
    obligations of Section&#160;5.4(a)(i) and (ii)&#160;of this CVR
    Agreement by providing copies of such successor entity&#146;s
    Exchange Act Documents in the case of Section&#160;5.4(a)(i) or
    such successor entity&#146;s financial information in the case
    of Section&#160;5.4(a)(ii).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;In the event of any such sale, transfer or conveyance
    (other than a conveyance by way of lease) the Company or any
    Person which shall theretofore have become such in the manner
    described in this Article shall be discharged from all
    obligations and covenants under this CVR Agreement and the
    Securities and may be liquidated and dissolved.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.3&#160;&#160;<I><U>Opinion
    of Counsel to the Trustee</U>.</I>&#160;&#160;The Trustee,
    subject to the provisions of Sections&#160;4.1 and 4.2, shall
    receive an Officer&#146;s Certificate and Opinion of Counsel,
    prepared in accordance with Sections&#160;1.3 and 1.4,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    as conclusive evidence that any such consolidation, merger, sale
    or conveyance, and any such assumption, and any such liquidation
    or dissolution, complies with the applicable provisions of this
    CVR Agreement, and if a supplemental agreement is required in
    connection with such transaction, such supplemental agreement
    complies with this Article and that there has been compliance
    with all conditions precedent herein provided for or relating to
    such transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.4&#160;&#160;<I><U>Successors</U>.</I>&#160;&#160;All
    covenants, provisions and agreements in this CVR Agreement by or
    for the benefit of the Company, the Trustee or the Holders shall
    bind and inure to the benefit of their respective successors,
    assigns, heirs and personal representatives, whether so
    expressed or not. The Company may assign this CVR Agreement
    without the prior written consent of the other Parties to this
    CVR Agreement to one or more of its direct or indirect
    Subsidiaries, provided, however, that in the event of any such
    assignment the Company shall remain subject to its obligations
    and covenants hereunder, including but not limited to its
    obligation to make any Net Sales Payments and any Milestone
    Payments.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;10<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">SUBORDINATION
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.1&#160;&#160;<I><U>Agreement
    to Subordinate</U>.</I>&#160;&#160;The Company agrees, and each
    Holder by accepting a Security hereunder agrees, that the CVR
    Payments, all other obligations under this CVR Agreement and the
    Securities and any rights or claims relating thereto
    (collectively, the &#147;<U>Junior Obligations</U>&#148;) are
    subordinated in right of payment, to the extent and in the
    manner provided in this Article&#160;10, to the prior payment in
    full in cash or cash equivalents of all Senior Obligations of
    the Company (whether outstanding on the date hereof or hereafter
    created, incurred, assumed or guaranteed), and that the
    subordination is for the benefit of the holders of such Senior
    Obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.2&#160;&#160;<I><U>Liquidation;
    Dissolution; Bankruptcy</U>.</I>&#160;&#160;Upon any
    distribution to creditors of the Company in a liquidation or
    dissolution of the Company or in a bankruptcy, reorganization,
    insolvency, receivership or similar proceeding relating to the
    Company or its property, in an assignment for the benefit of
    creditors or any marshaling of the Company&#146;s assets and
    liabilities:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;holders of Senior Obligations will be entitled to
    receive payment in full in cash or cash equivalents of all
    Senior Obligations of the Company (including interest after the
    commencement of any bankruptcy proceeding at the rate specified
    in the applicable Senior Obligation, whether or not permitted
    under such bankruptcy proceedings) before the Holders will be
    entitled to receive any payment of any kind with respect to the
    Junior Obligations;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;until all Senior Obligations of the Company (as
    provided in clause&#160;(a) above) are paid in full in cash or
    cash equivalents, any distribution to which Holders would be
    entitled but for this Article&#160;10 will be made to holders of
    Senior Obligations of the Company, as their interests may appear.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.3&#160;&#160;<I><U>Default
    on Senior Obligations</U>.</I>&#160;&#160;The Company may not
    make any payment or distribution to any Holder in respect of
    Junior Obligations or acquire from any Holder for cash or
    property any Junior Obligations:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;if any default on any Senior Obligations exceeding
    twenty-five million dollars ($25,000,000) in aggregate principal
    amount would occur as a result of such payment, distribution or
    acquisition;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;during the continuance of any payment default in
    respect of any Senior Obligations (after expiration of any
    applicable grace period) exceeding twenty-five million dollars
    ($25,000,000) in aggregate principal amount;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;if the maturity of any Senior Obligations representing
    more than twenty-five million dollars ($25,000,000) in aggregate
    principal amount is accelerated in accordance with its terms and
    such acceleration has not been rescinded;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;following the occurrence of any default (other than a
    payment default, and after the expiration of any applicable
    grace period) with respect to any Senior Obligations with an
    aggregate principal amount of more than twenty-five million
    dollars ($25,000,000), the effect of which is to permit the
    holders of such Senior Obligations (or a trustee or agent acting
    on their behalf) to cause, with the giving of notice if
    required, the maturity of such Senior Obligations to be
    accelerated, for a period commencing upon the receipt by the
    Trustee (with a copy to the Company) of a written notice of such
    default from the representative of the holders of such Senior
    Obligations and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    ending when such Senior Obligations are paid in full in cash or
    cash equivalents or, if earlier, when such default is cured or
    waived.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.4&#160;&#160;<I><U>When
    Distribution Must Be Paid Over</U>.</I>&#160;&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;In the event that the Trustee or any Holder receives
    any payment of any Junior Obligations at a time when such
    payment is prohibited by this Article&#160;10, such payment will
    be held by the Trustee or such Holder, in trust for the benefit
    of, and will be paid forthwith over and delivered, upon written
    request, to, the holders of Senior Obligations of the Company as
    their interests may appear or their representative under the
    agreement, indenture or other document (if any) pursuant to
    which such Senior Obligations may have been issued, as their
    respective interests may appear, for application to the payment
    of all such Senior Obligations remaining unpaid to the extent
    necessary to pay such Senior Obligations in full in accordance
    with their terms, after giving effect to any concurrent payment
    or distribution to or for the holders of Senior Obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Any amount received by any Holder as a result of direct
    or indirect credit support for the Junior Obligations from any
    Affiliate of the Company shall be treated as payments received
    by such Holder from the Company that are subject to the
    provisions of this Article&#160;10.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;With respect to the holders of Senior Obligations, the
    Trustee undertakes to perform only those obligations on the part
    of the Trustee as are specifically set forth in this
    Article&#160;10, and no implied covenants or obligations with
    respect to the holders of Senior Obligations will be read into
    this CVR Agreement against the Trustee. The Trustee will not be
    deemed to owe any fiduciary duty to the holders of Senior
    Obligations, and will not be liable to any such holders if the
    Trustee pays over or distributes to or on behalf of Holders or
    the Company or any other Person money or assets to which any
    holders of Senior Obligations are then entitled by virtue of
    this Article&#160;10, except if such payment is made as a result
    of the willful misconduct or gross negligence of the Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.5&#160;&#160;<I><U>Notice
    by Company</U>.</I>&#160;&#160;The Company will promptly notify
    the Trustee of any facts known to the Company that would cause a
    payment of any Junior Obligations to violate this
    Article&#160;10, but failure to give such notice will not affect
    the subordination of the Junior Obligations to the Senior
    Obligations as provided in this Article&#160;10.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section</FONT>&#160;10.6&#160;&#160;<I><U>Subordination
    Effective Notwithstanding Deficiencies with Respect to Senior
    Obligations; Waiver of Right to Contest Senior Obligation;
    Reinstatement of Subordination Provisions</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Holders hereby agree that subordination provisions
    contained in this Article&#160;10 are unconditional,
    irrespective of the validity, regularity or enforceability of
    the Senior Obligations, the absence of any action to enforce the
    same, any waiver or consent by any holder of Senior Obligations
    with respect to any provisions thereof, the recovery of any
    judgment against the Company, any action to enforce the same or
    any other circumstance which might otherwise constitute a legal
    or equitable discharge or defense. Without limiting the
    foregoing, and notwithstanding anything to the contrary
    contained elsewhere in this CVR Agreement, in the event that the
    amount of Senior Obligations are reduced or diminished for any
    reason (other than as a result of the payment in cash or cash
    equivalents thereof), whether because of the applicability of
    fraudulent conveyance or other applicable Laws, or any other
    invalidity or limitation on the amount of Senior Obligations,
    the subordination provisions thereof shall apply to the full
    amount of Senior Obligations (without giving effect to any
    reduction, invalidity or diminution thereof), and the turnover
    provisions hereunder shall be fully enforceable with respect to
    the full amount of Senior Obligations (without giving effect to
    any such reduction, invalidity or diminution thereof), even if
    the effect thereof is that there will be no (or a limited amount
    of) Senior Obligations to which the Junior Obligations are
    subrogated after the payment in full in cash of any of then
    remaining Senior Obligations (without giving effect to any
    reductions, invalidity or diminution thereof, except for
    reductions as a result of payments thereof in cash or cash
    equivalents).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;The Trustee and the Holders agree that they shall not
    (and hereby waive any right to) take any action to contest or
    challenge (or assist or support any other Person in contesting
    or challenging), directly or indirectly, whether or not in any
    proceeding (including in any proceeding commenced by or against
    any Person under any provision of Title&#160;11 of the United
    States Code, as now and hereinafter in effect, or any successor
    statute or under any other state or federal bankruptcy or
    insolvency Law, assignments for the benefit of creditors, formal
    or informal
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    moratoria, compositions, extensions generally with creditors, or
    proceedings seeking reorganization, arrangement, or other
    similar relief), the validity or enforceability of the Senior
    Obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;If any payment made or in respect to the Senior
    Obligations must be disgorged or returned for any reason, the
    Senior Obligations shall be reinstated hereunder and for all
    purposes of this Article&#160;10 (including, without limitation,
    the turnover provisions hereof) such payment shall be deemed to
    have never been made with respect to the Senior Obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.7&#160;&#160;<I><U>Subrogation</U>.</I>&#160;&#160;After
    all Senior Obligations are paid in full in cash or cash
    equivalents and until the Junior Obligations are paid in full,
    Holders will be subrogated to the rights of holders of Senior
    Obligations to receive distributions applicable to Senior
    Obligations to the extent that distributions otherwise payable
    to the Holders have been applied to the payment of Senior
    Obligations. The Holders by accepting the Securities acknowledge
    that to the extent that the Senior Obligations are determined to
    be unenforceable, or the Senior Obligations are subordinated to
    other obligations of the Company, such subrogation rights may be
    impaired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.8&#160;&#160;<I><U>Relative
    Rights</U>.</I>&#160;&#160;This Article&#160;10 defines the
    relative rights of Holders and holders of Senior Obligations.
    Nothing in this CVR Agreement will:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;impair, as between the Company and Holders, the
    obligations of the Company under this CVR Agreement and the
    Securities;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;affect the relative rights of Holders and creditors of
    the Company other than their rights in relation to holders of
    Senior Obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;If the Company fails because of this Article&#160;10 to
    pay any amounts due in respect of the Securities on a due date
    in violation of Section&#160;8.1, the failure is still an Event
    of Default.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.9&#160;&#160;<I><U>Subordination
    May Not Be Impaired by Company</U>.</I>&#160;&#160;No right of
    any holder of Senior Obligations to enforce the subordination of
    the Junior Obligations may be impaired by any act or failure to
    act by the Company or any Holder or by the failure of the
    Company or any Holder to comply with this CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.10&#160;&#160;<I><U>Distribution
    or Notice to Representative</U>.</I>&#160;&#160;Whenever a
    distribution is to be made or a notice given to holders of
    Senior Obligations, the distribution may be made and the notice
    given to their representative in accordance with the terms of
    the instrument or other agreement governing such Senior
    Obligations. Upon any payment or distribution of assets of the
    Company referred to in this Article&#160;10, the Trustee and the
    Holders will be entitled to rely upon any order or decree made
    by any court of competent jurisdiction or upon any certificate
    of such representative or of the liquidating trustee or agent or
    other Person making any distribution to the Trustee or to the
    Holders for the purpose of ascertaining the Persons entitled to
    participate in such distribution, the holders of the Senior
    Obligations and other obligations of the Company, the amount
    thereof or payable thereon, the amount or amounts paid or
    distributed thereon and all other facts pertinent thereto or to
    this Article&#160;10.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.11&#160;&#160;<I><U>Rights
    of the Trustee</U>.</I>&#160;&#160;Notwithstanding the
    provisions of this Article&#160;10 or any other provision of
    this CVR Agreement, the Trustee will not be charged with
    knowledge of the existence of any facts that would prohibit the
    making of any payment or distribution by the Trustee, and the
    Trustee may continue to make payments on the Securities, unless
    the Trustee has received at its address for notice specified in
    Section&#160;1.5 at least five (5)&#160;Business Days prior to
    the date of such payment written notice of facts that would
    cause the payment of any Junior Obligations to violate this
    Article&#160;10. Only the Company or a representative of Senior
    Obligations may give the notice. Nothing in this Article&#160;10
    will impair the claims of, or payments to, the Trustee under or
    pursuant to Section&#160;4.7 hereof. The Trustee in its
    individual or any other capacity may hold Senior Obligations
    with the same rights it would have if it were not the Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.12&#160;&#160;<I><U>Authorization
    to Effect Subordination</U>.</I>&#160;&#160;Each Holder, by the
    Holder&#146;s acceptance of the Securities, authorizes and
    directs the Trustee on such Holder&#146;s behalf to take such
    action as may be necessary or appropriate to effectuate the
    subordination as provided in this Article&#160;10, and appoints
    the Trustee to act as such Holder&#146;s
    <FONT style="white-space: nowrap">attorney-in-fact</FONT>
    for any and all such purposes. If the Trustee (or any other
    Person acting on behalf of and at the direction of the Majority
    Holders) does not file a proper proof of claim or proof of debt
    in the form required in any proceeding referred to in
    Section&#160;8.2 hereof at least thirty (30)&#160;days before
    the expiration of the time to file such
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    claim, the representatives of the Senior Obligations are hereby
    authorized to file an appropriate claim for and on behalf of the
    Holders of the Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.13&#160;&#160;<I><U>Amendments</U>.</I>&#160;&#160;The
    provisions of this Article&#160;10 are expressly made for the
    benefit of the holders from time to time of the Senior
    Obligations, and may not be amended or modified without the
    written consent of the representatives of the holders of all
    Senior Obligations.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;11<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">REDEMPTION&#160;OF
    SECURITIES
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>11.1&#160;&#160;<I><U>Notice
    to Trustee</U>.</I>&#160;&#160;If the Company elects to redeem
    the Securities pursuant to the optional redemption provisions of
    Section&#160;11.5 hereof, it shall furnish to the Trustee, at
    least forty five (45)&#160;days (unless a shorter period shall
    be agreed to by the Trustee) but not more than sixty
    (60)&#160;days before a redemption date (but in any event prior
    to the notice provided pursuant to Section&#160;11.2 hereof), an
    Officer&#146;s Certificate (a &#147;<U>Consent and Purchase
    Offer</U>&#148;) setting forth (i)&#160;the clause of this CVR
    Agreement pursuant to which the redemption shall occur,
    (ii)&#160;the redemption date, and (iii)&#160;the redemption
    price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>11.2&#160;&#160;<I><U>Notice
    of Redemption</U>.</I>&#160;&#160;At least thirty (30)&#160;days
    but not more than sixty (60)&#160;days before a redemption date,
    the Company shall mail or cause to be mailed, by first class
    mail, a notice of redemption to each Holder at its registered
    address. The notice (the &#147;<U>Call Notice</U>&#148;) shall
    identify the number of Securities Outstanding and shall state:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;the redemption date;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;the redemption price;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;the name and address of the paying agent;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;that Securities must be surrendered to the Paying Agent
    to collect the redemption price;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;that, unless the Company defaults in making such
    redemption payment, all right title and interest in and to the
    Securities and any Net Sales Payment, Milestone Payment or any
    other amounts due under this CVR Agreement, if any, on
    Securities called for redemption ceases to accrue on and after
    the redemption date;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;the clause of this CVR Agreement pursuant to which the
    Securities are being redeemed;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;that no representation is made as to the correctness or
    accuracy of the CUSIP and ISIN number, if any, listed in such
    notice or printed on the Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At the Company&#146;s request, the Trustee shall give the notice
    of redemption in the Company&#146;s name and at its expense;
    provided, however, that the Company shall have delivered to the
    Trustee at least forty five (45)&#160;days (unless a shorter
    period shall be agreed to by the Trustee) but not more than
    sixty (60)&#160;days prior to the redemption date, an
    Officer&#146;s Certificate requesting that the Trustee give such
    notice and setting forth the information to be stated in such
    notice as provided in the preceding paragraph.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>11.3&#160;&#160;<I><U>Effect
    of Notice of Redemption</U>.</I>&#160;&#160;Once notice of
    redemption is mailed in accordance with Section&#160;11.2
    hereof, the Securities shall become irrevocably due and payable
    on the redemption date at the redemption price. A notice of
    redemption shall be deemed to be given when mailed, whether or
    not the Holder receives the notice. In any event, failure to
    give such notice, or any defect in such notice, shall not affect
    the validity of the proceedings for the redemption of the
    Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>11.4&#160;&#160;<I><U>Deposit
    of Redemption&#160;Price</U>.</I>&#160;&#160;On or one
    (1)&#160;Business Day prior to the redemption date, the Company
    shall deposit with the Trustee or with the paying agent (if
    different from the Trustee) money sufficient to pay the
    redemption price of all Securities Outstanding on that date. The
    Trustee or the paying agent shall promptly return to the Company
    any money deposited with the Trustee or the paying agent by the
    Company in excess of the amounts necessary to pay the redemption
    price of all Securities Outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the Company complies with the provisions of the preceding
    paragraph, on and after the redemption date, all right title and
    interest of a Holder to any Net Sales Payment or Milestone
    Payment, if any, shall cease to accrue on
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    the Securities. If any Security called for redemption shall not
    be so paid upon surrender for redemption because of the failure
    of the Company to comply with the preceding paragraph, interest
    shall be paid on the unpaid redemption price from the redemption
    date, until such redemption price is paid at the Shortfall
    Interest Rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>11.5&#160;&#160;<I><U>Optional
    Redemption by the Company</U>.</I>&#160;&#160;The Company may,
    at any time on and after the Redemption&#160;Eligibility Date,
    redeem all (but not less than all) of the outstanding Securities
    at a cash redemption price equal to the average price paid per
    Security for all Securities previously purchased by the Company
    calculated as of the Business Day immediately prior to the date
    of the Call Notice mailed by the Company in accordance with
    Section&#160;11.2 hereof.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">[Signature
    Page&#160;Follows]</FONT></B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    IN WITNESS WHEREOF, the Parties hereto have caused this CVR
    Agreement to be duly executed, all as of the day and year first
    above written.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    CELGENE CORPORATION
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">&#160;&#160;&#160;<FONT style="font-variant: SMALL-CAPS">&#160;</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">

</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    AMERICAN STOCK TRANSFER AND TRUST&#160;COMPANY, as the Trustee
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">&#160;&#160;&#160;<FONT style="font-variant: SMALL-CAPS">&#160;</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">

</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CELGENE
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <FONT style="font-family: 'Times New Roman', Times">No.
    </FONT></TD>
    <TD nowrap align="center">    <FONT style="font-family: 'Times New Roman', Times"> Certificate
    for
    </FONT></TD>
    <TD nowrap align="right">    <FONT style="font-family: 'Times New Roman', Times"> Contingent
    Value Rights
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This certifies
    that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    or registered assigns (the &#147;<U>Holder</U>&#148;), is the
    registered holder of the number of Contingent Value Rights
    (&#147;<U>CVRs</U>&#148; or &#147;<U>Securities</U>&#148;) set
    forth above. Each CVR entitles the Holder, subject to the
    provisions contained herein and in the CVR Agreement referred to
    on the reverse hereof, to payments from Celgene Corporation, a
    Delaware corporation (the &#147;<U>Company</U>&#148;), in an
    amounts and in the forms determined pursuant to the provisions
    set forth on the reverse hereof and as more fully described in
    the CVR Agreement referred to on the reverse hereof. Such
    payments shall be made on a Payment Date, as defined in the CVR
    Agreement referred to on the reverse hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Payment of any amounts pursuant to this CVR Certificate shall be
    made only to the registered Holder (as defined in the CVR
    Agreement) of this CVR Certificate. Such payment shall be made
    in the Borough of Manhattan, The City of New York, or at any
    other office or agency maintained by the Company for such
    purpose, in such coin or currency of the United States of
    America as at the time is legal tender for the payment of public
    and private debts; provided, however, the Company may pay such
    amounts by wire transfer or check payable in such money.
    American Stock Transfer&#160;&#038; Trust Company has been
    initially appointed as Paying Agent at its office or agency in
    the Borough of Manhattan, The City of New York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Reference is hereby made to the further provisions of this CVR
    Certificate set forth on the reverse hereof, which further
    provisions shall for all purposes have the same effect as if set
    forth at this place.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Unless the certificate of authentication hereon has been duly
    executed by the Trustee referred to on the reverse hereof by
    manual signature, this CVR Certificate shall not be entitled to
    any benefit under the CVR Agreement, or be valid or obligatory
    for any purpose.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    IN WITNESS WHEREOF, the Company has caused this instrument to be
    duly executed.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dated:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    [&#160;&#149;&#160;]
</TD>
</TR>
<TR valign="bottom" style="line-height: 24pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    By:&#160;<FONT style="word-spacing: 100pt; white-space: nowrap; font-size: 1pt; color: #000000"><U>&#173;
    &#173;</U></FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Name:
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Title:
</TD>
</TR>
<TR valign="bottom" style="line-height: 24pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Attest:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <DIV style="font-size: 0pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Authorized Signature
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">[Form of
    Reverse of CVR Certificate]
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;This CVR Certificate is issued under and in accordance
    with the Contingent Value Rights Agreement, dated as of
    [&#160;&#149;&#160;], 2010 (the &#147;<U>CVR
    Agreement</U>&#148;), between the Company and American Stock
    Transfer&#160;&#038; Trust Company, a New York limited liability
    trust company, as trustee (the &#147;<U>Trustee</U>,&#148; which
    term includes any successor Trustee under the CVR Agreement),
    and is subject to the terms and provisions contained in the CVR
    Agreement, to all of which terms and provisions the Holder of
    this CVR Certificate consents by acceptance hereof. The CVR
    Agreement is hereby incorporated herein by reference and made a
    part hereof. Reference is hereby made to the CVR Agreement for a
    full statement of the respective rights, limitations of rights,
    duties, obligations and immunities thereunder of the Company,
    the Trustee and the Holders of the CVRs. All capitalized terms
    used in this CVR Certificate without definition shall have the
    respective meanings ascribed to them in the CVR Agreement.
    Copies of the CVR Agreement can be obtained by contacting the
    Trustee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;On each Net Sales Payment Date, the Company shall pay to
    the Holder hereof, for each CVR represented hereby, a pro rata
    portion of the Net Sales Payment, if any, with respect to the
    Net Sales Measuring Period ended immediately prior to such Net
    Sales Payment Date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    3.&#160;In the event of any conflict between this CVR
    Certificate and the CVR Agreement, the CVR Agreement shall
    govern and prevail.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    4.&#160;Subject to the terms and conditions of the CVR
    Agreement, on each Milestone Payment Date (or, in any such case,
    if such day is not a Business Day, without accruing any
    interest, on the next succeeding Business Day), the Company
    shall pay to the Holder hereof, for each CVR represented hereby,
    a pro rata portion of the applicable Milestone Payment with
    respect to the occurrence of a Milestone.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    5.&#160;Each CVR Payment, if any, and interest thereon, if any,
    shall be payable by the Company in such coin or currency of the
    United States of America as at the time is legal tender for the
    payment of public and private debts; provided, however, the
    Company may pay such amounts by its check or wire transfer
    payable in such money. American Stock Transfer&#160;&#038; Trust
    Company has been initially appointed as Paying Agent at its
    office or agency in the Borough of Manhattan, The City of New
    York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    6.&#160;If an Event of Default occurs and is continuing, either
    the Trustee may or the Majority Holders, by notice to the
    Company and to the Trustee shall bring suit in accordance with
    the terms and conditions of the CVR Agreement to protect the
    rights of the Holders, including to obtain payment of all
    amounts then due and payable, with interest at the Default
    Interest Rate from the date of the Event of Default through the
    date payment is made or duly provided for.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    7.&#160;No reference herein to the CVR Agreement and no
    provision of this CVR Certificate or of the CVR Agreement shall
    alter or impair the obligation of the Company, which is absolute
    and unconditional, to pay any amounts determined pursuant to the
    terms hereof and of the CVR Agreement at the times, place and
    amount, and in the manner, herein prescribed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    8.&#160;Each CVR Payment or any other right, claim or payment of
    any kind under this CVR Certificate, if any, shall be
    subordinated in right of payment, as set forth in
    Article&#160;10 of the CVR Agreement, to the prior payment in
    full in cash or cash equivalents of all Senior Obligations
    whether outstanding on the date of the CVR Agreement or
    thereafter incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    9.&#160;As provided in the CVR Agreement and subject to certain
    limitations therein set forth, the transfer of the CVRs
    represented by this CVR Certificate is registrable on the
    Security Register, upon surrender of this CVR Certificate for
    registration of transfer at the office or agency of the Company
    maintained for such purpose in the Borough of Manhattan, The
    City of New York, duly endorsed by, or accompanied by a written
    instrument of transfer in form satisfactory to the Company and
    the Security Registrar duly executed by, the Holder hereof or
    his attorney duly authorized in writing, and thereupon one or
    more new CVR Certificates, for the same amount of CVRs, will be
    issued to the designated transferee or transferees. The Company
    hereby initially designates the office of American Stock
    Transfer&#160;&#038; Trust Company at 59 Maiden Lane&#160;&#151;
    Plaza Level, New York, New York 10038 as the office for
    registration of transfer of this CVR Certificate.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    10.&#160;As provided in the CVR Agreement and subject to certain
    limitations therein set forth, this CVR Certificate is
    exchangeable for one or more CVR Certificates representing the
    same number of CVRs as represented by this CVR Certificate as
    requested by the Holder surrendering the same.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11.&#160;No service charge will be made for any registration of
    transfer or exchange of CVRs, but the Company may require
    payment of a sum sufficient to cover all documentary, stamp or
    similar issue or transfer taxes or other governmental charges
    payable in connection with any registration of transfer or
    exchange.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    12.&#160;Prior to the time of due presentment of this CVR
    Certificate for registration of transfer, the Company, the
    Trustee and any agent of the Company or the Trustee may treat
    the Person in whose name this CVR Certificate is registered as
    the owner hereof for all purposes, and neither the Company, the
    Trustee nor any agent shall be affected by notice to the
    contrary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    13.&#160;Neither the Company nor the Trustee has any duty or
    obligation to the holder of this CVR Certificate, except as
    expressly set forth herein or in the CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    14.&#160;<I><U>Redemption</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<U>Notice to Trustee</U>.&#160;&#160;If the Company
    elects to redeem the Securities pursuant to the optional
    redemption provisions of Section&#160;11.5 of the CVR Agreement,
    it shall furnish to the Trustee, at least forty five
    (45)&#160;days (unless a shorter period shall be agreed to by
    the Trustee) but not more than sixty (60)&#160;days before a
    redemption date (but in any event prior to the notice provided
    pursuant to Section&#160;11.2 of the CVR Agreement), an
    Officer&#146;s Certificate (a &#147;<U>Consent and Purchase
    Offer</U>&#148;) setting forth (i)&#160;the clause of the CVR
    Agreement pursuant to which the redemption shall occur,
    (ii)&#160;the redemption date, and (iii)&#160;the redemption
    price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<I><U>Notice of Redemption</U>.</I>&#160;&#160;At least
    thirty (30)&#160;days but not more than sixty (60)&#160;days
    before a redemption date, the Company shall mail or cause to be
    mailed, by first class mail, a notice of redemption to each
    Holder at its registered address. The notice shall identify the
    number of Securities Outstanding and shall state:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;the redemption date;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;the redemption price;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;the name and address of the paying agent;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iv)&#160;that Securities must be surrendered to the Paying
    Agent to collect the redemption price;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (v)&#160;that, unless the Company defaults in making such
    redemption payment, all right title and interest in and to the
    Securities and any Net Sales Payment, Milestone Payment or any
    other amounts due under the CVR Agreement, if any, on Securities
    called for redemption ceases to accrue on and after the
    redemption date;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vi)&#160;the clause of the CVR Agreement pursuant to which the
    Securities are being redeemed;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vii)&#160;that no representation is made as to the correctness
    or accuracy of the CUSIP and ISIN number, if any, listed in such
    notice or printed on the Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At the Company&#146;s request, the Trustee shall give the notice
    of redemption in the Company&#146;s name and at its expense;
    provided, however, that the Company shall have delivered to the
    Trustee at least forty five (45)&#160;days (unless a shorter
    period shall be agreed to by the Trustee) but not more than
    sixty (60)&#160;days prior to the redemption date, an
    Officer&#146;s Certificate requesting that the Trustee give such
    notice and setting forth the information to be stated in such
    notice as provided in the preceding paragraph.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I><U>Effect of Notice of
    Redemption</U>.</I>&#160;&#160;Once notice of redemption is
    mailed in accordance with Section&#160;11.2 of the CVR
    Agreement, the Securities shall become irrevocably due and
    payable on the redemption date at the redemption price. A notice
    of redemption shall be deemed to be given when mailed, whether
    or not the Holder receives the notice. In any event, failure to
    give such notice, or any defect in such notice, shall not affect
    the validity of the proceedings for the redemption of the
    Securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;<I><U>Deposit of
    Redemption&#160;Price</U>.</I>&#160;&#160;On or one
    (1)&#160;Business Day prior to the redemption date, the Company
    shall deposit with the Trustee or with the paying agent (if
    different from the Trustee) money sufficient to pay the
    redemption price of all Securities Outstanding on that date. The
    Trustee or the paying agent shall promptly return to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    the Company any money deposited with the Trustee or the paying
    agent by the Company in excess of the amounts necessary to pay
    the redemption price of all Securities Outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the Company complies with the provisions of the preceding
    paragraph, on and after the redemption date, all right title and
    interest of a Holder to any Net Sales Payment or Milestone
    Payment, if any, shall cease to accrue on the Securities called
    for. If any Security called for redemption shall not be so paid
    upon surrender for redemption because of the failure of the
    Company to comply with the preceding paragraph, interest shall
    be paid on the unpaid redemption price from the redemption date
    until such redemption price is paid at the Shortfall Interest
    Rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Optional Redemption by the Company. The Company may, at
    any time on and after the Redemption Eligibility&#160;Date,
    redeem all (but not less than all) of the outstanding Securities
    at a cash redemption price equal to the average price paid per
    Security for all Securities previously purchased by the Company
    calculated as of the Business Day immediately prior to the date
    of the Call Notice mailed by the Company in accordance with
    Section&#160;11.2 of the CVR Agreement.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TRUSTEE&#146;S
    CERTIFICATE OF AUTHENTICATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This is one of the CVR Certificates referred to in the
    within-mentioned CVR Agreement.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    American Stock Transfer&#160;&#038; Trust Company,<BR>
    as the Trustee
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="45%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dated:&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -14pt; margin-left: 14pt">
    By&#160;<FONT style="word-spacing: 100pt; white-space: nowrap; font-size: 1pt; color: #000000"><U>&#173;
    &#173;</U></FONT>Authorized Signatory
</DIV>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    B-43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='185'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;C</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">VOTING
    AGREEMENT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This VOTING AGREEMENT (this &#147;<U>Agreement</U>&#148;) is
    entered into as of June&#160;30, 2010, by and among Celgene
    Corporation, a Delaware corporation (&#147;<U>Parent</U>&#148;),
    Artistry Acquisition Corp., a Delaware corporation and a wholly
    owned subsidiary of Parent (&#147;<U>Sub</U>&#148;), and the
    Persons whose names are set forth on the signature pages hereto
    under the caption &#147;Stockholders&#148; (each individually a
    &#147;<U>Stockholder</U>&#148; and, collectively, the
    &#145;&#145;<U>Stockholders</U>&#148;).
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">W I T N E
    S S E T H:</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, as of the date of this Agreement, each Stockholder owns
    the number of shares of Common Stock, par value $.001 per share
    (the &#147;<U>Company Stock</U>&#148;), of Abraxis BioScience,
    Inc., a Delaware corporation (the
    &#145;&#145;<U>Company</U>&#148;), set forth opposite such
    Stockholder&#146;s name on <U>Schedule&#160;A</U> attached
    hereto;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, concurrently herewith, Parent, Sub and the Company are
    entering into an Agreement and Plan of Merger, dated as of this
    date (the &#147;<U>Merger Agreement</U>&#148;), pursuant to
    which Sub will merge with and into the Company and the Company
    will survive as a wholly-owned subsidiary of Parent (the
    &#145;&#145;<U>Merger</U>&#148;), and each share of Company
    Stock (other than Excluded Company Shares) will be converted
    into the right to receive the Merger Consideration, in
    accordance with the terms of, and subject to the conditions set
    forth in, the Merger Agreement;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, as a condition to the willingness of Parent and Sub to
    enter into the Merger Agreement, and as an inducement and in
    consideration therefor, Parent and Sub have required that the
    Stockholders agree, and the Stockholders have agreed, to enter
    into this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    NOW, THEREFORE, in consideration of the foregoing and the mutual
    premises, representations, warranties, covenants and agreements
    contained in this Agreement, the parties, intending to be
    legally bound, hereby agree as follows:
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;I<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <U><FONT style="font-family: 'Times New Roman', Times">DEFINITIONS</FONT></U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.1&#160;&#160;<I><U>Defined
    Terms</U>.</I>&#160;&#160;For purposes of this Agreement, terms
    used in this Agreement that are defined in the Merger Agreement
    but not in this Agreement shall have the respective meanings
    ascribed to them in the Merger Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.2&#160;&#160;<I><U>Other
    Definitions</U>.</I>&#160;&#160;For purposes of this Agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<I>&#147;<U>Company Options</U>&#148;</I> means options
    to acquire Company Stock granted to a Stockholder by the Company
    and held by a Stockholder as of the date of this Agreement as
    set forth on <U>Schedule&#160;A</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<I>&#147;<U>Company RSUs</U>&#148;</I> means restricted
    stock units with respect to Company Stock granted to a
    stockholder by the Company and held by a Stockholder as of the
    date of this Agreement as set forth on <U>Schedule&#160;A</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I>&#147;<U>Immediate Family</U>&#148;</I> means lineal
    descendants (whether by blood or marriage), ancestral forebears,
    current and former spouses, and persons related by blood,
    adoption or marriage to any of the foregoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;<I>&#147;<U>New Shares</U>&#148;</I> means any shares
    of Company Stock (other than Owned Shares) acquired by a
    Stockholder at any time during the Voting Period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;<I>&#147;<U>Option Shares</U>&#148;</I> means any
    shares of Company Stock issued or issuable upon exercise of
    Company Options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;<I>&#147;<U>Owned Shares</U>&#148;</I> means all of the
    shares of Company Stock owned by such Stockholder as of the date
    of this Agreement as set forth on <U>Schedule&#160;A</U>.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;<I>&#147;<U>Permitted Transferee</U>&#148;</I> means
    PSS and any PSS Entity or any charitable foundation or
    organization, in each case only if such parties agree to be
    bound by the terms of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;<I>&#147;<U>PSS</U>&#148;</I> means Dr.&#160;Patrick
    Soon-Shiong.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;<I>&#147;<U>PSS Entity</U>&#148;</I> means any trust
    for the benefit of PSS or any members of PSS&#146; Immediate
    Family and any other entity in which PSS or any members of
    PSS&#146; Immediate Family separately or collectively hold,
    directly or indirectly, a majority of the outstanding equity
    interests.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (j)&#160;<I>&#147;<U>Representative</U>&#148;</I> means, with
    respect to any particular Person, the officers, directors,
    employees, trustees, investment bankers, attorneys and other
    advisors or representatives of such Person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (k)&#160;<I>&#147;<U>RSU Shares</U>&#148;</I> means any shares
    of Company Stock issued or issuable upon vesting of Company RSUs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (l)&#160;<I>&#147;<U>Transfer</U>&#148;</I> means sell,
    transfer, tender, assign, pledge, encumber or otherwise dispose.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (m)&#160;<I>&#147;<U>Voting Period</U>&#148;</I> means the
    period from and including the date of this Agreement through and
    including the earliest to occur of (i)&#160;the Effective Time,
    and (ii)&#160;the termination of the Merger Agreement in
    accordance with its terms.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;II<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <U><FONT style="font-family: 'Times New Roman', Times">VOTING
    AGREEMENT AND IRREVOCABLE PROXY</FONT></U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.1&#160;&#160;<I><U>Agreement
    to Vote</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Each Stockholder hereby agrees that, during the Voting
    Period, such Stockholder shall vote or execute consents, as
    applicable, with respect to the Owned Shares and any New Shares
    owned by such Stockholder as of the applicable record date (or
    cause to be voted or a consent to be executed with respect to
    the Owned Shares or any New Shares owned by such Stockholder as
    of the applicable record date) in favor of the approval and
    adoption of the Merger Agreement and the transactions
    contemplated by the Merger Agreement, at any meeting (or any
    adjournment or postponement thereof) of, or in connection with
    any proposed action by written consent of, the holders of
    Company Stock at or in connection with which any of the holders
    vote or execute consents with respect to any of the foregoing
    matters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Subject to <U>Section&#160;3.2</U> hereof, each
    Stockholder hereby agrees that, during the Voting Period, such
    Stockholder shall vote or execute consents, as applicable, with
    respect to the Owned Shares and any New Shares owned by such
    Stockholder as of the applicable record date (or cause to be
    voted or a consent to be executed with respect to the Owned
    Shares and any New Shares owned by such Stockholder as of the
    applicable record date) against each of the matters set forth in
    clauses (i), (ii), (iii)&#160;and (iv)&#160;below at any meeting
    (or any adjournment or postponement thereof) of, or in
    connection with any proposed action by written consent of, the
    holders of Company Stock at or in connection with which any of
    the holders vote or execute consents with respect to any of the
    following matters:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;any merger agreement or merger (other than the Merger
    Agreement, the Merger or any business combination or transaction
    with Parent or any of its affiliates), consolidation,
    combination, reorganization, recapitalization, dissolution,
    liquidation or winding up of or by the Company or any other
    business combination or extraordinary corporate transaction
    involving the Company or any of its Subsidiaries, or any sale,
    lease or transfer of a material amount of assets of the Company
    or any of its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;any amendment of the Company&#146;s certificate of
    incorporation, as amended to date, unless such amendment is
    consented to by Parent;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;any action, proposal, transaction or agreement that
    would reasonably be expected to result in a breach in any
    respect of any covenant, representation or warranty or any other
    obligation or agreement of the Company contained in the Merger
    Agreement or of such Stockholder contained in this
    Agreement;&#160;and
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iv)&#160;any action, proposal, transaction or agreement
    involving the Company or any of its Subsidiaries that would
    reasonably be expected to prevent, impede, frustrate, interfere
    with, delay, postpone or adversely affect the Merger and the
    other transactions contemplated by the Merger Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Any vote required to be cast or consent required to be
    executed pursuant to this <U>Section&#160;2.1</U> shall be cast
    or executed in accordance with the applicable procedures
    relating thereto so as to ensure that it is duly counted for
    purposes of determining that a quorum is present (if applicable)
    and for purposes of recording the results of that vote or
    consent. Nothing contained in this <U>Section&#160;2.1</U> shall
    require any Stockholder to vote or execute any consent with
    respect to any Option Shares or RSU Shares not issued to the
    Stockholder prior to the applicable record date for that vote or
    consent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.2&#160;&#160;<I><U>Grant
    of Irrevocable Proxy</U>.</I>&#160;&#160;Each Stockholder hereby
    irrevocably appoints Parent and any designee of Parent, and each
    of them individually, as such Stockholder&#146;s proxy and
    attorney-in-fact, with full power of substitution and
    resubstitution, to vote or execute consents during the Voting
    Period, with respect to the Owned Shares and any New Shares
    owned by such Stockholder as of the applicable record date, in
    each case solely to the extent and in the manner specified in
    <U>Section&#160;2.1</U>. This proxy is given to secure the
    performance of the duties of such Stockholder under this
    Agreement, and its existence will not be deemed to relieve such
    Stockholder of its obligations under <U>Section&#160;2.1</U>.
    Other than as described in this <U>Section&#160;2.2</U> and
    other than the granting of proxies to vote Owned Shares or New
    Shares with respect to the election of directors and
    ratification of the appointment of the Company&#146;s auditors
    at the Company&#146;s annual meeting of Stockholders, in
    accordance with the recommendation of the Board of Directors of
    the Company, such Stockholder shall not directly or indirectly
    grant any Person any proxy (revocable or irrevocable), power of
    attorney or other authorization with respect to any of such
    Stockholder&#146;s Owned Shares or New Shares. For Owned Shares
    or New Shares as to which the Stockholder is the beneficial but
    not the record owner, such Stockholder will cause any record
    owner of such Owned Shares or New Shares to grant to Parent a
    proxy to the same effect as that contained in this
    <U>Section&#160;2.2</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.3&#160;&#160;<I><U>Nature
    of Irrevocable Proxy</U>.</I>&#160;&#160;The proxy and power of
    attorney granted pursuant to <U>Section&#160;2.2</U> by each
    Stockholder shall be irrevocable during the Voting Period, shall
    be deemed to be coupled with an interest sufficient in law to
    support an irrevocable proxy and shall revoke any and all prior
    proxies granted by such Stockholder with regard to such
    Stockholder&#146;s Owned Shares or any New Shares acquired by
    such Stockholder, and such Stockholder acknowledges that the
    proxy constitutes an inducement for Parent and Sub to enter into
    the Merger Agreement. The power of attorney granted by each
    Stockholder is a durable power of attorney and shall survive the
    bankruptcy, dissolution, death or incapacity of such
    Stockholder. The proxy and power of attorney granted hereunder
    shall terminate only upon the expiration of the Voting Period.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;III<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">COVENANTS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.1&#160;&#160;<I><U>Voting
    Period Restrictions</U>.</I>&#160;&#160;Each Stockholder agrees
    that such Stockholder shall not, during the Voting Period,
    (i)&#160;Transfer any or all of such Stockholder&#146;s Owned
    Shares or New Shares, or any interest therein, or enter into any
    agreement with respect to the Transfer of any or all of such
    Stockholder&#146;s Owned Shares or New&#160;Shares, or any
    interest therein, or (ii)&#160;except pursuant to the terms of
    this Agreement, grant any proxies or powers of attorney, deposit
    any Owned Shares or New Shares into a voting trust or enter into
    a voting agreement with respect to any Owned Shares or New
    Shares; <U>provided</U> that the foregoing shall not prevent
    (a)&#160;the Transfer of Owned Shares or New Shares upon the
    death of such Stockholder pursuant to the terms of any trust or
    will of such Stockholder or by the laws of intestate succession,
    but only if, and any such Transfer shall be void unless, the
    transferee executes and delivers to Parent an agreement to be
    bound by the terms of this Agreement to the same extent as such
    Stockholder, (b)&#160;the Transfer of Owned Shares or New Shares
    to a Permitted Transferee, (c)&#160;the Transfer of Owned Shares
    or New Shares solely in connection with the payment of the
    exercise price
    <FONT style="white-space: nowrap">and/or</FONT> the
    satisfaction of any tax withholding obligation arising from the
    exercise of any Company Option or the vesting of any Company
    RSU, (d)&#160;the conversion of any Owned Shares and New Shares
    into the right to receive the Merger Consideration pursuant to
    the Merger in accordance with the terms of the Merger Agreement,
    or (e)&#160;the granting of proxies to vote Owned Shares or New
    Shares with respect to the election of directors and
    ratification of the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    appointment of the Company&#146;s auditors at the Company&#146;s
    annual meeting of Stockholders, in accordance with the
    recommendation of the Board of Directors of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.2&#160;&#160;<I><U>No
    Shop Obligations of Each Stockholder</U>.</I>&#160;&#160;Each
    Stockholder agrees that such Stockholder shall not, and that
    such Stockholder shall use its reasonable best efforts to cause
    the Representatives of such Stockholder to not, directly or
    indirectly, (i)&#160;solicit, initiate, or knowingly encourage
    the making, submission or announcement of any inquiry regarding,
    or any proposal or offer which would reasonably be expected to
    lead to, an Acquisition Proposal, (ii)&#160;enter into,
    participate, continue or otherwise engage in discussions or
    negotiations with, or provide any non-public information to any
    Person (other than Parent, Sub and their Representatives) with
    respect to any inquiries regarding, or the making, submission or
    announcement of, an Acquisition Proposal, or (iii)&#160;enter
    into or approve any letter of intent, agreement in principle,
    option agreement, share purchase agreement, acquisition
    agreement or similar agreement relating to an Acquisition
    Proposal; <U>provided</U>, <U>however</U>, that each Stockholder
    may, and may authorize and permit any Representative of such
    Stockholder to, provide non-public information to, and
    participate in discussions or negotiations, with any Person if
    at such time such Stockholder has been notified by the Company
    that the Board of Directors of the Company is permitted to
    provide non-public information to, or engage in discussions or
    negotiations with, such Person in accordance with the Merger
    Agreement. The Stockholder shall immediately cease and cause to
    be terminated any ongoing solicitation, discussion or
    negotiation with any Person conducted prior to the date of this
    Agreement by the Stockholder or any of its Representatives with
    respect to any actual or potential Acquisition Proposal. A
    Stockholder shall notify Parent orally and in writing promptly
    (and in any event within 24&#160;hours) after receipt of any
    Acquisition Proposal or any request for information or inquiry
    which could reasonably be expected to lead to an Acquisition
    Proposal. The written notice shall include the identity of the
    Person making such Acquisition Proposal, request or inquiry, the
    material terms of the Acquisition Proposal, request or inquiry
    (including any material written amendments or modifications, or
    any proposed material written amendments or modifications,
    thereto), and the Stockholder shall keep Parent reasonably
    informed on a current basis of any material changes with respect
    to such Acquisition Proposal, request or inquiry.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.3&#160;&#160;<I><U>General
    Covenants</U>.</I>&#160;&#160;Each Stockholder agrees that such
    Stockholder shall not:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;enter into any agreement, commitment, letter of intent,
    agreement in principle, or understanding with any Person or take
    any other action that violates or conflicts with or would
    reasonably be expected to violate or conflict with, or result in
    or give rise to a violation of or conflict with, such
    Stockholder&#146;s covenants and obligations under this
    Agreement or make any of its representations and warranties
    contained herein untrue or incorrect;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;take any action that could restrict or otherwise affect
    such Stockholder&#146;s legal power, authority and right to
    comply with and perform such Stockholder&#146;s covenants and
    obligations under this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;3.4
    </FONT><I><U>Stockholders&#146;
    Capacity</U>.</I>&#160;&#160;Parent and Sub acknowledge that no
    Stockholder is making any agreement or understanding herein in
    such Stockholder&#146;s capacity as a director or officer of the
    Company and that each Stockholder is executing this agreement
    solely in such Stockholder&#146;s capacity as the owner of
    Company Stock and nothing herein shall limit or affect any
    actions taken by such Stockholder in such Stockholder&#146;s
    capacity as a director or officer of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.5&#160;&#160;<I><U>Letter
    of Transmittal and Delivery of Merger
    Consideration</U>.</I>&#160;&#160;Parent agrees to provide the
    Stockholders a copy of the letter of transmittal referenced in
    <U>Section&#160;2.2</U> of the Merger Agreement a reasonable
    time period prior to the anticipated Closing Date to allow the
    Stockholders to complete the letter of transmittal and provide
    such letter of transmittal to the Paying Agent prior to or on
    the Closing Date. Parent agrees to use reasonable best efforts
    to cause the Paying Agent to deliver by wire transfer of
    immediately available funds the Merger Consideration to which
    the Stockholders are entitled under the terms of the Merger
    Agreement on the same date as the Closing Date.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;IV<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <U><FONT style="font-family: 'Times New Roman', Times">REPRESENTATIONS
    AND WARRANTIES OF THE STOCKHOLDERS</FONT></U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each Stockholder hereby represents and warrants to Parent and
    Sub as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.1&#160;&#160;<I><U>Authorization</U>.</I>&#160;&#160;Such
    Stockholder has all power and authority (or legal capacity in
    the case of an individual) to execute and deliver this Agreement
    and to perform its obligations hereunder. This Agreement has
    been duly and validly authorized, executed and delivered by such
    Stockholder and, assuming it has been duly and validly
    authorized, executed and delivered by Parent and Sub,
    constitutes a legal, valid and binding obligation of such
    Stockholder, enforceable against such Stockholder in accordance
    with its terms, except to the extent that enforceability may be
    limited by (i)&#160;applicable bankruptcy, insolvency,
    reorganization, moratorium, fraudulent conveyance or other
    similar laws now or hereafter in effect relating to
    creditor&#146;s rights generally, and (ii)&#160;general
    principles of equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.2&#160;&#160;<I><U>Ownership
    of Shares</U>.</I>&#160;&#160;As of the date hereof, all Owned
    Shares, Company Options and Company RSUs owned by such
    Stockholder are listed on <U>Schedule&#160;A</U> attached
    hereto. Such Stockholder (a)&#160;is the sole beneficial owner
    of all of the Owned Shares, Company Options and Company RSUs
    listed opposite such Stockholder&#146;s name on
    <U>Schedule&#160;A</U> hereto free and clear of any Liens,
    voting agreements or commitments of every kind that would
    reasonably be expected to violate or conflict with, or result in
    or give rise to a violation of or conflict with, or adversely
    affect the exercise or fulfillment of, such Stockholder&#146;s
    covenants and obligations under this Agreement, and (b)&#160;has
    the sole power to vote (or cause to be voted or consents to be
    executed) and to dispose of (or cause to be disposed of) such
    Owned Shares without restriction, and no proxies through and
    including the date hereof given in respect of any or all of such
    Stockholder&#146;s Owned Shares, Company Options or Company RSUs
    are irrevocable and any such proxies have been revoked.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.3&#160;&#160;<I><U>No
    Conflicts</U>.</I>&#160;&#160;Except for a filing of an
    amendment to a Schedule&#160;13D and a filing of a Form&#160;4
    as required by the Exchange Act, (i)&#160;no filing with any
    Governmental Entity, and no authorization, consent or approval
    of any other Person is necessary for the execution of this
    Agreement by such Stockholder or the performance by such
    Stockholder of such Stockholder&#146;s obligations hereunder and
    (ii)&#160;none of the execution and delivery of this Agreement
    by such Stockholder, or the performance by such Stockholder of
    such Stockholder&#146;s obligations hereunder shall
    (A)&#160;result in, give rise to or constitute a violation or
    breach of or a default (or any event which with notice or lapse
    of time or both would become a violation, breach or default)
    under, or give to others any rights of termination, amendment,
    acceleration or cancellation of, or result in the creation of a
    Lien on, any of the Owned Shares pursuant to any of the terms of
    any understanding, agreement, or other instrument or obligation
    to which such Stockholder is a party or by which such
    Stockholder or any of such Stockholder&#146;s Owned Shares are
    bound, or (B)&#160;violate any applicable law, rule, regulation,
    order, judgment, or decree applicable to such Stockholder,
    except for any of the foregoing as would not reasonably be
    expected to impair such Stockholder&#146;s ability to perform
    such Stockholder&#146;s obligations under this Agreement in any
    material respect.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;V<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <U><FONT style="font-family: 'Times New Roman', Times">REPRESENTATIONS
    AND WARRANTIES OF PARENT AND SUB</FONT></U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each of Parent and Sub hereby represent and warrant to the
    Stockholders as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.1&#160;&#160;<I><U>Authorization</U>.</I>&#160;&#160;Such
    party has all power and authority to execute and deliver this
    Agreement and to perform its obligations hereunder. This
    Agreement has been duly and validly authorized, executed and
    delivered by such party and, assuming it has been duly and
    validly authorized, executed and delivered by the Stockholders,
    constitutes a legal, valid and binding obligation of such party,
    enforceable against it in accordance with the terms of this
    Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.2&#160;&#160;<I><U>No
    Conflicts</U>.</I>&#160;&#160;The execution and delivery of this
    Agreement by such party does not and the performance of this
    Agreement by such party will not (i)&#160;conflict with, result
    in any violation of, require any consent under or constitute a
    default (whether with notice or lapse of time or both) under any
    mortgage, bond, indenture, agreement, instrument or obligation
    to which it is a party or by which it or any of its properties
    is bound; (ii)&#160;violate any judgment, order, injunction,
    decree or award of any court, administrative agency or other
    Governmental Entity
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    that is binding on such party or any of its properties; or
    (iii)&#160;constitute a violation by such party of any law,
    regulation, rule or ordinance applicable to such party, in each
    case, except for any violation, conflict or consent as would not
    reasonably be expected to materially impair the ability of such
    party to perform its obligations under this Agreement.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VI<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <U><FONT style="font-family: 'Times New Roman', Times">TERMINATION</FONT></U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This Agreement shall terminate upon the earliest to occur of
    (i)&#160;the Effective Time, (ii)&#160;any material amendment to
    the Merger Agreement that is adverse to the Stockholders that
    has not been approved by the Stockholders (it being understood
    that any decrease in or change in form of the Merger
    Consideration shall constitute a material amendment to the
    Merger Agreement that is adverse to the Stockholders), and
    (iii)&#160;the termination of the Merger Agreement in accordance
    with its terms. Upon the termination of this Agreement, neither
    Parent, Sub nor the Stockholders shall have any rights or
    obligations hereunder and this Agreement shall become null and
    void and have no effect; <U>provided</U>, that, with respect to
    termination pursuant to clause&#160;(i) above,
    <U>Sections&#160;7.1</U>, <U>7.3</U> and <U>7.5</U> through
    <U>7.12</U> shall survive such termination. Notwithstanding the
    foregoing, termination of this Agreement shall not prevent any
    party from seeking any remedies (at law or in equity) against
    any other party for that party&#146;s breach of any of the terms
    of this Agreement prior to the date of termination.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VII<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <U><FONT style="font-family: 'Times New Roman', Times">MISCELLANEOUS</FONT></U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.1&#160;&#160;<I><U>Publication</U>.</I>&#160;&#160;Each
    Stockholder hereby permits Parent, Sub
    <FONT style="white-space: nowrap">and/or</FONT> the
    Company to publish and disclose in press releases,
    Schedule&#160;13D filings, and the Proxy Statement/Prospectus
    (including all documents and schedules filed with the SEC) and
    any other disclosures or filings required under the Merger
    Agreement or by applicable Law such Stockholder&#146;s identity
    and ownership of shares of the Company Stock, the nature of such
    Stockholder&#146;s commitments, arrangements and understandings
    pursuant to this Agreement
    <FONT style="white-space: nowrap">and/or</FONT> the
    text of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.2&#160;&#160;<I><U>Waiver
    of Appraisal Rights and Actions</U>.</I>&#160;&#160;Each
    Stockholder hereby (i)&#160;waives any rights of appraisal or
    rights to dissent from the Merger or the adoption of the Merger
    Agreement that such Stockholder may have under applicable law
    and shall not permit any such rights of appraisal or rights of
    dissent to be exercised with respect to such Stockholder&#146;s
    Owned Shares, any New Shares, any Option Shares or any RSU
    Shares and (ii)&#160;agrees not to commence or participate in,
    and to take all actions necessary to opt out of any class in any
    class action with respect to, any claim, derivative or
    otherwise, against Parent, Sub, the Company or any of their
    respective successors relating to the negotiation, execution or
    delivery of this Agreement or the Merger Agreement or the
    consummation of the Merger, including any claim alleging a
    breach of any fiduciary duty of the Board of Directors of the
    Company in connection with the Merger Agreement or the
    transactions contemplated thereby.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.3&#160;&#160;<I><U>Amendments,
    Waivers, etc</U>.</I>&#160;&#160;This Agreement may be amended
    by the parties at any time. This Agreement may not be amended
    except by an instrument in writing signed on behalf of each of
    the parties. Except as provided in this Agreement, no action
    taken pursuant to this Agreement, including any investigation by
    or on behalf of any party, shall be deemed to constitute a
    waiver by the party taking the action of compliance with any
    representations, warranties, covenants or agreements contained
    in this Agreement. The waiver by any party of a breach of any
    provision hereunder shall not operate or be construed as a
    waiver of any prior or subsequent breach of the same or any
    other provision hereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.4&#160;&#160;<I><U>Enforcement
    of Agreement; Specific Performance</U>.</I>&#160;&#160;The
    Stockholders agree and acknowledge that Parent and Sub would
    suffer irreparable damage in the event that any of the
    obligations of the Stockholders in this Agreement were not
    performed in accordance with its specific terms or if the
    Agreement was otherwise breached by the Stockholders. It is
    accordingly agreed by the Stockholders that Parent shall be
    entitled to an injunction or injunctions to prevent breaches of
    this Agreement and to enforce specifically the terms and
    provisions of this Agreement, this being in addition to any
    other remedy to which Parent may be entitled at law or in equity.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.5&#160;&#160;<I><U>Notices</U>.</I>&#160;&#160;Except
    for notices that are specifically required to be delivered
    orally, all notices, requests, claims, demands and other
    communications hereunder shall be in writing and shall be deemed
    given (a)&#160;on the date of delivery, if delivered in person
    or by facsimile or
    <FONT style="white-space: nowrap">e-mail</FONT> (upon
    confirmation of receipt), (b)&#160;on the first Business Day
    following the date of dispatch, if delivered by a recognized
    overnight courier service (upon proof of delivery) or
    (c)&#160;on the fifth Business Day following the date of
    mailing, if delivered by registered or certified mail, postage
    prepaid, return receipt requested, addressed as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;If to the Parent or Sub, addressed to it at:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation<BR>
    86 Morris Avenue<BR>
    Summit, New Jersey 07901<BR>
    Tel: 908.673.9000<BR>
    Fax: 908.673.2769
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    George Golumbeski, Senior Vice President Business Development<BR>
    <U>ggolumbeski@celgene.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with copies to:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation<BR>
    86 Morris Avenue<BR>
    Summit, New Jersey 07901<BR>
    Tel: 908.673.9000<BR>
    Fax: 908.673.2771
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Thomas Perone, Corporate Counsel<BR>
    <U>tperone@celgene.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and a copy (which shall not constitute notice) to:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Jones Day<BR>
    3161 Michelson Drive<BR>
    Suite&#160;800<BR>
    Irvine, CA 92612<BR>
    Tel: 949.851.3939<BR>
    Fax: 949.553.7539
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Jonn R. Beeson,&#160;Esq.<BR>
    jbeeson@jonesday.com<BR>
    Kevin Espinola,&#160;Esq.<BR>
    kbespinola@jonesday.com
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;If to the Stockholders, addressed to them at:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience Inc.<BR>
    11755 Wilshire Blvd., 20th Floor<BR>
    Los Angeles, CA 90025<BR>
    Tel: 310.883.1300<BR>
    Fax: 310.998.8553
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Dr.&#160;Patrick Soon-Shiong, Executive Chairman<BR>
    <U>pss@abraxisbio.com</U>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with copies to:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience Inc.<BR>
    11755 Wilshire Blvd., 20th Floor<BR>
    Los Angeles, CA 90025<BR>
    Tel: 310.883.1300<BR>
    Fax: 310.998.8553
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Charles Kim, General Counsel<BR>
    <U>CKim@abraxisbio.com</U>
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and a copy (which shall not constitute notice) to:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fried, Frank, Harris, Shriver&#160;&#038; Jacobson LLP<BR>
    One New York Plaza<BR>
    New York, New York 10004<BR>
    Tel: 212.859.8000<BR>
    Fax: 212.859.4000
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="11%"></TD>
    <TD width="85%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Philip Richter,&#160;Esq.<BR>
    philip.richter@friedfrank.com<BR>
    Brian Mangino,&#160;Esq.<BR>
    brian.mangino@friedfrank.com
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    or to that other address as any party shall specify by written
    notice so given, and notice shall be deemed to have been
    delivered as of the date so telecommunicated or personally
    delivered.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.6&#160;&#160;<I><U>Headings;
    Titles</U>.</I>&#160;&#160;Headings and titles of the Articles
    and Sections of this Agreement are for the convenience of the
    parties only, and shall be given no substantive or
    interpretative effect whatsoever.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.7&#160;&#160;<I><U>Severability</U>.</I>&#160;&#160;Any
    term or provision of this Agreement which is invalid or
    unenforceable in any jurisdiction shall, as to that
    jurisdiction, be ineffective to the extent of this invalidity or
    unenforceability without rendering invalid or unenforceable the
    remaining terms and provisions of this Agreement or affecting
    the validity or enforceability of any of the terms or provisions
    of this Agreement in any other jurisdiction. Upon determination
    that any term or other provision is invalid or incapable of
    being enforced, the parties shall negotiate in good faith to
    modify this Agreement as to effect the original intent of the
    parties as closely as possible in an acceptable manner to the
    end that the transactions contemplated hereby are fulfilled to
    the extent possible.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.8&#160;&#160;<I><U>Entire
    Agreement</U>.</I>&#160;&#160;This Agreement (together with the
    Merger Agreement, to the extent referred to in this Agreement)
    and any documents delivered by the parties in connection
    herewith constitutes the entire agreement among the parties with
    respect to the subject matter of this Agreement and supersedes
    all prior agreements and understandings among the parties with
    respect thereto. No addition to or modification of any provision
    of this Agreement shall be binding upon any party unless made in
    writing and signed by all parties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.9&#160;&#160;<I><U>Assignment;
    Binding Effect; No Third Party Beneficiaries; Further
    Action</U>.</I>&#160;&#160;Neither this Agreement nor any of the
    rights, interests or obligations hereunder shall be assigned by
    any of the parties. This Agreement shall be binding upon and
    shall inure to the benefit of Parent and Sub and their
    respective successors and assigns and shall be binding upon the
    Stockholders and the Stockholders&#146; successors, assigns,
    heirs, executors and administrators. Notwithstanding anything
    contained in this Agreement to the contrary, nothing in this
    Agreement, expressed or implied, is intended to confer on any
    Person (other than, in the case of Parent and Sub, their
    respective successors and assigns and, in the case of the
    Stockholders, the Stockholders&#146; successors, assigns, heirs,
    executors and administrators) any rights, remedies, obligations
    or liabilities under or by reason of this Agreement. The
    Stockholders shall take any further action and execute any other
    instruments as may be reasonably requested by Parent to
    effectuate the intent of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.10&#160;&#160;<I><U>Mutual
    Drafting</U>.</I>&#160;&#160;Each party has participated in the
    drafting of this Agreement, which each party acknowledges is the
    result of extensive negotiations between the parties. This
    Agreement shall not be deemed to have been prepared or drafted
    by any one party or another or any party&#146;s attorneys.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.11&#160;&#160;<I><U>Governing
    Law and Consent to Jurisdiction</U>.</I>&#160;&#160;This
    Agreement shall be governed by and construed in accordance with
    the laws of the State of Delaware, without regard to its rules
    of conflict of laws. The Stockholders hereby irrevocably and
    unconditionally consent to submit to the jurisdiction of the
    federal courts located in the State of Delaware or any Delaware
    state courts (and, if appropriate, appellate courts therefrom)
    in connection with any action or proceeding arising out of or
    relating to this Agreement and the transactions contemplated
    hereby (and agree not to commence any suit, action or proceeding
    relating thereto except in those
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    courts), waive any defense or objection they may have or
    hereafter have relating to the laying of venue of any suit,
    action or proceeding in any such courts and agree not to plead
    or claim that any suit, action or proceeding brought therein has
    been brought in an inconvenient forum.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.12&#160;&#160;<I><U>Counterparts;
    Facsimiles.</U></I>&#160;&#160;This Agreement may be executed by
    the parties in separate counterparts, each of which when so
    executed and delivered shall be an original, but all
    counterparts shall together constitute one and the same
    instrument. Each counterpart may consist of a number of copies
    each signed by less than all, but together signed by all of the
    parties. This Agreement or any counterpart may be executed and
    delivered by facsimile copies, each of which shall be deemed an
    original.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">(Signature
    page follows.)</FONT></I>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    IN WITNESS WHEREOF, Parent, Sub and the Stockholders have caused
    this Agreement to be duly executed as of the day and year first
    above written.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>CELGENE CORPORATION</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD valign="bottom" align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Robert
    J. Hugin</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Name:&#160;&#160;&#160;&#160;&#160;Robert
    J. Hugin<BR>
    Title:&#160;Chief Executive Officer
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>ARTISTRY ACQUISITION CORP.</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Sandesh
    Mahatme</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Sandesh Mahatme
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Secretary and Treasurer
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><U>STOCKHOLDERS:</U></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>DR. PATRICK SOON-SHIONG</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Dr.&#160;Patrick
    Soon-Shiong</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>CALIFORNIA CAPITAL LP</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    By: Themba LLC, its general partner
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Steven
    H. Hassan</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Steven H. Hassan
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Manager
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>PATRICK SOON-SHIONG 2009 GRAT 1</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Patrick
    Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Patrick Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">[Signature
    Page to Voting Agreement]
    </FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>PATRICK SOON-SHIONG 2009 GRAT 2</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Patrick
    Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Patrick Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>MICHELE B. SOON-SHIONG GRAT 1</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Michele
    B. Chan Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Michele B. Chan Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>MICHELE B. SOON-SHIONG GRAT 2</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Michele
    B. Chan Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Michele B. Chan Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>SOON-SHIONG COMMUNITY PROPERTY<BR>
    REVOCABLE TRUST</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Patrick
    Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Patrick Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Michele
    B. Chan Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Michele B. Chan Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    [Signature Page to Voting Agreement]
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>THE CHAN SOON-SHIONG FAMILY FOUNDATION</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;C.
    Kenworthy</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;C. Kenworthy
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    SVP
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">[Signature
    Page to Voting Agreement]
    </FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>CALIFORNIA CAPITAL TRUST</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Patrick
    Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Patrick Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Michele
    B. Chan Soon-Shiong</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Michele B. Chan Soon-Shiong
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Steven
    H. Hassan</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Steven H. Hassan
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Trustee
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    I acknowledge that I have read the Voting Agreement, dated as of
    June&#160;30, 2010, among by and among Celgene Corporation, a
    Delaware corporation, Artistry Acquisition Corp., a Delaware
    corporation, and the other parties thereto, and understand its
    contents. I am aware that by its provisions all or part of the
    shares of common stock, par value $.001 per share, of Abraxis
    BioScience, Inc., a Delaware corporation, held by my spouse,
    Dr.&#160;Patrick Soon-Shiong, including my community interest in
    such shares, if any, are subject to the provisions of such
    agreement.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>MICHELE B. CHAN SOON-SHIONG</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Michele
    B. Chan Soon-Shiong</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">[Signature
    Page to Voting Agreement]
    </FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><U><FONT style="font-family: 'Times New Roman', Times">SCHEDULE&#160;A<BR>
    </FONT></U></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">STOCKHOLDERS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Stockholder</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Owned Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Company Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Company RSUs</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dr.&#160;Patrick Soon-Shiong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    183,635
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dr.&#160;Soon-Shiong may be deemed the beneficial owner
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    California Capital LP
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,987,159
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Patrick Soon-Shiong 2009 GRAT 1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,759,109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Patrick Soon-Shiong 2009 GRAT 2
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,759,109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michele B. Soon-Shiong GRAT 1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,759,109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michele B. Soon-Shiong GRAT 2
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,759,110
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Soon-Shiong Community Property Revocable Trust
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    716,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    California Capital Trust
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    144,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    The Chan Soon-Shiong Family Foundation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,301,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,186,067
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    183,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 29,545 vested and 154,090 unvested Company Options as
    of the date hereof.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    C-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='186'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;D</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NON-COMPETITION,
    NON-SOLICITATION AND<BR>
    CONFIDENTIALITY AGREEMENT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    THIS NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY
    AGREEMENT (this &#145;&#145;<U>Agreement</U>&#148;) is made as
    of June&#160;30, 2010, by and between Dr.&#160;Patrick
    Soon-Shiong<B>, </B>an individual (the
    &#147;<U>Principal</U>&#148;), and Celgene Corporation, a
    Delaware corporation (&#147;<U>Parent</U>&#148;). Capitalized
    terms used but not defined herein shall have the meanings
    ascribed to such terms in the Merger Agreement (as defined
    below).
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">RECITALS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, Parent, Artistry Acquisition Corp., a Delaware
    corporation and a wholly-owned subsidiary of Parent
    (&#147;<U>Sub</U>&#148;), and Abraxis BioScience, Inc., a
    Delaware corporation (the &#147;<U>Company</U>&#148;), have
    entered into an Agreement and Plan of Merger (the
    &#147;<U>Merger Agreement</U>&#148;), dated as of the date of
    this Agreement, pursuant to which Sub will merge with and into
    the Company (the &#145;&#145;<U>Merger</U>&#148;), which will
    result in the Company becoming a wholly owned subsidiary of
    Parent;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, the Principal is the Executive Chairman of the Company
    and owns, directly or indirectly, approximately 80% of the
    outstanding shares of Company Common Stock and, as a result of
    such position and ownership, has occupied a position of trust
    and confidence with the Company and has become familiar with
    Confidential Information (as defined below) of the Company and
    its Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, as a result of the Merger and pursuant to the terms of
    the Merger Agreement, the Principal acknowledges that the
    Principal is expected to receive significant, substantial and
    material Merger Consideration in exchange for the shares of
    Company Common Stock and for options to purchase, and restricted
    stock units related to, Company Common Stock held by him (the
    &#145;&#145;<U>Company Equity</U>&#148;), and that the sale of
    the Company Equity to Parent is significant, substantial and
    material to the consummation of the Merger;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, the Principal acknowledges that the Company and its
    Subsidiaries are engaged in the Business (as defined below)
    throughout the Territory (as defined below);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, Parent&#146;s specific intent is to continue to conduct
    the Business after the consummation of the Merger, and Parent
    would not be willing to consummate the Merger unless the
    Principal agreed to be bound by the terms of this Agreement,
    including the restrictive covenants designed to protect the
    Business and preserve the value and goodwill of the Business
    being acquired by Parent;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    WHEREAS, the parties hereto intend for this Agreement to be in
    compliance with any and all applicable Laws and further intend
    for it to be fully enforceable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    NOW, THEREFORE, for good and valuable consideration, including
    the inducement of Parent to consummate the Merger, and other
    consideration, the receipt and sufficiency of which are hereby
    acknowledged, the parties hereto hereby agree as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;<I><U>Effective at Closing</U>.</I>&#160;&#160;This
    Agreement shall be effective as of the Closing. This Agreement
    shall be void and have no force or effect if the Merger
    Agreement is terminated prior to the Closing or the Merger is
    otherwise not consummated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;<I><U>Non-Competition</U>.</I>&#160;&#160;The Principal
    hereby agrees and covenants that, during the Term (as defined
    below), the Principal will not, will not attempt to, and will
    cause the Principal&#146;s Affiliates not to and not attempt to,
    without the prior written consent of Parent (such consent to be
    given in Parent&#146;s sole and absolute discretion), directly
    or indirectly, own, manage, finance, invest in, control, engage
    in, operate or conduct, lend the Principal&#146;s name to, lend
    credit to, render services or advise to, devote material
    endeavor or effort to, or assist any Person or entity to
    conduct, the Business, or have any interest in, as a principal,
    owner, agent, employee, shareholder, officer, director, joint
    venturer, partner, member, security holder, creditor, consultant
    or in any other capacity, an entity (other than Parent or its
    Affiliates) conducting the Business; <U>provided</U>
    <U>however</U>, that this <U>Section&#160;2</U> shall not
    prohibit the ownership of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    publicly-traded securities constituting not more than 3% of the
    outstanding securities of an entity conducting the Business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The covenants set forth in this <U>Section&#160;2</U> shall be
    construed as a series of separate covenants covering their
    subject matter in each of the separate states and countries
    within the Territory, and except for geographic coverage, each
    such separate covenant shall be deemed identical in terms to the
    covenant set forth above in this
    <U>Section&#160;2</U>.&#160;&#160;To the extent that any such
    covenant shall be judicially unenforceable in any country or in
    any one or more states in the United States, such covenant shall
    not be affected with respect to each of such other countries or
    states in the Territory. Each covenant with respect to such
    country or state in the Territory shall be construed as
    severable and independent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    3.&#160;<I><U>Non-Solicitation</U>.</I>&#160;&#160;The Principal
    hereby agrees and covenants that, during the Term, the Principal
    will not, and will cause the Principal&#146;s Affiliates not to,
    without the prior written consent of Parent (such consent to be
    given in Parent&#146;s sole and absolute discretion) directly or
    indirectly:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;(i)&#160;solicit, knowingly encourage or induce, or
    attempt to solicit, knowingly encourage or induce, any customer
    with whom the Company or its Subsidiaries was engaged in a
    contractual relationship, or substantive discussions or proposal
    negotiations, in each case as of the Effective Time, with
    respect to the Business to cease doing business with the
    Company, Parent or any of their Subsidiaries with respect to the
    Business within the Territory; or (ii)&#160;otherwise knowingly
    interfere with, impair or damage the Company&#146;s,
    Parent&#146;s or their respective Subsidiaries&#146;
    relationship with any customers or prospective customers of the
    Business (it being understood that nothing in this
    <U>Section&#160;3(a) </U>shall be interpreted to prevent or
    preclude the Principal or any of his Affiliates from developing,
    manufacturing, commercializing, importing, selling, marketing,
    distributing products or services that are not Albumin Bound
    (Nab)<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Products);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;(i)&#160;solicit, knowingly encourage or induce, or
    attempt to solicit, knowingly encourage or induce, any
    suppliers, licensees or business relations, or prospective
    suppliers, licensees or business relations with whom the Company
    or its Subsidiaries was engaged in a contractual relationship,
    or substantive discussions or proposal negotiations, in each
    case as of the Effective Time, with respect to the Business of
    the Company and its Subsidiares to cease doing business with the
    Company, Parent or their respective Subsidiaries with respect to
    the Business within the Territory; or (ii)&#160;otherwise
    knowingly interfere with, impair or damage the Company&#146;s,
    Parent&#146;s or their respective Subsidiaries&#146;
    relationship with any supplier, licensee or business relation of
    the Business (it being understood that nothing in this
    <U>Section&#160;3(b)</U> shall be interpreted to prevent or
    preclude the Principal or any of his Affiliates from developing,
    manufacturing, commercializing, importing, selling, marketing,
    distributing products or services that are not Albumin Bound
    (Nab)<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Products);&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;solicit, encourage or induce, or attempt to solicit or
    induce, or assist any other Person in so soliciting, encouraging
    or inducing, any employee, consultant or independent contractor
    that was engaged by the Company or its Subsidiaries as of the
    Effective Time to terminate or breach an employment, contractual
    or other relationship with the Company, Parent or their
    respective Subsidiaries; <U>provided</U> <U>however</U>, this
    clause&#160;(c) shall not prohibit the Principal or any of his
    Affiliates from soliciting or hiring any person who responds to
    a general advertisement or solicitation, or efforts by any
    recruiting or employment agencies, not specifically directed at
    employees of the Company, Parent or their respective
    Subsidiaries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    4.&#160;<I><U>Non-Disparagement</U>.</I>&#160;&#160;The
    Principal hereby agrees and covenants that, during the Term, the
    Principal will make no, and will not permit the Principal&#146;s
    Affiliates or Representatives to make any, public statements,
    verbal or written, that directly or indirectly disparage the
    Company, Parent or any of their respective Affiliates. Parent
    hereby agrees and covenants that, during the Term, Parent shall
    not, and shall not permit any of its Affiliates or
    Representatives to, make any public statements, verbal or
    written, that directly or indirectly disparage the Principal or
    any of his Affiliates. This <U>Section&#160;4</U> shall not
    prohibit the Principal or his Affiliates, on the one hand, or
    the Parent or any of its Affiliates, on the other hand, from
    exercising or enforcing their rights under any agreement between
    the Principal or his Affiliates, on the one hand, and the Parent
    or any of its Affiliates, on the other hand or (subject, in the
    case of the Principal, to <U>Section&#160;5</U> below) from
    responding to any inquiry, request for information,
    investigation, audit or proceeding involving a Governmental
    Entity or as otherwise required by Law.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    5.&#160;<I><U>Confidentiality</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;The Principal (i)&#160;will not use Confidential
    Information (as defined below) for any purpose detrimental to
    the Company, Parent or any of their respective Affiliates,
    (ii)&#160;will not, except as directed by the Company or Parent,
    use for the Principal or for others, directly or indirectly, any
    such Confidential Information, and (iii)&#160;except as required
    by Law or as directed by the Company or Parent, will not
    disclose Confidential Information, directly or indirectly, to
    any other Person. The obligations set forth in this
    <U>Section&#160;5(a)</U> will survive the expiration of the Term
    and any termination of this Agreement. The Principal
    acknowledges that this covenant is necessary to protect the
    trade secrets of the Company, Parent
    <FONT style="white-space: nowrap">and/or</FONT> their
    respective Affiliates. If the Principal is required by order of
    a Governmental Entity to disclose any Confidential Information,
    the Principal shall immediately notify the Company and Parent so
    that the Company and Parent may attempt to obtain an appropriate
    protective order, and, in all events, the Principal shall only
    disclose the minimum portion of the Confidential Information
    required by such order to be disclosed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;All physical property and all notes, memoranda, files,
    records, writings, documents and other materials of any and
    every nature, written or electronic, that the Principal has or
    will possess, control, prepare, develop or receive in his
    capacity as an officer, director or employee of the Company or
    any of its Subsidiaries and that are reasonably related to or
    useful in the Business are and, unless agreed in writing by
    Parent, will remain the sole and exclusive property of the
    Company or its respective Subsidiaries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Notwithstanding the foregoing, Confidential Information
    will not include (i)&#160;information that is already in or
    subsequently enters the public domain, other than as a result of
    any direct or indirect action or inaction by the Principal or
    his controlled Affiliates in violation of this Agreement,
    (ii)&#160;information that is approved for public release by the
    Company, Parent or any of their respective Affiliates, or
    (iii)&#160;the product of the Principal&#146;s general
    knowledge, education, training or experience obtained prior to
    his association with the Company or its Affiliates or its or
    their predecessors in interest without the benefit of any
    non-public information of the Company or its Subsidiaries and
    which does not relate to the Business of the Company or its
    Subsidiaries, (iv)&#160;information that is subsequently
    rightfully disclosed to the Principal by a third party without
    any violation of duties of confidentiality and restricted use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    6.&#160;<I><U>Future Employment</U>.</I>&#160;&#160;The
    Principal agrees that, during the Term, if the Principal accepts
    employment with an employer that is a commercial enterprise not
    controlled by the Principal other than the Company, Parent or
    their respective Affiliates, the Principal will, within ten
    (10)&#160;days after accepting any employment, notify the
    Company and Parent of the identity of any employer of the
    Principal. The Company
    <FONT style="white-space: nowrap">and/or</FONT>
    Parent may serve notice upon each such employer that the
    Principal is bound by this Agreement and furnish each such
    employer with a copy of this Agreement or relevant portions
    thereof. Further, during the Term, the Principal will
    communicate the contents of <U>Section&#160;2</U> to
    <U>Section&#160;5</U> hereof to any Person that the Principal
    intends to be employed by, associated with or represent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    7.&#160;<I><U>Reasonableness of
    Restrictions</U>.</I>&#160;&#160;The Principal acknowledges that
    (a)&#160;the Principal will significantly benefit from the
    transactions contemplated by the Merger Agreement, including by
    the Principal&#146;s receipt of Merger Consideration,
    (b)&#160;Parent&#146;s specific intent is to continue the
    specific conduct of the Business after the consummation of the
    Merger and a substantial portion of the value of the Business is
    the goodwill that the Company and its Subsidiaries has
    established, (c)&#160;the covenants set forth in
    <U>Section&#160;2</U> to <U>Section&#160;6</U> are necessary to
    enable the Company, Parent and their respective Affiliates to
    retain the goodwill of the Business that was based on the
    Company&#146;s and its Subsidiaries&#146; efforts prior to the
    consummation of the Merger, and (d)&#160;the covenants set forth
    in <U>Section&#160;3 </U>are necessary to enable the Company,
    Parent and their respective Affiliates to maintain a stable
    customer, supplier and employee base in order to conduct the
    Business, and that it could disrupt, damage, impair and
    interfere with the Business if the Principal was to engage in
    such solicitation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    8.&#160;<I><U>Specific Performance; Limitation of
    Remedies</U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<I><U>Specific Performance</U>.</I>&#160;&#160;The
    parties acknowledge that the failure of any party to perform his
    or its covenants under Sections&#160;2, 3, 4, 5, 6 and 7 of this
    Agreement in accordance with their specific terms will cause
    irreparable injury to the Principal, the Company, Parent and
    their respective Subsidiaries, as the case may be, for which
    damages, even if available, will not be an adequate remedy.
    Accordingly, the parties consent to the issuance
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    of temporary, preliminary and permanent injunctive relief to
    compel performance by the Principal, the Company or Parent of
    the obligations hereunder or to prevent breaches or threatened
    breaches by the Principal, the Company or Parent of this
    Agreement, and to the grant by a court of competent jurisdiction
    of the remedy of specific performance of the obligations
    hereunder, without, in any such case, the requirement to post
    any bond or other undertaking, in addition to any other rights
    or remedies available hereunder or at law or in equity. The
    parties agree to not oppose, and hereby waive any defense to,
    the granting of an injunction, specific performance and other
    equitable relief on the basis that the Principal, Parent or the
    Company has an adequate remedy at law or an award of specific
    performance is not an appropriate remedy for any reason at law
    or equity. The parties further waive any requirement under any
    Law to post security as a prerequisite to obtaining equitable
    relief. Notwithstanding the foregoing, no party to this
    Agreement shall under any circumstances be held liable, whether
    in contract, in tort, under any warranty or any other theory of
    liability, for any punative damages.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<I><U>Limitation of
    Remedies</U>.</I>&#160;&#160;Notwithstanding the provisions set
    forth in <U>Section&#160;7(a)</U>, above, or any other provision
    contained in this Agreement, the Principal, Parent and the
    Company acknowledge that no remedy conferred by any of the
    specific provisions of this Agreement, including, without
    limitation, this <U>Section&#160;7</U>, is intended to be
    exclusive of any other remedy, and each and every remedy shall
    be cumulative and shall be in addition to every other remedy
    given hereunder or now or hereafter existing at law or in equity
    or by statute or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I><U>Notice</U>.</I>&#160;&#160;Parent shall not
    commence any action seeking injunctive relief or other remedy
    for violation of Section&#160;2 unless and until Parent first
    provides Principal with at least 10&#160;days prior written
    notice specifying the alleged violation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    9.&#160;<I><U>Miscellaneous</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;<I><U>Definitions</U>.</I>&#160;&#160;The following
    terms referred to in this Agreement shall have the following
    meanings:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;<I>&#147;<U>Albumin-Bound
    (Nab)<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Products</U>&#148;</I> means (a)&#160;the Products (as defined
    in the CVR Agreement) and (b)&#160;any pharmaceutical or
    diagnostic product developed or manufactured using the
    Albumin-Bound
    (Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>)

    Technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;<I>&#147;<U>Albumin-Bound
    (Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>)

    Technology</U>&#148;</I> means any and all methods, techniques,
    know-how, trade secrets, and other technologies (including
    manufacturing methods, techniques, know-how, trade secrets, and
    other technologies) for the association of, or related to the
    association of, any agent (such as a therapeutic or diagnostic
    agent) with albumin in the development, manufacturing or
    production of albumin-bound nanoparticles or albumin- based
    nanoparticles, as practiced by the Company or any of its
    Subsidiaries as of the Effective Time; provided, however, that
    for purposes of this Agreement, &#147;nanoparticles&#148; shall
    mean any particles with a size less than 200 nanometers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;<I>&#147;<U>Business</U>&#148;</I> means the business
    of researching, developing, licensing, manufacturing, selling,
    offering for sale, importing, using, marketing, distributing,
    practicing, or otherwise exploiting any Albumin-Bound
    (Nab)<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    Products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iv)&#160;<I>&#147;<U>Confidential Information</U>&#148;</I>
    means any information of a confidential or proprietary nature,
    including but not limited to trade secrets, or that derives
    value from its not generally being available that is owned or
    held by the Company or its Subsidiaries at the Effective Time in
    whatever form.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (v)&#160;<I>&#147;<U>Governmental Entity</U>&#148;</I> means any
    domestic (federal or state) or foreign court, commission,
    governmental body, regulatory or administrative agency or other
    political subdivision thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vi)&#160;<I>&#147;<U>Law</U>&#148;</I> means any foreign,
    federal, state, local or municipal laws, rules, judgments
    orders, regulations, statutes, ordinances, codes, decisions,
    injunctions, orders, decrees or requirements of any Governmental
    Entity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vii)&#160;<I>&#147;<U>Term</U>&#148;</I> means the period
    commencing as of the Effective Time and continuing for
    10&#160;years after the Effective Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (viii)&#160;<I>&#147;<U>Territory</U>&#148;</I> means the United
    States and all other foreign countries and jurisdictions
    worldwide in which the Company or its Subsidiaries was engaged
    in Business as of the Effective Time.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;<U>Notices</U>.&#160;&#160;All notices, requests,
    claims, demands and other communications hereunder shall be in
    writing and shall be deemed given (i)&#160;on the date of
    delivery, if delivered in person or by facsimile or
    <FONT style="white-space: nowrap">e-mail</FONT> (upon
    confirmation of receipt) prior to 5:00&#160;p.m. in the time
    zone of the receiving party or on the next Business Day, if
    delivered after 5:00&#160;p.m. in the time zone of the receiving
    party, (ii)&#160;on the first Business Day following the date of
    dispatch, if delivered by a recognized overnight courier service
    (upon proof of delivery), or (iii)&#160;on the third Business
    Day following the date of mailing, if delivered by registered or
    certified mail, postage prepaid, return receipt requested,
    addressed as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;If to the Principal, to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Dr.&#160;Patrick Soon-Shiong
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="white-space: nowrap">c/o&#160;Abraxis</FONT>
    BioScience Inc.
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11755 Wilshire Blvd., 20th Floor
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Los Angeles, CA 90025
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Tel: 310.883.1300
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fax: 310.998.8553
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    pss@abraxisbio.com
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with a copy to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fried, Frank, Harris, Shriver&#160;&#038; Jacobson LLP
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    One New York Plaza
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    New York, NY 10004
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Tel: 212.859.8000
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fax: 212.859.4000
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="13%"></TD>
    <TD width="11%"></TD>
    <TD width="76%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Philip Richter<BR>
    philip.Richter@friedfrank.com<BR>
    Brian Mangino<BR>
    brian.mangino@friedfrank.com
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;If to Parent (or Company), to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    86 Morris Avenue
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Summit, New Jersey 07901
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Tel: 908.673.9000
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fax: 908.673.2769
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="13%"></TD>
    <TD width="11%"></TD>
    <TD width="76%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    George Golumbeski, Senior Vice
</TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 24%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    President Business Development
</DIV>

<DIV align="left" style="margin-left: 24%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <U>ggolumbeski@celgene.com</U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with a copy to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Celgene Corporation
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    86 Morris Avenue
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Summit, New Jersey 07901
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Tel: 908.673.9000
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fax: 908.673.2771
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="13%"></TD>
    <TD width="11%"></TD>
    <TD width="76%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Thomas Perone, Corporate Counsel
</TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 24%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <U>tperone@celgene.com</U>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Jones Day
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    3161 Michelson Drive
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Suite&#160;800
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Irvine, CA 92612
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Tel: 949.851.3939
</DIV>

<DIV align="left" style="margin-left: 13%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Fax: 949.553.7539
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="13%"></TD>
    <TD width="11%"></TD>
    <TD width="76%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Attention:&#160;&#160;
</TD>
    <TD align="left">
    Jonn R. Beeson,&#160;Esq.
</TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 24%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    jbeeson@jonesday.com
</DIV>

<DIV align="left" style="margin-left: 24%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Kevin Espinola,&#160;Esq.
</DIV>

<DIV align="left" style="margin-left: 24%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    kbespinola@jonesday.com
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    or to such other address as any party may have furnished to the
    other parties in writing in accordance with this
    <U>Section&#160;8(b)</U>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;<I><U>Entire Agreement</U>.</I>&#160;&#160;This
    Agreement constitutes the entire agreement among the parties
    with respect to the subject matter hereof and supersedes all
    prior agreements and understandings among the parties with
    respect thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;<I><U>Waiver</U>.</I>&#160;&#160;Either party hereto
    may waive compliance with any of the agreements of the other
    party or conditions in favor of such party contained in this
    Agreement (provided, that a waiver must be in writing and signed
    by the party against whom the waiver is to be effective). Any
    agreement on the part of a party to any such extension or waiver
    shall be valid only if set forth in an instrument in writing
    signed on behalf of such party. The failure of any party to this
    Agreement to assert any of its rights under this Agreement or
    otherwise shall not constitute a waiver of such rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;<I><U>Amendment</U>.</I>&#160;&#160;No addition to or
    modification of any provision of this Agreement shall be binding
    upon any party hereto unless made in writing and signed by both
    parties hereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;<I><U>No Third Party
    Beneficiary</U>.</I>&#160;&#160;This Agreement is not intended
    to, and does not, confer upon any Person other than the parties
    hereto any rights or remedies hereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;<I><U>Assignment; Binding
    Effect</U>.</I>&#160;&#160;Neither this Agreement nor any of the
    rights, interests or obligations hereunder shall be assigned by
    any party hereto (whether by operation of Law or otherwise)
    without the prior written consent of the other party; provided,
    that Parent may assign any of its respective rights, interest or
    obligations to any direct or indirect Subsidiary of Parent.
    Subject to the preceding sentence, this Agreement shall be
    binding upon and shall inure to the benefit of the parties
    hereto and their respective heirs, successors and permitted
    assigns.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;<I><U>Headings;
    Interpretation</U>.</I>&#160;&#160;Headings of the Sections of
    this Agreement are for the convenience of the parties only, and
    shall be given no substantive or interpretive effect whatsoever.
    If a term is defined as one part of speech (such as a noun), it
    shall have a corresponding meaning when used as another part of
    speech (such as a verb). Whenever the context so requires, the
    singular shall include the plural, the plural shall include the
    singular, and the use of a gender shall include all genders. The
    terms &#147;hereof,&#148; &#147;herein&#148; and
    &#147;hereunder&#148; and terms of like import used in this
    Agreement shall refer to this Agreement as a whole and not to
    any particular provision of this Agreement. Whenever the terms
    &#147;include,&#148; &#147;includes&#148; or
    &#147;including&#148; are used in this Agreement, they shall be
    deemed to be followed by the words &#147;without
    limitation,&#148; whether or not they are in fact followed by
    those words or words of like import. The terms
    &#147;writing&#148; and &#147;written&#148; and terms of like
    import used in this Agreement shall refer to printing, typing
    and other means of reproducing words (including electronic
    media) in a visible form.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;<I><U>Severability</U>.</I>&#160;&#160;Any term or
    provision of this Agreement which is invalid or unenforceable in
    any jurisdiction shall, as to that jurisdiction, be ineffective
    to the extent of such invalidity or unenforceability without
    rendering invalid or unenforceable the remaining terms and
    provisions of this Agreement or affecting the validity or
    enforceability of any of the terms or provisions of this
    Agreement in any other jurisdiction. If any term or provision of
    this Agreement is deemed to be so broad as to be invalid or
    unenforceable in a particular jurisdiction, the parties agree,
    with respect to such jurisdiction, to reduce the scope,
    duration, area or applicability of the term or provision,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    to delete specific words or phrases, or to replace any invalid,
    void or unenforceable term or provision with a term or provision
    that is valid and enforceable and that comes closest to
    expressing the original intention of the invalid or
    unenforceable term or provision.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (j)&#160;<I><U>Governing Law</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;<I>THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
    ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, WITHOUT
    REGARD TO ITS RULES&#160;OF CONFLICT OF
    LAWS.</I>&#160;&#160;Each of the parties hereto
    (i)&#160;consents to submit itself to the personal jurisdiction
    of any court of the United States located in the State of
    California or in any state court located in the State of
    California in the event any dispute arises out of this Agreement
    or the transactions contemplated by this Agreement,
    (ii)&#160;agrees that it will not attempt to deny or defeat such
    personal jurisdiction by motion or other request for leave from
    any such court and (iii)&#160;agrees that it will not bring any
    action relating to this Agreement or the transactions
    contemplated by this Agreement in any court other than a court
    of the United States located in the State of California or in
    any state court located in the State of California.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY
    CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO
    INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH
    SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY
    RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
    LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO
    THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT
    (A)&#160;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY
    HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY
    WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
    FOREGOING WAIVER, (B)&#160;EACH SUCH PARTY UNDERSTANDS AND HAS
    CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&#160;EACH SUCH
    PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D)&#160;EACH SUCH
    PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG
    OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
    SECTION.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (k)&#160;<I><U>Attorneys Fees</U>.</I>&#160;&#160;In the event
    action is brought by any party under this Agreement to enforce
    or construe any of its terms, the prevailing party shall be
    entitled to recover, in addition to all other amounts and
    relief, its reasonable costs and attorneys fees incurred at and
    in preparation for trial, appeal and review, such sum to be set
    by the court before which the matter is heard.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (l)&#160;<I><U>Counterparts</U>.</I>&#160;&#160;This Agreement
    may be executed by the parties hereto in separate counterparts,
    each of which when so executed and delivered shall be an
    original, but all such counterparts shall together constitute
    one and the same instrument. Each counterpart may consist of a
    number of copies hereof each signed by less than all, but
    together signed by all of the parties hereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (m)&#160;<I><U>Construction</U>.</I>&#160;&#160;This Agreement
    shall be deemed to be the joint work product of Parent and the
    Principal, and any rule of construction that a document shall be
    interpreted or construed against a drafter of such document
    shall not be applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (n)&#160;<I><U>Independent Review and
    Advice</U>.</I>&#160;&#160;The Principal represents and warrants
    that the Principal (i)&#160;has carefully read this Agreement,
    (ii)&#160;executes this Agreement with full knowledge of the
    contents of this Agreement, the legal consequences thereof and
    any and all rights that each party may have with respect to one
    another, (iii)&#160;has had the opportunity to receive
    independent legal advice with respect to the matters set forth
    in this Agreement and with respect to the rights and asserted
    rights arising out of such matters, and (iv)&#160;is entering
    into this Agreement of his own free will.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>[Remainder of page intentionally left blank.]</I>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    IN WITNESS WHEREOF, the parties hereto have caused this
    Agreement to be duly executed as of the day and year first above
    written.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>CELGENE CORPORATION</B>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Robert
    J. Hugin</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Name:&#160;&#160;&#160;&#160;&#160;Robert J. Hugin
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Chief Executive Officer
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>DR. PATRICK SOON-SHIONG</B>
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Dr.&#160;Patrick
    Soon-Shiong<B></B></DIV><B></B>
</DIV>

<DIV style="font-size: 2pt; margin-left: 49%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>[Signature Page to Non-Competition, Non-Solicitation and
    Confidentiality Agreement]</I>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    D-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='187'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;E</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">[LETTERHEAD
    OF BANK OF AMERICA MERRILL LYNCH]</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">June&#160;30,
    2010
    </FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11755 Wilshire Blvd.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Suite&#160;2000
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Los Angeles, CA 90025
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Members of the Board of Directors:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We understand that Abraxis BioScience, Inc.
    (&#147;Abraxis&#148;) proposes to enter into an Agreement and
    Plan of Merger, dated as of June&#160;30, 2010 (the
    &#147;Agreement&#148;), among Abraxis, Celgene Corporation
    (&#147;Celgene&#148;) and Artistry Acquisition Corp., a wholly
    owned subsidiary of Celgene (&#147;Merger Sub&#148;), pursuant
    to which, among other things, Merger Sub will merge with and
    into Abraxis (the &#147;Merger&#148;) and each outstanding share
    of the common stock, par value $0.001 per share (&#147;Abraxis
    Common Stock&#148;), of Abraxis (not owned by Celgene or Merger
    Sub) will be converted into a right to receive 0.2617 of a share
    of common stock, par value $0.01 per share (&#147;Celgene Common
    Stock&#148;), of Celgene (the &#147;Stock Consideration&#148;),
    $58.00 in cash (the &#147;Cash Consideration&#148;), and a
    contingent value right (a &#147;CVR&#148;) issued by Celgene
    under the CVR Agreement (as defined in the Agreement) (the
    &#147;CVR Consideration&#148; and together with the Cash
    Consideration and the Stock Consideration, the
    &#147;Consideration&#148;). As further described in the CVR
    Agreement, each CVR will entitle the holder thereof to potential
    payments equal to a pro rata portion of (x)&#160;certain
    percentages of the Net Sales of Products with respect to the
    periods set forth therein based upon the amount of such Net
    Sales in each such period and (y)&#160;certain pre-set amounts
    contingent upon the achievement of certain Milestones with
    respect to the receipt of certain regulatory approvals for one
    of the Products, as such terms are defined in the CVR Agreement.
    We also understand that, concurrently with the execution of the
    Agreement, Celgene, Merger Sub and certain stockholders of
    Abraxis will enter into a voting agreement pursuant to which
    such stockholders will agree, subject to the terms thereof, to
    vote their shares of Abraxis Common Stock in favor of adoption
    of the Agreement. The terms and conditions of the Merger are
    more fully set forth in the Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You have requested our opinion as to the fairness, from a
    financial point of view, to the holders of Abraxis Common Stock
    (other than Patrick Soon-Shiong,&#160;M.D. and his affiliates
    (together, &#147;Soon-Shiong&#148;)) of the Consideration to be
    received by such holders in the Merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with this opinion, we have, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;reviewed certain publicly available business and
    financial information relating to Abraxis and Celgene;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;reviewed certain internal financial and operating
    information with respect to the business, operations and
    prospects of Abraxis furnished to or discussed with us by the
    management of Abraxis, including certain financial forecasts
    relating to Abraxis prepared by the management of Abraxis (such
    forecasts, &#147;Abraxis Forecasts&#148;);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;reviewed a certain research analysts&#146; publicly
    available financial forecasts relating to Celgene (the
    &#147;Celgene Analyst Forecasts&#148;), as well as publicly
    available consensus financial forecasts relating to Celgene (the
    &#147;Celgene Consensus Forecasts&#148;, and together with the
    Celgene Analyst Forecasts, the &#147;Celgene Public
    Forecasts&#148;);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iv)&#160;reviewed estimates as to the amount and timing of
    certain cost savings and operating synergies (collectively, the
    &#147;Cost Savings&#148;) anticipated by the management of
    Abraxis to result from the Merger;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    E-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Page&#160;2
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (v)&#160;discussed the past and current business, operations,
    financial condition and prospects of Abraxis with members of
    senior managements of Abraxis and Celgene, and discussed the
    past and current business, operations, financial condition and
    prospects of Celgene with members of senior managements of
    Abraxis and Celgene;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vi)&#160;reviewed the potential pro forma financial impact of
    the Merger on the future financial performance of Celgene,
    including the potential effect on Celgene&#146;s estimated
    earnings per share;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vii)&#160;reviewed the trading histories for Abraxis Common
    Stock and Celgene Common Stock and a comparison of such trading
    histories with the trading histories of other companies we
    deemed relevant;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (viii)&#160;compared certain financial and stock market
    information of Abraxis and Celgene with similar information of
    other companies we deemed relevant;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ix)&#160;compared certain financial terms of the Merger to
    financial terms, to the extent publicly available, of other
    transactions we deemed relevant;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (x)&#160;considered the results of efforts on behalf of Abraxis
    to solicit, at the direction of Abraxis, indications of interest
    and definitive proposals from third parties with respect to a
    possible acquisition of Abraxis;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (xi)&#160;reviewed the Agreement and certain ancillary
    agreements thereto;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (xii)&#160;performed such other analyses and studies and
    considered such other information and factors as we deemed
    appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In arriving at our opinion, we have assumed and relied upon,
    without independent verification, the accuracy and completeness
    of the financial and other information and data publicly
    available or provided to or otherwise reviewed by or discussed
    with us and have relied upon the assurances of the managements
    of Abraxis and Celgene that they are not aware of any facts or
    circumstances that would make such information or data
    inaccurate or misleading in any material respect. With respect
    to the Abraxis Forecasts and the Cost Savings, we have been
    advised by Abraxis, and have assumed, that they have been
    reasonably prepared on bases reflecting the best currently
    available estimates and good faith judgments of the management
    of Abraxis as to the future financial performance of Abraxis and
    the other matters covered thereby. As you are aware, the
    management of Celgene did not provide us with, and we did not
    have access to, financial forecasts relating to Celgene prepared
    by the management of Celgene but directed us to the Celgene
    Consensus Forecasts. At Abraxis&#146; direction, we have
    assumed, that the Celgene Analyst Forecasts and the Celgene
    Consensus Forecasts are a reasonable basis upon which to
    evaluate the future financial performance of Celgene and, at
    Abraxis&#146; direction, we have used the Celgene Public
    Forecasts in performing our analyses. We have not made or been
    provided with any independent evaluation or appraisal of the
    assets or liabilities (contingent or otherwise) of Abraxis or
    Celgene, nor have we made any physical inspection of the
    properties or assets of Abraxis or Celgene. We have not
    evaluated the solvency or fair value of Abraxis or Celgene under
    any state, federal or other laws relating to bankruptcy,
    insolvency or similar matters. We have assumed, at the direction
    of Abraxis, that the Merger will be consummated in accordance
    with its terms, without waiver, modification or amendment of any
    material term, condition or agreement, that the CVRs will not be
    redeemed and that, in the course of obtaining the necessary
    governmental, regulatory and other approvals, consents, releases
    and waivers for the Merger, no delay, limitation, restriction or
    condition, including any divestiture requirements or amendments
    or modifications, will be imposed that would have an adverse
    effect on Abraxis, Celgene or the contemplated benefits of the
    Merger in any way meaningful to our analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We express no view or opinion as to any terms or other aspects
    of the Merger (other than the Consideration to the extent
    expressly specified herein), including, without limitation, the
    form or structure of the Merger. Our opinion is limited to the
    fairness, from a financial point of view, of the Consideration
    to be received by holders of Abraxis Common Stock (other than
    Soon-Shiong) and no opinion or view is expressed with respect to
    any consideration received in connection with the Merger by the
    holders of any class of securities, creditors or other
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    E-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Page&#160;3
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    constituencies of any party. In addition, no opinion or view is
    expressed with respect to the fairness (financial or otherwise)
    of the amount, nature or any other aspect of any compensation to
    any of the officers, directors or employees of any party to the
    Merger, or class of such persons, relative to the Consideration.
    Furthermore, no opinion or view is expressed as to the relative
    merits of the Merger in comparison to other strategies or
    transactions that might be available to Abraxis or in which
    Abraxis might engage or as to the underlying business decision
    of Abraxis to proceed with or effect the Merger. We are not
    expressing any opinion as to what the value of Celgene Common
    Stock actually will be when issued or the prices at which
    Abraxis Common Stock, Celgene Common Stock or the CVRs will
    trade at any time, including following announcement or
    consummation of the Merger. In addition, we express no opinion
    or recommendation as to how any stockholder should vote or act
    in connection with the Merger or any related matter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have acted as financial advisor to Abraxis in connection with
    the Merger and will receive a fee for our services, all of which
    is contingent upon consummation of the Merger. In addition,
    Abraxis has agreed to reimburse our expenses and indemnify us
    against certain liabilities arising out of our engagement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We and our affiliates comprise a full service securities firm
    and commercial bank engaged in securities, commodities and
    derivatives trading, foreign exchange and other brokerage
    activities, and principal investing as well as providing
    investment, corporate and private banking, asset and investment
    management, financing and financial advisory services and other
    commercial services and products to a wide range of companies,
    governments and individuals. In the ordinary course of our
    businesses, we and our affiliates may invest on a principal
    basis or on behalf of customers or manage funds that invest,
    make or hold long or short positions, finance positions or trade
    or otherwise effect transactions in equity, debt or other
    securities or financial instruments (including derivatives, bank
    loans or other obligations) of Abraxis, Celgene and certain of
    their respective affiliates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We and our affiliates in the past have provided, currently are
    providing, and in the future may provide, investment banking,
    commercial banking and other financial services to Celgene and
    have received or in the future may receive compensation for the
    rendering of these services, including (i)&#160;having acted as
    a financial advisor to Celgene in connection with an acquisition
    transaction and (ii)&#160;having acted or acting as lender
    under, or otherwise having extended credit under, certain
    letters of credit and other arrangements with Celgene.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    It is understood that this letter is for the benefit and use of
    the Board of Directors of Abraxis in connection with and for
    purposes of its evaluation of the Merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our opinion is necessarily based on financial, economic,
    monetary, market and other conditions and circumstances as in
    effect on, and the information made available to us as of, the
    date hereof. It should be understood that subsequent
    developments may affect this opinion, and we do not have any
    obligation to update, revise, or reaffirm this opinion. The
    issuance of this opinion was approved by our Americas Fairness
    Opinion Review Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based upon and subject to the foregoing, including the various
    assumptions and limitations set forth herein, we are of the
    opinion on the date hereof that the Consideration to be received
    in the Merger by holders of Abraxis Common Stock (other than
    Soon-Shiong) is fair, from a financial point of view, to such
    holders.
</DIV>

<DIV style="margin-top: 20pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Very truly yours,
</DIV>

<DIV style="margin-top: 40pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Merrill
    Lynch, Pierce, Fenner&#160;&#038; Smith Incorporated</DIV>
</DIV>

<DIV style="font-size: 3pt; margin-left: 49%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    MERRILL LYNCH, PIERCE, FENNER&#160;&#038; SMITH INCORPORATED
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    E-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='188'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;F</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">[LETTERHEAD
    OF GOLDMAN, SACHS&#160;&#038; CO.]</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><U><FONT style="font-family: 'Times New Roman', Times">PERSONAL
    AND CONFIDENTIAL</FONT></U></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    June&#160;30, 2010
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11755 Wilshire Blvd.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Suite&#160;2000
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Los Angeles, CA 90025
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Gentlemen:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You have requested our opinion as to the fairness from a
    financial point of view to the holders of the outstanding shares
    of common stock, par value $0.001 per share (the
    &#147;Shares&#148;), of Abraxis BioScience, Inc. (the
    &#147;Company&#148;) of the Per Share Consideration (as defined
    below) to be paid to such holders pursuant to the Agreement and
    Plan of Merger, dated as of June&#160;30, 2010 (the
    &#147;Agreement&#148;), by and among Celgene Corporation
    (&#147;Celgene&#148;), Artistry Acquisition Corp., a wholly
    owned subsidiary of Celgene (&#147;Acquisition Sub&#148;), and
    the Company. Pursuant to the Agreement, Acquisition Sub will be
    merged with and into the Company and each outstanding Share (not
    owned by Celgene or Acquisition Sub) will be converted into a
    right to receive 0.2617 of a share of common stock, par value
    $0.01 per share (the &#147;Celgene Common Stock&#148;), of
    Celgene (the &#147;Stock Consideration&#148;), $58.00 in cash
    (the &#147;Cash Consideration&#148;), and a contingent value
    right (a &#147;CVR&#148;) issued by Celgene under the CVR
    Agreement (as defined in the Agreement) (the &#147;CVR
    Consideration&#148; and together with the Cash Consideration and
    the Stock Consideration, the &#147;Per Share
    Consideration&#148;). Each CVR will entitle the holder thereof
    to CVR Payments (as defined in the CVR Agreement) on the terms
    and subject to the conditions set forth in the CVR Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Goldman, Sachs&#160;&#038; Co. and its affiliates are engaged in
    investment banking and financial advisory services, commercial
    banking, securities trading, investment management, principal
    investment, financial planning, benefits counseling, risk
    management, hedging, financing, brokerage activities and other
    financial and non-financial activities and services for various
    persons and entities. In the ordinary course of these activities
    and services, Goldman, Sachs&#160;&#038; Co. and its affiliates
    may at any time make or hold long or short positions and
    investments, as well as actively trade or effect transactions,
    in the equity, debt and other securities (or related derivative
    securities) and financial instruments (including bank loans and
    other obligations) of third parties, the Company, Celgene and
    any of their respective affiliates and affiliates of Patrick
    Soon-Shiong,&#160;M.D. (&#147;Soon-Shiong&#148;), a significant
    shareholder of the Company, or any currency or commodity that
    may be involved in the transaction contemplated by the Agreement
    (the &#147;Transaction&#148;) for their own account and for the
    accounts of their customers. We have acted as financial advisor
    to the Company in connection with, and have participated in
    certain of the negotiations leading to, the Transaction. We
    expect to receive fees for our services in connection with the
    Transaction, all of which are contingent upon consummation of
    the Transaction, and the Company has agreed to reimburse our
    expenses arising, and indemnify us against certain liabilities
    that may arise, out of our engagement. In addition, we have
    provided certain investment banking and other financial services
    to the Company and its affiliates from time to time for which
    our investment banking division has received, and may receive,
    compensation, including having acted as financial advisor to APP
    Pharmaceuticals, Inc., a former affiliate of the Company and
    Soon-Shiong, in its acquisition by Fresenius Kabi
    Pharmaceuticals Holding, LLC. We also may provide investment
    banking and other financial services to the Company, Celgene,
    Soon-Shiong and their respective affiliates in the future for
    which our investment banking division may receive compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with this opinion, we have reviewed, among other
    things, the Agreement; annual reports to stockholders and Annual
    Reports on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    of the Company for the 3&#160;years ended December&#160;31, 2009
    and for Celgene for the 5&#160;years ended December&#160;31,
    2009; the Company&#146;s initial registration statement on
    Form&#160;10; certain interim reports to stockholders and
    Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    of the Company and Celgene; certain other communications from
    the Company and Celgene to their respective stockholders;
    certain publicly available
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    June&#160;30, 2010
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Page&#160;Two
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    research analyst reports for the Company and Celgene; and
    certain internal financial analyses and forecasts for the
    Company prepared by its management and approved for our use by
    the Company (the &#147;Forecasts&#148;) and certain cost savings
    and operating synergies projected by the management of the
    Company to result from the Transaction, as approved for our use
    by the Company (the &#147;Synergies&#148;). As you are aware,
    the management of Celgene did not make available its forecasts
    of the future financial performance of Celgene. With your
    consent, our review of the future financial performance of
    Celgene was limited to the current consensus forecasts for
    Celgene, publicly available estimates of a certain research
    analyst and our discussions with the management of Celgene
    regarding the current consensus forecasts for Celgene. We have
    also held discussions with members of the senior managements of
    the Company and Celgene regarding their assessment of the
    strategic rationale for, and the potential benefits of, the
    Transaction and the past and current business operations,
    financial condition and future prospects of the Company and
    Celgene; reviewed the reported price and trading activity for
    the Shares and shares of Celgene Common Stock; compared certain
    financial and stock market information for the Company and
    Celgene with similar information for certain other companies the
    securities of which are publicly traded; reviewed the financial
    terms of certain recent business combinations in the
    pharmaceutical industry specifically and in other industries
    generally; and performed such other studies and analyses, and
    considered such other factors, as we deemed appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of rendering this opinion, we have relied upon and
    assumed, without assuming any responsibility for independent
    verification, the accuracy and completeness of all of the
    financial, legal, regulatory, tax, accounting and other
    information provided to, discussed with or reviewed by us, and
    we do not assume any responsibility for any such information. In
    that regard, we have assumed with your consent that the
    Forecasts and the Synergies have been reasonably prepared on a
    basis reflecting the best currently available estimates and
    judgments of the management of the Company. We have not made an
    independent evaluation or appraisal of the assets and
    liabilities (including any contingent, derivative or other
    off-balance-sheet assets and liabilities) of the Company or
    Celgene or any of their respective subsidiaries and we have not
    been furnished with any such evaluation or appraisal. We have
    assumed that all governmental, regulatory or other consents and
    approvals necessary for the consummation of the Transaction will
    be obtained without any adverse effect on the Company or Celgene
    or on the expected benefits of the Transaction in any way
    meaningful to our analysis. We also have assumed that the
    Transaction will be consummated on the terms set forth in the
    Agreement, without the waiver or modification of any term or
    condition the effect of which would be in any way meaningful to
    our analysis and that the CVRs will not be redeemed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our opinion does not address the underlying business decision of
    the Company to engage in the Transaction, or the relative merits
    of the Transaction as compared to any strategic alternatives
    that may be available to the Company; nor does it address any
    legal, regulatory, tax or accounting matters. This opinion
    addresses only the fairness from a financial point of view, as
    of the date hereof, of the Per Share Consideration to be paid to
    the holders pursuant to the Agreement. We do not express any
    view on, and our opinion does not address, any other term or
    aspect of the Agreement or Transaction or any term or aspect of
    any other agreement or instrument contemplated by the Agreement
    or entered into or amended in connection with the Transaction,
    including, without limitation, the Stockholders&#146; Agreement,
    dated as of June&#160;30, 2010, by and among Celgene and certain
    stockholders of the Company, the Noncompetition and
    Confidentiality Agreement (as defined in the Agreement), the
    fairness of the Transaction to, or any consideration received in
    connection therewith by, the holders of any other class of
    securities, creditors, or other constituencies of the Company;
    nor as to the fairness of the amount or nature of any
    compensation to be paid or payable to any of the officers,
    directors or employees of the Company, or class of such persons,
    in connection with the Transaction, whether relative to the Per
    Share Consideration to be paid to the holders pursuant to the
    Agreement or otherwise. We are not expressing any opinion as to
    the prices at which shares of Celgene Common Stock or the CVRs
    will trade at any time or as to the impact of the Transaction on
    the solvency or viability of the Company or Celgene or the
    ability of the Company or Celgene to pay its obligations when
    they come due. Our opinion is necessarily based on economic,
    monetary, market and other conditions as in effect on, and the
    information made available to us as of, the date hereof and we
    assume no responsibility for updating, revising or reaffirming
    this opinion based on circumstances, developments or events
    occurring after the date hereof. Our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    June&#160;30, 2010
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Page&#160;Three
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    advisory services and the opinion expressed herein are provided
    for the information and assistance of the Board of Directors of
    the Company in connection with its consideration of the
    Transaction and such opinion does not constitute a
    recommendation as to how any holder of Shares should vote with
    respect to such Transaction or any other matter. This opinion
    has been approved by a fairness committee of Goldman,
    Sachs&#160;&#038; Co.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based upon and subject to the foregoing, it is our opinion that,
    as of the date hereof, the Per Share Consideration to be paid to
    the holders of Shares pursuant to the Agreement is fair from a
    financial point of view to such holders.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Very truly yours,
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Goldman,
    Sachs&#160;&#038; Co.</DIV>
</DIV>

<DIV style="font-size: 3pt; margin-left: 49%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (GOLDMAN, SACHS&#160;&#038; CO.)
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='189'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;G</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">[LETTERHEAD
    OF LAZARD FRERES &#038; CO. LLC]</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><U><FONT style="font-family: 'Times New Roman', Times">CONFIDENTIAL</FONT></U></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <FONT style="font-family: 'Times New Roman', Times">June&#160;30,
    2010
    </FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11755 Wilshire Blvd.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Suite&#160;2000
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Los Angeles, CA 90025
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Dear Members of the Board:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We understand that Abraxis BioScience, Inc., a Delaware
    corporation (the &#147;Company&#148;), Celgene Corporation, a
    Delaware corporation (&#147;Buyer&#148;), and Artistry
    Acquisition Corp., a Delaware corporation and wholly-owned
    subsidiary of Buyer (&#147;Merger Sub&#148;), propose to enter
    into an Agreement and Plan of Merger, dated as of June&#160;30,
    2010 (the &#147;Agreement&#148;), pursuant to which Buyer will
    acquire the Company (the &#147;Transaction&#148;). Pursuant to
    the Transaction, Merger Sub will be merged with and into the
    Company and each outstanding share of the common stock, par
    value $0.001 per share, of the Company (the &#147;Company Common
    Stock&#148;), other than shares of Company Common Stock held by
    Buyer or Merger Sub (such holders, but only with respect to such
    shares of Company Common Stock, &#147;Excluded Holders&#148;),
    will be converted into a right to receive 0.2617 of a share of
    common stock, par value $0.01 per share (the &#147;Buyer Common
    Stock&#148;), of Buyer (the &#147;Stock Consideration&#148;),
    $58.00 in cash (the &#147;Cash Consideration&#148;), and a
    contingent value right (a &#147;CVR&#148;) issued by Buyer under
    the CVR Agreement (as defined in the Agreement) (the &#147;CVR
    Consideration&#148; and together with the Cash Consideration and
    the Stock Consideration, the &#147;Consideration&#148;). Each
    CVR will entitle the holder thereof to potential payments equal
    to a pro rata portion of (x)&#160;certain percentages of the Net
    Sales of certain Products with respect to the periods set forth
    therein based upon the amount of such Net Sales in each such
    period and (y)&#160;certain pre-set amounts contingent upon the
    achievement of certain Milestones with respect to the receipt of
    certain regulatory approvals for one of the Products, as such
    terms are defined in the CVR Agreement. The terms and conditions
    of the Transaction are more fully set forth in the Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You have requested our opinion as of the date hereof as to the
    fairness, from a financial point of view, to the holders of
    Company Common Stock (other than Patrick Soon-Shiong,&#160;M.D.
    and any of his affiliates (together, &#147;Soon-Shiong&#148;)
    and Excluded Holders (as defined above)) of the Consideration to
    be paid to such holders in the Transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with this opinion, we have:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;Reviewed the financial terms and conditions of the
    Agreement and the ancillary agreements thereto;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;Analyzed certain publicly available historical
    business and financial information relating to the Company and
    Buyer;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;Reviewed various financial forecasts and other data
    provided to us by the Company relating to the business of the
    Company, publicly available estimates of a certain research
    analyst, as well as current consensus forecasts for Buyer (the
    &#147;Public Forecasts&#148;), with respect to the business of
    Buyer, and certain cost savings and operating synergies
    projected by the management of the Company to result from the
    Transaction, as approved for our use by the Company;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iv)&#160;Held discussions with members of the senior
    managements of the Company and Buyer with respect to the
    businesses and prospects of the Company and Buyer, respectively;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (v)&#160;Reviewed public information with respect to certain
    other companies in lines of business we believe to be generally
    relevant in evaluating the businesses of the Company and Buyer,
    respectively;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    G-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    June&#160;30, 2010
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Page&#160;2
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vi)&#160;Reviewed the financial terms of certain business
    combinations involving companies in lines of business we believe
    to be generally relevant in evaluating the businesses of the
    Company and Buyer, respectively;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vii)&#160;Reviewed historical stock prices and trading volumes
    of Company Common Stock and Buyer Common Stock;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (viii)&#160;Conducted such other financial studies, analyses and
    investigations as we deemed appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have assumed and relied upon the accuracy and completeness of
    the foregoing information, without independent verification of
    such information. We have not conducted any independent
    valuation or appraisal of any of the assets or liabilities
    (contingent or otherwise) of the Company or Buyer or concerning
    the solvency or fair value of the Company or Buyer, and we have
    not been furnished with such valuation or appraisal. With
    respect to the financial forecasts related to the Company that
    we have reviewed, we have assumed, with the consent of the
    Company, that they have been reasonably prepared on bases
    reflecting the best currently available estimates and judgments
    of the management of the Company as to the future financial
    performance of the Company. As you are aware, the management of
    Buyer did not make available its forecasts of the future
    financial performance of Buyer but directed us to current
    consensus forecasts for Buyer. We have assumed, with the consent
    of the Company, that the Public Forecasts are a reasonable basis
    upon which to evaluate the future financial performance of
    Buyer, and are appropriate for us to utilize in our analyses. We
    assume no responsibility for and express no view as to any such
    forecasts or the assumptions on which they are based.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Further, our opinion is necessarily based on economic, monetary,
    market and other conditions as in effect on, and the information
    made available to us as of, the date hereof. We assume no
    responsibility for updating or revising our opinion based on
    circumstances or events occurring after the date hereof. We do
    not express any opinion as to the prices at which shares of
    Company Common Stock, or Buyer Common Stock or the CVRs may
    trade at any time subsequent to the announcement of the
    Transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In rendering our opinion, we have assumed, with your consent,
    that the Transaction will be consummated on the terms described
    in the Agreement, without any waiver or modification of any
    material terms or conditions and that the CVRs will not be
    redeemed. We also have assumed, with your consent, that
    obtaining the necessary regulatory or third party approvals and
    consents for the Transaction will not have an adverse effect on
    the Company or Buyer in any way meaningful to our analysis. We
    do not express any opinion as to any tax or other consequences
    that might result from the Transaction, nor does our opinion
    address any legal, tax, regulatory or accounting matters, as to
    which we understand that the Company obtained such advice as it
    deemed necessary from qualified professionals. We express no
    view or opinion as to any terms or other aspects of the
    Transaction (other than the Consideration to the extent
    expressly specified herein). In addition, we express no view or
    opinion as to the fairness of the amount or nature of, or any
    other aspects relating to, the compensation to any officers,
    directors or employees of any parties to the Transaction, or
    class of such persons, or the holders of any class of securities
    other than Company Common Stock, creditors, or other
    constituencies of the Company; in each case relative to the
    Consideration or otherwise. We note that Buyer, Merger Sub and
    certain stockholders of the Company have agreed to enter into a
    voting agreement pursuant to which such stockholders, subject to
    the terms thereof, will vote their shares of Company Common
    Stock in favor of adoption of the Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Lazard Fr&#232;res&#160;&#038; Co.</I>&#160;&#160;LLC is
    acting as financial advisor to the Company in connection with
    the Transaction and will receive a fee for our services, all of
    which is contingent upon the closing of the Transaction. We in
    the past have provided investment banking services to the
    Company, including having acted as financial advisor to APP
    Pharmaceuticals, Inc., a former affiliate of the Company, in its
    acquisition by Fresenius Kabi Pharmaceuticals Holding, LLC, for
    which we have received compensation. In addition, in the
    ordinary course of their respective businesses, Lazard
    Fr&#232;res&#160;&#038; Co. LLC and LFCM Holdings LLC (an entity
    indirectly owned in large part by managing directors of Lazard
    Fr&#232;res&#160;&#038; Co. LLC)&#160;and their respective
    affiliates may actively trade securities of the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    G-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Abraxis BioScience, Inc.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    June&#160;30, 2010
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Page&#160;3
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Company
    <FONT style="white-space: nowrap">and/or</FONT> the
    securities of Buyer and certain of their respective affiliates
    for their own accounts and for the accounts of their customers
    and, accordingly, may at any time hold a long or short position
    in such securities. The issuance of this opinion was approved by
    the Opinion Committee of Lazard Fr&#232;res&#160;&#038; Co. LLC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our opinion does not address the relative merits of the
    Transaction as compared to any other transaction or business
    strategy in which the Company might engage or the merits of the
    underlying decision by the Company to engage in the Transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our engagement and the opinion expressed herein are for the
    benefit of the Board of Directors of the Company and our opinion
    is rendered to the Board of Directors of the Company in
    connection with its evaluation of the Transaction. Our opinion
    is not intended to and does not constitute a recommendation to
    any stockholder as to how such stockholder should vote or act
    with respect to the Transaction or any matter relating thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based on and subject to the foregoing, we are of the opinion
    that, as of the date hereof, the Consideration to be paid to
    holders of Company Common Stock (other than Soon-Shiong and
    Excluded Holders) in the Transaction is fair, from a financial
    point of view, to such holders.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Very truly yours,<BR>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    LAZARD FRERES&#160;&#038; CO. LLC
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="3%"></TD>
    <TD width="48%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Stephen
    Sands</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 52%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 52%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Stephen Sands
</DIV>

<DIV align="left" style="margin-left: 52%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Managing Director
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    G-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='190'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;H</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">DELAWARE
    GENERAL CORPORATION LAW</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Section&#160;262.
    Appraisal Rights.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (a)&#160;Any stockholder of a corporation of this State who
    holds shares of stock on the date of the making of a demand
    pursuant to subsection&#160;(d) of this section with respect to
    such shares, who continuously holds such shares through the
    effective date of the merger or consolidation, who has otherwise
    complied with subsection&#160;(d) of this section and who has
    neither voted in favor of the merger or consolidation nor
    consented thereto in writing pursuant to &#167;&#160;228 of this
    title shall be entitled to an appraisal by the Court of Chancery
    of the fair value of the stockholder&#146;s shares of stock
    under the circumstances described in subsections&#160;(b) and
    (c)&#160;of this section. As used in this section, the word
    &#147;stockholder&#148; means a holder of record of stock in a
    stock corporation and also a member of record of a nonstock
    corporation; the words &#147;stock&#148; and &#147;share&#148;
    mean and include what is ordinarily meant by those words and
    also membership or membership interest of a member of a nonstock
    corporation; and the words &#147;depository receipt&#148; mean a
    receipt or other instrument issued by a depository representing
    an interest in one or more shares, or fractions thereof, solely
    of stock of a corporation, which stock is deposited with the
    depository.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (b)&#160;Appraisal rights shall be available for the shares of
    any class or series of stock of a constituent corporation in a
    merger or consolidation to be effected pursuant to
    &#167;&#160;251 (other than a merger effected pursuant to
    &#167;&#160;251(g) of this title), &#167;&#160;252,
    &#167;&#160;254, &#167;&#160;257, &#167;&#160;258,
    &#167;&#160;263 or &#167;&#160;264 of this title:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (1)&#160;Provided, however, that no appraisal rights under this
    section shall be available for the shares of any class or series
    of stock, which stock, or depository receipts in respect
    thereof, at the record date fixed to determine the stockholders
    entitled to receive notice of and to vote at the meeting of
    stockholders to act upon the agreement of merger or
    consolidation, were either (i)&#160;listed on a national
    securities exchange or (ii)&#160;held of record by more than
    2,000 holders; and further provided that no appraisal rights
    shall be available for any shares of stock of the constituent
    corporation surviving a merger if the merger did not require for
    its approval the vote of the stockholders of the surviving
    corporation as provided in subsection&#160;(f) of
    &#167;&#160;251 of this title.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (2)&#160;Notwithstanding paragraph (1)&#160;of this subsection,
    appraisal rights under this section shall be available for the
    shares of any class or series of stock of a constituent
    corporation if the holders thereof are required by the terms of
    an agreement of merger or consolidation pursuant to
    &#167;&#167;&#160;251, 252, 254, 257, 258, 263 and 264 of this
    title to accept for such stock anything except:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    a.&#160;Shares of stock of the corporation surviving or
    resulting from such merger or consolidation, or depository
    receipts in respect thereof;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    b.&#160;Shares of stock of any other corporation, or depository
    receipts in respect thereof, which shares of stock (or
    depository receipts in respect thereof) or depository receipts
    at the effective date of the merger or consolidation will be
    either listed on a national securities exchange or held of
    record by more than 2,000 holders;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    c.&#160;Cash in lieu of fractional shares or fractional
    depository receipts described in the foregoing subparagraphs a.
    and b. of this paragraph;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    d.&#160;Any combination of the shares of stock, depository
    receipts and cash in lieu of fractional shares or fractional
    depository receipts described in the foregoing subparagraphs a.,
    b. and c. of this paragraph.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (3)&#160;In the event all of the stock of a subsidiary Delaware
    corporation party to a merger effected under &#167;&#160;253 of
    this title is not owned by the parent corporation immediately
    prior to the merger, appraisal rights shall be available for the
    shares of the subsidiary Delaware corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (c)&#160;Any corporation may provide in its certificate of
    incorporation that appraisal rights under this section shall be
    available for the shares of any class or series of its stock as
    a result of an amendment to its certificate of incorporation,
    any merger or consolidation in which the corporation is a
    constituent corporation or the sale of all or substantially all
    of the assets of the corporation. If the certificate of
    incorporation contains such a provision, the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    H-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    procedures of this section, including those set forth in
    subsections&#160;(d) and (e)&#160;of this section, shall apply
    as nearly as is practicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (d)&#160;Appraisal rights shall be perfected as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (1)&#160;If a proposed merger or consolidation for which
    appraisal rights are provided under this section is to be
    submitted for approval at a meeting of stockholders, the
    corporation, not less than 20&#160;days prior to the meeting,
    shall notify each of its stockholders who was such on the record
    date for such meeting with respect to shares for which appraisal
    rights are available pursuant to subsection&#160;(b) or
    (c)&#160;hereof that appraisal rights are available for any or
    all of the shares of the constituent corporations, and shall
    include in such notice a copy of this section. Each stockholder
    electing to demand the appraisal of such stockholder&#146;s
    shares shall deliver to the corporation, before the taking of
    the vote on the merger or consolidation, a written demand for
    appraisal of such stockholder&#146;s shares. Such demand will be
    sufficient if it reasonably informs the corporation of the
    identity of the stockholder and that the stockholder intends
    thereby to demand the appraisal of such stockholder&#146;s
    shares. A proxy or vote against the merger or consolidation
    shall not constitute such a demand. A stockholder electing to
    take such action must do so by a separate written demand as
    herein provided. Within 10&#160;days after the effective date of
    such merger or consolidation, the surviving or resulting
    corporation shall notify each stockholder of each constituent
    corporation who has complied with this subsection and has not
    voted in favor of or consented to the merger or consolidation of
    the date that the merger or consolidation has become
    effective;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (2)&#160;If the merger or consolidation was approved pursuant to
    &#167;&#160;228 or &#167;&#160;253 of this title, then either a
    constituent corporation before the effective date of the merger
    or consolidation or the surviving or resulting corporation
    within 10&#160;days thereafter shall notify each of the holders
    of any class or series of stock of such constituent corporation
    who are entitled to appraisal rights of the approval of the
    merger or consolidation and that appraisal rights are available
    for any or all shares of such class or series of stock of such
    constituent corporation, and shall include in such notice a copy
    of this section. Such notice may, and, if given on or after the
    effective date of the merger or consolidation, shall, also
    notify such stockholders of the effective date of the merger or
    consolidation. Any stockholder entitled to appraisal rights may,
    within 20&#160;days after the date of mailing of such notice,
    demand in writing from the surviving or resulting corporation
    the appraisal of such holder&#146;s shares. Such demand will be
    sufficient if it reasonably informs the corporation of the
    identity of the stockholder and that the stockholder intends
    thereby to demand the appraisal of such holder&#146;s shares. If
    such notice did not notify stockholders of the effective date of
    the merger or consolidation, either (i)&#160;each such
    constituent corporation shall send a second notice before the
    effective date of the merger or consolidation notifying each of
    the holders of any class or series of stock of such constituent
    corporation that are entitled to appraisal rights of the
    effective date of the merger or consolidation or (ii)&#160;the
    surviving or resulting corporation shall send such a second
    notice to all such holders on or within 10&#160;days after such
    effective date; provided, however, that if such second notice is
    sent more than 20&#160;days following the sending of the first
    notice, such second notice need only be sent to each stockholder
    who is entitled to appraisal rights and who has demanded
    appraisal of such holder&#146;s shares in accordance with this
    subsection. An affidavit of the secretary or assistant secretary
    or of the transfer agent of the corporation that is required to
    give either notice that such notice has been given shall, in the
    absence of fraud, be prima facie evidence of the facts stated
    therein. For purposes of determining the stockholders entitled
    to receive either notice, each constituent corporation may fix,
    in advance, a record date that shall be not more than
    10&#160;days prior to the date the notice is given, provided,
    that if the notice is given on or after the effective date of
    the merger or consolidation, the record date shall be such
    effective date. If no record date is fixed and the notice is
    given prior to the effective date, the record date shall be the
    close of business on the day next preceding the day on which the
    notice is given.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (e)&#160;Within 120&#160;days after the effective date of the
    merger or consolidation, the surviving or resulting corporation
    or any stockholder who has complied with subsections&#160;(a)
    and (d)&#160;of this section hereof and who is otherwise
    entitled to appraisal rights, may commence an appraisal
    proceeding by filing a petition in the Court of Chancery
    demanding a determination of the value of the stock of all such
    stockholders. Notwithstanding the foregoing, at any time within
    60&#160;days after the effective date of the merger or
    consolidation, any stockholder who has not commenced an
    appraisal proceeding or joined that proceeding as a named party
    shall have the right to withdraw such stockholder&#146;s demand
    for appraisal and to accept the terms offered upon the merger or
    consolidation.
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    H-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Within 120&#160;days after the effective date of the merger or
    consolidation, any stockholder who has complied with the
    requirements of subsections&#160;(a) and (d)&#160;of this
    section hereof, upon written request, shall be entitled to
    receive from the corporation surviving the merger or resulting
    from the consolidation a statement setting forth the aggregate
    number of shares not voted in favor of the merger or
    consolidation and with respect to which demands for appraisal
    have been received and the aggregate number of holders of such
    shares. Such written statement shall be mailed to the
    stockholder within 10&#160;days after such stockholder&#146;s
    written request for such a statement is received by the
    surviving or resulting corporation or within 10&#160;days after
    expiration of the period for delivery of demands for appraisal
    under subsection&#160;(d) of this section hereof, whichever is
    later. Notwithstanding subsection&#160;(a) of this section, a
    person who is the beneficial owner of shares of such stock held
    either in a voting trust or by a nominee on behalf of such
    person may, in such person&#146;s own name, file a petition or
    request from the corporation the statement described in this
    subsection.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (f)&#160;Upon the filing of any such petition by a stockholder,
    service of a copy thereof shall be made upon the surviving or
    resulting corporation, which shall within 20&#160;days after
    such service file in the office of the Register in Chancery in
    which the petition was filed a duly verified list containing the
    names and addresses of all stockholders who have demanded
    payment for their shares and with whom agreements as to the
    value of their shares have not been reached by the surviving or
    resulting corporation. If the petition shall be filed by the
    surviving or resulting corporation, the petition shall be
    accompanied by such a duly verified list. The Register in
    Chancery, if so ordered by the Court, shall give notice of the
    time and place fixed for the hearing of such petition by
    registered or certified mail to the surviving or resulting
    corporation and to the stockholders shown on the list at the
    addresses therein stated. Such notice shall also be given by 1
    or more publications at least 1&#160;week before the day of the
    hearing, in a newspaper of general circulation published in the
    City of Wilmington, Delaware or such publication as the Court
    deems advisable. The forms of the notices by mail and by
    publication shall be approved by the Court, and the costs
    thereof shall be borne by the surviving or resulting corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (g)&#160;At the hearing on such petition, the Court shall
    determine the stockholders who have complied with this section
    and who have become entitled to appraisal rights. The Court may
    require the stockholders who have demanded an appraisal for
    their shares and who hold stock represented by certificates to
    submit their certificates of stock to the Register in Chancery
    for notation thereon of the pendency of the appraisal
    proceedings; and if any stockholder fails to comply with such
    direction, the Court may dismiss the proceedings as to such
    stockholder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (h)&#160;After the Court determines the stockholders entitled to
    an appraisal, the appraisal proceeding shall be conducted in
    accordance with the rules of the Court of Chancery, including
    any rules specifically governing appraisal proceedings. Through
    such proceeding the Court shall determine the fair value of the
    shares exclusive of any element of value arising from the
    accomplishment or expectation of the merger or consolidation,
    together with interest, if any, to be paid upon the amount
    determined to be the fair value. In determining such fair value,
    the Court shall take into account all relevant factors. Unless
    the Court in its discretion determines otherwise for good cause
    shown, interest from the effective date of the merger through
    the date of payment of the judgment shall be compounded
    quarterly and shall accrue at 5% over the Federal Reserve
    discount rate (including any surcharge) as established from time
    to time during the period between the effective date of the
    merger and the date of payment of the judgment. Upon application
    by the surviving or resulting corporation or by any stockholder
    entitled to participate in the appraisal proceeding, the Court
    may, in its discretion, proceed to trial upon the appraisal
    prior to the final determination of the stockholders entitled to
    an appraisal. Any stockholder whose name appears on the list
    filed by the surviving or resulting corporation pursuant to
    subsection&#160;(f) of this section and who has submitted such
    stockholder&#146;s certificates of stock to the Register in
    Chancery, if such is required, may participate fully in all
    proceedings until it is finally determined that such stockholder
    is not entitled to appraisal rights under this section.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;The Court shall direct the payment of the fair value of
    the shares, together with interest, if any, by the surviving or
    resulting corporation to the stockholders entitled thereto.
    Payment shall be so made to each such stockholder, in the case
    of holders of uncertificated stock forthwith, and the case of
    holders of shares represented by certificates upon the surrender
    to the corporation of the certificates representing such stock.
    The Court&#146;s decree may be enforced as other decrees in the
    Court of Chancery may be enforced, whether such surviving or
    resulting corporation be a corporation of this State or of any
    state.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    H-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (j)&#160;The costs of the proceeding may be determined by the
    Court and taxed upon the parties as the Court deems equitable in
    the circumstances. Upon application of a stockholder, the Court
    may order all or a portion of the expenses incurred by any
    stockholder in connection with the appraisal proceeding,
    including, without limitation, reasonable attorney&#146;s fees
    and the fees and expenses of experts, to be charged pro rata
    against the value of all the shares entitled to an appraisal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (k)&#160;From and after the effective date of the merger or
    consolidation, no stockholder who has demanded appraisal rights
    as provided in subsection&#160;(d) of this section shall be
    entitled to vote such stock for any purpose or to receive
    payment of dividends or other distributions on the stock (except
    dividends or other distributions payable to stockholders of
    record at a date which is prior to the effective date of the
    merger or consolidation); provided, however, that if no petition
    for an appraisal shall be filed within the time provided in
    subsection&#160;(e) of this section, or if such stockholder
    shall deliver to the surviving or resulting corporation a
    written withdrawal of such stockholder&#146;s demand for an
    appraisal and an acceptance of the merger or consolidation,
    either within 60&#160;days after the effective date of the
    merger or consolidation as provided in subsection&#160;(e) of
    this section or thereafter with the written approval of the
    corporation, then the right of such stockholder to an appraisal
    shall cease. Notwithstanding the foregoing, no appraisal
    proceeding in the Court of Chancery shall be dismissed as to any
    stockholder without the approval of the Court, and such approval
    may be conditioned upon such terms as the Court deems just;
    provided, however that this provision shall not affect the right
    of any stockholder who has not commenced an appraisal proceeding
    or joined that proceeding as a named party to withdraw such
    stockholder&#146;s demand for appraisal and to accept the terms
    offered upon the merger or consolidation within 60&#160;days
    after the effective date of the merger or consolidation, as set
    forth in subsection&#160;(e) of this section.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (l)&#160;The shares of the surviving or resulting corporation to
    which the shares of such objecting stockholders would have been
    converted had they assented to the merger or consolidation shall
    have the status of authorized and unissued shares of the
    surviving or resulting corporation.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    H-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">THIS
    PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS<BR>
    ABRAXIS BIOSCIENCE, INC.<BR>
    FOR THE SPECIAL MEETING OF STOCKHOLDERS<BR>
    TO BE HELD</FONT></B>
</DIV>




<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">October&#160;13,
    2010</FONT></B>
</DIV>



<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The undersigned hereby appoints Patrick Soon-Shiong and Bruce
    Wendel or either of them, each with the power of substitution,
    and hereby authorizes each of them to represent and to vote as
    designated below all of the shares of common stock of Abraxis
    BioScience, Inc. that the undersigned is entitled to vote at the
    special meeting of stockholders to be held at the Fairmont
    Miramar, 101 Wilshire Boulevard, Santa Monica, California on
    October&#160;13, 2010 at 10:00 a.m. local time, or any
    adjournment or postponement thereof.
</DIV>


<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED
    BY THE UNDERSIGNED STOCKHOLDER. IF NO SUCH DIRECTIONS ARE MADE,
    THIS PROXY WILL BE VOTED &#147;FOR&#148; THE ADOPTION OF THE
    MERGER AGREEMENT.</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CONTINUED
    AND TO BE SIGNED ON REVERSE SIDE</FONT></B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="font-family: Wingdings; font-variant: normal">&#226;</FONT>
    Please Detach and Mail in the Envelope Provided
    <FONT style="font-family: Wingdings; font-variant: normal">&#226;</FONT></FONT></B>
</DIV>

<DIV style="font-size: 3pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>    <FONT style="font-family: Wingdings; font-variant: normal">&#254;</FONT><B>&#160;&#160;</B></TD>
    <TD align="left">
    <B>Please mark your vote as<BR>
    indicated in this example.</B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=01 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="67%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>FOR</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>AGAINST</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>ABSTAIN</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1.
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Proposal to adopt the Agreement and Plan of Merger, dated as of
    June&#160;30, 2010, by and among Celgene Corporation, Artistry
    Acquisition Corp., a wholly-owned subsidiary of Celgene
    Corporation, and Abraxis BioScience, Inc., as it may be amended.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY
    USING THE ENCLOSED REPLY ENVELOPE.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    SIGNATURE(S)&#160;<FONT style="word-spacing: 395pt; white-space: nowrap; font-size: 1pt; color: #000000"><U>&#173;
    &#173;</U></FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    SIGNATURE(S)&#160;<FONT style="word-spacing: 395pt; white-space: nowrap; font-size: 1pt; color: #000000"><U>&#173;
    &#173;</U></FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    DATE:&#160;<FONT style="word-spacing: 100pt; white-space: nowrap; font-size: 1pt; color: #000000"><U>&#173;
    &#173;</U></FONT>, 2010
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="7%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>    NOTE:&#160;</TD>
    <TD align="left">
    Please sign as or on behalf of the stockholder whose name
    appears on this proxy card. If shares are held jointly, each
    person should sign. When signing as attorney, executor,
    administrator, trustee or guardian, please give full title as
    such. If a corporation, please sign in full corporate name by
    President or other authorized officer. If a partnership, please
    sign in partnership name by an authorized person.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y85641dfx8564116.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y85641dfx8564116.gif
M1TE&.#EAEP!-`-4@`(B1QDQ:J<3)X_'R^!\QD^+D\6IVMZ:MU#U,HM/6ZI>?
MS>MN>RX_FEMHL.$E.;6[V_.HL'F$O^^+EN=08?WQ\^5"5/OCY??%R_G4V.,S
M1O&:H^U\B?6WONE?;A`CC-\6+/___P``````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"``+`````"7`$T```;_
M0)!P2`19%HZ/\I/I:"S%J'1*K5JOV*QVBX4DEV!E14/AFL_HM-H,";O!"^AZ
M3J_;H^VW7KDHW_^`@5487V\+'!5O#A*"C8Y_B7H30Q)Z%1B/F9I<>7H<1!>%
M88R;I:9%%*)A&5$4$Y:8I[*:&GL?$%,;>@ZXL[Z"&7L.?E)>>@N_R78<MLB#
MJDL5Q,K49AVVL546D6X.V=7@5Q:VK%@4W&$.G^'L5+5[&UH4"WN][?=#KWO?
M6/1ZI/C:4;#EX(P_0P';=7K3`<U!-\X25GOHQIZ9=P@E4@NV3\W",!$USAHG
M;,Y'.")]G00S:8ZN8REEO?Q7AR+*F*7TZ;&XQN:2_Y`X'=GZ<.&.3SY!'Y'<
M(\?.T0]`D]ZY,#00NC`:I`:J9"O0N7I:_W"5).CKSK!V=+YI&<@"-"7>T-)1
MZX9M($*[^,DU,S3J'PQ[,DS;RV4HP$8KQ0PFG,6PIL10&?.U=?B,!0@+@OD5
M\C2>9"V.+6NX6I3*T\6?IX3><N&:FW)5CC9-765U%KI@>$ZQN9EVD:&EM;S]
M4##+A043)BP([KNV+>98<"NI?*9`@.L!%.`<(*"[@`)8@'.Y"A<UEP,>TGLX
M@!.]^@?AGQ=^DU4*`/7IX5.)@#\!3O[J#1#?'M0-\@9L111``'X>`%!%`.H1
M$!0"ZC'0&&5;S`3&.E$TP/^@!P%4@5\#0>%GP(4$;@&-740(\*$'%D[AHGK:
M-3>$;5:L--L0`S!0(7X"2J$`?@+8>".&67`$1H$@W)<>`0D0.84!^(%0@`(`
M9.F?%-Y]!\(`6`)0I!#<96GF`T$244"7:0[1I9<@).#=ED0D$&:6!_@W'%)8
M,!-&!5,4@)^#^-48A8_I!0`@?@&T^25^!SRP8'HU>OAB@T7,F-Z)1%`9(7@@
M3`IBBQ2^:(!T2[!(!6YZ"0'ADP*^Z@&G10R`GZ@,(M"FIK,R6*2@EVY:!*(>
M2#C$D!%N"6QZ#@KAWJ4':%A7%VXP^>QZ0ECJ`0)<!LM@LT(@^R2#0O!ZW8=T
M@G#_+7L@/,`@G=?JMZQZ",@Z`&1*8*&D&%,,("JW0CB9GGT,!N!?`J6F%Z,0
MGA9<;\`!'`!JN(,.JQZ)">#*KA"+>@"JN+.F*8!V2^EQQ5AP[3A$QV.VVU\4
MLH[*(ZX3$\NLHU3("F[`_=F\L:L5#B&P!_I%L:\;T!51LA))E\MHBY!&07,1
MVGHPIJV%;J%SK:+B&D$4(PJ-'P(3$R$M5E5<59\4"7M<1,5JFAC%T&.:2\65
M!F!WG:@_,VQJ%+P:RFNQA@ZQ-$A4H!S9%"`'\*;=1,3;H91-1@UXS)>V/,2\
MPD8!LN8-J]=H$:@2-\5'@`:*J[?%%M$QSFT'6;44UWHK_T7HG5-=91%#IZ<K
M*/(5@5<TYH%0->OIE=UV%%@K/`2Q(2:(JP$"!+GHPF*_6+80Q`)<!,+?DKX'
MBQR((@T5@R-O-1'D\BZWE?A]703(?1-+8N3XV4PKF?%3$;KW0G`+6$!``<6=
MCPHVBX"9%@B`T(%K<$7[$J[&Y"[U]`T$#0.@NK+FIEL-('9$J&!Z+LBC]A$!
M7QWH@"KZ4(6A14\*S?/`_4``LFT%J0!M>^'0TI6M"J4I8Y2+$Z[\<ZV=[5`(
M!0!`FZ(DNF(,9116X!P/B_"O(1P/1GE#UQ!D92SWT2M+5YR9Y4(5H31Q\5C%
M,D"6(H"KG9WPB4QH6A%BMC\IQ/_L>3\*UL]$]<*X7:I[9&K;_CIF*#Y:T5L$
MP-D0,%"Z111O""(LEB([):48/N"*Q8H@$YDUA=KY3H3WB]GO-I<_(6P24T)8
MW=BF&(7CB&("9,C"G0`001DM$#Q)-!-X```]!3@JEUI"7P,FA0#V",!,14H`
M`[='PUM:R9GEBH`H#5!++%Q`94;*IC:WJ0DYT:$[W+R#`K`3`3I1R`J7O(X!
MF"F$;873#@@@0``H1`!0!:".14"//"&DR`0$P(WO3(/,[E.X%K6)0EM:XB0'
MP$J&,D]S<6)G:ES4K/O`9TA%&H"V1@<"'SEJ42'B#WC\^21VW0=`!&"7=6BD
M+F)*E#'_]U$CE0!&I0%\L$''E!E_&%`T_@3@`0\H4@`LY*^4"H!"`O(03R5%
M5!^)26+H<=R0\/F9JD%)"`C@UI#D!X)S<DQ8@NHC"&0(`OZ8='T$J"?0:.B!
MPA&``4%ZF(W>^J4AA<A6)_+0Q"!4IP4)`#T_HVA7/_2=63V/6_SL8,%L)"A:
MM<Y%VN'K\[K(LRRM#XU%VM:;!N`N=N$5!))U&O7F9"/TU&A()+J/?Z@T)BJ=
M**$0^BLJ>P@T1]T'5"YB#X3H%*499I,_]5H0`\`CV2@10)HVM)4\%W37!37`
M`"=B`,#<10#H,L`_`>BB:EUVW`:PAT((`$`#?$N;`RSP`$%2*,#&$I"W?PH(
B3-@Q5`':RQY:0K(!UY$?`#9F7C?A-P#@&0``L%/-(```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y85641dfx8564117.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y85641dfx8564117.gif
M1TE&.#EA?@![`.8``.7EY4U-35555<C(R.;FYMO;VRTM+=;6UC$Q,<[.SM+2
MTL#`P']_?WIZ>K:VMLO+RZRLK-34U,/#P\K*RKV]O9R<G+2TM"@H**JJJAT=
M';*RLA@8&+R\O(J*BB0D)+FYN=#0T*BHJ*"@H)B8F`0$!,;&QA$1$;"PL,3$
MQ!45%9Z>GI"0D&IJ:J2DI(*"@J:FIG!P<&AH:"$A(3P\/(2$A)24E`P,#'9V
M=E)24EY>7HB(B#\_/Z*BHGAX>&YN;G1T=(V-C6)B8JZNKI*2DHZ.CDI*2H"`
M@%A86&!@8$)"0C@X.):6EEM;6VQL;$9&1EQ<7`@("$]/3T!`0&1D9')R<C0T
M-$1$1#8V-IJ:FCHZ.GQ\?$A(2&9F9H:&AO[^_OO[^_S\_/W]_??W]_CX^/GY
M^>[N[N'AX?KZ^O+R\NWM[?3T]/;V]KJZNO#P\/'Q\>+BXN_O[][>WNOKZ]G9
MV=W=W?/S\^SL[+N[N^CHZ./CX]C8V.KJZNGIZ>#@X````/___R'Y!```````
M+`````!^`'L```?_@'^"@X2%AH>(B8J+C(V.CY"1A@IBDI:7F)F9!SA^;%Z:
MH:*CF7).?GX87Z2LK:Z%=3&H?A!@K[>XFC49-JALN<#!CFP7?@DR?A+"R\R$
M$0A^26`R&P7-U\%U3B0&#V,F7&G8X[<8)C(.8P50/6[D[Z1FQ2MP?Q9^0>+P
M^YDW?CL1!.GPTX(,OX.2!BC),.",H!Q^Z""<V*C.@FT-U@RJ0D(.Q8^(\KC(
MX,>#-4%[3"11`[(EH1504+D`)4B#'P<T^8W!L,#EH#Q3#)@H`H(0"S]F$)I!
MXL?&"$-B"*SB%^*"`1LB'`Y*LJ',034-9NTH=.;!#7W[&I!`98&0F2I1_S3R
MFY.!!`LH8PD5P'&A#3\\1SR8V'&`4`L9+6SQ<V'C!I\@>075J>`GRT$@-C;8
MJ$4(!PFT\+Y`D6%+3N0_*S)D>,K/GZ]".S9HW4>9Q:#(:3;X4>)Q7YQ.?GX`
M(!2G2A&$%Z!`N"TH#?#3[]@80,4AYY\&)H@@))&A\!\Q8\>$]9-AQ<$?:_WT
M)+3CYL$#?A#8$01F!Q@%Z6?4.<@$%0X\Q%611$#\'`7!;"(D,)T'_QRDQW1^
M-*"8("'($,,;!Z7@1QR$+`"-#>>(<)`*,?G!0"$"0%&#7_OP@0I+@_1G`A9^
MS%`//^/-<$<A5?CQP83OC.`'"4!"D8(./OAQQ/]!:`2`"@L`#H+&!22LM\\/
M?@1`DQ<PV'`$`;U8"<\"NOEA'B$6F!`$A_R0=*(@0NKWP)#6O;/$6@:(^0<&
M-E2`QD&H)"`(`2;XH0`:#/C!VF)^I,!`E(,@0<*/_-B!BCL$*-$@'D6D<.,^
M91Q%`@U`XI$!%,KP`Q\47X3A@!]0!#2`"1<@E$`20RXJR`=^1#''01WX0<,?
M?$PWP1][*8I0L/@,1TB2)QC$SPQ^&'3*#X(LT.A4_"3JAPIU-I$,0EGX\0<*
M?LA0R1_:UGI0`?W14@@8.:3`YCY@3!=&"BFD^D<5)JB`D`@D;2`H(;L4X14_
M#YPJ@A\YL/@'-^X<Y&W_`'(-(H`?)2`T@@U"H"+Q'Y5-Y"T5A8A!K1X(40L-
MC(*48("_H"8)10B%O"4#`8Z$8<:]KFCJQPV$A.$!=/``5=(`A9P@`PXP*Q*&
M!ED$P&TK0J\KR!A^.#$1!-/EH+4@,$"A72-NH**$LZV$T6,5A?3AAPX(<8D*
M#(8D`84&C83!ZVZ]M3(!285X480?#R!4Q\8F%J+&#$$DQ4@:&C982!ADH`&'
M&K-%HE80*:,RD0(D7>!`(4:D((*TB^1`@I-:&+)`>GZ8<,,`H#'"IQ\O$.*%
M&8U.]*H?./11R!8V4-!('R;,<'C@@R2PP_0[*+&!`1TL\,#(B*!19@N$?/$P
M_]X'@=$"*CVD/,,6$C$2`PD\B+X('QTD47H(0!Z"P2Q\#^+&X8D[2!NP!(5A
M$>)!6!@#([Q@`A+TP`_N8@09QH.#L1FB#KA"A7<$(3<_L&T?$B#)#'Z!,!N<
MCA'QLX("_("A1GQA/$T(@R)N8`)HD&"#?TA`\!`"`51D@82"4,,-4H""1L2D
M`AVPP2,*\`14G`D18YC!J"`HN5WYX3@(>0$JCH##$CB!"U5,Q!M0`03B.0(,
M%4"`"4S0/T1,P``"Z,0-*O:'+PCI!`CYP@I0\:9!)#%:C'A@%91``@4XX@T"
MF`$"I-`^1/0@`P[0#08FY`8GL6X?<[""3`KA#STA(O]0&TB"([Y0@362(':)
M@$,6IM!!"N0$`%2R!!D4<(<"6/`0;I#`![AGB!:LY0(X&T0;<N`!0RX"#36B
M"PX5H0>A*:%CB6!`%0:@!E0$4!`4,,$&+/$&*<Z@!GE01!Q@4*@=)6(,S&+"
M2021@!D@X5.(\,+Y<)"#"UQ2$128!0RN5@@.9``&`!A`[=;Y!Q^0`'22*$,4
M4.$!$<CP$'%`0B_\L,Q"[$%<0\O8'RJ0@@8\-!%?<))N;-.(-52`!%#80`UF
MZ`<-G$&+3N#9(*A41$LX`$))`!HA,#JD15``&GXXVR!N(`,1%>(+:N#6&(3F
MAV,A8@]64@@);*#.1-3!=3W_"4L-,@8&*&3@GH\(PPN*X0<1\/,/;+!!7?R`
MRD0,`14I`.(?`""`R!G"#C=P`004J(8>]8J7@LB##[8PB(<-R8"($$$*8I"4
M4QP@)\#S&B;.L(##P8![$@@E(:'`"!J@X@($!8()7/#104015E%@`1,*Y8<_
M":("0'#M%\J8ES,,!&(Z+<032/``4+0'4M<A@5$%408:N"`2>CA"`%K(3DVU
MH!=$4X088("**L!S"BD`WR%XP*!9H,('#WW`!JIP$COL(`7'_<,:PF*#E2:"
M`%+80CWXH"GH:0:(:1@!%.`6"0C\P'@H"8(-KG`**"A/$7.@%O$^*H<D"*"1
MAA#!_T1G$<X_@,%)2N##'\C0!1LH07)HH`($"82("FQ@"*!P0#&@5SNFL7,Z
MY(/$'A)`QP[HYA3XD&DB--`+&SSQ#QH8#`-<4(#2^K$!42C1(,;8("\4(`4F
M>),8(-`C`2A"#8DTY@CJ@A8QE(2YP3*!,3%1@.F0H%!'^-4B;KL!#`QB`$!%
MA0%&L`<C6Y@*Z9D/`?PZ%@*<(@OS"0,$2N=B1+C`!$MXZ):=`+.CZ$!KFC)`
M*!@0D[78JTZ'\)8!#J:TW02E455P<R'(T-V(_(%Q#4*7<`5!!V3XP0IV'H0:
M=F"#M@@B11SXZ%H(D).4MO$2"HBS'^Z0OT.<P345%(0*-/\4@P&880$78,((
M*JJ66:#A#87"E1/,X"03<&C*J"#!%!2Q`!FP0,.":`]H4,&Z$Y#`"0K,A`YH
M5X-X+X(`"\6'(%!P"A,.X@-]P+0""I6>/_2'!">X8@T86@D0^%4&0E`$I8>+
M!FIIC6M^F,H8ZB+*3!0@WWY@0><4,:LG_:$-U.U:[D0`@X4)0FA.Z$492$`"
M(%`&"A>00C2^L[^I.B$-!V@``X3`O8V)^@\JML%L7K4%FMS#!B3%Q*%1P00U
M-T);L#JN:)U8"!H4RNI"NML&9%`,`XS!U0:XAP#`8($-9*`))#C"`\@*===N
M>`9.&/.6D4"(L!Q8#86Z@%P3`E3_'!0`TXA0@V$]L``UQ,L$MA[$0DG0/CID
M,`,Y,,%$?[06$QQACU.XPP4RT('X92"#<%U4"TRP@OW`B?2$*,9P"$`M%V0!
MGI%00!%B`GE[,\(,LLB2&DI0N1RX7+WM48(^IF`#!C6!!1-]P1B^@(H9#"`(
MY"F&$O;00YI?0`-LZ$\2].&"F^0D1>X5Q%K$X"H(C@!I002`_`%@=T+P(46U
MJT']&5&`(Z`B"&>P<!"T'(00;"&W"@,P'5?`,4RP%B3`$EX0`)LV!F$'03L2
M0N21%6&P`%F0`8;T0@C`,K<A+X(`!WY0!6&0!H=#`4H`'7BP`DXP`THP@THP
M`TGP!$.@_P!FT`(QD`2]0`(W<'R-0'RH0`4E0!)#8PCD1!!_4!P1@@I[H&"%
M9G\L@`,N,!^"<`<NH%&)(B(H8`4=8&]VH"GF]`?8)R@Z9P!K8#F",``D00(Q
MD`!E4`9FT$3>=8=`<%:,@'76=SZ#08"#0`;4T@3#L07<P"MB`P=Z`&&^,P9K
M<$E@<$]O901J0`,(1PB9`@56HBG?43MVD`=L6`"Z@0`)X'MJT`<B<`0:8@!'
M,!TF<$*0,`8]I"0%4'Y^$`/`A1HQ<0)>4`,Q80$]=`>(9PEQ<`4VH`4L8``X
M=!@!(()_P(D]@@,Y-#=_,`8Z``50(`#0$SYKD`9O4`9S`!&J(/\)`"!B$#,`
M3K(:I151M2,!)=<!:8!].A8*8!!F)F!\A!``)(`$;$(`%W`%!K4!3-,&T0`!
M"-`+,)"+B3`";E<4DB`!E7,##I`"4``$QX<&/U`H*Z`&U)4$C_4\K/`&?B4A
MA$`M$"`M(:!Y:\$%?W(&L$(2'O`!VRAQ?N`#@,4('#`+6D`92*,%LV`!F@0%
M)[$#.*!1HF`&_M='@C`=5O(QJ-!Q@B`$+5!AD/`&V!=YD7`/-?(&M5$($+%%
M'<`@!Q9LU\0*`U`$2AD")"``!-4CN74)55$$5`D);N!9O>(&7;EA!^!_M)("
M:U%`BF%C0B@*9P`#.R`F8>$#'P1TH^#_!EPP-'K("`H`(3[P!P]C?`!@`>UA
M`S#P`$=!/!N4!"1P2Z$0!P'``M#C#VP0:Z(0`G6!6)%P!^%F!'\P`0@`!1.V
M`6WA!@W@`2MP?#L0!:\``1Y`!?67))Y$"F&!`V,6"<.3`0=6`JYV4)]"!L6V
M`UC4"CI@`TH9!D&@B;=@-TKIG&I3?VX`!Y%)"`"@!-+H"D>AE!70)Z[G"@Y@
M`E904Y*`1J@`?XUP``@03*V0>4\4!X1T,*\P$.EE"6V0;U`9":DQ>*.0`\Q9
M6"E@``HY"F6``R90`9CP!L@`!4MB"3B``&5)"CD``S?B!=@WGJSP`5!@>)@@
M`:B0`1QJ"0MP_P"^9Z(]L"YQL`-0<'2NH$4-D)Z,()M^D"<@H0,5,!4"0`)%
M`&"NL`8T8`/:=0E:.0-@Q0\+@`'6D`#S0*29@`$94`2X!PEAP"S\N0\LD!UA
M\)@>0#.L\$)^T`3%]@AB@"LD0%@@<0,DP`!S<!5`D*.D```Y``4U>@EN0!(F
MT``MH18Y`!%14%&D(`09<`'.:`D`4%T$-1$?`%12(*FCX`7E)P"LZ0AT@`H!
MX!)?8`%%4`3-Z0H)$`4VD*"6X`4@4#NT"A()8*"WD$36EPE?8!,(`*H^T0I>
MX),L8)21$*R[L0?%&@QJ`'T=H`G,NGW/"@QS4`5.<*F6P*PS$#77ZK0*)0!U
MRAH)81`!03!<X>H*8H`!*?!CD\5<Z^H*_5<$4SBO+4$!)-``(X>O%'$&JZ>N
M_OH1[90!$#JP/'2DC(BP"!$_.S",#/L.8``$Z!6Q'_$`56``T&2Q/.2DX,JQ
M[^`%0V`"TPJR!U$&4W`!<&JRY#`'.R`%\\BRY)!-.`"F,AL,P1(#-[L/#*"R
K.QNR/9`$@_FSRR`&4Q"B1(L-=I`$49>TS6`',9!^3LL,ZI"E4^NO@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>y85641dfx8564120.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y85641dfx8564120.gif
M1TE&.#EAJP$6`>8``./AWL7!O&QF8]31S.;DX='.RXB!?')L:?S\_,G%PL&]
MN&)<6L[+R?;V]/'P[E%+2M[;V>WLZ8)\>9>2C9N6DDE$0NKHYHJ%@;VYM-C6
MTJ*=FD$[.@@&!WQU<;*NJN#>V[JVLNCFX];3T9.-BCHT,[NZN*JEHL;#P*&;
ME;6PK-S:U6=@7<W*QJJDG/7T\EM54_[^_KJUK:ZII:6@FW=P;?KZ^9&+A3$L
M+'UX=;&KI?+Q[_CX]RDD)*ZKJ9Z8DA41$O#N[.SKZ(2"@C\\.QT9&=K8U2XI
M*8Z(A"$='::BH/3S\28A(OKZ^$9`/E=03A@4%3<Q,(Z*B5514LK(Q\W)PK:S
ML$Y*29Z:F/GX]W=T<>[MZT5!0%Y85??W]OGY^$Y'1I:3DMK7TGYZ>.OIYU]:
M6`\,#=[<UC4O+CTX-_O[^AL7%R0?'RLG)LK'PB0@'Q(.#RTG)]S:TXZ'@,_,
MQU-.3?S\^_[^_?W]_?W^_O/S\:ZGG_W^_9./CHF'AV1?7____R'Y!```````
M+`````"K`18!``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+VI,#LJ$,-:OL;'R,G*H5T:
M3B_/$L7+U-76U\H-(TAN!P);/UEYV.3EYN>J06L<+T$`(&A/'^CT]?;WD19O
M;QZ"0#0_5.`;2+`@O1!ED`QRT"&@P8<0(QK3]R.`((8.)6K<R-'5&"(<%NR(
M`.+&CWD=4ZI<Z:E!E"=N!"QH\N:`#I8X<^I\!$-)%#0;@AX@L+.HT:-_8.BH
M`J*I0*10HZJ40:9(@QD/B$K=RK7@!1YM'.#(V+6L67,&P&)\>K:M6V5I_\,V
M9/NVKMU<<=?>W<MW5MZY?0,+5O67[.##B#T5IINXL6-*BQ]+GOPH,N7+F`M9
MSLR9\N;.H!M_#DU:\.C2J.^>3LVZ[>K6L+F^CDT;Z>S:N'7>SLU;Y>[>P#7^
M#D[<X/#BR.\=3\[\G`$D,P(L,-R\.CX)9=;`^?$C#`SKX.G=@<"G0L(-^[+(
M:'`N31`@W\,7#Y%``(<R"VP,$("&@Q$-$'B!#1`%!&``'PR,(1]P-8`@P1=E
MD.!$$'?\L4,*0_"PA``FB&`-#`'0\04)&SS`1Q`+YA9`$F<\`8<5,9A!"!8!
M'#$$$7`<4`0,\26CA!AEG.'#!4O<H$$7*<)V1_\>)\"1D!0RW&2('5ZHX,<3
M:M"1A`7+%($$&QK\$<0$2S2A59*HJ0""&&@00<(,XRP"`05<_*"&`0DHB(P(
M3SPP"`0K#($2FJ$%T<,*&SS1Q`@I"-@(`@S00`(/5DA0@@O'\.FG((`*2FA=
M=5285!T($`(#`G60*FHA>4P`11E-")""#CTVX@4`,Y!AA!H58.!H+R+\@`8+
M%L+C*2AWI)KJ'3#<@8`=@X1:ZZ?(U!`%!G\@H((05Z#X1PU3]'&!$'U4\6L-
M#O0@`1ME?*%`!&E0<NL$-[0;!0LNE+I+$43\P$4!)5BAA@#3M`3"!>,*H4$1
M)_"1P45)**`$M<LT\(/_`']XD0,'4`P@"`,/E$$$#VK<($,>,!`@@P!+J$&"
M``/\6@D0,BP`QQ,;B"'"M+8`<0`/1#1!P@\5@``*#`/42\026!J0A1I)"&+&
M!AV$0'$V%V>\,10%_&&!`6_P0`$(?I0Q5``KL,$#'1,D,/$F8V"P@AH_O'"%
M!0-0<(0-%X@@,RP6I"#!`R]($("WGEB`0QD5S+"F&@O,'?4?*FQ`@]57(V/Q
M"L"TP''7;=#!@PU`_%%"%E7\2,03%X3%<R8%1+$%$1N`<``<2RRQQ@L>RA+!
M$3,0D,`<`(A20(L&-``#`R20L<(/='30@0!K7)ZYYD&*T0$=G_^!P09?%/^'
M_PMC[/!'%7V`$<+KFM211P!1@$%O&2_T\<`3+\CBP`5K^/$'%EIX&R@2\`0T
MM$$0'_C"#<Y0AC<\@3L<L-[UC-&`,J"!#U'P0_>^MX7>W2$"-T%`#=+`/D[<
MP3T"(,(+YG"'$]S@#;(@0!-NT(,_3$$,DQO@$TA@D3\DD`1H>`,7^M"'+"Q!
M@A/LA<4PIC&.Q6`$.+`"$0X@B!/X00)G.H4*T/`%%HBJ`C",!0'`)R`-/&$!
MHH``%\H@``(@(`5+B!S4!%$Y)"9Q%TO4&@<4M80O4&\)?O!#$]2``\1I$0UD
M8`L8!3&"#]2!%5V0@1J^X(4Q"*`,_@M%`Y+``3?0P?\/&UC"",3PA,G5$7-W
MW$47U$"#;Z6``VRP#PDF,!;N0$\$\4K%%J'#GC_0Y`\M6((3BL`*!V`G"7<H
M`AJ:H`!1P,`"(]A`&7Y`!`,`H`]+R`$"FR`&+J5R%PC0P!3^<`<`4&`&(^"8
M"8J@`0I0X`H)6!4J"+`%#@@@``.(`A)X\(<.<.`'*V"%!9SP@R+<80H\\$.<
M0@$#(&#`G3.81P%,@!(EI(`!O?SF,0H`!77*H@950(,:UK"$']P@"1'HZ![G
MH(HNQ&"'.AC#<Z*@KU"D(0$&D(-.#3`KC6+#`BB00PL&!8L:!&`"-K#!$4Z@
M!324@0-0-8+'4.$"$[SA"'?_(``-T-"U433``$\(:U@%``&?7L-]0%!"+F7A
M!1TXP`%`J(%]H$I7'J"2%'9@0$GUX`(/J*$)XA.%"W!`5ZA6Q:R/(4-AZ:I-
M4]PA`&5XP!AT,`,D4`!)HQCL8@_;&A9<80)@\,&.FB."&RS6/[XJ11`,4(:`
MZD`#/$A!*31+US?@(`*M*4`3RL!;6)V@.3!0`0E.RX,9E*(`:VCM'Q1P@]C.
MEK!T14,*Y$D:$;S`GFV8PPO>4(%F,B=E<W##8I<0`U(P0`T\@(\)?N"'OQTM
M`4V@:Q.,QAH65.`)?!@A`!18P^:<$`1+*.P3)$"**I@4&!=X0BM-D0$GR)>^
MJ9E"_P4$(+X:2(&&X'&!`NB@!KJJ00*8"L4&JOF',!#!"+(MQ'A0(`$<2$`"
M"M`"'ZIP$S,8(&:0",-UH;J%$K1&PD,1A(4Q;!T8=$$%+7@#79%@`&;<P`@A
MN`,5?O`%*1$""$1"PHB"5H4*'&`>'CBIE1NA8ZB600QW+8V$?Q`%0>2!#D26
MSQP*RX903(`#9[##&%Y`OT,40;$'"($&ZD4!$BQ`("U`@@\<D.,=EQ(V&;BN
M`*A0`"<PKH<+,@$1GFHV:'D"!V#YPQB_@-E"_+D"9?T#'F`0!A)\(48X>,*B
M&PW51\-F`!LH;!,20*@@2*#6!W"O)6#0`"CP@`5I.,$DA?_]YR\0M=6+G?4C
MM+"X/>:0-6EH`PK<*0</&')!'QP!#[@C``3PZ-SH3K>ZUUT#!400"`P)20W\
M3`9G"R("(F`!"4@@AQE,QP=!@,`C&W$'#W1T#2EN31XR`(`N=$$"&^@'H6#P
M/CZCX0,Z@$`!-L[QCGO\XQZG``=&D($@'.`-('B="A:P`19XP0%@(`$*FB<"
M+&B`""A0@!6FD`?J(J(*PWU`Z6#C`20(01!D^$&8*":"YUDA"D;HK=2G3O6J
M2YT''K@?40FA5?H)#@YKF(&A$6W9^')`#QE5!-#+0`;:2/+H?TCZTBGV@15`
M50TE^H+>]\[WOON][S2!ZAG&7`C_%5P2JD28@0J&L(*RZL$-&J`!!X@P@+6J
MG01L=[L:X"[WJV&A`%S@P!HD@(5-K+:!<A@X(CZ`@A'8(`<%F,,(]%"`,`3`
M!F'XP"`+8/E$8&"W;8_-VY&N=(J!M`*PU$!--0$$'S!-`>9CQ`R,,+(E$$$-
M3S"`%A;PA"6`H-2*J($/>$!@X6^>^'-'4PT8$-\E\`$42J"`&TB`@;0C8@0=
M7BP-QB"&"E"@](Q0!SI``6006*TQ?'%7?(22!M;%`4B``ZKG"7D@!T\`!:FE
M"/BW6#^``@+$"$8F`BWP`F]B?ZB!@)V')BX``KEV`V`@;)S0`#;`!FQP+\M7
M"!E86&A`_TR/$`$^0`)N@`1EL`0&<`(AEAHFJ(`IT@`Q$%]$<`6]!PH60`%&
M\`-.4`(U.`@3`!*%94>)``,N4`)BP`-OX`1'L``F40%1<`)7V!E'F'[R407U
MA`3E9PI:0`')U00E,&^&H`##55LZN`@,>`%!%$LE<`<Z8`)?D%Q?<`)`\(29
MT89)(@);(#)9X&FG$`0XL&F+&(&#L`!TMG6&D`8A$`#V@01<0`'+%P990#)T
M@`)M4#!L>'X)Z(;5D6U?P`%"Z(*C0`!B<(=>9`B>2%<TT(&A.`.28D'2<`@?
M8`("P`9+L`$VD&:8`8GA`5*Y9@1.V`HA0`%GP`%T<`+4%8Q09?\"KP,#:;`#
M47!]=-`W0W<(=P`$(/``;X`$?@`"#E!"C4&-UM$`&-`?4%.$K!`$%%`O5A``
M>B@(XO@%!<`SMZ(!8D!-*W20BZ``?0`.&Y`%&$``$BD9^E@=\<@!=R(+(7`$
MFT8');!6XG@!"S4(1>`!-``'1``%%X!ICI`&52``4/`#39`%!>!S^2B+)U@=
M)V`>1"`$CL@*!&!$C,,"^A*,B0=^)>8'4/`$5F``$C<)%N`!?K!I"Y`$08"/
M@=&1R:$`TJ0&(["1L/`!7U$&5@".?Q","AD?"/`/5K!'`I`!*TD):ED!:H`$
M"T`!WN088ED<,G`&;W`#%`"6`>D#'87_AS40C`<@/@V``W0P30<P`WJ2"6F@
M`F(G,AU``)PX&(,9'`E``F_0`29`>+1@`6``A%:@``L0A#/@`CN0`!>`!-[8
M2$=Y"57P`&O``UR0!`6@BW<QFKV!`4Y@6U&V"Q8@`<EE!:]"`Q!P`A=0`3')
M!7.PFY@``PE``2M0!C?P`"/`&'UAG$@)!BSU!P4`!EF$$PE`!P-&`):H"Q`P
M`0^P!--4!0%`!FN`!"M@`ETU"@LG`;')`P)`*Z()E$@8"P$@2H)@`SS`:Y#0
M!0`0!KT4!!^PD2$0!F&`6\D0`2TP-%'@!8HI"^9(`!>P:23`!MG'`@Y@;J>P
M`UI@`YLV!"]`_YQM89ZKH`!N8`."(`=+\%N0T`8",`0,4"$7$#Z#H`48\`)#
MP'BJJ0L`$`,O8`0#9H#&``!U608\@`,?P".K8`$FL`#X.0+F(`)]`PLR0`0X
MT`,S\`)/0(NJ$`)1\`$(H`!$4`$(TP1!&@DQD&N%^)8_\#!_D`8K<`8;,!,_
ML``D>`L.<`5<\"H<\`49L(:]X(F(Z4:NX`5%@`(<$%#D8`!6X`9.T)ZJL*9G
M0`)G4%)RB@I*\#,8T&X/M`9K\`-]"@E_R@&!.AV$J@,_8`0>,``8``5O`(JV
M4`<78!*QTEJF:@R>N`%"^@IW,`"?>@U=(`=3R!UEP`9?8`&-.@H(X/\"*/`$
M'/`&/]!`?-"(JN`%$;``AED&,=!NIF@")L`%M_H(N9H$9A`"4C"H]\8.$Y,&
M+#";N2"`*+`!Y^HN?+("S>H+SQJMKC"MU5H-`9!@_L$`)<`R$6(`H2D*!&`"
M9$`$M#,!#-`!2$`$5H`"6E"BFC``1X!Y:^`$'D`K/'H$@D`D$-L(N3HRX_8&
MA!H!GQIBS:(+*?`%:I"G/?`!6```3\"PU/"PL2"QH*H,5$`#N[($!Y``YA@"
M)_``HK<"56`**K`"(KL!,Y`!C&8!/O`%)QN9I9``8D`":K`A"@``T<>C/OH'
M0)JSC)"K5B``!\`&/ONO*P"0N)`!8O`J2##_`A"`64SKM,L`M;`@M<OP`4.`
M?1V0`@!PD%Y0`&)@I5"0!0<4"GG@`5N@!F5`!PS@`*("`UK``#(P8ELP`8'Y
M"6;P`D3P!@+@`1"P`SV"MS]ZKXZ0KQ\``%+P!!ZP`F0``@YX`EY0`SE@!4"0
M`"_@!]*X"D$`!EN`!`#E`>LS``?@`8_;L)?*`=`:M=0ZM;[0!4&0!4Y5!E'0
M<()P!RY``&-0!_3!!S^`/VT`E9F``"!0`5%G!1Y0J:'H`BPP!$&X!3V`EI?0
M`"$@B$]@6RJ@/(6@!26`$A]0`NTXO(!:(643#V4P`T]U!F!`!VS``1:0`_OP
M``#PK:5P*]C$=E7P_P$-X`(#\`(_P`<`H`:0JPR2*ZWI>PQID$)!2`,LH`0]
MH@5'\`-K@`'-X@!'4%)$<SCM`P`H`!)LT`(`0$*)<`<?X`'#]0044'.9X`7[
MD5Q$D`4!``3S20AWX&G-PK*#P`)F.`5(RDP"\`-5D`-&<`,XP@8^4`<$8`#X
M>4948+BDT`5A(`&;5@$M8`%UH`540`?G*@`J,+Y/:[Y\NPJ4ZPM8\0,<8`41
M8,&$L`-50*YW,@=&-@`3L%L#UL&4$`(=@'E((``YH)V$4`<*T`&;%DN]4PDG
M<`#B=08'<`(-X).;D`9YH`4U\!T03`,2P`,5,,E:@`(?X,Q_8`==\`$2P/^$
M.$#'F/!&1H!G-'`":9`&>O``N%D!-@`!Y=2TY,L+01RQ0\P+R+EI9T!RB-!0
M,4!8+G(`7<#,5'!=:H`&8"#.A?`!7+`/=(`!8P##AR"C("``J(L&EJ``$+(&
MHFL!.`H*(8`$)84Q@J`$-?B.!=`?3_`%84L*[]F?*]`&05!Z(\`N,ED$.A`O
MFARYG(R^$WL+=U`#(2`#3J4&,I`!.F"IV^P%TQN;``4!C1@"/K!;.@D".Z#,
MA@`,`'`$:N!`+V`!SSP)[)J)(B,`1>`">\`(=I`&0$`%3C#!EM6("KW,;1``
M`3#/@I`&$&`"<.!`7Q``7H#5E$!Q<T`#<-T!03#_$EGW`V^`!B;0<X.PTY)P
M!]T\``00V$&M+VE0`X*-"?7<"I]L"^4$`E9@?7!``2:MF.:8`"N`!'AG`SKP
M<AEP`7UM!1I0P9V-+B9`?5J6`*EF"2'``'Z`!$_`!H`I(%W@`@)R*@U0!UL+
MM]17/4SU"N;H!8'M@4M2``U!93(``)W-$S7P.VQ`!&MP`%-``%U`I&Y`!#<P
M`B+`:(0@V9!0!P!@`@]@!"N0`R'P`1B0:G.``;7K"9_-"J%="Y;T5%^@`=_V
M"!\@`$##!2EVIU]`KB1@`YF)"`IP`$_U!&;0L99@`7#P3Q"NMP=07G>@`A(P
M`'5P`KC+`:/SA\L`!$E@_QX1A*65@`4*0`9/!5B"0``^T(TU08R1+<^3D`&A
MIP9.$%\2X,M]\!WP>96?,.">?,^T<`=I\50&<.&3``,FP`/_M``2&@$!`"$<
M<`$++@@-,$CW,0/IZ0D?D`.;Q@5_0#<!50,>P`8H\'`<``='0*C8,`8I8&FB
ME)>1``,B$`]XU@("<17LP@X*<+V"(-^/8`(''0`1T`?ML@!(T.1_\.2B(.6J
M4."Q`$=050$GX.&14`-`P`=*Y@1S@`?W]IWW00&L.PAIT``A_@,XH,B>X.-R
MWF%$X`,UD`)XO@-"<`,H0`\J@'R3)P.4L'[E_`,V@"3T&P5*1@)S$'V)(.F*
MP/\`/+`&5Z!I^?,'.@``.B`!'Z8%76`%/P#E`M[3DTOEFSJ*B:N3'B#7F=`L
M>3`#:.`&1$-1:>``"<`%8D@$%$```.`!W'?0(V`!<SW973`.'28R`1`#>.Z%
M0>"_V(``6N`!$\X&.'`"Z$UP`-`"]X,$%3`!7:`$!7`$N\(&"X`!7JP(W)[5
M77`%7LXZ2:!"@M`L=H#N;R"RT^3NG0#JJ2#JJY`&!8`#:/`#/$`&"@"`G&!D
M<R`'39]]19`'::`%&C`T<$`#1MP$-/#"W]T)854ON(SG!.$%()`VPD(#;:#+
M>:`"&MXN%S`&+J`%\1B$"]`"<=4(-;_+(:``Y7P?`D#_`4@P[C#@`!'@R&BP
M`BS3[DK0<`^_"$:/"DBO"@UNET1("F&PQT^PSTK[!P-P`2G\3VA@RJKP`R2`
M'4]P!&J_"BX``2(@`IM;"CM`!7,SJ0H`!#!:")LI!]V(,UUP!TK``@<`A#QP
M!*A^"($O9"+@FX5E:&OP`"CS-320_)P.GS+@*E6@\9=P^:>0^:DP!Q""`_!=
M"@V@!\-5!E#``H\T$J_B`5J>"L("7_<1^ZG@!3(`"$ME95L#"'^(B8J+C(V.
MB%@"3X,V&0TPB7=I<T2#2&%!=5H^;QP_=`1=CXX`3RL$CVDB%1RUMAQO;T0^
M!!(_#RM(?9AT1#9L'$@#J\R/_PL<&R?-T]2K=P,<*]7;W'-?66.(#3I>W.:)
M(T9E&PQUB!ME4^?SCC]H%A!K'&PH]/1I/8RH@;/DAY-E_KB-64&$0YD+!&K8
M43)@QH\R;G+`J`,D!@Z'/&"=:_7*$1`-7V[=,K*`Q,4G:!080!(%TPLB'CJ4
M0:,B8:-GT7P*O99-:$)O62(@,M&AC=%F=C`(.#,#R+MX3^>1X*+%P04C%7)D
MI09``!(9:4+@*"/$P=AF5*3P(.(DQ10))(B<.8"AP0X,!]0LV2!!!#V2(A4A
M`'!`I6,I069D`5&NS1%I?WI,P-#!5>*G0#&_Y494V^AM2)7^6?#CRFE'#JI`
M*/<'GO^\U],PM*GQQT4*$"%P-[HSAPY/1"5XD%`@O)&(&2^0++E1YLD%##6P
M9$C!@P.4"502(E8<08$`Q[>6H,G2H)D'ZE`RO`W=?%KI^LQ2(V+M&G\CV_X%
MR(T7&A!QW!\$5/#$#`(B(HH!/W"PA!^(!`'"`V6\8<0,JHCGF2(A3%`*>J:0
MP`<`!-S13`)-&.%!>V/1UR`C]\VHB'ZKM6;C5;?MZ*,B$*QPH`Q$+.&!CU"\
M,04>?\S!Q1-T&?`')CZ-AT@(`HQX"Y1-K'!!%U1.`T,::829E8P_UN@CCOSY
M"."/%F`@)P8`S%B6$29\D`$.3_C1TXY)WJ83'1?HD-5X6I3_T$&$MKQQ!@D=
M7,#"CS]!(YJ/:N[(IHX[ONDC""1`<084/LP8Q`5(D"#``FZPX8&9#0:*B`92
M%)#&6(AY80`)9=ARPQ<K>``"C)0R@B:FV)BVYC>JM=DI5C\J0(<55M"A@8T*
M0.%0KP+4B:22B*1!P*VX/D'&!U7TZI`:UGX0PB'%.G+LCIG:N&E_-GJZHPL0
M]`N*C6TT<<,+%1"!@Z'?]GA:*V=T8`013U1`AI0JQKO*O#:F$4-1/][K)K0^
M!O#""U*\<&F``>/@@`(5'/RCK+BU4@L:&E#P`;D6KP*`%?M<``'.,W9Q`BU-
M**#$LDGMQVF^(._8A@`KK$##!P`W_Z$RRRXGC-L=,C31JQ,Y4T/`!6N0@`0/
M`ER!<(,`1/%`+3]L(0088%#@0H,>/ZNPC7ED((((WLZ8\LHMKVTCS&]YT4`-
M>G2-41(=ANW(V$:0,(,$&PA&P1AUP(I;`V`<0,0;7*Q@UA-JJ$&$$%%$84((
M+NC@@AVXY<WTWC,.(,3N8#AM->%9`PKN6VE@H``0+MQ1118WK''%)9(S0CD)
M)H!9@A5/\$!#%7\*UP``?438Q`$6@!D%%XS:LL0!8N#`QP`0%$&`.V/9/J.^
M-H(*!10O^'YUX2\;WE-0%(0CI,`MB9#!&I!P!"UX+F<6R`(/N`""/"0B``;(
MW`T>8"O<M/]A!&0H`QPJ$`#:3(DQU$'/$[;P@"\(P`0IR,$<B'449BD-7_=K
MFHTBD(`>RJ=J_PO>X00HE`]DH580,-P?[I""A^$@"-%#!``,H`8G%(`17B@`
M!0Z`A`T<(`.\&4L`:(`&(AAA,D4(8R:`(),FD*@69>`!''C0!`\`C1[V:Q#^
M9@2#&N@@#S04T."PIL18$?$?,S``"#0@@0\\$`8RX`$/)!#%$!R!#4T8ECBZ
M4+$_.``"1RC#*20``!,FY!I.>,(3!*`!`L"K$76P@`?>]L9;7&`'0LFC@/;8
MH#QXP`]^Z(#_@%=(`2'N''<(`0%$T`0DF*`!0+CC(DQ@!"3P@4G_.0/`):%0
M!1BEX0(^6X06HI!*-;Q@!`_<AA9$<`'L$8&4IGR$"U@@AC.HBT102$$:7*""
MOT7D'+H,$"\%!`0*W(!_PR1D`.4Q!P7PI@8!<$HBO#``$&``!"S`)2*Z8`(#
M>$``7\``-?AP`QYHX)64.M4-2."#NR&B!GX0@&$8004^\(H',SC9-O(P@06<
M;0%@L$`Z32*#J:3O%F4X0`AJ8`(!D($,6?``Y[IAPQSA4(\ZG!$"(B""(@2N
M08,$H-8JP(9P!,$(&T@$%F)P!B2X80U0N((#DF``"XCA!P<HP@<L.(T&G.`&
M/Q!`O`#`)SH$@(8P^$`J'E&`(YSA"6PX_T`5N,'4%ZB!`PM0P!@ZR0T'B$`(
MEU7)&63@!2$LX0Q9$,`/SL+7:@34/P,-D`Y,8`4_:%1POU.HUN!0AN"$H`Q(
M0`03J`"%,AB`#[0X``!H@(0DR*`"$KBMF+#`'>L<S4<A0)45^K*(&N!``MUC
M1`U"4`4P_&"%$IU&#\A@A#=48`0%B-P\[@"!)&SAGC^HZPZLP`,P?$`%*_@!
M"1A`U:19]6.X:Y`6CO"&&TA7D+D5J_#D800.!$`$)P"N.#Q0!@%$(`\,,`$#
M0D`##I!R#N&MAA<40!`)<%9``+B`&\X0`/DBP@M6>,$5']''!I@`8B30L54<
M<8>Y;N`'/!`#`_]T\.+Y=H$%%+!"*8PPV2YL`0V848$3WE""`C=K:<WQ0@`&
M$+G8^@<+(M!`#U`*X2`6,T"RN@$'AK"%(4A('#+X`046T040T`$,@32'!Y8`
MAQ'0+T`N"$`'>'`#%`1ZB2!0@!:F40,-"$`=6RA4(PA0A0[<``D"D,%GGI*'
M$TB@"4>`A94WD(!$'.`'749-566`@TG5)P8"N$$'$F-F_P`!!0>0IG_"*L09
MR:K"IEL!!]:`9STSH@L02%%"8)"$,ZCA``)R@0P*`H4<N-0G:5'`,XCP@`F\
M$@@3J,`:GO"%"7R@R5EQ0`8F_8=5M_H/82`!!V+MVB_0(#B]`0(6ZN/_`32\
M80T@&#@BT)#5&7W@`6MX-'Z(_6;_R`H.'!!!$#*@X1UH^P<3D*(`A/#@A/09
M#J[PCQ(\H(\***#DB3@""5:`$&H@@``F\!H1OI`"&+A@`IUX0!**D+SZI*$+
M1]_"&R1@@3_,``G[IJH:Q&"&BF=%!W.0`A)^X(8)W*T.$;C`)!+<H"X4@0'P
MGGB$BVU(>?#6MV6X@1Z,T`0#Q/'"-'C#"B1.CRXHP`C6J8\7K@!U-"0@GHO(
M@NHNT/1JP*`+*D@"&\I0`1IL`&(+2$`#TCX6)11@`4:@`0`\`/@#;*$3!@!X
M-2#0`2*LH0)B4($:1Y-=$JC!"`8(`!3_@('H_[P>`L5J0!MF(&RUNWFA?WC[
M'WYKA`1P@`@7".6CU@"'*-A8*'TVP@WX<.C1>`$$%;Y!%6`.I`2<``+D9T8>
M>F"V3I3A!548LG#F*0$T"$8"(?@`&=#PA0V<`0<?T'W3T`4`D`2Y1@1TH%-&
MX0))P`5+P`%DH``6<"MM4']5Y`%D5BP?L`(+P'G-07'(9P,T<#1*$"DN\#`V
M0``V(``",!DAX(%]5P5P$%D@<!I>@`':<@,OT@Q5@`,'X`'RMPT^-P4C(`!N
MA`05<``X0`,>@$!O40(TT`1$`"E54$I84`0#4`!9&`+%UPQ8H`4:<`8<\`1.
M$`!C404D\`0<4`$^$/^`?Q`!##$(!A`10Y5M5&`&/@*"6N,"#D`[=J`#2J`'
M#H$&=P!-0.``72@43#5Y.O@678`!:D@"&(!XC;`";]!AP#=?+@`$(I`#-,`#
M@U`&`U%2(Q`!:5`#-5"'S3``9#`)<-`!(H"(IX$%$2`Z@[`"C></".``&M`=
M&V`"0)"*.A`'"S`(<F`)JB@@,'`'R>A!:V=U]7%,BC`!.S%J818`&$<J0`"#
MU=``,M`K3V`(U.``(1`".L!FW.`!-$`%=:`$(2`$#8%4N7")(Y`!89`!.]",
M?]``!7``@[`Z%@`]KP$#,!`$!>`$@T`#&$!OYZ`%*/`%Y[4!.=`>7M`&*R#_
M""X'!.A(*?/$D+AU?%K3"/(&`-SHB%7@!J;0!"C0`BS9DB[YDC#YDB,`=3B1
MB(LP`'HP`S/D#PE``3U!D%K``@L0CXYQ7JJ$`SG`DE_%9P-``T3P`T2P`"S@
M0/KH$]<P`6F(!%:@!SI0E3XW`*^FE2CP`0W@!4`@>6^`!C30!C:Y(Q"P`&;H
M.U/C`58#C<TAC<62!F4!1ZG3EW[YEX`9F).P!BF@<-0@.FHP-?Z@!&,@7W4P
M!IUF3V_T!C_P`VJP`5`C-1D0!)P9`"MP!C\`!3@0`V.PD<)1`UH0`#9@!#\`
M!R80!&W91P!@`U#PE`*0`8BH!2G`!:"(!C(0`NGW_R,PH`,!8`$E>1HLL@1;
MD(8J\R,DP&6SYR,PL(L)P`50QP82,`,^L)W<V9W>^9W?B0(><%W4``/#AP()
MT%KGT`8HD&+[&`(8D`0/H(:U5!V5200;4`'Z"05/L`0T$``AP'?^@0'ZM@\S
MM0II$`"E0`@A0#\00`O/9P(U<)PV<@<Z``#NLB/9<@L"8(T"0@<:0F#%<@<`
M\`)PQ`%-<*!#<:$[%0(6$`$$P&3TD`(=,`>KX`5CL&6U1"*N4`,"2"D^H&]0
M@`*JMPA>H`(3$"$D$)=_8`$IX`2X(`3J&45_``$I\7PQX*$QXP,;\'PD<`.E
ML``8D(LSP@5QEXH_\G,.L?\$3D`'**JB/N$",K$-(Q!:''`!4WH:WJ`E.ZH&
M%;![T7,'7%`*:&`#U\<"<M9A<:D#+>`U:]@"X4"EBM"EE&<*&\`'T7D:04";
MIO`%)00`&E!A92`&0=@<([`"(IH&*_`$&S`&5=EY*4`'O?(`!'`"M9"B'6,`
M-$`#!U!"\Q`!%,`%%)"ICC`#`59+B<D<DKI\(M,)!W`"6H`S5:"6Z>D%>5``
M?/(#7R`#`(`%%&HC=:`"7K,&.!`"-E`0JR0"$6`'KRHFCQD`:Z$&7*```)"*
M=[`#+,`%;D`$KND`"-"NCO<!(M``5!`#`#><OG`&;6"8S3&=:9``#^,&).`!
M*C#_`%VZ!$?PHPGA`!/0`M60!@W@`B&+IB-!`S=P`-?G"%C`1AB`!MVQ)4/0
M`BY`K&&C"6,PE+DP`BQ`+GF@`M&4!A!`36_`;@K@!=\J#BZ0M`"+3$5`"T0P
M@G;@`KVG!F4`!4>@`GF@L><PG7DP`&*G"P)@!FG`68\I`_>%!!J0`1J9%8^'
M!35P`!L`1D:K"'GP!65P!BQ`LV-1B"IP`H+``RA``%[@&VH(!2;P%D`@!Z4R
M#0BP.)@`LEK;#&D1!B'@E36@EP'``Y/@$#2P6,O*"&$@A6.H>_1S!T`P`&@P
MACPW#U@P!C,P`1-``5J:%4!+J6)`GH@P"T@0=S90`#H0_[G5H!TCP%MT$1ZK
MH`!.T`E0<`%A`+S<T``YD`(A<`!<L)2*4'@)L+0[!0$M``\_4`'],"4!4*`D
M(`-O80<-L%G30``RP`+N,``:X$CGD`<*,`$*8)K3X`--L`$T\+G,X`&=L`8"
M$`8-T`4?<&K/UP'8Q`UVL#+%J"YD$`0"ZA-%`*68Y0@ZD`/SN0X3H`(3S`Q*
M,`>TH'?F*R8S0`>7]0`0L'G^D`8ZH`5FL`5(X`,8$`:KL!8[`:BC@043@"%E
M4'>*P`04P"CEZX@QL`"SJP@Y0`)BT!X2H`9)L+0J8*8O\,'^ZQ-M(`<7@00K
M8`!K4!U<P`)YV@S3.0!?,#I/D/\"0UD&:_!%5GP.=OL&@K4*$8`!EO@$<"`!
M7?FJA5@`UED&1(!ME)4%NXL$4^.\PU$'=W`"7&`$42`'7U`%R4A%'$`"F<BV
M-5``<C`(<*``.@P#(6#!E5S"\68`3T`#W+C$.*`$,/#$47P._.@!!7"T5VP.
M8Q(!'4"UHF0%'Y"RS``##2`"($`=:^`!74F`+V!G2#`!$IP5"#`%2$`$4D+&
M::``3_($$C!BE$@C>5`"-E`=0R``#A"<C[`#0>`'$7(`*:`%`CD-%J``);!>
MB>D%78#(B'`,^\``VLL(:9`'4V`"@P`%9/!#BM`%,V`+94`']Y8544L``/!M
MC[#$+^#_`0I`!C_PRN9P!TH0`:Q<R_B!`\O9+?,``#WP!4^@E2&G",DT!%!R
M`1Y0KT*1!B>P!DN0!=R0`&3T!%`@`0H@N*NP`Y'7*U!P`%2SL0*P`;MK`^.I
MB@T0;0E`!S_`!R60!0RR#>C6$'`@`GI;#7;`GBAG!%)`!8@'`Q9`!K:@!B-P
M&KXQ`I/%#$NL"TA0"AC-#4"0`D?P.AZ-'V%0@^<`!$4@`;O[`'65"%V0`6#T
M!P.P`FR@!DAP``.PSXA@!R<`>#2@P]1P!PFP`&`*!1UP`O[:"!^@`,%`!#P@
M4D_1!F*@+420`K/A"%TP!B(@`!V@`!J@!@)0U.;0`&*@AE8@_Z+T,`8#X#4&
MT0(,JPC?=PMH?1H$@-1SO`I+O!X95`9SO0T08!8;X+%Y'44N4`67%IH"(%2*
M4``E=0'FVP!S0`'(L`%7,`4$B4Q5P-A'X(3FH`,#@`,%`VI70))4D@%@4$9+
M\`4Y4'-9P0+\]01-\`$W2#=@<`5`$`(&<`"BS0%6$``CH`%V^0A8,`.31P(I
M,-(F\`)+H`9-8`-%R@@`4*"UD-RC$01B(`/OYM9,[,10#+"/%P8!$``$G=T6
MTP`A$*J4]ZQ*\&)F<`#%U5PZ`+(Y,)0K%+_FD`8F0`(\,`&^O`T&?`1;H$I^
MD`1*<*W*UB<:8`'VO+7:!K<9(`-G,/^TE2D&;8`&2&``,W`#2S`!?N$3/0"*
M<"`#K^H"8<!<9?`%%_`!),L(!7D!]\0!*OX6),H'4@WC3?P'K@RP-:``?=`'
M4=#6.EXL=0``,I#:K%H"?#=;7%`D1Z``5*,%$B!E;5X`EGVC380$(_#&U*``
M#["[/"`#?!`=;B``8WP:&D!<',`%`N`'27($0+<$*#`"J+;-YG`!W7$#(%"2
M_*(!H_T%;<#4/4"4M;`$UW(:&<"O%\`,&&`%1Z`*$P`%KY+;1X`$9V/3ETXI
M,"`")BNQO0K1CJ`$%NA%-GP'&;``/+`$=#`!D<H,3GX&2R!,;Q$`1T`'2``%
M/V`$_PX$D/W_O!N#!,&A!"U0!DN0`2M0!M5+!62:$!%@`]U!8W5X#3X@`*WR
M!6)0`%N-"!G@IBJQ!3:\,&1P!+;V"`"04[<R`#Z@`@";!FT0!2,P`4S:[C;R
M`2:P`+J@D*I!QBYP`B]PB5R@`=%$`!3P`&S`!ATP!<$)`SG``T@@`4GL#S60
M`09`+3.0X_C1`!LC`+3S!T7P!!$GZ]_^%EHP`0_X!<HJZ#`@,FZU`3Y0`+B[
M"C)`G[>P`+BQ`WXS`]8[&FG``G5S!0IH]/41`B-PQFK@!WAM#@0`!AO_`V3`
M!S,[!AYP7ZI2`L*6!AJP!$9``?(]&@8\!FTY&FQO7(D0]\R6!D`P__A/X8W%
M!073#<P)<`%)`@<7``"SOU%VYAB(_QK36P%JT)S>`R%0V;^4+UL#,`*"\`51
MD`'M?0YIH`)"0`ML``8JL`/=?``W\`1T(`,6@%)>P'Y+0`$>^1HC$`;)/Q98
MH*`;``@1?S4!;VY_B(F*BXR-CG\N,SQE:`IWB1]74DL\*TD?CXXN/$ME'*>G
M"Z&KK'\?4&QD)CJMM8^$?7U1(+:]OK_`P8M=+%$O1C<K)37"BE@*=#=K`E<%
M?R$R`CQG.#T$B#4F:&P7><V]'07,Y\!W!!4<-C(S"V4K[+4N43=E7P%W0!0<
M8%.F@@90O](DN2*@0@4B'-38P/=(B0P-)O^2,+A$L1&,,?,TR+#6\=<'#TE2
MJG"19`"6/P22F``"HR0P!`%>($'B!(P(%QVQ!`#S``D<`0P0%9`P!`F)$0#N
M]""Q!,<WFX]$.."(E967%D^V&?E!ATI71P1&L'E#!XR!+T^2R4@3#$:#`%D\
M8,#AY$`81#`"VX0!8<0".`:\G$4T)@J)%PM("$"X^!$``R2@?"%QX`24(UK^
MQ+AA1`37RHY@J!!PI@R;$004#V8"0`*1'V>R?+C3H``?$DB:2%D#9\08U(O$
M%*"+W&.#)$>B\S'37)$#$W`XO'G#1H("(+*!K7APYHF5%RT2+)B`J,2*$X-[
M/$%RH`3SKA!H$/G_<H*%'S4'9%"=(@0(H,86$X"PP!HC/'&`!7_,8$H""`S(
MR`<=/&'$`2D$@1H`20BP!A$=!#`&#%YX\(4:',#A`X06KI#`.A8F`L,=->28
M1DTU.L#'&3<(D((YPB!@QAL_+##"#1P<,`427"!"@1HS#`;!%1I@$`!E6)V`
MQ@T!_'%'`4XT@4&-?PS01!E'=`'#`"9@\,0#(+!`PRD4HID(`U88D0.7E2'P
M01).(+$!ASITT88`3T0A2(TL:'&:GI0J8@$&(``*C!("<$"#"`W(0$(3/JP1
MY1\4/*$!5BI,8(,5:`A`4I<D;+$#(GE(T`0(:;`P0@!`(:?F!O\D$L<3_VJ0
M,,02>%9(*9]#T&+A#@H(`(4:&WB@&`5(E.!LI>"&6Q(0)'"@0AU_Z&#`&1+P
M<(,$8EBA*E8%D#&)$3BP<-8)M=[Z1ZZ[-L`'#U^`0&-7(APA@!M<4&>LABL<
ML$&SE4)+"P,'1%&=%S&A488$M'#K;8UI',`%!.*F3!&Y'"2"A0EG&##)#S^4
M\425-@%1!0TT4)!!"`=WY"41$U0(PAF[UE#%)&<LH,`.DYX#0Z\K//%&&6Y,
MT,`?)BQ001D+9!"!#:;DD`-[>EK\AP=+2&%A`T6<\`%=(G];'09&0"&"RGPW
MPW(8=.D@`;M+5'#""5G,:Q,`1RA;P19T:,!C2?\B<,$!#U%0D04'+\SQ1V^#
M_V`$#9H*`P0&6=Q`A!%1&`"'&R:,`(7-34(H(0=;`!<FFFKWL(;;E=9=HP53
M%+!UW\C[`@0:'#QP@@XV($'XJ:FN6A(,*:Q1Q@L4.,'#`R%@U<`)*\"!!!1(
MW(!!L']84$`6:CSA!P4`L!.$#:I#(<8)6LR!@QML0$(92&"#'SPH0J;0P`7*
MD(.T62%:?_`=\"@E/`L%8`4TJ%_R-MB*'4CH#4U8`0\X((440$E*BNL(#))0
MAB:P(`@@H`,13'"?CC0@`TG(0@<Z,`,BV:@($R`!$=A`!SUT(1A=``$7V-"\
M%`"`+DJ```IVF!<`X"#_!D`9P`Y#H`(X;(!]`^K=[\!5P0$U"`FSXJ`:&V$'
M'21A`4A2`P42,(4E^`$15T!"$@:3A!\(X!(NT``;A'"\P;B``"$(@;06@0`'
M*,`'LS,""+;BBP!PH35&&`$+_)4('222``U```'R<(D=(/(`#V`1C"PDQ@GJ
MJ8S5^4`//."`-=K2$8+J@0Q`T`4$G(XD'P#!5528A"?0`#!5@(,$P(@F!'2A
M"DUX@_1DH,%5^#(&'EL##13@@JBU0@/FNP`GP_A`6DB0C-VR6W/F(`$<:.`X
MMXPGN%9H3$0`X``<6*:XTA`"#3B!9E#0@3<[:8,'_(`(3D"!$IJQ@P]`8)SD
M_X3@.8.7SAI%[PEH2*,\-SJ@%7)@""KP0A+6L(84#!1-.OC`#%Y`A"8<@)F(
M:$`.OD"$)VS`!$6H)4<7T4ITCLQ"`"@!"!*PR)T:]2PHTD$&#N":,R"!`VA0
M`?)<```!E$%T(]#I'V"@@QP($`T>*$`WCZJ(GE+TI]6YX0`*8(8CDO6M)=%"
M![;P*48]@0WI<"OR/A"`&_Q@"5M(P!\B$`,K\(,'"FA`#=]J5@I6=$`G\.L/
M2*!1N%H6&`"H1QFR@(`(B$`$*M`J!S^``3=P@`@HB.8/*C`!"*#KLHAH["L?
M6QT+^,`&<M"#AV#+VUY\P`D<*(,3%KI3!%2!6:;@P/\-=!`>WLH63;!$#@*4
MH`,=N$"=O<VN(UYPM2]88'(<58''#O`%.-Q`N[$M9P3'>%;L5D8)"5``!N9`
M7/3:%S!Y6,%5G1`^LGX`#6\`0@AN<%[T/K=&T44-%9K`!C9\86_WM:\=+$`#
MFKT`96_][QL0@0S['MA"":Z,!5`P@B/DX%$1UJX.'G`*`8CVJ!KF<(&U^^$!
MA;@Y=CAIBLD:@@5P8`UQ<`%X80Q@&7M8O1-U+%J;XP.(G,().\XN&=[`@Z!E
MN,A_Z+"!D<Q>);OW+.HBPP(6X`0?1!FV'^!"2PDPY"MO.,LSSFZ-JW/CKMPA
M#P!@01NT(B85:`$!*,I``]K_?.8-AH"[36@#H?V+92W3&,EM&Q`_1?`!V=09
M*W7XP`5NTX045)<($M!"&@90!@PTM]#!2$..:K#H9D3@"V6X01%T;-08P_G(
M$,3`!@2`XS2$804<:,)?4$5;Y!!@"]JI&0?D,`9[6"`-">!`"_2*ZE_4`0L#
M:$,;$L`^%&'AV^`.M[C'_6TON*`#E_NN=FWM:#G#:IC(L4L86K"!J_IAMY>V
M"0IXH(83-."?'(B!LZ$M;6I7NQ=4N,`3RF`*&FP%!A&0PP4F3O&*6_SB$[>!
MFDF@[G4W.LZ]Y9,:)+!*U!"``AM(GP#^]`<O%*$#:EAR9>P@KQDP0P?`%CB=
M$N"#_X(?_!<ZL-QG4/`%#AA`":J!@M*7SO2F.YT$+`KN%_)@!_NR&^2\+<(!
MI"D&!DBJ*S"P0QX*(`8BO*$"&!`$#(I0!8.Z(0&T[@C-X0`?1/`AX`Q'PAJ>
MX/.?]Z(0')A!`]P1;`_M@`542+SB%\]XQHN@'ARH0&5[>_7[BJ`HL9[``*S,
MCH8F879$>(`'Q-0%`+S@JCRX0%%10W/$U@0&1\![7&XPPFG[O1<Y*,,:"N"L
M%L*S&08HPQNFT.K+5OZ^.%G!&3A@A!D4H9#G2(,9-``/-AQ@]#!1@`T>HDP,
M=]0/1*!!$.Z@`)H&8.#1MOWM:Y'[#D2`1[[_W+830/_ZV____O8_@086[@'H
M>_S-[69?#I`$%;`$<+`""L!YO7`'8Q`B1O`$%<`';C4&%]`$2V!])@!O`^(!
M8W$!)E!O`@``Z-=WZ\<*;8`$/&`:O=)"00`#'U`!31"#,CB#-%B#!L4!*U`Z
MO'5\*98'`S`"36$%%*`"@`8,-?`!8H`$9Y<%`^``7!4`'>`&!?%.7X8<0(`#
M4L`#2*`&%3`'.R`%$^``=5`$SJ.`);@(:6`Y>=$&1?<%+?@!=/``<CB'=%B'
M=BB'\V$"$<:#.U8'";`"\7,`(%!RM2`58K`=0R`"M^(%!3`!L'8#+U`%Q8<<
M=^``+D`#="``&;`C8]!-4_-LDWC_AHB@!SR`&R]`,^7P!YT5!*S8BJ[XBK#(
MBBOP!J=B=1]7;05@`&NR!!?``B_V"*,F`T3@%`>@+VE@`3-U6DY0!1`EBK"E
M`0+@!!M``SA0$A9``FQ``'%'9`"(=5&6`1T`!6O`&0I07XW0`!@@!AO04DG@
M.7]0&"+$`R\P`;OEC.A5!T$P;"61!A>`!"M`$^C%AX56!P!@`C@`!3]@!>6X
M:"#P`$_P`UF0`F[B2QVP!*%'`7-0C_:XD:R@`E+P!!FPC3LED*CF!4"0!*UA
M!?L#!*?1!7U0`1#)!SI0`VE``#V@'T\@!2S`:AS9DZTP`AP@`#Y$>;>X?H%T
M#`EY`6/`_Q4N<`-L\`)`$%,!<``D\`1-(`%GXI-:N0H,L'!M8(:,UHVB2``"
M878+8`/PA`#R=14B<`!0P`%(X`,#4(5;69=_@`,<P%_:%0$7<`^WYHQ74@%/
M\#L4H`@?(0!P02)7X']VV9B)```TDP0P!5<U*55_X`.%Z8QWH"@4<%@>$`)W
MI@*GUR0S,`:,Z9BH:0,X2(B650<18`8?\`%F4$W.&!@?2`1H0`8!<`2GMP1T
M\`&OA9K"J0@1L`9GP`N]%08T(`4O\`)<<``0MI$U<`(C0`=E@#[)X`'1.9S<
M^0=I(`%JX`3-^%9RL'!.X`2"J0H^V0``0`%050*LV9W#&01;0/\$&@A7`O`#
M4`$`5?`$1*`'6^D`)5``!B>?W=D!/_`%O<4H#B,"_'!,6YD&=Q"*!EJ7`=`:
M[GA9C-)?(<!4O%:A(&J7']`$><E;&XH(&>`Q'QJB+-J32C`#P=4"L)6?9(`(
M6X<$9M&B.FJ/,!`"$$$'L#4`7Z,&1,!P7R"2.YJD*58#'L`!/Z``IV94C(@&
M/``'1D`'EJFD6NIW,!`$$[,"O_=68_A9E+:E9NIW78`"''`&`W"F;OJFS=$I
M)%!U<%JG=DH1+<`!;I`",="G?OJG@!JH@:J1=UJH.^H%3,)PBKJHC-JHCEH&
M)6"HDKJC0&`$97`&,^`#FKJIG-JIGJK_J3/P3QN@C9-:JO()`S6P0#<P!0V@
M!*[ZJK`:J[+JJNP)8`NP>J::JW7I!2G``6PP!ZCJ`F[R"U[0!56G'T@P`#NB
MJ\RZE3H`7`]``$+1,XO5"BF058@@`2VR&\W:K1OI`/!P`PW@!2>P<&CC"UQ0
M!C0`(2%P"BUPFMX:KZC6!>?W`P:``%;$?/WE"V/`)#1P'!I0I#,PF?):L"F6
M`+,C`$K`E[H7`W3Y"`@PB\32!5W`5#R0H0:;L1%6`[.(!(@0`&KP!@?0#"ZP
M)DVP-QB`!$]@``2KL2X+5VJY=X6I`_5P`_H8#!XP0M83``L'H"_[L[`5`@]9
MC7\`E'"@@[Y`_P/S\0$5P@]<$)5`&[5'%0+!MP$*D`8,L(XC2Q&G>`9L)@)%
MQP4M*[5DFSP3<%4YT``1P&(+<)_"\($_,`,Z@(ZFD)5E>[<<9`%KD)<AX`4]
MX*0G`):_D`.`NP-C<'H;H`+5BK>,6RD$<"<58`;\M`9O(`%8L3P<L`#G,@;+
MQP6AT;B@"RX^P`,@Z0X7P`$;<!8%\)8/T@57P`D:(+BA.[M8T08/0`0'0!,C
MA:F+,0)E0`15@`BGBP8W2[O&NQBG1P)"I@4/\`8X<Q8?\`)/0`=_X0)L8$SP
M>KS:VPPPX#MJ<`&?@P-/0`*?NQ@$8`65BP@3P`9J,`$4NKWPRPK9P_\FQW%^
M6U!WJ)$`/&`$>C@&>$D$WA>_`NP+>9"N:%`$?]`&IV<#O]@5(:!P)``$7:``
M5E`&!^"V`YS!YW@%:X`&24`+9("#(K"X6'$'(4"B1_`Y52!\>JC!+FP9\"`'
M@M"5;[`<`^(%`8L$5=`%(9"N9(#`+QS$B1`".$`$E%4#1<!=!V".S=$`$Q!Y
M45$$\B(`A"K$&6P;2$!#=6`;'>"$>E(!:D`#.I`&"A`6SVO%&BP%91""?W`%
M-[`$9O"PBZ$`)'`#)P`#`+`F"T#":*R]I\?&*7<!14@I'G`!>P,$:G8!P=G'
M`MP#M.<#70`&8+"OE&*2-?!,-X`&;<K(&6S_!TI+`MRJ,G8@`DM``E7P$IR<
MP8]'!&3P`>]KA31@P4R<RO`+`R9@=E>;,A9@&VNPR;2<P02@7Y+'Q]4!`QE`
M`C]@`HO\RP(,`)9J!0("+J+Y`TV`I,P,NBA0I.=**=E,!QA\S=L+!$V&!!FP
MS`-BO4B``J\,SJ#KS!R``N/9'&C@(%#+SAKLMV?`!C,0I:A1!Z264?8LQ*=;
M!O&Y&#60>QR0`J@<T"X<!"RR`&&*&B[0*67@!>O,T(UK!P3P`QR``^5;&7F@
M`:>P.QC]PC#@!""4`!<-#*55!A3`SR7=S()9`3#=$1/]`S=`FS'MPB"@!F4P
M`"O="[.X!KBZTQJ\YW5$4-0=<0,@9-1H/*(M<A8U,#$5H--.K<$N((PN/6@(
M$`0%0*9@'=9B3:8#``"*@0"Q]P0L(,=7?;PPH`1/_`944`,N0`';<`9XG==Z
MO==[#0<7G"8UU0$MV-9"?`<0`!$V$`3J0J1$T-B._=B0#=EJ0`<0X`5L.\N$
MK<%U<"Q$,`)!S0A8@`%G\`,H4-.9/<!RP'P1'0P!,$(SL-"G+<1``!=TT`.V
M?=NXG=NZC=MT\`8D$-N<G``"1#/$7=S&?=S&?:DI`-R,?$]2\-S0'=W2/=W2
530>)Q=S8G=W:O=W<W=W>O6.!```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>y85641dfx8564121.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y85641dfx8564121.gif
M1TE&.#EA,@$Q`>8``*>AG,;!O-31S;&MJ!`-#CLU->/AWH-\>.7CX-S9U?CX
M]\*]N&-<6>KIY>WLZ?'P[M#.RO3T\O;V]-;3T(B!?=G6TU-,2BLE)<G&PM[;
MV,;#P9>1C*JEHDI$0N#>V\W+R<W)Q).-BGQU<OKZ^5I44VMD87-M:HN%@:.>
MFK6PK+VYM)J5DD$[.OCX^+JVLGEQ;?+R[Z*;ENCFXY*+AJVHH[FTK6=@79Z8
ME#$K*[Z[N7%I9>_N[.SJZ%=03O3S\?GY^(Z(A):2D']X=*:BH+:SL$5"0N[M
MZXR)B*ZJJ&UH9?S\^YZ:F?S[^T9`/O?W]E9244]*21X:&H6"@/?V]NKIYUY7
M54Y(1F]J:'YZ>&9A8%]95_7U\W9Q</7T\_O\^S0P+V]F8W9O:_/S\20?'R4A
M(3<P,/S\_/[___O[^OW]_/[^_?O[^_W^_OKZ^OW\_/[]_?W^_?OZ^OS]_/S]
M_?K[^OGZ^?7V]%)/3OO\_/?X]DY&1<&_OLC'Q_W]_?[^_O___R'Y!```````
M+``````R`3$!``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMG]J(W]G:FI^?5L9+C0?#[]],A\"QF<\
M(!@&3GYG9[?6U]BQ:1*[9B-^,ALW&Q0F)Q5F9BI5)A73%55Z&%ML9VM^V?GZ
M^Y]^;FEL[IDQ4"[#%@4?N`A),"(`BQX3S$@08Z%,AA%I(IC!QZ^CQX^._"@Y
MTX=;%PX70IA!DZ9/D"\GTB3H\"1!'S1][ES(T.:-@GL@@PH5ZB<-&C]KW""@
M$"4'FQ].E.0HHN7!A"9:*D@PTP?*!0/WU/3A.+2LV6QIG`@")V1,@"E__\PH
M(5*`!`\792S$`/+BQ04<'O#].$NX<"V1?I#ZB8!BS`(S;9!.39)F00$3#O"=
M@5(&`1H%?0R+'FW(SYNUA/RHV97X3VO7OAXA_E&TC0`]%!0H0?,G1)D5?S"P
MN"+C5QHH/1P<W46ZN6&1/\[\\F-&.I,?:,RL6=-G;/<1<=:L;E14^YH1([:X
ML!(#!@P,4H84I8&#BX,T2AIT:.(97Y]JS@4X%'5([9)&=+^@X<1V(ZQA!AM>
M<.4'3B&E\4T?/W3W``HOI#"`"$@8,8(1)Q3!10)HH%&#'A8(D.$T`L88U"]J
M1#7"3?9$4,$00VC`0Q]*_$?2=!4R(<8>'WPV@O\9"2`!@`M4_/!#`RFXD$(%
M(_P0``I#)/"#&1&2)>.8^13EH#=RH0'""U@`\((%88"0F%S3C"5;%_3ID8($
M:2A05)":]9(E5THHX8<<3HQE1AIBDNFH-4K`P(8"6Z!A0`Q54/"!#QZD<(`-
M(1C0'3X4DB<!!A<00``4%>2291].*)"E:FH$^4=W&W'WRZ.\7H/4"'68@<`-
M13#P`17>($6%"F`P<(,!?_Q@:$@"?*$J`18X\,,62JSQAP(9+EG46$K`<<9&
MTAT#8*_LCB)=-8EQ-(UTKIUGP`T,;,#!!'%A=-H?3E3`@0@'J+##B_+&ZQJ\
M?U2@A:I1A#!!'_@EIL3_"$H0:@8<V:G!*(%KP=CNR/WT$9E(<'R#5$M=^*$`
ME1=TX,</#B"RZ!E.T-"!"!7`4.E8.*WAIZ%(=7&'J@7XT4:Z)#=-"W>N*7A>
M+GV,(($"$VS0`0L\N"'&1HT.@FL?1AS`8@I=^.P=4GW(2L7#8VPP@6(6.FUW
M+'!,R&B:7_XP`0`LD"#G"&?\\`#'B70+I!((",%""`'(L*03D;G!A`Q6$(`#
M!6R$1IT2=X?NBJU]F/$#N&D8P8$)&VBP0QIJF(Z&$EN$+4@:;HSP&;=]:'#"
M$270P$/&?L3Q@`@$A/%!HO>L<51HHD>/"I!(&?I#!2C<(`('L[8T@JQHP`!Z
M_VF%*L`;##;JCD4/0$S0+0\`1'%`[6O4XT>89DBO/REOS#R=`D-(@@E0,`$U
MT,8)9E"#G^+`!CAXJS0S<QYZG)"EW4QA"$"@P!$<@`0MA`!6:CC*O$"VOQ)^
M@COWR-`:++`'9/E!+7^XQX3\P`0_P`%ZA;!8.LRPA38`0T%&@4$"```%"^0@
M,;R9H6+&8\(F;D)7L?,##`"@@+6,+V3I>DT.\=$:J'%G6FGXPP-PT`$/4&,U
MN]J5$]>HB7@EI@\(J($N2N$'%AG@C&S,8R=^`901("``O*%C"2Q@`"[J\9"9
M&)4@S"`&`[C!%$H0@@4\D#]$6M(28V%:!#[`!%.H0?^2'AB?[2Y)RD7`(3)P
MI.(IP$`"!$"/B:6,Y2)&U88_QN$4%B"!`2HY2C9>;!!,`)V=XJ4$!1IJ(ZYA
M(]B4(`,$A+$49M`#`T3%'%**Y$:%,IVTS"<6ZOA@"V;PP3T8Y<2Q,`H_RKCB
M*/I``@8@@#IGJ,<EJ=.@ECC`!2*8P08^8"@E/,`%&X@!!$[G!FXTT4Y_P`D(
M//#,4G2`D$RH8B_7B!\%:"0$.'C(!2[`@>M5@05@T,,%:/``C#@Q,8PR%$,F
MR@DOX,`"&:!1*2<4)#-D@`$D6(`'!L""`SA`!#A8@0<P4(`+?*!M;'1C#IQI
M"C_D,@.N42<BCY$B!6#@`SW_;,`=1-"`+Y1!`T[80OSV$(>&-E%A*3"`647!
M!@9,\@SDM*8;I*0$+P1$"1'@0`<XD`8<E"`P?W`!`0"P`ZF6L)M_4`$L1Z&$
M"U3AG=YBJ8RXB,QJ;*2AMDI-=[I#$EF)804="((#MG`!'8CJ#!L@P`R,L,8S
M*.$-9VB#&FK@`[)0!X>81"8A"'``*@QB6NWR7NDT$Y>B(,96QWAC'^1`DIM\
M0`IZ`(('@($#$EQ$#3$@0`J<8%`3NO8-;&B#$FH`@\W.29&5H!@R%4D&(?#`
M92R1;(#&LH6QO&$PNQ@+8@9Q#.@!J;D"*,$%@""Y"9&`!2XH:0FBH`$SP+")
MC"J=_QE2X)T^Q":&\DT$5UR37#^P0`C%,=\W2/:#;W"EBH*0@XF54`\`O48D
MU4G`@BTPCP!4``W"T8,+!A`%$R0@`FR,RLSZ@(&0Z>U6ZYJ$+VZB7]<40`@-
M*,H?1MRN,XCAD3>"[R^D(4,_S*&2TJ%88M3`+#ULK0EE8``$NH""#GR!!2O@
MP1;FV$3=J28-,`"!`;ZG7]AEPF.9_`%WR/""XHP@`B)C%TE:@H;(]$\Z::"7
M$])5S'3U@0VN\0$//)"!!'@:`0]8@P00D``/;&$'WWAP">?T#3<`X!MO\'.!
M,+'A7O3/#P0H00,@K=LJQZ$[6T""`=!0NRF`0`-\F,`.-O_2'0X?0PYKV(($
ML+.%"<S``B^(@0`<T#8FN&$+:]6?/<33@@K,@`@3^$$:X!*M3%!H"FXP0P4"
M$(4>)-BUB=;'QSB<"390IPL:P($(H!-P''P!"@.(LIB-`B@_2,`)<?!!!G)@
M@Q(L``,DT,(0^A,DWI!3BT:>1AK=^,8,TR(QU(B7+U"^BW3]P``3`(,(QG``
M#""@OM]R#4(5T9K6V,F'T0K8"TB`!1'TH`9_`+(:QSP(2X<FY?[AR,JU:!J.
M)-D23N@%219+B:/(@`,62%ZT#&`!,@B@#RM@00R6E(8T>,LHEY;``R!P`S`(
M`0/2Z$,";F"")+C``*"YD1/@@!__7=!(-9\[@Q>^`9`T$`I#.$&\/OP1Z3.@
MP4$L08,<+'P&.*@!`430`1<"T(47(`$,.MA#S6AS,45YCN6#6$--N:.`1_K"
M`1-8P`M,`((I;"$`[L.``+;`^C[,(4.$;RYZO$QXN>@F@6UP_(28,R$[79T2
M(C<Y(Z@7@S$D(0H#]X,`QF"#,,J``F7(3H:Z0S0%(,`%8;``!WP@Z#](8"09
MN`,+7@"-:%E(`4[`&WC@/*[1$C9T0^DP*OI5.O=03/H00BOG6J"3)7-0![QA
M`!]P`E4@7=71`T8@`R7```#`!^6E`++E8&C@"P:89!8B.W\0)%:Q`@P`!!K@
M'6E06U,0_P900`0(=']HT"!>0!N;-1:"I@9M@$!"8R@BU!*=<UZ;D"L-=7V1
MP!5G,`%#(`";@R$"<`$O@`8_\`%E@`,1X"VQ8P8*(&]"<`!+L`=&@!/H(325
MEP8[L`0;T`,A4#YYPPW-\P<'$B0,DE_L=Q,/@$#RM`_44#J6AQ-Q`(`CT``G
MH`-`L`</`!K40``:("49,`0A.'\*H$"RHP!MEVC>T">T\0<-<`,'\`(H``(2
M(!+9D1:"(`-((`(0D(``^$8_N%FWT@8W$A>7I0"GT1+%Y`ULT&N8,!9RP$12
M"`DSY(4>4`9"\`=MD`!Z4`````('0`!?(`%]L`;2X`<>$`)7(/\$.<`M&1(7
M#B(2JU$Z$I``*P`$P>,!,.`R840=.C<"!@``29`$84!2_M$'*6`"*B`>VN<*
M)"$'B5%BU]%V&1`#(L`%-.!;9C`%GY$&N3:/;*`$$W`$#"`"+O`9;=,%M)%O
M+3%E(^".%``&`N4#W<@-2O`Q+W0&6U`!"$`B00`"(YD&X8$Q6?*"%'(3+TDY
M(G%IM?,-F)9,F?``%L8<R_@(U..%U0($#@(#2!`%%\`"&_`$.#`-IN,`0V`#
M,X`$,F`ANO,?<X`A`2@>G:A"#;`"/6`!,X!H5?,:3)``)]`$![`"68`#-,`5
M?:`"+$``*X!`<94-BX8+6^`$;J`$(##_`R(0`DB0`0C4+=QQ(P00!6.9!F)`
M'0L0`EJ0!:QX((@0!]DQ`D/P!#VP!,5@/J7S`SMP&@D2'4R@'0_``55``JWR
M1C!P!%B`!5F``;>U`#<```90*%-@@#%``Z!Q*+=2D(F``;.2@EP7"?YF>4K@
M`1=P`A@B!@(0`P-`#'=0`'R(`"@`!B]``PW0/6,Q`LQU+M>A!.:C'(N"#QH`
M!"2@!Q*30(/`)!20!3MP!AI0!EF0`3"@-640!2O0B6?(#R)G!@Z```-@`0>P
M``V04.G0$ACR'SA``!O``W4S(3ZP`!ET`,N#"-T1`QEW`P$``V(!&B5Q$'XP
M9QZC(-V($S^@_P$<8`0-L`!_``$O<`(JH`(WT`,`<!`"4`0(V@"[<10($`5-
MT`"^H`NX=0D<$"M*=`EGH#)K@``X``9C40$LT`2#00-DP`$%V@0V4`/*P70O
M2#2"D"*;96<^YW`R``$L$`6>T7(3\@`\X`01``(%<`#P]@$@``1?L`0.MQS[
M`)1_L`)?8`(3(`,^6#K=.`)JT#]J``8$P`!1IA9.<"`%)0-#\!<S0`U)%@`=
MH`<T(`,^\`W<X79B,4=MMYQ'T3F1D1Y^8``HD``VT`&[=%]7P`)$D`9;T`3:
MN`>@6"M80`!ED!E2]D"9X">&E`DPHI$74*I;\``AH(TU$`4TQ@(,D/\`PW8(
M(!<O4$<(U7`@;P`_3?`%`6!0-Z%S2W`!*'!+B\(%8[`$?*A]]S,(=7,KE>2+
MGF!<#T`#!6`#`<`#4T=RC'*.V4@`-X8/WR@2;.`$$.`X>D(;!L`!-D`"<N,G
MOL`T,&);(RL(]-(:W[8"40`&4U!%:[``<#863T`$13"8)J,"%&`#7*,``@``
M>K`!V"`A+Z0""*1`6W`I)U``+``$/&`$2MF-EZ`RG>,-$%H"+Y``NV$U'Y`%
M!<`!+3-<*U`&B,H$TVFBD1<O9EBK<K$&A;D):J"K.D`!`D`%+7,(_L9L^$`#
MJG(`#9""TI!$8D$[/$`#4%`%'/($0>`!46'_8?AP897@!RMP`1M0-4>!!B0`
M!6!5!;Y#!D`P!7;*`1EE!#<P!@"0`@1``3X`*772C4GH>+Y@!N#ZBM-1MI"@
M7UY(,6F`A3908CP0`#W0!`"00"&K!BG``OKJN(RP!G(I%M7!"^J%>,[)"#]P
M`BQ0`Z`1`4!V"&X018-0`1`3`%O@8K]P,5RQ$3*``B4@5&@[.XGA;Y<`N1>P
M`A<*#$]P!91$`GR0`"Q0!3Q``13@`010`#P0!E$0`!S```<``]8`%(#"C;("
M.WXP`GH@!&V#.S\PFY>@!NE8+VVP!A[``%60I<(Q!D'0!C`P!1E3#1SP&V-F
M<A-R694'GTR`!EXP_UR>``-7\`01,,/-=@BP`S:)X037<@,+8V'IL!9M`!JR
M)Q+BA5Z4&KV$H`9(<`$,`(HILAXHX`0P8`4:\`=<<`$#8`4?0`?,R@,D<`%J
M@08)T$FWD$DWXK(LL0:T`;L]@`L!>"!3*@EN\$;S:88&4`(VT`<"P``!?`(S
M0`$H4$B)<0,X<`-[8W)M,R$_:"@IXP1.@!W0R@D.P`!W<#`+$K"%X`M-&!NI
M0@!-D$#VT`=N0`V=@T;XP;B.%\N_4(B68%,E\`4?$`??4`):(`!^U`$:<`8R
M@`,ID0$_0``78`0S-Y@>$`8*;`N71@UI\`;<8'E`XW`LD`3W,,,CT`5YK/]D
MI1-A3`(&-A`P(2`%)@#(51`$"2"M&G``>[`VCM`'/I```9`"D@,#+8$?3I``
M,B![GF`$-O`$,'`ZLY,([2MR?U`%UP)59X"0IBH6JU$K^=-?LHP+)E7+5L4`
M>C`#]WP"1&`$;8`$."`$9L0`'3`!;X`!EXD$*J`'47`%#!`#6W`+ON`%"5)Y
M/R`H,],!)]`ML:,$^'4)HU(4$793)8`3"@`#!E`!&3`!#2`!:^!:#^`!1F!<
MCY`!26`%%I#-`U4K&3(`)>`"BQ+0.!4'<E$HW_R"0E(-?4`#5VD!,H`+G$<=
M%!)F8]$+E'HK:Y",F85]P"8`*$`#->`"&:``9_#_`)Z2`@Y@!L=F#""P`B@`
M`0\0`$L@!"2UUK&P@-7J!QFY'2QP`L;U'XI@`)RV`P[W`!^`(MT80B&G=>"(
M4SKW!]`F"$JPRD.B<A.5(1VL!E?P!11`!"<`C=0@-!-@!6.``B7F"0Z@!210
M8C9HHIH!+P%&`[4X`B`0!D`@!MV1C+\@OES$11","3T7Q`X``U2H`$;@`&W0
MG-+7!8+@'<ST$6JP+HD1VDW7E'[``5^``P/`AXS<`15`-'2`T`8`!G4L';0[
MSV<`&NX;!B(`%[=1!1/2!B!``LA,10M."<U-`KH3,H_0K33`#7[`8R*PRK#1
M.;(D&_4=&OAMLDV96#C`_P`]@P894`!0$&4O&6[\=>`)KAJ70#01+`@((`:"
MD`)C(`)C80!94`0A`&=0O`B;3`)B,0D90``0``P'4P8'H`"(C8@QON*ID2M_
M\.(MA]`+\`57D`&S(P-H^@`FNY3D:@`V``6FF@GPPD1HL`,/``9%X`&^$`)1
MP`4S@`-+X.7,+=MG'@D$<`/P+0A10`&#$#MBSN*#T`0GD-^*X`)?4`484`&Y
M]P4VX`"_QI6(D*LV8`&]D&^38'G@%:5.X`,5<``=,`!&0`79:&\]0`9QAF*:
MC%,)'0D&0`!!X-(!\`&Y%@?J0@V5S@C3,1:8KNF(D`9$90,JP`$Q0`%D8`+H
MO?\QO92K)5#'JA'FC#`'2U:*#D`#)5``G.0'$R!2TC0&!/`$*;`#B4X"T!L)
M#\!;87`%**"R-L"-Z0ARS4ZN>2,>9L[LHQD`99`$%7#)%5``.C"/S67@J6YA
M]7T)XY2A3)`"Q%P#M2*'"P``-!`"QJHGJJ8)4_[=Y%X(`D```O#,$D!S56Y<
M&WY)R%0HN!!FN?`'37`#NZ+PB.`".!`&P[8&,@"N.Z``<``'XZ/L]3@8J$X"
M9L!<B*#P=K)D'/$#CX0+*6@H<6"L8]#O21`$X/$Y!T`&B/H/(>,+L5$_ZP)I
M(E%-A;#R\Q()$`#S-A0:\M.:+%_P+^AX;;`HTG`NB7'_'65P`Q*BUB8ZJC:0
M`+^@`GZU`Y6+RAMAA@3X!W1N`]]]]?9P3G/2L#34'5UFAG^P!!S``4B0^CGP
M`-7Q"P*0`AD`)&@@`4O2/W)Q68F!8N)Q%-XBA3QPFS#^"!K\,#,@`\"``7W/
M-LT+^*]\@]S$'69('58`\C,#*(BP`]H.S'_``R_``@50`Q-@TJKQC>)E!JZO
M^3;```1/"-WQ$T1B0+4R0X"20$BA!O7E)QD"%30,"'U.6TQ]AGUH9FIK:8=N
M4WU^:']_D7UG?G]IF92=#3TD9V>4HIVFIW]F3D)0(1YO.Q0F0$9N9V8CJ+J[
MO+V^O\#!PL.Z:DQ*;7X_:P]^_Y%^:VI_+"AJ?F:<NTX"1'L\?UL:>P,>/'M4
M'#)H:WY,6R,_D1X,#+[.9GU*:PIH?DI^9Z;T4T`I39HM?_PH]+*F!;01C90I
M0(1-B00G^!0J4**FW[4SE_Q(HS0B6R<94$*-2FB2EYP?'B!D\.$G@DP(3M1@
MBI2&F,^?0(,*[;5R!)M1['[,R?6GR0F"I-B8(?IC4J<M?2[6(-!D`1IK7?Z@
M29.A2A5,::;JBB0F@IE2;;#^>9-K%(Q-"A3`Z/.CTH,&?D9(,-7HSYH^FM[\
ML?9'@>)^AA6NZ<M+AA65E/RP$5826Z<(+1$-'4VZM.G&7HR,8>#AP1\C``A$
M$;)`@?^-`(%_*'2V=J/"/FM&]'%L39D?'3UDP)"!&-N\>G]*H0JLP(4(%A=T
M")#@Y\$+*Q989)BB0$QTA6:V[``!QH(-$C2ZH'G`/0W$^4[BE&L`0XV"JE,\
MH(`3\4C3DB>@2">=+F<P5I`8_93$W`\C",?2:1AFJ"$O3B10``$E(*`0%&/$
MD$('!/QA`0<*+::$6M,I-((23OR366Y])-.&$2<T$0!"?QA0@@TM[A('&@$T
MT00%!^`010QQF!"%'B+@0,`)3HS"QA9.^""#"&5HH`8,*>@`P%YR*%35.SL`
M0`(44)B0`1IM@"""#4*($(,,E`")"@]5D"",*"OYT0`:;/#_I40EF;38!U,;
M1BII:164$$(4&S20AA(]X.#`#P&D6(4`%%K31T;1[:2&(?A$MPDED"UF&"(R
MA,%"`(@)68(D)7%2I"0J<*%"6D",L<(/062J1`,$]/#`&@DYX<<42!`00QH_
MF-$%!1=((<D_U_R#!0Y``(#%!188H$:Q))!PAQ`0:,1;.\_PT*XSEB"V6SN*
M%;>)&IN(808:%@+<AWV1*('8I`PW3(P#$R@P&V!]'$#`$4&0@,,(=P0@@0+7
M,)'()GW(<>I8PIB1AAH_*$"#`4:XL$$/!Z#Q0TZ&8&(PP#\XL`4TX][@1!H-
M/`#!!@2$8`3(2NQ5:Q0)W,P.!U$(_ZI$'(>U@>T!(O!PAA)9-('`&25<@,L.
M<GQU<,G.9.M'&C+H08)!BI@QU:F1_-"(WOGPEH8;\:25D!IO^7/PH@XGKO@N
M!)N!*0_`'1`%`S804,`#3;`V$2((7:-RR4ST%,QAQ4&+P`QD1&%#`__DF$\_
M/_1E1K9]P%!#!R<@D!`;%9@PAK4/*+%%(V888$,41MQ\30H7W.$#(DXXD8\3
M1C0`LKTSB&$`"P0<<$<5`!BAA`*;7(,8(GUXP,(=.T@P/#SGEZ[$5S`LB@8B
MRE0%+1V#];'%JFF`UN(&.,!3P2`*(C!`^J(0!@AX8`AE>`(-2&"%*RCA!^^8
M$4_F`(<#]?_"(WZ``V(\((("H,`&MT'$".+P*+LI0#CI4<`)<(`%#T@`$6PP
M`@B0,(8"4"$XV/`#`DH0!1`H802*0,$8DM`%C,RO;8>!6Q(N``(WI(`,-EC`
M$$CP!1H`9Q1F$(.,))"#(A2@!PSH@!6X<`,5P,`):(A#ZV*WAIA`H'Z/ZH,8
M5A``3<3A(;]9&`$'V3"6_0"!,O`##0AP`Q^@P0AEL,`4)H`"!I1@`!&PSP\D
M8(8UM.%@H@/&-122!A@<``L;@,`/*G"#$H@@"(<B&!SM@PT92.$"2Y#!,L0@
M``5TT`DG(``"@BB6!PR```!(@P):\(<@%&``=!H!'&&@`),I80'_6M`#"G:@
M!!EH0$1F\``!;""-?J`!#6^``1*T4`4*?&`"`Q`""Z)`!APTP0I)*%<-:H``
M-_0!`E;X`A)^LQXRZ.!G:`#9&U[H04(Z%$-O$T,4=(``-,B``!;@I@$(P(&A
M/6`"(6!`%9`P@HVD)0T7::@N'+`I"6#@"2;(`16@H9X<B*`)64@`JXYX3@&4
M#0L\R-8(VE"$(@@`(R(@@`%&(,9L_4`&0B"!UM:0@1?<0`9B/)4FTW`&%[!`
MH#"8T8LF`3("6,$UD0BC!K30@Q-`@`HV\Q($]H""*A#@KE&X``YP4`4,Q`$&
M96A6)Q"@`P*`03?Y2`@^U("XASH60VAP_X,?QG"""6TT"E8JP+XDM`$6L$!I
M,!!CJSC#@Q2P``<IT,0Y13(2"<P`!S;`@!B=D8856*F'>B@``$8`ABAT8&8$
MV`#30,H"#4B@"T+XP@%,`(88[`!@(AA#&"H`LCZDX`MZ$$`7NN"#.%"@1(NB
M010.D`D?-*`&+*"9`?RQA=C]+7]^P(`\HW#7NR*!'20X@&:A`0`&$&`&?X!)
M```0@!HYX;$(QM#P.+`7@)2$`D)(B`24Z0]I]<$'`\!!#UR`006(HD@L`?&J
M8#"`)I!A`A)HD"5:H`AKV*T!MUS!#D`V`A0`(04B*($.7E`#D$W@!0480VU\
M\(`,=*`,'O@'MO].!2N]*2$-*6@""U2P!3K850L;,($.5O>'+PB9"@08@P!&
M(`,9V.`"'6B#)F#4@K"\R`SZZ`D'3'"!NP[@!V\HP`>2,%0GX"`'X_S#'J)@
MXJ2!*\&(=AB^V/`#);0N`T*PP@O<J(`*#*`".?G#%#R0`@PH90<"&$()P+"`
M$<`A#@&@P0U2X("#/4``'(B!"S)PWA(PX`0N,,(?9C2M$:!A?(3;R!D4H`$*
MZ*`)$X@#I$Q1"D.`(P,KJ,(+8F"#'MC`DC8H`6!D`&06'.`=$R#`%X2@2U(L
MZ!0M<G$%8L"`/40"!WRH@0:F8((0A)L"*L(!`E1P`1(,+92)#KB&<J3_!)"X
M+1%^R$%*D)`!&A3@#B[P@34&<($2/``-&Q!"7S>A!".$H`!0*`,+1)`!!W"@
M`V1H0@&>`(`U-``%6H#"":A;(678C&>;PL`0H+!A,;J%0:,HDK(SD&,@#$`&
M$M";&[2V"23ZP0D!"$,3UGN8&_&B1;1U!C3B@0,,I,$".2A#!3+PWRZ7004W
M.$`-L"%(@;O=-,Y@@Q=>O9='@N"=04!!!B20U";LP1_;&T(D5G#T1IM!`43H
M7@,6`(`OV)L$!5A"!2@0!2U,)@XR(,(+DG`"%3@@48?AQQHJ@((."($#2_6U
MHXF""86X(3@8D`()KK"`+@"''P!Y<@6.0`$L_PP!1E;?!;X(I[!K$`X-7]#`
M&BQW51`00`A]Z$`1WN@!&5_C[=@O#5_8X(`37*$":'`"$=J%!2E(804"$($5
M<,"`7B*`!1Q(%)P5,)413$$%#&B`<"!0`!,TX`8Q@`U$@`-/$#W\,`(&``06
M4`4K@`"-=A`5$`0YQ@4PQ`XC($"ZX`=OT"@*H022A0]$H`4E<`,!0'_"(4TJ
M(`0,H`(WY&C9<&[HAC>9P08*8P8[<`$Y$`=CP`)&L`,J0`!W8`9`0`8'D`(S
MD`4[D'U*.!K3$@`HP@(5<'@>H`%4>`,%D`5$AP0"8`5-D`$_4`1+$`]F$`=R
M80E;,#\R<``7D``*$/\'$O!K-Q`%)J`WV-("A",#$&`K7.`!'I`%7\`!$.``
M#Z`(CT(*`&<*;\-5G;`;$>`$;``#$'``'7`'!H`&.\`%4```'[!4C-$(*_$+
MK?<H3L<()5`&<O(!"-`'5"")%I!K1``&++`"'J`WE+&$MC@,:0`!3:`%9=`$
M,H`/P<$&/,`U'R`!67!G*%`&0B``38`"_0!Z>J0&8L!3?>!P)L!H)3$"$*`'
M)5`!:;`.WR@'<<!5&<`!+Q`&-H`".?!<NT8PGT0)#I*!6K4JSM`X72`<!K`'
M.@`%5\``).`""(`MTM(@"O&)O;`&[)`0AO`;?O`![Q0!D?``4Y``$``!,K#_
M!DY@`'R0BFC0`H=XBR!Y=:65`#8@-ATQ$6;062A0(R*P`3+P`"%P`2M0`!RP
M4'`P"HU&,%/035XE`K\(#3#@`CC0`1``9T&D$(PA"`A0!%9@`(V`"#NQ,KD`
M$,4P%?NB&6S@!^X3#VS`!A$@`W$8!3.P``[0!1+`!))@$IB0@0#!6JOU!R_B
M!Q-A#;F`"/]P>)'A/X9P&`89DGZI"V8@`3"@`RP@`&^04`I@`"10`@DP(PP`
M`/<XC!]"`Q+P#]:@&Q&2`2:6!`CP,VG@`13P!06@`2"S!NB$E*WR846@!4:P
M!<G#'3>R,'T9?(B8"6F1":+@!A&``%%``3W2`Q_P_P`5\@R8L(&]LAMJH`9.
M,!&-DIP<J'6_D1`AIB^8L"@%.9M_F9TBT4WAD0'XH@``<`%!D!,P0`(OD`%G
M,"-50@3/T#I*P`9I,`%UAF0>@`!BX`%70`!%P`,(8`#Z!T;X$`FFT`')40&C
MB0:#H2'_$`!1,``/D`#SU`-(8``"L`7]D`9B<`88:15K$`$P<#]MEYTBNB'X
MXP`]4`0-@`UO8`0'H`<5()<JT`0V``'#1A8'@`$WM`99N1L/,`-WI0<F4`!-
M,`#'%`5E4`)J=`#HB9RXN1M%8`,.L!5[T)$:`@U^P`&,)`9Q,0._$UA&P)#0
M$&*[<P9;X"<C>J89X@=>P/\#%@`%"8&0`L``83`P>)$`#J`F/_``/Y"5D8!P
M;/``-0``A+<"*Z`#*"``0B`+2;`!&Y`".R`2?3`29R`5D5`$)N`#L<$'4)$A
M^&`&6T$$,_('3H!-]&4!*C"+^+,8:'"3`P-G`HJFL`IW:?``-E`$W/1K-,`"
M)Z`R1W0)(S`!0^`!^(!PD>`%OW&"QN%Z6P`X^@(/<.D&B-A!HU`$%I>IE1`I
M:[!('+8H_V$`%&`E7Y`%2U`3'T`$*:`!RI0`*4`$%?`SL?JNI'$&3D`#1^``
M\X,&&G`"`7`_1W2"`*!G;],&X,)D;6,SUT`AUQ`'AY<,@K0&`1H=#J($1:`#
M,+#_2'S@;)R*&+$Q`'"D"I[T`P/P.P1`!JJP`F4`!3F`!ETP!/TG`!\*KS`+
M%/@B`9`S,+4C`UWP(I'`!!`!`(49";?`=LVA$'(`$K.3#"H3+@%Z/H<`L9DP
M'Q-;L02@`K6((9T*`%'@`G]4$0R[!%\@&S+`!D,0!5=P@4I`<5)`(%81LR(J
M"@JC,*-@#7`$$"':"10&J<[@!9A`,`E1(7*`#3'0!!^`#:T'$$&'FQ=R(_N2
MN)WP870;`4U@`B1&`'OPD:?A!RA``'S`"2L1=!!`1`GP!QPP!AMP1&>+`T?P
MC6O+MG_IN`<H''TP!RZV*AG8!N8Q'`K`#OXP%GSQ`ZLR_WAZ,`$J-12$D@:'
MR0,L(+D6"WRG(0IF<`,$H`&;H0LP\0$@,P1C$`+0T`8+\%E:Q[HBJI4*X`:`
M0W]^(#!;A['H9A]P0'\@-#]\(4TTA@8Q``51.+Q`09"MET,L$`8^L`*:6[>E
M\6$QH+D-I0P[\#-#0``D(``;```;@+J=U%C@&Y(E-0(-T``58``&P`,UH@C1
ML+J=D".:,1S4U)].(`9J,`((D`$98``P@*D],`'Q:!H$&6);T`1@L`/'Q`>Q
M`E$`D:DP2`G#L08F@Z4EL`,\P`,+H`='@"\5G)TPL``4L`$H0`%58`/HN@8;
MF)QLZ0=M<$X^D`/@X04V,P&\Z/]9!T!ZHXF!S;L2ZZ`&6U`$5V`$BZ0!RC!P
MFE'`&$"5,>('<C`%*$"VQ),#!7`$7AS%?MF0!0!4TA``_1L\-N)!':$,,/``
M2,`]))"51I`$92`"`V`!!!`$,=`#WHB_/[$;<'D)$F"I#]"]1;FI&:($`(S'
MPN>!@6DQ69!T9D`U4A`!LJS(MM@'28`#2+"0O<P".:`;HR#`_D`)70``3\`%
M%Q`&AO!:-P`#'K``00`!0%"8\9"F0$L2,L`"%*L`PJEF>GP&!;RY'N0,)>$#
M0""N'A`00]`$!Q``CRK,(?D$?K<OZC,#864@1-$%&J`"_,<`AS%%!Q`$5R`%
M1"`#W_S_HE?YS*/1!UZPD`B8O#[0AJ\R</^`-&(R$NBV&S\P`1FP!?5<:2Z@
M`14@1L+G*"%J/OP\0/Z\`-`P'`+``C/@`R,@#0<6(^?1!VSP`5]P!YN2!%'`
M!1P0`DU0!BFP`AU`T?22!E)QT6FQ!0K`!@$PA"0``5-P&*@<%-\(O6+"O'`G
MH`N9B.AQ,&-=TZ3A!Y`W+`/QKRI`5@3RQ7SZ3U]@`;Y6S`,`'$-P`5@P`U`P
M`?/3"/>C)D.AE39C4Q0@J%B\`7L1S!CB!"F@N881*6]S)`OY!I'*"0D)UPSC
M!\5R`#P@"6G``&4@`&[@!(5@'JCP8<D@61^`+L*1!%/F:QKP_P4V<`)6(``*
M\0"9%!CJ"Q0#XP<RT`,L,`&3T`6C"P2MAIVEH0:QX6[3BR$K$V+I)B/62=VD
M?;D.8`4L0`0060--,`-=T`AR;+F9P0Z(P0=18`&2@`+-Z`\H0`8A<``]$#5]
MX$^3`6=,F)PW<`$GX`/1HP0.,`96D`%PN2']@#2;"]Y"`0VQ8C,8&1+;'=X,
MTZTG4`(4,`,OX`*?Y[N;(L*941S5^0%-`'U*\`!84`8DP``%H`48X-3@MP94
MX`'2)%D1,!0OH@1),,K8H@1RD`96P@=LH!@9<@MJ`+WN)L`#WH$_(`=J\$F)
M)0D<SC"1N@;5DP`-8`0^D`QK\$8E<?_+YV$&"(`"N"&8/```)J`%\((`6H`#
MP3D"*5`%'["37-S8-2$E*^`'2S,17Q`%'_#6/I&5;I"Y-Y"A&K+8S]`%"5`!
M>I.@5;OE&D(\"X,1`79XZ"<]0:<3'S$<HI`/2[8RY^1K?E`!'``$26`%0O`!
M7=``+-`$X!<!(/$VT2GENG";E"<%6YL&3C`&>I`!;BQ*N'FX^T*/"O,'*?"D
MY!`!NBN@UM!ZC?LK)N%/8O$,*ZP&'L`!5Q`"+I``73`5EHWII;TI]@(&N#$*
M1V+EOB1-UU`A">$&:4,GS%`!5V`#LI@`EP$"VW`'%$#I9Z`;>!888C$,<+8'
M34`"S)$/&##_!C?P`'`P#/>@&:$H%8V@#[LQ/@BP`7=@J`@P$5^AH:*^UG"0
M*$A9&-;P0AB:+1GA`;;6`!Z`1IJJY>BN.&_@!"4A!T%@!4A`"6WX:S/R`YA0
M(;/S9CTA`QP@`E8EK/R``+*7S2,@`E6@`E\C0BS#Z[S0!3N9`GJ0!1H0:CVP
M`LE#(\*0!G$@%D:OW$,0!E>03\X]`CR``B60!&QD`$/`!3I@;W#P%N6>%2^R
M*3R+"]AP3J:>"8=!)W#F!#U0`'_7,SB@68CQT3E?VDXFZ$/``D,P!7X@68CP
M>IJ1+02#"$9/!$EP`$.`HV>P*8<GT5/=!\9C!5*@,K%#YL20'_.A_P)!,`,'
M,`-#("!X=NZ[@`B,U0]KP`%?T`%24`+]QP-H(`4%(`)'T`-E0`1FX``WP`(D
MD`-S(#Q.T+[_,C"+OP:WL)R,=3X5,(@KK`!?H`4.?D15`#5$C.B7+Q3\*@0'
M("(A``AE&UU]/WYM?DIN:7%F?7Y]6SE<6A0?2FIF<$J/(WT-%!8#$A@;42A.
M<2-_?F9K?["QLK-*;6IH:WY_$`L)3'V>?FBSQ+2(?JU!'2D^"1TX"4@7-D9J
M-18I"F8*-`<])`UMGG]JJVD_L(EIP&T-&$,465`"?WU,#1<]%;`/)E$!;?Z<
M*4:PH,&#"!,J7,BP(2PW?A34B!+"`9H*./\H.%"`[`>:0@J,L'J`110")V(D
MF#'CT<^/!PKFP*A`1@>"'SD(+%"P8YPNA7ZVQ$'VYR.N-+K4/%J8"%<?)6FH
M&-BAP`T)%AZTC!D@H$2,#%/>^#DSPLD'`DW*)I+PI@\:-7_*LNGC`8`.'/F0
M")@0`5D<%V1L9(!KQI\370,=*E[,N+%C@V?<F$%#`\<&&'X$1#G@L@$D/TC7
M0+#!(D2%'[D@I9FKY@R<1\C:#,`QP\@6`S]&(/T!HZ&8'VD>;$'V48V/-`(9
MGCD#J8\3"4K\C#"S@DR8+D^BD"D0Y<*8#UW^/.C3!X:!$!<80/##AM6:/G]X
M<+#1@84%'2L@&#'_Y*=.!A`N/-`!`1K`,H(%9+20V&,,-NC@@[/\P(83"@30
MQ`P._`""!0",!\<:$<"0P`TLV/#!%".@X8<79B#C(AO$11>1`QWT((,?:I3S
MT4K,];$@068HP80C/_2AAA\PF#$":)`L=$8?+;(QUQI3&'!"`5J`T,<3!*#@
M`!4+7$""+F)Y@<P6$[Q0A@X?(-"7<R`(\0(&`C30!0P-3/`!!'?AT,1E-911
M@@]4!,"""G2,-<>/$#;JZ*,$J2B=622<`($3&'0`1`9H/(!!"F"(D,(*+D"I
MA`%[I)HJ%9\IL=*D?;B0A0Y&M-A&&FC\8`9S(\#1(T$NCD74'V()NYR3_Y.I
MH8@2/WS`0`%"5#""$EJPL$>+:'S11"S,I6.&`PN$P8(('QA!GA-&[/"`!P+P
MD4((-CR1Q`8`U$F(`S24,,`&.G0XV1^(0"KPP(_Z^(<"\$&`I0P_-,!"%1^H
M0`*I"4@1!1=OS%''`6-<X+&UR*SFQ4</M!AD`2`@/-,$"520@1]K?"1'0`3#
M<D8:TS&!2099$!`"#R-H@T4/1,2Q1@9?F`"L,#Q<8\$-%3R`P`1\#``$`QV0
M(,)Z2JRAK)%(14?!"A@XD>LPAM2L]MJ+)8:4CQX\\4("53;1!``@1*#"LV/,
MH(0"#5QU0PHU&*`-LRM1N$8::N2&P)(.A#!#"/\QK*`%!@CG`I_:R[ERC@,'
M$#"&"9/?P`,$3;!P`Q#U!?#3+*U,^T,7&(!!P@LZF!!&&"L,(&V1:/2JA@*(
MJ*@`VL)(X,8?2K#M_/,*N17R&6L8(44"9G2QP1V<&('"$$M<G(82$+!`0@PA
MH.#!%.2]P?PMD*SQQ@CO)5`"`QXXXH$(';B.%!MF6-LAIO,#'B!!"EP(@PAL
M<``>Q`H+8+``%C0@@=?)`C10HD,`'1"$+U``!`9H&0_,@"L'\$`"G^"!$Y84
MEU?\0%EP*0I2H$?#&O[!#&IX`QYTH8O)P``B,`##%920*QDX@0,$,,$C-%"&
M*J1`"`4(@P>8XP<G1.?_#%O80BYN^(<91`$`J$$1!LK0!)BMXQ5J@QEP<"6!
MD#A@!QYHP`.&880$8*!DO2D&)*+CB)@)P`HTV$$,[&8!+@C@!U*P``E(``4H
MG&\*`"M$'-*P$IJIR(:89-M'!'(&I1QK#2,X@QALD(4^O*=Q0XC"%2`Q@0-P
M8`<52,(%7""!"##!$WU@PP]^T`+XM.`//8C"`GXP/P5,@#L-<(L3-D<P)I'P
M*1Z!$FK,,(7)[$H!C)B"$X`%I7I\1`!00,$&6'"%%9B@`$&0@`N.$(8D6"`*
M94@!#!XA`15QXBEM<(0%,\G/1R4B%V=00GO^D*01M,$')7@"*W+U!B0J[0R\
M_UFA&8AP`2P8H$7!J*)2ME"D/T`A"C7H0T#Z,`$<1$%7H!'@D5JSAA8]XE6/
M8([FYM)18D"BDRI"PQ8^4(80G&!02JB`#4I@@*=T(0(GP`$`G)"&%2J!$WY@
M`CK\((=^6A4A4ZA`(2)P!C:$B)/+<8`')#"MN,`'&0,9"SG$`J,(F(`$]6C!
M6#BPF3^LH0(GV`.%7(`##D!5.F?EH2ZVX`\`N.</$[A`%%1DR@`^;UBL0$PL
M)-LM@@RD6S@2@!YRX(,'X`@")#@"<%IZ@PL$80<!#%8Z?L*HJ[H6%DH``0X(
M``4'_"$#`V*!EOR`@@)4`0=S,QLSBY$&!?S!"1LP`?]_8(&$,8B@EB`H`!<:
M@(`KX&`/8^F"C/08@RC<0`&'Z0,?QG`"Y+CHM8[Y``FFH``VT&$-4OB""GX0
M@<,DH0`NN"0GT<M?8*V!#A,@``/".X0QE*`/*;!`&+1*!R1(]P%>TR,R'N&#
M%VBAJ7Z(0Q>(`(45X*P!)R@"%/30`0Y44`UK\%5KB^('!I3A`S[X`Q%,8`*S
MG:-Y_5W,!SJ``3=L00!<*$T%GX*Z&XC$9D?*L9)CH00Q5&`,07!+')9`!BY4
MX`Y7*.H?)/`#$US@`\@IQA69LX,2D,`,%1Q?'5F"#`7((`$):,`/X'"+/LR!
M#2M>@Q,04((>T.`#/<B"#YC_==,5+]D@$&"`#QR0@C*P(`5*.(,9XJ"``UA!
M`'#@UK$.W=\))X`V(X"!`H90!@K$X`)'*"N4!O`%%Z"C&'!!:P0.<.#8*:"E
MWJ1?BYZDC?&9@0[#E44?=J`$']3@!"%(@!-0*P93;IK3"9F`37+0A`(@H8V9
MZ(,,LE:!74-[R6]048"K\)\`G.`"7`#`!:1PF""9(05?&``D"^*B![R``6Y!
MQY-D]@,GK-`)/W"#0+W0A]4DF1C1Z9H?8JR`XZVB%:[Z=D($8`,-:(&V0EC!
M"F+@`31\H``'\(Q:)=[I=4P@"EJ0008J(`4"5"$'Y@.!/GF+`PW4E!B4/%(0
MQ[22_[+(H5>)V"6SZ`#1Z/R@>4LA+AO2D`8)I($YKL`@"4E^D`]H80)+T'@0
MA)`$`"0S`R;(P1:"3777@N8-$Q@#$$S9!Q1$(0LP*,$85H#GQ04Y`9]X@/N.
MA.-@],$'8*C"KJ+ZPCZX@0UMF"HG`@H?1T26($=R40Q76W:$`)H'75"*`@Q0
M`1^,Q0D9:/8^*V]58?C@Y#?`D1^H;`(%A(`,)1CK#X@`K0:@P01/,``5I[`\
M:(X@`BFX@QR$@0:<*0`.JF'%.5Y->H+QH0D)0(,CGMU\3I>4`"RHP0@0B?T)
MF*$K+*#`"VP``![`H@@$*,,`(H!G6'3A)SZP`;D[$(7$-/])!AO8P$<,77T(
M\:$'$G`LN]1_T/8`"]!5\.$..')<NN(!$/``?S`%8X<&Z$<`!$`#70"!<+$%
M"B`!76`"6;`'M(4&$4`>TW($!)`$2C(,!"@P?(`R1X<&S#%0+<A?TO$`RO(V
M"E`D/\`1+L)&H00,&U`&%FB!4'`CJ>$'4Q`"8T`"!&`!`Y$&B1<#8Y""F1`=
M-?@H?-`!#1!U([`*66B#:D!)2B`!KX!BC.,*:S!\9H,&'^$$`=0')E`%95"%
M38`$1N"&G2($3^`,%_`:2C`%+L`"]5$"12('-!B&#O)\V#,^ZZ"(-H@(.-0B
MB*,B*4(>C[!".M,BO^``&K`]%GC_`)YU!EV@`TE0`2R@!V;@!C]0`1;``@/`
M=::T29"XB%;0`)&W!CA6BXX2+&,!&Q/V!TA!1:W`"@(5!^D`'^,CC)CH>']0
M)(X`%P6'!AY``E9`$=CU`#T@`A50`&4P%!YP`&1``7R2!)Y`?;+P)+J0=(^7
M4HK8)&RF`1V``(P#%<1`'J/'BPSQ'AG6(JHQ`D,1@Z'ACX[5&$O!)+JP`RA@
M`SA`;B9P!150AV@``S=@@2S``F1`!B&``.AH,S?C!HN@5C<#!Q`19EF((Q.)
M!A7$B&B`,%!E>$E!2?FHCPB1"#(``R/@`[GB"204`74`&KD0#`%4D(N!5FK@
M!KHX$'2Q_P%-4`(X``;'Q`)-I0%8H'%7`$\#P`/,-PLW(QW0J)3%MTU<5(.%
M@",*<`M=,`!6D"$\Z8]]0&<]1'8T69,[D`1-L`(.8`=M\!1I0`)%<`((4`_-
M02&L\!C+,6$&`R4^(`!`@!8<0`9-4$];X`!BX`0IP`)@X`/;`(;$`"/XV!Z,
ME0CDP((MZ`>+T!O(,`)[,`8AX`1]893(H'"0-9=`L0,B,`8%H`)D14(3@0,N
ML`53("RM$$!;J1A))BRK"`-,4!=:<``JX`)"H!TRL`7!TY(9L`$<L$=R:09L
MX`9MT`9\-'R,L`:_4H,PPU'B8`0I\`0E8`,KX`'C84K3T2/L2/^;T=,'XT0`
M8<!52A(%!'`!`K`&"D`%,*!"TN$@IB0L3"`#`?8%"%,48E!2%V`I#<`X:E!+
M5<0^$@853W$D*!15?@`'3E`'60@,D6`&'@`$+"``0<4`!'`"/#`%2#&&A#&3
M]ED0:L`%.M`$."``+1(``%!M$/`#XU0%>C``?2`&R=$8L9D+:``N!-!7RFD@
MSB$#!U``>L`!%8`&,A*B,QDD?=`RT!$=/,`#&>`!1M`DYOD("@`"+"!?8P<1
M%?`,,R``G@=P12&7-TH0;Z`&/Y4"4"`$4W-I)'`!`$(`,I`"4=`#74`#1+`^
MYN4^Q_(9LO`+];`43#<0$X`")L`",P#_<&Z1#J\!,PBP`AW0`2Y@`!(P),%V
M<+`0)E_V"@]``GA!!K#87TF'#!`AF&K*CCC2!0(@COJP)+%C-!I@I!L0`#SP
M"AGU>$CG#BF``1`08ZWP`#E`!`%@6U"25B-'>E!!`B50`2)P`0/P!&&P`Q:`
M,B<P!@&0`J3D``5``)6"`A`P+=LJ:=O'H1>:*&Z(#$R`!C(P!#I0`AM`E,*V
M"L"P!AYP`E;``._IC[`@`SQ0`1``2>II`5$Z`<-``V5P``(0`/$*@:YU)"WU
M5'+P<SY2?*$:29D`"3!``U:0?@F0(RX"2D^Q`WM0`A9@*0I`1$H0!T_!IJX0
M!@4`!250`%C@_P</H`)8H`=&*@("T)(L`B5Z2G)0<'4J,`9%L`P'4@8@<``7
M\%2`8P1$:(%1T`%'P`$0L`/>Q!+$,VE,H(Z/P`89,``A4`)#,`&W1A"%4`^Z
MI@![8`(,\`)(8`!C(0`KP`$I```KL`<5\`(W4`8X``%M@01#X`,OX80-\%I&
M4@]M@`9RX`5*@0RO@HRNXA9>%0+Q6@"09@:]Q'0\=$L`"P"ZPP$>H$565'"Z
ML`8[$`4D``$0``4$T#(QFZHW<`<,8#1FPSR[2'H14!\NP`-0\`0T0`5!0`9E
M<`,T0`!'(`4G0`$\0`9F6X07\`18<`3H>P0Y$#-F`)ZPX`,0$`1'4/\".G`#
M&9!%8JE'_)@).-,\$'``57`%2[`$)'``1"`#'A`&6D,#,/"*`5I5;"`#02`%
M%U`&!>):KH&/4")]2)%ACX`.N6`&#Q`"6."?%P@#0W`$)X`"N@@:,\$!+B`9
M'G`#%I`%*P`"*,`!GH5-9M``)J`!,+`#+T``7+":.C$",M!=-&"SB="\E:<`
M'\`',J``&3`>?Z`!*@`!%2`!.:`J.>`$>Z`"&L`'J=+%1'`"+%"$."`"A8MB
M?0`"-D`"`[`'.>`!.O,1TZ%'2'$.C_`&V_`;;Y`!>\`!(R8``>4%#U`%!)"=
M/7`!$!"`'!$!&K`'3'@"K]55OD@';T$63##_%F(P`N'F!`M@D43`!PX@!$5X
M"N,C5%_0'4$@`U`Q`3G`!P9P![-43R;Z"&@PRGOP`1G@H@R0`!`P6S.P2ZNH
MN\VW#@5W)$7R'FV@.<OT/U_X`,AA!A&`,-MP.BI``T*@!P50`$\P`S=0`F%`
M`Q#``Y/$IN&62Q(&"<.W'(50?/_J!XVF!5,T+2-0'3?@!<'T`6AF!@O@"3^`
M`01P`Z_E!Q)@!W\32FLP!Q$@!IW,G5SJ!PT@`E]@@0+0!EM`A5>0`RAPJB"0
M!H-T!"E@ESE0#HL3`7$P`2'0!'?``3+0!QR!`,^R!`*A(65`!D4@N-Y%292X
M1:1W",/7!0B#(W.+_T6X@!B)$`=FHP[GX%(C,)G"#`$?$`!ZT`0#(`8<2%^Y
MXE)IH[^1!@EHX`5ST&]*H080T`,=``(\J`1`,`9#``<]0`88P`1N,-<0``-4
ML`($4`.O=0-^X@+'`R-^<`!?``0RD`N'H0#7:($QP!Q.4!D,LP4IT%=P$`)5
MD-=#<`%+L$MLP(&%L`,`0$8B<`)=0`50H%0[T#D-,,LY``(S<`%48"1`69]4
ME\&)X",M$AJ`=9:<%)M'8@9O,`7\H011K=50H00R4`0'@`!!(GU*,*J:0YJP
MXR(X5-MM,"0ZA04=``'G@`@,\`4Y@`96T`03@!DI@+WWA@-E\`"7)5@V6O\S
M"O.B.VP&3G`'!0T#N8`4<7`!1;@#`-0'#W!(:O``O14`?;`".!`$K90EN`(E
M"F"O-'"'&:`'#\`"8Q`#,F`$1N!F6&`%?*$".*`'.)(&7M,<>UK=<9``![``
M]+0`"T0!"S#%?7`'!W`CP#&;#8("9(`"8B"@"%`$>*D$-+`!'J`$7/4'87`!
M6&'4I$L>$5=#!H"Q_0--)X"Q$.`6#^``&6`$"("Q42`00`D)6S`;,R`,.5"V
M43`#,-`2GGDD8/L!?E``,D``42`$/5``7_!*BHH#X3./*5Z3#\`!&%X#'*4!
M9'`!5TT`)8!W+RU]#Q'?C`$$)0```3``.@`$!A#_9M(''^VQ3#AT=.5`0L>C
M+#3$'`%P`&@<!"]1`SU0`@2P!S^0`"NP`5?K`0N`;W^`E`%H!@D`!(H^0A7`
M`"2``C&@!3@P`#)5)#O8!TDEYTV0`K2F`PS@S2"0DS&@!S9``?08Z`=!!4>`
M`QBIL3"@`3:``3\P`7?05VMP!RLP3Y$GZ8KA!GV```!@:@XP%GAVNM%1LH4`
MFF$=0&<@!\6Y-LR18).`#0W``$3`US4@`3:@`TE\PL*P0A\!`QA0!61P`KGQ
M`ZD4`J$D`&7`ZD,A?5QJ!E<"`4K0`S`@MCY23\H2'6H0![GA[09A`$``!#1P
M`16JM`*`6A4`!2S@`F?P_P0W_CZ/H@@4[0'S!%5VA85L\%3?:8PI(E-]H$'.
MLQP+DO$Y@`1?8`-`8`,3L+T?X`1)XP$9(`(!\'YF,'9L,`(@``43N@,8Q`&L
MZ0HJ<`$AL`6(`"5?B)]04`%KP`([H"+C$P'/N!)<V@@%;_/$@`:([L]N@3,P
M@!Y2`&%W$`28,4.]"#-]<`-+``/Y]!,H#APR31P+)5-?:%P"U*U<GP$]\`4=
M@`0P``"Q_@,%$`+#D`$"L`5O(`',XP8-,,0XH,)2<`1(X`$FD/DK8)<ID`O/
MK`M,=P`=T&TLX`!!D@N]04ENH23NZ/BPUM`?P*YNT3408`(XD`3>QP,EYHP=
M^?\8I(LZ7(!:1.$*2_$WV/0&?5$!+`H(9WYL?2-K?XB)BHN,C8Z*?GYG?WY*
M+E8J"C5E2%M^!P0#8G=C(DXG*EUQ:'\C?3`I>P,K-`Q8%7XR-"\D)Q,PE6A^
MB)%">KA-.VE]?4Y.?VL_?F9KA3^/V-G:V]S=WHF1$@,7%6MK$@%:8T(((WX(
M12@_:4I^U=_;:V9^!E8'4_70T.D3R<P?!?3Z_%#RYT*!`&C2+&C2(06^BXC.
M:$2T)L*1+TA@=*&!P(^'$P1ZR,"@@\"%&3N4]%FCQLR(-,!^^)ABP($:)6BV
MR,A`10V;,V;Z_"&(*$R'"GU8/(BD)$V:-7Z4#BJT#*/_UZ]@O2F1@`#,F!1K
M1FCX$J4#"!AB1BBP(.\-,Z9>(V5-0XS9.RM)C+C1.TS0GQ]J:J9Y9N/"@T(:
M]+"0$;;;1F)F$$PPLL^',"<R/E3X\4,&'SY4"`J*1%`IL6&$_:A1JC$2)4E^
M1#2IL$6/@VEPIK'QD\;/"#,*S*@Y5+FY<[#3#("Y(""7$`(L#H28`2!!GSM+
M8*`Q&OPK\7K#_IA9/R)#!Q%;T+A>9+PXLS]0<)AI`\=#D@(9/"?@@(WXT485
M+%201@E314+(&4HH8,\4/SB1%8$89LB('VAXL$$'TF1@0Q0DEGB$$U`,P5`D
MDX!E1D0RO;&521T(X<0\!4K3_PPB!5RP!0P-9*!#$09I:"1TU8"QFQ]-R)"5
M&B-(\(<3-4F0QA:%/'/DEL]EY0=H6?6AAFP-(/#``Q+L``4'#NKU52&'_&``
M#Y(0DD`1(DSQ2!]G=)65%A<$0,,)"_30Q`-<)NH-&C(AB(L06YSAQ`B(,+I8
MF&WLH^BF>?DA1Q?$O=B'$FLHP$28$EC`05+#%/<5&A'(0$0(+P@Q@`QI_*`!
M"R=@E=XB2"F`!H1.Z($#)7UDD$41E'+J;(%`'<#"!)],]8,$S`!39Q<92.`$
M7\^&JXUME>S3!QI3.&'&#WW(H80!3;"9V*]?R7`""U>@@,4=(<#0QP(%'.$*
MO8F<L?\&&@V800\../2A0!\"6,"LN!1'@H803YU!P0X82(&%%$$84$\72&!1
MQ0%#.$#QR@7J9:X]"F";U`@CP,M!GP39YM49`D!1``A^-,#%'0(HH4(!(6"%
MS0(43,`0#A<X(:P&!30A!LOAIO&&#DN:$,$3+)#PQ04B*+$#"F5T4`(+(&'M
M]FT%R=9'&VB,4'<:(RB!XLW!*5#/5V<D0$('"*011Q`%#"`'P"%`,RJ'TW!8
M00ELJ;!%#&64@8$?.]R0^0IO<QJ)DA4H(8(8.JB00`H%$.!'`AU<`($,`[#0
M`;)X/:*$&H<I5<]PE4#"T%+N:/K'9:$CH@8:9K`ADS!*V#W_@HQ^*-"`%1R@
MX<0:NX=5P1,7I&#2%60@H08&+(20U8LCR*%7#5\00$`4`ICA0045[*"]#!5,
M8$#RFU(#`U@@``G,8`H>^)8,"$`"-_`A"C401`,.<"S"9.-+?H,!!VP@A!C(
M`"@C\(`+5-<N`W`@!BJ(`^^.UR(`$@8YE9!`J*!1%0_$RR\<FL]%^K"%$$2!
M``6('0L"X(>CA8!=>G$"Q'H@/_D50`:"X)U>6@A`+K&*!06`"@"<@`8#D."'
M=.(#`18P@N6YX`LX8B'R%+&]-[PA`V480@9D$``6("$2"@"B$\3@APD,,`!*
M8V$5*8&W/AA@"#506-V:D0(.&``>_QQ0@AED0A/S*&!U(0"""D10!`R8@7%)
M890/(#`#'!!@#`6P50:$\3`FW`4W*QRDAKQD@02E@0*@:D`*3I"V!&@@"@GX
M01RV0(,+^,`=Q"D.%1/Q!OG$``<WX,%@M@`&'%A$`3W0@QB6`8,AL,`#1\G(
M,M\6B1$@P(=<V,L:NK"`#G0@!UU8TW`F-2;S-&`%0A``##S`A1(4+@!(4P*I
M>,"!"T1A#"S@@`Q@D#=A(#,-"E"`^W0F2PW-`PQ62(`?8,*#'T0`!@$@0"RB
ML(`=J$$"2/B""H]73T=$(@T%&,,'I"<!$(RA!%GIP1?6HP8>K*`(3AAG%0U4
M`1V8\@G,4/]`!KQ)@":X(`'I0\`\_F:>'6"!#"+8PQ6L(+XT`/0(9G#"!"@P
MAB@\(08.B,L#W""APJQ/#6>`@R0K.DM)]*``U!("!H1@`#/L(`8$X(``.F"#
M+2A!`%:X749D0U%%S,8/42A#!=S0!R.DH0)?($$;_D`"'&1``WSXP+T00->"
MP6`#8Z@F`WZ@L"44@`(D*$`*'%""`N@@!SN0`%4Q,HT/A*$`7[C#`$;@2O1)
MX0$IB.U989`&;$%C&1QBZ0^VT`8_R$BHI:U,-=A0`!QP``(H`,4!,*`!+>``
M`0@(0Q10P(<@D.$`4Y1-2X&%!B9$X0NEDX89*H!%80`*"'>`@@W_RE`$'V3W
M>$KP``I`T(02*`1AO/F/^!J0@R!4(0P>J(>8=.8K8+5P&L41:`0JD(`NK.<@
MN[J#"4SP74I)0!H26J0DZ-.'P1QX$L:K!U_.H!!PI*>E3`#7:_R`A"A8X`@H
MZ,`"CD"&`I`@#!#H@QD,<(`FD"`+'-`6:V"3'IWQ&`T]D"E?]K&'*`BA%0QH
M0E:4@(`3%.'`X!A!`'!P!R\4@AE*2()3Y9,F%X2!`AMP`0_F11#T.`@19EA-
M0:+1#"5.RF(.6,$%"&""";1A#6ZXT3[0(`PF),8+:2@2G!5Q%/;\H1Y,N)%"
MSK44@ZBA.')AGA]^4%T_Y&`%59`""!R`_X8KZ"`,)8C!`NCDACCXX0$YV(,'
MI,BJ5R?E!TQ0F"2,$``L?``#7^#"_\RP!0``\]16*$)]$$"!(@B9KJPQ@PK(
MH(4?O"%OA4@""U(0H?C\(`,IR$(3@&`$@IA!2J&6-B+\C95S*2$.R!&F!,;3
M@`V(X`4'X$(65J`!R_Y`UNLQT$R2(NI1$R,-`$&#KY1`FC(*=$;GJM`/:#:W
M-1!!!#T`P@"`<2,/#$$$%CC`9JOG4#0@Y-7$X1./Y7`.-/P@.68(00?&0`0S
M'.`"(<`2"$AP@'4UI``*B,,:,-`!%F2`3Z65FQ\64(8K7&4+<LG`75.P'Q["
M(`Y_2,``;/"%%?_X@`VL\`,<@C,-89B+D.NRB0)NY`(P@.$`')C`#CIW@*[7
M0(D/\X,,F?$,PW@<$HQZS`N7@96KW&94"D`[HSYP``;8```\<&4;EF$W#9;`
M`CTH'=[DLZXP54(:&JD)&N)@A!NP0'XXT(`$9```$=R@!S1`P0Z^!``2G+X+
M6TB!#4H0!OEDUP]QZ`,2"%"%H-,C`19PZC28D2L'2(,*$RA#%`8P!4K-"RG#
M>8-!%(*521Z;`A=H0@AF)\,W'/T!'H`!9'`!,3`5KJ`$,.`&,J(EEY<1#9`&
MS-,*Q`!CPF!=U@"!KL0Y)G`!.I`_AG`N.1-B;<`#?A0%,P`JPQ`AGU?_%9%`
M&I%`96/01%'@`E'R`SP@`Q,@!MBB#SS``PWP`*&V`T9@!#)@?6$W#"D0!5G`
M)VCP`&*P!?I&!!5(#<S`!FH@#3PP`U]0`!X@0QP25.JQ:EZ2%15@`SC``#5@
M`%.0!F,2#=%C6+&"`A9P`5I@``_0!DQA>0V("#>``C10"7P4!PU``S4`%;)Q
M!FP`/,0A'1=@!0/@`U(V)M)VA1-($.Q4`&6P`0E@(0;R`/N1@OO01T`0/P1`
M!BR@B=+@!Y[!(O:`&P\C9057/-@5.F]0?S)0`QI0#?+!#"```9Z@#_;@#A'!
M!L5Q21O``@/P`>:G%Q>G!&>@``8P`2H0!B0`_P`+Q2X:L1"/EBEB<G0-$``A
M@`,'L`$"4!+"L(<#!P%D$`4,8#$3T`-FY@1PT$P2\!@_0`4"("TZ$``/H`#<
MHP938&S&Y@8_X0=UP`P4H@0D&`8X0`,3(`,/('^LP`0+T0!$T`0DDDH)T(]`
M00A,8%B\LQI\$3U&0`C[H3<$,TB,)7);L!#$V`=,P`0T8V@\-G(.\P9S,!8`
MD`1:0`%`<QP_`0.R`FP4P`$9T`5PQ2BYIP;4<WM683%;``$#D`4VD%4>4!QM
M6#"S&#K01@`X$`5[T`=MAI$G0`TC8`19IP`(``0]0`+*=PVQX6]?HBG#\6R4
MD!DG<`<60`$%%#W$`?\#`G`O!?`$(?`!#"5%DM`,TB!.U8,L])`I;H*.WZ`7
MC#)^*V`%+_`!$_`'5/`!>W`#>L`%$&"$V\!:>`AB2J$6)O`%+R``<Q)ZYR()
M6_DV^Q`%*R`_/\`'%4$&*N`&R$8#"\`'"#``17`$#0`=?.$'6[`$5M`#`]"%
M(]``0]`#9[@`,/`3!Y,41V$<#B.9&<)CE"5E!H$5&@1S(7``/7``*1!,;#@\
MVY`49_`#<@5W)H$!.Q``0``$#N=!05$5L511!#$&*&`%43`"%&`"`D``+N``
M,1`/51`%)V`$"2,''8</A5`)QV$`0$`")4`#`R`")(`%)44((N<*1D</9?3_
M!V[@G1BR>L\E4(B`$,Z@+T.``5RD!FW`16*1!F=01L0Q`5A``E"0!5QP"`(@
M!2P0`^Z@!&WP!MDE(5&0`QA``!%0`$3P`010F"00+QO``"L0G\=1H1=1"6L@
M"&9`!130=0=@`*%F`$%@`B)P`A@P#XHT`E*0`C&1DBP*%C+Q!ZZB!BUP$,WT
M!VH``TK@?P]C-R+G#9.@%W#0$AO``5Q``"KP`&=0`7H@!%ZP9LQ!5Z<R@Q[`
M?2$@!A!``(3"`A:@`0F0``:P!7'@C&"A$&;:!?6'`";``AK`/&J``A?0`10`
M!18`%=&3`%E@JE3@*GOZ'&*"H_,0$2<``)8E930`_P0,0`$T(`%,D!R6\2+#
M0!!E0``RH``#0`!`(`%J,`$=$`9]`'>L5EIM\``09``NT0`_,`$$<``0(*1&
M,'8KL')^`QUH(`=X*"R2!`,GT`0"T`?!L0(,X`(-P$L?T"X`8`&F!`#_DZS/
M\8RIN0];``I-X`'&40-1T`0T\$4D8'7>X";?H@<$(``-T!()X"03D!UZ,5\5
MU4=1L`&A"@"&Q`!-]0,`-;)ZL`$)UP=L\!5N@"6RN69&<``/D11_\`#TZ@<G
M$`4:<`9M<`,WD`!0UP#5A;'.L:F',0("\)4I80`C\`#NM`/W1@(L$&5B^@A0
MBR7#00/R\T-1T`=\(0!).O\>LG%@/Q`"-@`$/U`#<@$!);`"+X``71``%'``
M%:`NOJ*GW<"*S!$)#?`"18`+QB$-`0"/>(5'$I`!%W`"#1!(8/L</B```/`'
M30`@4T:N]*``0$`&-Y!HW@!VT/`#47`!#L`#+6$#!S$!34`!RA.WJ9LA#2`"
M#W%J#*$&-R"X5JL1U;`&.,`'4S";R=L-\S(-%8(#=?@'"P0$*;@$8Q`"/X$/
MB-$A@14!3I"@+,`0":`'.C"&R+N]SZ$&#2`$+(`!K*"61N"G3F`!5T!:TZ`"
M8W`#GDBY^+L-N1,F#<$`!M!%64H0/Q`$47``%5*YPZ!$2I``65J$&D``'<`,
M,QO_`G<A90T\2SP@!%9@`.=2`2<0`T:`!@B@-AZ@'F80`3BPN!*RPA>A'#6[
M'FB0-AX`C010I,?V`@^!$-P[#,+0!SO0`000!B=@A@MP:A^``RH@#*$&Q!G"
M#U=P!V*`!A(P`5>``R%``QM(!%0R#"!P`210`6#L%7[1(FA`!@R``#L@`Q;P
M!#\@E$W0!"4A!Y8Q"3Q&$`*P`C:`!0<`$8@"`5\0`U&L0W7L'('#`"1`&A%1
M`2]@`TU0!6@E)M5@`'K``0_PGY>L#;7!(G!P"%'@3UO0!1@P!@Q@`EEP`4$P
M>3NT#TSP!QG@`#*0,!)P!A/P6J&XR@.2R4^0-U:1&2#@_P("\`"_[#A*L`<.
M\+7*O`V7,287H@4N``,6H@!8<`$LP`(KL*_&<\B,M:+/B`9=4"E\>P,_@!3-
MLLV5X0<5P`!/L`6'\%A0<C!_DQ00F!4_C,\7X0#NH!4^D`$&8`!MQ<#<D!X/
MS+<+X!=O<`9S8!`:,0)PQ[U_8`0S\`(],!M1_`<:H#89@)6'P2Z260%:0`+%
M01H:H0#NH,->,B\'(=&+0)&((#5+`0?.6QC:B]!V#`&OA0AB`,-L8);:Z@U8
MX0`5\$,"``T/L`8"@)%)<`UG0`>4\I3H:``E8`4?9`80<)X+\``#(P`T<``'
M0`,>8,;X\")`83`>S5J)H!Q&C?\A9_`!9"`$1':W,4@`5Z!W/,T(\S`!44`&
M.!`?>(<"+@$Z?^``'O``_KQ&H_8Z-D`"(Z`K=]4Z/>"_*A`_#$,`>N`!J#LN
MD9`8=W%J2I$[>TT@?O`!9>``:P`#$^`"0#`#L4,#:)`I13UPDI2@"7I'4\8`
M2U`&)^`$$+`",T`!2^`!]]&`:D"L'>`!RYD$+M`')T`&ZD,")``""N`&5,P'
M.'K8F#$JSJ`7.7-QMQ';!`(!+.``UE`]',`"7,`#-GUNVE`J?5"J`L``5M`%
M#R"'2(`#,6``-M`#-5`"8Q`$6+*'9C`!66`!7GL<6^`!0@!U1/8+GO9%'W`-
MW]`,"*#_F8^1<;=AL_!=&6GP`4T0`&QU<0GP!"7@`=D:'^A-#$B1H`_Y!>0X
M1!S@W1_P!26``6R,`BJSA_K,`%7P!VW`6H@[!@V)?1#E!0D0!7>`W3/&#4HP
M`1P``!MP`B?@`O%1#P*WXL]A!AB`5W%P(]UT`4BP<E.2!SE.J$K`!*4*`G^@
M!5'P`B>`!APP!D#P0%S@##R``#"`CF]0AB2@PVL0`&%P!RP`!#*P/1*0`G>E
M`>H"5]V@`57```%PGPP`!0&@!`J(AS>!YA@Q&(DA(64Z`5"0L.N"J1W`&</P
MA([`%-X,+BWP`RY`J=%'`%;P``YP`%&`!0[`!59`!`T0!$.@_R>E51O5I15J
ML,]-+G)2%C2QY0)FL+P7D*I=,!Y.<+3!HQ[$<`C9_@!<(%M2U@<R<`!9H""C
M,N^J?A%C,AYHX"]*\`$L``*OU@:_!`8O-3>LT#)GX,V\HP\%3@`;0+8OP`%I
MD`$,P(X5X`(L@`-08`(88`C1+@C%00V1`--WT(-+L`).T@!W4`8N``$C0@(!
M\##"$L5K`"ZN<2%ZTT5%``4-4!!F,`3BQUBP7>_>P"XTLQ1##@)]T`(*L`=?
M8*-38$&/L!K*TPP1$`#*]@=;T`"YM;H:,,T/``')E@%*9,E#M:F4\H5GL`>H
M2ME),`9<@``S<`%8T,+W!0`8<`(KT/\`-4\0XX&U%F,<25$!.'"R!,$&/62;
MZ\$GC27TW4`0LX'2G64"!T#96%`$Q9P5=7F_B,`&P6&),*`PGO`3M;$[3%`/
MN3==BQEV1I>T?N`&#G",I;L#4T`$4!`%.+`"Z*5O4-,C!:`",G0&I\)C7$:%
M<=`%:3`!P:7WT3,"/D\$6TZ:C%^Y>ML%#5``/1#26L`"*C``"\`:1NO>V>#2
M;Z``.D`!/$`)-S$"'I]W:5!K3AB9-PM1A!I1&MZ_&C#(-/``-U(](P`(;69^
M:WU^;'Y;2A)^3B-]:$Y_?4X.`2-^?GTP5P4+"A)*"24](#]]:IE_JZRMKJ^P
ML;*SM+6VM[C_?F<C%0=1-DI]9F(T/20I.R-_F69K;[-G"GU*'BEE-#*9A)EK
M@YEN2FAHF#].2KCHZ;;;2@8S&'$P.WYN"6$%5Q\^(VC!CFI*VIA39<C/B!]_
ME,A(T8,%`G,*_*`8PT#&B"DIH-Q0DD88$S_J0HH<23)DGQ%B!K`@0,*(&7%P
ME#B@4<5$"`U.!OU`",O0&35H*E1A`<&,,#./,"D!Z"U-&H-KUJ!14[+J+3]I
M%&BPD06%DTQ]%.24$>*.B!PR8/2#,4+"%#6GT/QQ@B:.'R434`CI06%GAAP#
M'OA1<4>'BR%)3CP`Y:1/1Y!6(TMNVH>5MLJK-$UR\^?,F56>C;)Z__HG32JG
M#E84('`'#9MSDQ[U,4"A1Y44/H)-`FDHU9]"F0*(T*(!C:8S?ES_43-"S2`U
M9]*<6W.N#^:1FEMI@[Q,URI#CR890C/HZ2#DJR"XZ.*"RS1-PJ92W:+"Q@L*
M'"Q6'K'EI>^3$7BP1`DZS&#`&5,0D00#6,C0QQ80<(#"#2HXH(!<'2TEV896
M&=<&>7Z8L0PBWO@!1S<[=:;-&6O\(&)R']ZEA!]>N"!$%`18@`!/KZBA``1`
M9'$$'W:,4YYCAAAEA@86W('`9W?%41EW',(2XB80Y""``\+T\=D/!@BPPVEK
M.+&&<WU,$,`$`LSXPXQ,5#```R]@XM@C<O^]XD<&*>B@!P49C+`(1SO)H8`9
M#@QQ0@D4(*#$#BE(T<,50QA7Y:68KA+1F7^P@08J8;WYU!E(<13'IY0H,()3
MF7RJ1`36_<`!&000H(<'<E&EIQMT1*`!!238X()TTTACAG-FH&"!"`*85IH$
M#TB2J9Y/O>$#!RQT`(`:UIGAA`M:F)`-&MU$,(*9%+R@0@UA>""!&3K1``0'
M"1"R!EAYLG(&&WW\L`8/+H1A!:"5S:B`&PK08(4-2.SP8`(,Z'$`$0I(I<"T
M&$=6'C_;A?A4&@<5TN\C(?+3T8-*N"C&#W[4\,08M8(1P#(LPP*4DC!H@(45
M5V"P!7.0&')`&2G_\##.C&H(I$S&EOGAHP(>'$``"SYHHD8#(A!0P@AT?.J'
M`DIL(0(4&DPAPP0L4#$"`"@HP$,#\!F2&94JFB''%F.E`(06S!HWW@I+3&#.
M!!0\80($\FA"'M.,B[2+&FDP(4$;T4D`SHR.L3&'$F[TNT7%UAG"1-#2.%%%
MK01<,($$;TR!BI6HP)7!#22,$<47203PP*=3T-`$#54GAPA8(.F:\5UW_0!"
M"55$L2T:/IS`0A1)H#&%`PEXL,,/0URP@033C$``!3MXX`&\9IP15F>5>=:9
M^YDI,4+%?L"`P`<S6'%`!3#0X48&.VA`!I+`@@UHP`/D4`.WC->X!M["_QMQ
M4((3J""###BE#05Q0@.,\`,F$"L3#X"6#!P@`S&,8`1,(`(."!"%&NR`"0J(
M2+ZT8Q`G*.``33#!"3I``!LPP`03X,$*.I""+D2@']XY3F88IS@_,&$!)IB!
M'FRP@S<L0`@48$$21J""#:R@!R;P`!?&@(1%K&$$42@!#$"RC?'L*PW+F))W
MD&,&(\A`!CL`VU(00`$<%"`$%8@6!K)X@A@X(`UHB$@:MM"'-ZS!@9"TQ8PR
M\8,!7(`,+'"`*OS0A1!$`0H>,(AQOB8!!+Q@#'JX0!(JH(`MP#$**I"2`G[R
M2"L-H@\<*$,08."`!?0`"1/H0!0*,(87-.`!B/]<`W*08YW/-`XKK?R#"PJP
M@@]<8`9B"$$00&"!*R2@`R'PP0HNH`$37*`&#D`#<@IP@0P$PR"ZT(5G,N$^
M^/4+`BN)0A-<<`H9U.!&J.,`!SJ@`QG$X3=.ZX,$D&.B2#IT%I/DR1!2!P(T
MG(P/8R@`!\*!BC4\!0(6T`$'TX`%3T3$#QZ@RCS;0(L^1,`&95@!#2A`@PR(
M80HDT$`&`&"!0-T%.IC05P-/PL8<0*%H)&C"#43P@1PTH00&`*,*7%`T+$0A
M!#^8@Q]^8*L'4.([V2E-GCS#T#500007$,(!OF`#&4S!!%$P00H80(`FC($,
M&'""&[:P#!AFIA\\>JC_8$%3HDS$0)\XV)T39'"`,62!!V;8`@(\@``8=$$$
M#/A`0?PPAB8@P`QL$-%5-#&")!"`#`Q@P#`'@$\^C``(!9C`4ZPSV&7XC0,X
M<($:EA"%*%S!#[C5`@^JL,HU0``!`\#!`;KP*2800`;H@,,<WA,`+81@!UTH
MP04@8``MO"`#F[B`","0R3?PQ#>U3:\KO-&-082`F@2XP:?XH`44D"``#KA!
M"%)P@ALLH`A2>``;HN('+1!@`O<*+"VPHH0I:)<&2G@`#7"0!`AT@`]FV``+
M*F`(Z]`MDC+B[0G2,(HJ<&D%O]B!"*)@!2DP0`5D:<("!@<$OEZ%":[IQBI^
M_X"`&Y2A`^`UPXPTL.(5Z*$)/&"C(4BCWB9/<A"K$$(!*M"$)G@@`3,XP1=!
MH((F<$$#5[``#3IP!'.MR@]9FX"4U-&'-73"!9IH0!&2(``][$$.,YAR>9CL
M4*(F\@8%.$`:C#"`C3*!!A8X``\T4`(6L"`$5.`(%DRP`A?<H&8/Q-!2T-`&
M,0RA![]PT%9E4((O$$`%'2B!#^@XPR:[VFG.^8,Y?9"",81`61D(`@M2<(`.
MW``$1.#`!.[0H%,@A0)1F`#R<`&),RCAO4.P#A_*<`(0L&`//]A`$Q(`O\'V
MBV8"<,$$$C(">*4!`0+@WP@RH`$,(&`$T=C"$%:0@O\%I`.10C;$#Q0`@QP@
MH0JQ?<H:$+`$&I0A"\MB9(A$)#=7O[HM?S@`#OQ@`!Q$H0H:D,!:8R""`B`!
M#F;X``*N4`8DZ+4/#L!!%630AHCD(G(_<(`)"A"N`H@@`2I@00X4H.T$&$6!
MHGUH&MX%E#9C11C<6K)8PG&L5!3"#&V@!PP86(N[/!)J`GC`"-:07`I0`00(
M4!4:*``S$_3G.JIP>&UG%$<X@@$'$LAV%+@0`24<H0P`B,$%CNJ"`PC`VE?0
M^@@P0``7R"8=_!F'!X)@`RV<(`%H@(`6()#M)F1@>&EWJ!FZX`:`?"45:#B%
M=5I0[D*TX5Y_>,E35A4)U-__8I[BJ`,2.A`#0:F@`"G(00=8@('D6"`*."A!
M%X"R'&>JO;:Z@/+7FE`&$/0A`2$`P0@@T(,"O``!`-!#&<0L!B<000<H`,`+
MSN*#QAA_'4IXR0_@\(#)6D@.".@!'Y[-@@PH$"2P<6B(:)8&,UP,/K?T!E@!
M!Z$%!PRE"P71$>='"\Z&"4Y3`270`2=@`BS0`PD@`UHP!E9P`E5`!D/3`?,P
M/,9A/-MQ?)"T27V0`0FP!<D!`RRS!1Z0`0CP(!XP`1GP`(,0`3VV`!D@`]7Q
M80O&1O*T#!<"!PF@!0+0!TF@.LEA'NGE-'$$&O3D3/0TA9WA"D`X"YD7!Q#`
M`#CP_P4Z\`%O8@`U4`4XH`4Q8``74`(.\`;J<TL.&!U&05O:\#XFJ':>,3Q_
M8``2<"F9`#((<'-^``0;I@D@L31W&$DM5UC'DGI)-P8]\`!)EQ"9\`9XD!E]
M$`>?9P9/X1V)Z'!(M%E5PE!*('D3T`=&5B\,=1V?^$R\\7.?LAPAX@6<508N
MH0!4L4;]MQTMMPPJE7FMB'P=!C2QR"$A`AT>8`,"8`8S8'ELQ`;!Z$"OTP=P
M`!^C<R]1EP8$8&)&(1=M$`[,(%K?MB]9&(T@]B8<\8?EB!U/`0<(4`("X`<A
MH`?@I0N(8(Y,A!7/81U>8Q#3,#XXB!1(01W<H@T!@8O=TO]P^"A8I3=;ZT@2
MHZ,&-4`4?1`"%N`!J(<>"XDQG-A_;>8U\'(77L!5.M`%TN`';:`"*C`%F@`'
MAB`_.[`8J5=N&_E0R-$YF5"-ER(.A0``':!L7,`"'O`85%>359()0+$&..DT
M?N`#@Q`'!*`#BN``V7(!%_`"$/`3.0@N`8!(CY!^1@E)\R2$"\AFM60=!$D(
M:<`!/5`!?G`"])@*P!B6?BB7^K(+SZ`&%V`"#B`!*D``&_`!W=,!R5$_0T`&
M.$`#I.(&!_&0=-F*?O`&TR"`J2"`#Q(#!0`!:D"!H>0<8?68&/,3VJ!`%U``
M1B`!"3``77`&'\`"6C`"<-`%&/#_>P40`"$R.N(`FF'I-"!#'J;Q`P<Q`BE@
M`1,P`B50!CY7$!>CFZ&)%4[##UK3!3:T1GP@`F1``=*1`SU@`QSP!2DP#BTP
MA\Q9DT:G"0*8">]D`%#P`?)(`@;@!"[BB>,Y+4&5"O'U%:&#`V1P`0/@!#Q0
M?2#`!TU0`?MV%/-IE&<$G.0RAVN0`4_P`6-G!09`6@IYH)>""0Q%`$```YSX
M)@^0`$T0!1#PEU:F0D#`7/S!@A9JCJVB#!F`!$.0`D1`!`;@`CW0)CB4`491
MARO*(6]0D.K3`N,C`5V0`SNG`#L`!`3@DP5@`4E55RH@'J+1HY!I'8@4`RQ0
M``Q0!2\@_P`!<``9P`$D()1(XIA4F@X_:HA*P`,$P``9P`-`T`0?(`808`-C
MH`'[101!,$;,HCX5>J9WB)XC(`(DL`1$@`0!8`1BD`%3,`!:@`.?\$ZK,$HS
M$G2OX!AV2%NZ68?;02I"Z!@I8`)-@`-9H"9U50)04`!+4*9]H`%$,4NKT'^E
M41"[`:CJ=1>K,@%0@`4.\`@@\Q$<,0$'H`<Z``(2H`:AQ3*%64M60BZA,Z6@
M.9K]8AS1<2BZ@`0Z%`08,``OX`(.,`,,T`-80`/.L09TP$@9$`(<VB]Q(&0%
MB17`R8JV^E"5Z`?35`9-0`9D0`2+\`,^$EFI>0%@,*%5J$Q^(/\&/3$C"--R
M"E:3W;:*^%=N2H`"^AD#/(``3A,!$<`#'5";3O`5'F4&;G`76_`I(6D&+J($
M8I`'?O``F#:O@N5_?_`#6#`&);``(-`!9+!12L`&U9B+?7<!.B``3M`&3X$0
M<*0G?B`':R``-V&`CXD<OM$JHG4(*-`$++`"$^``X;`,I((&(,!\`B`6BY05
M):L-0M8=?[@%/^`&:P:S@G4<;/```I`!DP,`%R`%1B`'+ZD`&/0#/M``R14#
M'W`@(5*.:_`!37`!BEF6+,I&2L!V2\<#%3!F5N`"#<""$@!'C.`$:1`':4"W
M:-```/`!/.`#IW`7%W((,=((F(!!<PG_M](X(VD``0-@04R`!#@0!(T!+RMC
MB)X+`R#`!1*S!S(P%5:R!A6`!8C)`7+@N-&(%2KRAR/P`!!P`EH@+#(`GPH'
M>DZ1!EVP"A&`4C;0!`=043O`!SJE!%X@#'#P`Q#`!SS@*7W0>;+K;4J`!1<0
M!`@P`10X`*G0!RVPBY-P+Y6J`E>``R>@`="E)QE@`MM9!BCPLAMY"-U1&C#@
M`2[P!'<0`^_6+R72LP9Q*"SY@TZ0`D4@`ELP`59``$D@!F"1@EF:`V@P.F!S
MOX.5!F`F!2D0`EFP`@;02.'A)7]@*>"C/EV`!%QP!S0P`::K#1+0"QVP`E=`
M!D,0NQNI!E&L_P$"H`)9,`,(L!P_`$>&Z!A0>,1NT(?\T!E;((8CD`-C\`0N
M`"MKX`$A0`8FL",.(``?,`$<VC'0B\.):`1(@*HA,`@0L!HLP`"FU@0<\`!A
MJ3X/L``G``1+P`==`!(=D09RX'2H-RJV]`.,(&1^60(WH`<I`+\B\`(L(`0R
MH`$OL`+-R`!M$CKR*<CFJ``J4`;>60&8=01'(`5E$`5:H`(^$,D(L`$,``0)
MH``%V@+^.@V&X`;'PK9;!80H&1&1JP08P`"ZQP`>P`$'0`,L<`(P0`%$,Y$7
ML`<*\#&X7,$DU@0=L`"J,0!'6P)1L`2(6)-^0`0=(`0/(0,H<`58`/\"7<`R
M&3`$(A`",;`"&1`7'T9/R^`41D`#)2`#(I"8,O4!@;8#20`%()``*8`$#>!1
MQ_C.^`@)$U`&!P`#*%``RXA!2#`#%<`9D<P!38`"(7><56`%.+`!._`'*/`%
M+&`!>@`%&X!`4$8M+U(_`Q`&:!``>H`#%.`!&/`%4@`#7'"1/Y$"H>0TEH+2
MT>L'`D#5P,4"V>`4:"`&TB"O"^EC`#`"+E`$6-`%%=`!34`Q6A`%CXQ'H>!Z
M6*@$RX0<#3`#5:`$"C`#+#``/Y`"'L@#)W!Q&=!Q`>!*12S6YK@O%:`'+Z``
MN*4"I.6Y"[>;0]`$,<!)5,`#6V`$=U`"]7+_!R!]1XJ`08[+4*'W!PZP`630
M`Q-@!CD``#*``"?P!7J0`SQ@`;72!"G`@B"!O)C=BLA1UB8@!JI!H"V2-.%A
M@LR0&=`!);J"`BP``-I@!!QP`000`G5@``7P!47@:`2P`D;P'GJ"&5BA0/W0
M"LUD?,$0#&>P?NICIL]=6^HC`"P`!B,PU!@0C:F0"A$Q")6J)'<Q`!8``'(0
M>F+@`@Q`$0)@`%=`!+S4``50!LH6U@&.V2%70!&P`5\``M$XLKT!%_-T0G_H
MV18P`-6[KFAP!5<ERNL'G"O&!_T"X"5^IIJ`-@L@`4LP9=$H.O"R"F8P!S?,
ME&HP!'I0`U&-`LOX_Y9?\&M```$*@&,=,`8?D']#CM)%7@`S@`9#D)E+_H=1
MD7IAP01OP!&/Q`%Z,`!^@)E/```IT`%6L`<#4`8]$`,8P`4$$`8-D+1ECM+]
M(@#6]P`AT`0PH.#OHCB%`#9^("6()!&EL"<W<`=?0'-%PP.Z1M2J)`"1L.AB
M?1>.?@,P$`(L$-3!:!`@@Z0S(C)]^`/S@`)N"BM=\`%(P`&(<PH-$`#!3@1I
M\1*JONH0\-,)P)D*W@<IL!HX`-J5T04^1@`%8&G$Z35.9QJ"<)Z\,;)%N>SW
M>]<<8`0G4`3[S`IF;!4HRPK*WA'[QFP"$`6T1U="4#430`!<$``6<)77Q_]P
M;FWN97X7$,"X!A`&+,`#LA`);W((`!XVR0$1"F``&.!5HCP50OX'0E`&;OD#
M6VH$&<`"(@`7?-`##`"/`JAZ!F_NU?L!8\`!%6`##F$E2K9D``X?;B`85$`#
M&3T`49<<8XP.9B`!/Y(#47`"/)`"44`#`W`#-+\$#,!!)?+RRWX(?$```^`!
M!.0`L.`^5N=A5]$-6.$.[$21H<-GM6`<<K`#);`:+B`#D0T$55`$6EH"6@`#
M??"\FHKU!]\'6P\`@=@$LMX3/B$=`,X</S`.&L``*Q`"'6``ZL0&>G@+\*D$
M73`#%$`&6I``%$``)G!,0V!J3C(.6`SXS^T'A(?_`HS5!$;0$W#`*F3%;*=@
M%UM@$7Q@!0W`!/^=^C;3&&EP"N7M`LC&3WV``%)3!6O@DH:H^HON!QI0>`:@
M`T40"W[``P-@`G=0!0V##I&)"8-@!GRP8<%P%$+.!ICE`730!S(/`'O`]9"0
MR`2@!7T@YV0/_;C<H!0`"%DB!QE]:'P$-1XE17]]9FQG?7U^?C0L!5HD94((
M?Y^@GV=F9I].?I1H6WU*#T0=#6LC;).LM:%G2GYJ?G\C?B)1(BI`!1T5!B5-
M`RX,%V$'J&EIE*'6U]C9VMO<W=[?X.'BX^3E?3U?*T!C56U]&`0J"3I-#A)J
MCVH_(R-7%C0>,EPH(P";_X1*?7Z843+"C(0':/:(,!"B@P<%/]@@7".G$IL1
M?7BI0:,D(24$."[@B$)@P@@%&BZH)&,"@8$U9B95*L>SI\^?0(,*%3>&BA\8
M0@@XTA`%A0T617:M^>%'B9E*(G\XL5(``K8S9V#H>O/'S8\'(%XTJ<$AI0X&
M>CI`8=##F)`3!WI4Z5!&BPT2#.Z$03%C`P4P&P;HT'$BS(8P#"BDT")BPA0F
M/]8,W<RYL^?//1,J@2'@@E))/W90($#"R0,_:'Y0FW3F3QHT$RX(D9&-21HQ
M:1[\\1"`P1@2?LSD(-`!P`HA88100,'A!H4#BP^<H*",@1`A%1KK`?.%PET1
M.O\*O!`R"(P>%A=..-$%NK[]^_B!3OGA($89`A3L$,=L1J"@!1(_9$82)7Y$
MXL`0>F!A0"_7].'$"&E@&,!?0XBA@`<H'"&$`'ZDH08;;,AA!AQ]I'&5$FJ8
MH54:L"GPARX7VK@#AJ>@L48?=:`BQA!8P("&`DSDI^223#*YA001+!!&$1V`
MH``I,CHP@!4IP/`#&FC(49L?`MS`0A4(H-$'-F8<.8(,08211``9"B!$$R(D
MD!Q(.I7(BII7M8%&3F:,L(4O?OP801I4F:%`0ORP4=(:/'A0`0@&_-#DIIQV
M&M0.#RB0QA;PW)!&&ZC\((8,&W20`IA65=)`$A=4L8#_`KQDDV`&7!`PP$@-
MK%`%%RZ8,84?;J!1"1R5*)$&0VNH^8=L&4[SB1\_\++&%FK,!IL3?31$2A\!
M#':HI^BFJZXV*E@@0((:$```@Y08\D`0/1Q0@3YQ^`%$%&10,``--R!`WQ0F
MUH8``(V%\`<&0H"APPI>V+C+M3O]D1,UO-1F1K<(81P*0I50:)LN%G)`P@K5
MN)A<C"9_XD8OB6K6T;HXY_Q3`E$4L4$0!43A`#9^[)`"`U)(H,`::<P`1155
M0)$2'WVL(4M""%0`A0A[.+!&$!V<,``"L"FQ;7X-)F<&#T,,$`=#<;!B8C6?
MA,0+RFOFJO/>?'_#A@I/--$$_PDY9%.)$PM8@`)5:<A000(8:"#Y`VE(<)4,
M2'B70P9;;$%!`41X\,,;\SF"1GYO4$)*&C#`8``$#9@-)B4CT4PAF*;TK?ON
MV9RA0`(??)#!"+TKL$47+MBPQ`-**``226I6(H$/Q17P005QR*`!"5_PL0-5
M4QE"57ZL_+%3N`!`(<0$"]&(+:J5G+$&*M%.R_O]]V-%8<;6@/7#%&QP00>2
M4(&K@.D'C[#0!FS0!!6<0@$3:,(%4-`'!93L6F=@@V;P`Y82J>$/9ZA$#'#`
MA0;,07Z/\,,9W*&Z2OSB#Q_$GPSW%JV2P>9TUTC;#[;P`R+8(`P?D`"-0@B#
M"H2`#/\Q,-(6C!@%(3@@A'MJ0P:O\@C\[*0J5RG1#Y0P&0#`H`O94F&A^O"`
M!D0`7'YH`PQGR$:<57`7:E"#!8F&%8:@(0$BL,$$*.&`%(2@!ROXGA]`0`$+
MB``#3*C$&.M%(Q>AC7;FRPDJ%/``":A`"/HJ$1L0"`,PV$`&3KB*IOI0FS::
MLE.Z`$L&S4?'3V#$$0TX@`B0P($3W($&#G`4!X(`AA+\P8+\6TAR3H>*);6H
M;JJC41]DP`(`48$29TC#``@P!AEL05EFZ%?,3LE-_)G!`#8H``LH$``8*&`/
M4H#"%6H`@VWV+8XBD4$5Q)D#4H[B"@4HP`X6)8$!;)$-("S_)5BZ25"^]6$!
M5UB&'R"`A#"0(`@.>$0I[A>2JJ1!`&$XP1=LD('1<<`$8:C'%##``1O<``3$
M&VA`"\K2=<V.-"!(PA.0,`$>S*^#,N0%-18`N@.,(082$$`!7%"`,C@``&58
M@`=Z4`09J+(V*FVI5#E5406@(0=:2`%PJ@$6'-YOBY7```[V``$6](`*6E@!
M%<1IA`.080,I&(0,<$B+J=J5JI-0PA9X8(!0ZD*%"G&##-M0BC6HX`LY<((+
M<-`$%@C`#&0H@`-64(`*.``!`F@`\?X`!\'>];-*0I83T.`;7H1$?FRX"@SP
MYR=4J(`%.4"#!()V@P>8(0H%,``2^\B0A`E4(`LR2`,(XU=*T!KW,V80[A^<
M$`>-P>@3-91AB]#0!B;4X`L<@,$:OB,#.\"```2H0`9Z`-ZW'DJE43VN>M?K
MD\S\80L+X``(=K`F(<*@!C3P(P)^@($3J$!9[`VP@'^BR'R4I#:B\H,3/F$$
MJRAAP:0<L(0G#(ZNEJ1LE%#"&Y)S(TH0=G7NI+"(1VS#.=2K&O'[`QIF\P@E
MC/C%,+Z62![A#D?X046)TL6/UJ3"&/M8PM3PEA9Q7+)P(40"FBGNCY=\7%ZX
MD!\ZN<JT)J$1";2H%U)FLI8_2UP;=K`73JZ;R7J\Y3*;^<QH3K.:U\SF-KM9
%PH$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>y85641dfx8564122.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y85641dfx8564122.gif
M1TE&.#EA!P'0`.8``,#`P$%!01L;&\C(R,3$Q,+"PM?7U[JZNN;FYHZ.CLK*
MRNCHZ$9&1KBXN+R\O"PL+*&AH;*RLE555::FIJBHJ(B(B+2TM**BHH:&AL;&
MQLW-S9"0D)J:FK"PL*2DI",C(ZRLK*JJJI.3DX*"@FQL;'Y^?A$1$6]O;TE)
M271T=(R,C):6EC8V-IB8F%%140L+"Y24E'M[>WIZ>GAX>&1D9("`@(2$A'%Q
M<8J*BCDY.4Y.3G)R<G9V=FIJ:F!@8%Q<7#$Q,5Y>7F=G9S\_/V9F9F)B8EA8
M6`$!`3P\/$Q,3)V=G5M;6_[^_L[.SMO;V_W]_?S\_/KZ^NSL[/O[^^WM[?CX
M^-K:VK>WM_7U]?;V]OGY^?+R\IZ>GL_/S^_O[_3T]+^_O_#P\//S\]G9V=_?
MW_?W]_'Q\>OKZZ^OK][>WJZNKM/3T]#0T-+2TN7EY>KJZN/CXY^?G^#@X-34
MU-'1T>+BXM75U=W=W;Z^OMS<W-C8V.3DY.'AX>[N[K:VMO___R'Y!```````
M+``````'`=````?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK94&"*ZRL[2UE4M*MKJ[O+:XO<"$3\'$GK_%R,G*DL?+
MSL_0?\W1U-6\T]:E4`IQ%R%Y3-GBV.*B!A0A(!$3?>76Y.Z?$0U03%,;:?'4
M\/J<:@?AF(@@TP\:OX*90#00]`0&083+#D*T1,&/("8)[DQ4)G'C)"<71*Q8
M<2&,1V0=3T9JTB%"!'`JB:6,Z:@>DW`T@\W,R3/;SIZ(F$29$F[*,*"U?B(M
MY&=%DRA_)L!92DMI,IR?F&SP<6#*GQ-ML%)E9;57!`*"(/3@`XH)!QH'_Z#\
M*6%`[%A597EY6/@G`0HKH*+`@"MW0Q>H=\GFRG;!@J`$#,:`TM*"!!BY(]C(
M3;PJ[RX($H2<,!(9%)06A/_,F&.7LRG/NB"TH+-F!@/`6448`3BWKFN\BZU-
M.""H0@`]H8B8@"!H"-K?J6#;JN+U3QDSFS_16"X(R7/HIZ3WW,[\3X[OX$N)
M5Z0%`192(-"4Z2LA'RCR@@*@3S]J/:(R&I"0`2D3N*!`7PP@!XH/W/T!!`#\
MO1;<)E"LD8(+&6!11FN<Q,&``U%44-J"RXGQQ8,1JC=A)E&`X`(767R5@A.B
M5%3"%15(\-`G0@@0@Q%&/+!?BI_X]\<3`U2PA/\/._YQ01(8B`$*%Q'\@0$*
M?X&R!0DLZ#`!!P'$81*1H?C`Q253G$%`"CMTP,8@6M2AQ@EJK"#$!`K4<90E
M3TC1S@4+<9'$;8*\$0:'D921AP<TJ$$%8F^H0$,<;F1'YB8_K!C)%AJ(T$,$
M6TPA%Q1O$%!"!0J4404=/+A0@@9G["D)%F1,`,8?9UFW@@_VJ6%!'E_("LD4
M"!R0@@AC(#9(%@J,4,$`5%AZZ25F4O+$`B`84<(6A%0QQ@8_4!!C(10PD$`>
M52":"!-;$*!"E8L<(,,!"U0'B1ELC+#$@8I0,,0*8Y0A[;23Y/7%`2>D8-\?
M62RP!A<W<+!`(D\D0`/_!QH\4D8=<W@PP<2-M+@"O8]D,0`&=#K"1`5"K#"!
M`<(2#$FFD\`1PW=36#$!#".,H!$C9U0P`QIIQ$R(%@:H`4$<&4>"``1<$(`'
M'_864@4"!DQ0`Q=20B(%#BG4H`8?`Y>B;C]F.O#&(%=\4<@7?JAS"!->@#%"
M#!Y`^`@3;)PP0@->&+W%`264,(<;E9A:`@QR&/*$'&BT@$$-=5BB0`\;-&!&
M*@HHD$$39>N#RP.W"O(!C81$D,00#(#1!2%BS`%""G&\1XD(0H"@P!JV_P'%
M`FJDH"DE3"P=UD5AL)%`#RV`H,E@$SBQ>2EVV&!#"1BLX='HI?]Q>B%`T&C&
M_Q`G#!)&!"G(@+HE?>`@F@5V,)&%!BWLH/TF4K"L@1YEC#'!"2+PA!=.@($+
MP"%TG/C!4?@P@^TI`0@SB`,7E""`]0DB?(>X`PQPDXDGA($,(YA!")0P`RZ<
MC1)0,$#A5C`"#%0.%'"8006<-PHAV,X*,?"(F7(@`3:1H(+@LR`IGC`''*Q`
MB)UX`AU8,(!20``)I.C!]-)0`H\4@0LLT)OWG%"%"'!`$`^@41D@X!A])$$0
M9H`7)ZI0GB8$((JVRT,-'$BZ0510#"58`@2J@#DEK(`&-NC'&__@!"AV0@HF
M$(0;2<&!"#C``>OP2!"X(`,##.(&(%,"#<2P@!/XH/\'"&&`()PP2$Y0(9%_
MZ((H25&!#21@`B>IEB&PT$J5#-()+/#$*071A5*6PFC]*$(<#I$``11N7!.Y
MY1!TB<I%DH("O#'9":TAS$.L``/'],@R";E-4S;3D**`PA)BH(4_G"$!TZR&
MD:JQ35QZ`I&*!&<HM$"$&KCM#0G8R#JIT<Y<'O*;I*@"#>QI3G1.9)_1Z.<[
M`3J**M3S/>=,YSZ&EQ.%=F*7?VB"/$$AT!+$2`KY/"A%:6)13L`SHQO]A!9H
M4(+Y@%2?(XU)2?''4%$\P0<RD(L45`#3L<Q4$QC5:"E^,(-PG`$'/:7**MWY
M3T7Z,A02*-\?$#!'D8[EC'__L((_O<G+58X"""X0!!]`:56ECO*IF:""`)Q:
M"@$8,@\_2.I2VIE23`2UKIYPZRB7(%>D2&"4W=R$6@7!!JR.P@0Y&*41^@J4
MI2:VJ1E%ZR<0J]A0&``).="!(!3@@T&@CQ0(A<8VK2#92PP6I:5XP6.ML%A0
MH*``7?"#*`'@50Z$M3\Q5<DVL_"F3D2AB:@EA6HK"PH64(%A`P)`*3F@6=Q2
M!0H?*.,H8/``"I#"!`)(P`<PT-Q//$`*A"C`"XY`WB/<5A2A7484$I`"$BRA
MMY_(0PYF<(4E/"``4_G$$I$P`P/0@`:6_`0+P#L(,.3@#%*0P@:Z&XKT*N,.
M2,#"_Q<<,(022/017I``"LB`A2=\H0Z%34$5.+&`'_Q@`.AB`A8HH(,1<*L3
MW_U#&A(+AFXR]P\J\!$H'(P,+RP!7E4@`P2(L`(*[*%JDM!"&CA0!#SL02Q3
M<,($EI"`!92S$EI8`PPD@`<$U&-9>:"`!$"`@"M/P@T'$,(@'(""'*"`+0.(
MJR`F4(0_4.$$4C5&;B&BA2L$8<2#V,(`5E`"'[0!F7O#0AB4NP$#*(L03/B"
M!E3``P5<^29[RP(!7%`!,CQZ$)'NP@Q(,(#>/2(*".A!#.!;A3M8X2%9V,,@
MS!"+/VQ@!I_6!(^)<8<<(+H08S!"#-*0ZT24H0L^8(`/NO_&B#&H0`5M*'8B
MJF"S"S`;@5%P0!"$T`8W2+L03!!#!1[0!4!#(@MGV(!U]=P3,7@@!8OX0@)T
MX`%S*P(**?"!&@8$B2=H(`$4&%,C$D!02'P!`BQ8`@6.NX@Y)$$%OWY$!5Y`
M@AWON2!I..\BR)`"';Q.$6A``@<(/(DO1&`$&^#7(;2P#JY88@WN#7`BB#`D
M7UR\'X*&Q!U((`,"2($H@ZB#!4Y0`H9?8@$:H,`:1C#R/_"`#H+@``'LD(4+
M)Z(+)(B!VG`RA9QQP`@<[,6N@3$`MSW"@Q2@00L*,`8Q>&$.)2"!`\1@=44P
M00M04`$*G->#IE7A"<"4Q.\FT`/_$3A!"WL80`:*T&@D[V+LNZA"%GZ0WTB$
MH0<?^`$(XO``)4S/$R7X002^<((FB"(,.R@"`600@`!,P/'7N+D[KFD#DD?"
M!T>XP0DJ\`$M>F($$:#`!7SP\5"DP),<0,(1KI`,R-L"#CH(`.(H@?O%G"<4
M%;!(!89@>E'03A`Z>`%?BN%\6CQ!!DKP`.P=X8,7#/,/+"A`*("/JQ_<+Q0G
M6$SXQR\3V5OC"6G@5950!"^P&/$7"A,`7(8W"CMP)G\0?LR'$OY7#7U0`[Y'
M"4'P`N511^5``OIW!!8A@2H!`3*0"?@!?_('"EWP0M`R"AX(?LO7?!,8#7=0
M!-UW"3+`_P(@$`X&4G>/@`%EE`)0)PHO^(`Q*((>$0,BL#:8L!4.,`PW<#R?
M0']_L`/P!0I%J`-'2'XS"`T?<(.6P`0K0`1X,`R&XX..,`(V,`]",(2AD(5;
MV'\G(0!@6`D"X0-/^`<CL`:!=PD8(`2G8@17^`EP&(%<.(=U:"TK0`)XX!4C
MT`4(Y(=E9(4N^(&&*(<>08>9,`4MD`(',&(CH`'KAPD)0!Q_((25"(.7J!-=
M^`R:B`E/(`(GX`#EM&I]:`D#\#,.`#)O:(DRB(B:D`!"T(A_<`/WEPV%^(N9
MF(B4H`<$@`#AT((=Z(M(N!&O&"')6(T3<8V7``7#\`1H&`S9>/^(RZ@)!``!
M',`%DA$/XXB)ULB,DD``$X`'!^``(C!]TZB*ROB."<$;.)8'[$B-Y,B/F#`/
M<A$%*\`6[E"$$A"'K`B,F(`&%N`56K`!39(--S!!(3`$#@D,Y><*W%@)'3"1
M?S`%C!,/;2`'DQ8`'["#V@@1(4D)"'`!*3`#,@`"$2<.<```<W(#8W"+LO"1
MK1"3E+`%"'"4IM8/3+``8/`#81=[$$D5:/``#Y!G%X`&@H`#6$D(9>`$+J`&
M#UF.G1".K&``)-`$3<`!#[`"??%%?U"$A6``&.`""OEXK>@,1'D)9+D*3=!9
M?_`&8$`0&^"`WW<(<G``/E`![:`+0LG_"E\X%DW`5X6P`B]0F4?@@(G@`0R`
M`8QYE\J`!"\0`?;6$Y%I"`FP`0E&`[GU.!O```3@`%7AF<%P8D)@!5Y0!S_`
M4TO1!*UE`2;`F3!0'B^8!"9@`J8(;DB#`DL@`>O8"HWY"5ZP!5*7`!)`!Q<`
M`P-0'610.&X@!T!9$%5P`0R0`R?@!,>E!+"DA]8%!PQ@G!2S!PB`!CIPC\32
M&;+Y"=^I!1I2!MYP`1$``16@!$Y``EK$!&<@`S2@`PCPG3AW!TY0:W\0G8)P
M!M-C!`(``K?8!4`P`B=`!GX9'??)"K/32E90`AVP`6BA`\!E"(ZD`XV3'F8@
M!6?```N#"!I@_TA6P&#A$:*K,`8PX`$8$`()@`$]P'^)(`=MP!\N,%ZK>`A"
M]0=ZH*,20@M'0&`G10@@<`25*9E1`0$4,`)[0`(TQ`ADH`,7>!(3<`.<T`3M
M]%?`00LO0&`8Q3;GA085(`ARH`)X$`+'Z0A24)/-Z1%?(`)(M0EL.DI2JB)4
M"@!H"0:H-`A^X*9_4`6V\P0<0`%E\&U!X04JP"M[J0QN4`/2E0F'2DB)"EH\
M>@E'(`"L*@"/*@A7<*J7\`010`-ZH*GE,`<]P(NDVDZRBEZI:@E'P'"#1057
M@!97<%YP('.90``2,`%G,!%,T`8EN*:^:I]4*J<?\`=M$``/D%$W@/\&$0`"
M%8"9F<`$?)`"%<"K^H`%!+"5AGJM;SH+.O!B6]!:30`$@N"L1J`#(=4),=0"
MS!H/"Q`"+QJOB(JMP&`%$K"BH^`%UJ,`=C"*T4`&(C`?UIJP\\H+85``$R!G
MI6`&<1`$)%!SU;`'Z9FQIJJPO*`'1=!`J``%)A=8_%&J3O"K#1:L[@`&I?4,
M:00"#HNP*[NQKL&SXI`%#2`"%<`TGF"S.&MQX&&TV;`'\,8$*M2T\@JBX$%;
MXB`'H,0$M8&U&JNUT,&UUL`$,?0'3#`'.=0)3LNRKF&VU<`$<K`#1S('@>2V
M68L*SXD,<EL-80`"(3`!$Z`W;Z`!!L"$EJ#_2F/+MSI;#LI5#EN@!(TD"`O`
M`3Y``A$0B8W`N%DEJ8Z[M3U[LACP`2]@`DE@LH_0!=Y1`5;@`IQ;)(\K#I&K
M#V8P;B9`7@)P`D\9"7@0`#B@!H/#H)S0M\50N_'@!3?@JB90F1^0`+%K"`>W
M`BG`!4U`L<Y5MJ,;#5%``"=@NN.E6DWC"&5``!C@2A&PF,XYN]F`O)VP!2MP
MFF#Y!W-`'%!@!0/;"770`BA@F2\P`D:W"&M0`2J@!G4`H:Y@O,3@OIO@!AA@
M!VW0!@?P10>P`;XSKJ.`!6-P`#_T`@+``3E)"'#``R?0`'49FU&[O920!T)P
M$U:+`5IP`"L@%!8P_ZIM,05UH`0,H%IX`'(^<`%49Y?@40`H$%\T,`AC4`%F
MX`"[EP`JT*>C0`4.H`,"0`-N6`B%@P?JVYE;*X";D`85)PAZ4`$3]BP*X`%-
M*@I:0`<E,`05X`6%($<38`<Z8:Z<00"&Q0EW0%9_()=9<`"Y,`4'`,6E\`8=
MP`.E\P1BL"L<`,=AR1DWP<"4@&11H`<RD+DBT`X6<*=,@`;E@0@T\`$"``2L
M\0</`,=>\*TH1`5C$`9^8`1((`)R,)I0"1U2FPEA@`+V,05R8`5W`(UT4VM]
MH+B&<`(<@)9L(`&F9P+'-:>4$`5!D`(.T`9G\*F*>A=2T`(S4#E;P,0J\/]Y
MDU`A$J`&SJIRDR`!'3`(>B`E)O``0,`":X5E-0`"=4#+CXP4U1,`$J`!MH,%
M72"+%!".],6_!2`"15!\DO"5AB``$0`&%A#/E.`'*H#`^\@33&`!H&D">58(
M82`"21"TCE``0)`!"W`$!&`!6R4)1J!&=<3,?W!2Y*6OC^`$)6"D%1T3TOD`
M'OP`%1#"D]H%4=6[BL``T/0!:,`&+D"AE2`&$N"J`E``4/$!S8Q*9P``$-T(
M)8`#CNP,"KP*9?`%2_`!Y84&9A846R!F<;``Z;((0S`"`0`"8*"O9O"I6R"C
M9U`=5!`0ZLL&,MT(!#`#-GW3'K$#0?`!S0L$#H#_L8SP!4Y0`S0P+PLP,$_@
M!G>`!RS@7EIPD:/@!',P`4_[!V$P`B&0E!S!OK6P!5[088(``%8]R@80O:!V
M!GPP`"1P`T[P:5N"!!W@!R<F0#^7"%3)`)I]"!=0`0IB$*8]"UJ0`C10FWNR
M!"![$9(P`$.0`'R@+&:0!VX0`%O,"0)P!/#H-"=@PUR=W*Y0D<>5!2(@:X)@
M!;CJ"$_``P&@1@$0WII@V`A="1.0``$<"IC6"5TM"EBP`<<%!3+P,Y[0!45P
M`@A`;J3PW?;M"&V``:K;"1P0!"X`KYD0X*$0!4NHMB,PW)LP`;D;X9D`X9BP
M`C9@S8U@`5<0#EQ`R+=@_]ZM\`48,#%0$.*B,``"D`/''0HH;@EBD``5P.*,
MX`>\<0$.8.0<'@HB$*WB=L*>\`0?(-1Y!=Z7X``J`-*@<``-,`Q*8`'$NPA-
MGA474`!T,``)@(^@\#T/CN648`9=L`$I2PHU/`P>`)NZ1N.ND``),`)L#@H"
M8.6=$.22$`5@(`$)P-ZE<`6\$0?^B`EE+@Y`].8FC@AZH`+C;3;1&`**!P)M
M,.:*,.F=P`<O9@J#WE9P'@E:``(QX`7,)@I,<!1H<#<5S@Q\K@IAL`)T?`J5
M/@J&W@A3X`5Y<``54.>D\-^RBQ`60`"Q_N!(]`EB;>)]4@`@P`4;4`)$D`*]
M;O\*;A#HQ9OKJ)`&%`#NP![MGC#M<^,$>/"?*X`#)2`#-=`"`+`'?A`#:G#%
MH>`%#L`&X0".`"[NIL`$>DK:YUX*IGN#49`&!'`!%Y``)4#"?N-SA-`$/7#9
MW1X8&N``#)<&T1KN^K`';/`#^MY6Z+X)8G`%KCH`5M#P#\_<)-`"!$`'_3T(
M4:`&5"D$&F#DAL`$"*`&Z\@'$7#RE$#J>LD!1*`$[&KRHG!P-%"9,X!--#`#
M2@`BCI#$+B``1F`'L!T)4NP'(U8%<&WPEF#TEJ!"/U"COD[TE^`%.'`"&F`#
M*0`$7'`'[VT(44`%(B#**-`5G%`&"P``%W!<3\`2Q+S_Y_'``1P`!J>."K_>
M"6:@`@3J!C:0,`@^"0H@`<6I`P?0^)?0!0D0!_Q2!Q$P!Z+>"&9?"0>0\:GP
M^)N0!1O0`_12`2<0`^5F"56@7<7)`!,@<.PC`C&`!B/6S0U`]I>0^I:;GDZ@
M1H2`!WY^C*S@^IGP!73F<US@`W1P!EV?"!E@!,5I`J[G^9)0!2>S!NRM`"\#
MM<"0KX*@!AJWVC6@^#=@SJL@_9>@8"0P!U8P`BD`"&U/?X2%AH>(AU`3'R:.
M07R)DI(&)'2%>AL%4).=GH1+2I^CI*6%30^$(#J(2AN$8&2FLZ0"3K2=81LG
M!0@Q*1J#N))C*"\O2!-BPX1P_PE*G']A7$IAS)^AU]J?30(_10&LAZ[;Y82V
MYG]5%4(-4B,W`U'IA%,E`@$77M=2$R-]A)X,D-&&'J)L!M,U^9!`!`T)K5XE
M'(:N7)@5*0[423"#`):)`$Y`>*--0PP%A<8D@%!F8B&$+K5UR4&H`\0_`):L
M^,,A`:$6&F+6NJ4MS)X+)`:8:7&BS;R)5=+L(W1EPXH5`#U->=/F0((E)$9(
ML>/!!DFA,(4.:P)$E3@$/9;\<9."`0,59]5V$E"!P+)A6!(PZ&$'SB\V4_02
M4@)@C8$V%1`4JD)FP`$/7&HLD4"D1`4(:"RL,+*D@BRU:16;VH+R#]=""7X0
ML@(`@/\;U9,D@!APH02-&"#RCLH"@02'`6YB\!B@!7<%07^FW)`5`0,$#A;P
M.+8S8$`7*W+.B*'<@P$&86A%X3;G!(//]9-DZ%#R10L<!0X(H$D@X\*<3UA$
M0`,>82PP0@H*5+%>`ETD%D4*<OQQAP)CC+%`&%%$DT@45YP0PP%ZI08?+@?H
M<$)K(Q:B1`I<4`#"%XA004<!!R@Q0P6;;`C"#VB840<'.RCP%&X)L,')%#Q$
M2$L8>DR`(&KJI3@,''ZP(24A'```0@HU%#%`)U/`,0``%(Q`@P\4K$%(&5Q(
M8$$?%;`@A!V)P3?"&DS\P00):3`C16]_N23BE822$L<*&:#_,4,$+@"PQT>?
M,)'%`G7PX4`)@\7@PP!9<'!"!';D.>(9O@71PQQ#XK+%"A>D5^BKI"@Q@0%&
ML+"!#")T`2,N6.PQ!QT)&!&#$D9PFBI\<.1AA17'TL($`BLT$-.@L%;[QP$C
M'""#!PI$\$,*)!!U#11GY*%$#P0T9^TV3^A!P9<34;MNH6G(H((2=V*!!PTK
M[+H-$V_HT=*\VU1!``22)20OP5=Z\<,)):@`Q@(,5TS(`"!(H7"4%L<DA0F)
M$&""`"44`L<.-/3``@@=,ZP%!U<H2,_"+6_3QP>'1&!"$E)0@0,-A<B1`@1>
MJ%OSNE74.3/'1Y<3A1Q.:/#"(1:8_Q``(5Y0'!`5@38];Q^!2E$&$VZHBX"H
MI-#LM2EU),'"`T<<HL8+**R]]@IH/)4`2CX0Y0.D:3-MMS8?1R?%/AV\</4?
M670].,$5H.`'(2,0\,<28Q""A#6EJ/TX*5+$W<01.,^=!"%??5YQ!0Q$0,@,
M`/S!@!V$,+"%*9ZK[@D5(/_132%@''$$";HSC`$%)>@P1^5_^,#`$#H$8`;N
M@A<_C`%#9&Y]QQB$0,@)*&3PAQ':)W%[&D[TZ4GNVT^"A0(4]-"^Q3900$@%
M.A3PQP]6U#Y]#3PH@1[65[WYD6(-`FB+`1EV`3`4`@<HZ<$=".&#OSS!"K+I
M!/L6R,&C/50!;9V8D0RP4<`.FI"#`W`!"@:@/PV6\(0PW!X&4A"#"HS0A3',
MH0XGL<$=^M!Z/?RA$!\7Q"$:L6DKB-T1E\C$)CKQB5",HA2G2,4J6O&*6-QA
$(```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>y85641dfx8564123.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y85641dfx8564123.gif
M1TE&.#EAW0&E`.8``*.<F%-*2&EE8Z>AG(J"?;:QK`H'!_GZ^=W;V;*LJ+V]
MNTM$0_[^_CTW-<7!O)J2C=/0SI*.C='.R\G%PLS(Q<[+R,&]N<7#PEM44_7V
M]=K9UM;3T7]_?^;DXN+AWGIQ;;VYM9J5DFMA77MT<?+R\)**A*JEH=C6T^GH
MYD0Z.(6"@H-\>8J%@ZVHHV1=6_K\_')L:KJUL8-Z=/S\_.WLZG%I9O;Y^>#>
MW/S^_K:SL>CFY"LE)%I03C,K*O#P[JVJJ&%95N[MZXZ*B>3BX)Z8E:6CH>KJ
MYTE`/HV(A>SJZ?3T\YZ:F>KLZO#N[>?EXV!65):1D&A=6O+V].+AX1X8&.;H
MY'5R</;X]W!F8N[P[7AN:N_R\/CX]_K\^_+T\G]V<^/DX(=_>WMX=O/R\=[@
MV]?8TC@Q,'=L9I>.AHA^=I^7CW]U;B8@'Y"&?_?W]I>/BF=:5L'!P%1/3B@>
M'_S]_?S\^_W^_OO[^D`_/_G[^[FZN<"_O^OO[+&OK69@7O___R'Y!```````
M+`````#=`:4```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^OW\^+\#$Q;8(%S<:4\;-
MK2%<IVM0",[6UZ5C80L#+AS8X*(4!BBG7T]8P^'K[)03!`I-2"&F=Q4>(-6Q
M=NV&#$XF#`PAQ$`4`P0+]/5;R-"0G0LB`N20L,%4A2=]7/QHQ:^AH3P);!CH
M0*AC*!]M''A<R?!%GBLPH&0PI2-$"CTE5+*B0X<4C2(3#OQ!,2"!$U451`@Q
ML.2.J0(/UFQA234<@X*""I@H1RI#@0(N'%0XVDJ=*`0!A(SY0X0#E!.J_R8@
MX6"`1;12(9!4-%FU;S$[_"`(^1+C"BDZ,6!8,2,DR*H"+,BRX*#A&X.>G5:T
MN,(%`Q(46%<98*:*K]_3P`2;&'B8@A`Q9B(X5E5@1X4_&SA0-O#GLB<91+9P
M$<,C!-=5`GR<RH``LZ8->IVBGHXH-+$,-2:TPG,[#!((?\R`8O`%@!)!.7CH
M7(F``Q8A4!(@R&,)AY,S+B@(I7Y)!P5!&?S@!C`@(!&#!IOXL-8?=)CF"1T)
MW+#=;4NX(`"$XX4!@!>"'(#%>@TE@,X*'WRPQA<UU##`!DU8IPA6=(Q`10VS
M\6?)!#((LL$"3?P2`P]`A-&"@X_0X4,%#V@!A/\,M]'A8C_<"5+%&0C@`(H&
M"_30QPTD%I%$*V^`,8H26BRPQ(!_O#"$!41$\(`,0&`P0@$>/$F0($S(H8(9
M!<QD8R40M"&(!@$HUTL'9E`11@P@$*G(`628X`<&-93P0`@A:('!"8ZR$^4?
M7#SP7Z>6=$"$"A7H,,``'3AW"@,;+(9!#AF0^H@=UND@QA,M2#<(/UU4P28+
M0L@``PQB)%`%9@T68H$,)&C8XY^4`+"```)@<$2-N\0`Q`H-Q%"%(P=X,(`5
M`GS1AG<#5$`#/QH@(4`?YYEBUBE][`##`2%8(0,-O9F2AZNE9*!"%&(0(00/
M5H!8R658;5"#'Q7<*PC_5OS088,7$P`@!`MIC%"#%41H0!\A%=1`PQ<)+$BM
M)`GHJ4(->'"KBPD`D""''OL%7(@7%"QA10T?(!&!$"UL4&\A283@F82@W-"O
M!6X07,H>$2QQ0`M0_(?*P':"8@('-4!AA"``K"#"9Y@X^0<`6(AQF\4E,7BR
M($H$K0(',K2A@@H_G/V'%U]8$8`$/;\,B0,$"%+!`H;R\@X*/.SA*XP41/"W
M#&%PH,(2"BEB0Q$\K$!2)R3D`$,-`O@1`02VCA)[)$;`$,),#LBA0"%ET+Q`
M`DM_0@$>(N1@1$\A#$"'&Q6$@`<49%5BPQ,\@!#\)`S<D<0&%^@1`!&#H+`'
M_^**3P)""5(6ZHL;3^`!`]2"Q.`''G*DT<(>$V@01!>1,*#!%T>`W28*<*T"
M@*$)$BC!`E9@,U2$K1(W2`$0//"'"!C`!"6IP0J*8).*?,(#,`A`"#;0LPKP
M0`0(:D(?L!``KTWB!#``0E`Z08<PR"!RY:M$$RB8)@KXBA<2^($&>L:'!;#`
M!#%`@!)FIP@NX:%EF/!`&`(0`0EP80(#T4$,L""'`K@L%!:0PP)<H(,_R*$$
M7[+#`D!0$"8>P@,8Z$'@Q&"`(A!!#GYP0@&P<)LK:.$!`"N$E2IAAQ7((5EW
M&<0+)E"#`'Q!$!*(`!!<4"<W_B&,*]#`##XH`@_FT/\235C`(*\!`!1V(@E+
M6$`-X">)FCSA"PH@@0<,Z<D3%"$*+H!+*#80A0@4`0F%,@`5;F,!`P"`'P]D
MA`?6T`,H/(L-+OB""F`P@#8\@"PF($#T?D4)!L2@!D"`P@U^2(@3+.$#<C`!
M`WS0AQ$\(0)60T0>WA"`,(3.$RM`@^`^20DP&""9O%!'"F*`)DY<P01/2,XD
M(%`#.)3@!`>``CH`,*T.%<@%!"AH)]JPAC(:H0<W$&8+S$B%`2```W(8Z200
MD`81K$$.(TB!&79`!2HLX`PRT(<#U@`'-92!$'1KA`.B$``T("!QA["#$T(0
M``Q4HPDFB,(1'D"0)WFA3`/_F%8\,S&$!FB'GY1P`F^P@08>',<3"*C!#L;U
MB!NL(0``V$`&++"`)YC``_&T@076P(;->"(%>\#,&0*R!ADP80=16$,#`$"$
M`-S3$1#XP`"`T`-KI4`$1;C`"6Y@IC^0P`QJD(`:4K"#`#S`!P`U1!!6<(0(
MG.!ZBIB!!I;0@QK0X0!#R($(*)8(.+I@`QH-A1Q6L$VP/L*?V+@"%2RPR5"@
M(`1L($(B$X&",)BA!G(]00V.,``/7&&K##)"''CPNTR\H`!MV,`3+,"_/RR@
M``880`_4@`49:,$`;&"#`1SFB!NHP0%^6(`#%A`!M>Z`HB!8P`YVL(8AT"$(
MW#/!_P>.4-H82($1+\B!'++3HD.X#1$DL(`(PO6'`]Q`!4<8`0\)`8`&B.$&
MX.T$!1;@0N,^0@=CM48)@'!64"CA`CUHPY>2FH<--.`)%>@`%R)PA!5LP`NS
M.P@!_;!/2!R@"@/`@!DP4``?`"``&F"`!:@P!`/0E0H36,,'J)#9"<"V$5Q`
M`0DTL`$?0``%&HC#'CQP@`Q(8`][Z,`/28"`">RA"%_`PP*98#4[6,`/0`#`
M41-QE4<AH`5P`$(,_N"$/HA`#@-8&@MX0`0QE8(?7`#"&P)I8T<@]QILF``Y
M0S&!!?CAPH;0@!9`?0(<4``#,"C`0"KMB`Q4@`!X^`)2$_]Q@#T(H*E?,,$>
M(.`#.AA!!GC`PQ$`4`<#[*$$!LA`%%I`A`80[Q5C0$`<]*"&B&`@#";[PPVT
MP`,H4#L3QHY``*R0@0QHH`@!\,,$;+`$'L0`AZ/`R@2`<(%6/T*LUP#!$=9B
M24M48`0+,+4@Z$!/`EQ@#!*3PP,T$-Q',$`'X\7``!)!!P^P8`&J+$(<*(``
M$EBG`Q?`'PG^<`$?H"`.?SA!$WR@Y]O(P@Y&T``%!I`"`PCS#'SNQ`$T4((>
M@(\.*'A`#Z@0@`T41$-!#0406%!QL+[:&0).;2=\,``JJ-,.%=C!`B!@@S%H
MP0Q&+?LA2-""%*1@*H,`@QH68%/_`(#@!*AMR`Q\D`0Q!,`PA'!``TIZ"08<
M(`8+:$`!_C`#$\`A`05Y7`G::PH''(&5#D\$Q)U1`BR\V1-@-@!X!%&&'BS@
M"%0H@!L.D`,JB``,LVX$?1STX#=P70U`H,(<O@`!#XPAQOU0@1S^8(4(#&(+
M&JC!$L)NY2$(H0<RL`,(VJ"=+4Q`!&C(@!P,@`3H9^(.=EUVZ@MQ=F,$8".D
M```;)&``3_YA"(@U1!J0`D?@+FJ7"`%`!24@`0LP"`Q``CO2`RV@`0C@`WJ'
M#=+W!P*@`H20!%^P>9J@!`A01A2`!MKQ!@DP`B7`=F;``WXR"A.P`X_%`&[@
M!!V`<-U"_P5FX`$.(%]90`JK9PPF<#BD4`$:T``5D`9!0%,`(`A/@#@M4%((
M@$P7J`%#D`#JD0*#<`)L(&9X4'*GD8$;2`@P0`4LP'V24&DYD`83<`5RP`8U
M%0)+@@4X^`E<T`,@T%R#T`0KL&!'``P#$`=F4`(%@`8]@(::4'^TH`1.X`1*
MT`1?M'';MG.B<`4E0`$-8`%&,`,RL`./]`=/@%<0,`&4>`D#T@()P`2"\@=V
M``&\40%X0"UBR(&]41#T=3J<(%K:@2LE$`8?4`!?L`9W,PHQT`"L,4ANH!+L
M4PQJT`8)``%1X'Z8$(2T8`-T80`\D`*T2`A,9W2B``94X'0&0/\#&L`#9P`$
M@A`%CX4)(&``1Q`ZKO@'$Q"+?R*&+%`(")``%:4)O@8`$C`()9``1M```;`#
MLU<*/2`!HT0($-"$Q%``(!")WYACM.`$8K(!#O`$2%`(+[``%2"-E_`"_!`E
M'T```+"*(K!BG(`#<[`[@Q"/L&@C@#&+@Q``!C`'(-@)#I`2L:`&1X`@A>`A
MQO`%Q34*U&@+`P`",>`P6Q``NF0*>/`?9&``-NF$&M<)*7"0?\!_?Q"3]3A]
M8R@(8X`"/J"'G#`!)A@+=&`&H58(2@`'F8`KC6`'(-E;Q:,&0U8*]8>(J<`%
M"4`!/$$(;K``)O""I4`#F&$$&3!D40#_E)N0`#T0+H8)D_1H(S19"FA98ZZ@
M!DY)"'2@`0D`"3J@`P7A`31@!'?1!&#H",3&"&%04R)0E#XV#H+0*HR``PO)
M"`=0;;U1)4/$>?YW""<``J4X"!/0=;+0F#2D`TE@EEOYBI7)'Y=)"IDY"W*P
M:8-``FW0*3K0`49`01W0`1S@`DQ@1BS@`A)0$)HA?Z)0EY;P!G/0(TQP!*SV
M""A``TZ@(,L&`FO@&'Q`!>`X4F)U!76@!*1'"`F`085P!WY0`H;I"LI9"I0I
MBV"YC3"(!IKI"@/P!(9`!Q4P!G"A!#?@`]7``1L(EE8``\9D1A$``__X!Q\`
M`--%"B]P@)>0_P8S\@<:(`?%V0A)X`*C%@9M\*+<^`$]4@4&(`4&(!X=8`!7
M,`%:```.<`)&\%V"0`$9:@$!8`&S$*&DP)5>:9D5:@K5*0NAI!TM``8_T`)E
MM@<[\`<#(`=%T(`F*H96(`:J)`%Z\@0J4`0`5P`'ZF$V\`=NT#U<X`,G(`%/
MV0@,D`'N:0DQ(`(]4`1H48>),`01T`,J``4Q4`"H=TD+$`)%$`%4@`!F(`)A
MT*3E*([XY4A$@$1WED@OX`=$\*BBX*6C,*%?J8$6*@IE&@L'$`98\`<&$`-.
MUZ0*\*9Q.J=_4*=R0`=^<*<L(``AT%HU8`;9Q@9M,*/4!00+P`00@/\B*_!P
M>_`#$Q`$=7D#>Q`'"'`'-W!G@7HG?Y``'Y``RW4$^\@(2!`&A_2@A!`#.V!N
M#<`&97`$$X"'!G`"-LFJK&I3*_`#@$8!%^`"?4`+N"H*8!J=U#&=%YJAK<`%
M2)`C>'"<>)`$>."F<)I.=+J!`7```G"G0K`!6$`%0H`%$S`,*Y``P8<(!5`#
M6[`!`[`$UL<(8Y"$>!``]58QCL`!;-`#5G!M&-`"#<1-?]`":?`'`=``D`,)
M8H`'5"`'980(%?`!CJ$!`!H`*```9B!["\NP;NMT5,`&8<`:R>F8N0J=%,JK
M9)J6LJ`!9L!6A3!C?Z`Z.>`'S7JB&B@&'"#_!'^@!6:(!1+`#U_0`C9P`ZOI
M+",`!C=@`:.X"'8`FG7U)0,&!'J0!*D5`1'P`V$`!F_P@;AH"$V0!'EPD@Q"
M!0U``SI0GXR0-8H0`T;Z!^!(!H4R!&M[`R(@CN%84\H;M_FU8(I29;!@2J60
ML7D[AJT)"FCY5;&@!</Z""9`!#^PD2'P`SF0`W^P!1R0`P!P`P7QC%+P!4B@
M4HH``EH@FX2``_`B26?`I0P9`&NP!"IY"`QP`7[``@S@`14`!O$:##_P`2"P
M!?API4C0!`!0`T1@J9!`G#>@>PS`!#7`!!%0-1N``4S0!RSP`#%``1,0!Q)P
M`T;`!SZ0!Z&QHRLW_PM8L(Z?H*MBJK>LV`=5=(&+,`$/X(VOH`%'P+_]8QUR
MB0@:``,B$`$3`%Y;%,"&<``=8`(P@`$*0`,+_`!R0`!%H+N%8`(-,$&)8`<Y
MP`)^,`*05PAVP`0R$``LL`=M3#LMX`*ONPDP\`48C`K\(+U?BK>[&I8>L!A:
M0,69D+T00IQT,``1,`1[T">G(`(K$+8FQP"`<;^DX@4>(`?%`0'+=@`/D`)%
MP(K(9!TDT`=?,%SYFFLO1P#8B0@[Y3"51@%$P`.YE`B#I`$N``018+>.<`(K
MP`,ML,"8(+,38*.C``?!Z0E8H</2.::XD00+EY-G:8(OD"(:@`)^P!@?D/\"
M]NL)09"0:>@BUZL(88`!(F`"ELR*2G!'WQ"8Q'8`$H`$&(`%'GL(7&`!'_`$
M*V((F:,A-F,'-U`$(L`K3<"7?Q`$&UH#.2#&B<!(3Z`?H3`";="C"?<D_(,%
M6KD)7`,!05"QS]F5&CL='/L"+/,)$Q!:?]"#-^`!2C!@3.=+4]L))?`!>=Q-
M!V@'>;`"3W`&"M`1)H')A4`'-U#!+F`!.\MR(,`#6+`:A#"G?H#$>/(#+_4`
MKZ<(*#`"0$``%M#'K-C46M`!!:',D#`!66G6CR"2!]`'^G$``R`$8'`"LB$(
M*V`'O^<))"`"9O`$9:"%?P#-&RO-60$`='O-VA'_`VJ@#UX0;#L@!@T``MS*
M"8BB`4!,"?PP`W0M`@)@`?="U+V!=$C@`B,``NSIHP.`!?Y\V(7@`S^@!2,P
M`*P-"78`'2(``W$PV7]@!"J@<BZCUHKP`LSR!"L("EU@!U>@`B5``A(`!0OP
M`0Y@`"]J`';P!&3@"4;@!170`U)P!I`DR#L<EG^P='N`T8G,DQ8@:8+0!RV`
MUD,PN>:]"2.`!35M"HXV32Q`I(3@!2`@!A\`.IAP!QL@!$`P`C'`(81P``XP
M32&``,XY"2$V3:]C"!:P`C70!Z>-"<)MG`O0S#J950@P!A>0`DI@`".@`C:@
MA5&`R)G0!`%@`UXCV"8M_\T3P`-^``-4C0E!4$;9^P<@T%U=6002('E#<`8M
M()&;@`)S8`&V^@D)8`5G\,N#D`<5,*TQRPE*4`!A(`(J0`1[(`@(T*(KP#.<
M\!.K`P"6O'`C(`%U@`I/0%&BD-[3D@$!4.)<C41_<+&;X`!+<#?4NZM%8+Z7
MA"XPT'"9<$4L$`,,0`&B0@<KP&6_9@564`!F8#@.D.&7T%@]QA$H$`%RT@(T
M<`/N@5E+;0D,O5U00`(@\`$B``#0NPG0$06EK:8"$`:?2@H_TM&=8`$M0(D%
M``!=,$S'R0\U`,R:<&E5X$DR?AI&4`,+<`#GK`B69`$U$`5OP+[.;0)T\`-"
M0/\!&A`"0A`"-W`!$5`!NIT):!'%M#`#'5"&`6`&"]`'>0D*/F`"C00#@3,*
M=(``1\`&*4`%,)`!T3X*!^`"^A0*(*`&CN$`+0`!>6``%="S!0$$2J0&T%((
M`\\(`TB0/_7=)`W<U3$**C`"'I0!`T`:DW`'">"M1U`#1+P(.%`%<F#LAC`$
M)?`$*V`!)'`#>&H&`>"-E^V`!4$#_)I2B/`%6(#DL)"I2U`#WU`*/A`#1*#K
MH>`"&!`"#6`9(&\)$"`'^8P)!P`#/7`!1)!M`;`%WAH`LZ?V7.``(J`1SI'Q
MBV`$(1`!4$!Z-``^,8`'6^\/H]`'&("=!'`$^GTK)S#_`@T*`B"PR@1`\_Y`
M`CM0^"4Q!@F``5'0!SH0!"T`!#"0`#$P`EHL%'TO]$,QJD]`#X9``@%0RK<0
M`0VX!T]?"G+_"2Y@?0(0^Z6A<J./"%V0`Q%P`P[0)EJ#`"&@4B!@4VP$'4\@
M0XM`[1N``U!@Z(W@!BU@!FPP`.5)"3C01J5`!Q]@OM!!A)&``B9`VCDP+3?0
M]'[0!]+8`'Q0'1HP`K7O`%=``6H3`1Z$`&O``P4`"%=_@X2%AH>(?UR")BU]
M`@DDA$18$(F7F)F:AQ$+=GL<FZ*CI*6'?A%_`J&FK8D%0#>$!TL"`E!NKJ,M
M`2LP(E8037UB(D((=(D0&'MY_S!]FVX3`F<<*R(U&W\,#*4('!O=7$4>``C=
MNHE@9R`D$Q25I#,.0%@`0X<G2S`"%P>99JH@"A*!QX<8+Y@0"!#&PC]"3@8`
M"8,O'2(:!2CT,<.#PA\Z.)X4X&*QY*5..$"97,F2$"I5K%J2ZB+'`:$[;9"P
M\#-&)B$&2OP\,<$E2XP51T+04=+B@X@2*!)QV&,#@`1-=FKPB$#AQ1@')3#`
M.&'*2(`)@RJD@/"DC,\_53Z`((+'#!49'3;A0.`B0`X$=A+1N4$D@`!+EXZ0
M.10BP!D*28R4"!"A`@U$=#:(>%*198("8*`\$>'13AB*;U=V^J,RM>M1+U>]
MWD1A@?^D;9<K#`"`!P\.F1,PK-$V".B%,`&@T$%Q7,Z`J(:FTDF2(9.`!24J
M!-[&P$V%$!C\$!^EI<(?/BUX@$GS4&:6$2!N7,@1H$!U33+PL*A`,I./"C($
M4`-TAZ0`1B$TR`'$#PC\\8,<6K1`8"((E""'!+\=@@$>-#2A!1XK;#)`#A.D
M@88,'N%@1@[MS=;*:JVY*.,A+J0BVXR)'&"&`UUL]T<;'9S`@P$>L61""DLX
M@<@0/\`AWAU#@""""S'D0LA4F="1`!YGQ''9(0PTL4<8&$0P828UV%3"!EA4
MX4%J([!Q!CY@"'`5)@Q0$``61>A`B@=]:($!!2W2`8(!>`3_\4<2(RPP0@49
M#"$`#P^<H,0F8!`@1PNW;3.('@8X$80,(5`A""9>)%"!!EH=T<(?+41!%HZF
MP!@3K3/6"!.NB`"P@!/H_,&9&D_T8%,A)`!0@P<V%+'`,40<>TD;*1#!Q"49
M5+`"#ROH<``%#P`AP'A87A+<$TO(@LD!0^0PZ:O<9/)!&57LD`(5>+R06APF
M3'!I!A#X@(D'?AP!P`9=F-(%`F\\<1@A=@QA@@D9%!"`"`F@,,0*"X1Q0:=8
M)5&$'#(\%*P!'=S1@0]')/"%HSDFH<0!%>RA@`<O`)&#E;R*8FO/N=IX*]`D
M4)'`'8,8<08$"Z@1P)VS7+"&!!HD_\#!$R"$4<0E2CP1P`_W88)"#%_(L40>
M/L1!``](>)!#`WXT>,@6!8<P08::=`$!$CRX8$&PB=1@008_#)"<CT`/(D,#
M,H"`N"DVE'A$&ST14L8"`:B!#Q,I?"VP*70X\`0<7Q(2ZB`9!*!##`VP\0(#
MCR<R`!SJ)J[)S[:_INN-N9=P1%Y_J(&`#EK,$44`AW1PL!)*^/"!"3&DP8,9
M>QCBP<4;(+V)'1X8+@!93>0@PA$?`.#O(6BDL$:5II!0P60BH)6(!'8E\8<7
M\<@$@QD__)$!!EKP4R%$0`4J\.`/,=@!%BK`,XMDX`918,,`+G4>$.C@#A!(
MP1P*8`0[V/]`%TG`@AENH*]!H&P0&DC#'GB`A0"$+1,G.`(2;!"[W!D"=S9\
MR^Z&!K0[L*$%&<!!3^C@`P@$H3.$&`(:Y"<9AS1A`%38&B':T(,0?(X4=W#"
M&\R`@1.$"00!:``$``>`!O!@`QD`7"FXT($W-"`*4"L$%S0`@1E\)`G)D(D`
M#,`!.A2@!RY`(AJ.T`<%\"`-!AN"]E@RA#@LX`@VR<,5C`"#'A"!@<5)A_+,
MH`#MG4X*`TA""<S0@A[4D!`:",'T[O6%_N0P$3A\94MV^$H01$%NFG""&N0W
M@0$(+`0UZ$'__F`#&*0@!-<J!>S^0`,(L"`%7T"!&Q#0@C<-8@/_"^!!`@!C
MDB!`(`PIB,,+KJ""'NR``#J00`\.Q`4"[,`G>\2"$<+0`Q$X(``[$,$)J,"B
MP1C`4H.0@DQ><(($I$`$8#A!`T0@@<H5P@YY-(420)`"`OQA2%A((!5VL(8=
M-&`!&C!$'B`P@@;T(`!M`,$$(%`!.82@=+(L1"QC:A):YI`/5&C`%Q`0A!(F
M`@4#,,\$6K`!(^``!F(XP@_H<(4`\,`!8SCE*&@`CP680`EN0)H11A"`$)R@
M@29)@@1`0`,88$$!"N@J``SP`1_0H`$&@"<>U@""&BR``$!800XP\`8JS.H/
M<25$PEK2#2500`L-"``(<&F(>+F""VEU_P$%]@`!%.SAL@B@P`0VT!,?@.`#
M<A#0`WZPAPH,(0.!80`$&M`'L,9TIC2UB$US5P4Y(*$/:A#!`N0@``LDLQ`'
M,,$.5I``'GBT#PQ000/,0(`$N*`&$'"E11;V`#E@P0%2@((<:A"'($2T)79H
M`AA<,(`NO``$0$C##GHPA!BD(*X?D@,?3+(*#BR@#3(H00\,P%\_&`!J@961
M`0XTFP68(8Z#R$,9"&`&`U`!#A:`:2&N``$C_.$$_)/N:Q?`&A[&5A>S39P=
M#$`$Z6XA!G#@[P+>0.!-H,$,4GQ+`AH<"QDY`$6$D,,'SD"%"6@A#090PPZ,
M4``.EV05(3```?\>H-\E(&`*2H!#`SJ@!""D`$>GFPT7:D`%'G7AQOOM01HL
M8(0@N.&[AK`!!L[@)PDT``H?_@-LX]R*$+N(#K&;0PM(\MMM'*`)3JC`%^9@
M`#,0P0AH+H0+S-"'4[VE#ASX@1+4F!HR`"$!']$3`=8`AP?,(<DRX*^#2^(%
M((B!`OP;@!IBP`8'AX`+`>!O`QSJH@'+Z`X4$#4/U.``%)"@"]R0*B&8((<1
M5"<!#1C/ACM,YY+8F5<+>,(_6L`&@8+I#DWH0`4($.8U.*!3-F#!$R1@Q]>4
M:T88^(`D7-`&-3P@`08X@@4,8((YG*`#9W+%$+SE@3%D@`0'0``$--#_$Q1`
M``)(K+629-2!.0R@PDKPJ2CR0`<$/.$!TJQ`#V*@81O.N=FD>+:,Z,``!`0`
M"$YPPP#8(`1-T&$,'MB`!$P@`C.D0`L?.((($+!(UYQ;1A#XP`[8H$\'I$$)
M9FC#"0S05#;TP`2N>8&P!=SBV6`A"CJ8^B6X4?(&O($&=(A!#PK@6MM]'.2B
M$+F,.!<`CYB`"@]0U"@8D`$GG,`!"3BY!!+]EI^[R`Y)D#D*[N"&(##@!CXX
M@"4Z`($-7+$D=J!T[K(\&Q\8(`DD:,-BTD$&I5:G`E3H0XMR=W:T:T+MLU$"
M#W;^!R-080"C)X4=[*`!'K!`\C[QN^EWKPE;_[O(#&BP@P0,8.UTY`$/%OW#
M!'9P`5F6GO>)0/UK>,"905"A#11TA04\0H01=!#W+-$]CD@.?9E0WC6YID$'
M`E""E>`@`";(PQ\`0`7G<SA&Y=^$]%/SA0"\:0MX4``E001P,`$V(`;5XR+B
MEQJ1EW^NX7NI$294X!:^TA(OT`,E0`,'0`1^Q7>XL@1X<`%0P`'@YX".-0(K
M,`%R(`8>^!8W``1/<`-T(`$+$`):IW]B$`3T4"3FEH`.^(.FLW`_<8.B<``-
M\P=CT``@T(*MH`$-P`)@P`5?<`05P(2N`5$?`0)RL%X<4'5`*%@)8P<6$`#F
M)``H4((L`4$B4`%YDO\":&`_)F$!<%`$!\`#4.`#:&@1"_B%NP>!AD"$F8``
M9B!0`!``"6<254`%*Z`D6M`#&M!SN(("-?`!?Q`$-;`">9A_5P`#0N`%Y)0#
M'><335`/R""(#R!A%B$&5M`!`Y`".5!NJ;&'?(AVY_>'>-,*=@`$:_`'&T`%
MW.036]``3Z`OOA,#B4,/(?4'(?`!%C:+AB`!;4`<#H`&M9,:"/`%!(`/%=``
M%",3!*,"!S`"0,"#?>>#S@A]?EB).9`##)`$(-`'?U4*8+0!7)`"6!"*Z>`C
M3!,!R0``/"`_O&(!-7`%L`,"T7B.A6`!!*`N%-`&C"43#*`!9J4D<8`!+1#_
M>R91!"Z@`5E@>R\D$[*(D!]6BR>P`&S``!4@`/;8"B1P!`,P!C/V>#Z!DBE0
M!"3@`P^@6#TC`5$``HH0!C70C"()`5JPA%I2`H>X$G9P`B.`!1-@!W$`!"5P
M*5(G$W0@!)(V`!WA<^8HDK3HA7]P`>_T$3G@!Z00+P,`4ERP<9EH$130``#@
M!IG'!@")(TT0!BZP!WW@!W#FE8/``F*@`'I@!>SC@C`0!<TG`1A0!!1T!1*W
M$C&`!5<A`"7PD>'7E7Y)9[48EN]D!U,```#0EA_!`#K0`Q+`!7IP!,7'@(-`
M!JQ%`F[@`E20C+1R`RN`!POP`QCIC$Q@!;VA`C+)_Q(Z`%I+:&DA`#*IX0)6
M=$][5XZ9:7H&,`6'()8?H0<-@`&.)@HBH`4^(`$I4(VI@3<W$``6Y08\8);/
MF9Z$``$"$`#F`0)^``+X*!,G\`0)<`!G,`+Y9A(AJ9Z3!SR%();H8`$NL`6D
M<`$]<`)V@`4CD$FNP04_H`)L*`$-^@)E(`#^J9Y"D`(.8`<Q@`JT-AM(L$`T
MX"H](9I_$'E2U9\9"C31:0@T@`0]-@$1$`8$(']%B`4$,`84<`3R`XBM("2A
MI01T,%]Y`"`M^IQ((``'D`%"$`(6``5[X`X"Y!HHX`)(H`2BH0THFJ(D)WDL
MFJ2X4HLW\`5`,``#(`<P8/\>HV`Q3I`!/-`&<#@;!7`&>4`%I4,')0``8NJ7
M2Z`%))`!3'`#DQ$`>_`!=9D:L&`>-=@$KN!8T6&.0-JG;^$'7M`28"`')4`'
MA4B;LW$"4>`"``"++]`&QDBIYV@')D``UK9M)P`$??``GIH:=/`!)4`"(+``
MB8H)*A<!4N`#1*`%>W`"(."H@W!NRX2JO'(`4"``?@``).`!=O(';@`"8K";
MF#`"-7`"")`"(%!V/O$";H`$.R`$[7$`!:BLSJ@E85`%>-8$0L!7.G`"R/D6
MJO4T=L`"`B!WFN`&8?`$6>`#)@`$0C``!#"G<2"=@S"IZEH2=Y`#1Z`"*L`#
M`'#_*$_P!QW``U10KYB``QH@!Z"H6T`0`QE@`[;0`5TJ"G1``0-0`'-`($I@
M(`T[BPZ@=+-W`#]P!#7PD+/Q`5K@!$-@56U9`%]``K`#`"%0`":P'1H0`0(@
M!EZT`B'@J,4$`M@ZLQ81!!@P`(,`!2TS:A"P4=_!`44PGX2PB4*@`TYH`BZ`
M!C1@`1R@J<&Y$@7P!!S0`+^5`2E@H%@+A!10`H@A`0.0``N0`ZZ1`Q%P%1/P
MI!;0`RV@!$5P!-F7"60S7Q<@!RR@`7)S`V&P"GXP`A+`!FQ@"1I@`&U@F7UK
M$3A@!&9`"!@6`SDU`>[E=0$@!C#0?)F@!&RP!PR@!B$P_P8QT`(Z^`>Y:DT^
M,00CF`!U0`@^,`<?E+H."`$E(#\;$`96L``6X!I]\`0`H*I(D4!'L`$VX)*H
M>PAD<RT7`$!_E0#L<&%F0P4&`(H1<'T0H`(<`)[0BXL=T`.$L`$[4`!&PP-G
M0$4"P`8+T`,LH`D7J`=Z(U`M,`!R!P8!1"M.$&#Y"WTH\&[%00$1T`ZNX04$
ML`1AXJ]M8%P[`P(]@+^(<+Z#`"X\J`*X,`AAP(%^D`8:T!=J<`1(=647G`Y-
M$`!?,`A8L``5,`=*$&][T`-:$`!%4`2((2\R()V!T0(`\"5?X`#9Z2(=8,$]
M;'HD0`10AR-2$,*$$`(@<`(3H/\#=:`&"U"E7!,G8C`!T?8#G:("2/`Y*]!7
M&U&C3]`"A88'!I`%7>P*,R#'<B`'3Q`##C`'?\!%&40`#2`'?L"FF0`!<D`!
M.%H`"2`P+9`#%7"I.`(&7#S(S78`(8`&+I*L1K`"?/H'-P``GFH&'(<)$'4`
M%A`!.7`#(6`"U9@`(H!<&K``4#`'"M``._`#:_``!C`"$1`!!_"\I%P*M\P5
M7(`"4&<!$]`$9VP"$;`$27D(=(`!.5`=!W`$*3`!!,`&`?`$QOL6C^,!C!S-
M:,<`2``#J<QU-!`&7/L'V%P!%)0%<\"OB9"LF)`$```$ARP#&\`&%X`$;!`'
M,A`KNV7_4?IRB_+,*P#`4!\!!4)P`P6`!$C@2[12!CQ\T<VF`N@),2D["A&P
M`U:``F'0`'C0!I]3`F%PM6!R2AB!!`"0%P#@!!V0`#I0`2B``!$@!`)HTKF3
M`0L08[FC<4I]TBY`*PAP`1IP!1MP`1<P!.6FJU&MK%I0,C9$!V]P!E\=9Q'P
M`18--)JQGV>MG@B``>TL(UP0`C.M/72@P6]-4P"P`N6+*S40`LN[UTEJ!Q@0
M`U9(GUA@`FSP)2_P`#)`V#&UJA2$`PQK"I`*,0N@!Y(MI@[P*[1"`9B&-?H2
ML[/:V8G3![?Z!TH@!J\'QG]M$DP@726@!3R+VIEY!W-PVJ_A_UY_``<#$!AC
M<`1]AMM`4P%HT"!"8`5ES0-+^QJ9W0!Z`(G&G9D\0`#9![L.D`<30`6GRA((
MP`.M9DTQ"Y;532LG`+A_4`,<T#7;2BL3T`"[>MY>N5K&^\-DP``DL&0R<0`7
MD`8UT!\H8``X2M^\<@)M8!Y6(``>\`2ZZ1E'$"):"`4VH#.$,`)$,*<&[I=T
ML`-62P@!(!`,4``/(!-OF08Z@`Y;O.$]TP%MD+T6(`=F\#0M04D8&@0K@`1,
ML`#0\!$]$`>)S>+Y]QL@0#N$P`-E,'MJL,^O,02C+.2S(05OX).#@#4^H0(8
MJHPAD`5JD(SPH,)0[HP&`)!3Q@TFT/_*5SC@2A;F,I(!,M`_8C`'Y,@26-ZU
M2_!"A%3@;(Z0(B"G@_`T='`':J`&LX$"`;``X4T%(;#GJ9$!4&``J2"7@RT3
M=3Y_(2"46W`$",;H#MB`@^`!1V`)+;!1&Q"V]9<:3?``.T`%P^$!%1``<[`F
M(<KIIE`'4V`X&'`$`L!SJ=':0(!5*B`#YS`(#\!FM(Z0=,`#/JD$C<<%&+3I
MAJ`$)V!A=N`$"`"NA?`"'K`X/R`!W`8#$B`!,8`!#=#EDWOLF\``8S`!(A``
MEZ0%5/`$%F"L,I&KLJPG5)`*#'``?F`"U(WN/YA;I$`'R?`#!J`"?^`$`C`'
MO$O+%K`#+E3_"&M`!5&P`0$'!'!7!3@-\'\P`T;P!E644'X@02,P!RK`!24(
M%`M7!TU``W37"A,`!W/.\3_8`3L0&#:`<%P0Y"*0P(`)`)IS2F0`19MZ"#J`
M!52@!3?@!D/``W/P!1VP\9P>)D1@!B`%!E8P!Q]@;:\Z`C<`BX<P!B(06!=0
M0$VP`*LI"EJP!@)-\_DG?VY0`P)(!OMU!NUW>BJ``T(@!!O@;8E@!,63"480
M!7,@`B$EQW<AR&Y/""BP`#M@C`[`$7-N`P<\WX2PXG\@`XT`!P@E"EL@"5F`
M!ZFP^'S8O'%P`BB@>%^`!QB0!CEP`1Z@!(/E$BI``MV\!5]`Y8(%_P%TL00<
M>P@TT!C]7NHP(`=]8`-3$`=[T%"T3@(%``,!D`!N\P%/<`%93`CCS@,Y,.M_
M(,J#8`8HL`$&@&F)0`(:<`%](`.'W`=V@`9K\,2D#X0'/,![@'C*AP;+%08M
M$`=#``AN?X-^*B0J$1)I%(.#8Q4!"U.-E)65/F$-&`D(&SI3*SUL"R`'EJ>H
MJ:JKK*VNK["G&A<3-T,#9F);$R-'+%NK8%\-)C0SE1T&@STZ$,J5#%Q#%"98
M9@$`-W]W3D\`2K'AXN/DY>;GZ.DO%@$]6&H7&DIT540-9F<_%`@=<C!-4&"T
M,8&BD1$B1QYD&#>$0`,1)PX(<3'$!H$S&__2:=S(,=:-%#MV!,#2`,(-$V8$
M:&/%@$&,%&$D+&PTY%F*&Q"H4!JC@4(?+3WD`/#PAXL3"2#6'+'0L:G3IU"C
MGKLS(0T5'@]R0,@PPPB(=D]$4-GQHX.8%(S^K-.RH,6Y)BT<(%@18A"-&C^D
MZMT+*X66`S2B',E`!(Z9C*X.T/GC1`Z/$D$&O7!@`,*?-&E*$/CC9D,,-#R.
M/"G0A3."`@!D-#@RP,-BOK!CRYZ]ZG4C!R-<G"$0HL\).U(F(/&CA4"$"HUN
M+`GPX0:#<BT;(2B18!`)/P-H:]=KQ\"+01L,#/%C0MSS/P6`U+"0X<`2.74E
M^!$!8L";,RY&3'#_8\?K$B0?N*`%"$'<L=V!"":X%Q<.U!``$&GTH<`-!]AQ
M`Q(8E'<'!3($D`,XYZ$3Q`HJ"!(#%DPIJ.(Y-N@TB`8ZX3".'8V`@0$/2^AP
MS"`5_!#"&1A@`4)[0UA@PAM88$">%"LVZ>23Y'"Q00@8`#'"``IX(,@?-/2A
M)')-_2!""$7X\8814*;92HL7S,#%`"ZF\\8"7X#YQP</`A`-`O41`(0<-5"0
MQQ]VT*CFH8@B&H0%7RSP!`$_3$#!&W(@X82A'>7QPP)XK#!$HJ!6LL(1>O2Q
M``P<W<`#%A<((D$>;MQP00XR8!``"Q*$JNNN:2;Q@PI6I("!!B'R:NQ3_T5P
MH$)U'7&1@`M6A)``"RRLH8(0?:!Y[+;<;F?'>$)T*ZZN-IP``Q58U,!"`C.-
MZ^Z[47&`1+'PUJMB!@;T<86]_/:+CKSGT>OOP'HY8`8X!">LL"H<A#N(P`M'
MG$X::Q@H\<4*RXOQQAN5!#''('>K<<@DB^-=R2B+['#*+*=219PMQYQHPZE@
M*C/'=K2`ZLT\ITDS*A_WG#`)/50A]-$K_FS)=TA?C((!-C<MM6Q*5V+;U`G?
M`#/67.M5]1\>1&OAGW)TS2\#%D1A]MKQKCS(%02@@8,:`"S'-KP98.'`W7QS
M]/4?,3SP@A$S*/%%W^.B8,:6B#=.SLB4H+;O'_\2,.OXBC"08@<0(871+B4H
MI'#YZ.'\G8`:3+^!&.D)5E"#"0@HL`<4+7S>B`4UL*X[*W_'``#3(R"P.X)5
MA)&`$J:4`,+5C6@!P/#06_*U%'@8P-0$`]`0_6PM2<'"`(/^$4):EIBAP/;H
M_TV#$Z\%C7Y468117AX4@*!M)4S,0?[[N__-/VUT>`T-(#6(!TR`:94H`QR$
M]S_6T<$'5@A#'1C0A)D<P`C,:^!>7&"`)U@&`!3P@<T8D(0-.`!A&G3<"R10
M`RHT@`(.D`,1GO.&!IP@A;'1@!5V$`$N^8$'#`1/`W;0@`+@T'%YJ($*<&"!
M#\B@!P%(PA\68``['5'_+P^@@@"4P`0\L"%7C:""`W#PDBMR[0<!^(,0#)""
M"0Q"`!BXX1\TP`,J5*`,/*AB``Q@@#B8$2H`,,,"3A.`%"1@!P;```)V`(>"
M_'%J(&A``#J`!C<V(@,):``50%"`$AQ!`3)00P]*T(,;3.`(CW1*!&0`A#T$
M(`I/,(`:E,"#'/SA#52@`A%2B;09_.`)*!"!2(SHAB&@P`<6@(,6SB`#+.Q`
M`7A8@P%"L@->=B0$89`!#U+P(P.,90<$J$`&@G""'ECS:#$`@A/:\(`1?.`/
M-Q@!$B1P`1&DX0T%8$,`-H"',.Q@`#$`XSG3`84UJ&$'(A@`%J@@@P(XP`,]
MNK``!`H@NH'R#`0"8$`(])F6!*3`FPFP0`D@L``B@&&?6LBEVBR*C@0```$+
M^`$9VA`#3>Z@`B:@@C>SPU*D1:>G*J)#U(!*5(N^8*B-$"$=*F#%HCIUH$9@
M1P<F8`8\2`"I3\WJ$2WPAA0@0`M%V(/%M$K6/S(@``@0@!FH0*RRNO6(='C"
M$`#``NQD\*UXC5[.2-`/.3"!`7?-JV"WQX#P#?:PB$VL8A?+V,8Z]K&0C:QD
))TO9R@HV$``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>y85641dfx8564124.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y85641dfx8564124.gif
M1TE&.#EA8@&V`.8``.SLZOCX]]W;V8."@O;V],W+R;V\N_KZ^8N)B2TI**:C
MHOCX^,C&QJBFI/3T\I:3D@@&!QL7%SHV-O+R\&EE9.;DXI"-B[6SL<'`P/'P
M[L?%Q*VJJ7Y[>D5#0XB%A$Q*2M33T?S\^VMH9EE55(!^?5514<"^O6%=6U%-
M3&YJ:<_-S)V:F;"NK/GY^.+AX&5B8>+@WL3"P7%M:W5R<<+`OLK)Q]+0SM+1
MT.3BX=K8U^?EX]_>W:"=FWAU=.KHY_S[^YB5E-;5U+BVM+.PK^CFY=C6U4A%
M1;JXMS`L*YN8E_?W]J*@G\7$PJNHIHV)A_;V]H*`?];4TEY:69.0CWMX=_/S
M\4`\.W1P;B`<'%103N_N[&-@7O7T\TM(1S0P+PX,#%M75B4A(?S\_/O[^OW]
M_/[___[^_?O[^Q01$?KZ^OW^_OW\_/W^_?[]_?OZ^OS]_/O\^_S]_?K[^O7U
M\XF'A\"_O_GZ^5-03_O\_&EG9_?X]L7#P_7V]/W]_?[^_O___R'Y!```````
M+`````!B`;8```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UH7VVN;J[O+V*9683?P&^Q<;'R*=]!``!
M8WZXR=+3U-6+8UQ^<V1F:6+6X.'BOF?19V0'8^/K[.VL?@Y3?WYK9USN^/GZ
MG'XZ7_,M?@C;1["@P47]ON`ZT$?=P8<0"Y;QAZL,&X>5^O@A%,*,GS(:_X0L
M\T?,1D$D(ZI<R6GBOS]E4EKJ$X*;GS%C^IB$XT<,&3\MB/TX^9&ET:.47**4
M.?.GGZ$96G`8<0?%B1T'6OSYH60>1J1@PR92"I,I)3$,8Q[PDV)$!`AP_[^@
M`*IDS5HQQ,3JW8O2WU),?<ZPJ7(@Q`LT$*X`F?(`\8DQ+?SX,4.3K^6P9&-B
M"B%F#($S?MZFV!$@'0<T7R;X"?%T7K3+L%5F-CMI#8$6:M3(^'*%",Z>/IQ`
M0#&!=9HQ`=K$7@YQ-B:T+1HF@,!`LAB39'#`/2`F31\R<YB+K\:]A4,E(01I
M)&G2^27S2L3TF:[A8_2/.N#^R6FFQ8'QD40&C2"1]>=:2>I`0U(?<9"4QAD^
MB60&@)"0X5\?;M#41QDAL#%9'^OY518F9&"X#!+4]?232#OH%T(`;H@Q(86.
MF(36&B7YH09K/WA#F4Z2@;C:&.7T,6%--#ZR1O\(;CPSQQAE3""C9&6(H8:(
MFF$RF1\+3,>$&GVLX<<!9+0(005BA/"&2-\DR0A-W`30AQ)*`*43:V4$4(5D
M088PQC?7^722FXKX(4(3(9'YQUTRSG/E2UE>$D)6(1R!1A@WE$$`-`)(\$4#
M<P1F!DBO$8K(=S`]$P)K<)3AQXIB9%@3GV<$\`.89*QH:B)^P.#6`Z"9H44`
M<OI1#DQ8TB;)&:R5%AH$:`BA40L)?/%%`.7H>$97NY[:4P;3GG%&9'I.5H46
M:/5D$F=DM#$&:P3\U^TA961P`P,C)%##34*ZYE&R6BK1@A@>%A`&!&$@D<!T
M7\2@$[:2K='FO(2D(1G_:'\H\5V=.HF4SF3SF/$CGRW4I!S%AC#K!P@:E)#`
M!3Y`E@9K^$&J;"1GY`043C8P(`%<$"A0@QB1@3A&JX.B[!H!ZIU!``$E_A%"
MG7Y4X4,()3MUP!E_^#>'$F0H38A'DOVD0ATO6"%`B:!9"?`E9G1D1HD-A=`!
M!AA\`4(?T?VQ!IC6B2T(F7/TY(<*792@,1EG;*-`!S.4>%T;%G1@>0<;W):T
MX(8P%,$7#/PQ(1D"O#0C*!T(HC=,H(0T2&2+1K.I;'\P\$4$)6E%$P(0?##&
M?[P##70#YW#.:Z\J(/$%$=M4\`\!(.7E2>I_K'[S)3%E#YJQ0P4SS_7ZD&1[
M_P3&[DBF!Q`8X8`?Z$-P@@XZY"`#!%\DL;GQ@_#]G0\ZH`:"\P'82&L^03WK
MA4(S'@&(&B23GI6([W9`.0#9>/>!FY#`?>`2W02Z`($'@$]P&"I,`,00A!M8
M(0%HT$))9D=`U8&`=9_("9C:8"PC_:X/:F!A<VIW.Q7<P`8W".(,AG,`"Z`!
M#!68DQ(.4`4!6`$-/,#?(6REC=\9"P1-0,,.=-`'>;6P>B_\("6T((`JC&&)
M1E("$8B@!`+,;4,1>2`$(D#'.B+F`R$8``1$``WY?*</'X``$*1H"%=!8S*1
MB4$8G/<%`)@$=2Z$82<^\`4%K,%59UC+YPS`P/M)A/^']+.6*.'R`3)``0)Y
M6&`$KQ/(!Q#2$!H#R>`28(-!(&$'7/NB`3T1R":<@SLD^1P#MK8H3^[C@1'@
MUA^V1<$_Z#$%?A!8"&YSAE:^<FP;B4DF]1:,]-#@=I`$HR0YT<N^"<(,PA1C
M^'@8@3D1[55TZ)TS]RB(-+0*0M:\YN!:(*X0:``)/CB$`!+@A2#(2!V3`L`>
M&$`#$^3`#!F(BA)`4R(RJ*$,+5`!`S9ZAY=]P09\HHP8XM6326QM#&0(I`(T
M\BI<?*X^+3"#F`X"C?_X00.W`TT?O.,'WG4AIGHL@0`X,P87=*"#96!(3S84
M4T>8P22288-3WB`&'&C@JAK_V`%KA!0"UQFD#QEX40V\8(.PI4P'3"B!"520
M@3(0@0$>$.47NA`$)OV`;S^X81`V:@0O^)4%.I!``EA`@#6DP2+<21`D^*2N
M:D+``QN-+`->^HP_N/&KW6GI^$`$(N]0T`P'F`(6O@"&C3)!!!#`@@+>\)T0
M'(=/CM@2LT#$.!PPX`IR38$+?E"RGC#D(0=HD,_^4(73%6(U&HB`%P20`0[0
MSXX0Z$`%WE48'(`@B$:@XP:LLZD^S$$"0[C!`ER3%9#%-DR2X4(:R(`"X;D7
M=#95IS@$9(;PX#0"9/A!`'N"/CRZP0\/^!S0T!`!%I!!"6<40QG6X-4WR0<:
M02$#_P!2\-P(C!8"*=""'RXRAZ$\Q"-#Z(`*:.;)$`"@#0&H`0H4`"T1O"@`
M2<`"!.@P-0*D-0%(0`(#/`*B$&3`#0?8E!.]T(0F..``2\*8([ZSP..(H0I&
M0)C"%J8P:^UA0NTQB*O&X)$UC-4*VY@;E'B`!`JTX#,?\<"4'Z"!(@N`L^\2
MF7S_0(81]G$,PHD`%+HX!BB\Q0(6RDE.'M*3".QAFL;R)%`0#8`K8($#?2S'
M$)``AA'W^0)F*$<Z0J"&-#%)4&=0@P\^\($&W`8]9FU$",ZA$YRPH9=F0*D?
MXA``88KN.L9T1QPTLH86_#>"&ND#&]CPG310IJL;7HT-?O_6P>AX%Z&Y/JZ0
MR("6')P@`0JXR0C%H(`$7.5W_X6(&8:``A5$AD.>)$,5WB!!!D!@!,*6SQJ:
M9`$(#`#..8D)UCC3$*:M)=0W60,8DC"$'ZSE$9)9%`%H``/'-J%LC"/#2_T6
MP(-D>M6X(`"8"O>&57E\IVDR#SIJH(`2`.T!]Y%:HI?<$17-`0CVQL-U_M2"
M%NAQ"<](X$-N\`$01(8UCS2$9`[@@-J]>S)/754:ZCV`H<?+(\#(M)P07"66
MDB%>0>C"!S`PH"5KI`9'>$$-JOD%1'4Q#>[Z7`R^H3.#;#4=P=8(6KC<!J>4
M00TUETP`+'`PH,E@!T;R`P'Z=5[_K*VE"?:&T)DY>_.M22S:U0A)U,1P@Q>8
MP+)X,28T.#,/#;P[,$$B`Y[MW6H0'2M'E872?F0JF;`>0``=J,,--A)K03!V
M'@+L@POJ0`$C;&"GO6R/&88B3&ZQ!AE&Z@,-(8_-],3Z)JH2&<WF1HA^\5UX
M@&[6.\]KQ<XTP-ZP_0X9]-@`/S@C/I8XY(;XU(;7)#SAYV2^);K:AP!$I@$G
M8$)L2T2`.NWA\V=`0T\E!O4&!6CQ)-RP?U(C>EK0!2>P`41@`3R@$=36?C9@
M`4.`4AH@`R@@!'[P!F.0!H%4?B#!&:'Q!4P0`A@E?[$`(LM$*?!'"BSE!PT@
M8W`Q!6/"_QI^PH*Q]B<]$0+?-P!I(@824PYZI`!D\"(2E'[OXA\[DH2_!0UL
M("&'1#`>`@HEXB=IH``S4`.E@A"0(24[T%>_%S;?H0(H(`$7L`S.D&J-4#9H
MT0<`D`-.X&Y8L`'\T54/,!Q@(P0*,$+4U0)3(`+[`B0FT0,RD`-*4`9U8@QI
M8BP#PQES=@D0HB$F!Q<6D!7E$'1+9AX;U@<%8`5=$`,U]P,E@0%=8`7[,E(M
M<#*5L!HM$!\0(A(0$C==!556`A*<V`F",@870`$@H"AO6'\@PA"(AP1#P`:N
M4@!@``$($&OE$!`L*#J4P4#>%0!,`!=>P`([!2%[6`+V-W0XD?\3+;`&$_4J
M&Q$`.Y(315<4QE!3IG@`;C")EK!I!W``3F"#(^`"8!-K#58H']%29R8<*&`"
M+9"$)M!>%@`4(_1;E1!KD[(UN!!I?G(=.M$@Q[:+G$!;)G`"($`T$X,0Z"`&
M\>%//X,$0)"2)H<%!H8U.'%\CQ`W8<(=&7``,0`TOE,R8_"-]M<0?5,8&R$D
MK/9S<D(W_Z@+($(2Z9"$QB4*KW(``:`$`>`!?<<`7/`,A,<(+:4&Z:`$$W`!
M*&(%#_``4V`%$.`%0^!=)0.3E%!_8I`#4Y"2#V`"?A("-#"7PC8SW\$"#_!0
MH.`38@`$%]`93[)__E$%?.,'0G`'S(;_,'=`!S>A7P'P("PX(#+%&AK3`IZ'
M!EZ0`.4G'S!W!V5`;7;086."#C8!%)FT(3HSB[K2"[AV`%^37U\8"FW051?B
M!_D(`0XC"*M2F9/"D,9R`$U0`B@"%TB``@V`4MJTA`^9`Q9P`L)C!1=P9JA%
M`3W6$'UP5`W0E)S@DA]!`.$VC-?!'0&0'F40!1Z``'0@!"01:&?P`T18F1/I
M$6:P/F3@;CHF!6%@`?*QARAPCU#E(20Q,#2$'6E!)D"Q$1JY"SKA'X;50*9`
M;4_A!I0Q`N]6!(K"EHL`$F=`$KP%&2^B`0@P`!ZP!W/0AM"@9)4PAA"0`.SI
M`8&$;2U``1A6_S);8U'<Z9V:T"3<`1-NX`93Z%31<0!O4%)EP&Y2\Z$B833S
M%I*,`!(>`290Y6X)H`0L%@9_N(=W<(\=$B3H&!.K<1-^9#AK\1W3^`I9409-
M$`-PH&"G@&NK\B<;4"TF\!M'B0AW)R-QTP(WT`1$8YX(EBL*2A,<*@GZN5+\
MM`<<)`)]@%HI,#!OX!3<F::0X`9D$"EYB@@&TG5_$2DA\P<Q`@D@$9`G(08T
M``%(X`8V\`+#00#?*#5CH(PB$::N0H%@&G2;6A(,D2#45HW*YXZED!5_,`*0
MJ4T3N1%=Y0EC,!2&Y`Q^H``1\`(N8"."EQ[9Y"HH<1$P82Q_4B(-D/\`7)=)
M$=12A/":6LE2\[`#%!`!OT<TKA(#:7A:>X0+DRH9W%F;82$&=:"J'5$$=X`$
M0L"E?@0*+S(NSU``=,">='`$)6*I&?$;*S`#U<$OF682@]8)S4IM&@$'$<D!
M6)`'"'`U?L`%Q)"$P189)?(?HWF>.J$"/6`%),`=Y[!$6G*D3S4&)O"B/>&#
M.K&'"(!:5K"P=$"TTU%^EM%%^ID[.)`%8>`%$-"E4*H)_3$&3]('0W`'4`LT
M87`!Q5,*ABHC(H``0#%W8G`.$-L(I8&FZC$&'H`")&`!%H`")7`'=W`#;-(0
M`JH1JQ(WV$(&0G`"/7`"!BD?./$#KI@4>/?_*B'0KPE0.%!9ET!+8>XE/`UP
M&:!UDPE`)A`R!4#3I7#4"73A'S8`M5XPE@_07EX@+:;PE*!A`"*P`>5P!F\P
MFNBZ";_S)_(1`A8P`E?0ESFQ`JA+`2,`!B.``V+P`]F"FCTQ0GWP`"/0`%U*
M-V$3@Y-09XF6'ACPH@$`$KY6(D`KM*B+NM/1!)=!DO^'!#1#!C9PB7>0;Y\P
M)P0@!@8``59P!`QF!C5P!QVDKY_01XR3!B)P;RBU#%N5MEHI!I-J<S,`!#<P
M-5,"#V+`ET``O<8[`LSR5.+2$(I)`3/P`A<0`')PJW]R"6WP7V<:`"S`LQS<
M!WD%M'F`2GZ$1I6:_[2:J:IGY"<'T#)1ZPS_NRHMD`,!Z[!M8`8$$``,@`16
M<'FEP"<ZT0='0`4Y<)[FAPO+V@E)>09#0`$],#1ED!,$X(,:HR,Q\0`(L)X4
M0`$BT`/<T0T"0`$L,`4?@!9GD`:141B9<!,WT0)1(`,1L`*@%Y5"8`6J&,,I
M\+!;(P8US!=\HP-3L`1"D`4H@`)9D`4G8`%>F['\@!Q_L+U9P#B2T0(30``F
M-TBFD!5YE6E08`!&FHY9N0FA#`17,`4Y\"=A'$%):'XE8C$:D09_8`%3,`4D
M,,DH0`5,D`47<`)#`&301V?^^PAW]PP_&``WB050D`9SD`9-@"(I4`:0JO\C
M\D%GW(FY-5$G.&``>&,`!A`$1B(H\<L=VXL"0,(WSL"_IBR#4S/&8K`#+W`$
MLS('9_O,E@`%'4`".?`B*(6I';)`=V(QK&%W;*`&9U`%>%,'/"`!$9``(P`2
M5-5`5))^(&(&(U1G6G!!$=`!5M`!T]$!4=`"J)4')E&U9C#.EF$L56""D)$G
MH>(3S/()*(8U\1PD*,49)N=*3?PJ;2(9-[`%G#0F;3`PT%Q_Z-!K;#(B#6`$
M`V``.X`<Z0!54&=[`R)`V7I(MJ<%&#`_(S`9'))+92$3-1$3AGM1#BEM_2$?
M*M`!6U`!&'!!<'$'&``"VV*C>?`CXN('-)VT2H#_F#1A`Z3V`0-0-#RJ)0'@
M`#]0OY\<)"%CSZ_P`0J`D?Q$GS7$#31#$Z"Q`2F@`$7P8&&\JXU`$Y/AN6E]
MCRZ(>X8D"/QWCL&&%H<`#30A'_6+!A3P>@TPW`P`([]#<DS@:41#!D?0`#N`
MP/O`V^:A$SXPW`V0@L3ZO_9W`$1``E@P!2*3)G^P`5CP`@+P"G5P`A=`$GK`
MIR+SWO`=WU>G,A1Z1GV@`!^0`C7`6QASBP*ME<CA!SG0`%3``3X8%"41-E'C
M+#C1)*ZE$U.+>VQ0#C1@EM`R`%UE%RB+IECS`[&FP.AHO6*Q&O*Q%B]&+*$W
MV_P0&9"QO6AP!:+7!@$&_P%3P-:K,#`H\`!UPU@\WN.2808:XQ%)*!(MP`.'
M4@/D"!H"TZ1,N"FQ"`0HP!5D(A_\M!]W82%*,`=*-<I$<PAF$".X\'U`D]:=
M(96+$D!/PPVM=7Q<X$5[T;S0@!-_%`?]T;TBGL=B,`<9,`83<`70LC`)(&,R
MH`.1;0H:86U"(`9:($'QW>CP_2I1.0_ZM01((`4"$$"SA4.3*C+0C7M^HA,Z
MX`0I\-8?DGM0]P9+,B&&F@Z[#20@8(,(\U!ZUQ4-06TF09F<<08R"1MSD@VL
M40,XA@0RD&_TB'!I8K4ZL`=^#A=YP``Z<,6LD"9F,`(/=T,^?NU]P`7U5UR4
M?O\">_"1N"#2N6N[G3X(0(&?#8`"<[`J0XZR6\$X8I`!<_`&A''3*GY<WN!N
M7X`PLV<L\=)&Q(:;Z+$:'DXL7`8;=48D:O`'&8`!)K#..N$-_PL959#+?8`#
MZ9P#.^X*-91UE_/Q(!_R(L_4*@`D6^$&K$43(<C:C>`JE)$3(=#=2=!=:>`L
M6>$=]74"'6``5>`&V:)H:[`&.<!L7E`#JZ+K'0*"./$3\[RR!0SM;ZX1<7,7
MO1TDX2RZ-<%E&QP")D`"/,`#=%/NE^`3`4`"3F``=5`'>+/V;-_V:X_.>#,%
M*"!Z!]\9&W(`0_&P)5P)AF0A0&(!4'`&<)`3I=$UT?'_+F,P'4AP!+%FG[NM
MU'`A`2H`#5$3$T],0S%1Q*K48P^;M+I^`%^,C6@@!9!!-L/VOV`=)`U0`@/0
M=.MA"CB!>XOR7PT!!DM@,9J,$'+S!TQ@!3D@^\"?<)IQYY.P)1OA`S)`MI,"
M55UD$GT@!4#S!4/PX]J@Q\:B<D6`&%90!,)J[ILCXL0?%D[\#&J@!#J@!;$(
M&>E0[$FQ^@-``BK(_I00)/+(4CEQ!TZ`'EX@5_P/"%^"@X1W9T<=?G^+C(V.
MCY"1DHM^`QP!?GYD?7Y]:B%]9R@0I!`*8HI*?F5]2A.*?0<@I!]G9W"3N;J[
MO+V^O\"48XJ=&B>?PWYB?<'-_PTH4!Y^(63-S<JH+6/:?A\6/WXJ-B#DY>;G
MY3M^=1T'+=;PC3Y45&EG!TK#U'T47Z5.KP+T:7,@Q`$`FUJ$*!#A"QH8G13%
MFTBQHL40<S*M&28F@PLQP\;,:2'1XJ0&=P90R9C)Y*0RFLBHB=.'$Q@+/LP<
M^%'0C,^?0(&&P-0"`(LN)%T"$U.!"@4QRWZDX:1E%(0O%@`$X/(C`*I,/\[X
MR:!D"`0L4=;X@:-$J=NW<*>)(4/R0)5.(:859`;W$<H!)%"!ZMO(#QL_`0*H
M&7/P0Y,S2L"9R42YLF6-9@)<0*&"+^&7G1"4F'!`K,P^5]"0`@)@;@@S-?L,
M:Q5B#/^-!!%J!`C1HL6:S\"#^_)S)LV81B#]C$D3X)WP9R1(A$@C1CC41BT.
M=&BP[,^!/D'#!PVA*DV##L)U]9EC0<:F/V+NC1`$`<.<`W]&CETDQSD!!E]$
M\,<:5?Q!7'H()LB(&&T96-T90I1@H!F+U/0<*22,1`!^PK40P!]J^-'"=GUX
MU0)X)>DR1@5C\-!!'VE4H^`B\?VAA`4BN/%'30=\4`H#BT#6QF1E_#%!*,Q`
M@`0.I55XW(Q0IH?1&$M`T($%$(SP57H/0'`'"1#($,"3P(7`6PN;!$`"!A4J
M4@69NOB!7P,?E%%DE(N,<=P/(B#0W1\^0F"!'T0N,MD818+_$`$I!S#@A8AH
M?@<GGI1>\\<F!R330A43Q.`!!14`4$4%*WAQ@@8N^*'&#WG]`4HFGF2""B3*
MI+&*K`;6IL4>)'B1@@L`9*##%%YX@*H8(2#;!QEOF"'&`<K!UL>KTT[3"QDA
MV(*M`%34L,B=D_72B7D?C!$`&<B21`:Z<)"1`P,XC+$A&2E61&@?8J0Q0`\[
MD!$`&*1X\$JX?A3```,C>"&!%4SH4$$;`=!@10&<T"5CI1@#0Z$R(0!P`(-<
M;!`&!0#4%!\7.%B`!14WQ%L0K&K802]LF=S92(G**7?`''^4808`/(1QP@Y:
MN-$"5!/`L$48)(#@P&Y^*''&,O3&_T%O322UD`9,XIXQ1F8P4##``O!HHL04
M(YP+"DAGJ*%&'V_@@,(7,^@@!@%NV&Q1)V[,04`&+PSJ0P<0H,'#'&/T`0,Y
M2&"!Q0455`!#"VJD\4=S3"!1Q!GX?ICQY^(2@Z\6#H#0@!7*N-,)2"UXC4`$
M+]S0&C.99(`F96(]<N\""[2@A:H3J.#$'1.$>`!1[D#K1P\1*'#7K;+)1@`9
M9_#L7<WU3D)]=G^(0,=A9?>AP@>:Z+GA'_<<0`0()Y0R@`-)*24GM&LH<04'
M1$!1^`J+JW##!Q&(0!$RP)A-X8L5G(A%#L*P`Y)D#W00=,0T\M('`EB0!VB0
M0+(2TX;?D/\A#;Q10HDL@`8.U,`'TTH<<7Y`+TGX82HV^H,#&$#"$1A(.209
M0P@,M(;:B,$,*.!!`7Q`*`)4AQ,GLE8&Z,**7H!$3SLX@05.5+8S@``IREM$
M&QB#@RN4@A0I``#-Y(?$.82@#")((P0\H((LH.&-"A#A`K:D!'K]A@!^6(.=
M;&"$',@F@H"41!].I(4&.*$'G"@.NO("*WH%8`&=.(,'/C`#'*QA`@&`%GQ:
MJ+LQ*($`L@&`!3Y`@3^8`13)(L,8?N`&Y3C@.W0A0`\^0(4&`"`O0QE#?/J0
M@2*U@8J]",$$N!"`$GP/?-;H!`C(UX<%Y*X%$[@!P+Y(BBD"TR7_(#'9&*:0
M``@DH`L?N,!KUE:<W2P#,2&H`H66X8DSF.`$!@BD/`LSI@-,8`D=0,&S8/*L
M8;`A1#R14^OLH1PJ+`$#/O#*)@A%H4>42"QBJ`,/MF`M,AS`#+W!1\\H<TI4
M()$$'3@H68;1`F>M(H%P\(PNE"#"'.1!`7#XTS4FH(`>+.,XF?"!`=I'S3!T
MH`FO4DH;9".'>V1G``E0@%=T.1DUM$`);%`E&U28B7=H`S]E2$,-7N"M><JS
M#ZW!P!)*,)FI=6(G>8E#JVIV@.],ZPUBF$$'IL`"%XQ)+"V1H!A\@`$,=&`+
M(:+7NGAC&;=19BY'RY0?MA!2A(*"$P;`_X`!ZK"'-W"(%R`1P0/F\L!?*$J7
MV"J#&G``)FHFH`,*($-FKFF1,[12$V?,P0"6T))JE6$9V6B5+0CE@$Z,(0.<
M4`,93)``KP+'#S@XF'(/E@&)V(`!S=4$,?Z``218X0ST0@5LZI>7353C@'8J
MTC^+9`8*),`"#*@"*B-"B3]D@`$;2$`"6M`&4`CD23"!#3M[IMI%F,D,B2O#
M&$Z0@"@HH0TUT,`7(\`$2E"&7C4S4$UJI@,**`!?G(@$UR9C&49D0E$3+`,1
M&-"#+Z)!ODN`"O54:A)^KDL,:!Q`)R@TAHO]`91_@&%,">4J72H'%&.H@15N
M<$.]&9<B$QP`-?])(8,<#*.;=9@&`=:0@2E,(0L`R,2'.NL+,<@`!1RP0+_*
M<-$=9H<$*!@!@+&EB8G0I8YI2()JLH""+G3`'P\8UR:FC"886?1$G$"`",30
M'$XZXBN$'J29&*,<`^D`"B<@0RM=4((O)B`+0&A5<*`"&U:(8`!*R4$6+A`K
M+A\9&)#2GQ=&P&HP+.H%10@!$B`0SUCXP`*L_@Y&)\/B9M3D"B.`P@.X@+4_
M/&`*,@!`EH\&X7B`1PE+_,.BC'"T*KA@!%>)A1B(P`.O+34`7ML)&6HP@Q64
MY@P[A$0KO78TJ[8B:CO:0P1V*(`'R*`46`!#$V*48>`@:5JA$)M;-/#_@B%(
MV-2G%I=LP#2HDT)A40TX0S<-\``@/``*8,@A9#+2WXE,^`\#&($3'H`#!0!A
M!%(@0D9V...&6L-,Q#F`G%%0!,0I!P=W^`(0E"`&#41`#D5@`0P48"9WG,$,
M`Z``8\8P-2.W5X3**0,9UL#.Q+VA#A'P`1!>0(HPL-H#9E"E8C==D!Z&P``I
MV``9C_"""_BL#TY/^"^4T0<E6^`]B2.<`OS0S=(6S@.LR,Q=T-UK8&@M(CJY
M0Q<\4`(C""0`OP/T#R=2FTTHP1\@^!`J+JH#4HBA!37`0@`4T`$,S#=?(@0!
M%2P0@!^,8:@/Q)K8R\`Y'?Y&#&]@`!H\0(H(_WP`"LNJ%AL\5'BW"/2'(:``
M`HS/AC_480OQS*O<KT$]_5F`$V4(01.Z>8IN>ND..?^"'_"HBD&R(=W6*$,5
MECJ-3CB``E&8@-0ZH0IJ\#H>)S(KYO4"K3X(@!3;P`#S=AYU@`1_8`-#X`8A
MT``R8`!KD$FJ5'BA8!`$\"0;008$L`@[,`.D@`4E$!@]UA5K@5TVUA=T00W:
MT"=ND5]E$`-;H`']-GW!@$-@T@4#<(,#$`99H@(AT$U28"-^T!!^T%OH0@:J
M,!%BP`8$@&ZU,50(,``"D!^F]`8%4AG%UPL7E1U^X`\WD!QC(@;_!P'4LP=8
MX`:DMP-3T`<,T`"^1?\"@V8831()2D!0U0`*QU,%%10#80`%`[!WV50;@-8;
MUQ$<V_!40T`%,7"%X=,&?[`#4'`!,IA,>J)D2_8"(-!*LW8$Y!&$XH<OV.))
MRA`//R1"(`0K".`!.]`FR@`]<!</W^$&3(=Y.Z0&($$&G2>&8[`#%F`&-[`$
MBW0`;A`;=4`%I$9FD\(("K`#?8``J3(`H.`#4[!G.,`!"-`'P2@6*91$;64A
MP9&-RC>(9-0)PPB)D1@,MJ!D5D`!%)!&(I`#L`)EV-@0KI$)+%<=2"A=WU(&
MO?$'-<8)JE(DFA!WOT`S8R`#7]`#.+`C>>$#'``!(L`)7]$)$%D=1"(&="#_
M`JADCX_P`#T``!&P!WZ0!PA0!2"0`)N`+R80`242"LYB*&1@)YJ@B";A+*A$
M`73P'BY16W*P#$(@`T,`'I>B:>7H0IEB=XKECZ$P!MUD`CLB!O+8(7XP!U"!
M'S%H$2^&"D[Y!2DP%V3`D%?1"Z$@!!10`)PC?8UP!F@``O=3`2T``9%#`G)!
M!D6P!5.0%_&!?C,"&^BB`A1P`<-`1IB2+P%`!V`@&U[S-4,Y";"B/TXP80)6
M$[HT:Q@`&V;0$.EQ5TRX(P@7#'/1'$O8`_ZPCBDP'Q!P!6#I!@>@6>?T0`&`
M!9GG!3'0`BFP1#\$'O%Q`Q&`+;5Q1E&25P]``:6Q_YG`(%H>I2<M0`<E8$93
MH0DNEYB/$!_6ESC:,$X4(ID289G"$0`O(`4Y<"EEZ186E4M*P`-34`HE!`0E
MF`LH^0(LL`IQ)P9`4`(XX`5[4`:0=`;-A3ZR000>X`%S(1L"&1P2Z0=`(`*J
M=(P5`1*G1%,I<`%U!&&&YIR-L`;!:'<6M1N)0R\`L)3Z&`(-<08=,@4(4`'\
M."MN$0OXD@;9T0((0`<(\``^(%/J$0HM``;5>(4.$`$JL`(X0&;*P`7O4!T8
MN$P7-77-J2!00:`I(!=*L9*X10!0(`*)$QNZ)*&0,$@_X"DUL`UU:`;HI@5)
M@`"IR!A.@`!X21@R(`(R4/\$"J&92I$-JA1N9L!S43D,Z2E(TZ)]*2`$5=D(
M`0"CR?('.20&$[`(BW$`,-`#4T!?9ID@F@`A#8H))WH`JM22@F808W`8(0`.
M5BI!.H0O`-9=G)`LV6%$)>H`B2,<=$`"4)@I_"B<OS`,;X!=?>``J-`6GU0Q
MO4![WZ$$+X``C?HMW&`@F90MGB2HE4,`<V`#/<`#,"&3A%$;?4`'(Z`$)!&@
M\%`&L\HQ@H8L4\-.L"IWV$,DJH)$O5H</),IZ!:N2+@L!4(7?8ID`\J/6G@`
M:7!*!N)$U#$U.7`%2Z!A9B0&:B!@@)8/KJ(37],"YP$3[-JDVH``(Z!#=F)\
MG`#_&R%PD;'Q-C'9J8T07I0!DXK`62UT'+'1L+]@&B?2`BCP`2AP`T62I&\A
M?7-Q*;#R"]>!+V+P:=\QL:ZB"*V$??!!CWRA#)S3`C`P!50@$3A;8SR;DQ[5
M,V_3!PJ0`DPP2"!J?+#2!TN0`MX283?$L?($"EXS+?;0``VP`0!0!AE@2B:K
M('Z`FL]*8ETX$^`!<+SPJ''@!WXE*U>U!M)"L:IB6)T`!4HG%VV;"WE4&5%Z
MN&`+)14+=2+T!K92'6T1H?+40^,'/U!0!YS`!C03KRX4`B&"`Q[@!$]U4S`6
M(DKQ`VV17YEP#P,@I3H4K!/A!VU@&#$5NXTK=U*WBJYR_P`2(%\24"3#@*T9
MTU;H,@;!>$5"P`;/DDFYLPLX0QD8@`)4MS.\P9M-FBQM,08.L(1R$+MAYRQW
M&@]TYV-)IY&[ZU4P45*7HUHUP``:8``"9KF!5!.\@8%Z4`9&L`1+6+*PJ@R,
ML2$9P`%0P`JH@&[N8'R\84IFL@8<*0!R,J7RHTI^D*54H`[K>V1VP@DZH`K!
M*U]><$.VPL'*`16#!`(E<`&<HP1P$*XYLRP@40$]<`7X20!FT`9#I11#H0S9
MH0J5(&/,2;OF6ZGK,``ULL%>]3%Y44=FL`=]90)L,@'G9%PU(74M(!4E]0%+
MH"=GX+Q'&KI5\`XS!K%CDA>,X?\69N`&]S5(1V`$)``%4Q0+"%J[A)()=2!C
M8:S$$*1H<L()&T$<*8I'1P8KY\8Y!V`#[$DOU!'`9R`'[G!*?N`"^[(,K#`8
M+A$+R>('+/!7)K`#CD@"G7-9%B%:9@`3&#``T,K'E#*[N:(&8?!&:(`%5&F\
MH--AF?`!#Y`,D[<+7'/'Q/``Y!.X%J)8<,`&G+"SM-=^+P$3R=`)#Y`%&F`#
M$ND#)-`#4L<,V<*(V<>X$U(&SIO*WLS*QR4B7I%3.I#.1`!C)V++@309%9`%
M+)`IXE'/]AR523`""91A/T8HR]%"9J"QD6`&S?4#+RRM!O`%6,880&P'6J!\
M<<`*$*;_!%DDB@?0!!V@!0?@SN2<EY4Q!EJP0YY$/<_*T1%$:&,P`DWPMC9W
M&2[]TOG2`"70&Y)*`'6Q=)EP/(ZD28Y@B^%Y!J_@!QI@!""P`U`U8<=C!CI`
ME_TQL%`QL$BF!N=!#>7;T90B(O$1&2'@!8X3!@FP'^.,)\I@!C!@!5WM.&B=
MUFJ]UFD=!EB`!A%``CC@`A5P)&92(FX0%C`R2'Z;/?T<-3A``UCP`1+<CQ!%
M514&!1EP?I0J(E6]"S'<!$;@N6%MU6^!+8AC1@?#!'O``*T3+D.I!9CP7,M5
MVJ9]VLLUOUMP%E[0VD`PUUH@?V107PD4$@\DR"U@`@K#`"``_RT!T%L_P`T@
M\0;^QP%.P`6P<@9OX,TYXP?G84&5;=E*H01FMMR,8*V+0$#1'269P0RI:@U&
MTP`8T@)P4`;8!@&7<`;P(P9F=#3H<]O?L0?%!0DMX``]@\"B=52->3DJY&S@
MU@16,`$>(MT0Q%E*\`9916R-]MY#N1NN\"2@ZPM=0@H#L`EYD4F\1PIY9B-B
ML`;Q$PE*LB/34QR)(Q8M,`=E$``-L@EE$`=WT`04;=*2@(%DT`!=D('X0N"?
M$R/Q02@!H!JD\`4"<3U#F6'G<B[Q@`#N0V:`!A\!(`=2=]ZT5AU-VPB=IZUX
MY!P.%=$[X@;5T1*Z'+1(1B>N<K4ZCO\Q,^8'-Y``7^#52,#F7U`#`AV)MQ5<
M$V8KRG"[2F`G);6**#H=K)L!H%D*TE$;+4$9!J(%,(`#.G`"K;T!&G`P!E$#
M`"X!.W!*(<`%;6#FA2$1B,X*;```*>`!1/!LE$,9ADXHK#`,.H%'8P``RN4!
M86`%01"HL*'BR/+=9YX>@OP'7E`X)D#7-B`!5V'HY9BUJ]`">1MS/\`)<9"W
MTQ*<L8`)?C`!*^`/0>X!<W"2D.`3"@$`B\[5CE,#(!`&L`D#"[4&7,`U=TM_
M`/`"`R"5&-'L*-)_'*:7Y'$#*M``:+T%0``!0X8#;]L";.`W%:3ENQX<^!`"
M"Q0!,)A5?8#_`U@``2KPX=.WFO2BT0J9"6WA``[@+T5"+<J@!57R17<0E2P!
M";-].U'ICTZ)!3#P6VV`1VUV('=;(C_@*B?0!.NW&_12I2?"&#H!`C80`T,0
M0'>087VP`4`^`@+_'AY"Q`D?LX@Q\0ZJ"#[1!A-P%1H\E,Y2EJ#@$VN@L5FK
M!G[K+%+I`QEN\A,&NKT!"WT0TJ^R"@6`W-OP0H7:1'>++!SF!Q*P`EK`(+&A
M"CI0(@50`"KP1A%@DNAFL,_"`D!>`C6``W@5/5,O',M"`(O"`,U!%$D"`3HP
ME(32'=^1`83L`&+!<XE&J`YB477P`<1>"A$P`.BV#9'@+V;R>2OZ_QUGT`8E
M(``@@3XP@9.\8":T)P?+\@,]``7J<%%2DP9-T`!3\`$?T`421FC]=%\GON:E
MT`67>`O;??DS2@:;KUX9L`;?\0>D$/KE^!/2I?KM!Q.[,11\(1:@0&Q_<`.Q
M#P$?``@A!$I^?7U_B(E_!R%_`2TM$R%58HU^`2%G!'\M9F1GAXJBHW]E8J!E
M?2UD5!9$50P8)A@='25E91E]?F-C?I4!&62/!V=+81#)(B8"8GZDT-'2T]35
MUM?8V8EC9P=8$`P$8X9SSLD5VNGJU7Z_9P%D1S0`?E5DA60T-$J[?Q-^$Q@P
M8,(@2(T$"%\H&1-"U0%2[1#YR2"GH1\"J?_*=/)S[\<!9Z'873K3[AXN"DX8
M6$&"T,<N7)QV<?03(D"A10Z<(4C&\T6.B.G\<"GBITR[HQ(C*NT746:A9V2<
MMF#P#)%1JT:KCCKZ+*O29^W,,#A@M`PBIU:C%3K$%9>?-D$8`&@AQLH7'AG,
M=FK!!$("'V;7"1Z,B(P9,7W*F$$"04$?`GU^7$P&@\R8/W,T).$)04(0,VT0
M!=ATH`4T,J'_-/PCYD`?L0()M%/RYZ:?A]8,F0K!L.@:-B@@:&#J.N(:7V.4
M'/YE6O4",DF^\8P`Q1#2:QRCH&A@@DT:,6/2M&MSIF$(-VO$K/JUBV[#CWT>
MF9DP9`62)D("U';_5DI-GS/0B!%5'.WTT48EZ9GQ!QE"*)#`"AM,$,H!A2!F
M""FX]%$:&1SV)D<+-'21P!"@],$8"1G\00`!#23#FE:$Q:A-AL\D`$$#8]SS
MT1_G'/!0$Q!\D8`7"7R#!!-B#-9'C@FP)(""@K711AD$N`:)`0*,(48$`P"0
MI$U]6#:3-2M(A\4#:GAD2#]F0!F@AN/0``8%#US0PG%FA.!C'R$,TP)8X&5B
M!BAFC'&`+V4DX<$(4B@AA11.\-"'$F2XT0<;AY$B1I)&.;5&::_Q\(`4(Q!`
MJ@=)D)&D'R1QD^0H9?#V!YQGG$'&&D-,<8(-B:7QWQ5H0$#%`T!X\,T(_W_*
MJ.R,J=38&*OI/90,#E7P`@$:(B1V@`%&0(!"8.N0,8>O\?DR&&]JM--""'.0
M0$412E"`1@\P`&2&'^*%9,T10[*P2QJ^M#`.G_=$T\(<D#VEP@<G*,`$0V*L
M&$((O[RQ2Q^(:40&)&L$X$L##70!Q@YMY%4$"A^`?$`Y-+E!BAL'<$@3(V0<
MZD<=#7SP01%T^:$%&!\HT(`8;@2@7C1F!!"`(6+$P88:("CPP@<LH"*&&2W\
M0,$'7_!D!0I_.%#PLF130^,?-C9P\:%G]$B``A!0`(">EA4@@00%#.:K'T(W
MT(06@_V"*2_SE,'!$;[8B`'%9!!(,;AF^_'`T/]F]&&`T#PL040(_!D,.$<A
M9,C"!UL<L<HN*_.6!AQ7%XH88DK\6<4%.FLAIKE^[/!!%T=\-ZF^BOC1PD,M
M.+"*&$<TL,4'`MPSP:QSG`'`!R@HD(%Z_UPV"AFQ<V-("#?T\,$0;1#,)JLM
MC(!R"3E<M@;%9<<?S=DVRM`WR$M,2X`.R6PJQK@$F``&("""P2#&##K[P`@$
M$#B.F`0*KF`#J^)PHE:-X0?E@=PT4J$)`JB@`1+@#`F(8"EI4.@Q>L)%&=I`
M!A:\``,[Z!,95A25/JSA&;$3GJ_&P(0&W`$D#)GAO6C2!QMLH0Y(<D`C1M&&
M-YP"8X;(@0%>T`$#K"O_!/<ZPSCH<H86=(`%,:!)<B#2`@)TT0]%J,,`+%"Y
M004`8*H20QL(\$0_#(H`C>B'_/:H"/IQYH\0P,$8*I",>SGC'GX88`$'`P<V
ME,$.[TC-.GCA,1#@P`];J`%\_'""8&&`$/%9Q+VL42#PG<`OM>A`!"#@BFG8
M\0!:N,TXR`(>$`S@ED/PQ0'D8$=GN,$28VB!`@;0`P_@P":M84/H8M("7^5@
M`%08`!"6*(HUK&L,,`O`!J*Y`S%:JAT!X`)B;'*`#'B@![><`XP2$9$#*$$#
M5""!`<2HHT/HJ4)BL,EWRF@:^/'QGWX<`0=N>4L2),,%?B`D!'(4@#8HX2,F
M_R!@X%JPA():0`=*"H`;W#""!Y#D#VZXA\`8$\A/!#-,ZXQ&F$+0`A%TA@ES
M:,$9&H",)HQ#+7RJS:%4P2K7F&$((I"!OU1#L:O%KG)C:$`*1*`#-2@!,<*#
M0RE8J@:6ID(,.Q#!"5A`"CA%A04>2,$1"F0HBCVE6C4[A!;Z4`$14,`"*:W-
MO52``!F8K@6J:$1-WE"&-RRM$%@47CNX\)#._7./?FR`$MI`L6!.JP_\@X"`
MS!C,$$1TD9/T@P5>D(<4S,`%2L)`#5J0A!G4@!>&\!,)OL&!#!P@#9B(*S0P
MYH<CW,TQ[6"(!;`@A1L`3Q0P$<5:HI*D(Z2`#@S@!O^K5#&.!H2U`&Z9PQ_2
M]0M$7(8F1<%8;6J0`@1L(!%0Y-P>$$"!9<"O'Q13`QG48)9=5,(/Z"&#%DZ`
M@`8$MQ1^*``"9B`"(*R%3\\8APHI15VDF$4__CSL-=PBH)O(E2O/$(,$"\&8
M!E"L//HY1Q^TX-(55&L<6,U#&!IPC5&>Y1DD>8P?E+#8L[`S-$"9E8!"$98S
M#"$%4?##"HZ@"H%5PA<=2`84?("(9+'*-B8I1!G4<*_7N'0`SN!(Y?H09!+'
MJ`]"&,$,'I!<_]4!"!08P1YDNZ\1O``(-6#-&,Q@@@?T8`070"DI+S.',/4A
M!R.@`!`:<(_$5.`*(X"K9;[_H^!"2V07V.S%(;3($?/YZ@^>J'!Y?J`E'D&@
M`KW@$1:`T(<ZYV`&WB+#-1!]()+4S`PL>,`#(@4`49>'%U)>BVH"P#:,6;8`
ML$4`%510$U\\M`]I&$:0K^4!1+Q:0[\`G1DZE8H?]$D,>8#``'[P`UMSKLK*
M*D0#1,#M-KN5`D&("IFKP=(:O(#;#:"!",Y-HD_PE92-^%,A?%0$"I0W"0Q(
M00J20&L]=9&:AOZGDFOV@V$\8GCC"$%Z^OP&/]A(`9D(::?/X88\N11;6Q!!
MM\*0A!]@`VN66<,<QM`#$4@G2"<8@]ARA-?(^`$.#2FCA4X1@@90P$XM>,`6
M3*`&_P$=2CSL<L)TSL((/O%I;Z\Q%-8N@*.60H`$Q7C#&QH2`&S+R#_/8`(=
M*#`#Y/Y@HXD1S+P)@`$ZS."X#%":1YRA0;4`:(;I4D)-","`"%R!VQW@4TC'
M,/57!?RP2SY4T2IK3<Z1@3<7NTV%"6"30A!@6A2CS0!2P),$U#?&U+C5430Q
M@Z[EP0.@#Y8,1GX4HP]C25H<0QE^0)<_G$$(5+@`%EE0`(JUX1E%98,2>/(%
M&4!53R#Q44/4H,4<O$"L<0B!2TF`*.9Z\48R"J<:+,:1#8"`3VM8A-_5P1&?
M!X`&++C-0I:#>6EDY?1\$H/'&9"`&BS!`!TX``'2\`=#C?_[[\K:F(8^T8(R
M"(';W&9O;I4'`)@'JV0$`@B`H"<)2N`&KH4#"(``=-`$F](<N4$3>(48JY0"
M+E`:!\`!7_`%5:4**29&Z$,7%_!M(G`$8K`'L7<ZJO`?@54&CX``79,,>>!Z
M2[(`M+$Q9&`*#"`"5T`'%T``,"<$=V-?CS$'(;!;4F`#HC88&C$'>/`ZB'$/
M(?`#;^1(@N$)K=$:XN`G?K`&B'1_HH!2:O`G%!("[)<<\)<<OO!CVH-_>X1L
MEC$';G`!!+6'?+B'4,"''``%6O`#<Z`?:(5:89)/V(!ZKG$`=(`&*8`#]V`K
M1&!0`[`7W;`+-7$`'J,"`S!LR=#_!6-6!R9P`&[@"P'P*21A-,/S!S>8#.OR
M'RV00Z(&`E"`3DL0`"S6"V3@4A+``)-R`$V`#`T0,X1A"$7S8T5E:TKS;I/$
M>CD"'K2V+F/89[\E#;S0)Q2R+FD0`PE`%[30#A)D%IE&AWR$;&-0B'D`96=P
M-7846._56(32#RT``3JP,KP0*PZ`-4>1)]LW#4NR-$6S2B`P$WW2`@I%:_'Q
M$96@!$I3`R,``1U``K<40EV``9"@'F[`!LYP-8Y`,:;QBD]G&`'3`CMP2R(P
M``K@#`#CA3869%U`4#;R`C=@8H)A"-T@*.U0(D[T:$JRC*DE!JD@:ACC)J[T
M$)_0'KR@_P3>2!<FD'?B:&?FR$=BI!AB,`0RP``-P&DY<GB[H"IV-#PAP`9&
M<P\.8`$H$$N5\`=*$#V'9Q/ZEPU:$E($^08*(@9K<`8PD`Q]X`:M41MQ]#0/
M``%>P`260@8&8`72ME%>^11`H4M_,`4B*0-KI00"4`);X`06L`0"LBD%<B]Z
MP@1.0%(0D`46``,6(2-<`5Y@H4<Q@GENH2#EAXVK`A:-,"CLUPYUT`%%41MV
M9(93.4EMHBI#<`)!H`!44`/<8`:F&!$P<6$KU@<`0`'Z\04Z<`J(0`#E,RL>
MYP=OL(A@T0[!`@(^U29C@`/)$(>@5`B5,P1(X`5A]`L34P-&D/\`"J`@AH%(
MX/(2BR"2"5`!`F`$1M``1W!X=E0;3%$5!1(#(-,`.1!8P!F<$LI^B$`+$EIH
M[-)+#Y`%+3``),`/E4``%GB&9P`'?J`#"6!'2;`%,)`B:?!18G<;&',`XPF6
M'+$&D:5^KF4&K-<Q8S"8'X!22^(+3U8,NY`NT/`=4!`LR3``)5`"#[`"F'`A
M%UJE\4.A?V"A5LI'&Q,"2G`$%#`$I44#\)`)M2);%N$`"C`"G(,%-T`;LA&%
MZ\`(6!090(`&79`#KR(&+B`%7_``JH!'KE%P2P.DQW$>2T,`+R!M#:8E;8<(
MSE``$?`%0``!D,(##E5M<[BEG$H86*K_I9U:-@5"`%,P`F,@`E"76FP15VYP
M>UD!`88P`"<@=[[`!N?R@\?3`JMD!2#@%ED0@O47A^N"5^-0J1]0"(;R`QI!
M`=*F&E#T5*20'#Z0!&@R!4O`!2!Y10`7JMR*#9_:`=U*-M6U`E*0`TO``3L@
MHD:Q,0#25=S`>'W`?CYP`TB0+(:U#ID090=0`,$2!@C!&%]0`_<"2\*3)R3A
M!E,``1]@?R;H4C/P#[?AF5WE#``"$'RR"=U'(>&ZL=;PK1RKFGT``E<``F)@
M`0B0?AJ5C6^",6)`?T?0`3"P`5TP%UY*&+]9&B2A`1@00LFP!#%0&Y!!%YB0
M(\R)`U<0`1R@_XM7.`58\`(",#PS%@UK]0[6U2:\<1O/(:<?N[6BX+%<*QA+
MI@'9L@%;X`*00$2S8I3!4P5/T&2L89T@\`5X55U=6!2LLPMWL`-E4`,8@`%'
M4`5&40PUP9YY,@$.\`>#&0%+X*5SL%M/MQ`R<09<.`H"<RB0H$Y05#E0];6<
MBPA>V[DS<@,E4`-#\`(TP#G^DQ2/RJYEJB`;,`(WD`0?X`@1&@VHD0H79`81
MT*M2]0>\M*XTT1"T@3Z,4`0RX!>[TP7(T%LRI1X6(EM9NRF^\#V^0C'7"+K=
M^KG8BR'_\5]*P`0=``(A\``C`!2SN14GIA5#(`'\,RNU"PU%@51D$/\&+*`?
M\-N:OID46E``+I4,(U``1'84MU<*CUH;L.(515'`V]NIVKO`PC4&U6(&OD(+
M?5"J@H0;@G$&!8`$9P`"$0!LA.$:[H4&($`8/@`"-L`!%!!3&.S`+NRM"5"A
MX/K"6W$(C[$!1B``?H``)?!4_Q@4$R`$80``$-`.*G3$2)S$2?Q&NR`%++!6
M@U$K;_``V8*D-'S%U-#`5SP':\!XI-4%;6`#%%`$:U`^[TL*;Q0%:.`"#-`%
M1*#$<`S'4C8&`-`%O';&PG5[8E`!>M:N6/S'T*#%-,R)'!(%)7`#"\``>;"4
M/ADN:<`%0Q##_SD8NA@5F<D%D"$8G+@FW87_QX`,NH+\PJO`!2J`!K)1!S$\
M!@N@+-*#"!!0!UX0Q[*,Q&?1`0I09X3Q#B1Q7-?[R5@<R@M\";PP`2"`!A6:
M`(FHL811!7I2CPS@!3+2`4?P`="EP-70`O9;"2+@`3_LR[\<PUDZPW^\8G[`
M`%@``\PY`2Y1AIXL"H:4.TC``R$XS_1<S_9LSZ^L`Q$0!`WDI<\A`@C0SMZ\
ML<#&`$C`$*!ZQ87P)TH@!%@0,[WP"PG7S=F`%&IP`5Z@`QJ]T1S=T1[-T1(P
M!0`0!PEP`?O87C*Z8+<1``77`U3@`XCA;&.P-`/MP';$?FS0!PE-PY=0.0=0
M!&&0)0U1'F5TOME@_YZST@16$#AFD`.BJ`9!$`9%<"%XI%W6<%4!4`4(^0((
MT"<$4`7%4=/;&Q;L5S-/^<E&<09*D`8%\`$MH`5#="\VN0XO(11(@`.#T1M=
ML`%<,`%88``3(%TJXIK7#*V70`$#D-4D\9L"+=93Z0<8I`%(@#$88`2`;`IV
M=`@V8`0Y$"MSP'_E(84=(W(%8`5$-ABN\0<=@",A$`$:\)N+H`;8(4;,V0)7
M(`,JX`-Y.8V][-C=FFP@<`(4HP(S`,BWP3HL708-D'?<P\S601@*5P4\0@"V
M2LF^,`,6D`%5<`=`0&04@AC7$`*^`@<?T0X#$`8<8``X$#%"Z=N<FT^3LO]F
M;M`)OHQ'8J`$96`"+Z`"C2@;$A0X!"`NX=C8J@$'+?<!&G`U2&``M4$@O0T1
M`5!G16`"`[`$)-`!'F``.T#8[LVQ1Q$"#M!%>>++3+.3&'`'*O`,86+%=+T+
MA(2Y@S$(_T(!"B`A75`#?`+1B]B.1+`'(H`$5+`'%>`'5Y``'`#%';ZU[/D+
M]Z`@;F'4H"L>]W)=&(`$C=!%,E(\D?S<@3,&$K0&NXL8,QU@B6'$ME%=2\%B
M.``%#T(&#X`$),``/N`'*;`$<N&^2I$5-&;-27Y8!0(#3=``"M`$&G!5#[[`
M?:`!5E``-V$@#60#<LL)!(Z@1"0!`K`D&L(6T6C_HL/@&F.P":JR,0$``DV0
M`E<`1;<A`PDP`PT@`"A@Y$T``^`180-#&R_2YU-)!C@`!(O*$UY0!ZCW&I]\
MTWF0:1.C)`#@!%(@:JD=HPVW"ZY%$F)@#];A.V+P!F10!6H03+S0&D'@9B.0
M!!,SHU!E`2,@`T30!XO"!*"`5U226XB08+@><&90`0:%!@D40D80`X\`'A0=
MS&10!")``T-$&&5@`RE*&X300(AF"!J;5`VZ`63PHM,K&6,P`1Y#!CD`!4'#
M"^+!"R#69%#@!`U0&2_::;T+#T24+//^=VM@`-="`9X0`BK`&"/@!NW@(X"\
M)'[0!"^`)&,S218`!NGX_S@V^Q[<X`M"T"*\QV=]@C4!@%03D`,*T`,<P`MN
M`(UV9"B,,$M;HY("P`\YT@`;L`)^8S1SW?(*E@&2N05\DGH;D`"+'AE!?\6"
M@#%```8M-QCS:P.T$0"3*YPW^P,$P`3(D$H2$()6%'/?LV$7/@"I(..CP2=S
M0`C<HP03H`1P0`5&<`$40@,PWS4AB`%_(!YJ'W`#A,R/D"-]LA,CH"&M]\>%
M8BL,8#]4N@ZWI`/5%78WV0XMVP=5,`:K]`(4D@&5V#]X]&H[<(L-T#/I8E+!
MQK)%^5`B.DM<``3?<$M00'G2!J.GKV"IGU<?T8YT``$C<'C@_<<\KR%34`(W
M)?\87W!)-&'`2@)8/D(`%H`&[$,Q!``(/UHG$`IS9V=$"%`B)"%E;V-^?6('
M+6,A?9IF8F1^92%F9&(M54@0*&IE9Q6$$'U^?[*SM+6VM[BYNKN\O;Z_O1@0
M"7YBQBU_?G008&.78L#1TM.XDWUO)B\:(7L(WM_@X=\ZL@@O&674N&1]:F)^
M9V\1$-LMQ9DZ$!W)9BXB%G_ZC/DCQDU`@<C$]"E3!I:?6&/ZM`GU(,*((J"*
M:1$!(4D5=2!#BAPI35B",<8.*/%C!@&$$6,"*!E(LJ9(/R'$A`CA!,&8!B5&
MC``#1JC1HT*+YA@(@9Q-6<7&F,$YCT&?$/!:D,G701/_UCXB0WB:I\%/BP,A
MW*0A,\SIT[=PX^;*<0<-!X6>S)BPDF#%&25*UL@=K`NG,4P&7HB@0&&QB,>0
M(T-N##G%A+=DR)SQXR84635]5@9HP_7O&"700)99VV=>C-!^E&@-T9:P[=LC
M^QCX@H;$&S]D<EAA1N:`0)JX;Q<C\\=,B#%'O'GP@(".!SK5Z6C?CAT*=NR?
MWKZY*C`TV3X!`BA4@D/?#WO(0I8Q%H)L,3]28=5.SK\_KSX"<!1!'@3>`8$$
M0XA!@!)G@.4?8>5YXLP8%)X1D$(/9:CA&`3\)F$L3S&$5TQ3H%%"#@?XH9X/
MA#2@"0$6AL1%&BV<099"!(QQ_\!E^SWHXX]B"##`"!`4&08)%\AQ5@`._A@7
M&2VTL)(2?%#HR27-?<+0E@Q),LE#F\'5!SM]_,7&/"\T=``14!0)%GIC&`02
M`0<<0`8=$;RP0VAGI$'$`!`\<)F3A/(GAA)]J$#"``,L(8F.=6I2Z%-F'.!&
M"W.T((<<?QP0`)3Y:<EE0V8!UP(E(-IDQAJ:814`&PC,P^@`*:#QQ0!BI-&&
M/7*J8XP2(020``0OP-*'"U04F<ZDS`[F!XU^'/`#&^]D-@89/Z"46K,WG3$&
MM0&,409^:`$7`AO+UL(&?FE$ZLE;?7"BTP\XD<&#!45"@$8/4_R1QAEFR,%0
M2&*H$6^E&4O,<\<(=PP'@07O<"NQ39,D`]:79H@"XD,3W[100&2,JV'&J:X3
M<5P/.60L2WXTT4`#0V3PIBQ;BL00+']<T$2^:+P<4,D=!RWTT$0'_<#1/!2M
<]-),-^WTTU!'+?745%=M]=589ZWUUEP_'0@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
